,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,olabel,orig_index,label,prob_0,prob_1
0,22-oxacalcitriol,0,1,0,16,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,0,-1,0.99992204,7.796786e-05
1,secondary hyperparathyroidism,2,4,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,1,-1,0.00013330023,0.9998667
2,low bone turnover,6,9,75,92,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,2,-1,0.00020485623,0.99979514
3,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,3,-1,0.00012888553,0.99987113
4,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,4,-1,0.9999442,5.5828892e-05
5,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,5,-1,0.9999076,9.2374874e-05
6,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,6,-1,0.00013710576,0.9998629
8,suppression of bone turnover,27,31,180,208,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,8,-1,0.0002305775,0.9997694
9,lead,34,35,220,224,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,9,-1,0.000559432,0.9994406
10,adynamic bone disease,36,39,228,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,10,-1,0.0001467297,0.99985325
11,vitamin D,2,4,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,11,-1,0.99990344,9.659469e-05
12,22-oxacalcitriol,6,7,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,12,-1,0.99992216,7.788463e-05
13,OCT,8,9,44,47,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,13,-1,0.9998234,0.0001766289
14,OCT,9,10,54,57,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,14,-1,0.99953985,0.00046015458
15,impaired renal function,22,25,119,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,15,-1,0.00042606506,0.9995739
16,N,10,11,52,53,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,16,-1,0.17766432,0.8223357
17,N,19,20,84,85,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,17,-1,0.14357072,0.8564292
20,OCT,19,20,108,111,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,-1,20,-1,0.9998559,0.00014407757
22,OCT,26,27,156,159,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,-1,22,-1,0.9998646,0.00013545308
23,OCT,6,7,21,24,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,23,-1,0.9991435,0.0008564815
24,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,24,-1,0.00013560067,0.99986434
25,secondary hyperparathyroidism,2,4,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,25,-1,0.00013800738,0.99986196
26,OCT,5,6,48,51,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,26,-1,0.99980026,0.00019978684
28,hyperphosphatemia,9,10,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,-1,-1,28,-1,0.00026394852,0.999736
29,OCT,7,8,39,42,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,-1,-1,-1,29,-1,0.9996681,0.00033192767
30,OCT,4,5,12,15,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,30,-1,0.99971944,0.00028053817
31,abnormal bone formation,6,9,25,48,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,31,-1,0.00015231989,0.99984765
32,osteoid,13,14,64,71,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,32,-1,0.00082412193,0.99917585
34,OCT,3,4,13,16,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,-1,34,-1,0.99953675,0.00046331433
35,OCT,8,9,53,56,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,35,-1,0.9996383,0.00036162176
37,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,37,-1,0.00013163128,0.9998684
38,secondary hyperparathyroidism,33,35,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,38,-1,0.00013055488,0.99986947
39,low bone turnover,40,43,259,276,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,39,-1,0.0001644791,0.9998355
40,adynamic bone disease,53,56,323,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,40,-1,0.00014962682,0.9998504
49,ischemic cardiac disease,5,8,23,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,-1,-1,-1,49,-1,0.00014218976,0.9998578
50,hemoptysis,9,10,62,72,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,50,-1,0.00010794483,0.999892
51,renal failure,13,15,94,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,51,-1,0.00014358042,0.99985635
52,hypoxemia,17,18,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,52,-1,0.000106441556,0.99989355
53,ventricular arrhythmia,7,9,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,-1,-1,53,-1,0.00012632042,0.99987364
54,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,54,-1,0.00013648473,0.9998635
56,IVMP,18,19,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,56,-1,0.99984694,0.00015304872
57,cardiac disease,4,6,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,57,-1,0.00012500165,0.99987495
58,ventricular arrhythmia,20,22,126,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,58,-1,0.00012480633,0.9998752
60,Parkinson's disease,4,7,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,-1,-1,60,-1,0.0002308987,0.99976915
66,postural hypotension,1,3,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,66,-1,0.00010144674,0.99989855
67,Parkinson's disease,4,7,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,67,-1,0.00019413502,0.99980587
68,Parkinson's Disease,5,8,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,68,-1,0.00064402283,0.999356
69,Parkinson's disease,21,24,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,69,-1,0.00025814964,0.99974185
70,PD,25,26,148,150,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,70,-1,0.00014610912,0.99985385
71,mg selegiline,31,33,177,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,71,-1,0.99968684,0.00031319933
77,PD,14,15,94,96,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,-1,-1,-1,77,-1,0.0004787331,0.99952126
80,PD,15,16,92,94,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,80,-1,0.0005230887,0.99947697
86,reduced the supine systolic and diastolic blood pressures,4,12,39,96,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,86,-1,0.0018396649,0.9981603
89,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,89,-1,0.9998122,0.00018782912
91,metamphetamine,20,21,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,91,-1,0.99993896,6.102125e-05
94,Picloxydine,0,1,0,11,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,-1,-1,94,-1,0.99992776,7.221122e-05
96,tetrandrine,2,3,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,96,-1,0.9999182,8.176441e-05
97,fangchinoline,4,5,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,97,-1,0.99992466,7.527849e-05
100,Tetrandrine,0,1,0,11,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,100,-1,0.99989736,0.0001026632
101,TET,2,3,13,16,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,101,-1,0.9986064,0.0013936756
102,fangchinoline,5,6,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,102,-1,0.99991477,8.527793e-05
103,FAN,7,8,37,40,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,103,-1,0.99933136,0.0006686166
104,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,104,-1,0.999892,0.00010798343
105,TET,10,11,63,66,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,105,-1,0.99960536,0.0003946682
106,FAN,12,13,71,74,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,106,-1,0.9997198,0.00028015915
109,EP,23,24,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,109,-1,0.98642135,0.01357863
112,TET,16,17,61,64,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,112,-1,0.99958867,0.00041131073
113,FAN,18,19,69,72,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,113,-1,0.9996897,0.00031033996
116,ASA,39,40,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,116,-1,0.99983716,0.00016279088
117,platelet aggregations,4,6,19,40,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,117,-1,0.0003103684,0.9996897
118,TET,14,15,80,83,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,118,-1,0.9997352,0.00026479646
119,FAN,16,17,88,91,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,119,-1,0.9997751,0.00022485542
120,TET,4,5,21,24,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,120,-1,0.99843806,0.0015619165
121,FAN,6,7,29,32,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,121,-1,0.9989802,0.0010197457
122,TET,6,7,45,48,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,122,-1,0.99906033,0.00093963096
123,FAN,8,9,53,56,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,123,-1,0.9994406,0.0005593187
124,tubular damage?BACKGROUND,6,8,51,76,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,124,-1,0.0026276044,0.9973724
125,renal tubular dysfunction,13,16,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,125,-1,0.00016011392,0.9998399
126,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,126,-1,0.9999279,7.207583e-05
127,PAN,5,6,36,39,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,127,-1,0.999765,0.00023507395
129,PAN,4,5,31,34,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,129,-1,0.9965957,0.0034042816
130,protein excretion,40,42,226,243,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,130,-1,0.045960836,0.95403916
132,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,132,-1,0.00030271127,0.9996973
134,cauda equina syndrome,18,21,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,134,-1,0.00028481323,0.99971515
135,cauda equina syndrome,32,35,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,135,-1,0.00030307224,0.99969697
138,mg,13,14,72,74,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,-1,-1,-1,138,-1,0.9104185,0.08958145
142,neurological deficits,4,6,30,51,All cases sustained permanent neurological deficits.,10225068_6,-1,-1,-1,142,-1,0.00012617558,0.99987376
144,mg,24,25,149,151,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,-1,144,-1,0.97685325,0.023146713
149,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,-1,149,-1,0.0001469774,0.999853
153,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,-1,153,-1,0.00014774743,0.9998522
155,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,-1,-1,155,-1,0.0001414115,0.9998586
162,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,-1,-1,162,-1,0.00013620208,0.99986374
164,capillary leak,7,9,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,164,-1,0.00018072732,0.99981934
165,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,165,-1,0.00012274127,0.9998772
167,ACE inhibitors,3,5,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,-1,-1,167,-1,0.9998963,0.00010372495
172,thyroid disease,30,32,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,-1,172,-1,0.00024715578,0.9997528
173,Affective Disorders,2,4,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,-1,173,-1,0.00096306595,0.9990369
174,bipolar disorder,15,17,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,-1,174,-1,0.00027835375,0.9997216
182,thyroid illness,7,9,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,-1,182,-1,0.00024932047,0.9997507
193,thyroid illness,3,5,22,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,-1,193,-1,0.00014067449,0.99985933
197,mood disorder,1,3,16,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,197,-1,0.0001354558,0.9998646
198,psychiatric symptoms,7,9,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,198,-1,0.00013267732,0.9998673
199,mood disorders,17,19,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,-1,199,-1,0.00026303885,0.99973696
200,mood disorder,5,7,55,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,200,-1,0.00017801939,0.99982196
201,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,201,-1,0.0011026699,0.9988973
202,mood disorders,12,14,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,202,-1,0.00014279535,0.9998572
203,mood disorder,17,19,105,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,203,-1,0.00014872414,0.9998512
204,psychiatric symptoms,24,26,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,204,-1,0.00013256402,0.99986744
205,CIMD,4,5,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,-1,-1,-1,205,-1,0.013034119,0.9869659
206,CIMD,6,7,40,44,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,206,-1,0.77739906,0.22260089
207,depressive disorders,15,17,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,207,-1,0.00021401279,0.99978596
208,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,208,-1,0.028864019,0.97113603
209,mood disorder,15,17,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,209,-1,0.00026253902,0.99973744
210,CIMD,11,12,69,73,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,-1,210,-1,0.012065277,0.9879347
211,fucoidan,2,3,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,211,-1,0.99994075,5.9230282e-05
212,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,212,-1,0.00011470871,0.9998853
215,Intracerebral hemorrhage,0,2,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,-1,-1,215,-1,0.00013634982,0.9998636
218,fucoidan,5,6,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,218,-1,0.9999207,7.932005e-05
220,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,220,-1,0.00011384502,0.99988616
221,fucoidan,9,10,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,-1,221,-1,0.9999416,5.8373094e-05
223,impaired blood clotting,5,8,44,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,223,-1,0.00014976371,0.9998503
224,hemodilution,9,10,72,84,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,224,-1,0.00010337363,0.99989665
225,hematomas,13,14,97,106,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,225,-1,0.00015543065,0.99984455
229,white matter edema,1,4,6,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,229,-1,0.00015471158,0.99984527
230,neuronal loss,6,8,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,230,-1,0.00017611227,0.99982387
232,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,-1,232,-1,0.00012254773,0.99987745
234,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,-1,234,-1,0.99993587,6.4110485e-05
236,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,-1,236,-1,0.9999248,7.527068e-05
238,hemolytic anemias,10,12,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,238,-1,0.00012695088,0.99987304
239,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,239,-1,0.9999342,6.583884e-05
241,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,-1,241,-1,0.00013067444,0.99986935
242,NSAIDs,9,10,71,77,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,-1,-1,-1,242,-1,0.99983907,0.00016090137
243,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,243,-1,0.0001352956,0.9998647
244,SAH,6,7,50,53,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,244,-1,0.0001290471,0.9998709
245,ketoprofen,13,14,89,99,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,245,-1,0.999948,5.2005504e-05
246,mg,16,17,105,107,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,246,-1,0.994282,0.0057180207
247,ketoprofen,23,24,128,138,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,247,-1,0.9999435,5.6449782e-05
248,n,26,27,146,147,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,248,-1,0.03235717,0.96764284
249,NSAID,33,34,163,168,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,249,-1,0.9998832,0.000116793766
252,n,48,49,230,231,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,252,-1,0.051860426,0.94813955
253,aneurysmal SAH,58,60,281,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,253,-1,0.0001294637,0.99987054
255,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,255,-1,0.9999218,7.8147015e-05
256,ketoprofen,14,15,108,118,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,256,-1,0.9999474,5.2570293e-05
257,P,4,5,23,24,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,257,-1,0.120537244,0.8794628
258,ketoprofen,10,11,39,49,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,258,-1,0.9999435,5.655098e-05
260,contrast,1,2,3,11,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,260,-1,0.017113978,0.982886
264,P,25,26,174,175,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,264,-1,0.0761493,0.9238507
265,ketoprofen,4,5,19,29,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,-1,-1,265,-1,0.99994195,5.8101028e-05
267,Ketoprofen,0,1,0,10,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,267,-1,0.9999471,5.2944357e-05
269,SAH,10,11,77,80,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,269,-1,0.00017730637,0.9998227
270,ketoprofen,1,2,3,13,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,270,-1,0.99994886,5.1171748e-05
271,cerebral artery aneurysms,7,10,40,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,271,-1,0.0001603613,0.99983966
273,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,273,-1,0.9999182,8.176838e-05
274,flushing,11,12,79,87,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,274,-1,0.11582546,0.8841746
275,respiratory arrest,1,3,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,275,-1,0.0001555408,0.99984443
276,desaturation,5,6,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,276,-1,0.00026568968,0.99973434
278,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,-1,-1,278,-1,0.00019996388,0.9998
281,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,-1,281,-1,0.98633444,0.01366558
286,mg,10,11,48,50,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,286,-1,0.99321073,0.0067893146
288,mg,15,16,71,73,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,288,-1,0.99274933,0.0072506513
290,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,290,-1,0.99921703,0.00078298285
298,myocardial ischemia,8,10,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,-1,-1,298,-1,0.00010403709,0.99989593
299,Nitric oxide,0,2,0,12,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,-1,299,-1,0.9998801,0.00011988059
301,reactive oxygen species,4,7,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,301,-1,0.99344903,0.00655096
302,nitrotyrosine,26,27,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,302,-1,0.99990153,9.851517e-05
307,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,307,-1,0.99693716,0.0030628575
308,lead,30,31,157,161,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,308,-1,0.9998727,0.00012725218
310,MDA,11,12,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,-1,-1,-1,310,-1,0.99983025,0.00016975225
311,rise in blood pressure,5,9,35,57,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,311,-1,0.0005175686,0.9994824
312,MDA,11,12,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,312,-1,0.9998411,0.0001588619
313,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,313,-1,0.99991906,8.092047e-05
315,MDA,8,9,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,315,-1,0.99981874,0.00018130917
316,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,316,-1,0.99991894,8.107542e-05
317,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,317,-1,0.9996538,0.00034614993
318,lead,11,12,76,80,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,-1,318,-1,0.9998425,0.00015749798
321,Glyceryl trinitrate,0,2,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,321,-1,0.999936,6.400486e-05
324,Migraine with,0,2,0,13,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,324,-1,0.00050456816,0.9994954
325,aura,2,3,14,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,325,-1,0.00040939607,0.9995906
327,aura,6,7,40,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,327,-1,0.0004144441,0.99958557
330,aura,18,19,106,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,330,-1,0.0004445475,0.9995554
331,migraine without,20,22,115,131,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,331,-1,0.00058038346,0.9994197
332,aura,22,23,132,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,332,-1,0.00039661588,0.99960345
333,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,333,-1,0.9999006,9.94038e-05
335,migraine without aura,23,26,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,335,-1,0.00022003603,0.99978
338,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,338,-1,0.99993646,6.3557396e-05
339,GTN,30,31,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,339,-1,0.9998312,0.00016876696
343,migraineurs,5,6,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,343,-1,0.00016344007,0.99983656
344,GTN,14,15,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,344,-1,0.9998443,0.0001556258
345,p=0.037,17,18,104,111,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,345,-1,0.05446109,0.94553894
346,h,26,27,148,149,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,346,-1,0.034792956,0.9652071
347,p,28,29,151,152,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,347,-1,0.075454004,0.92454594
349,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,-1,349,-1,0.00027432202,0.99972564
352,migraineurs,10,11,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,352,-1,0.00041339078,0.99958664
363,nonsmall cell lung carcinoma,4,8,32,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,-1,-1,363,-1,0.0004775039,0.99952245
365,nonsmall cell lung carcinoma,6,10,39,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,365,-1,0.00074075273,0.9992593
366,NSCLC,11,12,69,74,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,366,-1,0.0002730255,0.99972695
369,VNB,10,11,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,369,-1,0.9994665,0.00053356955
371,GEM,15,16,89,92,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,371,-1,0.9998216,0.00017844886
374,GEM,12,13,69,72,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,374,-1,0.9998666,0.00013335134
375,VNB,14,15,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,375,-1,0.9998473,0.00015264616
376,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,376,-1,0.00015689603,0.9998431
378,NSCLC,6,7,43,48,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,-1,-1,-1,378,-1,0.00018892497,0.9998111
381,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,381,-1,0.9998153,0.00018470653
382,GEM,11,12,49,52,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,382,-1,0.9997961,0.00020387338
390,P,28,29,151,152,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,-1,-1,390,-1,0.06672539,0.93327457
391,GEM,5,6,32,35,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,391,-1,0.9998369,0.00016306213
392,VNB,7,8,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,392,-1,0.9998635,0.00013649215
395,NSCLC,16,17,116,121,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,-1,395,-1,0.00020022184,0.9997998
397,calcium chloride,7,9,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,-1,-1,397,-1,0.99990475,9.5183816e-05
399,respiratory arrest,9,11,55,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,-1,-1,399,-1,0.00012951568,0.9998704
401,calcium chloride,3,5,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,-1,-1,401,-1,0.9999162,8.37902e-05
405,calcium chloride,18,20,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,-1,-1,405,-1,0.9999137,8.627525e-05
406,decreased renal function,2,5,14,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,406,-1,0.00015808205,0.9998419
407,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,407,-1,0.00011797914,0.999882
408,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,408,-1,0.0001481218,0.9998518
409,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,409,-1,0.00012746618,0.99987257
410,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,410,-1,0.0001197628,0.9998802
411,decreased renal function,48,51,350,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,411,-1,0.0001503661,0.99984956
412,reduction in renal function,8,12,55,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,412,-1,0.00029698145,0.999703
413,CHF,15,16,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,413,-1,0.00013616975,0.99986386
414,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,414,-1,0.00017261649,0.9998274
416,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,416,-1,0.000115408366,0.9998846
418,Decreased renal function,0,3,0,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,-1,-1,-1,418,-1,0.00021012838,0.9997899
421,mm Hg,30,32,192,197,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,421,-1,0.006220161,0.99377984
424,diuretic,45,46,260,268,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,424,-1,0.9999087,9.125124e-05
426,decreased renal function,14,17,81,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,426,-1,0.00024965397,0.9997503
427,P,20,21,121,122,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,427,-1,0.052136775,0.94786316
429,diuretic,14,15,78,86,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,429,-1,0.9999249,7.505392e-05
431,decreased renal function,22,25,130,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,431,-1,0.00015771454,0.9998423
432,decreased renal function,10,13,59,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,-1,432,-1,0.00015656587,0.99984336
436,Diuretic,0,1,0,8,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,436,-1,0.9999336,6.6421155e-05
437,decreased renal function,10,13,64,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,437,-1,0.00018248036,0.99981755
441,renal impairment,4,6,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,-1,441,-1,0.00012081669,0.9998791
443,decreased renal function,13,16,64,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,443,-1,0.0001893724,0.99981064
444,CHF,19,20,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,444,-1,0.000118200194,0.99988174
445,Diuretic,0,1,0,8,Diuretic use and advanced age increased this risk.,10539815_14,-1,-1,-1,445,-1,0.9999238,7.615845e-05
447,renal impairment,8,10,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,447,-1,0.000120893106,0.9998791
448,CHF,14,15,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,448,-1,0.00011174905,0.9998882
452,psychotic disorder,13,15,73,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,452,-1,0.00016645298,0.99983346
453,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,453,-1,0.00013965738,0.9998603
456,NRA0160,7,8,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,-1,-1,-1,456,-1,0.9988624,0.0011376771
457,NRA0160,0,1,0,7,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,-1,457,-1,0.97732246,0.022677543
460,NRA0160,0,1,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,-1,-1,-1,460,-1,0.99925226,0.00074768445
463,NRA0160,0,1,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,463,-1,0.99946374,0.00053625007
466,NRA0160,0,1,0,7,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,466,-1,0.9913669,0.0086330995
470,MAP,10,11,86,89,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,470,-1,0.99927527,0.000724717
471,NRA0160,0,1,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,-1,471,-1,0.99381155,0.00618846
473,NRA0160,0,1,0,7,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,-1,-1,473,-1,0.89214504,0.107854985
476,NRA0160,0,1,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,-1,476,-1,0.9656984,0.03430154
479,NRA0160,0,1,0,7,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,479,-1,0.73068875,0.2693112
481,phencyclidine,6,7,50,63,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,481,-1,0.9999267,7.3311094e-05
482,NRA0160,4,5,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,482,-1,0.9998084,0.0001916077
483,antipsychotics,20,21,142,156,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,483,-1,0.99979764,0.00020238846
490,calcification of the artery,9,13,57,84,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,-1,-1,490,-1,0.00053949637,0.9994605
492,contrast,1,2,3,11,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,-1,-1,492,-1,0.010021412,0.98997855
496,ad,27,28,161,163,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,-1,-1,496,-1,0.84306264,0.15693742
498,calcification of the artery,11,15,81,108,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,498,-1,0.00050215144,0.9994979
499,ad,18,19,122,124,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,499,-1,0.99575764,0.004242318
508,vitamin D,10,12,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,-1,-1,508,-1,0.9999219,7.8024306e-05
511,vitamin D,3,5,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,511,-1,0.99991274,8.7262604e-05
512,calcification of the artery,9,13,43,70,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,512,-1,0.0007205983,0.99927944
513,vitamin K antagonist Warfarin,4,8,18,47,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,513,-1,0.99990046,9.9575795e-05
514,calcification of the artery,13,17,72,99,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,514,-1,0.00072874804,0.9992712
517,vitamin D,9,11,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,517,-1,0.99992144,7.849744e-05
519,vitamin D,19,21,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,519,-1,0.99991953,8.047262e-05
521,vitamin D,32,34,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,521,-1,0.9999211,7.893825e-05
526,vitamin D,14,16,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,526,-1,0.99991345,8.649568e-05
528,vitamin D,22,24,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,528,-1,0.9999168,8.3143335e-05
532,vitamin D,17,19,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,-1,532,-1,0.9999167,8.330048e-05
537,dopamine agonist,4,6,28,44,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,-1,-1,-1,537,-1,0.99970585,0.00029410038
544,contrast,1,2,3,11,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,-1,544,-1,0.02997013,0.9700299
546,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,546,-1,0.99991345,8.6581014e-05
547,DA,6,7,32,34,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,547,-1,0.99983346,0.00016647918
548,HVA,8,9,39,42,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,548,-1,0.9999093,9.074371e-05
549,DA,10,11,43,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,549,-1,0.9998274,0.00017255954
551,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,-1,-1,551,-1,0.00042460705,0.99957544
553,acetazolamide,4,5,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,553,-1,0.9999404,5.9626484e-05
554,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,554,-1,0.00047329435,0.99952674
555,renal impairment,15,17,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,555,-1,0.00013343833,0.9998665
556,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,-1,556,-1,0.0005186005,0.9994814
560,TAM,2,3,11,14,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,-1,560,-1,0.9998493,0.0001506086
563,TAM,6,7,35,38,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,-1,563,-1,0.99986255,0.00013740206
565,TAM,0,1,0,3,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,-1,-1,565,-1,0.9998305,0.00016946277
568,TAM,13,14,81,84,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,-1,-1,568,-1,0.9998363,0.00016363483
570,TAM,6,7,46,49,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,-1,570,-1,0.99984956,0.00015043022
571,hemolytic,1,2,4,13,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,571,-1,0.00012783389,0.9998722
572,TAM,4,5,24,27,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,572,-1,0.9998771,0.0001228878
573,hydroxyl,24,25,158,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,573,-1,0.9965649,0.0034351316
577,TAM,6,7,34,37,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,577,-1,0.99986815,0.0001318676
578,AAPH,15,16,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,578,-1,0.99981004,0.00019001505
580,TAM,3,4,20,23,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,-1,580,-1,0.99981993,0.00018013704
582,TAM,2,3,9,12,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,-1,582,-1,0.9998191,0.000180923
583,TAM,9,10,68,71,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,-1,583,-1,0.99667597,0.0033239848
585,tocopherols,9,10,60,71,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,585,-1,0.9999443,5.568533e-05
586,TAM,15,16,98,101,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,586,-1,0.9998079,0.00019210584
588,TAM,13,14,100,103,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,-1,588,-1,0.99977213,0.00022781707
590,cytotoxicity,10,11,57,69,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,590,-1,0.00015669342,0.99984324
591,TAM,21,22,139,142,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,591,-1,0.99976426,0.0002357707
593,ATP,4,5,22,25,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,593,-1,0.99986637,0.00013361812
594,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,594,-1,0.99989665,0.000103363585
600,N(G)-nitro-L-arginine,34,35,222,243,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,-1,-1,-1,600,-1,0.99982846,0.00017148208
601,ATP,9,10,53,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,-1,601,-1,0.99981636,0.00018369767
603,ATP,30,31,165,168,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,603,-1,0.9998357,0.00016422335
622,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,-1,-1,-1,622,-1,0.9999368,6.32084e-05
633,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,-1,-1,633,-1,0.00010948299,0.99989045
634,phosphodiesterase inhibitors,3,5,11,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,634,-1,0.99982375,0.00017624364
635,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,635,-1,0.9999447,5.5290053e-05
636,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,636,-1,0.000111558365,0.9998884
638,heart failure,4,6,31,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,638,-1,0.00010734505,0.9998926
640,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,640,-1,0.99994874,5.1210598e-05
642,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,642,-1,0.99994826,5.1730887e-05
653,venous thromboembolism,10,12,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,-1,653,-1,0.00013527405,0.9998647
654,venous thromboembolism,8,10,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,654,-1,0.00015349008,0.99984646
655,VTE,11,12,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,655,-1,0.00016096735,0.99983895
657,OC,19,20,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,657,-1,0.9998198,0.00018024477
658,OC,27,28,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,658,-1,0.9997831,0.00021691187
659,VTE,13,14,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,-1,659,-1,0.00021156437,0.99978846
660,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,-1,660,-1,0.00039125964,0.9996088
661,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,661,-1,0.00030046765,0.9996996
662,OC,12,13,68,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,662,-1,0.9996704,0.0003295983
663,VTE,14,15,92,95,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,-1,663,-1,0.0001901838,0.9998098
664,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,-1,664,-1,0.99969876,0.00030125646
676,mg,6,7,32,34,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,676,-1,0.99520266,0.0047973953
678,mg,23,24,114,116,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,678,-1,0.997056,0.0029440008
696,CyA,14,15,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,-1,696,-1,0.94970626,0.050293785
699,CyA.,15,16,104,108,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,-1,699,-1,0.9176138,0.08238622
702,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,702,-1,0.00021714011,0.99978286
703,IDDM,16,17,97,101,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,703,-1,0.0044792877,0.9955207
705,gastrointestinal (GI) toxicity,27,32,128,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,705,-1,0.00024764996,0.99975234
708,IDDM,52,53,237,241,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,708,-1,0.002702591,0.99729747
710,GI toxicity,62,64,268,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,710,-1,0.000162486,0.9998375
712,lmphoproliferate disease,74,76,321,345,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,712,-1,0.001338861,0.99866116
713,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,713,-1,0.00029012325,0.9997099
718,CyA,12,13,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,-1,-1,-1,718,-1,0.9992168,0.0007831772
726,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,-1,-1,726,-1,0.00014283416,0.9998572
727,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,-1,-1,727,-1,0.00013766749,0.9998623
728,iridocyclitis,10,11,49,62,Thirty-six of the 210 patients (17.2%) developed iridocyclitis.,1079693_2,-1,-1,-1,728,-1,0.17489605,0.825104
729,Iridocyclitis,0,1,0,13,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,-1,-1,729,-1,0.015582359,0.9844177
731,uveitis,8,9,39,46,"However, 30% of the patients developed uveitis after 16 years of age.",1079693_4,-1,-1,-1,731,-1,0.00012478848,0.9998752
732,uveitis,17,18,87,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,-1,-1,-1,732,-1,0.00013460305,0.9998654
733,uveitis,6,7,40,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,733,-1,0.0001268184,0.99987316
734,uveitis,13,14,82,89,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,734,-1,0.00012588322,0.9998741
735,uveitis,5,6,36,43,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,735,-1,0.00011239807,0.9998876
736,signs or symptoms,11,14,73,90,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,736,-1,0.00022046862,0.9997795
737,ocular pain,20,22,109,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,737,-1,0.0001200744,0.99987996
738,decreased visual acuity,23,26,122,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,738,-1,0.00016486489,0.99983513
739,photophobia,28,29,150,161,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,739,-1,0.00015066033,0.9998493
740,uveitis,13,14,65,72,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,-1,-1,-1,740,-1,0.00011553333,0.9998845
742,uveitis,17,18,94,101,"Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.",1079693_9,-1,-1,-1,742,-1,0.00012474396,0.9998752
744,keratopathy,3,4,18,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,-1,-1,744,-1,0.00012933623,0.99987066
746,hydroxychloroquine,4,5,23,41,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,746,-1,0.9999341,6.591221e-05
747,chorioretinopathy,16,17,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,747,-1,0.0001443182,0.99985564
750,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,750,-1,0.00029621966,0.9997037
751,uveitis,8,9,61,68,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,751,-1,0.00012082014,0.9998791
752,uveitis,3,4,22,29,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,752,-1,0.000117028765,0.99988294
753,JRA,5,6,34,37,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,753,-1,0.00027999122,0.99972004
755,band keratopathy,5,7,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,-1,-1,755,-1,0.00027241392,0.99972755
759,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,-1,759,-1,0.00014230967,0.99985766
762,ruptured aneurysms,12,14,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,-1,762,-1,0.00015961364,0.9998404
764,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,-1,-1,764,-1,0.00017811482,0.99982196
767,P,19,20,108,109,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,-1,767,-1,0.109177366,0.89082265
770,mm,18,19,89,91,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,770,-1,0.0015857636,0.9984143
771,mm,24,25,110,112,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,771,-1,0.0012834705,0.9987166
772,P,26,27,114,115,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,772,-1,0.047060207,0.9529398
773,P,5,6,21,22,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,773,-1,0.17286639,0.8271336
774,P,12,13,41,42,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,774,-1,0.2681779,0.73182213
777,aneurysmal rupture,5,7,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,-1,-1,777,-1,0.00013914789,0.9998609
780,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,-1,-1,780,-1,0.00015863999,0.99984133
783,reduction in blood pressure,19,23,134,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,783,-1,0.00093808793,0.9990619
784,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,784,-1,0.0001208569,0.9998791
786,n=100,22,23,130,135,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,786,-1,0.0662291,0.93377084
788,n=101,32,33,168,173,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,788,-1,0.057547726,0.94245225
790,n=94,43,44,210,214,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,790,-1,0.07160206,0.9283979
791,n=92,12,13,73,77,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,-1,-1,-1,791,-1,0.04244751,0.9575525
793,reduction in systolic BP,7,11,61,85,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,793,-1,0.0013558244,0.9986442
794,and,14,15,92,95,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,794,-1,0.007501032,0.99249893
795,BP,16,17,106,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,795,-1,0.0031197758,0.9968803
796,DBP reduction,8,10,60,73,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,796,-1,0.03614938,0.9638506
797,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,797,-1,0.08335939,0.9166406
798,reduction,4,5,20,29,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,-1,798,-1,0.0015856776,0.9984143
802,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,802,-1,0.00012462828,0.9998753
806,visceral pain,14,16,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,-1,806,-1,0.00011223174,0.9998877
807,visceral pain,7,9,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,-1,807,-1,0.00012044778,0.9998795
809,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,809,-1,0.9997483,0.00025169313
810,acrolein,22,23,129,137,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,810,-1,0.99992716,7.282433e-05
812,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,-1,-1,-1,812,-1,0.999721,0.00027902782
815,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,-1,-1,-1,815,-1,0.9988991,0.0011008767
817,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,-1,817,-1,0.99982494,0.00017509225
818,mg,5,6,15,17,i.p. and of 20 mg.,10840460_10,-1,-1,-1,818,-1,0.95104295,0.04895707
819,acrolein,6,7,31,39,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,819,-1,0.99993443,6.5539905e-05
820,mg,11,12,56,58,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,820,-1,0.96719354,0.03280647
821,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,-1,821,-1,0.999778,0.00022200427
823,behavioral disorders,4,6,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,-1,823,-1,0.00012001694,0.99987996
824,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,-1,824,-1,0.99971694,0.00028308012
828,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,-1,-1,-1,828,-1,0.99973565,0.0002643306
829,mg,6,7,31,33,Administered at the dose of 20 mg.,10840460_20,-1,-1,-1,829,-1,0.9740441,0.025955897
830,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,830,-1,0.9996847,0.00031532836
831,acrolein,11,12,67,75,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,831,-1,0.9999292,7.0823815e-05
832,mg,14,15,83,85,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,832,-1,0.97878647,0.021213504
833,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,-1,-1,-1,833,-1,0.9997862,0.00021385493
834,acrolein,2,3,12,20,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,-1,834,-1,0.9999268,7.3197654e-05
836,visceral pain,23,25,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,836,-1,0.0001100244,0.99988997
837,painful syndromes,32,34,212,229,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,837,-1,0.00010302754,0.999897
843,clonic fits,21,23,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,-1,-1,843,-1,0.00031242485,0.99968755
844,fits,1,2,4,8,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,-1,-1,844,-1,0.0013593102,0.9986407
850,emergency department,11,13,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,-1,-1,850,-1,0.0005883208,0.9994117
854,emergency department,26,28,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,-1,-1,854,-1,0.00051399297,0.99948597
855,fracture,32,33,164,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,855,-1,0.00020744509,0.9997925
856,dislocation,34,35,176,187,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,856,-1,0.00017660717,0.9998234
857,emergency department,37,39,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,857,-1,0.00062526186,0.9993748
858,trauma,42,43,229,235,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,858,-1,0.0007214792,0.9992785
859,Ketamine hydrochloride,0,2,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,859,-1,0.9998795,0.00012048408
860,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,860,-1,0.08501551,0.91498446
861,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,861,-1,0.03843165,0.96156836
865,fracture,14,15,93,101,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,865,-1,0.00015367827,0.99984634
866,dislocation,16,17,105,116,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,866,-1,0.00014069703,0.99985933
869,fracture,32,33,162,170,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,-1,869,-1,0.0004201723,0.99957985
870,fracture,1,2,9,17,Adequate fracture reduction was obtained in 111 of the children.,10901305_9,-1,-1,-1,870,-1,0.00034232705,0.99965763
872,emesis,10,11,56,62,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,872,-1,0.000114095616,0.9998859
874,clumsiness,21,22,109,119,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,874,-1,0.00014936981,0.99985063
875,ataxic,25,26,132,138,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,875,-1,0.0002595252,0.9997404
876,dysphoric,33,34,171,180,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,876,-1,0.00012612376,0.9998739
880,emergency department,23,25,150,170,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,-1,-1,880,-1,0.00043389614,0.99956614
882,emergency department,11,13,59,79,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,-1,882,-1,0.0008235427,0.99917644
883,muscle dysfunction,1,3,21,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,-1,883,-1,0.000112496826,0.99988747
886,glucocorticoids,3,4,15,30,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,-1,-1,-1,886,-1,0.9998901,0.000109844084
891,twitch,7,8,32,38,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,891,-1,0.00020161261,0.99979836
892,tetanic,10,11,49,56,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,892,-1,0.00031423807,0.99968576
893,body weight gain,2,5,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,-1,-1,893,-1,0.0007201806,0.9992798
895,twitch,3,4,16,22,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,895,-1,0.00020936383,0.9997906
896,tetanic,5,6,27,34,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,896,-1,0.0004327688,0.9995672
897,neuromuscular dysfunction,5,7,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,897,-1,0.000109160675,0.9998908
899,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,899,-1,0.00011856435,0.9998814
900,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,-1,900,-1,0.0001199515,0.9998801
905,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,-1,905,-1,0.0003480983,0.9996519
908,immunoglobulin G,23,25,169,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,-1,908,-1,0.9998683,0.00013176189
912,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,-1,912,-1,0.006877485,0.9931225
914,TMA,12,13,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,-1,-1,-1,914,-1,0.93821263,0.061787397
915,TMA,10,11,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,-1,-1,-1,915,-1,0.0010388459,0.9989611
918,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,-1,918,-1,0.003030623,0.9969694
921,TMA,13,14,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,-1,921,-1,0.09983272,0.9001672
924,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,924,-1,0.00023970149,0.9997603
925,TMA,22,23,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,925,-1,0.0009797951,0.9990202
927,Parkinson's disease,6,9,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,-1,927,-1,0.00034478153,0.99965525
929,Parkinson's disease,12,15,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,-1,929,-1,0.00023457578,0.99976546
930,Parkinson's disease,17,20,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,-1,930,-1,0.00019910187,0.99980086
936,dopamine agonists,35,37,209,226,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,-1,936,-1,0.9999039,9.608372e-05
943,Parkinson's disease,12,15,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,-1,-1,-1,943,-1,0.00018104068,0.999819
944,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,-1,944,-1,0.00035301902,0.999647
945,increase in pupil diameter,14,18,78,104,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,-1,-1,-1,945,-1,0.00042829948,0.99957174
948,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,-1,-1,-1,948,-1,0.99994683,5.3133823e-05
949,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,-1,-1,-1,949,-1,0.9999509,4.91164e-05
952,mg,12,13,58,60,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,-1,952,-1,0.9881065,0.011893529
953,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,953,-1,0.9999455,5.441952e-05
955,impairment in word recall,16,20,117,142,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,955,-1,0.0005302754,0.9994697
956,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,956,-1,0.99994683,5.311153e-05
957,p,22,23,138,139,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,957,-1,0.08620196,0.913798
958,p,30,31,175,176,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,-1,958,-1,0.08298125,0.9170188
959,impairment in word recall,12,16,81,106,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,959,-1,0.0007385594,0.99926144
960,p,25,26,152,153,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,960,-1,0.053077124,0.9469229
961,pupillary,6,7,36,45,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,961,-1,0.00019606335,0.99980396
963,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,963,-1,0.9999467,5.3339438e-05
969,opioid addicts,15,17,89,103,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,969,-1,0.30978572,0.6902143
970,MM,21,22,141,143,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,970,-1,0.998946,0.0010540457
971,n,25,26,156,157,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,971,-1,0.04744102,0.952559
972,n,37,38,220,221,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,972,-1,0.05023884,0.9497612
973,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,973,-1,0.005084331,0.9949157
975,hydromorphone,32,33,188,201,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,975,-1,0.9999316,6.839547e-05
976,mg,34,35,204,206,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,976,-1,0.9873395,0.012660497
977,ketorolac,40,41,244,253,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,977,-1,0.99994695,5.307366e-05
978,mg,42,43,257,259,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,978,-1,0.9893478,0.010652159
979,MM,3,4,20,22,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,979,-1,0.02998659,0.9700134
980,CP pain,10,12,71,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,980,-1,0.00045959366,0.99954045
981,MM,4,5,25,27,These data indicate that MM opioid abusers represent a pain-intolerant subset of clinical patients.,11027904_6,-1,-1,-1,981,-1,0.82836294,0.17163709
988,NMDA,9,10,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,988,-1,0.9998715,0.00012847285
989,antagonists,11,12,76,87,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,989,-1,0.999778,0.00022201867
991,analgesia,23,24,144,153,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,991,-1,0.00020772457,0.9997923
999,nausea and vomiting,10,13,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,999,-1,0.00017639225,0.99982363
1000,drowsiness,14,15,66,76,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,1000,-1,0.00014983941,0.99985015
1007,mg,9,10,63,65,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,-1,-1,-1,1007,-1,0.9976064,0.002393586
1008,drowsiness,3,4,25,35,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,-1,1008,-1,0.00012808596,0.99987185
1013,morphine analgesia,3,5,21,39,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,-1,-1,1013,-1,0.03446138,0.9655386
1018,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,-1,-1,1018,-1,0.00013956233,0.9998604
1019,Spinal Cord Injury,5,8,30,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1019,-1,0.00027887066,0.9997211
1021,spinal cord injury,23,26,138,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1021,-1,0.00014881803,0.9998511
1022,corticosteroid myopathy,13,15,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,-1,-1,1022,-1,0.0038714132,0.99612856
1026,damage to the muscle,7,11,38,58,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1026,-1,0.0009914973,0.9990085
1027,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1027,-1,0.00022376023,0.9997763
1028,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1028,-1,0.0046122707,0.99538773
1029,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1029,-1,0.0042432793,0.9957567
1031,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1031,-1,0.00014152522,0.9998585
1033,corticosteroid myopathy,21,23,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,-1,-1,1033,-1,0.0034466053,0.9965534
1035,RAPA,13,14,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1035,-1,0.999613,0.0003870274
1037,CsA,20,21,117,120,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1037,-1,0.9998684,0.00013163492
1039,Tac,25,26,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1039,-1,0.9998555,0.00014441607
1042,RAPA,13,14,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,-1,-1,-1,1042,-1,0.9999176,8.241555e-05
1043,CsA,6,7,40,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1043,-1,0.9998678,0.00013220274
1044,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1044,-1,0.003537619,0.9964624
1045,CsA,15,16,78,81,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1045,-1,0.9998605,0.00013950566
1046,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1046,-1,0.014473418,0.98552656
1047,facial dysmorphism,24,26,110,128,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1047,-1,0.00013973037,0.9998603
1048,posttransplant lymphoproliferative disorder,30,33,134,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1048,-1,0.00017729301,0.9998227
1049,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1049,-1,0.00018247252,0.99981755
1053,P<0.05,25,26,162,168,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,-1,-1,1053,-1,0.04963017,0.9503699
1054,dysmorphism,1,2,7,18,Facial dysmorphism improved in two patients.,11063349_7,-1,-1,-1,1054,-1,0.00013649723,0.9998635
1055,PTLD,3,4,14,18,No relapse of PTLD was observed.,11063349_8,-1,-1,-1,1055,-1,0.00039576605,0.9996043
1056,pneumonia,3,4,24,33,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1056,-1,0.000121885896,0.99987805
1057,Pneumocystis carinii pneumonia,6,9,39,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1057,-1,0.00051934994,0.99948066
1058,infectious mononucleosis,11,13,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1058,-1,0.00024047268,0.9997595
1059,PTLD,15,16,116,120,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1059,-1,0.00036768572,0.99963224
1060,bronchiolitis obliterans,22,24,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1060,-1,0.00026220432,0.9997378
1062,RAPA,0,1,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1062,-1,0.9994286,0.0005714361
1063,pneumonia,9,10,51,60,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1063,-1,0.00012436937,0.99987566
1064,PTLD,13,14,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1064,-1,0.00020857161,0.99979144
1065,aphtous ulcers,19,21,91,105,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1065,-1,0.00023217866,0.99976784
1066,RAPA,0,1,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,-1,-1,-1,1066,-1,0.99988365,0.00011637165
1067,RAPA,2,3,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1067,-1,0.9998672,0.00013279682
1068,CsA,9,10,75,78,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1068,-1,0.99983,0.00017001257
1069,RAPA,6,7,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1069,-1,0.99924767,0.00075234444
1070,Pneumocystis carinii pneumonia,19,22,133,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1070,-1,0.0030755864,0.99692446
1071,visual field constriction,15,18,142,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,-1,1071,-1,0.00019315073,0.9998068
1072,visual field constriction,3,6,21,46,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,-1,-1,-1,1072,-1,0.00014495372,0.99985504
1074,visual field loss,16,19,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,-1,1074,-1,0.00016368681,0.9998363
1076,visual field constriction,6,9,38,63,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,-1,-1,-1,1076,-1,0.00020709076,0.9997929
1077,visual field constriction,3,6,19,44,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,-1,1077,-1,0.00015515965,0.9998448
1080,Myocardial ischemia,0,2,0,19,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1080,-1,0.00011793968,0.9998821
1081,coronary artery spasm,4,7,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1081,-1,0.00013872671,0.99986124
1084,myocardial ischemia,14,16,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,-1,1084,-1,0.000111695044,0.9998883
1085,lesion in the coronary artery,12,17,57,86,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1085,-1,0.0010455835,0.9989544
1086,coronary artery stenosis,28,31,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1086,-1,0.00016562575,0.9998343
1087,myocardial ischemia,10,12,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,-1,-1,1087,-1,0.00011544852,0.9998845
1090,spastic angina,8,10,46,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1090,-1,0.00011365356,0.9998863
1091,coronary artery stenosis,14,17,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1091,-1,0.00017922644,0.99982077
1092,anginal attacks,3,5,17,32,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,-1,-1,1092,-1,0.00017712406,0.9998229
1096,coronary artery stenosis,13,16,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,-1,1096,-1,0.0001530191,0.99984694
1098,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1098,-1,0.00013435801,0.99986565
1099,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1099,-1,0.00013097496,0.999869
1102,spastic angina,14,16,98,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,-1,-1,1102,-1,0.000108958506,0.99989104
1103,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1103,-1,0.00017530673,0.9998247
1104,coronary stenosis,13,15,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1104,-1,0.00013544998,0.9998646
1108,myocardial ischemia,11,13,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,-1,-1,-1,1108,-1,0.000106105006,0.9998939
1111,technetium-99m sestamibi,14,17,89,113,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,-1,1111,-1,0.99988604,0.000113998176
1117,mg,29,30,176,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,-1,1117,-1,0.99779546,0.0022045728
1119,predobutamine,7,8,42,55,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1119,-1,0.9998952,0.00010472167
1120,mg,20,21,123,125,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1120,-1,0.9988223,0.0011777091
1126,myocardial ischemia,13,15,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,-1,-1,-1,1126,-1,0.00010995287,0.9998901
1127,mg,2,3,11,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,-1,-1,-1,1127,-1,0.9990109,0.000988999
1130,LID,36,37,216,219,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,-1,1130,-1,0.00023794203,0.9997621
1133,LID,52,53,360,363,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,-1,1133,-1,0.0007363286,0.9992637
1134,P,8,9,48,49,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1134,-1,0.20058239,0.7994176
1135,LID,31,32,145,148,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1135,-1,0.0004371735,0.9995628
1141,LID,17,18,109,112,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,-1,1141,-1,0.001190432,0.9988096
1147,LID,26,27,137,140,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,-1,-1,1147,-1,0.00088089245,0.9991191
1153,nonsmall cell lung carcinoma,15,19,126,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,-1,-1,1153,-1,0.0011189219,0.99888104
1154,nonsmall cell lung carcinoma,13,17,103,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1154,-1,0.0015903497,0.9984097
1155,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1155,-1,0.00030933152,0.99969065
1160,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,-1,1160,-1,0.00017002746,0.9998299
1161,NSCLC,7,8,66,71,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,-1,1161,-1,0.00019216667,0.9998079
1165,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,-1,-1,1165,-1,0.0001880497,0.99981195
1178,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,-1,1178,-1,0.00023485038,0.9997651
1179,Serotonergic antidepressants,0,2,0,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1179,-1,0.9998995,0.00010048857
1180,urinary incontinence,3,5,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1180,-1,0.00015784815,0.99984217
1181,serotonergic antidepressants,2,4,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,-1,-1,-1,1181,-1,0.9998822,0.00011775661
1182,urinary incontinence,1,3,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,-1,-1,1182,-1,0.00014233492,0.99985766
1186,serotonin reuptake inhibitors paroxetine,17,21,114,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,-1,-1,1186,-1,0.9998574,0.0001425139
1189,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,-1,-1,1189,-1,0.99990356,9.640614e-05
1192,serotonergic antidepressants,7,9,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,-1,1192,-1,0.99991655,8.341232e-05
1202,emergency department seizure,6,9,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,-1,-1,1202,-1,0.00030935806,0.99969065
1205,emergency department seizure,23,26,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,-1,-1,1205,-1,0.0002630765,0.99973696
1212,seizure disorder,9,11,68,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1212,-1,0.00011454692,0.99988544
1215,amphetamine abuse,26,28,171,188,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1215,-1,0.12895255,0.8710475
1219,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1219,-1,0.18416493,0.81583506
1220,p,22,23,129,130,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1220,-1,0.08327878,0.9167212
1222,amphetamines,13,14,80,92,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,-1,-1,1222,-1,0.9998828,0.00011722814
1225,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1225,-1,0.9999143,8.566163e-05
1226,syndrome of inappropriate secretion of antidiuretic hormone,6,13,40,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1226,-1,0.8932508,0.10674919
1227,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1227,-1,0.99992216,7.78135e-05
1228,VPA,14,15,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1228,-1,0.9998821,0.000117931806
1229,syndrome of inappropriate secretion of antidiuretic hormone,21,28,119,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1229,-1,0.90462184,0.09537816
1230,SIADH,29,30,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1230,-1,0.99937314,0.0006268848
1231,VPA,4,5,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,-1,-1,1231,-1,0.9999039,9.607987e-05
1233,VPA,2,3,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,-1,-1,-1,1233,-1,0.9998375,0.00016248584
1236,SIADH,5,6,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1236,-1,0.0015072585,0.9984927
1237,weakness of the central nervous system,17,23,91,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1237,-1,0.00034754837,0.9996525
1238,VPA,28,29,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1238,-1,0.9999112,8.8749744e-05
1240,tizanidine,5,6,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,-1,1240,-1,0.9999347,6.526623e-05
1243,alpha-2 adrenergic agonists,2,5,17,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1243,-1,0.9998516,0.00014843681
1244,spasticity,16,17,110,120,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1244,-1,0.00010730301,0.9998927
1245,disorders of the central nervous system,19,25,132,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1245,-1,0.00040138827,0.9995987
1246,spasticity,6,7,32,42,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,-1,1246,-1,0.00010991901,0.9998901
1248,enzyme inhibitors,6,8,55,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,-1,1248,-1,0.9998685,0.00013146644
1250,lisinopril,9,10,63,73,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1250,-1,0.9999498,5.0219096e-05
1254,tizanidine,27,28,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1254,-1,0.99993837,6.157968e-05
1255,spasticity,37,38,248,258,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1255,-1,0.00010066868,0.99989927
1256,tizanidine,4,5,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1256,-1,0.9999366,6.3409316e-05
1257,antihypertensive agents,7,9,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1257,-1,0.99981266,0.00018739908
1259,spasticity,22,23,153,163,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1259,-1,0.000105827836,0.99989414
1266,pentylenetetrazol,24,25,140,157,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1266,-1,0.9999428,5.7162346e-05
1267,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,-1,-1,1267,-1,0.9998944,0.00010565904
1269,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,-1,-1,-1,1269,-1,0.9999026,9.736707e-05
1270,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1270,-1,9.622668e-05,0.9999038
1272,ADR,27,28,158,161,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1272,-1,0.9998035,0.00019654757
1273,nitrite,12,13,68,75,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,-1,1273,-1,0.99977,0.00023004983
1275,aminoguanidine,21,22,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1275,-1,0.9999269,7.312824e-05
1276,AG,23,24,123,125,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1276,-1,0.9997814,0.00021853836
1277,ADR,11,12,75,78,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1277,-1,0.99971956,0.00028037533
1278,mesangial proliferation,16,18,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1278,-1,0.00024313571,0.9997569
1279,tubulointerstitial inflammation,20,22,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1279,-1,0.000207215,0.99979275
1281,P,15,16,101,102,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,-1,1281,-1,0.070296116,0.92970383
1282,nitrite,1,2,6,13,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1282,-1,0.99978703,0.00021293566
1283,P,11,12,80,81,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1283,-1,0.163442,0.836558
1286,AG,2,3,15,17,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1286,-1,0.9997851,0.00021491664
1287,nitrite,15,16,98,105,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1287,-1,0.9997402,0.0002597673
1289,melatonin,3,4,16,25,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1289,-1,0.9998932,0.000106800864
1290,narcosis,6,7,49,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1290,-1,0.000722227,0.9992778
1291,Melatonin,0,1,0,9,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1291,-1,0.9998785,0.00012148315
1292,narcosis,17,18,108,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1292,-1,0.0017185294,0.9982815
1293,Sodium thiopenthal,0,2,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1293,-1,0.9999224,7.7594836e-05
1294,melatonin,10,11,86,95,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1294,-1,0.999902,9.794863e-05
1295,Melatonin,0,1,0,9,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1295,-1,0.99986887,0.00013110893
1296,barbiturate narcosis,7,9,50,70,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1296,-1,0.3703522,0.6296478
1297,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,-1,1297,-1,0.18164018,0.81835985
1298,contrast,1,2,3,11,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1298,-1,0.15335868,0.84664136
1299,melatonin,7,8,33,42,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1299,-1,0.9999052,9.478149e-05
1300,narcosis,28,29,153,161,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1300,-1,0.00029223863,0.99970776
1301,Melatonin,0,1,0,9,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1301,-1,0.99989045,0.0001095184
1302,narcosis,16,17,103,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1302,-1,0.0003036043,0.9996964
1303,melatonin,6,7,25,34,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1303,-1,0.99989116,0.000108876564
1304,narcosis,9,10,54,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1304,-1,0.013640037,0.98636
1305,barbiturate,16,17,92,103,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1305,-1,0.99993455,6.5384585e-05
1312,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1312,-1,0.98515433,0.014845681
1315,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1315,-1,0.0044153817,0.99558467
1317,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1317,-1,0.00068207656,0.9993179
1318,MBC,9,10,61,64,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1318,-1,0.00076000736,0.99924004
1319,Myocet,26,27,162,168,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1319,-1,0.034971543,0.9650284
1322,C,46,47,259,260,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1322,-1,0.9996112,0.00038886457
1323,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1323,-1,0.00014623119,0.99985373
1326,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1326,-1,0.0001222268,0.9998778
1327,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1327,-1,0.00011961305,0.9998803
1329,MC,5,6,24,26,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1329,-1,0.01827935,0.9817207
1330,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1330,-1,0.00012429836,0.99987566
1331,AC,18,19,80,82,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1331,-1,0.011053,0.988947
1333,P,23,24,118,119,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1333,-1,0.030116942,0.9698831
1335,MC,13,14,76,78,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1335,-1,0.09772599,0.90227395
1336,AC,19,20,102,104,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1336,-1,0.10998676,0.8900132
1337,P,21,22,106,107,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1337,-1,0.054033685,0.9459663
1338,MC,0,1,0,2,MC patients also experienced less grade 4 neutropenia.,11230490_7,-1,-1,-1,1338,-1,0.058349032,0.9416509
1340,MC,3,4,22,24,"Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months.",11230490_8,-1,-1,-1,1340,-1,0.9656624,0.034337606
1341,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1341,-1,0.88056654,0.11943342
1346,MBC,33,34,247,250,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1346,-1,0.0019243924,0.9980756
1348,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,-1,-1,1348,-1,0.9998642,0.00013573004
1356,contrast,1,2,3,11,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,-1,-1,1356,-1,0.10518235,0.8948177
1360,cyclophosphamide cytotoxicity,6,8,56,85,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,-1,1360,-1,0.15756425,0.8424358
1363,cytotoxicity,23,24,131,143,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,-1,-1,1363,-1,0.00015789871,0.99984205
1374,se,10,11,74,76,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,-1,1374,-1,0.0060699577,0.9939301
1381,cytotoxicity,7,8,63,75,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,-1,1381,-1,0.00015387783,0.9998461
1396,Graves' disease,6,9,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1396,-1,0.00087590574,0.9991241
1397,febrile illness,11,13,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1397,-1,0.0001212651,0.99987876
1403,propylthio-,15,16,116,127,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1403,-1,0.9998522,0.00014776376
1404,propylthio-,15,16,116,127,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1404,-1,0.9998522,0.00014776376
1405,uracil,16,17,128,134,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,-1,1405,-1,0.99990535,9.470091e-05
1408,propylthio-,13,14,101,112,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,-1,-1,1408,-1,0.9997837,0.00021635831
1411,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,-1,-1,1411,-1,0.00017453669,0.99982554
1413,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1413,-1,0.00016551194,0.9998344
1414,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1414,-1,0.00012445076,0.99987555
1417,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1417,-1,0.00012487214,0.99987507
1418,pulmonary edema,8,10,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1418,-1,0.00011034643,0.9998896
1419,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,-1,1419,-1,0.8357966,0.1642034
1420,mg,7,8,35,37,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1420,-1,0.998384,0.001616053
1424,amine,24,25,137,142,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1424,-1,0.99987674,0.00012327074
1426,mg,18,19,90,92,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,-1,-1,1426,-1,0.9997055,0.00029444127
1429,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,-1,-1,1429,-1,0.00030849804,0.9996915
1430,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1430,-1,0.0001974249,0.99980265
1431,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1431,-1,0.00014029993,0.9998597
1432,diuretic,12,13,71,79,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1432,-1,0.9999219,7.802885e-05
1433,angiotensin II,4,6,23,37,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,-1,-1,-1,1433,-1,0.9998683,0.0001316634
1435,angiotensin II,8,10,46,60,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1435,-1,0.9998543,0.00014565284
1436,antagonist losartan,11,13,70,89,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1436,-1,0.9998603,0.00013974277
1437,renovascular disease,21,23,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1437,-1,0.00012903393,0.9998709
1438,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1438,-1,0.00012358544,0.9998764
1439,CIPS,5,6,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1439,-1,0.00037340436,0.9996265
1440,Bone pain,0,2,0,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,-1,-1,-1,1440,-1,0.0002066988,0.99979335
1443,oedema,6,7,52,58,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1443,-1,0.00013406978,0.9998659
1444,painful,9,10,66,73,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1444,-1,0.00015679849,0.9998431
1446,foot pain,8,10,49,58,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1446,-1,0.00014891088,0.9998511
1447,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1447,-1,0.00015249662,0.99984753
1449,Morton's neuralgia,18,21,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1449,-1,0.002691891,0.99730814
1450,gout,22,23,131,135,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1450,-1,0.0002141571,0.99978584
1452,avascular necrosis,26,28,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1452,-1,0.00012819751,0.99987173
1453,intermittent claudication,29,31,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1453,-1,0.00011851146,0.9998815
1454,foot deformities,33,35,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1454,-1,0.00014147583,0.9998585
1455,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1455,-1,0.00016268907,0.9998373
1456,hyperparathyroidism,40,41,250,269,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1456,-1,0.00012878038,0.99987125
1458,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,-1,-1,1458,-1,0.9999063,9.3715964e-05
1460,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1460,-1,0.00012226666,0.9998777
1461,CIPS,6,7,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1461,-1,0.00019472864,0.9998053
1464,lead,6,7,41,45,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1464,-1,0.0051895897,0.99481034
1465,CIPS,18,19,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1465,-1,0.0004971341,0.9995029
1466,haemorrhagic myocarditis,1,3,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,-1,1466,-1,0.00011364523,0.9998864
1468,Haemorrhagic myocarditis,0,2,0,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,-1,-1,-1,1468,-1,0.00011293224,0.9998871
1471,Anthracyclines,0,1,0,14,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1471,-1,0.9998938,0.00010616603
1472,antineoplastic drugs,3,5,29,49,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1472,-1,0.99080265,0.009197309
1478,acute leukemia,29,31,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,-1,1478,-1,0.00010986608,0.9998901
1480,acute leukemia,3,5,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,-1,1480,-1,0.00012600343,0.999874
1481,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,-1,-1,1481,-1,0.00011618005,0.9998838
1482,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,-1,-1,1482,-1,0.00012237945,0.9998776
1483,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1483,-1,0.000115281546,0.9998847
1484,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1484,-1,0.000108372325,0.99989164
1485,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1485,-1,0.000114094204,0.9998859
1486,DNR,16,17,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1486,-1,0.9997564,0.00024356888
1487,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1487,-1,0.99976534,0.00023465029
1488,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1488,-1,0.00011588509,0.9998841
1491,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,-1,1491,-1,0.00010924616,0.9998907
1492,remodeling,4,5,39,49,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1492,-1,0.00014379703,0.99985623
1493,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1493,-1,0.00014882429,0.9998511
1494,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1494,-1,0.00017143974,0.9998286
1495,AF,15,16,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1495,-1,0.0007241595,0.99927586
1496,AF,20,21,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1496,-1,0.0011160908,0.9988839
1497,AF,8,9,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1497,-1,0.0025127756,0.9974872
1501,nadolol,13,14,81,88,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,-1,-1,-1,1501,-1,0.99994373,5.629405e-05
1502,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,-1,1502,-1,0.0002655714,0.99973446
1504,AF,4,5,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1504,-1,0.00020685967,0.9997931
1505,AF,14,15,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1505,-1,0.0001596007,0.9998404
1508,P<0.02,19,20,109,115,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1508,-1,0.045354713,0.95464534
1509,ms,27,28,142,144,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1509,-1,0.0046847877,0.9953152
1510,AF,52,53,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1510,-1,0.00025604037,0.999744
1512,AF,6,7,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1512,-1,0.00057482754,0.9994252
1513,AF,10,11,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1513,-1,0.00042143985,0.99957854
1515,n=5,24,25,136,139,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1515,-1,0.14873554,0.8512645
1517,AF,11,12,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,-1,-1,-1,1517,-1,0.00017917878,0.9998209
1521,AF,6,7,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,-1,-1,1521,-1,0.000262813,0.9997372
1523,AF,4,5,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,-1,1523,-1,0.00037646864,0.99962354
1528,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1528,-1,0.999913,8.70652e-05
1530,primary headaches,13,15,64,81,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1530,-1,0.00017118899,0.9998288
1532,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1532,-1,0.9998012,0.00019875569
1533,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1533,-1,0.99979514,0.0002048662
1535,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1535,-1,0.99993336,6.664105e-05
1536,GTN,22,23,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1536,-1,0.9998248,0.00017517674
1538,GTN,9,10,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,-1,1538,-1,0.99981374,0.00018628739
1540,GTN,11,12,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,-1,-1,1540,-1,0.9992105,0.0007894397
1542,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1542,-1,0.9998468,0.00015316786
1543,GTN,15,16,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1543,-1,0.99945575,0.00054430513
1544,P=0.65,23,24,115,121,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1544,-1,0.029567584,0.9704324
1545,P=0.48,28,29,136,142,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1545,-1,0.039057042,0.9609429
1546,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1546,-1,0.986666,0.013333947
1547,P=0.36,15,16,82,88,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1547,-1,0.18059711,0.8194029
1548,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1548,-1,0.99986935,0.00013066547
1549,GTN,16,17,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1549,-1,0.9997391,0.0002608822
1550,P,21,22,110,111,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1550,-1,0.12908408,0.8709159
1552,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,-1,1552,-1,0.99976796,0.00023201732
1553,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,-1,1553,-1,0.0018746352,0.9981254
1554,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1554,-1,0.0008022656,0.9991978
1555,TDP,12,13,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1555,-1,0.0007909231,0.9992091
1556,fluconazole,16,17,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1556,-1,0.9999361,6.39021e-05
1557,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1557,-1,0.00069132773,0.9993087
1558,abscess,14,15,88,95,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1558,-1,0.00013645206,0.9998635
1559,TDP,16,17,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1559,-1,0.0018575946,0.99814236
1560,fluconazole,22,23,143,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1560,-1,0.9999392,6.0775244e-05
1561,TDP,31,32,197,200,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1561,-1,0.004819239,0.99518085
1562,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1562,-1,0.00015077257,0.9998492
1564,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1564,-1,0.00011547231,0.9998845
1565,fluconazole,56,57,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1565,-1,0.99994266,5.7280868e-05
1566,TDP,58,59,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1566,-1,0.99730575,0.0026942603
1567,TDP,1,2,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1567,-1,0.00023886673,0.99976116
1568,fluconazole,4,5,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1568,-1,0.999941,5.9009006e-05
1569,premature ventricular contractions,15,18,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1569,-1,0.00011894325,0.999881
1571,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1571,-1,0.00022726668,0.9997727
1572,fluconazole,47,48,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1572,-1,0.9999416,5.8379275e-05
1573,TDP,52,53,347,350,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1573,-1,0.00024701728,0.99975294
1576,QT prolongation,13,15,74,89,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1576,-1,0.00017487051,0.9998252
1577,TDP,16,17,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1577,-1,0.0005104729,0.99948955
1578,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1578,-1,0.00016577696,0.9998342
1579,premature ventricular contractions,23,26,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1579,-1,0.000117897616,0.9998821
1580,fluconazole,39,40,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1580,-1,0.9999367,6.332599e-05
1581,fluconazole,7,8,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1581,-1,0.9999417,5.8348334e-05
1582,prolongation of the QT interval,16,21,87,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1582,-1,0.0007329674,0.99926704
1583,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1583,-1,0.0008416449,0.9991584
1584,fluconazole,7,8,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,-1,-1,1584,-1,0.99993956,6.042026e-05
1588,renal failure,12,14,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1588,-1,0.00011066245,0.9998894
1589,cephalothin sodium,22,24,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1589,-1,0.99993694,6.305127e-05
1590,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1590,-1,0.999881,0.00011897661
1592,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,-1,-1,1592,-1,0.00014134705,0.9998586
1596,lung toxicity,17,19,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1596,-1,0.00011834985,0.9998816
1598,IH636 grape seed proanthocyanidin extract,25,30,207,248,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1598,-1,0.9991591,0.0008408512
1599,Grape seed extract,0,3,0,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1599,-1,0.99962103,0.00037892966
1600,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1600,-1,0.99988985,0.00011013273
1601,IH636 grape seed proanthocyanidin extract,6,11,35,76,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1601,-1,0.99922955,0.00077044585
1602,GSPE,12,13,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1602,-1,0.99819654,0.001803448
1606,lung toxicity,22,24,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1606,-1,0.00011074416,0.99988925
1609,GSPE,13,14,71,75,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,-1,-1,-1,1609,-1,0.9997559,0.00024409803
1610,GSPE,11,12,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,-1,1610,-1,0.99983335,0.00016666183
1611,AAP,7,8,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1611,-1,0.9998429,0.00015714546
1612,h,13,14,64,65,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1612,-1,0.14921488,0.85078514
1613,AMI,15,16,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1613,-1,0.9997893,0.00021071522
1614,DOX,23,24,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1614,-1,0.99986994,0.0001300462
1615,h,29,30,121,122,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1615,-1,0.14882918,0.8511708
1616,BUN,11,12,63,66,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1616,-1,0.99974436,0.0002556252
1617,PAS,39,40,247,250,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1617,-1,0.99583983,0.0041601313
1618,GSPE,3,4,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1618,-1,0.998417,0.0015829313
1619,AAP,7,8,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1619,-1,0.9998573,0.00014261682
1620,AMI,9,10,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1620,-1,0.99979585,0.00020416285
1621,DOX,11,12,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1621,-1,0.9998479,0.00015213121
1622,BUN,26,27,142,145,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1622,-1,0.9989039,0.0010961677
1623,tissue damage,13,15,94,107,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1623,-1,0.00013281987,0.9998672
1624,GSPE,30,31,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1624,-1,0.9997465,0.00025351383
1625,AAP,9,10,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1625,-1,0.99987495,0.00012501238
1626,AMI,11,12,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1626,-1,0.99982005,0.00017993446
1627,DOX,13,14,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1627,-1,0.9998646,0.00013539808
1630,GSPE,31,32,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1630,-1,0.9998766,0.0001234073
1631,AAP,1,2,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1631,-1,0.9998596,0.00014041008
1632,AMI,3,4,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1632,-1,0.9998061,0.00019386328
1633,DOX,5,6,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1633,-1,0.9998499,0.00015008636
1634,GSPE,21,22,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1634,-1,0.9997825,0.00021755314
1636,GSPE,7,8,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,-1,1636,-1,0.99973124,0.0002686987
1637,Cutaneous leucocytoclastic vasculitis,0,3,0,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1637,-1,0.00011556836,0.99988437
1638,oxacillin,5,6,54,63,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1638,-1,0.9999397,6.0305076e-05
1639,oxacillin,7,8,39,48,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1639,-1,0.9999485,5.1485007e-05
1640,bacteremia,15,16,95,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1640,-1,0.00010675228,0.9998932
1641,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1641,-1,0.00011240943,0.9998876
1642,purpuric lesions,26,28,164,180,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1642,-1,0.00015889917,0.9998411
1644,leucocytoclastic vasculitis,6,8,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,-1,-1,1644,-1,0.000118588556,0.9998814
1645,Oxacillin,0,1,0,9,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,-1,1645,-1,0.9999441,5.5870107e-05
1648,Leucocytoclastic vasculitis,0,2,0,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1648,-1,0.00013435018,0.99986565
1649,purpura,5,6,49,56,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1649,-1,0.0002875183,0.9997124
1650,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1650,-1,0.00012912464,0.9998709
1651,arthralgia,16,17,119,129,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1651,-1,0.00013114129,0.99986887
1652,renal involvement,19,21,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1652,-1,0.00016225872,0.99983776
1654,collagen vascular disease,10,13,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1654,-1,0.00051335036,0.99948657
1655,neoplasia,14,15,105,114,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1655,-1,0.00014260145,0.9998574
1656,corticosteroid,8,9,43,57,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,-1,1656,-1,0.999861,0.00013892713
1658,Oxacillin,0,1,0,9,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1658,-1,0.99994123,5.8799767e-05
1659,leucocytoclastic vasculitis,10,12,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1659,-1,0.00011040348,0.9998896
1660,mania,1,2,23,28,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,-1,1660,-1,0.00019475428,0.9998053
1662,mania,9,10,58,63,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1662,-1,0.00036099833,0.99963903
1664,bipolar depression,25,27,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1664,-1,0.0002474864,0.99975246
1665,bipolar disorder,11,13,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1665,-1,0.00042418833,0.9995758
1667,Mania,32,33,216,221,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1667,-1,0.0010224291,0.99897754
1669,hypomanic,6,7,36,45,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1669,-1,0.00035574488,0.9996443
1670,bipolar I,26,28,149,158,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1670,-1,0.011300651,0.9886994
1671,bipolar II,29,31,163,173,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1671,-1,0.009721836,0.9902782
1675,serotonin reuptake inhibitors,56,59,333,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1675,-1,0.99983287,0.00016709177
1676,SSRIs,60,61,364,369,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1676,-1,0.9998024,0.00019765411
1678,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1678,-1,0.00012160008,0.9998784
1679,mania,6,7,34,39,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1679,-1,0.0001465123,0.9998535
1680,N,15,16,73,74,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1680,-1,0.040035095,0.9599649
1681,SSRIs,31,32,134,139,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1681,-1,0.9998203,0.00017976727
1682,N,40,41,154,155,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1682,-1,0.07240344,0.92759657
1684,N,52,53,198,199,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1684,-1,0.12189804,0.87810194
1685,hypomanic,57,58,217,226,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1685,-1,0.0001436178,0.99985635
1686,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1686,-1,0.51484364,0.48515636
1687,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1687,-1,0.57244605,0.42755395
1688,contrast,1,2,3,11,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1688,-1,0.025831418,0.97416866
1691,p,31,32,142,143,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1691,-1,0.09016581,0.90983427
1693,p,37,38,236,237,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,-1,1693,-1,0.09338168,0.90661836
1696,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,-1,-1,1696,-1,0.0002466617,0.9997533
1697,transplant glomerulopathy,8,10,50,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1697,-1,0.00035495084,0.999645
1698,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1698,-1,0.0033303546,0.9966697
1699,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1699,-1,0.79828423,0.20171572
1701,chronic allograft nephropathy,19,22,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1701,-1,0.00013212839,0.9998678
1702,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1702,-1,0.00013269986,0.9998673
1704,malignant hypertension,17,19,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1704,-1,0.000112000715,0.99988794
1707,TG,11,12,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1707,-1,0.0061176154,0.9938824
1708,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1708,-1,0.007862537,0.9921375
1709,malignant hypertension,5,7,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1709,-1,0.00010665532,0.9998933
1711,lupus nephritis,11,13,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1711,-1,0.00011488691,0.9998851
1712,nephritis,15,16,113,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1712,-1,0.00011100266,0.999889
1714,acute renal failure,22,25,175,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1714,-1,0.00010904197,0.9998909
1715,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1715,-1,0.99501544,0.0049846037
1716,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1716,-1,0.00011468541,0.9998853
1718,TG,17,18,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1718,-1,0.009481297,0.99051875
1719,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1719,-1,0.0031737206,0.9968263
1720,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1720,-1,0.00017288448,0.9998271
1721,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1721,-1,0.9996176,0.00038242477
1722,injury,5,6,37,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1722,-1,0.00015393623,0.999846
1723,immunologic injury,8,10,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1723,-1,0.00040280152,0.99959725
1724,renal pathology,1,3,4,19,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1724,-1,0.00013465389,0.9998653
1725,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1725,-1,0.0002748792,0.99972516
1726,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,-1,1726,-1,0.00023940501,0.99976057
1728,cardiac arrhythmia,1,3,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,-1,1728,-1,0.000105380524,0.9998946
1729,mitral valve prolapse,7,10,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1729,-1,0.0001561264,0.99984384
1730,ventricular fibrillation,13,15,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1730,-1,0.00010909243,0.9998909
1732,BD1008,4,5,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1732,-1,0.9998252,0.00017484851
1733,oligodeoxynucleotide,8,9,63,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1733,-1,0.99983144,0.0001684859
1735,BD1018,17,18,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1735,-1,0.9996086,0.00039148028
1736,"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",19,20,117,181,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1736,-1,0.99932945,0.0006706016
1737,BD1063,22,23,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1737,-1,0.9996283,0.00037173188
1739,LR132,28,29,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1739,-1,0.99963605,0.00036398842
1740,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1740,-1,0.9994686,0.00053133385
1741,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1741,-1,0.9994686,0.00053133385
1742,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1742,-1,0.9994686,0.00053133385
1744,NMDA,22,23,134,138,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,-1,-1,-1,1744,-1,0.9998535,0.00014654052
1745,BD1018,8,9,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1745,-1,0.9997912,0.00020881917
1746,BD1063,10,11,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1746,-1,0.9998354,0.00016465815
1747,LR132,13,14,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1747,-1,0.99990046,9.952368e-05
1749,LR132,4,5,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,-1,1749,-1,0.9999224,7.7549266e-05
1750,contrast,1,2,3,11,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1750,-1,0.02130301,0.97869706
1751,DTG,18,19,135,138,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1751,-1,0.99980265,0.00019731816
1752,BD1031,26,27,177,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1752,-1,0.9995359,0.0004640918
1753,"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",28,29,185,249,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1753,-1,0.99935037,0.00064967223
1756,BD1018,13,14,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1756,-1,0.99982965,0.00017030217
1757,BD1063,15,16,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1757,-1,0.99984384,0.00015608441
1758,LR132,17,18,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1758,-1,0.99989474,0.00010526422
1760,oligodeoxynucleotide,21,22,139,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,-1,1760,-1,0.99984,0.0001599554
1767,allograft dysfunction,20,22,136,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,-1,1767,-1,0.0001706873,0.9998293
1768,eosinophilic,8,9,61,73,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,-1,1768,-1,0.00034121843,0.9996588
1769,Cholestatic jaundice,0,2,0,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1769,-1,0.00014439406,0.99985564
1770,metformin,7,8,48,57,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1770,-1,0.99989367,0.00010635187
1771,cholestatic jaundice,6,8,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1771,-1,0.00013904402,0.9998609
1772,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1772,-1,0.99989116,0.000108815424
1776,Metformin hydrochloride,0,2,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,-1,-1,-1,1776,-1,0.9998808,0.000119223056
1779,metformin,12,13,61,70,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,-1,-1,1779,-1,0.9998466,0.0001534276
1785,chronic liver disease,17,20,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,-1,-1,1785,-1,0.00012605857,0.9998739
1789,levobupivacaine,8,9,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1789,-1,0.9999262,7.3779025e-05
1790,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1790,-1,0.999943,5.6962042e-05
1792,levobupivacaine,2,3,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1792,-1,0.9999268,7.321259e-05
1793,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1793,-1,0.9999424,5.7564415e-05
1794,mg,13,14,72,74,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1794,-1,0.9282957,0.071704306
1797,mm Hg,13,15,84,89,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,-1,-1,-1,1797,-1,0.020488057,0.979512
1798,levobupivacaine,4,5,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1798,-1,0.99993134,6.862183e-05
1799,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1799,-1,0.9999405,5.9449278e-05
1802,levobupivacaine,4,5,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1802,-1,0.9999368,6.322685e-05
1803,dysrhythmias,7,8,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1803,-1,0.000116388976,0.99988365
1805,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1805,-1,0.99994516,5.4782646e-05
1808,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,-1,-1,-1,1808,-1,0.99994445,5.553408e-05
1810,levobupivacaine,7,8,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1810,-1,0.99993443,6.5556655e-05
1811,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1811,-1,0.9999428,5.7181267e-05
1815,levobupivacaine,40,41,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1815,-1,0.99993134,6.8607376e-05
1816,rabbit syndrome,1,3,20,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,-1,-1,-1,1816,-1,0.00023769283,0.99976236
1818,Rabbit syndrome,0,2,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1818,-1,0.00065781065,0.99934214
1819,RS,3,4,17,19,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1819,-1,0.000330874,0.9996692
1820,neuroleptic,14,15,78,89,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1820,-1,0.99988925,0.00011078705
1821,RS,7,8,46,48,"Here we present a case of withdrawal-emergent RS, which is the first of its kind to be reported.",11532387_2,-1,-1,-1,1821,-1,0.0012859288,0.9987141
1822,RS,3,4,22,24,The patient developed RS during dose reduction of risperidone.,11532387_3,-1,-1,-1,1822,-1,0.00035206,0.999648
1825,RS,5,6,48,50,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1825,-1,0.00025830694,0.99974173
1828,RS,37,38,261,263,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1828,-1,0.00026681065,0.99973315
1829,E4031,6,7,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,-1,1829,-1,0.99949336,0.00050656253
1833,Torsades de pointes,0,3,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1833,-1,0.0053035724,0.9946964
1834,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1834,-1,0.015515274,0.9844847
1836,MAPD,24,25,156,160,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1836,-1,0.04459855,0.9554014
1837,TDP,0,1,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,-1,-1,-1,1837,-1,0.01287987,0.98712015
1840,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,-1,1840,-1,0.007415699,0.99258435
1841,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1841,-1,0.00039170688,0.99960834
1845,E4031,19,20,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1845,-1,0.9997713,0.00022871527
1849,E4031,28,29,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,-1,1849,-1,0.9996586,0.00034146965
1850,TDP,5,6,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,-1,-1,-1,1850,-1,0.034339536,0.9656604
1854,TDP,13,14,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,-1,1854,-1,0.999747,0.00025300964
1855,Amphotericin,0,1,0,12,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1855,-1,0.9999248,7.520689e-05
1857,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1857,-1,0.0051224316,0.9948776
1859,AIDS,21,22,130,134,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1859,-1,0.0012664667,0.9987336
1860,amphotericin B,24,26,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1860,-1,0.99992716,7.2856565e-05
1861,grand mal seizures,9,12,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1861,-1,0.00013992931,0.99986005
1862,amphotericin B,16,18,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1862,-1,0.99993706,6.294644e-05
1865,hydroxyzine,7,8,57,68,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1865,-1,0.9999299,7.008652e-05
1866,promethazine,9,10,70,82,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1866,-1,0.9999274,7.2577175e-05
1870,lorazepam,5,6,40,49,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1870,-1,0.99993634,6.3669744e-05
1872,amphotercin B,14,16,99,112,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1872,-1,0.9999404,5.9650767e-05
1873,AIDS,2,3,12,16,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1873,-1,0.0022524002,0.9977476
1874,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1874,-1,0.00017426015,0.9998258
1876,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,-1,-1,1876,-1,0.015976707,0.98402333
1882,amphotericin B,7,9,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1882,-1,0.99993527,6.47165e-05
1884,AIDS,17,18,94,98,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1884,-1,0.0003910944,0.99960893
1885,Amphotericin B,2,4,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,-1,-1,1885,-1,0.9999285,7.157555e-05
1888,amphotericin B,10,12,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,-1,1888,-1,0.9999354,6.463645e-05
1889,retention of urine,1,4,8,26,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,-1,1889,-1,0.0002991665,0.9997009
1894,wall rigidity,9,11,71,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1894,-1,0.00016657174,0.99983335
1896,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1896,-1,0.00013398376,0.999866
1898,urinary bladder retention,5,8,17,42,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1898,-1,0.000150333,0.9998497
1899,hydronephrosis,14,15,95,109,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1899,-1,0.00021482608,0.99978524
1902,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,-1,1902,-1,0.99993956,6.048431e-05
1903,Calcineurin inhibitors,0,2,0,22,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,-1,-1,-1,1903,-1,0.99988055,0.0001194331
1910,immunosuppressive agents,3,5,23,47,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1910,-1,0.7832687,0.21673132
1911,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1911,-1,0.9999387,6.122484e-05
1915,myeloencephalopathy,1,2,6,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1915,-1,0.00011358823,0.9998864
1916,vincristin,6,7,56,66,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1916,-1,0.99993634,6.364449e-05
1918,acute lymphoblastic leucemia,18,21,116,144,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1918,-1,0.00011438277,0.99988556
1919,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1919,-1,0.000117210475,0.9998828
1921,sensory and motor dysfunction,12,16,70,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,-1,-1,1921,-1,0.00018941375,0.99981064
1923,degeneration of myelin and axons,12,17,92,124,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,-1,-1,-1,1923,-1,0.00036274773,0.99963725
1926,Palpebral twitching,0,2,0,19,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,-1,-1,-1,1926,-1,0.00020962949,0.9997904
1932,palpebral twitching,18,20,117,136,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,-1,1932,-1,0.0001944088,0.9998056
1941,lymphadenitis,12,13,84,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1941,-1,0.0001192135,0.9998808
1942,eosinophilic,19,20,149,161,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1942,-1,0.00023367172,0.9997663
1943,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1943,-1,0.0004204908,0.9995795
1945,autoimmunity,22,23,139,151,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1945,-1,0.00012649522,0.9998735
1947,hepatocellular necrosis,6,8,51,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1947,-1,0.00013182196,0.99986815
1948,hypersensitivity myocarditis,10,12,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1948,-1,0.0001276754,0.9998723
1949,nephritis,16,17,144,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1949,-1,0.00011612723,0.9998839
1950,bone marrow necrosis,19,22,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1950,-1,0.00018202802,0.999818
1955,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,-1,1955,-1,0.00059104885,0.99940896
1956,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,-1,1956,-1,0.0024940383,0.99750596
1958,emergency department,13,15,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,-1,1958,-1,0.00047359892,0.9995264
1963,mg,7,8,49,51,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1963,-1,0.98812497,0.011874966
1965,mg,23,24,145,147,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1965,-1,0.9929052,0.007094775
1966,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,-1,1966,-1,0.0055589774,0.994441
1967,Akathisia,0,1,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1967,-1,0.00067481206,0.99932516
1968,restlessness,9,10,56,68,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1968,-1,0.00014659711,0.9998534
1970,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1970,-1,0.009579837,0.99042016
1971,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1971,-1,0.018707149,0.9812928
1976,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,-1,1976,-1,0.0014875408,0.99851245
1979,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,-1,-1,1979,-1,0.0005051762,0.9994948
1984,nimesulide,2,3,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,-1,1984,-1,0.99991846,8.155618e-05
1986,nimesulide,6,7,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1986,-1,0.9999248,7.520402e-05
1988,NSAIDs,24,25,188,194,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1988,-1,0.9998691,0.00013086523
1989,nimesulide,9,10,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,-1,1989,-1,0.9999244,7.562725e-05
1992,nimesulide,19,20,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,-1,-1,-1,1992,-1,0.9999199,8.004433e-05
1993,nimesulide,6,7,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1993,-1,0.99992454,7.5503165e-05
1995,urticaria/angioedema,19,20,144,164,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1995,-1,0.00013574996,0.9998642
1996,nimesulide,12,13,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,-1,-1,-1,1996,-1,0.9999236,7.635129e-05
1998,nimesulide,6,7,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,-1,1998,-1,0.99992704,7.295563e-05
2003,nimesulide,10,11,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2003,-1,0.9999242,7.578174e-05
2005,NSAIDs,20,21,147,153,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,2005,-1,0.99987495,0.00012506568
2017,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2017,-1,0.000106755244,0.9998932
2018,/-SD,17,18,110,114,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,2018,-1,0.12021641,0.8797836
2023,P,18,19,109,110,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,-1,-1,-1,2023,-1,0.041628677,0.95837134
2028,P,34,35,216,217,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,-1,2028,-1,0.10028474,0.8997153
2034,hepatitis C,10,12,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,-1,2034,-1,0.00023590427,0.99976414
2035,interferon,15,16,127,137,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2035,-1,0.9998902,0.000109783556
2036,chronic hepatitis C,26,29,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2036,-1,0.00031027605,0.9996897
2037,CHC,30,31,245,248,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,2037,-1,0.00027357138,0.99972636
2039,RIHA,15,16,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,-1,2039,-1,0.002928473,0.9970715
2040,RIHA,15,16,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2040,-1,0.81226206,0.1877379
2041,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,2041,-1,0.0015883967,0.99841154
2042,RIHA,17,18,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,-1,-1,-1,2042,-1,0.01215831,0.98784167
2043,RIHA,10,11,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,-1,2043,-1,0.9994424,0.0005575877
2044,RIHA,2,3,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,-1,2044,-1,0.023603568,0.9763964
2045,RIHA,7,8,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,-1,2045,-1,0.044046775,0.95595324
2047,RIHA,9,10,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,-1,2047,-1,0.21719766,0.7828023
2048,RIHA,24,25,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,-1,2048,-1,0.02040906,0.979591
2050,RIHA,12,13,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,-1,2050,-1,0.0024950837,0.9975049
2051,RIHA,13,14,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,-1,-1,-1,2051,-1,0.99834013,0.0016598871
2053,lactate,8,9,74,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2053,-1,0.9998516,0.00014841105
2054,AIDS,11,12,96,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2054,-1,0.010936353,0.9890637
2056,CM,12,13,78,80,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2056,-1,0.00033208652,0.9996679
2057,lactate,18,19,105,112,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2057,-1,0.9998636,0.00013636674
2058,LA,20,21,114,116,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2058,-1,0.99980015,0.00019991395
2059,AIDS,23,24,121,125,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2059,-1,0.0061995317,0.99380046
2061,AIDS,12,13,87,91,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2061,-1,0.008594256,0.9914057
2062,TG,20,21,118,120,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2062,-1,0.07520226,0.9247977
2066,CM,17,18,118,120,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2066,-1,0.052585658,0.9474143
2067,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2067,-1,0.9998691,0.00013093126
2068,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2068,-1,0.99986136,0.00013860321
2070,LA,41,42,251,253,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2070,-1,0.9978719,0.0021281345
2071,TG,5,6,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,-1,-1,-1,2071,-1,0.9992151,0.0007848844
2072,ANF,2,3,13,16,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,-1,2072,-1,0.9997491,0.00025092423
2073,LA,2,3,15,17,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2073,-1,0.99969375,0.00030629302
2074,mM,10,11,44,46,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2074,-1,0.96626294,0.03373704
2075,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2075,-1,0.9863663,0.013633744
2076,TG,13,14,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2076,-1,0.99970907,0.00029095396
2077,CM,7,8,56,58,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2077,-1,0.0020271798,0.9979728
2078,LA,10,11,73,75,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2078,-1,0.083603546,0.91639644
2079,AIDS,12,13,79,83,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2079,-1,0.015859675,0.9841403
2081,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,-1,2081,-1,0.9995409,0.00045910542
2094,WR-2721,0,1,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,-1,-1,-1,2094,-1,0.9866303,0.0133697335
2097,alkylating agents,13,15,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,-1,-1,-1,2097,-1,0.9998988,0.000101232414
2112,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,-1,-1,2112,-1,0.00018337532,0.9998166
2113,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,-1,2113,-1,0.00015978495,0.99984014
2114,Neurologic toxicity,0,2,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,-1,-1,2114,-1,0.00012617426,0.99987376
2122,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,-1,-1,2122,-1,0.00012024237,0.9998797
2124,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,-1,-1,2124,-1,0.000113738235,0.9998863
2125,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2125,-1,0.9998895,0.00011048426
2127,gestodene,19,20,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2127,-1,0.9999323,6.775694e-05
2128,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2128,-1,0.99992836,7.1617615e-05
2131,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2131,-1,0.00012389306,0.99987614
2132,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2132,-1,0.00013043753,0.9998696
2133,factor V Leiden,3,6,16,31,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2133,-1,0.015363596,0.9846364
2134,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2134,-1,0.00012165541,0.9998783
2139,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,-1,2139,-1,0.00011913237,0.9998809
2143,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,-1,-1,2143,-1,0.0001133784,0.99988663
2153,mg,38,39,242,244,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2153,-1,0.9958448,0.0041551758
2155,mg,49,50,306,308,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2155,-1,0.9952957,0.0047042873
2157,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2157,-1,0.00013964059,0.9998603
2158,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2158,-1,0.00014083527,0.9998591
2163,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2163,-1,0.0001284147,0.9998716
2165,contrast,32,33,211,219,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2165,-1,0.044690978,0.95530903
2172,renal disease,1,3,10,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2172,-1,0.00015702772,0.999843
2173,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2173,-1,0.00016133644,0.9998386
2174,calcineurin inhibitors cyclosporine,3,6,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,-1,-1,2174,-1,0.99992967,7.038148e-05
2177,renal disease,18,20,100,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2177,-1,0.000180899,0.9998191
2178,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2178,-1,0.00018437959,0.99981564
2179,ESRD,9,10,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2179,-1,0.00014512091,0.9998548
2181,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2181,-1,0.00022027972,0.99977976
2182,n=834,22,23,133,138,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,-1,2182,-1,0.055273302,0.9447267
2183,CRF,10,11,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2183,-1,0.00107447,0.9989255
2184,ESRD,12,13,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2184,-1,0.00026978788,0.99973017
2185,n=748,14,15,67,72,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2185,-1,0.025011906,0.97498804
2186,CRF,16,17,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2186,-1,0.002524035,0.9974759
2188,n=41,25,26,118,122,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2188,-1,0.0077325557,0.99226743
2189,ESRD,28,29,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2189,-1,0.00021620364,0.9997838
2190,n=45,30,31,134,138,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2190,-1,0.010457602,0.98954237
2191,ESRD,17,18,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2191,-1,0.9856309,0.014369121
2192,ESRD,25,26,155,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2192,-1,0.0003744167,0.99962556
2194,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2194,-1,0.00022177091,0.9997782
2195,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2195,-1,0.00020799531,0.99979204
2196,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2196,-1,0.00086561876,0.99913436
2197,ESRD,7,8,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2197,-1,0.00084610924,0.99915385
2199,hepatorenal syndrome,22,24,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2199,-1,0.00015133445,0.9998486
2202,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2202,-1,0.00018103672,0.999819
2203,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2203,-1,0.0001712739,0.9998287
2204,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,-1,2204,-1,0.00025149327,0.9997485
2205,ESRD,2,3,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2205,-1,0.00016967441,0.99983025
2206,ESRD,10,11,62,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2206,-1,0.00016659225,0.99983335
2207,ESRD,26,27,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2207,-1,0.00016028118,0.99983966
2208,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2208,-1,0.00023175954,0.9997682
2209,ESRD,13,14,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2209,-1,0.00021090073,0.99978906
2210,ESRD,3,4,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,-1,2210,-1,0.00019184353,0.99980813
2211,ESRD,3,4,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2211,-1,0.00014689517,0.99985313
2213,hepatorenal syndrome,18,20,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2213,-1,0.00014338436,0.9998566
2215,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2215,-1,0.00025583903,0.9997441
2216,ESRD,20,21,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2216,-1,0.00025611947,0.9997439
2217,Epileptic seizures,0,2,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2217,-1,0.0001240291,0.9998759
2218,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2218,-1,0.99994195,5.8056827e-05
2219,fibrinolysis inhibitors,3,5,20,43,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2219,-1,0.6432921,0.3567079
2220,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2220,-1,0.9999403,5.967238e-05
2221,tAMCA,10,11,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2221,-1,0.9998056,0.00019435765
2222,tAMCA,2,3,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2222,-1,0.9996437,0.00035631665
2223,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2223,-1,0.000109671404,0.9998903
2224,tAMCA,5,6,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,-1,2224,-1,0.9998722,0.00012781999
2226,tAMCA,9,10,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,-1,-1,-1,2226,-1,0.9998803,0.000119680255
2227,tAMCA,4,5,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,-1,2227,-1,0.9998729,0.00012704013
2230,tAMCA,10,11,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,-1,-1,2230,-1,0.99989605,0.00010394794
2231,tAMCA,6,7,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2231,-1,0.9999229,7.714022e-05
2232,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2232,-1,0.000104806495,0.9998952
2233,n=6,15,16,85,88,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2233,-1,0.054600634,0.94539934
2234,tAMCA,22,23,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2234,-1,0.99992406,7.597493e-05
2236,contrast,1,2,3,11,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,-1,2236,-1,0.09445764,0.90554243
2237,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,-1,2237,-1,0.9999449,5.503582e-05
2239,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,-1,2239,-1,0.9997483,0.0002517565
2243,thromboemboli,19,20,126,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,-1,-1,2243,-1,0.00024081132,0.99975914
2248,thromboembolism,9,10,63,78,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2248,-1,0.00011616886,0.9998838
2249,platelet factor 4,14,17,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2249,-1,0.99951446,0.00048552037
2253,Thromboemboli,0,1,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2253,-1,0.0003186496,0.99968135
2254,pulmonary emboli,9,11,47,63,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2254,-1,0.00023337093,0.99976665
2260,thromboembolism,17,18,142,157,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,-1,-1,2260,-1,0.00012649581,0.9998735
2263,dopamine agonist,6,8,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,-1,2263,-1,0.9998814,0.00011855531
2266,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2266,-1,0.0005515051,0.9994485
2267,delayed puberty,19,21,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2267,-1,0.0001586294,0.99984133
2270,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,-1,2270,-1,0.9999411,5.8873095e-05
2272,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,-1,-1,2272,-1,0.9999409,5.9091897e-05
2273,Mental Disorders,17,19,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2273,-1,0.0018150925,0.99818486
2274,bipolar disorder,23,25,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2274,-1,0.00016615077,0.9998338
2275,psychoses,26,27,133,142,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2275,-1,0.00017737757,0.9998227
2276,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2276,-1,0.99994993,5.0087143e-05
2277,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,-1,2277,-1,0.99994075,5.9283066e-05
2278,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,-1,2278,-1,0.999946,5.397226e-05
2280,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,-1,-1,-1,2280,-1,0.99994063,5.941329e-05
2281,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,-1,2281,-1,0.99994206,5.789969e-05
2283,cholestatic hepatitis,1,3,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,-1,2283,-1,0.00020604806,0.99979395
2285,cholestatic hepatitis,8,10,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,-1,2285,-1,0.00022950956,0.99977046
2287,cholestatic hepatitis,11,13,68,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,-1,2287,-1,0.00022995488,0.9997701
2289,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2289,-1,0.99993837,6.157233e-05
2290,analgesia,9,10,59,68,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2290,-1,0.0014554913,0.9985446
2293,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,-1,-1,-1,2293,-1,0.9999443,5.5669607e-05
2294,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,-1,2294,-1,0.18051532,0.81948465
2296,cholestatic hepatitis,12,14,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,-1,2296,-1,0.00015284412,0.9998472
2297,Torsade de pointes,0,3,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2297,-1,0.0010264169,0.9989736
2299,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2299,-1,0.00052676623,0.9994733
2300,long QT syndrome,10,13,56,72,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2300,-1,0.00023169923,0.9997683
2301,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2301,-1,0.00089326425,0.9991067
2304,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2304,-1,0.00034559105,0.9996544
2305,torsade de pointes,15,18,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2305,-1,0.0005263439,0.99947363
2307,torsade de pointes,4,7,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2307,-1,0.00034070076,0.9996593
2309,erythromycin,10,11,66,78,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2309,-1,0.9999273,7.270741e-05
2311,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,-1,2311,-1,0.0006975214,0.9993025
2313,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,-1,2313,-1,0.001070127,0.9989299
2317,DA,2,3,10,12,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2317,-1,0.9998267,0.00017330139
2318,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2318,-1,0.00010699126,0.99989295
2319,Excitotoxicity,0,1,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2319,-1,0.00011825476,0.99988174
2322,DA,11,12,51,53,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2322,-1,0.99986196,0.00013799185
2327,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2327,-1,0.9999378,6.220258e-05
2328,KA,12,13,75,77,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2328,-1,0.99986684,0.00013316024
2333,neuronal death,9,11,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2333,-1,0.00011536522,0.9998846
2334,KA,21,22,128,130,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2334,-1,0.9997973,0.00020270806
2338,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,-1,2338,-1,0.000109093664,0.9998909
2340,pregnenolone sulphate,10,12,87,108,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,-1,2340,-1,0.9999274,7.2622526e-05
2341,Pregnenolone sulphate,0,2,0,21,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2341,-1,0.99991834,8.159966e-05
2342,PREGS,3,4,23,28,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2342,-1,0.99925977,0.00074021635
2344,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,-1,2344,-1,0.98268133,0.017318653
2345,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2345,-1,0.9767337,0.023266327
2346,NMDAR,11,12,63,68,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2346,-1,0.999871,0.00012892533
2347,PREGS,18,19,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,-1,2347,-1,0.9992731,0.0007268684
2348,11-ketopregnenolone sulphate,5,7,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2348,-1,0.99989057,0.00010941986
2349,epipregnanolone,19,20,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2349,-1,0.99989176,0.00010826408
2350,sulphate,24,25,161,169,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2350,-1,0.99976987,0.00023019312
2351,PREGS,42,43,243,248,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2351,-1,0.99346054,0.006539457
2352,PREGS,49,50,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2352,-1,0.9941214,0.005878604
2353,PREGS,4,5,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,-1,2353,-1,0.9989116,0.0010884436
2355,PREGS,1,2,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,-1,2355,-1,0.9903736,0.00962643
2357,PREGS,6,7,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2357,-1,0.50244176,0.4975582
2358,11-ketopregnenolone sulphate,8,10,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2358,-1,0.99990165,9.834818e-05
2359,epipregnanolone sulphate,11,13,70,94,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2359,-1,0.99990666,9.3371105e-05
2361,NMDA,27,28,181,185,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2361,-1,0.9998042,0.00019579135
2362,PREGS,34,35,239,244,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2362,-1,0.8981861,0.10181392
2363,PREGS,10,11,72,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,-1,-1,2363,-1,0.9945716,0.005428411
2366,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,-1,-1,2366,-1,0.000104517065,0.99989545
2367,damage,14,15,92,98,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2367,-1,0.00021388917,0.9997861
2368,dysfunction,21,22,131,142,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2368,-1,0.00011762979,0.99988234
2369,tissue injury,23,25,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2369,-1,0.00017236435,0.9998276
2372,DOX,14,15,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,-1,-1,2372,-1,0.9998227,0.00017730317
2375,PJ34,19,20,136,140,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2375,-1,0.99976784,0.00023214413
2377,DOX,36,37,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2377,-1,0.9998629,0.00013708485
2378,DOX,9,10,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,-1,2378,-1,0.9998604,0.00013957484
2379,DOX,3,4,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,-1,2379,-1,0.99983585,0.00016412631
2381,PJ34,9,10,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,-1,2381,-1,0.9998946,0.000105354295
2382,PJ34,3,4,17,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,-1,-1,2382,-1,0.9996487,0.00035134982
2384,PJ34,2,3,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2384,-1,0.9997837,0.00021637462
2385,lactate,11,12,77,84,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2385,-1,0.9998783,0.00012175429
2386,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2386,-1,0.99986446,0.00013553088
2388,DOX,9,10,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,-1,2388,-1,0.99979204,0.00020800563
2389,cardiac complications,11,13,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2389,-1,0.00010709957,0.99989283
2390,DOX,16,17,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2390,-1,0.9998228,0.00017717505
2392,amphotericin,11,12,57,69,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2392,-1,0.9999199,8.0113365e-05
2393,hypokalemia,13,14,80,91,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2393,-1,0.000105480154,0.9998945
2396,amphotericin B,25,27,168,182,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2396,-1,0.99992645,7.354959e-05
2397,AmB,28,29,184,187,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2397,-1,0.999701,0.00029905132
2400,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2400,-1,0.85001355,0.14998645
2402,tubular toxicity,30,32,205,221,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2402,-1,0.00013054491,0.99986947
2403,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2403,-1,0.8399223,0.16007768
2406,hypokalemia,51,52,342,353,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2406,-1,0.00011411641,0.9998859
2407,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2407,-1,0.00012128983,0.99987864
2408,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2408,-1,0.99982965,0.00017036244
2409,hematological disorders,9,11,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2409,-1,0.00011005588,0.99988997
2410,AmB,17,18,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2410,-1,0.99987996,0.000120064666
2411,AmB,20,21,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2411,-1,0.99988353,0.00011647601
2413,mg,25,26,163,165,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2413,-1,0.99932134,0.00067862717
2414,fungal infection,34,36,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2414,-1,0.00013938226,0.99986064
2415,AmB,5,6,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2415,-1,0.99987435,0.00012563019
2418,AmB,17,18,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2418,-1,0.9998647,0.00013529173
2419,P,20,21,144,145,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2419,-1,0.103617415,0.8963826
2420,AmB,3,4,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2420,-1,0.9997968,0.00020316218
2424,P,21,22,162,163,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2424,-1,0.17026962,0.8297304
2426,AmB,11,12,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2426,-1,0.9998759,0.00012402449
2428,AmB,17,18,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2428,-1,0.99985516,0.00014478905
2429,P,20,21,136,137,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2429,-1,0.11970633,0.88029367
2432,hypokalemia,13,14,96,107,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2432,-1,0.00014800306,0.99985194
2434,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2434,-1,0.00014417377,0.99985576
2435,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2435,-1,0.9997266,0.00027333284
2452,hemorrhaging,11,12,83,95,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,-1,2452,-1,0.00011174576,0.9998883
2457,circulatory failure,20,22,148,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2457,-1,0.00014381432,0.9998561
2458,hemorrhaging,23,24,175,187,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2458,-1,0.000110062494,0.99988997
2462,Erectile dysfunction,0,2,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2462,-1,0.0001729717,0.9998271
2464,of the,1,3,8,14,Lesions of the substantia nigra were confirmed by histology.,11890511_4,-1,-1,-1,2464,-1,0.05969506,0.94030493
2466,erectile dysfunction,9,11,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2466,-1,0.0001556181,0.9998443
2467,erectile dysfunction,21,23,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2467,-1,0.00014771982,0.9998523
2468,Parkinson's disease,24,27,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2468,-1,0.00026644638,0.9997335
2469,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,-1,-1,2469,-1,0.00010578577,0.99989426
2473,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,-1,2473,-1,0.999931,6.9033034e-05
2474,h,9,10,51,52,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,-1,-1,2474,-1,0.06917628,0.93082374
2476,infarct,8,9,61,68,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2476,-1,0.00014276798,0.9998572
2477,h,10,11,72,73,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2477,-1,0.01917144,0.9808286
2479,contrast,7,8,42,50,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2479,-1,0.006237351,0.9937627
2480,h,17,18,95,96,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2480,-1,0.2875984,0.7124016
2481,cardiac infarction,31,33,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2481,-1,0.00010742043,0.9998926
2494,mecamylamine,7,8,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,-1,2494,-1,0.99994504,5.5009325e-05
2508,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,-1,2508,-1,0.005544399,0.99445564
2512,Parkinson's disease,6,9,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,-1,2512,-1,0.0002256148,0.9997744
2513,Parkinson's disease,8,11,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2513,-1,0.0001975501,0.99980253
2516,LID,26,27,177,180,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2516,-1,0.00025220113,0.9997478
2517,Parkinson's disease,5,8,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2517,-1,0.00032766894,0.9996723
2518,Parkinson's disease,11,14,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2518,-1,0.00027954226,0.9997204
2519,LID,15,16,82,85,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2519,-1,0.00024855405,0.9997514
2520,n,17,18,87,88,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2520,-1,0.025694666,0.97430533
2522,Parkinson's disease,26,29,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2522,-1,0.0002763541,0.9997236
2523,LID,30,31,159,162,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2523,-1,0.00018981096,0.99981016
2524,n,32,33,164,165,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2524,-1,0.012369954,0.98763007
2525,Parkinson's Disease,6,9,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,-1,2525,-1,0.00082580507,0.9991742
2528,Parkinson's disease,10,13,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2528,-1,0.00032877387,0.9996712
2529,LID,14,15,80,83,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2529,-1,0.045885105,0.9541149
2530,Parkinson's disease,1,4,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2530,-1,0.00039986512,0.9996001
2531,LID,5,6,25,28,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2531,-1,0.0006062556,0.9993937
2533,P,27,28,141,142,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2533,-1,0.18081203,0.819188
2534,P,10,11,43,44,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2534,-1,0.047283173,0.9527168
2535,P,23,24,86,87,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2535,-1,0.04084749,0.9591525
2536,contrast,1,2,3,11,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2536,-1,0.06314242,0.9368576
2537,Parkinson's disease,9,12,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2537,-1,0.00044309782,0.99955684
2538,LID,13,14,67,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2538,-1,0.00047144527,0.9995285
2539,P,9,10,38,39,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2539,-1,0.096143104,0.9038569
2540,Parkinson's disease,15,18,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2540,-1,0.0005701157,0.9994299
2541,LID,19,20,80,83,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2541,-1,0.0005519454,0.999448
2542,Parkinson's disease,22,25,92,111,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2542,-1,0.00072335324,0.9992767
2543,LID,26,27,114,117,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2543,-1,0.0005232944,0.99947673
2545,P,20,21,113,114,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,-1,2545,-1,0.16498934,0.83501065
2546,LID,8,9,48,51,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,-1,-1,-1,2546,-1,0.0011697342,0.99883026
2548,LID,4,5,23,26,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,-1,2548,-1,0.99787617,0.002123898
2550,Zyban,2,3,11,16,Bupropion (Zyban) toxicity.,11928786_0,-1,-1,-1,2550,-1,0.9998191,0.00018098236
2555,Zyban,0,1,0,5,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2555,-1,0.998066,0.0019339739
2556,bupropion hydrochloride,6,8,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2556,-1,0.999933,6.699072e-05
2561,drowsiness,5,6,38,48,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,-1,-1,2561,-1,0.0001394413,0.9998605
2571,Zyban,0,1,0,5,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2571,-1,0.99988496,0.00011507705
2572,cardiovascular toxicity,5,7,42,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2572,-1,0.00013809426,0.99986184
2576,PAN nephrosis,9,11,52,65,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,-1,-1,-1,2576,-1,0.00014714205,0.9998529
2578,glomerular injury,11,13,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,-1,2578,-1,0.00013528709,0.9998647
2579,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2579,-1,0.1637386,0.83626145
2580,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2580,-1,0.99993515,6.4813954e-05
2581,PAN,13,14,114,117,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2581,-1,0.9997631,0.0002369493
2582,PAN,21,22,68,71,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,-1,2582,-1,0.99897134,0.0010287024
2586,p,42,43,177,178,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,-1,2586,-1,0.10401993,0.89598006
2587,p,23,24,111,112,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,-1,2587,-1,0.050101887,0.94989806
2588,contrast,1,2,3,11,"In contrast, podocalyxin did not change significantly at this time.",11961407_9,-1,-1,-1,2588,-1,0.2207588,0.7792412
2589,PAN,14,15,92,95,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,-1,-1,-1,2589,-1,0.9991897,0.000810275
2590,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,-1,2590,-1,0.99986947,0.00013046851
2591,dizocilpine,3,4,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2591,-1,0.9999249,7.514589e-05
2592,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2592,-1,0.9997732,0.00022675995
2593,NMDA,12,13,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2593,-1,0.9998599,0.00014007912
2595,behavioral,4,5,22,32,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2595,-1,0.00023725379,0.9997627
2596,Parkinson's disease,12,15,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2596,-1,0.00019637111,0.9998036
2597,tardive dyskinesia,17,19,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2597,-1,0.000105309606,0.99989474
2599,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2599,-1,0.00016484759,0.99983513
2600,tardive dyskinesia,34,36,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2600,-1,0.00010333618,0.99989665
2604,Parkinson's disease,12,15,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,-1,-1,2604,-1,0.00024114267,0.9997589
2605,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,-1,2605,-1,0.9998758,0.00012421315
2608,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,-1,2608,-1,0.9998851,0.00011493601
2611,apomophine,15,16,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2611,-1,0.9999335,6.650265e-05
2616,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,-1,-1,2616,-1,0.9998853,0.000114661896
2621,h,8,9,41,42,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2621,-1,0.16809268,0.83190733
2624,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2624,-1,0.9998878,0.00011221292
2627,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2627,-1,0.00011463226,0.9998853
2628,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2628,-1,0.0003774846,0.99962246
2629,NMDA,5,6,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,-1,2629,-1,0.99987936,0.00012056764
2632,visual disturbances,4,6,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2632,-1,0.00011547319,0.9998845
2634,LSD,14,15,110,113,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2634,-1,0.99976903,0.0002309381
2636,LSD,10,11,55,58,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2636,-1,0.99977356,0.00022641191
2637,EPS,17,18,98,101,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2637,-1,0.00027383026,0.9997261
2638,antipsychotics,20,21,115,129,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2638,-1,0.9998591,0.00014083285
2640,visual disturbances,7,9,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,-1,-1,-1,2640,-1,0.00012546235,0.9998745
2642,visual disturbances,3,5,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2642,-1,0.00017568142,0.99982435
2643,LSD,14,15,99,102,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2643,-1,0.999782,0.00021801579
2645,visual disturbances,6,8,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,-1,-1,-1,2645,-1,0.00014393848,0.999856
2646,visual disturbances,11,13,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,-1,2646,-1,0.00015363094,0.99984634
2648,Antithymocyte globulin,0,2,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,-1,-1,2648,-1,0.9994685,0.0005314896
2650,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,-1,2650,-1,0.9998615,0.00013850757
2652,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,-1,-1,2652,-1,0.9997813,0.00021865903
2655,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2655,-1,0.9999443,5.564689e-05
2656,refractory seizures,19,21,136,155,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2656,-1,0.00011018052,0.99988985
2658,lead,23,24,138,142,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2658,-1,0.0020387482,0.9979613
2659,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2659,-1,0.009943697,0.9900563
2661,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,-1,2661,-1,0.99993634,6.3658816e-05
2665,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,-1,2665,-1,0.9999213,7.862406e-05
2666,charcoal,23,24,148,156,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2666,-1,0.9993587,0.0006413428
2668,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2668,-1,0.99994266,5.7292888e-05
2671,P<0.05,16,17,102,108,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,-1,2671,-1,0.06884074,0.93115926
2674,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,-1,-1,2674,-1,0.99994385,5.6159148e-05
2677,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2677,-1,0.999941,5.901058e-05
2678,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2678,-1,0.00011923283,0.9998808
2679,Ifosfamide encephalopathy,0,2,0,25,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,-1,-1,2679,-1,0.29047328,0.7095267
2681,antineoplastic,5,6,25,39,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2681,-1,0.010939727,0.9890603
2683,IFX,9,10,58,61,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2683,-1,0.9978794,0.0021206734
2684,neurological symptoms,18,20,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2684,-1,0.00011452662,0.99988544
2687,plasmacytoma,27,28,161,173,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,-1,-1,2687,-1,0.00013765188,0.9998623
2688,structural lesions of the brain,11,16,85,116,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2688,-1,0.0005384389,0.9994616
2689,metabolic abnormalities,17,19,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2689,-1,0.00019160843,0.9998084
2692,h,9,10,64,65,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,-1,-1,2692,-1,0.020453023,0.97954696
2697,IFX,41,42,265,268,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,-1,2697,-1,0.97787243,0.022127617
2701,thymidine,6,7,37,46,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,-1,2701,-1,0.9998592,0.0001407566
2702,thymidine,18,19,150,159,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,-1,2702,-1,0.999874,0.00012603239
2712,analgesia,11,12,85,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,-1,2712,-1,0.00046851317,0.9995315
2713,h,11,12,70,71,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,-1,2713,-1,0.017669542,0.98233044
2716,adenovirus disease,5,7,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,-1,-1,-1,2716,-1,0.0020611824,0.9979388
2717,adenovirus disease,4,6,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,-1,2717,-1,0.0039691934,0.99603075
2718,antiviral agents,4,6,22,38,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2718,-1,0.9996013,0.000398705
2719,adenovirus disease,14,16,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2719,-1,0.0019947866,0.9980052
2720,adenovirus disease,8,10,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,-1,2720,-1,0.0019702886,0.99802965
2722,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,-1,-1,-1,2722,-1,0.9999471,5.2964147e-05
2724,guanosine,3,4,13,22,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,-1,2724,-1,0.99991524,8.471525e-05
2726,respiratory syncytial virus infection,10,14,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2726,-1,0.00037085722,0.99962914
2727,interferon,20,21,129,139,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2727,-1,0.9998765,0.00012345023
2728,hepatitis C.,23,25,149,161,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2728,-1,0.011541034,0.98845893
2730,infection with hemorrhagic fever viruses,33,38,215,255,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2730,-1,0.00079581834,0.9992042
2733,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2733,-1,0.9999479,5.2124615e-05
2734,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2734,-1,0.004563919,0.99543613
2737,adenovirus disease,12,14,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,-1,-1,-1,2737,-1,0.00092135515,0.99907863
2739,adenovirus disease,18,20,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,-1,2739,-1,0.0009162811,0.99908376
2740,hemorrhagic cystitis,4,6,34,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,-1,-1,2740,-1,0.00012772848,0.9998722
2741,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2741,-1,0.9999403,5.9772792e-05
2742,pneumonia,6,7,46,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2742,-1,0.000121098805,0.9998789
2743,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2743,-1,0.0003000337,0.99969995
2745,hemorrhagic cystitis,22,24,147,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2745,-1,0.00012096528,0.999879
2746,pneumonia,30,31,216,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2746,-1,0.00012306699,0.999877
2747,adenovirus disease,6,8,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,-1,-1,-1,2747,-1,0.0035492596,0.9964508
2749,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2749,-1,0.9999496,5.0421648e-05
2750,progressive renal failure,9,12,48,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2750,-1,0.00011821226,0.99988174
2752,adenovirus disease,19,21,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2752,-1,0.0017562949,0.9982437
2753,immunodeficiency,35,36,233,249,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2753,-1,0.00012544704,0.9998746
2755,adenovirus disease,11,13,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,-1,-1,2755,-1,0.0010150688,0.9989849
2757,adenovirus disease,15,17,96,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,-1,2757,-1,0.00811447,0.99188554
2758,adenovirus disease,8,10,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,-1,2758,-1,0.0009113064,0.99908864
2760,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,-1,2760,-1,0.017257085,0.9827429
2761,adenovirus disease,7,9,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,-1,2761,-1,0.0029991884,0.99700075
2763,asystolic cardiac arrest,1,4,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2763,-1,0.00019282944,0.9998072
2764,diltiazem overdose,5,7,39,57,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2764,-1,0.19499087,0.8050091
2770,isosorbide nitrate,21,23,96,114,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,-1,-1,2770,-1,0.99992526,7.474231e-05
2773,charcoal,16,17,104,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,-1,2773,-1,0.9998543,0.00014566368
2777,asystolic,15,16,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,-1,-1,2777,-1,0.00038623443,0.9996138
2782,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,-1,2782,-1,0.15443613,0.84556395
2785,diltiazem overdose,11,13,63,81,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,-1,-1,2785,-1,0.17675714,0.8232429
2788,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2788,-1,0.99972016,0.0002797777
2789,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2789,-1,0.99927706,0.00072292285
2791,LMWH,3,4,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2791,-1,0.99984396,0.00015602491
2792,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2792,-1,0.8399604,0.16003963
2793,UH,23,24,151,153,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2793,-1,0.90212375,0.09787624
2794,LMWH,20,21,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,-1,2794,-1,0.9999083,9.160775e-05
2795,LMWH,11,12,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,-1,-1,-1,2795,-1,0.99986947,0.00013049885
2797,n,21,22,123,124,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2797,-1,0.021557495,0.9784425
2798,n,34,35,192,193,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2798,-1,0.012217026,0.987783
2799,c,40,41,203,204,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2799,-1,0.08393695,0.916063
2800,n,50,51,244,245,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2800,-1,0.011692199,0.9883078
2801,n,63,64,282,283,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2801,-1,0.016795771,0.98320425
2802,thromboembolism,4,5,22,37,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2802,-1,0.00013453003,0.9998654
2803,c,28,29,106,107,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2803,-1,0.27371767,0.7262823
2805,LMWH,10,11,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2805,-1,0.9999217,7.834311e-05
2806,UH,15,16,103,105,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2806,-1,0.9354183,0.06458164
2807,LMWH,5,6,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,-1,2807,-1,0.9999162,8.374841e-05
2808,LMWH,16,17,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,-1,2808,-1,0.99991095,8.9012145e-05
2816,mg,5,6,39,41,The patient received metoclopramide 10 mg i.v.,12139551_2,-1,-1,-1,2816,-1,0.9894181,0.010581935
2821,mg,7,8,36,38,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,-1,-1,-1,2821,-1,0.9959571,0.0040429477
2825,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,-1,-1,2825,-1,0.000401127,0.9995989
2826,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2826,-1,0.99989414,0.00010589002
2828,arteritis,27,28,151,160,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2828,-1,0.00013138173,0.99986863
2829,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2829,-1,0.9999441,5.5964603e-05
2831,vasodilators,36,37,209,221,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2831,-1,0.98924667,0.010753291
2832,Arteritis,0,1,0,9,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2832,-1,0.00013460228,0.9998654
2833,vasodilators,5,6,29,41,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2833,-1,0.9601743,0.039825734
2834,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2834,-1,0.99994135,5.86073e-05
2836,nitric oxide synthase,20,23,144,165,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2836,-1,0.99925774,0.00074229884
2838,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,-1,2838,-1,0.99994516,5.4849035e-05
2841,arteritis,31,32,172,181,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,-1,2841,-1,0.00014211726,0.9998579
2843,cholinergic agents,19,21,140,158,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,-1,-1,2843,-1,0.99986935,0.0001306372
2849,neostigmine,8,9,50,61,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,-1,2849,-1,0.9999287,7.1314076e-05
2852,ACh,11,12,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,-1,-1,2852,-1,0.9998343,0.00016568325
2854,ACh,1,2,12,15,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,-1,-1,2854,-1,0.99817204,0.0018279065
2859,neostigmine,14,15,89,100,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,-1,2859,-1,0.9999312,6.874071e-05
2860,ACh,13,14,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2860,-1,0.99979514,0.00020485604
2861,mM KCl,17,19,87,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2861,-1,0.9997124,0.000287543
2862,ACh,20,21,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2862,-1,0.9998048,0.00019524568
2863,ACh,7,8,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2863,-1,0.99962807,0.0003719245
2864,KCl,14,15,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2864,-1,0.99988234,0.00011763248
2865,ACh,2,3,17,20,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2865,-1,0.99961084,0.0003891673
2867,ACh,12,13,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2867,-1,0.9998116,0.00018842428
2868,convulsants,15,16,120,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,-1,2868,-1,0.66594833,0.33405167
2871,convulsants,10,11,65,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,-1,2871,-1,0.5818863,0.41811374
2872,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,-1,-1,2872,-1,0.0001140273,0.9998859
2873,painful temporomandibular disorders,3,6,23,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2873,-1,0.0002852744,0.9997147
2874,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2874,-1,0.00021412934,0.99978584
2875,nociceptive,8,9,52,63,This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw-stretch reflex and whether this process would be sensitive to length and velocity of the stretch.,12202650_2,-1,-1,-1,2875,-1,0.0003876827,0.9996124
2880,painful,17,18,106,113,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,-1,2880,-1,0.0001633963,0.99983656
2881,muscle pain,8,10,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,-1,-1,2881,-1,0.00012976378,0.9998702
2884,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,-1,2884,-1,0.00011264678,0.99988735
2885,AIDA,3,4,41,45,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,-1,2885,-1,0.99972135,0.0002786384
2886,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2886,-1,0.9996865,0.0003135525
2887,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2887,-1,0.00010483907,0.9998951
2888,contrast,1,2,3,11,"In contrast, 2R,4R-APDC injections were ineffective.",12231232_5,-1,-1,-1,2888,-1,0.09161314,0.9083868
2889,parkinsonian muscle rigidity,23,26,129,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,-1,-1,-1,2889,-1,0.00010874915,0.9998913
2893,GR 55562,21,23,128,136,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2893,-1,0.9997819,0.00021815595
2894,CP 93129,31,33,176,184,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2894,-1,0.9996797,0.0003203823
2895,GR 55562,7,9,39,47,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2895,-1,0.9997712,0.00022885118
2896,CP 93129,16,18,72,80,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2896,-1,0.99972683,0.00027315153
2898,GR 55562,0,2,0,8,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,-1,-1,2898,-1,0.9997298,0.000270216
2901,GR 55562,12,14,71,79,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,-1,-1,-1,2901,-1,0.9998288,0.00017120564
2903,CP 93129,15,17,74,82,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,-1,2903,-1,0.9997503,0.00024973968
2905,GR 55562,10,12,80,88,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,-1,-1,-1,2905,-1,0.9998136,0.00018636163
2907,hyperlocomotion,6,7,43,58,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2907,-1,0.0001554517,0.99984455
2908,GR 55562,37,39,255,263,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2908,-1,0.9992606,0.0007394331
2909,CP 93129,43,45,278,286,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2909,-1,0.99951947,0.00048051612
2911,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,-1,2911,-1,0.00013619623,0.99986374
2915,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2915,-1,0.00011933281,0.9998807
2916,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2916,-1,0.00012396491,0.999876
2917,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,-1,2917,-1,0.00012035111,0.9998796
2921,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,-1,2921,-1,0.00025097755,0.999749
2924,renal cell cancer,15,18,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,-1,2924,-1,0.0002464487,0.99975353
2931,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,-1,2931,-1,0.00038020354,0.9996197
2933,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,-1,2933,-1,0.00020493557,0.99979514
2936,postoperative myalgia?This,5,7,45,71,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,-1,-1,2936,-1,0.0016813802,0.9983187
2939,blind,17,18,99,104,"One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner.",12452237_1,-1,-1,-1,2939,-1,0.2319068,0.76809317
2940,PS,1,2,6,8,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2940,-1,0.041811917,0.95818806
2942,mg,13,14,76,78,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2942,-1,0.98252016,0.017479872
2944,mg,23,24,113,115,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2944,-1,0.98498684,0.015013197
2946,mg,30,31,149,151,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2946,-1,0.98008096,0.019919036
2947,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2947,-1,0.9999447,5.534123e-05
2948,mg,43,44,205,207,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2948,-1,0.9838154,0.016184578
2950,mg,2,3,13,15,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,-1,2950,-1,0.98452467,0.015475363
2951,thiopental,7,8,40,50,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2951,-1,0.9999337,6.630528e-05
2953,PS,15,16,90,92,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2953,-1,0.85819983,0.14180015
2954,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2954,-1,0.99994326,5.670369e-05
2957,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2957,-1,0.00018076366,0.9998192
2958,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2958,-1,0.00017136341,0.9998286
2959,PS,29,30,170,172,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2959,-1,0.40649343,0.5935066
2960,p,31,32,174,175,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2960,-1,0.0468419,0.9531581
2961,h,2,3,6,7,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2961,-1,0.022830248,0.9771698
2963,PS,12,13,54,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2963,-1,0.40512237,0.59487766
2964,p,20,21,82,83,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2964,-1,0.06849432,0.9315057
2966,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,-1,-1,2966,-1,0.00014582503,0.9998542
2969,postoperative myalgia,21,23,123,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,-1,-1,2969,-1,0.00013225594,0.9998677
2971,mg,9,10,67,69,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,-1,2971,-1,0.99718934,0.002810665
2976,mg,14,15,102,104,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2976,-1,0.9913463,0.008653684
2978,mg,22,23,146,148,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2978,-1,0.99374545,0.0062545347
2981,p,25,26,131,132,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,-1,-1,-1,2981,-1,0.080698065,0.9193019
2985,h,9,10,48,49,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,-1,2985,-1,0.015493193,0.9845068
2988,h,8,9,48,49,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2988,-1,0.022336707,0.9776633
2990,p,20,21,123,124,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2990,-1,0.042407934,0.95759207
2992,h,32,33,176,177,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2992,-1,0.019805338,0.9801947
2994,h,4,5,21,22,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2994,-1,0.010310563,0.98968947
2996,p,16,17,84,85,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2996,-1,0.042696834,0.9573031
3000,h,12,13,62,63,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,3000,-1,0.023328764,0.9766713
3001,p,35,36,185,186,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,3001,-1,0.04513204,0.954868
3003,"nausea, vomiting",13,16,92,108,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3003,-1,0.000236348,0.99976367
3004,phonophobia,17,18,110,121,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3004,-1,0.00014586827,0.9998541
3005,photophobia,19,20,125,136,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3005,-1,0.00014243186,0.99985754
3006,h,27,28,177,178,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3006,-1,0.028488545,0.9715115
3007,p,32,33,198,199,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,3007,-1,0.06400296,0.93599707
3008,h,12,13,62,63,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3008,-1,0.050894387,0.94910556
3010,h,24,25,115,116,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3010,-1,0.035420053,0.9645799
3011,p,33,34,166,167,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,3011,-1,0.04769462,0.95230544
3022,sodium channels,17,19,109,124,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,-1,-1,-1,3022,-1,0.84669226,0.15330772
3024,sodium channels,34,36,219,234,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,-1,3024,-1,0.97267455,0.027325392
3025,contrast,1,2,3,11,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,-1,3025,-1,0.036707975,0.963292
3031,glioblastomas,12,13,93,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,-1,-1,3031,-1,0.00023280778,0.99976724
3033,malignant tumor,5,7,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,-1,-1,3033,-1,0.00026746676,0.99973255
3041,glioblastomas,13,14,88,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,-1,3041,-1,0.00023932195,0.9997607
3043,visual disturbance,5,7,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3043,-1,0.00017363121,0.9998264
3044,h,12,13,71,72,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,3044,-1,0.027900109,0.9720999
3045,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,-1,3045,-1,0.17748341,0.82251656
3047,glycerin,11,12,79,87,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,-1,3047,-1,0.99992454,7.542832e-05
3049,ocular pain,13,15,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3049,-1,0.00012372022,0.99987626
3050,papilledema,18,19,142,153,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3050,-1,0.00014989584,0.99985003
3051,retinal detachment,21,23,168,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,3051,-1,0.00013658263,0.9998634
3052,chorioretinal atrophy,7,9,32,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3052,-1,0.0002012009,0.99979883
3053,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,3053,-1,0.0001503787,0.99984956
3068,absence seizures,4,6,37,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,-1,3068,-1,0.0001246315,0.9998753
3069,absence epilepsy,8,10,48,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,-1,-1,3069,-1,0.00012196066,0.99987805
3072,absence seizure,11,13,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,-1,3072,-1,0.00012754483,0.99987245
3073,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,-1,3073,-1,0.00012374099,0.99987626
3074,absence seizure,4,6,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,-1,3074,-1,0.0001484855,0.99985147
3075,absence seizure,21,23,136,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,-1,-1,3075,-1,0.00012338364,0.9998766
3078,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3078,-1,0.00011103165,0.9998889
3080,absence seizures,24,26,168,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3080,-1,0.000108518965,0.9998915
3084,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,-1,3084,-1,0.00011389223,0.99988604
3093,deterioration of renal function,7,11,44,75,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,-1,-1,3093,-1,0.00026192947,0.99973804
3094,acute liver injury,7,10,57,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,-1,-1,3094,-1,0.00011160923,0.9998884
3105,acute liver insult,10,13,62,80,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,-1,3105,-1,0.000113802234,0.99988616
3108,pyeloureteritis cystica,3,5,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,-1,-1,3108,-1,0.001333365,0.99866664
3113,thrombophlebitis,13,14,90,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,-1,-1,-1,3113,-1,0.00011869116,0.99988127
3114,pyeloureteritis cystica,15,17,98,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3114,-1,0.0007738567,0.9992261
3115,submucosal hemorrhage,18,20,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3115,-1,0.00017217593,0.99982774
3117,contrast medium,6,8,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,-1,-1,3117,-1,0.99968314,0.0003168931
3119,contrast medium,2,4,20,35,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3119,-1,0.9998266,0.00017343265
3121,contrast medium,9,11,73,88,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3121,-1,0.99983335,0.00016662116
3123,contrast medium,24,26,152,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3123,-1,0.99902606,0.00097393343
3125,contrast medium,38,40,229,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3125,-1,0.9993685,0.0006315853
3126,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3126,-1,0.99994016,5.9815837e-05
3129,mg,15,16,97,99,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,-1,-1,3129,-1,0.97251546,0.02748458
3132,mg,12,13,73,75,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3132,-1,0.84549403,0.15450597
3133,mg,22,23,118,120,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3133,-1,0.8278194,0.17218058
3138,mg,15,16,67,69,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3138,-1,0.63914955,0.36085042
3140,mg,24,25,116,118,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3140,-1,0.47657752,0.5234225
3141,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3141,-1,0.99994826,5.175852e-05
3142,P=0.001,32,33,155,162,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3142,-1,0.058261123,0.9417389
3144,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3144,-1,0.99994516,5.4801094e-05
3145,mg,45,46,231,233,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3145,-1,0.6641701,0.33582988
3148,mg,22,23,113,115,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3148,-1,0.8348764,0.16512355
3149,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3149,-1,0.9999478,5.2218547e-05
3150,P=0.002,45,46,213,220,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3150,-1,0.048617274,0.95138276
3153,mg,9,10,54,56,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3153,-1,0.87503135,0.12496868
3154,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3154,-1,0.9999474,5.2562475e-05
3156,mg,15,16,77,79,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3156,-1,0.72989327,0.27010673
3158,mg,24,25,126,128,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3158,-1,0.6329464,0.36705357
3159,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3159,-1,0.99994826,5.1685027e-05
3160,P=0.003,32,33,165,172,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3160,-1,0.057067316,0.94293267
3162,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3162,-1,0.99994695,5.2986576e-05
3163,mg,48,49,247,249,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3163,-1,0.7314217,0.2685783
3165,contrast medium,5,7,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3165,-1,0.99986005,0.00013993225
3167,contrast medium,26,28,163,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3167,-1,0.9998203,0.00017967969
3173,increase in blood pressure,15,19,101,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,-1,-1,3173,-1,0.00023873535,0.9997613
3176,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,-1,3176,-1,0.49506631,0.50493366
3180,reduction in glomeruli,19,22,99,121,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3180,-1,0.00082670763,0.9991732
3181,P<0.05,31,32,165,171,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3181,-1,0.070834495,0.9291655
3183,elevated blood pressures,23,26,108,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,-1,3183,-1,0.0013216421,0.9986784
3192,reduction in glomeruli,8,11,48,70,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,-1,-1,3192,-1,0.0003618475,0.9996382
3196,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,-1,-1,-1,3196,-1,0.9999267,7.33602e-05
3200,SRL,4,5,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3200,-1,0.99977976,0.0002201997
3201,calcineurin inhibitors,8,10,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3201,-1,0.99992275,7.724262e-05
3203,SRL,5,6,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,-1,3203,-1,0.9998753,0.00012464968
3205,SRL,7,8,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,-1,3205,-1,0.999648,0.0003519922
3207,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3207,-1,0.99992394,7.5992975e-05
3208,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3208,-1,0.999884,0.0001159347
3210,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3210,-1,0.99991524,8.478646e-05
3211,SRL,37,38,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3211,-1,0.9998337,0.00016626978
3212,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3212,-1,0.99988306,0.00011688802
3213,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3213,-1,0.9999311,6.895093e-05
3214,SRL,25,26,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3214,-1,0.9998822,0.00011774515
3215,Cr(EDTA,22,23,113,120,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,-1,-1,-1,3215,-1,0.999806,0.00019405656
3219,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3219,-1,0.99988043,0.0001195231
3220,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3220,-1,0.9999188,8.11222e-05
3221,SRL,6,7,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3221,-1,0.9998833,0.000116665644
3222,CsA,6,7,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3222,-1,0.99987817,0.0001218486
3223,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3223,-1,0.9999267,7.3302144e-05
3224,SRL,13,14,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3224,-1,0.9999007,9.926616e-05
3225,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3225,-1,0.9999263,7.367525e-05
3226,SRL,27,28,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3226,-1,0.99989617,0.00010380936
3227,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3227,-1,0.9998852,0.00011474524
3228,SRL,13,14,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3228,-1,0.9998926,0.000107390115
3229,P<0.001,15,16,94,101,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3229,-1,0.042880006,0.95711994
3231,P<0.02,45,46,274,280,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3231,-1,0.05668485,0.94331515
3232,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3232,-1,0.99992585,7.411129e-05
3233,SRL,3,4,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3233,-1,0.99988115,0.00011889495
3235,P=0.05,18,19,109,115,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3235,-1,0.100898646,0.8991013
3237,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3237,-1,0.999884,0.00011600228
3238,SRL,13,14,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3238,-1,0.99988604,0.00011393036
3239,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3239,-1,0.99992955,7.045884e-05
3240,SRL,18,19,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3240,-1,0.9998796,0.00012041356
3241,troponin I,3,5,22,32,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,-1,-1,3241,-1,0.99973994,0.00026005576
3244,myocardial cell injury,24,27,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,-1,3244,-1,0.00022069344,0.9997793
3248,cardiac disorders,38,40,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,-1,3248,-1,9.5878524e-05,0.99990416
3249,DOX,9,10,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,-1,-1,-1,3249,-1,0.9998528,0.00014717795
3250,LV,14,15,97,99,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3250,-1,0.005660182,0.9943399
3251,DOX,26,27,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3251,-1,0.99985206,0.00014788994
3252,DOX,13,14,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,-1,3252,-1,0.99981254,0.00018744465
3253,DOX,5,6,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,-1,3253,-1,0.9996977,0.00030234928
3255,LV,9,10,41,43,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3255,-1,0.014139946,0.98586005
3256,DOX,24,25,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3256,-1,0.999841,0.00015901739
3257,p<0.001,27,28,142,149,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3257,-1,0.08363725,0.9163627
3258,DOX,8,9,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3258,-1,0.99984705,0.0001528804
3261,DOX,8,9,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3261,-1,0.9996332,0.00036683114
3262,p<0.05,23,24,121,127,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3262,-1,0.06628888,0.9337111
3263,DOX,16,17,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,-1,3263,-1,0.99987113,0.00012882592
3264,DOX,12,13,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3264,-1,0.99975353,0.00024641652
3265,p=0.006,18,19,102,109,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3265,-1,0.13223127,0.8677687
3266,DOX,12,13,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,-1,3266,-1,0.99966514,0.00033483226
3267,LV,14,15,87,89,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3267,-1,0.029654969,0.9703451
3268,LV,18,19,125,127,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,-1,3268,-1,0.008454409,0.9915456
3269,ischemic injury,5,7,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3269,-1,0.00012427737,0.99987566
3270,DOX,8,9,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3270,-1,0.99979836,0.00020170608
3272,DOX,13,14,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3272,-1,0.99977916,0.0002208014
3273,DOX,38,39,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3273,-1,0.9997892,0.00021081147
3275,hypoxemia,1,2,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,-1,-1,3275,-1,9.837557e-05,0.99990165
3277,fistula,11,12,73,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3277,-1,0.00014867324,0.99985135
3278,necrotizing enterocolitis,13,15,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3278,-1,0.00012921174,0.9998708
3281,fistula,17,18,123,130,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,-1,-1,3281,-1,0.00014887468,0.9998511
3282,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3282,-1,0.9999486,5.1372208e-05
3283,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3283,-1,0.00041849317,0.9995815
3284,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3284,-1,0.0005002357,0.9994998
3285,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3285,-1,0.9999478,5.216852e-05
3286,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3286,-1,0.99993896,6.103993e-05
3287,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3287,-1,0.000105362735,0.9998946
3289,h,12,13,70,71,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3289,-1,0.12940405,0.87059593
3290,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3290,-1,0.99994135,5.8685153e-05
3291,n=8,17,18,88,91,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3291,-1,0.39001128,0.6099887
3292,n=6,22,23,104,107,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3292,-1,0.54196185,0.45803812
3293,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,-1,-1,-1,3293,-1,0.999941,5.896609e-05
3294,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3294,-1,0.9999459,5.4142332e-05
3295,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3295,-1,0.00054381974,0.9994562
3296,venous thromboembolism,3,5,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3296,-1,0.00013460536,0.9998654
3297,cyproterone acetate,8,10,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3297,-1,0.9999442,5.5773653e-05
3298,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3298,-1,0.9999536,4.634994e-05
3299,Cyproterone acetate,2,4,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3299,-1,0.9999441,5.593611e-05
3300,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3300,-1,0.9999517,4.823733e-05
3302,hirsutism,24,25,136,145,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3302,-1,0.00017603135,0.999824
3303,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3303,-1,0.00017444666,0.99982554
3304,PCOS,36,37,208,212,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3304,-1,0.00014361259,0.99985635
3305,venous thromboembolism,8,10,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3305,-1,0.00014580807,0.9998542
3306,VTE,11,12,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3306,-1,0.00015023554,0.9998498
3307,combined oral contraceptives,19,22,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3307,-1,0.9998795,0.00012051833
3308,COCs,23,24,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3308,-1,0.9998332,0.00016672922
3310,hirsutism,31,32,184,193,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3310,-1,0.00037102625,0.9996289
3311,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3311,-1,0.00020889663,0.9997911
3312,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3312,-1,0.0001854721,0.99981457
3313,COCs,11,12,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,-1,3313,-1,0.9967152,0.0032848245
3314,oral contraception,10,12,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3314,-1,0.9998147,0.00018531247
3315,menopausal symptoms,18,20,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3315,-1,0.00044537164,0.9995546
3316,COCs,65,66,305,309,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3316,-1,0.9998161,0.000183905
3317,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3317,-1,0.00017238621,0.9998276
3319,hirsutism,21,22,113,122,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3319,-1,0.0002322617,0.9997677
3320,PCOS,23,24,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3320,-1,0.00015938567,0.9998406
3321,gum Arabic,5,7,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3321,-1,0.99992824,7.174625e-05
3322,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3322,-1,0.0039830795,0.9960169
3323,gum Arabic,13,15,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3323,-1,0.9999224,7.757154e-05
3324,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3324,-1,0.000108555396,0.9998914
3326,GM,23,24,126,128,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3326,-1,0.9995739,0.00042610528
3328,gum Arabic,22,24,95,105,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3328,-1,0.9999163,8.371425e-05
3329,gum Arabic,35,37,150,160,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3329,-1,0.9999038,9.613385e-05
3330,gum Arabic,46,48,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3330,-1,0.9999051,9.485708e-05
3331,GM,50,51,223,225,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3331,-1,0.99974746,0.00025250838
3335,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3335,-1,0.9998808,0.0001191861
3336,GSH,18,19,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3336,-1,0.9998727,0.00012735502
3337,gum Arabic,7,9,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3337,-1,0.9999198,8.021068e-05
3338,GM,10,11,69,71,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3338,-1,0.9998791,0.00012087442
3341,cellulose,38,39,214,223,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3341,-1,0.99988115,0.00011882037
3342,GM,40,41,228,230,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3342,-1,0.99986637,0.00013365813
3343,GSH,48,49,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3343,-1,0.99956316,0.0004367986
3344,GM,61,62,314,316,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3344,-1,0.9998647,0.00013533639
3345,proximal tubular necrosis,66,69,339,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3345,-1,0.00012821867,0.99987173
3346,GM,78,79,415,417,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3346,-1,0.9998685,0.0001314766
3347,gum Arabic,81,83,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3347,-1,0.99991846,8.155657e-05
3348,GM,87,88,463,465,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3348,-1,0.99987996,0.00012004578
3349,cellulose,89,90,470,479,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3349,-1,0.9998857,0.000114361064
3350,gum Arabic,5,7,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3350,-1,0.9999305,6.949354e-05
3351,GM nephrotoxicity,22,24,136,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3351,-1,0.00033923416,0.99966073
3353,venous thromboembolism,3,5,23,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,-1,-1,3353,-1,0.0001272449,0.9998727
3357,venous thromboembolism,8,10,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3357,-1,0.00014437313,0.99985564
3358,VTE,11,12,70,73,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3358,-1,0.0001594381,0.9998405
3365,mg,29,30,182,184,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,-1,3365,-1,0.9981312,0.0018688143
3368,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,-1,3368,-1,0.00015622811,0.9998437
3370,VTE,14,15,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3370,-1,0.00014383187,0.9998561
3373,VTE,31,32,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3373,-1,0.00014526406,0.9998547
3374,p=0.025,33,34,181,188,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3374,-1,0.05906314,0.9409368
3378,VTE,19,20,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,-1,-1,3378,-1,0.00020941075,0.9997906
3380,cholestatic hepatitis,1,3,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,-1,-1,3380,-1,0.00014735518,0.99985266
3381,cholestatic hepatitis,8,10,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,-1,3381,-1,0.00015012942,0.9998498
3382,cholestatic hepatitis,7,9,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,-1,-1,3382,-1,0.00017211045,0.99982786
3385,Cholestatic hepatitis,2,4,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,-1,3385,-1,0.00015234693,0.99984765
3389,cholestatic hepatitis,16,18,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,-1,-1,3389,-1,0.00015414364,0.99984586
3391,adverse drug,7,9,52,64,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,-1,-1,-1,3391,-1,0.77012986,0.22987011
3395,Cholestatic hepatitis,2,4,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,-1,3395,-1,0.00021105947,0.99978894
3400,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,-1,3400,-1,0.00010014954,0.99989986
3401,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,-1,3401,-1,0.00011079633,0.99988914
3406,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3406,-1,0.9999119,8.812534e-05
3407,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3407,-1,0.00010299049,0.999897
3411,PAN,26,27,173,176,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,-1,3411,-1,0.9998406,0.00015935802
3415,PAN,11,12,51,54,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,-1,-1,-1,3415,-1,0.99973375,0.00026619827
3420,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,-1,3420,-1,0.00010123965,0.9998988
3422,GABA,4,5,33,37,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,-1,3422,-1,0.99989676,0.00010317725
3425,GABA,3,4,23,27,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3425,-1,0.9998863,0.000113693015
3426,GVG,5,6,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3426,-1,0.99979085,0.00020911243
3427,GABA,12,13,95,99,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,-1,3427,-1,0.99981624,0.00018378386
3428,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3428,-1,0.011955876,0.9880441
3430,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3430,-1,0.00028043494,0.99971956
3431,GVG,35,36,218,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3431,-1,0.9953531,0.004646945
3433,DA,47,48,289,291,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3433,-1,0.99985695,0.00014307108
3434,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,-1,3434,-1,0.99980694,0.00019307304
3436,GVG,5,6,34,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3436,-1,0.999806,0.00019400439
3438,oromandibular dystonia,1,3,17,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3438,-1,0.00061009,0.9993899
3439,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3439,-1,0.00014589276,0.9998541
3441,Parkinson's disease,6,9,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3441,-1,0.00019659722,0.99980336
3442,multiple system atrophy,10,13,75,98,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3442,-1,0.00022088438,0.99977916
3443,dystonias,1,2,8,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3443,-1,0.00015947674,0.9998405
3444,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3444,-1,0.00017223423,0.99982774
3445,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3445,-1,0.0002813876,0.9997186
3446,Oromandibular dystonia,11,13,74,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3446,-1,0.00047251064,0.99952745
3447,OMD,14,15,98,101,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3447,-1,0.00031140933,0.9996886
3448,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3448,-1,0.00021921577,0.99978083
3449,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3449,-1,0.00017093682,0.99982905
3450,MR,0,1,0,2,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,-1,-1,3450,-1,0.029688152,0.9703119
3452,MR,6,7,39,41,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3452,-1,0.0013248218,0.99867517
3453,neurologic symptoms,24,26,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3453,-1,0.00011771798,0.9998822
3455,MR,1,2,6,8,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3455,-1,0.00382955,0.99617046
3457,neurologic complications,20,22,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3457,-1,0.00011250734,0.99988747
3458,MR,9,10,53,55,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3458,-1,0.0086632315,0.9913367
3459,MR,14,15,75,77,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3459,-1,0.008058089,0.9919419
3460,MR,10,11,59,61,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,-1,3460,-1,0.03555079,0.9644493
3461,white matter abnormalities,11,14,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3461,-1,0.00020070943,0.9997993
3462,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3462,-1,0.00076818716,0.9992318
3463,MR,35,36,142,144,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3463,-1,0.016082104,0.98391783
3464,white matter abnormalities,5,8,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3464,-1,0.00020704398,0.999793
3465,MR,23,24,121,123,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3465,-1,0.01588333,0.98411673
3466,cortical laminar necrosis,19,22,105,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,-1,3466,-1,0.00017496107,0.99982506
3471,mg,4,5,27,29,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,-1,3471,-1,0.97705257,0.022947373
3473,P<0.05,16,17,113,119,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,-1,3473,-1,0.1302002,0.86979973
3474,mm Hg,10,12,56,61,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,-1,-1,-1,3474,-1,0.008166131,0.9918339
3477,increases in blood pressure,4,8,34,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,-1,3477,-1,0.0006513728,0.9993486
3480,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,-1,3480,-1,0.00011572606,0.99988425
3481,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3481,-1,0.00014134248,0.9998586
3482,ICH,7,8,49,52,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3482,-1,0.00013150659,0.9998685
3484,ICH,10,11,77,80,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3484,-1,0.0001574603,0.9998425
3485,ICH,15,16,104,107,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3485,-1,0.00016873961,0.9998312
3486,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,-1,3486,-1,0.00015006345,0.9998499
3491,ICH,21,22,144,147,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,-1,3491,-1,0.00014610855,0.99985385
3492,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3492,-1,0.00013853822,0.9998615
3495,ICH,18,19,119,122,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3495,-1,0.00016587137,0.99983406
3497,ICH,10,11,64,67,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3497,-1,0.00013669339,0.99986327
3498,ICH,20,21,109,112,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3498,-1,0.00012326628,0.99987674
3499,ICH,36,37,204,207,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3499,-1,0.000118083255,0.99988186
3500,Dexatrim,3,4,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3500,-1,0.9999279,7.210897e-05
3501,Phenylpropanolamine,5,6,23,42,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3501,-1,0.99992704,7.300442e-05
3502,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3502,-1,0.00010288252,0.9998971
3503,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3503,-1,0.99993694,6.306666e-05
3504,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3504,-1,0.99967265,0.0003273686
3505,amine,7,8,43,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3505,-1,0.9996598,0.00034022945
3507,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,-1,3507,-1,0.00011596002,0.999884
3508,PPA,7,8,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,-1,3508,-1,0.99966216,0.00033784285
3511,Dexatrim,7,8,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,-1,3511,-1,0.99993515,6.486504e-05
3513,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,-1,3513,-1,0.9990478,0.00095212366
3515,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,-1,3515,-1,0.9998072,0.00019285426
3516,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3516,-1,0.9999101,8.982902e-05
3517,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3517,-1,0.00017089493,0.99982905
3519,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3519,-1,0.00014336933,0.9998566
3520,SLE,12,13,70,73,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3520,-1,0.00017898102,0.999821
3521,renal involvement,15,17,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3521,-1,0.00015516927,0.9998448
3525,CQ,5,6,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3525,-1,0.99984,0.00015997185
3526,arthralgia,11,12,64,74,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3526,-1,0.00010601905,0.999894
3527,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,-1,-1,-1,3527,-1,0.99989617,0.000103830644
3528,Myositis,0,1,0,8,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,-1,3528,-1,0.00016013377,0.9998398
3530,muscular weakness,11,13,66,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3530,-1,0.000113808965,0.99988616
3531,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3531,-1,0.00011716455,0.9998828
3532,myositis,9,10,71,79,The neurological and electrophysiological findings were not typical of myositis.,12739036_8,-1,-1,-1,3532,-1,0.0001771347,0.9998229
3533,polymyositis,14,15,76,88,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,-1,3533,-1,0.0001912826,0.9998087
3536,affection of the musculoskeletal system,4,9,43,82,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3536,-1,0.0005038785,0.9994961
3537,SLE,19,20,155,158,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3537,-1,0.00024220467,0.9997578
3539,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,-1,-1,3539,-1,0.000880111,0.99911994
3543,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,-1,3543,-1,0.04595427,0.9540457
3547,clonic seizure,13,15,76,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,-1,-1,3547,-1,0.00014165658,0.9998584
3549,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,-1,-1,3549,-1,0.0072232853,0.99277675
3552,hippocampal injury,3,5,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,-1,3552,-1,0.00013871957,0.99986124
3553,Estrogens,0,1,0,9,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3553,-1,0.9998461,0.0001538834
3554,hippocampal injury,5,7,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3554,-1,0.0001384789,0.9998615
3555,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3555,-1,0.00026590505,0.9997341
3556,SE,14,15,113,115,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3556,-1,0.00084521406,0.9991548
3557,SE,16,17,130,132,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,-1,3557,-1,0.003310468,0.99668956
3558,oil,11,12,76,79,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,-1,3558,-1,0.99982905,0.00017087572
3559,SE,0,1,0,2,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3559,-1,0.009944777,0.9900552
3560,h,4,5,18,19,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3560,-1,0.09092611,0.9090738
3561,h,12,13,68,69,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3561,-1,0.054456864,0.9455431
3562,SE,14,15,88,90,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,-1,3562,-1,0.038708527,0.96129143
3566,Postoperative myalgia,0,2,0,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,-1,-1,-1,3566,-1,0.00013265783,0.9998673
3569,postoperative myalgia,8,10,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,-1,3569,-1,0.00012974844,0.9998702
3576,n,20,21,159,160,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,-1,-1,3576,-1,0.06255229,0.93744767
3581,h,2,3,6,7,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,-1,-1,3581,-1,0.020674992,0.979325
3589,postoperative myalgia,19,21,158,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,-1,-1,3589,-1,0.00011569185,0.99988425
3590,postoperative myalgia,8,10,59,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,-1,-1,3590,-1,0.00012779562,0.9998722
3593,postoperative myalgia,8,10,60,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,-1,-1,-1,3593,-1,0.00012759859,0.9998723
3595,Pseudoacromegaly,0,1,0,16,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3595,-1,0.00015773078,0.9998423
3596,minoxidil,7,8,49,58,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3596,-1,0.99994206,5.794211e-05
3597,Acromegaly,0,1,0,10,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3597,-1,0.0001253166,0.9998747
3598,endocrine disorder,3,5,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3598,-1,0.00017632972,0.99982375
3599,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3599,-1,0.9997346,0.000265396
3601,cutis verticis gyrata,30,33,172,193,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,-1,-1,3601,-1,0.0006463973,0.9993536
3602,Pseudoacromegaly,0,1,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3602,-1,0.00013365838,0.99986637
3603,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3603,-1,0.99988234,0.0001176474
3604,pseudoacromegaly,5,6,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3604,-1,0.00012388681,0.99987614
3605,minoxidil,13,14,83,92,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3605,-1,0.9999366,6.343079e-05
3606,pseudoacromegaly,7,8,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3606,-1,0.00013291705,0.9998671
3607,minoxidil,13,14,70,79,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3607,-1,0.9999379,6.215982e-05
3608,androgen,1,2,9,17,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,-1,-1,3608,-1,0.9998543,0.0001456634
3611,bone involvement,9,11,78,94,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,-1,-1,3611,-1,0.0002598471,0.9997402
3612,androgen,10,11,58,66,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3612,-1,0.99987566,0.00012431292
3615,bone involvement,19,21,133,149,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3615,-1,0.00019442901,0.9998056
3616,prostatic adenocarcinoma,8,10,60,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3616,-1,0.00038704532,0.999613
3617,C,14,15,100,101,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3617,-1,0.08356912,0.9164309
3618,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3618,-1,0.99992824,7.178842e-05
3619,mg,11,12,60,62,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3619,-1,0.98468274,0.015317254
3620,mg flutamide,20,22,104,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3620,-1,0.999746,0.00025401395
3626,SE,24,25,100,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3626,-1,0.06654084,0.93345916
3628,SE,47,48,191,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3628,-1,0.05912709,0.94087285
3630,p,29,30,153,154,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,-1,3630,-1,0.05614515,0.9438548
3633,C,50,51,221,222,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,-1,3633,-1,0.017860161,0.9821399
3641,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,-1,3641,-1,0.15805751,0.8419425
3643,3-methylcholanthrene,9,10,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3643,-1,0.99992406,7.5888034e-05
3644,MC,11,12,86,88,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3644,-1,0.9998055,0.0001945607
3648,PB,37,38,239,241,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3648,-1,0.9998167,0.0001832741
3653,cobalt chloride,11,13,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3653,-1,0.9999224,7.758655e-05
3657,se,27,28,186,188,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3657,-1,0.1597945,0.84020555
3658,PB,33,34,218,220,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3658,-1,0.99986863,0.00013139064
3661,venous thromboembolism,5,7,34,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3661,-1,0.00013613222,0.99986386
3662,cyproterone acetate,11,13,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3662,-1,0.99993885,6.116445e-05
3663,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3663,-1,0.9999467,5.3234446e-05
3664,venous thromboembolism,8,10,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3664,-1,0.000148564,0.99985147
3665,VTE,11,12,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3665,-1,0.00015994455,0.99984
3666,cyproterone acetate,16,18,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3666,-1,0.9999403,5.9697653e-05
3667,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3667,-1,0.99994576,5.4286214e-05
3668,combined oral contraceptives,28,31,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3668,-1,0.99976915,0.00023089407
3669,COCs,32,33,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3669,-1,0.9997991,0.00020091257
3670,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,-1,3670,-1,0.00022341484,0.99977654
3671,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,-1,3671,-1,0.99964213,0.00035788247
3672,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,-1,3672,-1,0.9997433,0.00025676007
3673,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3673,-1,0.00022125326,0.9997788
3674,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3674,-1,0.9993818,0.00061822566
3675,COCs,8,9,53,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,-1,-1,-1,3675,-1,0.9815258,0.018474279
3676,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3676,-1,0.00017835427,0.9998217
3677,COCs,24,25,106,110,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3677,-1,0.99789435,0.0021056351
3678,COCs,43,44,197,201,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3678,-1,0.9960556,0.0039443383
3679,VTE,9,10,53,56,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3679,-1,0.00020883788,0.9997912
3680,COCs,14,15,79,83,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3680,-1,0.9994759,0.0005240698
3683,NSAIDs,11,12,81,87,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3683,-1,0.99986434,0.00013558514
3684,developmental anomalies,19,21,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3684,-1,0.00015120217,0.9998487
3685,NSAIDs,25,26,167,173,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3685,-1,0.99985695,0.00014299304
3688,ASA,5,6,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3688,-1,0.99984336,0.00015660097
3689,developmental anomalies,18,20,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3689,-1,0.00014126796,0.99985874
3690,CA,39,40,198,200,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3690,-1,0.055592764,0.9444073
3691,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,-1,3691,-1,0.9985019,0.0014981192
3692,SD,12,13,80,82,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3692,-1,0.15940072,0.8405993
3693,ASA,18,19,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3693,-1,0.9998511,0.00014884585
3694,SD,43,44,247,249,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3694,-1,0.006850694,0.99314934
3695,gastrointestinal toxicity,53,55,297,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3695,-1,0.00011907035,0.9998809
3696,malformations,61,62,364,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3696,-1,0.00012187184,0.99987817
3697,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3697,-1,0.9998455,0.00015444375
3698,ASA,2,3,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3698,-1,0.9998435,0.00015646768
3699,SD,76,77,237,239,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3699,-1,0.019214721,0.98078525
3700,NSAIDs,7,8,50,56,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3700,-1,0.9998654,0.00013453119
3701,ventricular septal defects,9,12,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3701,-1,0.00017412493,0.9998259
3702,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3702,-1,0.00034461918,0.99965537
3703,MDs,19,20,119,122,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3703,-1,0.00024143088,0.99975854
3704,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3704,-1,0.00014714147,0.9998529
3705,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3705,-1,0.00036495936,0.999635
3706,MDs,30,31,163,166,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3706,-1,0.00018239443,0.99981767
3707,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3707,-1,0.00025208216,0.99974793
3708,malformations,53,54,254,267,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3708,-1,0.00011336057,0.99988663
3709,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3709,-1,0.99986076,0.00013915967
3710,malformations,62,63,321,334,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3710,-1,0.00011998272,0.99987996
3711,DH,5,6,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3711,-1,0.9982161,0.0017838597
3712,MD,7,8,28,30,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3712,-1,0.99882835,0.0011716177
3713,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3713,-1,0.92753243,0.07246758
3714,VSD,0,1,0,3,VSD also was noted following treatment on GD 11.,12852481_10,-1,-1,-1,3714,-1,0.0011751407,0.9988249
3715,contrast,1,2,3,11,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3715,-1,0.039979722,0.96002024
3716,DH,3,4,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3716,-1,0.25036845,0.7496316
3717,MD,5,6,20,22,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3717,-1,0.274827,0.725173
3718,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3718,-1,0.002704118,0.9972959
3719,developmental anomalies,6,8,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3719,-1,0.00014077996,0.9998592
3720,SD,11,12,82,84,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3720,-1,0.9573347,0.04266527
3721,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3721,-1,0.0004828808,0.9995171
3722,SD,22,23,134,136,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3722,-1,0.27551985,0.72448015
3723,hydrocephalus,25,26,146,159,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3723,-1,0.00012031762,0.9998797
3724,malformations,2,3,15,28,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3724,-1,0.00013674345,0.99986327
3725,ASA,6,7,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3725,-1,0.99986315,0.00013684688
3726,malformations,17,18,85,98,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3726,-1,0.00015546089,0.99984455
3727,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3727,-1,0.9998542,0.0001457305
3729,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,-1,3729,-1,0.99993896,6.106002e-05
3731,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3731,-1,0.99992144,7.8531295e-05
3734,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3734,-1,0.9999373,6.275854e-05
3735,Flumazenil,0,1,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3735,-1,0.999943,5.6967856e-05
3736,mg,6,7,28,30,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3736,-1,0.94534653,0.054653425
3739,meperidine,41,42,201,211,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3739,-1,0.999944,5.6036803e-05
3741,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,-1,3741,-1,0.9999299,7.00525e-05
3742,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,-1,-1,-1,3742,-1,0.99994195,5.8034184e-05
3745,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3745,-1,0.9999372,6.2825726e-05
3748,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,-1,-1,-1,3748,-1,0.99994564,5.4312924e-05
3757,n,4,5,19,20,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3757,-1,0.08154672,0.91845334
3759,mg,46,47,198,200,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3759,-1,0.9964204,0.0035796151
3764,MPEP,3,4,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,-1,3764,-1,0.99983394,0.0001660489
3772,h,25,26,143,144,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,-1,-1,-1,3772,-1,0.047740243,0.9522598
3774,MPEP,8,9,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,-1,3774,-1,0.99954444,0.00045556534
3777,MPEP,2,3,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3777,-1,0.9995647,0.00043528396
3781,veratridine,37,38,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3781,-1,0.99995196,4.8026053e-05
3784,MPEP,0,1,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,-1,-1,-1,3784,-1,0.99988353,0.00011644436
3786,MPEP,12,13,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,-1,3786,-1,0.9998673,0.00013271504
3788,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,-1,3788,-1,0.99989665,0.00010338457
3792,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,-1,3792,-1,0.00030322917,0.99969685
3795,fluvoxamine,14,15,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,-1,-1,-1,3795,-1,0.9999356,6.433328e-05
3808,renal disease,12,14,97,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,-1,-1,3808,-1,0.00012020478,0.99987984
3812,psychiatric disorders,14,16,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,-1,-1,3812,-1,0.00015110431,0.99984884
3814,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,-1,3814,-1,0.009919911,0.99008006
3819,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3819,-1,0.9999385,6.150023e-05
3820,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3820,-1,0.99994457,5.5474808e-05
3821,ganaxolone,10,11,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3821,-1,0.99993575,6.424219e-05
3822,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3822,-1,0.9999219,7.807506e-05
3827,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3827,-1,0.9999447,5.5304135e-05
3828,ganaxolone,18,19,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3828,-1,0.99994254,5.740949e-05
3829,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3829,-1,0.9999398,6.019373e-05
3830,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3830,-1,0.99994385,5.6164874e-05
3831,ganaxolone,6,7,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3831,-1,0.9999373,6.269011e-05
3838,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,-1,3838,-1,0.00014090366,0.9998591
3840,mg,14,15,78,80,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3840,-1,0.98941016,0.010589826
3841,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3841,-1,0.9991252,0.0008748056
3842,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,-1,3842,-1,0.99964297,0.00035698013
3843,Renal function significantly deteriorated,0,4,0,41,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3843,-1,0.00028345012,0.9997166
3845,p,11,12,83,84,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3845,-1,0.07761106,0.9223889
3847,h,37,38,180,181,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3847,-1,0.016447373,0.9835526
3848,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3848,-1,0.000121781224,0.99987817
3849,weight loss,5,7,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3849,-1,0.0003678414,0.9996321
3855,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,-1,3855,-1,0.7985633,0.20143673
3859,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,-1,3859,-1,0.000106836516,0.9998932
3860,retinopathy,3,4,22,33,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3860,-1,0.00012343551,0.9998765
3861,thrombophlebitis,14,15,91,107,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3861,-1,0.00012920989,0.9998708
3862,thrombophlebitis,4,5,29,45,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3862,-1,0.000121050194,0.9998789
3870,mg,28,29,134,136,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3870,-1,0.97190505,0.02809491
3871,rauwolscine,34,35,151,162,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3871,-1,0.9999378,6.2269704e-05
3872,mg,37,38,166,168,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3872,-1,0.97731453,0.022685545
3874,MAP,16,17,94,97,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,-1,3874,-1,0.024191082,0.975809
3875,MAP,2,3,10,13,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3875,-1,0.0358584,0.96414155
3877,MAP,17,18,88,91,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3877,-1,0.0427481,0.9572519
3878,rauwolscine,20,21,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3878,-1,0.99993706,6.296679e-05
3879,MAP,24,25,122,125,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3879,-1,0.07669815,0.9233018
3882,MAP,17,18,97,100,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3882,-1,0.00057740917,0.99942267
3883,n,19,20,102,103,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3883,-1,0.019019347,0.9809807
3884,rauwolscine,31,32,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3884,-1,0.99993527,6.470613e-05
3885,MAP,38,39,169,172,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3885,-1,0.0005759287,0.9994241
3886,n,40,41,174,175,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3886,-1,0.019493414,0.98050654
3888,mg,13,14,60,62,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,-1,3888,-1,0.9707285,0.029271504
3889,MAP,0,1,0,3,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3889,-1,0.0228602,0.9771398
3891,n,18,19,95,96,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3891,-1,0.15561791,0.84438205
3894,mg,23,24,138,140,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,-1,-1,3894,-1,0.9798273,0.020172777
3895,rauwolscine,4,5,30,41,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3895,-1,0.9999417,5.82357e-05
3896,mg,7,8,45,47,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3896,-1,0.9758547,0.024145253
3898,MAP,20,21,111,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3898,-1,0.010418751,0.9895812
3899,n,27,28,126,127,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3899,-1,0.07331864,0.9266814
3900,MAP,39,40,180,183,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3900,-1,0.00813979,0.9918602
3902,cirazoline,11,12,64,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3902,-1,0.9999386,6.135219e-05
3903,Abbott-53693,25,26,129,141,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3903,-1,0.9996469,0.0003530491
3907,cirazoline,7,8,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3907,-1,0.99994946,5.05514e-05
3909,n,16,17,103,104,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3909,-1,0.049601924,0.9503981
3910,n,27,28,144,145,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3910,-1,0.063497506,0.9365025
3911,Abbott-53693,9,10,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,-1,3911,-1,0.9998702,0.00012985167
3916,increase in locomotor activity,6,10,49,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,-1,3916,-1,0.0005625447,0.9994374
3917,increase in locomotor activity,8,12,57,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,-1,3917,-1,0.0004178878,0.9995821
3918,increase in locomotor activity,11,15,78,108,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,-1,3918,-1,0.0004326562,0.99956733
3921,physostigmine,10,11,84,97,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,-1,-1,3921,-1,0.999944,5.6041506e-05
3922,contrast,1,2,3,11,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3922,-1,0.14569686,0.8543032
3923,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3923,-1,0.9999237,7.62426e-05
3924,neostigmine,6,7,38,49,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3924,-1,0.9999267,7.332186e-05
3939,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,-1,3939,-1,0.0001098445,0.9998901
3942,in,13,14,97,99,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,-1,-1,-1,3942,-1,0.0018956105,0.99810433
3945,Li,15,16,102,104,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,-1,3945,-1,0.9997744,0.00022557544
3950,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,-1,3950,-1,0.00010308963,0.9998969
3953,rise in blood pressure,4,8,23,45,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,-1,-1,-1,3953,-1,0.00032575493,0.9996742
3965,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3965,-1,0.00024713695,0.9997528
3966,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3966,-1,0.9999474,5.2570045e-05
3967,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3967,-1,0.99992764,7.230755e-05
3968,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3968,-1,0.99994373,5.631473e-05
3969,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3969,-1,0.99992573,7.428705e-05
3970,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3970,-1,0.00036854658,0.9996314
3971,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3971,-1,0.9999467,5.328087e-05
3972,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,-1,3972,-1,0.0010612265,0.99893874
3973,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3973,-1,0.9999424,5.755755e-05
3974,mg,10,11,54,56,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3974,-1,0.9880938,0.011906258
3975,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,-1,-1,-1,3975,-1,0.9999455,5.453142e-05
3977,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3977,-1,0.9999484,5.165832e-05
3978,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3978,-1,0.0006023288,0.99939764
3979,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3979,-1,0.99995077,4.9217015e-05
3980,inflammatory bowel disease,19,22,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3980,-1,0.0001290892,0.9998709
3981,Amnestic syndrome,0,2,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3981,-1,0.000114877716,0.9998851
3982,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3982,-1,0.2764669,0.7235331
3984,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,-1,3984,-1,0.28428754,0.7157124
3985,impairment of memory,7,10,50,70,Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.,1423339_2,-1,-1,-1,3985,-1,0.000317101,0.9996829
3986,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,-1,-1,3986,-1,0.009234313,0.9907657
3991,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,-1,3991,-1,0.9999336,6.6372326e-05
3992,glaucomatous,1,2,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,-1,3992,-1,0.0002452184,0.9997547
3996,blind,3,4,12,17,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3996,-1,0.037574098,0.9624259
3999,p,28,29,180,181,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3999,-1,0.047831073,0.9521689
4000,betaxolol,4,5,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,-1,4000,-1,0.99993,6.999355e-05
4004,LY274614,11,12,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,-1,4004,-1,0.99978095,0.00021910985
4006,LY274614,0,1,0,8,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4006,-1,0.99908316,0.0009167971
4007,"3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid",2,6,10,88,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4007,-1,0.9994215,0.00057848747
4008,NMDA,18,19,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,4008,-1,0.99983764,0.00016238114
4012,iprindole,18,19,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,-1,-1,-1,4012,-1,0.99993944,6.05464e-05
4015,dizocilpine,11,12,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4015,-1,0.99992895,7.105273e-05
4016,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4016,-1,0.9997925,0.00020746766
4017,NMDA,19,20,125,129,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4017,-1,0.9998596,0.0001403679
4018,LY274614,24,25,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4018,-1,0.9998116,0.00018842124
4019,NMDA,30,31,185,189,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,4019,-1,0.999856,0.0001439378
4020,LY274614,4,5,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,-1,4020,-1,0.9998758,0.00012422631
4021,LY274614,5,6,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,-1,-1,-1,4021,-1,0.99987984,0.000120200195
4026,LY274614,10,11,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4026,-1,0.9998735,0.00012650788
4028,LY274614,19,20,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,4028,-1,0.99988806,0.00011195716
4032,LY274614,24,25,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,-1,4032,-1,0.9998267,0.00017334452
4036,NMDA,19,20,144,148,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4036,-1,0.99981576,0.0001842179
4037,LY274614,23,24,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4037,-1,0.9998265,0.00017351567
4038,NMDA,26,27,183,187,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,4038,-1,0.9998462,0.00015374494
4041,penicillins,15,16,110,121,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,-1,4041,-1,0.9998704,0.00012959895
4044,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,-1,-1,4044,-1,0.9999285,7.153864e-05
4045,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,-1,4045,-1,0.99991727,8.268642e-05
4048,hemolytic,9,10,57,66,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,-1,-1,-1,4048,-1,0.00015098002,0.99984896
4050,neurologic sequelae,1,3,21,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,-1,4050,-1,0.00010551657,0.9998945
4051,weakness of extremities,4,7,29,52,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4051,-1,0.00018235008,0.99981767
4052,legs paralysis,8,10,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4052,-1,0.0001670591,0.99983287
4053,dysarthria,11,12,70,80,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4053,-1,0.00012161296,0.9998784
4055,h,15,16,94,95,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4055,-1,0.022789985,0.97721
4056,mg ketoconazole,20,22,119,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,4056,-1,0.9998171,0.00018299228
4057,mg ketoconazole,16,18,84,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,4057,-1,0.9997652,0.00023482619
4058,adverse drug reactions,9,12,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,-1,-1,4058,-1,0.00048407234,0.9995159
4062,LIDs,3,4,30,34,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4062,-1,0.00034009456,0.9996599
4063,Parkinson's disease,14,17,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4063,-1,0.0005267918,0.9994733
4064,PD,18,19,113,115,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,4064,-1,0.00025232093,0.9997477
4065,LIDs,24,25,155,159,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,-1,4065,-1,0.00069125387,0.9993087
4068,LIDs,41,42,255,259,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,-1,4068,-1,0.00018274713,0.9998173
4069,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,-1,-1,4069,-1,0.99987864,0.0001213706
4073,contrast,1,2,3,11,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4073,-1,0.036038104,0.96396184
4074,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4074,-1,0.99988437,0.000115614326
4076,LIDs,27,28,179,183,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,4076,-1,0.00026288469,0.9997371
4080,LIDs,10,11,69,73,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4080,-1,0.00034447399,0.9996555
4082,LIDs,38,39,254,258,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4082,-1,0.00033298056,0.99966705
4083,sugar dependency,3,5,17,33,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,-1,4083,-1,0.13061598,0.869384
4085,sugar,13,14,85,90,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4085,-1,0.99984455,0.00015539004
4086,drug dependency,24,26,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4086,-1,0.013712425,0.9862876
4087,sugar,11,12,70,75,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,-1,-1,-1,4087,-1,0.99986386,0.0001360981
4089,sucrose,30,31,155,162,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4089,-1,0.999851,0.00014898188
4090,h,37,38,193,194,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4090,-1,0.64274263,0.3572574
4091,h,41,42,213,214,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4091,-1,0.03623564,0.96376437
4092,ad,10,11,49,51,"Beginning on day 22, all rats were maintained on ad libitum chow.",14596845_5,-1,-1,-1,4092,-1,0.9955088,0.0044911765
4094,sucrose,6,7,40,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4094,-1,0.99985266,0.0001473473
4095,hyperactive,10,11,62,73,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4095,-1,0.00029511776,0.9997049
4097,ad,21,22,136,138,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4097,-1,0.96744865,0.032551304
4098,sucrose,25,26,151,158,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4098,-1,0.9998609,0.00013908645
4102,sucrose,50,51,298,305,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4102,-1,0.999861,0.00013893575
4103,sugar,14,15,87,92,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,-1,4103,-1,0.9998692,0.00013078352
4104,sugar,21,22,132,137,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,-1,4104,-1,0.99986124,0.00013878256
4109,hemorrhagic cystitis,10,12,73,93,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,-1,-1,-1,4109,-1,0.00010851442,0.9998915
4110,Hemorrhagic cystitis,2,4,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4110,-1,0.000118854485,0.99988115
4111,HC,5,6,27,29,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4111,-1,0.00026266897,0.9997373
4113,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4113,-1,0.9985764,0.0014235773
4116,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,-1,4116,-1,0.0021057685,0.9978942
4118,h,33,34,122,123,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4118,-1,0.118933044,0.881067
4119,IFS,41,42,155,158,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4119,-1,0.9995322,0.00046774003
4125,h,4,5,26,27,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,-1,-1,4125,-1,0.032671724,0.9673283
4128,IFS,26,27,146,149,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,-1,-1,-1,4128,-1,0.4656998,0.53430027
4129,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,-1,4129,-1,0.99230134,0.0076985965
4135,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,-1,4135,-1,0.0044689868,0.995531
4139,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,-1,4139,-1,0.0076148836,0.99238515
4140,erythema nodosum,3,5,33,49,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4140,-1,0.00015586134,0.9998441
4141,acute promyelocytic leukemia,8,11,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4141,-1,0.00012800795,0.99987197
4142,Erythema nodosum,0,2,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4142,-1,0.00018120754,0.99981886
4143,ATRA,8,9,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4143,-1,0.9998041,0.00019591236
4144,acute promyelocytic leukemia,11,14,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4144,-1,0.00016174556,0.99983823
4145,APL,15,16,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4145,-1,0.0002676086,0.99973243
4146,APL,6,7,39,42,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4146,-1,0.0005837023,0.99941635
4147,erythema nodosum,9,11,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4147,-1,0.00020458862,0.9997954
4148,ATRA,12,13,81,85,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4148,-1,0.9987477,0.0012523226
4150,painful erythematous,4,6,30,50,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4150,-1,0.00017367724,0.9998264
4151,ATRA,23,24,133,137,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4151,-1,0.9998449,0.00015511588
4152,erythema nodosum,10,12,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,-1,4152,-1,0.00023545686,0.9997645
4155,lesions,6,7,36,43,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,-1,-1,-1,4155,-1,0.00015151869,0.9998485
4156,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,-1,4156,-1,0.9999007,9.928718e-05
4157,ATRA,0,1,0,4,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4157,-1,0.0008885434,0.9991115
4158,erythema nodosum,9,11,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4158,-1,0.00020064498,0.99979943
4160,erythema nodosum,9,11,60,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,-1,-1,-1,4160,-1,0.00015421906,0.99984574
4162,amphotericin B,5,7,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,-1,-1,4162,-1,0.9999274,7.263021e-05
4164,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4164,-1,0.00011385305,0.99988616
4165,amphotericin B,19,21,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4165,-1,0.9999368,6.31914e-05
4166,AmB,22,23,144,147,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4166,-1,0.999835,0.00016491834
4167,coccidioidomycosis,26,27,166,184,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4167,-1,0.0019046348,0.99809533
4168,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4168,-1,0.00011375158,0.9998863
4169,posaconazole,8,9,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4169,-1,0.99994004,6.0016053e-05
4170,AmB.,12,13,102,106,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4170,-1,0.91291136,0.08708868
4172,AmB.,25,26,184,188,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4172,-1,0.9092577,0.09074225
4175,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,-1,-1,4175,-1,0.99991024,8.9791785e-05
4178,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4178,-1,0.9998914,0.000108643835
4181,5-HT,26,27,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4181,-1,0.9998783,0.000121735946
4185,migraineurs,2,3,15,26,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4185,-1,0.0010625286,0.9989374
4187,mg,4,5,30,32,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,-1,-1,-1,4187,-1,0.9764839,0.023516042
4191,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4191,-1,0.99990976,9.0258356e-05
4192,P<0.01,6,7,51,57,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4192,-1,0.09034685,0.9096532
4195,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4195,-1,0.00013519012,0.9998648
4196,P<0.001,17,18,110,117,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4196,-1,0.10076156,0.89923847
4197,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,-1,-1,4197,-1,0.99992,8.002014e-05
4200,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4200,-1,0.9999056,9.438986e-05
4201,5-HT,8,9,63,67,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4201,-1,0.99984217,0.00015780042
4204,P<0.01,6,7,52,58,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,-1,-1,4204,-1,0.039821487,0.9601785
4208,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4208,-1,0.9999212,7.882556e-05
4209,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4209,-1,0.00012197798,0.99987805
4210,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4210,-1,0.99991107,8.89156e-05
4212,contrast,1,2,3,11,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4212,-1,0.09663223,0.90336776
4216,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4216,-1,0.9998826,0.00011736437
4218,hemorrhagic cystitis,8,10,78,98,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,-1,-1,-1,4218,-1,0.000106878586,0.99989307
4219,hemorrhagic cystitis,6,8,32,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4219,-1,0.000119133736,0.9998809
4221,Wegener's granulomatosis,13,16,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4221,-1,0.00043143032,0.9995685
4222,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,-1,4222,-1,0.9998865,0.00011349382
4226,hemorrhagic cystitis,17,19,106,126,"In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.",1468485_6,-1,-1,-1,4226,-1,0.00010597033,0.999894
4227,psychosis,1,2,6,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,-1,-1,4227,-1,0.00010405167,0.99989593
4229,psychosis,3,4,19,28,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,-1,-1,4229,-1,9.9253e-05,0.9999007
4231,psychosis,8,9,49,58,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4231,-1,0.00011203148,0.99988794
4233,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4233,-1,0.00012352761,0.9998765
4238,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4238,-1,0.6589096,0.34109038
4239,loreclezole,9,10,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4239,-1,0.9998989,0.00010103451
4240,valproate,14,15,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4240,-1,0.9999367,6.3348336e-05
4241,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4241,-1,0.9999286,7.1430935e-05
4242,Loreclezole,0,1,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,-1,-1,4242,-1,0.99989927,0.000100697674
4244,loreclezole,3,4,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4244,-1,0.9998869,0.000113122354
4245,valproate,9,10,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4245,-1,0.9999424,5.7517933e-05
4246,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4246,-1,0.9999325,6.7435925e-05
4249,BAY k-8644,9,11,74,84,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4249,-1,0.9998305,0.00016943352
4250,calcium channels,16,18,107,123,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4250,-1,0.8589369,0.14106306
4251,loreclezole,24,25,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4251,-1,0.99982435,0.00017565914
4252,valproate,30,31,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4252,-1,0.99993277,6.7231354e-05
4255,BAY k-8644,9,11,50,60,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4255,-1,0.9998543,0.00014570396
4256,loreclezole,16,17,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4256,-1,0.9999093,9.07181e-05
4257,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4257,-1,0.9999348,6.51789e-05
4258,loreclezole,10,11,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4258,-1,0.9999101,8.9913454e-05
4259,calcium channels,28,30,208,224,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4259,-1,0.9548016,0.045198362
4260,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,-1,4260,-1,0.005263885,0.99473614
4263,tubular lesions,13,15,113,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,-1,-1,4263,-1,0.00014017572,0.9998598
4264,mitochondrial injury,6,8,38,58,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,-1,-1,-1,4264,-1,0.0010150443,0.998985
4266,mg,10,11,59,61,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,-1,4266,-1,0.976405,0.023595022
4267,h,11,12,58,59,Additional rats received a single dose either 6 days or 2 h prior to euthanasia.,14736955_4,-1,-1,-1,4267,-1,0.48011383,0.5198862
4268,Glomerular and tubular injury,0,4,0,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,-1,4268,-1,0.00019711792,0.9998029
4270,glomerular and tubular lesions,9,13,47,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4270,-1,0.00015570389,0.9998443
4272,NADH dehydrogenase,18,20,117,135,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4272,-1,0.9997631,0.00023693439
4273,citrate,28,29,181,188,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4273,-1,0.9998486,0.00015132493
4274,tubular lesions,9,11,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4274,-1,0.00014663138,0.9998534
4275,glomerular lesions,16,18,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4275,-1,0.00015477014,0.99984515
4276,glomerular and tubular injury,4,8,19,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4276,-1,0.00016085917,0.99983907
4277,Injury,30,31,215,221,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4277,-1,0.00013170196,0.9998683
4280,renal lesions,28,30,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,-1,4280,-1,0.00014471204,0.9998553
4285,sexually dysfunctional,1,3,9,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4285,-1,0.0002618583,0.99973816
4290,mg,30,31,207,209,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4290,-1,0.9897626,0.010237397
4291,mg ephedrine,16,18,119,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,-1,-1,-1,4291,-1,0.99979025,0.00020977504
4294,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4294,-1,0.9999367,6.324819e-05
4296,n=94,17,18,97,101,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4296,-1,0.03558213,0.9644179
4298,n=35,28,29,147,151,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4298,-1,0.018838601,0.98116136
4299,p=0.032,16,17,88,95,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4299,-1,0.06868815,0.93131185
4300,p=0.026,27,28,142,149,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4300,-1,0.051593088,0.94840693
4302,oestrogen,9,10,56,65,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,-1,-1,-1,4302,-1,0.9999244,7.555487e-05
4304,leg cramps,13,15,85,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,-1,4304,-1,0.00034659117,0.99965346
4307,neurological complications,10,12,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,-1,4307,-1,0.000105934145,0.999894
4315,heart failure,19,21,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,-1,4315,-1,0.00010615489,0.9998938
4316,propafenone overdose,5,7,57,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4316,-1,0.13765255,0.8623474
4317,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4317,-1,0.001307761,0.9986922
4318,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4318,-1,0.0030476465,0.9969523
4320,cyanosis,36,37,245,253,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4320,-1,0.000112269096,0.9998877
4321,propafenone overdose,26,28,146,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,-1,4321,-1,0.13028209,0.8697179
4322,biventricular dysfunction,3,5,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,-1,4322,-1,0.000117102456,0.99988294
4324,contrast,12,13,74,82,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,-1,-1,4324,-1,0.78665537,0.21334466
4325,cholestatic jaundice,1,3,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,-1,-1,4325,-1,0.00015415628,0.99984586
4326,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,-1,4326,-1,0.99994016,5.981236e-05
4328,itching,7,8,44,51,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4328,-1,0.00016699683,0.999833
4329,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4329,-1,0.9999479,5.20443e-05
4330,mg,15,16,92,94,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4330,-1,0.9955325,0.0044675153
4332,mg,22,23,120,122,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4332,-1,0.9961085,0.0038915793
4335,emergency department,4,6,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4335,-1,0.00092414697,0.9990759
4336,icterus,14,15,74,81,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4336,-1,0.00017096699,0.99982905
4338,hyperbilirubinemia,19,20,97,115,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4338,-1,0.0001450902,0.9998549
4342,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,-1,-1,-1,4342,-1,0.9999418,5.8202117e-05
4343,cholestatic jaundice,18,20,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,-1,-1,4343,-1,0.00015036624,0.99984956
4344,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,-1,-1,-1,4344,-1,0.9999367,6.3240106e-05
4345,vascular dysfunctions,20,22,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4345,-1,0.00025148227,0.9997485
4346,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4346,-1,0.00012546379,0.9998745
4347,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4347,-1,0.00013722412,0.9998628
4348,vascular disturbances,12,14,102,123,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4348,-1,0.00016057369,0.9998394
4350,mm,5,6,18,20,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4350,-1,0.98862016,0.011379805
4351,increases in dural and cortical blood flow,14,21,62,104,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4351,-1,0.0009388591,0.99906117
4352,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,-1,-1,-1,4352,-1,0.9999424,5.754992e-05
4353,increases in dural blood flow,2,7,11,40,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4353,-1,0.00072249584,0.99927753
4355,mm,17,18,106,108,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4355,-1,0.97002226,0.02997777
4356,mm,30,31,152,154,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4356,-1,0.9515418,0.04845816
4358,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,-1,-1,4358,-1,0.00012263049,0.99987733
4360,neuropathological damages,5,7,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,-1,-1,4360,-1,0.000108624576,0.9998914
4361,organophosphorus (OP) compounds,1,6,5,36,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4361,-1,0.9997478,0.00025217974
4362,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4362,-1,0.9999207,7.922231e-05
4363,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4363,-1,0.99988306,0.00011696674
4364,sarin,12,13,74,79,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4364,-1,0.99987745,0.00012257064
4365,soman,14,15,84,89,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4365,-1,0.9998765,0.00012344011
4367,OPs,4,5,22,25,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4367,-1,0.99862313,0.0013768905
4369,ACh,27,28,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4369,-1,0.9997936,0.00020647838
4370,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4370,-1,0.99987936,0.00012063515
4371,pralidoxime-2-chloride,5,6,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4371,-1,0.9999051,9.4915355e-05
4372,2PAM,7,8,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4372,-1,0.999548,0.00045200967
4374,N(6)-cyclopentyl adenosine,26,28,154,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4374,-1,0.9998282,0.00017169902
4375,CPA,29,30,182,185,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4375,-1,0.99982554,0.00017444334
4376,dizocilpine maleate,39,41,228,247,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4376,-1,0.9999212,7.875598e-05
4377,-MK801 hydrogen maleate,43,46,250,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4377,-1,0.99942565,0.0005744215
4378,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4378,-1,0.9999236,7.635624e-05
4379,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4379,-1,0.99987555,0.00012442868
4380,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4380,-1,0.9999287,7.132645e-05
4381,olive oil,11,13,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4381,-1,0.9998615,0.0001384711
4382,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4382,-1,0.9998281,0.00017186906
4383,h,6,7,35,36,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4383,-1,0.13879368,0.86120635
4384,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4384,-1,0.99989283,0.000107138076
4386,CPA,1,2,5,8,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4386,-1,0.9994572,0.0005427837
4388,2PAM,5,6,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4388,-1,0.99989927,0.00010072898
4390,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,-1,4390,-1,0.047188587,0.9528114
4391,CPA,3,4,15,18,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4391,-1,0.99983966,0.00016034127
4393,2PAM,7,8,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4393,-1,0.99989986,0.00010008786
4397,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4397,-1,0.9997652,0.00023478412
4398,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4398,-1,0.00011399882,0.99988604
4399,gastric lymphoma,10,12,79,95,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4399,-1,0.00015447573,0.9998455
4400,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4400,-1,0.00013038964,0.9998696
4401,Steinert's disease).The,19,22,134,157,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4401,-1,0.060300317,0.9396997
4402,gastric lymphoma,30,32,222,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4402,-1,0.00014463217,0.9998554
4403,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4403,-1,0.00011423551,0.9998858
4404,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4404,-1,0.0001171993,0.9998828
4405,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4405,-1,0.000106096406,0.9998939
4406,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,-1,4406,-1,0.00011661015,0.9998834
4412,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4412,-1,0.99993753,6.245572e-05
4413,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4413,-1,0.99994004,6.001405e-05
4416,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4416,-1,0.999938,6.1952815e-05
4417,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4417,-1,0.9999368,6.317585e-05
4418,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,-1,-1,-1,4418,-1,0.9999336,6.635379e-05
4419,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,-1,-1,4419,-1,0.99994004,5.9984806e-05
4420,dilevalol antigens,16,18,120,138,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,-1,4420,-1,0.9993629,0.00063714694
4422,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,-1,-1,4422,-1,0.00010027702,0.99989974
4423,Nephrotic syndrome,0,2,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,-1,-1,4423,-1,0.0001076298,0.99989235
4427,Na,4,5,32,34,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,-1,-1,4427,-1,0.9998425,0.00015749695
4429,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4429,-1,0.9999356,6.4382744e-05
4430,PAN,11,12,74,77,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4430,-1,0.99975747,0.00024257237
4431,PAN,4,5,14,17,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4431,-1,0.999602,0.00039795123
4433,hypoalbuminemia,10,11,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4433,-1,0.00010923649,0.9998908
4436,contrast,1,2,3,11,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,-1,4436,-1,0.028730687,0.97126925
4438,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,-1,4438,-1,9.658161e-05,0.99990344
4440,behavioral disorder,2,4,23,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,-1,4440,-1,0.00010737413,0.9998926
4442,behavioral deterioration,4,6,22,46,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4442,-1,0.00014173413,0.99985826
4443,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4443,-1,0.000119674325,0.9998803
4445,sleeping difficulties,13,15,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4445,-1,0.00019430465,0.99980575
4447,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,-1,4447,-1,0.9999088,9.120645e-05
4450,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,-1,4450,-1,0.99994564,5.43122e-05
4453,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,-1,4453,-1,0.00011156794,0.9998884
4454,pyridoxal,3,4,13,22,The level of pyridoxal in the blood was normal during the periods of relapse.,150790_6,-1,-1,-1,4454,-1,0.99994683,5.3111686e-05
4455,kynurenine,7,8,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4455,-1,0.99991786,8.207594e-05
4456,tryptophan,10,11,65,75,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4456,-1,0.9998197,0.0001802774
4458,Parkinson's disease,15,18,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4458,-1,0.00031363618,0.99968636
4459,PD,19,20,127,129,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4459,-1,0.00017231307,0.9998276
4460,PD,8,9,62,64,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,-1,-1,4460,-1,0.00024374569,0.9997563
4461,PD,12,13,70,72,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4461,-1,0.00018812846,0.99981195
4464,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4464,-1,0.00010532145,0.9998946
4465,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,-1,4465,-1,0.00010592132,0.999894
4468,hyper- or dyskinetic,7,10,49,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,-1,4468,-1,0.00020548284,0.99979454
4471,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4471,-1,0.00015969876,0.99984026
4472,SE,11,12,75,77,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4472,-1,0.00019548244,0.99980456
4475,SE,40,41,276,278,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,-1,4475,-1,0.0013887899,0.9986112
4476,SE,1,2,3,5,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4476,-1,0.0060503576,0.99394965
4477,glutamate receptor antagonists,37,40,207,237,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4477,-1,0.9998301,0.00016985118
4479,SE,28,29,170,172,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,-1,4479,-1,0.11509519,0.8849048
4482,Urinary bladder cancer,0,3,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4482,-1,0.00019692461,0.9998031
4483,Wegener's granulomatosis,4,7,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4483,-1,0.00047464902,0.9995253
4487,Wegener's granulomatosis,21,24,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,-1,-1,4487,-1,0.00034578386,0.9996542
4488,Wegener's granulomatosis,17,20,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,-1,-1,4488,-1,0.0006011532,0.9993988
4494,Wegener's granulomatosis,10,13,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4494,-1,0.0015314099,0.9984686
4496,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4496,-1,0.0011684963,0.99883145
4498,n,11,12,70,71,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4498,-1,0.121189475,0.87881047
4499,n,18,19,92,93,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4499,-1,0.14420673,0.8557933
4503,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4503,-1,0.00082403055,0.99917597
4505,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4505,-1,0.0007975028,0.99920255
4508,Wegener's granulomatosis,35,38,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,-1,4508,-1,0.00033535398,0.99966466
4510,I1-imidazoline,7,8,61,75,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,-1,-1,4510,-1,0.99987054,0.00012941692
4516,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,-1,4516,-1,0.9999466,5.3405296e-05
4518,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4518,-1,0.99994373,5.632203e-05
4520,h,15,16,107,108,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4520,-1,0.006315214,0.9936847
4522,contrast,10,11,76,84,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4522,-1,0.016062746,0.9839372
4523,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4523,-1,0.27276787,0.7272321
4525,reduced locomotor activity,16,19,106,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,-1,4525,-1,0.00029106607,0.99970895
4529,left ventricular systolic and diastolic dysfunction,2,8,18,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4529,-1,0.00014644148,0.9998535
4530,epinephrine overdose,12,14,99,119,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4530,-1,0.008806106,0.99119395
4533,contrast,1,2,3,11,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4533,-1,0.049292836,0.95070714
4534,myocardial dysfunction,5,7,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4534,-1,0.000114264694,0.9998857
4536,mg,11,12,73,75,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4536,-1,0.9980184,0.0019816444
4538,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4538,-1,0.0001216851,0.9998783
4539,left ventricular systolic and diastolic dysfunction,30,36,206,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4539,-1,0.00015115808,0.99984884
4540,myocardial necrosis,44,46,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4540,-1,0.00010659808,0.9998934
4541,tincture of Crataegus,3,6,27,48,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4541,-1,0.9039174,0.09608263
4542,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4542,-1,0.000108562854,0.9998914
4543,Tincture of Crataegus,0,3,0,21,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4543,-1,0.99373984,0.006260186
4544,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4544,-1,0.95785195,0.04214804
4545,alcoholic extract of the berries of hawthorn,8,15,32,76,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4545,-1,0.9990503,0.000949703
4546,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4546,-1,0.99967384,0.00032612315
4547,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4547,-1,0.00010754485,0.9998925
4548,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4548,-1,0.98876745,0.011232586
4549,mg,37,38,206,208,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4549,-1,0.9579607,0.04203927
4550,h,50,51,254,255,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4550,-1,0.14612287,0.85387707
4551,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,-1,4551,-1,0.79590005,0.20409997
4553,TCR,0,1,0,3,TCR protected against pathological changes induced by isoproterenol in rat heart.,15233872_5,-1,-1,-1,4553,-1,0.73964053,0.2603594
4555,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,-1,-1,-1,4555,-1,0.9921983,0.0078017293
4557,valdecoxib,6,7,51,61,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4557,-1,0.99993205,6.7893925e-05
4558,agents,10,11,99,105,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4558,-1,0.9998135,0.00018651561
4562,NSAIDs,24,25,192,198,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4562,-1,0.9998599,0.00014002915
4563,valdecoxib,6,7,43,53,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4563,-1,0.99993813,6.1856714e-05
4564,osteoarthritis,17,18,122,136,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4564,-1,0.00014221716,0.9998578
4568,valdecoxib,23,24,160,170,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4568,-1,0.9999348,6.515019e-05
4569,mg,28,29,178,180,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4569,-1,0.9814152,0.018584771
4570,NSAID,33,34,202,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4570,-1,0.99992085,7.917443e-05
4572,mg,37,38,223,225,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4572,-1,0.9892135,0.010786429
4574,mg,42,43,245,247,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4574,-1,0.99145585,0.00854412
4575,naproxen,46,47,256,264,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4575,-1,0.9999372,6.286606e-05
4576,mg,48,49,269,271,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4576,-1,0.99342257,0.0065774247
4577,osteoarthritis,57,58,313,327,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4577,-1,0.00024117391,0.9997588
4579,n,11,12,63,64,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4579,-1,0.028115632,0.97188437
4580,mg,25,26,109,111,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4580,-1,0.99693227,0.003067675
4582,n,30,31,128,129,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4582,-1,0.0451605,0.9548395
4584,n,39,40,163,164,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4584,-1,0.028868133,0.97113186
4586,valdecoxib,10,11,77,87,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4586,-1,0.9999404,5.9567203e-05
4587,NSAIDs,12,13,89,95,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4587,-1,0.9998822,0.000117760086
4589,valdecoxib,11,12,64,74,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4589,-1,0.9999372,6.281758e-05
4593,valdecoxib,23,24,115,125,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4593,-1,0.9999325,6.748456e-05
4594,NSAIDs,31,32,142,148,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4594,-1,0.99987924,0.000120797
4596,valdecoxib,17,18,91,101,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,-1,4596,-1,0.9999378,6.224181e-05
4597,mg,10,11,66,68,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4597,-1,0.99771273,0.0022872274
4598,mg,19,20,107,109,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4598,-1,0.99532264,0.004677412
4599,valdecoxib,22,23,117,127,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4599,-1,0.9999417,5.828582e-05
4601,NSAIDs,37,38,227,233,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4601,-1,0.9998909,0.00010908025
4602,osteoarthritis,41,42,248,262,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4602,-1,0.00013814404,0.99986184
4604,Hypersensitivity myocarditis,0,2,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4604,-1,0.0001455597,0.99985445
4605,hypertrophic cardiomyopathy,3,5,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4605,-1,0.00016262163,0.9998374
4606,eosinophilic myocarditis,7,9,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4606,-1,0.00011641527,0.99988353
4607,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4607,-1,0.00011993057,0.9998801
4608,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4608,-1,0.0001108219,0.99988914
4609,biventricular failure,14,16,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4609,-1,0.00013915214,0.9998609
4611,ventricular dysfunction,8,10,55,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,-1,-1,4611,-1,0.00012934301,0.99987066
4613,hypertrophic cardiomyopathy,9,11,52,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,-1,-1,4613,-1,0.00011645047,0.99988353
4616,eosinophilic myocarditis,4,6,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,-1,-1,4616,-1,0.000120620876,0.99987936
4618,eosinophilic,7,8,40,52,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,-1,-1,4618,-1,0.00016693221,0.999833
4621,Eosinophilic myocarditis,0,2,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,-1,-1,4621,-1,0.000111078894,0.9998889
4625,Idiopathic subjective tinnitus,0,3,0,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4625,-1,0.0002349897,0.999765
4626,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4626,-1,0.0014032299,0.9985967
4627,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,-1,4627,-1,0.002408191,0.99759185
4633,vertigo,9,10,52,59,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4633,-1,0.00020066446,0.9997993
4636,lead,43,44,247,251,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4636,-1,0.03808608,0.96191394
4639,hypolocomotion,14,15,111,125,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,-1,-1,4639,-1,0.00019427705,0.99980575
4645,ion channels,3,5,22,34,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,-1,-1,-1,4645,-1,0.97365147,0.026348509
4647,hypolocomotion,12,13,76,90,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,-1,-1,4647,-1,0.00024814822,0.99975187
4652,hypolocomotion,18,19,118,132,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,-1,-1,4652,-1,0.0001635018,0.99983644
4661,SD,7,8,35,37,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4661,-1,0.040030975,0.95996904
4662,mg,14,15,56,58,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4662,-1,0.92937034,0.07062969
4664,mg,34,35,155,157,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4664,-1,0.9348378,0.0651622
4666,mg,9,10,37,39,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,-1,4666,-1,0.8823994,0.117600635
4672,rise in,1,3,4,11,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,-1,-1,-1,4672,-1,0.00063299417,0.99936706
4673,pressure,4,5,18,26,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,-1,-1,-1,4673,-1,0.0002763963,0.9997236
4680,Apamin,0,1,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4680,-1,0.9999341,6.5974215e-05
4681,potassium channels,7,9,49,67,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4681,-1,0.99141395,0.008586045
4683,Apamin,0,1,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4683,-1,0.99992776,7.2257375e-05
4685,mg,23,24,97,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4685,-1,0.94369835,0.05630162
4688,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4688,-1,0.017749438,0.9822505
4698,thiotepa,12,13,80,88,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,-1,4698,-1,0.99992883,7.111957e-05
4703,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4703,-1,0.000114869166,0.9998851
4704,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4704,-1,0.00011835662,0.9998816
4707,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4707,-1,0.0001669435,0.999833
4708,anthracyclines,66,67,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4708,-1,0.9998938,0.00010620644
4709,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,-1,4709,-1,0.000120003664,0.99987996
4712,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4712,-1,0.00013558168,0.99986446
4713,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4713,-1,0.00014140205,0.9998586
4715,CHF,9,10,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,-1,-1,-1,4715,-1,0.00012100578,0.999879
4722,obstructive lung disease,10,13,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,-1,-1,4722,-1,0.00012586077,0.9998741
4731,P,14,15,75,76,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,-1,-1,-1,4731,-1,0.38497412,0.6150258
4733,P,15,16,81,82,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,-1,-1,4733,-1,0.20876113,0.7912389
4735,P,13,14,86,87,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4735,-1,0.2052526,0.7947474
4740,sexual side effects,3,6,23,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4740,-1,0.00021820793,0.9997818
4743,impotence,21,22,140,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,-1,-1,-1,4743,-1,0.0012691795,0.99873084
4745,sexual side effects,13,16,70,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,-1,-1,4745,-1,0.00041786334,0.9995821
4748,sexual side effects,9,12,54,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4748,-1,0.00024104815,0.9997589
4750,obsessive compulsive disorder,6,9,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4750,-1,0.00014733129,0.99985266
4751,trichotillomania,10,11,64,80,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4751,-1,0.0003165941,0.9996834
4752,anxiety,12,13,82,89,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4752,-1,0.00015025174,0.9998497
4753,affective disorders,15,17,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4753,-1,0.00013401061,0.999866
4754,sexual side effects,19,22,127,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4754,-1,0.00021363157,0.99978644
4761,sweating,6,7,45,53,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4761,-1,0.00015643873,0.9998435
4762,anxiety,9,10,65,72,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4762,-1,0.0001371735,0.9998628
4764,sexual side effects,17,20,100,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4764,-1,0.00035162494,0.99964833
4767,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,-1,-1,4767,-1,0.00012309501,0.99987686
4768,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,-1,-1,-1,4768,-1,0.00011868403,0.99988127
4772,hemorrhagic cystitis,30,32,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,-1,4772,-1,0.00010442392,0.9998956
4773,hemorrhagic cystitis,11,13,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,-1,-1,-1,4773,-1,0.000116541116,0.9998834
4774,contrast,1,2,3,11,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4774,-1,0.02825652,0.9717435
4776,hemorrhagic cystitis,19,21,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4776,-1,0.0001136671,0.9998863
4777,hemorrhagic cystitis,21,23,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,-1,-1,-1,4777,-1,0.00011768287,0.99988234
4778,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4778,-1,0.99993455,6.542956e-05
4779,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4779,-1,0.99993026,6.974369e-05
4780,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,-1,-1,-1,4780,-1,0.9999409,5.90795e-05
4783,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,-1,4783,-1,0.9999349,6.508413e-05
4785,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,-1,-1,-1,4785,-1,0.999933,6.70136e-05
4786,venous thromboembolism,2,4,18,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4786,-1,0.00015503188,0.9998449
4789,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4789,-1,0.00019779569,0.9998022
4791,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4791,-1,0.9999428,5.724145e-05
4792,venous thromboembolism,18,20,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4792,-1,0.00013190908,0.99986804
4793,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,-1,-1,-1,4793,-1,0.9999367,6.3242645e-05
4794,Raloxifene,0,1,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4794,-1,0.9999423,5.773506e-05
4797,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4797,-1,0.00014220306,0.9998578
4799,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4799,-1,0.9999424,5.753697e-05
4800,venous thromboembolism,10,12,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4800,-1,0.00012238901,0.9998776
4803,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4803,-1,0.000132009,0.9998679
4807,lead,45,46,264,268,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,-1,4807,-1,0.0010135685,0.9989864
4809,dopamine agonist,24,26,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,-1,-1,-1,4809,-1,0.99989283,0.00010717486
4810,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4810,-1,0.00011262809,0.99988735
4812,psychosis,14,15,110,119,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4812,-1,0.00010135759,0.9998987
4813,sleep disturbances,16,18,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4813,-1,0.000112966365,0.999887
4814,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4814,-1,0.00015636328,0.9998436
4815,Parkinson's disease,5,8,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,-1,-1,-1,4815,-1,0.0004928958,0.99950707
4816,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,-1,4816,-1,0.00018777576,0.9998123
4818,DFO,5,6,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,-1,-1,-1,4818,-1,0.99987984,0.000120139
4820,SNHL,21,22,107,111,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,-1,-1,4820,-1,0.0003792152,0.9996208
4821,ototoxic,1,2,3,11,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4821,-1,0.00040966997,0.99959034
4822,DFO,6,7,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4822,-1,0.99988914,0.00011086989
4823,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,-1,4823,-1,0.0008041177,0.9991959
4824,SNHL,2,3,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4824,-1,0.0025968612,0.9974031
4825,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4825,-1,0.99990225,9.769779e-05
4826,DFO,7,8,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4826,-1,0.9949405,0.005059547
4827,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4827,-1,0.00013895045,0.999861
4828,thalassemic,7,8,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4828,-1,0.0012588942,0.9987411
4829,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4829,-1,0.00016716191,0.99983287
4831,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4831,-1,0.00012497471,0.99987507
4832,systemic sclerosis,21,23,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4832,-1,0.00011572794,0.99988425
4833,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4833,-1,0.00013115231,0.99986887
4834,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,-1,-1,4834,-1,0.00014090809,0.9998591
4839,anthracyclines,8,9,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4839,-1,0.99987805,0.0001219074
4841,heart damage,20,22,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4841,-1,0.00013010982,0.9998698
4842,systemic sclerosis,26,28,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4842,-1,0.000112162954,0.9998878
4843,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,-1,4843,-1,0.00025000743,0.99974996
4844,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4844,-1,0.99990034,9.960267e-05
4845,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4845,-1,0.00016060616,0.9998394
4846,diabetes?BACKGROUND,11,12,79,98,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4846,-1,0.0043951883,0.9956049
4847,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4847,-1,0.99989307,0.00010696159
4848,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,-1,-1,4848,-1,0.9998913,0.000108712855
4851,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4851,-1,0.9999021,9.783373e-05
4852,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4852,-1,0.00014689587,0.99985313
4853,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4853,-1,0.9999083,9.164112e-05
4854,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4854,-1,0.00015698595,0.999843
4855,n,17,18,106,107,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4855,-1,0.0060349093,0.9939651
4856,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4856,-1,0.00017098979,0.99982893
4857,n,26,27,141,142,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4857,-1,0.0049311696,0.9950688
4859,n,34,35,163,164,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4859,-1,0.0031103254,0.99688965
4861,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4861,-1,0.00021038519,0.99978966
4862,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4862,-1,0.00019003391,0.99981004
4865,folate,47,48,298,304,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4865,-1,0.99989414,0.00010584297
4866,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4866,-1,0.99989235,0.00010764867
4867,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4867,-1,0.00019771198,0.9998023
4868,P,76,77,444,445,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4868,-1,0.08993274,0.91006726
4869,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4869,-1,0.9999012,9.876056e-05
4870,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4870,-1,0.00018104,0.999819
4871,P,19,20,89,90,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4871,-1,0.22509056,0.7749094
4873,P,40,41,161,162,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4873,-1,0.20329219,0.7967078
4874,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4874,-1,0.999902,9.79448e-05
4875,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4875,-1,0.9998989,0.00010106959
4876,Vitamin C,0,2,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4876,-1,0.9999075,9.2499424e-05
4877,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4877,-1,0.0001390692,0.9998609
4878,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4878,-1,0.9999012,9.886082e-05
4879,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4879,-1,0.00017180451,0.9998282
4881,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,-1,-1,4881,-1,0.000108358276,0.99989164
4882,axonal degeneration,13,15,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4882,-1,0.0001120177,0.99988794
4883,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4883,-1,0.00010808233,0.9998919
4884,OCT,24,25,149,152,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4884,-1,0.7384412,0.26155874
4885,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,-1,4885,-1,0.99994147,5.855563e-05
4887,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4887,-1,0.99994254,5.745566e-05
4888,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4888,-1,0.00011306875,0.9998869
4889,contrast,14,15,88,96,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4889,-1,0.70028615,0.29971382
4890,optic neuropathy,8,10,34,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,-1,-1,4890,-1,0.00013163981,0.9998684
4891,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4891,-1,0.9999362,6.377803e-05
4892,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4892,-1,0.0001164788,0.99988353
4893,visual deficits,19,21,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4893,-1,0.00013325144,0.9998667
4894,contrast,34,35,237,245,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4894,-1,0.06335355,0.9366464
4895,OCT,3,4,13,16,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4895,-1,0.8287774,0.17122266
4896,OCT,5,6,18,21,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4896,-1,0.98112214,0.018877892
4897,CA,12,13,52,54,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4897,-1,0.34234804,0.65765196
4898,OCT,0,1,0,3,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4898,-1,0.7987093,0.2012907
4899,map,12,13,76,79,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4899,-1,0.062014893,0.9379851
4900,OCT,20,21,123,126,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4900,-1,0.9958033,0.0041966625
4901,n=661,22,23,128,133,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4901,-1,0.123237446,0.87676257
4902,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4902,-1,0.00012274596,0.9998772
4903,visual deficits,48,50,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4903,-1,0.00014990155,0.99985003
4904,C,56,57,282,283,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4904,-1,0.029284105,0.9707159
4905,visual deficits,60,62,298,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4905,-1,0.0001517292,0.99984825
4906,visual deficits,13,15,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4906,-1,0.00015561035,0.9998443
4907,C,19,20,92,93,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4907,-1,0.087535046,0.912465
4908,OCT,3,4,17,20,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4908,-1,0.87606555,0.123934396
4909,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4909,-1,0.00012181037,0.99987817
4910,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,-1,4910,-1,0.00011497623,0.99988496
4911,OCT,0,1,0,3,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4911,-1,0.7351506,0.2648494
4912,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4912,-1,0.0001404856,0.99985945
4913,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4913,-1,0.00010244228,0.9998976
4914,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4914,-1,0.99993575,6.428717e-05
4915,renal impairment,22,24,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4915,-1,0.00013757932,0.99986243
4921,n,19,20,96,97,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,-1,-1,4921,-1,0.33911026,0.66088974
4922,n,0,1,0,1,n = 9].,15572383_6,-1,-1,-1,4922,-1,0.22360063,0.7763994
4927,renal interstitial damage,11,14,74,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4927,-1,0.00011459632,0.99988544
4928,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4928,-1,0.00012906457,0.9998709
4931,focal glomerulosclerosis,7,9,42,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4931,-1,0.00013418283,0.9998658
4932,NS,14,15,78,80,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4932,-1,0.05763302,0.942367
4936,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4936,-1,0.00013712837,0.9998629
4940,diseased kidney,14,16,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,-1,4940,-1,0.00024336833,0.99975663
4942,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,-1,-1,4942,-1,0.00010187648,0.9998981
4944,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,-1,4944,-1,0.99992406,7.593409e-05
4946,tubulointerstitial injury,10,12,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,-1,-1,4946,-1,0.00022409181,0.99977595
4947,dUTP,16,17,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4947,-1,0.99976665,0.00023333554
4948,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4948,-1,0.0002400498,0.99976
4950,glomerular diseases,13,15,103,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,-1,-1,4950,-1,0.00013728524,0.9998627
4953,interferon,13,14,96,106,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4953,-1,0.99988735,0.00011265474
4955,hepatitis C.BACKGROUND,18,20,133,155,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4955,-1,0.0013636149,0.9986364
4957,interferon,35,36,239,249,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4957,-1,0.9998791,0.00012086577
4964,mg,14,15,72,74,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,-1,-1,-1,4964,-1,0.9879134,0.012086547
4968,P,26,27,96,97,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,-1,-1,4968,-1,0.08381508,0.9161849
4970,P,38,39,194,195,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,-1,-1,-1,4970,-1,0.10190562,0.89809436
4975,corticosteroid,17,18,97,111,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4975,-1,0.9998423,0.00015771395
4978,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4978,-1,0.00011132797,0.99988866
4980,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4980,-1,0.000116566676,0.9998834
4982,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4982,-1,0.00014715857,0.9998528
4984,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4984,-1,0.00013861405,0.99986136
4985,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,-1,-1,4985,-1,0.00011000446,0.99988997
4988,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4988,-1,0.00011811219,0.99988186
4989,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4989,-1,0.00012234948,0.9998777
4991,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,-1,4991,-1,0.00013322411,0.9998667
4994,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4994,-1,0.0001270285,0.9998729
4995,Cr,17,18,89,91,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4995,-1,0.0006269087,0.99937314
4998,n,18,19,108,109,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4998,-1,0.0045953295,0.9954047
4999,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4999,-1,0.00011813033,0.99988186
5000,n,26,27,134,135,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,5000,-1,0.0045237737,0.9954762
5005,n,38,39,240,241,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,-1,5005,-1,0.11046487,0.8895351
5006,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5006,-1,0.00011144981,0.99988854
5007,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5007,-1,0.004302676,0.9956974
5009,thiazide,31,32,193,201,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,5009,-1,0.9999286,7.144899e-05
5011,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,-1,-1,5011,-1,0.000117289295,0.9998827
5016,HAL,17,18,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,-1,5016,-1,0.99977297,0.00022709143
5017,PRL,5,6,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,-1,-1,-1,5017,-1,0.9998499,0.0001501137
5019,PCNA,8,9,75,79,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,-1,-1,-1,5019,-1,0.99933666,0.0006632983
5020,PRL,12,13,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,-1,5020,-1,0.99979943,0.00020057705
5022,hyperplasia,9,10,70,81,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,5022,-1,0.00018171898,0.99981827
5023,PCNA,18,19,132,136,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,5023,-1,0.99961096,0.00038910224
5024,contrast,7,8,55,63,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,5024,-1,0.8308576,0.16914244
5025,coronary stenosis,13,15,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,5025,-1,0.00012969674,0.9998703
5026,contrast,7,8,45,53,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5026,-1,0.94899845,0.051001538
5027,coronary occlusion,21,23,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5027,-1,0.00019690527,0.9998031
5028,coronary stenoses,26,28,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5028,-1,0.00017376436,0.99982625
5029,hyperemic,32,33,233,242,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,5029,-1,0.00014907453,0.99985087
5030,contrast,10,11,58,66,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5030,-1,0.015881548,0.98411846
5031,coronary stenosis,31,33,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,5031,-1,0.00014270212,0.9998573
5032,coronary occlusion,6,8,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5032,-1,0.00017489953,0.9998252
5033,contrast,15,16,83,91,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,5033,-1,0.76534164,0.23465833
5034,p,16,17,88,89,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,-1,-1,-1,5034,-1,0.07791909,0.92208093
5036,coronary stenosis,12,14,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5036,-1,0.00013657886,0.9998634
5037,contrast,21,22,129,137,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,5037,-1,0.4852849,0.5147151
5038,stenosis,9,10,47,55,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,-1,5038,-1,0.00012891709,0.999871
5040,stenosis,7,8,40,48,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,5040,-1,0.000182648,0.99981743
5042,contrast,44,45,251,259,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,5042,-1,0.93022805,0.06977191
5043,contrast,3,4,17,25,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5043,-1,0.5449468,0.45505318
5044,coronary stenosis,23,25,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,5044,-1,0.00019470692,0.9998053
5048,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,-1,-1,5048,-1,0.00018357264,0.9998165
5049,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5049,-1,0.00014675334,0.99985325
5050,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5050,-1,0.0001147343,0.9998852
5051,TD,13,14,106,108,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,5051,-1,0.00022028688,0.99977976
5052,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,-1,-1,5052,-1,0.00013975915,0.99986017
5062,orofacial diskinesia,16,18,103,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,5062,-1,0.00062942866,0.99937063
5064,degeneration of,9,11,74,89,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5064,-1,0.00038831736,0.9996117
5066,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,5066,-1,0.00013424658,0.9998658
5067,NMDA,16,17,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5067,-1,0.9998661,0.0001338839
5069,aortic occlusion,27,29,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,5069,-1,0.0004541687,0.99954575
5070,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5070,-1,0.0001696149,0.99983037
5071,aortic occlusion,6,8,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,5071,-1,0.0005087665,0.9994912
5072,C,11,12,50,51,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5072,-1,0.8683015,0.1316985
5073,n,13,14,53,54,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5073,-1,0.13617186,0.8638281
5075,n,25,26,92,93,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5075,-1,0.12369412,0.8763059
5076,h,35,36,135,136,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5076,-1,0.02095747,0.9790426
5078,n,48,49,185,186,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5078,-1,0.12239318,0.8776068
5079,n,60,61,223,224,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5079,-1,0.17764412,0.82235587
5080,h,67,68,250,251,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,5080,-1,0.027935373,0.9720647
5081,h,22,23,98,99,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,-1,-1,-1,5081,-1,0.020144591,0.9798554
5082,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5082,-1,0.9998621,0.00013795291
5083,spastic paraparesis,23,25,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,5083,-1,0.000105416904,0.9998946
5086,C,23,24,134,135,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5086,-1,0.7391993,0.2608007
5087,P,25,26,137,138,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,5087,-1,0.10128074,0.89871925
5088,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5088,-1,0.99985075,0.00014920352
5089,spastic paraparesis,11,13,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,5089,-1,0.00010432987,0.9998957
5091,spastic paraparesis,7,9,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5091,-1,0.00010739339,0.9998926
5093,NMDA,21,22,132,136,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5093,-1,0.9998634,0.00013662418
5095,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5095,-1,0.0001277927,0.9998722
5096,NMDA,15,16,85,89,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5096,-1,0.99985015,0.0001498627
5097,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,-1,5097,-1,0.00015574144,0.9998442
5100,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5100,-1,0.0001804437,0.9998196
5101,AF,13,14,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5101,-1,0.00015990627,0.99984
5102,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5102,-1,0.00012470306,0.9998753
5103,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5103,-1,0.00016638238,0.9998336
5108,gallbladder dysfunction,9,11,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,-1,-1,5108,-1,0.00017103252,0.99982893
5116,psychosis,5,6,38,47,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5116,-1,0.00011998179,0.99987996
5118,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5118,-1,0.00011420697,0.9998858
5122,psychosis,30,31,217,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5122,-1,0.000104437364,0.9998956
5126,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5126,-1,0.00012070268,0.99987924
5127,HVA,0,1,0,3,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5127,-1,0.9998425,0.00015750325
5128,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5128,-1,0.00011227402,0.9998877
5130,stereotypies,18,19,121,133,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,-1,-1,5130,-1,0.00018077935,0.9998192
5131,Coronary aneurysm,0,2,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,-1,-1,-1,5131,-1,0.00018577474,0.9998142
5132,coronary aneurysm,2,4,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5132,-1,0.00013650517,0.9998635
5135,vessel rupture,45,47,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5135,-1,0.00018661485,0.9998134
5136,coronary aneurysm,8,10,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,-1,-1,-1,5136,-1,0.00016893572,0.9998311
5139,mm,24,25,162,164,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,-1,-1,5139,-1,0.0039313473,0.9960686
5140,Pheochromocytoma,0,1,0,16,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5140,-1,0.00015908867,0.99984086
5141,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5141,-1,0.99993074,6.9262445e-05
5142,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5142,-1,0.9999354,6.465137e-05
5143,pheochromocytoma,7,8,40,56,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5143,-1,0.00014523209,0.9998548
5144,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5144,-1,0.9999324,6.764552e-05
5145,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5145,-1,0.9999385,6.154834e-05
5149,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5149,-1,0.99993575,6.424696e-05
5150,mg,24,25,150,152,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5150,-1,0.99494475,0.0050552473
5151,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5151,-1,0.99993455,6.544953e-05
5152,mg,28,29,170,172,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5152,-1,0.99463165,0.0053683682
5153,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,-1,-1,-1,5153,-1,0.9999366,6.346915e-05
5155,pheochromocytoma,15,16,113,129,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,-1,-1,-1,5155,-1,0.00034353277,0.99965644
5156,pheochromocytoma,5,6,37,53,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5156,-1,0.0001184797,0.9998815
5157,benzamide,14,15,103,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5157,-1,0.9999051,9.4856085e-05
5159,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5159,-1,0.9999343,6.569196e-05
5160,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5160,-1,0.9999316,6.8364556e-05
5162,pheochromocytoma,25,26,142,158,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,-1,-1,5162,-1,0.00012295459,0.999877
5163,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5163,-1,0.9999341,6.5963206e-05
5164,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5164,-1,0.9999285,7.1558774e-05
5165,neurological dysfunction,1,3,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,-1,5165,-1,0.000112499285,0.99988747
5167,neurological dysfunction,9,11,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,-1,-1,-1,5167,-1,0.000106694286,0.9998933
5172,asphyxia,3,4,24,32,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5172,-1,0.0001784504,0.9998216
5173,malformations,5,6,34,47,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5173,-1,0.00014346177,0.9998565
5174,haemorrhage,17,18,123,134,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5174,-1,0.00013397764,0.999866
5175,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5175,-1,0.00012235763,0.9998776
5176,psychomotor retardation,28,30,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5176,-1,0.0001081281,0.9998919
5177,neurological dysfunctions,9,11,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,-1,5177,-1,0.00017993155,0.99982005
5178,p<0.01,15,16,91,97,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,-1,5178,-1,0.08463683,0.9153632
5179,p<0.001,12,13,65,72,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,-1,5179,-1,0.090574145,0.90942585
5181,neurological dysfunctions,11,13,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,-1,-1,-1,5181,-1,0.00015298786,0.99984694
5183,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5183,-1,0.9999213,7.8660356e-05
5184,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5184,-1,0.0001168264,0.9998832
5185,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5185,-1,0.99994135,5.8669375e-05
5186,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5186,-1,0.99993944,6.0567658e-05
5187,VPA,7,8,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5187,-1,0.9998492,0.00015073403
5188,15-F(2t)-isoprostane,33,34,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5188,-1,0.9997799,0.00022016487
5189,15-F(2t)-IsoP,35,36,195,208,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5189,-1,0.9995245,0.00047551992
5191,VPA,23,24,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,-1,5191,-1,0.9999211,7.892048e-05
5192,15-F(2t)-IsoP,11,12,72,85,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5192,-1,0.99981016,0.00018980897
5193,lipid hydroperoxides,13,15,87,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5193,-1,0.99977034,0.00022970178
5194,LPO,16,17,109,112,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5194,-1,0.99981505,0.00018491903
5195,thiobarbituric acid reactive substances,20,24,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5195,-1,0.9998585,0.00014147583
5196,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5196,-1,0.9998616,0.00013836552
5197,15-F(2t)-IsoP,3,4,17,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5197,-1,0.99976546,0.00023451741
5198,VPA,14,15,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5198,-1,0.9999002,9.9806704e-05
5199,LPO,1,2,6,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5199,-1,0.9994443,0.0005556446
5200,p,16,17,86,87,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5200,-1,0.10752171,0.8924783
5201,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5201,-1,0.999869,0.00013099358
5202,p,15,16,77,78,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5202,-1,0.121922255,0.87807775
5203,Liver toxicity,0,2,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,-1,-1,5203,-1,0.00016619703,0.9998338
5207,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,-1,5207,-1,0.0001388294,0.9998611
5208,VPA,7,8,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,-1,5208,-1,0.99987936,0.0001206248
5209,VPA,6,7,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5209,-1,0.9999037,9.6308926e-05
5210,15-F(2t)-IsoP,18,19,106,119,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5210,-1,0.9997465,0.00025344183
5212,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5212,-1,0.00012172909,0.9998783
5219,n=25,45,46,252,256,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,-1,5219,-1,0.033456523,0.9665435
5225,antiphospholipid syndrome,11,13,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5225,-1,0.045740712,0.9542593
5226,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5226,-1,0.00011893054,0.999881
5236,DFU,15,16,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,-1,5236,-1,0.9998636,0.00013631576
5241,DFU,20,21,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5241,-1,0.9997893,0.00021070597
5242,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon",22,25,122,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5242,-1,0.9996401,0.00035988895
5243,phenyl-2(5H)-furanon,24,25,176,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5243,-1,0.99948764,0.00051229575
5244,COX-2 inhibitors,26,28,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5244,-1,0.9993309,0.0006691486
5246,DFU,18,19,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,-1,-1,-1,5246,-1,0.999887,0.000112981455
5247,VSD,8,9,56,59,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5247,-1,0.0018708291,0.9981292
5248,MD,13,14,74,76,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5248,-1,0.0009173183,0.9990827
5250,COX-2,28,29,166,171,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5250,-1,0.99984944,0.00015055333
5252,growth retardation,6,8,41,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5252,-1,0.00013029967,0.9998697
5253,increase of external and skeletal variations,10,16,65,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5253,-1,0.0002058403,0.9997942
5255,DFU,10,11,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,-1,-1,5255,-1,0.99927825,0.00072177016
5257,teratogenicity,2,3,8,22,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,-1,-1,-1,5257,-1,0.0001782363,0.99982184
5259,COX inhibitors,4,6,35,49,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5259,-1,0.9998827,0.00011726994
5260,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5260,-1,0.0007553955,0.9992446
5261,MD,12,13,80,82,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5261,-1,0.0006088168,0.9993912
5262,COX-2 inhibitors,22,24,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5262,-1,0.9998914,0.000108594744
5263,COX-2 inhibitors,6,8,45,61,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,-1,-1,-1,5263,-1,0.99986064,0.00013938053
5264,DFU,1,2,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,-1,-1,-1,5264,-1,0.99952483,0.0004752111
5266,COX-2 inhibitors,4,6,31,47,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,-1,-1,-1,5266,-1,0.9998958,0.000104145875
5267,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5267,-1,0.24766487,0.75233513
5268,rubella,6,7,40,47,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5268,-1,0.9998616,0.00013834045
5269,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5269,-1,0.93982476,0.060175255
5270,rubella,12,13,84,91,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5270,-1,0.99984205,0.000157943
5271,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5271,-1,0.18354309,0.8164569
5272,rubella,13,14,77,84,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5272,-1,0.847154,0.15284598
5273,hepatitis B vaccine,18,21,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5273,-1,0.99964976,0.00035028064
5274,hepatitis B,29,31,173,184,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5274,-1,0.99945337,0.00054664945
5275,hepatitis B,39,41,229,240,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5275,-1,0.69705915,0.30294082
5276,rubella,45,46,275,282,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5276,-1,0.9997398,0.00026012294
5277,rubella vaccine,53,55,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5277,-1,0.9998746,0.00012534372
5278,rubella,56,57,357,364,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5278,-1,0.9994572,0.0005427834
5279,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5279,-1,0.008453937,0.9915461
5280,rubella,13,14,62,69,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5280,-1,0.9997012,0.00029881846
5281,Hepatitis B vaccine,0,3,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,-1,5281,-1,0.99960035,0.0003996531
5282,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5282,-1,0.68595415,0.31404585
5283,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5283,-1,0.99709153,0.002908441
5284,birth weight,11,13,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5284,-1,0.0074504605,0.99254954
5285,hepatitis B,17,19,122,133,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5285,-1,0.9991478,0.00085223943
5286,rubella,13,14,66,73,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,-1,5286,-1,0.99966145,0.00033859382
5287,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,-1,-1,-1,5287,-1,0.9999144,8.552899e-05
5288,hepatitis B,18,20,126,137,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5288,-1,0.8441416,0.15585846
5289,rubella,21,22,142,149,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5289,-1,0.9997986,0.00020137517
5290,masseter muscle rigidity,1,4,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,-1,-1,5290,-1,0.00067678804,0.99932325
5291,Masseter muscle rigidity,0,3,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5291,-1,0.0010596244,0.9989404
5292,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5292,-1,0.000111088215,0.9998889
5293,masseter muscle rigidity,19,22,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,-1,-1,-1,5293,-1,0.0010896645,0.9989103
5294,masseter muscle rigidity,8,11,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5294,-1,0.00068469084,0.99931526
5295,steel,14,15,68,73,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5295,-1,0.05976596,0.940234
5297,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5297,-1,0.9997044,0.00029553866
5299,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,-1,-1,5299,-1,0.000108715554,0.9998913
5300,Dexrazoxane,0,1,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5300,-1,0.9999349,6.504082e-05
5302,drugs etoposide,8,10,78,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,-1,-1,5302,-1,0.9998354,0.00016465156
5305,anthracyclines daunorubicin,3,5,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5305,-1,0.9999037,9.6300195e-05
5307,epipodophyllotoxin etoposide,9,11,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5307,-1,0.99990344,9.6568714e-05
5310,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5310,-1,0.99993503,6.497958e-05
5311,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5311,-1,0.95798206,0.04201797
5313,hematologic toxicity,10,12,58,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5313,-1,0.00012937782,0.99987066
5314,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5314,-1,0.9999393,6.0731392e-05
5318,dexrazoxane,44,45,304,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5318,-1,0.9999347,6.530483e-05
5322,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,-1,5322,-1,0.99993503,6.495888e-05
5323,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5323,-1,0.99994195,5.800093e-05
5325,weight loss,9,11,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5325,-1,0.00023449282,0.99976546
5328,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5328,-1,0.9999393,6.0680275e-05
5330,weight loss,34,36,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5330,-1,0.0002240339,0.99977595
5331,cytotoxicity,41,42,274,286,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5331,-1,0.00018672805,0.99981326
5333,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,-1,5333,-1,0.9999411,5.8862708e-05
5336,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,-1,-1,-1,5336,-1,0.99994004,5.9906033e-05
5337,metastases,6,7,39,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5337,-1,0.00015354424,0.99984646
5338,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5338,-1,0.9999423,5.7696365e-05
5340,hematologic toxicity,24,26,166,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5340,-1,0.0001085965,0.9998914
5341,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,-1,5341,-1,0.00010713317,0.99989283
5343,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5343,-1,0.0001477056,0.9998523
5344,heart disease,7,9,57,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5344,-1,0.00020123237,0.99979883
5346,Thyroid disorders,0,2,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5346,-1,0.00016603371,0.99983394
5348,emergency department,13,15,66,86,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5348,-1,0.0013112493,0.99868876
5349,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5349,-1,0.00012980388,0.9998702
5355,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,-1,-1,-1,5355,-1,0.9985488,0.0014511718
5373,BE,13,14,80,82,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,-1,-1,-1,5373,-1,0.99950874,0.00049130025
5393,inability to repeat words,8,12,48,73,The mean highest BIS score corresponding to the inability to repeat words was 81.5 (95% CI = 78.1 to 84.8).,15930398_13,-1,-1,-1,5393,-1,0.03489396,0.965106
5394,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,-1,5394,-1,0.00020395037,0.9997961
5395,Ro4368554,5,6,40,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5395,-1,0.99986804,0.00013194531
5396,memory deficiency,15,17,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5396,-1,0.0001458794,0.9998541
5399,ACh,19,20,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,-1,5399,-1,0.99982774,0.00017217018
5400,5-HT(6,11,12,80,86,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5400,-1,0.99983954,0.0001603951
5401,) antagonist Ro4368554,12,15,86,108,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5401,-1,0.9988967,0.0011032409
5402,3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole,16,17,110,164,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5402,-1,0.9997733,0.00022672494
5404,tryptophan,35,36,271,281,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5404,-1,0.9998876,0.00011240332
5405,TRP,37,38,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5405,-1,0.99986005,0.00013991343
5406,metrifonate,56,57,399,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5406,-1,0.9999424,5.7602523e-05
5407,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5407,-1,0.99993765,6.238251e-05
5408,Ro4368554,33,34,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5408,-1,0.9998803,0.00011962834
5409,Ro4368554,2,3,6,15,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5409,-1,0.99984694,0.00015307733
5410,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5410,-1,0.9999418,5.8183527e-05
5411,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5411,-1,0.0001152268,0.9998847
5413,TRP,33,34,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5413,-1,0.99986565,0.00013438554
5414,Ro4368554,4,5,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5414,-1,0.9998833,0.00011664039
5415,retention deficit,10,12,65,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5415,-1,0.00016315903,0.9998368
5416,memory deficit,20,22,129,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5416,-1,0.00014024992,0.9998597
5417,Ro4368554,37,38,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5417,-1,0.99989676,0.00010324183
5418,Amiodarone pulmonary toxicity,0,3,0,29,Amiodarone pulmonary toxicity.,1595783_0,-1,-1,-1,5418,-1,0.14304239,0.8569576
5420,pneumonitis,18,19,122,133,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,-1,5420,-1,0.00012161436,0.9998784
5421,pulmonary toxicity,1,3,4,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5421,-1,0.000106870735,0.99989307
5423,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5423,-1,0.0001199412,0.9998801
5424,pulmonary toxicity,7,9,61,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,-1,-1,5424,-1,0.000106680964,0.9998933
5425,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,-1,-1,5425,-1,0.0001521199,0.9998479
5430,kainate receptor antagonists,7,10,43,71,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,-1,-1,5430,-1,0.9998623,0.00013771346
5432,Amino acids,0,2,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5432,-1,0.99979275,0.00020720491
5433,KA,12,13,64,66,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5433,-1,0.9997507,0.00024933022
5434,antagonists,14,15,76,87,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5434,-1,0.999355,0.0006450173
5437,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5437,-1,0.00011376134,0.9998863
5438,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5438,-1,0.00011210084,0.99988794
5444,pharyngitis,17,18,116,127,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,-1,-1,5444,-1,0.00019830593,0.9998017
5447,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,-1,-1,5447,-1,0.99993443,6.554015e-05
5458,macrolide,10,11,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,-1,-1,5458,-1,0.9998404,0.00015959461
5459,macrolides,36,37,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,-1,5459,-1,0.9998271,0.00017291053
5464,macrolide,2,3,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,-1,5464,-1,0.9998503,0.00014968247
5466,GNC92H2,6,7,50,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5466,-1,0.9982085,0.001791436
5467,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5467,-1,0.00909119,0.9909088
5469,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,-1,5469,-1,0.007697664,0.9923023
5470,GNC92H2,7,8,54,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5470,-1,0.99821496,0.0017850761
5471,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5471,-1,0.009673808,0.9903262
5473,GNC92H2,23,24,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,-1,5473,-1,0.9996909,0.00030915343
5474,GNC92H2,0,1,0,7,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,-1,-1,-1,5474,-1,0.9983718,0.0016282061
5476,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5476,-1,0.016398031,0.983602
5477,GNC92H2,12,13,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5477,-1,0.999699,0.00030108963
5480,GNC92H2,2,3,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5480,-1,0.99940836,0.00059164356
5482,GNC92H2,7,8,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5482,-1,0.99839216,0.0016078264
5483,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5483,-1,0.01063312,0.9893668
5484,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,-1,5484,-1,0.06459566,0.93540436
5489,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5489,-1,0.0001234335,0.9998765
5490,metabolic alkalosis,11,13,64,83,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5490,-1,0.0002487753,0.99975127
5491,parathyroid hormone,16,18,93,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5491,-1,0.9998833,0.00011668433
5492,"1,25-dihydroxyvitamin D",26,28,145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5492,-1,0.99987006,0.00012995845
5495,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5495,-1,0.9999509,4.9156977e-05
5496,mg,16,17,106,108,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5496,-1,0.9927375,0.0072625303
5499,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,-1,-1,-1,5499,-1,0.9998622,0.00013777596
5501,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,-1,5501,-1,0.99990916,9.087239e-05
5504,vitamin D,12,14,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,-1,-1,-1,5504,-1,0.9998934,0.00010653234
5505,Pamidronate,0,1,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,-1,-1,5505,-1,0.999948,5.1996674e-05
5513,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5513,-1,0.00011365788,0.9998863
5515,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5515,-1,0.00035714355,0.99964285
5516,leukocytoclastic vasculitis,1,3,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,-1,5516,-1,0.00010551486,0.9998945
5517,Leukocytoclastic vasculitis,0,2,0,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5517,-1,0.00014263095,0.9998573
5518,LV,3,4,29,31,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5518,-1,0.0004755834,0.9995245
5519,cutaneous small vessel vasculitis,8,12,48,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5519,-1,0.00016049285,0.9998394
5520,LV,6,7,37,39,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,-1,5520,-1,0.00042586896,0.9995741
5522,skin eruptions,5,7,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,-1,-1,-1,5522,-1,0.00014751332,0.9998524
5524,skin lesion,3,5,15,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5524,-1,0.00020992753,0.99979013
5525,LV Cutaneous lesions,13,16,77,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5525,-1,0.0005669748,0.999433
5528,LV,0,1,0,2,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,-1,5528,-1,0.001638024,0.998362
5539,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,-1,5539,-1,0.000116456686,0.99988353
5541,Parkinson disease,23,25,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5541,-1,0.00013838756,0.9998616
5542,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5542,-1,0.000117780415,0.9998822
5545,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,-1,5545,-1,0.00013802963,0.99986196
5546,lipid bilayers,6,8,45,59,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,-1,5546,-1,0.59458953,0.40541053
5550,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,-1,5550,-1,0.0006683519,0.99933165
5553,mg paclitaxel,8,10,42,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5553,-1,0.9994647,0.0005352627
5554,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5554,-1,0.00010199176,0.99989796
5555,mg paclitaxel,29,31,163,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5555,-1,0.99945337,0.0005466489
5556,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,-1,-1,5556,-1,0.00010748251,0.9998925
5558,Lamotrigine,0,1,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5558,-1,0.9999424,5.7540045e-05
5560,idiopathic generalized epilepsies,9,12,65,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5560,-1,0.00011835087,0.9998816
5561,idiopathic generalized epilepsies,3,6,19,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5561,-1,0.00013535934,0.9998646
5562,IGE,7,8,54,57,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5562,-1,0.0028971254,0.9971029
5563,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5563,-1,0.999948,5.1978728e-05
5564,LTG,13,14,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5564,-1,0.9997898,0.00021021113
5566,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5566,-1,0.0005848768,0.99941516
5567,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5567,-1,0.9997769,0.00022305387
5568,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5568,-1,0.010143685,0.98985636
5569,MJ,0,1,0,2,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5569,-1,0.018799236,0.98120075
5570,LTG,3,4,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5570,-1,0.9998503,0.00014971988
5571,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5571,-1,0.9997553,0.00024469712
5572,MJ,6,7,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5572,-1,0.0011421808,0.99885786
5573,myoclonic status,16,18,78,94,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5573,-1,0.00020492854,0.99979514
5574,LTG,22,23,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5574,-1,0.9998435,0.00015648082
5577,thyrotropin,16,17,116,127,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,-1,5577,-1,0.9998857,0.00011425828
5578,penile erection,20,22,126,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,-1,5578,-1,0.00019234007,0.99980766
5580,psychiatric disorders,12,14,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,-1,-1,5580,-1,0.000117168456,0.9998828
5586,memory dissociation,4,6,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,-1,-1,-1,5586,-1,0.0003244142,0.99967563
5589,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5589,-1,0.99993956,6.044568e-05
5590,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5590,-1,0.99993885,6.116445e-05
5591,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,-1,5591,-1,0.00012222027,0.9998778
5593,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,-1,-1,-1,5593,-1,0.9999279,7.21124e-05
5595,n,3,4,22,23,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,-1,5595,-1,0.21078551,0.7892145
5597,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5597,-1,0.99994016,5.982862e-05
5598,amenorrhea,14,15,101,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5598,-1,0.00013977783,0.99986017
5599,P,16,17,113,114,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5599,-1,0.13710433,0.8628956
5600,venous thromboembolism,9,11,50,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5600,-1,0.00012283132,0.9998771
5601,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5601,-1,0.9999373,6.2756866e-05
5602,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,-1,-1,5602,-1,0.00014435344,0.99985564
5604,neurovascular complications,8,10,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,-1,5604,-1,0.000112962494,0.999887
5607,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5607,-1,0.00015397117,0.999846
5608,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5608,-1,0.00012691662,0.99987304
5610,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,-1,5610,-1,0.00021202075,0.999788
5612,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,-1,5612,-1,0.00016868171,0.9998313
5614,p,35,36,226,227,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,-1,5614,-1,0.14097527,0.85902476
5615,p,48,49,316,317,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,-1,5615,-1,0.1488742,0.8511258
5617,aneurysmal SAH,29,31,209,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,-1,5617,-1,0.00010978209,0.9998902
5625,MAP,5,6,42,45,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,-1,-1,5625,-1,0.99803346,0.0019665062
5627,Aggressive behaviors,0,2,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5627,-1,0.00019103708,0.99980897
5628,psychiatric disorders,11,13,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5628,-1,0.000118036194,0.999882
5630,METH,20,21,131,135,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5630,-1,0.9997353,0.0002647137
5631,METH,13,14,63,67,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,-1,5631,-1,0.9998271,0.00017296331
5635,MAP,14,15,112,115,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5635,-1,0.9979898,0.0020101736
5636,METH,21,22,166,170,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5636,-1,0.9997837,0.00021629209
5637,p<0.05,5,6,38,44,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5637,-1,0.14199881,0.8580012
5638,METH,32,33,153,157,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5638,-1,0.9997898,0.00021019751
5639,METH,10,11,66,70,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5639,-1,0.9998375,0.00016244355
5640,METH,23,24,134,138,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5640,-1,0.9998417,0.0001582825
5641,METH,22,23,129,133,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,-1,5641,-1,0.9998204,0.00017956803
5642,MAP,6,7,43,46,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5642,-1,0.9996007,0.00039934347
5643,aggressive behaviors,20,22,151,171,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5643,-1,0.00015345731,0.9998466
5644,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,-1,-1,5644,-1,0.99992204,7.7958706e-05
5646,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5646,-1,0.00016123155,0.9998387
5647,antipsychotics,8,9,53,67,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5647,-1,0.99985325,0.00014668255
5650,ziprasidone,15,16,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5650,-1,0.999943,5.6969817e-05
5651,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,-1,-1,-1,5651,-1,0.99993694,6.311035e-05
5654,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5654,-1,0.99993086,6.9130074e-05
5655,mg,20,21,148,150,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5655,-1,0.9891888,0.0108112255
5656,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5656,-1,0.99993145,6.853042e-05
5657,mg,15,16,95,97,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5657,-1,0.99367875,0.0063212137
5658,psychosis,3,4,13,22,"However, her psychosis recurred after the dose reduction.",16225977_5,-1,-1,-1,5658,-1,0.00013053932,0.99986947
5659,mg,8,9,40,42,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5659,-1,0.9781073,0.021892684
5660,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5660,-1,0.9999341,6.5887194e-05
5661,antipsychotics,22,23,162,176,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5661,-1,0.9998673,0.00013264545
5662,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5662,-1,0.99993575,6.422417e-05
5664,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5664,-1,0.99991703,8.302007e-05
5665,dysphonia,1,2,10,19,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5665,-1,0.00012492968,0.99987507
5666,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5666,-1,0.9999275,7.245927e-05
5667,dysphonia,9,10,45,54,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5667,-1,0.00013057319,0.99986947
5668,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5668,-1,0.99994564,5.43704e-05
5669,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,-1,5669,-1,0.9999478,5.2263335e-05
5670,dysphonia,11,12,62,71,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,-1,5670,-1,0.0001066113,0.9998934
5672,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5672,-1,0.00014370136,0.99985623
5673,blindness,6,7,46,55,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5673,-1,0.00011813969,0.99988186
5675,deterioration of vision,14,17,101,124,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5675,-1,0.00023417421,0.9997658
5676,fatiguability,19,20,131,144,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5676,-1,0.00017136929,0.9998286
5677,dyspnoea,21,22,146,154,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5677,-1,0.00015467219,0.99984527
5679,syncopal attacks,26,28,181,197,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5679,-1,0.00013995747,0.99986005
5680,chloroquine retinopathy,5,7,49,72,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5680,-1,0.15040639,0.84959364
5681,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5681,-1,0.00013300324,0.99986696
5682,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5682,-1,0.00016168604,0.99983823
5683,right bundle branch block,21,25,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5683,-1,0.0004889763,0.999511
5684,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5684,-1,0.00013066771,0.99986935
5685,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5685,-1,0.000118445816,0.9998815
5687,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,-1,5687,-1,0.0084472,0.99155277
5688,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5688,-1,0.99989116,0.00010877766
5689,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5689,-1,0.00012189043,0.99987805
5693,ototoxic,11,12,60,68,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,-1,-1,5693,-1,0.00018171917,0.99981827
5696,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,-1,-1,5696,-1,0.00016509299,0.9998349
5697,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,-1,5697,-1,0.00012960253,0.9998704
5706,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5706,-1,0.00017363005,0.9998264
5708,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5708,-1,0.00014626468,0.99985373
5718,Cl,51,52,162,164,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,-1,-1,5718,-1,0.075287566,0.9247124
5722,tissue injury,27,29,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5722,-1,0.00024167733,0.9997583
5725,neurogenic hyperalgesia,6,8,60,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,-1,-1,5725,-1,0.0001251369,0.99987483
5732,mg,6,7,33,35,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,-1,-1,-1,5732,-1,0.9810575,0.018942425
5740,Mitochondrial abnormalities,0,2,0,27,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,-1,5740,-1,0.00047590805,0.9995241
5742,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5742,-1,0.00019695635,0.999803
5743,c,30,31,195,196,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5743,-1,0.9997675,0.00023247325
5746,mitochondrial abnormalities,3,5,22,49,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,-1,5746,-1,0.00032996395,0.99967
5747,suprofen,2,3,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,-1,5747,-1,0.9999006,9.9367775e-05
5748,suprofen,1,2,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5748,-1,0.9998752,0.00012476633
5749,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5749,-1,0.00011553663,0.9998845
5751,mg,10,11,54,56,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5751,-1,0.99421906,0.0057808957
5752,suprofen,12,13,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5752,-1,0.9998969,0.00010306063
5753,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5753,-1,0.99991846,8.1474245e-05
5756,suprofen,21,22,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,-1,5756,-1,0.99989164,0.00010837791
5757,contrast,1,2,3,11,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5757,-1,0.0128335925,0.98716635
5758,suprofen,16,17,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5758,-1,0.9999064,9.355131e-05
5759,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5759,-1,0.9999187,8.132025e-05
5760,suprofen,30,31,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5760,-1,0.9999106,8.937141e-05
5761,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5761,-1,0.9999044,9.561776e-05
5762,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5762,-1,0.9998921,0.000107910455
5763,suprofen,16,17,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5763,-1,0.99989426,0.000105723346
5764,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,-1,5764,-1,0.9998872,0.00011275597
5765,suprofen,3,4,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5765,-1,0.9998235,0.00017649624
5766,declines in renal function,6,10,34,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5766,-1,0.00024328273,0.99975675
5767,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5767,-1,0.9999063,9.373079e-05
5768,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,-1,5768,-1,0.9999527,4.7363515e-05
5770,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,-1,5770,-1,0.99995136,4.8642356e-05
5773,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5773,-1,0.9998216,0.00017846945
5774,saline+DMSO,13,14,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5774,-1,0.99968314,0.000316855
5776,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5776,-1,0.99994874,5.1313356e-05
5778,ritanserin,55,56,278,288,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5778,-1,0.99994683,5.318046e-05
5779,injection)+ritanserin,56,57,289,310,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5779,-1,0.9961278,0.003872213
5780,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5780,-1,0.9996226,0.0003773428
5782,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,-1,5782,-1,0.99995077,4.9273563e-05
5783,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,-1,5783,-1,0.99995255,4.747856e-05
5785,calcium channel blocker nitrendipine,4,8,22,58,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5785,-1,0.9998871,0.0001128474
5786,nephrosclerosis,9,10,62,77,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5786,-1,0.00010444863,0.9998956
5787,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5787,-1,0.00012308315,0.99987686
5788,calcium channel blocker nitrendipine,8,12,42,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5788,-1,0.9998994,0.00010065698
5792,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5792,-1,0.00011687185,0.99988306
5794,mm Hg,16,18,75,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5794,-1,0.018701846,0.9812982
5796,n,30,31,155,156,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5796,-1,0.036639765,0.9633603
5797,n,36,37,182,183,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5797,-1,0.043749474,0.9562505
5798,n,43,44,215,216,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5798,-1,0.058723506,0.9412765
5799,mm Hg,11,13,62,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5799,-1,0.054529317,0.94547063
5800,n,14,15,69,70,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5800,-1,0.14656778,0.85343224
5801,sclerosis,10,11,67,76,Renal tissue was obtained for determination of glomerular size and sclerosis.,1639466_5,-1,-1,-1,5801,-1,0.00012184407,0.99987817
5806,contrast,1,2,3,11,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,-1,5806,-1,0.013499465,0.98650056
5813,torsades de pointes,2,5,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,-1,5813,-1,0.00047280712,0.9995272
5815,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5815,-1,0.0001919491,0.99980813
5816,prolonged QT interval,12,15,72,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5816,-1,0.00026431723,0.99973565
5817,torsades de pointes,16,19,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5817,-1,0.0014204017,0.9985796
5818,TdP,20,21,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5818,-1,0.002083379,0.99791664
5820,fungal infection,28,30,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5820,-1,0.00025903917,0.9997409
5824,long QT syndrome,37,40,227,243,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,-1,5824,-1,0.00016663515,0.99983335
5826,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5826,-1,0.00028461535,0.9997154
5827,Graves' disease,9,12,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5827,-1,0.0006473313,0.99935263
5828,purpura,1,2,9,16,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,-1,-1,-1,5828,-1,0.0006154153,0.9993845
5830,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5830,-1,0.00033704666,0.999663
5831,Graves' disease,8,11,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5831,-1,0.00079000875,0.99921
5832,purpuric lesions,15,17,86,102,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5832,-1,0.00018775678,0.9998123
5835,PTU,36,37,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,-1,-1,5835,-1,0.99959785,0.00040215693
5842,Cerebral vasculitis,0,2,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5842,-1,0.00011346417,0.9998865
5843,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5843,-1,0.17107806,0.8289219
5844,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5844,-1,0.00012554169,0.9998745
5848,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,-1,-1,5848,-1,0.00012572485,0.99987423
5849,cerebral vasculitis,3,5,25,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5849,-1,0.00010115453,0.9998988
5850,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5850,-1,0.00011531398,0.9998847
5853,neurological symptoms,12,14,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,-1,-1,5853,-1,0.000116440366,0.99988353
5856,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,-1,5856,-1,0.9999323,6.77116e-05
5861,ACh,22,23,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5861,-1,0.99981385,0.00018622701
5862,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5862,-1,0.00041893483,0.99958104
5863,AD,37,38,224,226,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5863,-1,0.0001700896,0.9998299
5864,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,-1,5864,-1,0.9999249,7.510834e-05
5865,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,-1,5865,-1,0.99993396,6.601298e-05
5866,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5866,-1,0.99994373,5.621069e-05
5867,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5867,-1,0.22802791,0.7719721
5870,contrast,3,4,10,18,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5870,-1,0.07912414,0.92087585
5871,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5871,-1,0.99994123,5.8743324e-05
5873,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,-1,-1,5873,-1,0.9999435,5.6538793e-05
5876,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5876,-1,0.00014204816,0.9998579
5877,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5877,-1,0.9999424,5.7529727e-05
5878,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5878,-1,0.00020624601,0.9997938
5879,OAB,19,20,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5879,-1,0.001217589,0.99878246
5880,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5880,-1,0.99994636,5.3595955e-05
5881,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,-1,5881,-1,0.0048317895,0.9951682
5882,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5882,-1,0.9999337,6.624631e-05
5883,mg,2,3,14,16,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5883,-1,0.9922259,0.007774075
5884,nocturia,3,4,14,22,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,-1,5884,-1,0.00023668105,0.9997633
5885,dry month,6,8,32,41,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,-1,-1,5885,-1,0.0009115757,0.9990884
5887,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5887,-1,0.99994445,5.549946e-05
5888,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5888,-1,0.37278083,0.6272192
5889,Remifentanil,0,1,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5889,-1,0.99994195,5.8040438e-05
5891,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5891,-1,0.99993145,6.8485795e-05
5892,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5892,-1,0.99994516,5.483826e-05
5894,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5894,-1,0.9999397,6.0327973e-05
5895,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,-1,5895,-1,0.9999397,6.0342987e-05
5896,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5896,-1,0.9999443,5.5656128e-05
5897,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5897,-1,0.99994457,5.543398e-05
5903,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5903,-1,0.9999411,5.8904825e-05
5904,P,28,29,131,132,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5904,-1,0.045599926,0.9544001
5909,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,-1,5909,-1,0.99994135,5.8632122e-05
5910,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5910,-1,0.9999473,5.2630032e-05
5912,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5912,-1,0.99993825,6.1720246e-05
5917,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,-1,-1,5917,-1,0.99994016,5.9795762e-05
5918,MDMA,0,1,0,4,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5918,-1,0.99989474,0.00010526362
5919,impaired social and emotional judgement processes,10,16,85,134,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5919,-1,0.0014632723,0.9985367
5920,memory deficits,4,6,24,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5920,-1,0.00017414986,0.9998259
5921,MDMA,12,13,71,75,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5921,-1,0.99991274,8.723639e-05
5924,MDMA,9,10,48,52,"The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ""prefrontal"" mediated social and emotional judgement processes.",16574712_2,-1,-1,-1,5924,-1,0.9999194,8.062332e-05
5926,MDMA,6,7,43,47,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,-1,5926,-1,0.99990547,9.4570416e-05
5930,MDMA,11,12,81,85,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,-1,5930,-1,0.9998907,0.000109261375
5932,MDMA,3,4,44,48,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5932,-1,0.9999037,9.627155e-05
5935,5-HT,15,16,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5935,-1,0.99983656,0.0001634019
5936,5-HT neurotoxic lesions,33,36,214,237,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5936,-1,0.03715292,0.9628471
5937,5-HT,40,41,260,264,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5937,-1,0.9998491,0.0001509082
5938,5-HT,1,2,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5938,-1,0.9997814,0.00021856003
5939,5-HT,12,13,75,79,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5939,-1,0.9997509,0.00024906197
5940,5-HT,30,31,185,189,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5940,-1,0.99982077,0.00017922695
5941,MDMA,43,44,263,267,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5941,-1,0.9999082,9.17373e-05
5942,MDMA,14,15,74,78,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5942,-1,0.9999095,9.050624e-05
5943,MDMA,29,30,158,162,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5943,-1,0.99989974,0.000100301506
5944,MDMA,2,3,17,21,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,-1,5944,-1,0.99990606,9.393588e-05
5945,p,12,13,71,72,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5945,-1,0.13554083,0.86445916
5946,p,22,23,108,109,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5946,-1,0.0545728,0.9454272
5947,p,30,31,154,155,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5947,-1,0.06365048,0.9363495
5948,contrast,1,2,3,11,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5948,-1,0.025916422,0.97408354
5950,MDMA,12,13,71,75,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5950,-1,0.9998995,0.00010049431
5951,MDMA,4,5,17,21,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5951,-1,0.999915,8.498469e-05
5952,impaired memory functioning,18,21,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5952,-1,0.0001401491,0.9998598
5953,MDMA,25,26,135,139,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5953,-1,0.9999181,8.1849044e-05
5954,lead,28,29,148,152,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5954,-1,0.0012904033,0.99870956
5955,memory impairments,32,34,169,187,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5955,-1,0.0001168244,0.9998832
5956,MDMA,10,11,54,58,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,-1,5956,-1,0.99988854,0.00011144248
5957,mangiferin,2,3,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5957,-1,0.9999447,5.530155e-05
5958,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5958,-1,0.00010785089,0.9998921
5959,mangiferin,9,10,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5959,-1,0.9999397,6.0356746e-05
5960,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5960,-1,0.99971694,0.00028304962
5962,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5962,-1,0.00011634348,0.99988365
5963,MI,28,29,177,179,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5963,-1,0.00012927975,0.99987066
5964,ISPH,3,4,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5964,-1,0.99984825,0.00015177621
5965,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5965,-1,0.32728195,0.672718
5967,lactate,36,37,196,203,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5967,-1,0.99982136,0.00017868433
5969,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5969,-1,0.9998896,0.0001103657
5971,mangiferin,4,5,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5971,-1,0.9999492,5.0839437e-05
5972,triphenyl tetrazolium chloride,8,11,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5972,-1,0.99993086,6.916879e-05
5973,TTC,12,13,82,85,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5973,-1,0.9980116,0.0019884063
5974,ischemic,23,24,141,149,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5974,-1,0.00014897095,0.999851
5975,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5975,-1,0.9998522,0.00014778222
5976,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5976,-1,0.9997751,0.00022494809
5977,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5977,-1,0.99975115,0.00024881226
5978,glutathione reductase,18,20,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5978,-1,0.9998313,0.00016859343
5979,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5979,-1,0.99989974,0.00010027281
5980,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5980,-1,0.9998964,0.00010355261
5982,MI,39,40,272,274,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5982,-1,0.00056902994,0.99943095
5983,mangiferin,3,4,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5983,-1,0.9999496,5.0377857e-05
5984,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5984,-1,0.1811642,0.81883585
5985,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5985,-1,0.99989235,0.00010757643
5986,MI,23,24,138,140,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5986,-1,0.0032174399,0.99678254
5987,mangiferin,14,15,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5987,-1,0.9999455,5.4456435e-05
5988,MI,20,21,168,170,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5988,-1,0.00030248135,0.99969757
5989,mangiferin,8,9,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5989,-1,0.9999504,4.963396e-05
5990,MI,15,16,103,105,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5990,-1,0.00014436459,0.99985564
5991,cardiac damage,29,31,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5991,-1,0.00014048816,0.99985945
5992,cyclooxygenase inhibitors,3,5,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5992,-1,0.9999273,7.2717325e-05
5993,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5993,-1,0.00011880518,0.99988115
5996,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5996,-1,0.00012824117,0.99987173
5997,cyclooxygenase inhibitors,35,37,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5997,-1,0.9999291,7.087982e-05
5998,Cyclooxygenase,0,1,0,14,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5998,-1,0.9999043,9.569803e-05
5999,inhibitors,1,2,15,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5999,-1,0.9997942,0.00020580439
6000,cyclooxygenase inhibitors,7,9,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,-1,6000,-1,0.9998658,0.00013423391
6001,cardiovascular toxicity,33,35,217,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,-1,-1,6001,-1,0.00010701698,0.99989295
6002,Pilocarpine seizures,0,2,0,20,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,6002,-1,0.24002923,0.7599707
6003,impairment in auditory location discrimination,4,9,41,87,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,6003,-1,0.0019415166,0.9980585
6004,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,-1,-1,6004,-1,0.0002681329,0.99973184
6006,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,6006,-1,0.00021049756,0.99978954
6007,deficits in auditory discrimination,7,11,46,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,6007,-1,0.00171664,0.9982834
6008,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,-1,6008,-1,0.00020192008,0.9997981
6009,P,11,12,69,70,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,-1,-1,-1,6009,-1,0.28041798,0.719582
6012,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,6012,-1,0.00012060202,0.99987936
6013,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,6013,-1,0.0001551224,0.9998449
6016,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,-1,6016,-1,0.00025675003,0.9997433
6017,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,-1,6017,-1,0.00038970882,0.99961036
6018,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,6018,-1,0.00018715426,0.9998129
6019,impairment in auditory discrimination,9,13,61,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,6019,-1,0.0016210906,0.9983789
6020,impaired auditory location discrimination,7,11,41,82,This impairment may explain one cause of impaired auditory location discrimination in humans.,16596970_11,-1,-1,-1,6020,-1,0.0010945263,0.9989054
6021,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6021,-1,0.9997707,0.00022928842
6023,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,6023,-1,0.00016994124,0.99983
6024,NGF,2,3,9,12,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6024,-1,0.99985707,0.0001428994
6025,PGs,4,5,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,6025,-1,0.99983656,0.00016344288
6026,NGF,5,6,35,38,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6026,-1,0.9998254,0.00017462124
6027,PGs,7,8,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6027,-1,0.9996805,0.00031947822
6028,OAB,11,12,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,6028,-1,0.99774504,0.002254954
6029,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6029,-1,0.010441927,0.98955804
6030,bladder symptoms,15,17,82,98,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,6030,-1,0.00020931313,0.9997907
6031,NGF,0,1,0,3,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6031,-1,0.9997321,0.0002678582
6032,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6032,-1,0.99984646,0.00015356416
6033,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6033,-1,0.9998852,0.0001147297
6034,PGI2,6,7,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,6034,-1,0.99988353,0.000116430914
6035,NGF,6,7,42,45,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6035,-1,0.9997273,0.0002726197
6036,PG,8,9,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6036,-1,0.9997216,0.0002784416
6037,OAB,16,17,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,6037,-1,0.0059977705,0.99400216
6038,NGF,3,4,17,20,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6038,-1,0.9997782,0.0002217946
6039,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6039,-1,0.99987507,0.00012490574
6040,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6040,-1,0.9999019,9.809922e-05
6041,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6041,-1,0.011389467,0.98861057
6042,p,19,20,115,116,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,6042,-1,0.1177745,0.8822255
6043,PGI2,3,4,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6043,-1,0.9998374,0.00016255851
6044,OAB,12,13,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,6044,-1,0.008217971,0.99178195
6045,OAB,3,4,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6045,-1,0.009480781,0.99051917
6046,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6046,-1,0.9998369,0.00016304814
6047,p,20,21,126,127,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,6047,-1,0.14227703,0.857723
6048,NGF,1,2,8,11,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6048,-1,0.9997799,0.00022017265
6049,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6049,-1,0.9998876,0.000112425514
6050,PGI2,5,6,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6050,-1,0.9998977,0.00010224329
6051,OAB,15,16,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,6051,-1,0.0038985948,0.9961014
6052,NGF,2,3,13,16,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6052,-1,0.99985623,0.00014372781
6053,PGs,4,5,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6053,-1,0.9998436,0.00015638267
6054,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,6054,-1,0.000864147,0.9991359
6055,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,-1,6055,-1,0.012235488,0.98776454
6057,infected with hepatitis C virus,7,12,48,79,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,-1,-1,6057,-1,0.39074206,0.60925794
6058,Chronic infection with hepatitis C virus (HCV,0,8,0,45,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,6058,-1,0.907607,0.09239292
6062,HCV infection,5,7,31,44,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6062,-1,0.0008051207,0.9991949
6063,pegylated interferon,11,13,73,93,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,6063,-1,0.99992526,7.478274e-05
6068,HCV infection,20,22,138,151,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6068,-1,0.0070810104,0.992919
6069,renal or cardiovascular disorders,28,32,188,221,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,6069,-1,0.00016525835,0.99983466
6073,Viramidine,0,1,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6073,-1,0.99991,8.995675e-05
6077,hepatitis C.,29,31,189,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,6077,-1,0.009432795,0.99056715
6081,growth impairment,11,13,80,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,-1,6081,-1,0.00013847613,0.9998615
6087,reduced cerebellar growth,11,14,87,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6087,-1,0.00031765984,0.9996823
6088,decreased cranial to body growth,17,22,124,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,6088,-1,0.00051457237,0.9994854
6089,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,-1,-1,6089,-1,0.25337458,0.74662536
6091,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6091,-1,0.99992716,7.287004e-05
6092,CI-921,7,8,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6092,-1,0.99979573,0.00020425416
6093,NSC 343499,9,11,49,59,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6093,-1,0.99523735,0.0047626756
6094,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,6094,-1,0.00016472315,0.99983525
6095,CI-921,0,1,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6095,-1,0.99293643,0.0070635844
6096,NSC 343499,2,4,8,18,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6096,-1,0.90120596,0.09879402
6097,"9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide",5,9,20,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6097,-1,0.9996197,0.00038030162
6098,topoisomerase,12,13,117,130,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6098,-1,0.99851865,0.0014813612
6099,II poison,13,15,131,140,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,6099,-1,0.8556585,0.14434154
6100,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6100,-1,0.00022680039,0.9997732
6101,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,6101,-1,0.0001990299,0.999801
6102,squamous carcinoma,3,5,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6102,-1,0.0005113319,0.9994886
6103,adenocarcinoma,9,10,49,63,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6103,-1,0.0002595368,0.9997404
6105,undifferentiated carcinoma,28,30,137,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,6105,-1,0.0006473745,0.99935263
6108,grand mal seizures,21,24,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,-1,-1,6108,-1,0.00016969624,0.99983025
6111,phlebitis,16,17,78,87,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,6111,-1,0.00016905543,0.99983096
6112,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,-1,6112,-1,0.00047967088,0.9995203
6113,tumour,6,7,34,40,Further testing in this and other tumour types using multiple daily schedules is warranted.,1664218_8,-1,-1,-1,6113,-1,0.00042536462,0.9995746
6114,desipramine HCl,2,4,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6114,-1,0.99992037,7.9665115e-05
6115,cinacalcet HCl,7,9,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,6115,-1,0.99992716,7.286935e-05
6120,mg,31,32,191,193,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6120,-1,0.97791016,0.022089886
6122,mg,49,50,281,283,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,6122,-1,0.98242766,0.017572382
6123,h,9,10,49,50,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,-1,6123,-1,0.08607744,0.91392255
6139,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,-1,-1,6139,-1,0.00010495791,0.999895
6140,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,-1,6140,-1,0.99994123,5.8777394e-05
6143,hemianopia,8,9,50,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,-1,-1,6143,-1,0.00019329443,0.9998067
6144,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,-1,-1,6144,-1,0.00011166011,0.9998883
6145,"loss of central visual acuity, colour vision (Ishihara) and visual field",4,18,19,91,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6145,-1,0.0010047776,0.99899524
6146,visual field loss,1,4,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,-1,-1,6146,-1,0.00021489346,0.9997851
6147,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6147,-1,0.99994075,5.9198945e-05
6148,loss of visual function,8,12,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,-1,-1,-1,6148,-1,0.00025070895,0.99974924
6149,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,-1,6149,-1,0.9999397,6.0359678e-05
6151,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6151,-1,0.99993455,6.54154e-05
6152,chiasmopathy,9,10,61,73,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6152,-1,0.00011595615,0.999884
6153,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6153,-1,0.9999374,6.254459e-05
6154,affect the,14,16,100,110,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6154,-1,0.011296602,0.9887033
6155,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,-1,-1,6155,-1,0.0005333407,0.9994667
6158,depressive symptoms,4,6,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6158,-1,0.00015016452,0.9998498
6160,insomnia,14,15,89,97,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6160,-1,0.00012115588,0.9998789
6161,loss of appetite,16,19,99,115,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6161,-1,0.00038076632,0.99961925
6163,mg paroxetine,10,12,54,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6163,-1,0.9997986,0.00020138246
6164,mg alprazolam,14,16,76,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6164,-1,0.9998271,0.00017292982
6167,psychomotor retardation,14,16,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6167,-1,0.0001063038,0.99989367
6168,disorientation,17,18,110,124,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6168,-1,0.00011385533,0.99988616
6169,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6169,-1,0.00012416058,0.9998758
6172,C,8,9,38,39,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6172,-1,0.004885791,0.9951142
6173,mg mm Hg,19,22,96,104,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6173,-1,0.024455637,0.97554433
6178,BUN,28,29,155,158,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,-1,-1,-1,6178,-1,0.9998074,0.00019262308
6182,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6182,-1,0.0007401113,0.9992599
6183,NMS,10,11,72,75,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6183,-1,0.00034611335,0.99965394
6186,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6186,-1,0.0004937866,0.99950624
6187,symptoms,26,27,159,167,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6187,-1,0.00012618197,0.99987376
6188,NMS,4,5,25,28,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6188,-1,0.0024311845,0.9975688
6192,malnutrition,20,21,129,141,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6192,-1,0.0001379671,0.99986196
6203,tricaine,6,7,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,-1,6203,-1,0.9999354,6.463411e-05
6216,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,-1,6216,-1,0.0047695786,0.9952304
6218,lidocaine seizures,3,5,37,55,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,-1,6218,-1,0.017671993,0.98232806
6223,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6223,-1,0.0003147355,0.9996853
6224,carbamylcholin,16,17,80,94,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,-1,6224,-1,0.99994576,5.418566e-05
6227,mg,21,22,104,106,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,-1,-1,-1,6227,-1,0.9962239,0.0037760464
6230,sweating,12,13,74,82,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,-1,6230,-1,0.00016068167,0.9998393
6238,hyperhidrosis,3,4,19,32,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6238,-1,0.00016304845,0.9998369
6239,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6239,-1,0.0002731489,0.99972683
6240,bronchorrhoea,7,8,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6240,-1,0.00022056742,0.9997794
6241,miosis,11,12,77,83,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6241,-1,0.00013502405,0.99986494
6243,mg,8,9,33,35,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,-1,6243,-1,0.94491535,0.055084657
6246,dyspnoea,3,4,19,27,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6246,-1,0.00012676918,0.99987316
6247,bronchospasm,5,6,32,44,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6247,-1,0.00012248254,0.99987745
6248,Respiratory insufficiency,0,2,0,25,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6248,-1,0.0001395421,0.9998604
6249,Proteus mirabilis infection,6,9,50,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6249,-1,0.032876737,0.9671233
6250,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,-1,-1,6250,-1,0.00013928513,0.99986064
6254,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6254,-1,0.9998253,0.00017471868
6255,acute cardiovascular failure,17,20,105,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6255,-1,0.00011430154,0.9998857
6256,cognitive dysfunctions,12,14,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,-1,-1,-1,6256,-1,0.00016570381,0.9998343
6258,ethanolic extract of Daucus carota seeds,1,7,4,44,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6258,-1,0.9992175,0.00078247226
6259,DCE,8,9,46,49,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6259,-1,0.9995522,0.0004477476
6262,DCE,0,1,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,-1,6262,-1,0.9998061,0.00019395669
6263,DCE,7,8,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,-1,6263,-1,0.9998528,0.00014714876
6264,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,-1,6264,-1,0.99869883,0.0013011979
6268,Daucus carota extract,0,3,0,21,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,-1,-1,-1,6268,-1,0.9991974,0.0008025557
6270,DCE,10,11,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,-1,6270,-1,0.99987626,0.00012369874
6272,DCE,30,31,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,-1,6272,-1,0.9999132,8.674431e-05
6273,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6273,-1,0.9997186,0.00028132668
6274,cognitive dysfunctions,14,16,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6274,-1,0.00015378367,0.9998462
6276,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,-1,6276,-1,0.9999423,5.7636862e-05
6277,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6277,-1,0.999936,6.406709e-05
6278,VPA,3,4,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6278,-1,0.9998234,0.00017665011
6279,haemorrhagic pancreatitis,10,12,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,-1,-1,6279,-1,0.00010749501,0.9998925
6284,impaired consciousness,7,9,52,74,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,-1,-1,6284,-1,0.00014628127,0.99985373
6287,VPA,9,10,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,-1,6287,-1,0.99987924,0.00012072721
6290,Atorvastatin,0,1,0,12,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,-1,-1,6290,-1,0.99993706,6.28913e-05
6292,atorvastatin,6,7,37,49,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6292,-1,0.9999317,6.8269765e-05
6293,atorva,8,9,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6293,-1,0.99981815,0.00018192356
6296,atorva,22,23,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6296,-1,0.9998896,0.000110418754
6300,P,36,37,152,153,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,-1,6300,-1,0.1156389,0.8843611
6301,atorva,8,9,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6301,-1,0.9970073,0.0029926996
6303,P,37,38,169,170,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6303,-1,0.14738901,0.852611
6304,Atorva,0,1,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6304,-1,0.9984718,0.0015282262
6306,P,17,18,81,82,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6306,-1,0.17399909,0.8260009
6309,atorva,37,38,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6309,-1,0.99691904,0.0030809436
6311,P,41,42,174,175,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6311,-1,0.08473923,0.91526073
6312,P,29,30,154,155,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,-1,6312,-1,0.08201899,0.917981
6313,Atorva,0,1,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,-1,-1,-1,6313,-1,0.9992409,0.0007590859
6314,atorvastatin,2,3,6,18,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,-1,-1,6314,-1,0.99993825,6.170012e-05
6317,cytosine arabinoside,5,7,42,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6317,-1,0.99993217,6.7811365e-05
6318,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6318,-1,0.00013140618,0.99986863
6319,central nervous system toxicity,1,5,4,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6319,-1,0.00013823905,0.9998617
6320,cytosine arabinoside,7,9,49,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6320,-1,0.99993443,6.557942e-05
6322,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6322,-1,0.99993324,6.670284e-05
6323,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,-1,-1,6323,-1,0.00014851723,0.99985147
6324,cytosine arabinoside,9,11,60,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,-1,6324,-1,0.9999304,6.958637e-05
6325,cytosine arabinoside,5,7,30,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6325,-1,0.9999356,6.437888e-05
6326,numbness,28,29,159,167,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6326,-1,0.00014214584,0.9998578
6331,cytosine arabinoside,11,13,78,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6331,-1,0.9999343,6.565475e-05
6332,toxic to the peripheral nervous system,19,25,132,170,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6332,-1,0.0003781657,0.99962187
6337,free radicals,14,16,117,130,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,-1,6337,-1,0.9975973,0.0024026644
6338,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6338,-1,0.8052064,0.19479358
6340,DFO,21,22,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6340,-1,0.9998915,0.00010852559
6343,h,12,13,50,51,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6343,-1,0.39022487,0.6097751
6344,DFO,21,22,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,-1,6344,-1,0.9999212,7.878468e-05
6346,DA,5,6,32,34,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6346,-1,0.99986136,0.0001385715
6348,DFO,25,26,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6348,-1,0.9999199,8.004509e-05
6349,DFO,2,3,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,-1,6349,-1,0.99991536,8.461603e-05
6351,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,-1,6351,-1,0.9998541,0.00014585826
6352,DFO,8,9,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,-1,-1,-1,6352,-1,0.99990654,9.3484254e-05
6353,DFO,5,6,32,35,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,-1,6353,-1,0.99992144,7.85656e-05
6356,cerebral haemorrhages,12,14,84,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6356,-1,0.00013296647,0.99986696
6363,p,27,28,102,103,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,-1,-1,-1,6363,-1,0.028391605,0.97160834
6364,haemorrhage,8,9,58,69,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6364,-1,0.00011697846,0.99988306
6367,cerebral haemorrhages,3,5,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6367,-1,0.00013706628,0.9998629
6368,cerebral haemorrhages,5,7,45,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,-1,-1,-1,6368,-1,0.00013730463,0.9998627
6370,thioperamide,3,4,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,-1,-1,-1,6370,-1,0.99993753,6.243298e-05
6378,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6378,-1,0.99977964,0.00022037994
6379,thioperamide,11,12,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6379,-1,0.99992335,7.6652e-05
6380,THP,13,14,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6380,-1,0.99986494,0.00013505404
6381,se,23,24,95,97,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6381,-1,0.26395145,0.7360486
6383,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6383,-1,0.9998672,0.00013278719
6384,h,14,15,54,55,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6384,-1,0.19131735,0.8086826
6387,P,28,29,139,140,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6387,-1,0.035822466,0.96417755
6388,RAMH,4,5,27,31,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6388,-1,0.9998627,0.00013735518
6389,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6389,-1,0.99986136,0.00013866245
6390,RAMH,0,1,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6390,-1,0.98254997,0.017450055
6391,se,2,3,9,11,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6391,-1,0.92959136,0.07040867
6392,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6392,-1,0.9998677,0.0001323487
6393,se,24,25,124,126,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6393,-1,0.9342979,0.065702066
6395,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6395,-1,0.9998191,0.00018098547
6396,P,23,24,129,130,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6396,-1,0.0700102,0.92998976
6397,RAMH,2,3,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6397,-1,0.9998416,0.00015839799
6398,THP,15,16,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6398,-1,0.9998518,0.0001482005
6400,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,-1,6400,-1,0.99979573,0.00020434067
6401,RAMH,11,12,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,-1,-1,-1,6401,-1,0.99982256,0.00017748146
6402,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,-1,6402,-1,0.9987225,0.0012774268
6405,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6405,-1,0.99974066,0.0002593434
6406,RAMH,7,8,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6406,-1,0.99986815,0.00013177407
6412,dopamine antagonists,4,6,25,45,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,-1,-1,-1,6412,-1,0.99987495,0.00012502073
6416,fluphenazine,4,5,23,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6416,-1,0.99993765,6.237288e-05
6417,SCH 23390,8,10,52,61,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6417,-1,0.9998548,0.00014511746
6420,fluphenazine,3,4,14,26,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,-1,6420,-1,0.9999423,5.7671612e-05
6422,SCH 23390,2,4,15,24,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,-1,-1,6422,-1,0.9998584,0.00014155691
6425,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6425,-1,0.9998338,0.00016612651
6426,quinpirole,9,10,40,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6426,-1,0.9999399,6.011732e-05
6428,fluphenazine,15,16,86,98,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6428,-1,0.9999416,5.840171e-05
6429,SCH 23390,17,19,100,109,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6429,-1,0.9998621,0.00013791872
6431,SKF 38393,2,4,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6431,-1,0.99974483,0.00025521294
6432,quinpirole,5,6,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6432,-1,0.9999378,6.223326e-05
6434,dopamine antagonists,16,18,109,129,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6434,-1,0.9998847,0.00011521429
6436,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,-1,-1,-1,6436,-1,0.00047777983,0.9995222
6438,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,-1,6438,-1,0.00026216134,0.9997378
6440,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,-1,-1,-1,6440,-1,0.00080966804,0.9991904
6441,cauda equina syndrome,7,10,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6441,-1,0.00052280055,0.9994772
6442,triamcinolone,16,17,97,110,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6442,-1,0.99994075,5.9296635e-05
6444,leg pain,11,13,63,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6444,-1,0.00020143662,0.9997986
6446,contrast medium,3,5,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,-1,6446,-1,0.99866545,0.0013345999
6449,numbness,8,9,46,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6449,-1,0.00014990341,0.99985003
6450,lower extremity weakness,10,13,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6450,-1,0.00018602841,0.999814
6451,loss of sensation,4,7,35,52,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,-1,-1,-1,6451,-1,0.00029509945,0.9997049
6453,neurologic deterioration,6,8,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,-1,-1,-1,6453,-1,0.00011859466,0.9998814
6457,androgen,8,9,46,54,OBJECTIVES: To study the long-term effects of androgen treatment on atherosclerosis in postmenopausal women.,16938416_1,-1,-1,-1,6457,-1,0.99988174,0.000118297176
6464,n=11,14,15,79,83,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,-1,-1,6464,-1,0.012873464,0.9871265
6472,androgen,19,20,147,155,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,-1,-1,6472,-1,0.9998925,0.000107461405
6473,hepatitis B,8,10,63,74,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,-1,-1,6473,-1,0.0026374476,0.99736255
6476,Hepatitis B virus (HBV) infection,0,7,0,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6476,-1,0.005411736,0.99458826
6477,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6477,-1,0.00012171134,0.9998783
6481,hepatitis B surface antigen,3,7,15,42,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6481,-1,0.14690173,0.8530982
6482,e,8,9,47,48,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6482,-1,0.9946626,0.0053373994
6485,cibenzoline,6,7,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,-1,-1,6485,-1,0.99994147,5.856814e-05
6487,ventricular arrhythmia,11,13,93,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,-1,-1,6487,-1,0.0001108589,0.99988914
6488,Digitalis arrhythmia,0,2,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6488,-1,0.00050906715,0.99949086
6489,Na channel blockers,7,10,45,64,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6489,-1,0.9998797,0.00012025854
6491,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6491,-1,0.10307556,0.89692444
6492,Ca channel blockers,7,10,46,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6492,-1,0.9998592,0.00014072494
6496,SD,29,30,184,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6496,-1,0.053685382,0.94631463
6497,n,31,32,188,189,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6497,-1,0.1551585,0.84484154
6501,SD,29,30,185,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6501,-1,0.057680067,0.94231987
6502,n,31,32,189,190,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6502,-1,0.16825494,0.831745
6503,Na,21,22,141,143,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6503,-1,0.9996815,0.0003185169
6504,Ca,30,31,183,185,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6504,-1,0.99967325,0.0003267646
6506,gliomas,7,8,42,49,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,-1,-1,-1,6506,-1,0.00014682529,0.99985313
6508,brain edema,8,10,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6508,-1,0.00010186784,0.9998981
6509,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6509,-1,0.00013520365,0.9998648
6512,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,-1,-1,6512,-1,0.00017213836,0.99982786
6514,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6514,-1,0.00013951762,0.9998604
6515,metastases,26,27,120,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6515,-1,0.00015813828,0.9998418
6516,meningioma,29,30,140,150,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6516,-1,0.00014499271,0.99985504
6517,edematous,8,9,46,55,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,-1,6517,-1,0.00062607304,0.999374
6519,glioma,25,26,144,150,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,-1,6519,-1,0.00019324396,0.9998068
6521,meningioma,1,2,3,13,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6521,-1,0.00014255985,0.9998574
6522,metastases,3,4,18,28,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6522,-1,0.00022469556,0.99977535
6525,gliomas,23,24,122,129,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,-1,6525,-1,0.00016699302,0.999833
6528,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,-1,-1,6528,-1,0.00023676275,0.9997632
6529,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,-1,6529,-1,0.00017662958,0.9998234
6536,Ximelagatran,0,1,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6536,-1,0.9999299,7.005016e-05
6537,direct thrombin inhibitor,4,7,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6537,-1,0.9998056,0.00019443217
6538,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6538,-1,0.9999156,8.4350504e-05
6539,embolic events,23,25,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6539,-1,0.00013111079,0.99986887
6540,abnormal liver function,33,36,188,211,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6540,-1,0.00017319336,0.99982685
6541,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6541,-1,0.5341202,0.46587983
6542,Irbesartan,8,9,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6542,-1,0.99993956,6.046885e-05
6543,Vascular Events,12,14,86,101,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6543,-1,0.00014496768,0.99985504
6547,af embolic events,33,36,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6547,-1,0.0001463771,0.9998536
6548,Idraparinux,0,1,0,11,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6548,-1,0.9998233,0.0001767121
6549,Factor Xa,3,5,15,24,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6549,-1,0.9994455,0.0005544754
6550,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6550,-1,0.00012059018,0.99987936
6551,enzyme inhibitors,1,3,23,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6551,-1,0.99982005,0.00017992948
6552,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6552,-1,0.99987483,0.00012510478
6553,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6553,-1,0.00014952243,0.9998505
6554,cardiac remodelling,14,16,128,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6554,-1,0.00017540691,0.9998246
6557,EPS,6,7,52,55,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6557,-1,0.00016054398,0.9998394
6558,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6558,-1,0.9999424,5.7563757e-05
6559,bipolar mania,16,18,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6559,-1,0.00014677434,0.99985325
6561,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6561,-1,0.00017447096,0.99982554
6562,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6562,-1,0.00029353317,0.99970645
6563,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6563,-1,0.9999441,5.5912966e-05
6564,bipolar mania,18,20,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6564,-1,0.00015078837,0.9998492
6565,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6565,-1,0.9999424,5.7540263e-05
6566,n,12,13,65,66,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6566,-1,0.10572627,0.89427376
6567,n,19,20,90,91,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6567,-1,0.070131816,0.9298682
6570,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6570,-1,0.9999465,5.3565553e-05
6572,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6572,-1,0.99991727,8.277841e-05
6573,QTP,21,22,114,117,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6573,-1,0.9885871,0.011412942
6574,n,26,27,129,130,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6574,-1,0.049421754,0.9505783
6575,PBO,37,38,179,182,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6575,-1,0.99763167,0.0023682723
6576,n,42,43,194,195,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6576,-1,0.051663432,0.9483366
6578,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,-1,6578,-1,0.5419103,0.45808968
6579,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6579,-1,0.00032715237,0.9996729
6580,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6580,-1,0.99993706,6.291266e-05
6581,QTP,6,7,43,46,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6581,-1,0.37174478,0.6282552
6582,PBO,18,19,92,95,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6582,-1,0.99979895,0.00020111825
6583,EPS,4,5,26,29,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6583,-1,0.00020308045,0.9997969
6585,n,15,16,86,87,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6585,-1,0.12545292,0.87454706
6587,n,30,31,155,156,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6587,-1,0.086634256,0.9133658
6588,EPS,40,41,213,216,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6588,-1,0.00017443502,0.99982554
6589,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6589,-1,0.00034129713,0.9996587
6590,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6590,-1,0.9999341,6.589008e-05
6591,QTP,24,25,111,114,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6591,-1,0.058051534,0.9419485
6593,p,9,10,62,63,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6593,-1,0.0630139,0.9369861
6595,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6595,-1,0.99993956,6.041421e-05
6601,p,7,8,54,55,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6601,-1,0.043838978,0.956161
6602,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6602,-1,0.00030411678,0.9996959
6604,extrapyramidal syndrome,31,33,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6604,-1,0.00012678611,0.99987316
6605,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6605,-1,0.9999422,5.7763584e-05
6606,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,-1,6606,-1,0.99993515,6.488125e-05
6607,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,-1,-1,-1,6607,-1,0.9999331,6.686116e-05
6608,bipolar mania,3,5,16,29,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6608,-1,0.00016392423,0.9998361
6609,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6609,-1,0.00016144755,0.9998385
6610,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6610,-1,0.00030719754,0.9996928
6611,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6611,-1,0.99993753,6.240523e-05
6612,atorvastatin,3,4,24,36,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,-1,6612,-1,0.9999411,5.889573e-05
6616,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6616,-1,0.9998864,0.00011363742
6618,O2-,20,21,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6618,-1,0.9996886,0.00031145063
6619,Atorvastatin,0,1,0,12,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6619,-1,0.9999311,6.892029e-05
6620,Ato,2,3,14,17,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6620,-1,0.99968255,0.00031741677
6621,O2-,22,23,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6621,-1,0.9992329,0.00076708075
6623,Ato,16,17,70,73,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6623,-1,0.9996177,0.0003822407
6624,O2-,30,31,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6624,-1,0.9521249,0.047875114
6625,SD,34,35,177,179,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6625,-1,0.040963434,0.9590365
6626,SD,3,4,8,10,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6626,-1,0.018690156,0.9813098
6627,n,6,7,17,18,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6627,-1,0.1846838,0.8153162
6628,Ato,13,14,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6628,-1,0.99972135,0.00027861874
6629,drinking water,20,22,68,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6629,-1,0.99624455,0.0037554563
6632,P,30,31,119,120,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,-1,6632,-1,0.048689473,0.9513106
6633,Ato,2,3,7,10,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6633,-1,0.9563549,0.043645028
6635,P,29,30,106,107,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6635,-1,0.0359807,0.96401936
6637,P,48,49,192,193,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6637,-1,0.07305622,0.92694384
6639,Ato,12,13,84,87,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6639,-1,0.9996654,0.00033463922
6641,P,21,22,122,123,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6641,-1,0.14399959,0.8560004
6644,Ato,9,10,52,55,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6644,-1,0.9996848,0.00031515767
6646,P,20,21,110,111,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6646,-1,0.14681019,0.85318977
6647,Ato,2,3,15,18,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6647,-1,0.99968433,0.0003156999
6649,SD,15,16,111,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6649,-1,0.050471123,0.9495289
6651,hypothermic,6,7,38,49,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6651,-1,0.00023380543,0.9997662
6652,Chiari malformation,12,14,78,97,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6652,-1,0.00021673451,0.99978334
6653,hypothermic,9,10,67,78,"During anaesthesia and surgery, he inadvertently became moderately hypothermic.",17049862_1,-1,-1,-1,6653,-1,0.0009950452,0.999005
6664,lead,9,10,63,67,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6664,-1,0.002211318,0.99778867
6665,cardiac event,13,15,82,95,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6665,-1,0.00012409655,0.9998759
6667,chorea,1,2,18,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6667,-1,0.00014112591,0.99985886
6669,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6669,-1,0.00066520955,0.99933475
6670,Nonketotic hyperglycinemia,0,2,0,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6670,-1,0.0016497705,0.99835026
6671,disorder of amino acid metabolism,4,9,32,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6671,-1,0.005030163,0.9949699
6674,neonatal apnea,7,9,37,51,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6674,-1,0.0001161094,0.9998839
6676,hypotonia,14,15,79,88,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6676,-1,0.000105751074,0.99989426
6677,psychomotor retardation,19,21,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6677,-1,0.00010343989,0.9998965
6678,nonketotic,6,7,37,47,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6678,-1,0.0028297391,0.99717027
6679,hyperglycinemia,7,8,48,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6679,-1,0.0007357659,0.9992642
6680,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6680,-1,0.00016975486,0.99983025
6681,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6681,-1,0.00011851339,0.9998815
6682,nonketotic hyperglycinemia,18,20,103,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6682,-1,0.00053032883,0.9994697
6684,chorea,27,28,187,193,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6684,-1,0.00013128294,0.99986875
6685,valproate,32,33,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6685,-1,0.99993217,6.7798566e-05
6686,citrate toxicity,1,3,7,23,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,-1,6686,-1,0.012706146,0.9872938
6687,citrate toxicity,6,8,27,43,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,-1,6687,-1,0.013772419,0.9862276
6689,hyperlipidemia,8,9,54,68,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,-1,-1,6689,-1,0.00013378041,0.99986625
6691,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,-1,-1,-1,6691,-1,0.99993587,6.410253e-05
6694,the,14,15,80,83,"Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet.",17111419_5,-1,-1,-1,6694,-1,0.010930608,0.9890694
6696,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6696,-1,0.9999168,8.322219e-05
6697,muscle contractions,10,12,74,93,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6697,-1,0.00016134598,0.9998386
6701,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6701,-1,0.9999403,5.9762362e-05
6702,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6702,-1,0.9994646,0.0005354405
6705,citrate toxicity,22,24,161,177,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,-1,-1,6705,-1,0.01476774,0.98523223
6708,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6708,-1,0.00011229512,0.9998877
6709,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6709,-1,0.000109070155,0.9998909
6711,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6711,-1,0.00042992382,0.9995701
6712,MCAO,16,17,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6712,-1,0.00081306754,0.99918693
6713,brain edema,19,21,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6713,-1,0.00010872634,0.9998913
6716,n,5,6,22,23,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6716,-1,0.14869475,0.85130525
6717,MAP,15,16,58,61,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6717,-1,0.026856553,0.9731434
6719,n,5,6,27,28,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6719,-1,0.08664663,0.9133533
6720,MAP,11,12,39,42,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6720,-1,0.013779006,0.98622096
6721,mm Hg,18,20,65,70,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6721,-1,0.030565841,0.9694342
6722,h,22,23,83,84,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6722,-1,0.019222295,0.9807777
6723,MCAO,24,25,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6723,-1,0.0035388141,0.9964612
6724,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,-1,6724,-1,0.001794622,0.9982054
6726,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,-1,6726,-1,0.00316523,0.9968348
6727,ischemic,23,24,112,120,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,-1,-1,-1,6727,-1,0.00024115026,0.9997589
6728,neuronal injury,3,5,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6728,-1,0.00013527702,0.9998647
6729,"2,3,5-triphenyltetrazolium",8,9,48,74,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6729,-1,0.99984825,0.00015170965
6730,ischemic,2,3,7,15,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,-1,-1,-1,6730,-1,0.00021258024,0.9997874
6731,ischemic,5,6,24,32,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6731,-1,0.00017251926,0.9998275
6734,P,34,35,162,163,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6734,-1,0.044959307,0.95504075
6736,P,36,37,154,155,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,-1,6736,-1,0.059078444,0.94092155
6738,h,8,9,71,72,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6738,-1,0.020697266,0.9793027
6739,MCAO,10,11,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6739,-1,0.001439485,0.9985605
6741,ischemic,17,18,116,124,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6741,-1,0.00014546658,0.99985456
6743,ischemic,29,30,178,186,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6743,-1,0.00014647904,0.9998535
6744,neuronal dysfunction,40,42,244,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6744,-1,0.000118726144,0.99988127
6750,chronic allograft nephropathy,15,18,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,-1,6750,-1,0.00013728603,0.9998627
6752,autoimmunity,8,9,47,59,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6752,-1,0.0001246504,0.9998753
6753,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6753,-1,0.00013180045,0.99986815
6754,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6754,-1,0.00015233239,0.99984765
6756,calcineurin inhibitors,12,14,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,-1,6756,-1,0.99990296,9.70147e-05
6759,acute renal dysfunction,17,20,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,-1,6759,-1,0.00010515476,0.99989486
6760,chronic renal damage,10,13,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,-1,6760,-1,0.00011809114,0.99988186
6762,calcineurin inhibitor,19,21,143,164,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,-1,-1,6762,-1,0.99993193,6.806481e-05
6764,acute renal dysfunction,1,4,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6764,-1,0.00011424107,0.9998858
6766,delayed graft function,11,14,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6766,-1,0.00015696665,0.999843
6770,enzyme inhibitors,46,48,296,313,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6770,-1,0.99982053,0.00017954082
6771,angiotensin II receptor blockers,49,53,317,349,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,-1,-1,6771,-1,0.9998754,0.00012455534
6777,SRL,2,3,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,-1,6777,-1,0.99974865,0.00025130366
6781,SRL,18,19,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,-1,-1,6781,-1,0.99953806,0.00046197785
6782,SRL,13,14,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6782,-1,0.99986553,0.00013439104
6783,chronic allograft nephropathy,20,23,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6783,-1,0.00016870181,0.9998313
6784,CAN,24,25,120,123,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6784,-1,0.0018587596,0.9981413
6785,n,27,28,126,127,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6785,-1,0.005338633,0.9946614
6786,neoplasia,31,32,134,143,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6786,-1,0.00013057381,0.99986947
6787,n,33,34,145,146,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6787,-1,0.0044170176,0.995583
6788,Kaposi's sarcoma,37,40,153,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6788,-1,0.00033211062,0.9996679
6789,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6789,-1,0.00014866855,0.99985135
6790,intestinal tumors,46,48,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6790,-1,0.00020085971,0.9997992
6791,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6791,-1,0.022189453,0.9778105
6793,n,59,60,263,264,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6793,-1,0.0041493126,0.9958507
6794,SRL,0,1,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,-1,6794,-1,0.9971975,0.0028025338
6795,SRL,3,4,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,-1,6795,-1,0.9998933,0.00010673113
6797,P,23,24,108,109,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,-1,6797,-1,0.069108725,0.93089134
6803,membranoproliferative glomerulopathy,11,13,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,-1,-1,6803,-1,0.0001368226,0.99986315
6806,SRL,3,4,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6806,-1,0.9998902,0.00010979969
6807,P,15,16,71,72,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6807,-1,0.16772874,0.8322713
6808,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,-1,6808,-1,0.00070536224,0.99929464
6809,P,29,30,131,132,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,-1,6809,-1,0.08730489,0.9126951
6811,P,15,16,89,90,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,-1,6811,-1,0.14339027,0.85660976
6813,SRL,8,9,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,-1,-1,6813,-1,0.99988437,0.000115664516
6815,glomerular pathology,5,7,27,47,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6815,-1,0.00012677559,0.99987316
6816,SRL,8,9,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6816,-1,0.9998883,0.000111655536
6822,5-HT,26,27,157,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6822,-1,0.99989843,0.00010152677
6824,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6824,-1,0.9999306,6.9415844e-05
6825,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6825,-1,0.9998722,0.00012782168
6830,5-HT,3,4,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6830,-1,0.9998814,0.00011859828
6831,5-hydroxyindoleacetic acid,8,10,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6831,-1,0.9999039,9.603508e-05
6832,5-HIAA,11,12,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6832,-1,0.9998357,0.00016425185
6833,PCPA,0,1,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6833,-1,0.99988985,0.00011008609
6834,5-HT,5,6,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6834,-1,0.9998869,0.00011311027
6835,5-HIAA,7,8,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6835,-1,0.99988437,0.000115640905
6836,T,1,2,8,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6836,-1,0.9997434,0.000256624
6837,5-HT,5,6,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6837,-1,0.99989164,0.00010833399
6838,5-HIAA,7,8,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6838,-1,0.99989676,0.00010326142
6839,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6839,-1,0.9999136,8.6467735e-05
6840,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,-1,6840,-1,0.99991477,8.522938e-05
6845,5-HT,16,17,83,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,-1,6845,-1,0.999882,0.000118008065
6847,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6847,-1,0.18616477,0.8138352
6848,mesenchymal tumors,11,13,83,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6848,-1,0.00015745412,0.9998425
6849,malignant mesenchymal tumors,7,10,39,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6849,-1,0.00016600586,0.99983394
6851,Malignant Mesenchymal Tumor,28,31,199,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6851,-1,0.00024786493,0.9997521
6855,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6855,-1,0.9999455,5.4465625e-05
6856,IVA,23,24,120,123,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6856,-1,0.9992859,0.00071418966
6859,glucosuria,11,12,78,88,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6859,-1,0.018738534,0.9812615
6861,aminoaciduria,15,16,103,116,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6861,-1,0.071890995,0.928109
6864,renal abnormalities,19,21,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,-1,-1,-1,6864,-1,0.00015732567,0.99984264
6866,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6866,-1,0.00065133965,0.9993487
6867,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6867,-1,0.0003313418,0.9996687
6872,TDFS,8,9,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6872,-1,0.0013358205,0.99866414
6874,mesenchymal tumors,23,25,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6874,-1,0.00016420863,0.9998357
6875,UMB24,2,3,11,16,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,-1,-1,-1,6875,-1,0.99979025,0.00020980385
6879,contrast,1,2,3,11,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,-1,-1,-1,6879,-1,0.05640881,0.94359124
6880,UMB24,8,9,48,53,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6880,-1,0.9992454,0.00075463223
6881,1-(2-phenethyl)-4-(2-pyridyl)-piperazine,10,11,55,95,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6881,-1,0.9997583,0.00024167572
6882,UMB24,5,6,40,45,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,-1,6882,-1,0.9998053,0.0001947279
6883,UMB24,10,11,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,-1,-1,6883,-1,0.9998416,0.00015845134
6885,UMB24,18,19,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,-1,6885,-1,0.9998919,0.00010807232
6886,receptor antagonists,7,9,39,59,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,-1,-1,-1,6886,-1,0.9997764,0.00022357277
6892,hyperCKaemia,7,8,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,-1,-1,6892,-1,0.00014784044,0.9998522
6895,muscle pathology,3,5,20,36,We investigated the muscle pathology in 8 such cases.,17241784_3,-1,-1,-1,6895,-1,0.000197718,0.9998023
6917,antagonists,31,32,230,241,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,-1,-1,-1,6917,-1,0.9997335,0.00026644664
6919,contrast,8,9,49,57,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6919,-1,0.0112773925,0.98872256
6920,adenosine-5'-triphosphate,10,11,70,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,-1,6920,-1,0.99985063,0.00014935086
6921,receptor antagonists atropine,2,5,15,44,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6921,-1,0.99984455,0.00015541642
6922,4-DAMP,8,9,84,90,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6922,-1,0.9996183,0.00038165555
6923,methoctramine,16,17,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6923,-1,0.99993455,6.540355e-05
6924,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6924,-1,0.99994755,5.2424362e-05
6925,4-DAMP,0,1,0,6,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6925,-1,0.9998771,0.00012284677
6926,methoctramine,10,11,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6926,-1,0.99994195,5.8067344e-05
6927,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6927,-1,0.9999443,5.5698605e-05
6928,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6928,-1,0.9999441,5.591216e-05
6929,4-DAMP,24,25,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6929,-1,0.9999186,8.140948e-05
6930,contrast,1,2,3,11,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6930,-1,0.013653021,0.986347
6931,methoctramine,5,6,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6931,-1,0.9999422,5.784539e-05
6933,ATP,5,6,36,39,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,-1,6933,-1,0.999884,0.00011602252
6937,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6937,-1,0.0001359401,0.999864
6939,coronary heart disease,20,23,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6939,-1,0.00016729742,0.99983263
6940,heart failure,26,28,183,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6940,-1,0.00012842499,0.9998716
6947,bradycardic,2,3,10,21,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,-1,6947,-1,0.00019299278,0.99980706
6951,bradycardic,12,13,84,95,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,-1,6951,-1,0.0001579606,0.99984205
6954,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,-1,-1,6954,-1,0.00013563895,0.99986434
6958,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6958,-1,0.000106925596,0.99989307
6959,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6959,-1,0.0001067584,0.9998932
6961,restlessness,18,19,106,118,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6961,-1,0.00012971641,0.9998703
6962,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6962,-1,0.99993,6.9960304e-05
6964,anxiety,27,28,166,173,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,-1,6964,-1,0.0001547014,0.99984527
6970,mg,26,27,166,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,-1,-1,6970,-1,0.99727076,0.0027292299
6971,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,-1,-1,6971,-1,0.00012775333,0.9998722
6977,ARB,13,14,89,92,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,-1,-1,6977,-1,0.99986076,0.0001392356
6981,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6981,-1,0.9999186,8.146928e-05
6983,granulomas,14,15,108,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,-1,-1,6983,-1,0.000121250065,0.99987876
6985,cholestatic syndrome,21,23,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,-1,6985,-1,0.00015892494,0.9998411
6986,granulomas,3,4,19,29,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,-1,-1,6986,-1,0.00012536992,0.9998746
6991,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,-1,-1,-1,6991,-1,0.99992824,7.179006e-05
6994,atrioventricular block,6,8,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,-1,-1,6994,-1,0.00017041361,0.99982953
6997,sinus tachycardias,4,6,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6997,-1,0.0001950425,0.99980503
6998,carbamazepine overdose,12,14,75,97,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6998,-1,0.15699114,0.84300894
6999,bradyarrhythmias,13,14,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6999,-1,9.665993e-05,0.9999033
7000,atrioventricular conduction delay,15,18,126,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,7000,-1,0.00016177949,0.99983823
7003,neurologic and psychiatric,10,13,62,88,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,-1,-1,-1,7003,-1,0.00017325213,0.9998267
7008,cardiac damage,9,11,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,-1,7008,-1,0.00011315969,0.9998869
7017,mm,17,18,116,118,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7017,-1,0.004066741,0.99593323
7018,mm,23,24,139,141,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7018,-1,0.0040673944,0.99593264
7019,p,28,29,164,165,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,7019,-1,0.03190964,0.9680903
7021,mm,22,23,157,159,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7021,-1,0.0019555953,0.9980444
7022,mm,28,29,180,182,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7022,-1,0.002075729,0.9979242
7023,p,33,34,205,206,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,7023,-1,0.035238653,0.9647614
7025,iodine-125-metaiodobenzylguanidine,11,12,99,133,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,-1,-1,7025,-1,0.99990356,9.6469594e-05
7026,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7026,-1,0.99992275,7.722605e-05
7027,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7027,-1,0.9998487,0.00015124038
7029,NE,11,12,74,76,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,7029,-1,0.9998697,0.00013027086
7031,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,-1,7031,-1,0.23690511,0.76309484
7032,vacuolar degeneration of myocardial cells,3,8,14,55,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,-1,-1,-1,7032,-1,0.000420111,0.99957985
7034,p,39,40,202,203,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,-1,-1,-1,7034,-1,0.07410034,0.9258996
7035,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7035,-1,0.9998468,0.00015318741
7036,p,27,28,127,128,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,7036,-1,0.040791377,0.95920855
7037,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7037,-1,0.99984336,0.00015666029
7038,p,27,28,127,128,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,7038,-1,0.040653985,0.95934606
7039,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,-1,7039,-1,0.99980336,0.00019671537
7041,myocardial impairment,13,15,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7041,-1,0.000108683314,0.9998913
7042,vacuolar degeneration,19,21,130,151,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,7042,-1,0.00015178519,0.99984825
7049,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,-1,7049,-1,0.00018287837,0.9998172
7051,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,-1,-1,7051,-1,0.0002544561,0.99974555
7053,n=200,8,9,58,63,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7053,-1,0.036984213,0.9630158
7054,n=200,20,21,116,121,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,7054,-1,0.036376737,0.9636232
7055,n=88,14,15,69,73,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7055,-1,0.037104283,0.96289575
7056,n=76,28,29,121,125,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7056,-1,0.02858422,0.9714158
7057,n=36,41,42,165,169,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,7057,-1,0.039250355,0.9607497
7058,decreases of TEOAEs amplitudes at 4000Hz,14,20,89,129,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,-1,7058,-1,0.050561264,0.9494387
7062,QT prolongation,2,4,12,27,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7062,-1,0.00019685081,0.9998031
7064,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,7064,-1,0.082673505,0.9173265
7066,heroin,6,7,39,45,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,-1,-1,7066,-1,0.9998758,0.00012421826
7067,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7067,-1,0.00061848207,0.99938154
7068,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7068,-1,0.0013953011,0.9986047
7069,TdP,15,16,80,83,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,7069,-1,0.00090566394,0.99909437
7071,heroin,1,2,3,9,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7071,-1,0.9998965,0.00010342234
7073,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,7073,-1,0.00025503465,0.99974495
7075,heroin,19,20,113,119,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7075,-1,0.99988544,0.00011453361
7077,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,7077,-1,0.99993384,6.61595e-05
7082,p,14,15,79,80,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,-1,7082,-1,0.11538106,0.88461894
7083,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,-1,7083,-1,0.9999187,8.1242586e-05
7085,prolonged QTc interval,15,18,69,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,-1,7085,-1,0.0007235621,0.99927646
7086,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,-1,7086,-1,0.9999416,5.841302e-05
7087,mg,2,3,5,7,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,-1,7087,-1,0.9842988,0.015701128
7091,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7091,-1,0.00021282097,0.99978715
7093,heroin,17,18,109,115,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,7093,-1,0.9998944,0.00010555491
7094,compartment syndrome,3,5,34,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7094,-1,0.00012277394,0.9998772
7095,myonecrosis,6,7,59,70,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,7095,-1,0.00010748098,0.9998925
7100,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7100,-1,0.00014308553,0.99985695
7101,myonecrosis,15,16,118,129,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,7101,-1,0.00011323428,0.99988675
7103,arteriopathic,24,25,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,-1,-1,-1,7103,-1,0.00015477532,0.99984515
7104,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7104,-1,0.0006172322,0.99938273
7105,ziprasidone,5,6,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,7105,-1,0.99994445,5.5586643e-05
7106,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7106,-1,0.002003283,0.99799675
7107,NMS,4,5,32,35,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7107,-1,0.00051646127,0.99948347
7108,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,7108,-1,0.00011339462,0.99988663
7109,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7109,-1,0.00095815444,0.99904186
7110,NMS,9,10,54,57,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7110,-1,0.0003040933,0.9996959
7111,ziprasidone,16,17,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,7111,-1,0.9999428,5.7194466e-05
7112,neuroleptics,2,3,22,34,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7112,-1,0.99986565,0.00013432353
7113,NMS,8,9,71,74,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7113,-1,0.00065293314,0.99934703
7114,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7114,-1,0.9998399,0.0001600683
7115,ziprasidone,14,15,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,7115,-1,0.9999442,5.580451e-05
7117,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7117,-1,0.0002521925,0.9997478
7118,NMS,17,18,102,105,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7118,-1,0.00065221544,0.99934775
7119,ziprasidone,30,31,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,7119,-1,0.9999459,5.4174663e-05
7120,NMS,11,12,52,55,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7120,-1,0.003805586,0.99619436
7121,ziprasidone,14,15,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,7121,-1,0.99993813,6.180836e-05
7122,Neuroinflammation,0,1,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7122,-1,0.00010761604,0.99989235
7123,behavioral abnormalities,2,4,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7123,-1,0.00012911652,0.9998709
7125,autism,13,14,110,116,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,7125,-1,0.0001330668,0.99986696
7126,Autism,0,1,0,6,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7126,-1,0.00021579112,0.9997842
7127,neurodevelopmental disorder,3,5,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7127,-1,0.00022940474,0.9997706
7128,deficits in communication and social skills,12,18,78,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7128,-1,0.0007211386,0.99927884
7129,repetitive behaviors,19,21,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,7129,-1,0.00046306377,0.999537
7130,autism,19,20,120,126,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,-1,7130,-1,0.00014461631,0.9998554
7132,preterm labor,8,10,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7132,-1,0.00015638386,0.9998436
7133,autism,18,19,123,129,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,7133,-1,0.00014859287,0.99985135
7136,h,27,28,114,115,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,-1,7136,-1,0.1240959,0.8759041
7140,startle,37,38,210,217,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,-1,7140,-1,0.00085763866,0.9991423
7141,behavioral abnormalities,21,23,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7141,-1,0.00013507041,0.99986494
7142,autism,29,30,237,243,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,7142,-1,0.00015299546,0.99984694
7143,autism spectrum disorders,13,16,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,-1,7143,-1,0.00020211807,0.9997979
7145,C219,41,42,239,243,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,-1,-1,-1,7145,-1,0.9986033,0.0013967821
7148,tariquidar,14,15,108,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,7148,-1,0.99994195,5.8060807e-05
7149,injury to the brain,10,14,67,86,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,-1,7149,-1,0.0007997837,0.9992003
7151,xanthine oxidase,2,4,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,-1,7151,-1,0.9999243,7.5636184e-05
7154,xanthine oxidase,7,9,26,42,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7154,-1,0.99991786,8.213679e-05
7155,reactive oxygen species,20,23,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7155,-1,0.623108,0.37689197
7159,allopurinol,21,22,114,125,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7159,-1,0.9999373,6.2672174e-05
7160,allopurinol,26,27,143,154,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7160,-1,0.99993336,6.6670924e-05
7162,urate,13,14,73,78,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,-1,7162,-1,0.99991083,8.9186324e-05
7164,P,15,16,45,46,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7164,-1,0.075806804,0.9241932
7165,decreased thymus (P,20,24,60,79,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7165,-1,0.015557941,0.98444206
7166,0.001,25,26,82,87,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7166,-1,0.04987665,0.95012337
7167,0.001,25,26,82,87,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7167,-1,0.04987665,0.95012337
7168,and bodyweights,27,29,89,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7168,-1,0.014033338,0.9859666
7169,P,30,31,106,107,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7169,-1,0.12372285,0.87627715
7170,Allopurinol,0,1,0,11,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7170,-1,0.9999459,5.4117394e-05
7171,urate,3,4,28,33,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7171,-1,0.99987006,0.00012990492
7172,P,16,17,72,73,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7172,-1,0.041375082,0.9586249
7173,P,37,38,151,152,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7173,-1,0.060350243,0.9396498
7174,Allopurinol,2,3,3,14,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,-1,7174,-1,0.9999372,6.283627e-05
7175,allopurinol,8,9,47,58,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,-1,-1,7175,-1,0.99994445,5.551163e-05
7183,n,10,11,38,39,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7183,-1,0.12850305,0.871497
7186,n,37,38,175,176,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7186,-1,0.10881936,0.8911806
7187,"nausea, vomiting",9,12,60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,-1,-1,7187,-1,0.00018315618,0.99981683
7189,postoperative emetic symptoms,8,11,44,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,-1,7189,-1,0.00013148726,0.9998685
7193,"nausea, vomiting",24,27,162,178,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,-1,-1,7193,-1,0.0002053332,0.99979466
7195,iron dextran,1,3,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7195,-1,0.9999056,9.437167e-05
7196,degeneration of dopaminergic neurons,4,8,32,68,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7196,-1,0.0002688063,0.9997311
7198,Parkinson's disease,11,14,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,-1,-1,-1,7198,-1,0.00024433853,0.9997557
7199,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7199,-1,0.019689186,0.98031086
7200,SN,17,18,119,121,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7200,-1,0.01106895,0.9889311
7203,degeneration of dopaminergic neurons,51,55,330,366,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7203,-1,0.00032039083,0.9996797
7205,SN,61,62,401,403,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7205,-1,0.01016923,0.9898308
7206,iron dextran,63,65,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7206,-1,0.9998772,0.00012278881
7207,iron dextran,5,7,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7207,-1,0.9999076,9.234958e-05
7209,SN,23,24,160,162,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7209,-1,0.0027341167,0.99726593
7211,iron dextran,5,7,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7211,-1,0.9998361,0.00016384016
7213,SN,14,15,86,88,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7213,-1,0.008905857,0.9910942
7215,degeneration of dopaminergic neurons,21,25,122,158,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7215,-1,0.00030926694,0.9996908
7216,iron overload,2,4,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7216,-1,0.024860596,0.9751394
7217,iron overload,14,16,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7217,-1,0.025435781,0.9745642
7229,myocardial ischemia,13,15,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,-1,7229,-1,0.00010400227,0.99989593
7230,myocardial ischemia,11,13,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,-1,-1,-1,7230,-1,0.00010468144,0.99989533
7231,myocardial ischemia,36,38,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,-1,7231,-1,9.8280485e-05,0.99990165
7236,myocardial ischemia,34,36,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,-1,7236,-1,0.00010578506,0.99989426
7237,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,-1,7237,-1,0.00010509281,0.99989486
7242,atherosclerotic obstruction,6,8,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7242,-1,0.00015447735,0.9998455
7243,coronary occlusion,9,11,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7243,-1,0.00015754906,0.9998424
7245,thrombus,17,18,109,117,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7245,-1,0.00016338647,0.99983656
7251,delusional parasitosis,5,7,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7251,-1,0.00013625366,0.99986374
7252,chronic hepatitis C,9,12,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7252,-1,0.0002673102,0.9997327
7253,pegylated interferon alpha-2b,14,17,89,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7253,-1,0.99992,7.996453e-05
7255,chronic hepatitis C,3,6,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7255,-1,0.0002308932,0.99976915
7256,interferon,8,9,54,64,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7256,-1,0.999882,0.00011804746
7259,psychosis,6,7,33,42,A minority of patients evolve to psychosis.,17511042_3,-1,-1,-1,7259,-1,0.00012707889,0.9998729
7260,psychogenic parasitosis,10,12,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7260,-1,0.0001095255,0.99989045
7261,interferon,14,15,83,93,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7261,-1,0.99983263,0.00016739382
7262,delusional parasitosis,8,10,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7262,-1,0.00013835206,0.9998616
7263,pegylated interferon alpha-2b,13,16,92,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7263,-1,0.99991584,8.4165054e-05
7265,pegylated interferon alpha-2b,6,9,46,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,-1,-1,-1,7265,-1,0.9999038,9.6136326e-05
7268,LID,3,4,27,30,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7268,-1,0.0002330716,0.9997669
7269,Parkinson's disease,13,16,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7269,-1,0.00028688446,0.9997131
7270,PD,17,18,100,102,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7270,-1,0.00016591059,0.99983406
7271,LID,14,15,73,76,"To this day, transcriptome analysis has been performed in a rat model of LID [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking.",17532790_2,-1,-1,-1,7271,-1,0.039009236,0.96099085
7272,PD,25,26,170,172,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7272,-1,0.00016582613,0.9998342
7274,MS,42,43,294,296,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7274,-1,0.5272336,0.4727664
7275,LID,16,17,90,93,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,-1,7275,-1,0.03683727,0.9631627
7276,LID,6,7,26,29,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7276,-1,0.9931906,0.0068093534
7277,LID,14,15,86,89,"In conclusion, this study provides new insights into the protein changes occurring in LID.",17532790_8,-1,-1,-1,7277,-1,0.56743234,0.43256763
7279,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,-1,7279,-1,0.00012158211,0.9998784
7280,contrast medium iopamidol,13,16,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7280,-1,0.9996704,0.00032966808
7281,contrast medium iodixanol,21,24,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7281,-1,0.999595,0.00040508484
7284,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,-1,7284,-1,0.000124773,0.9998752
7286,contrast,4,5,17,25,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7286,-1,0.16324526,0.8367547
7287,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7287,-1,0.00012980054,0.9998702
7290,P=0.39,31,32,131,137,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7290,-1,0.050277803,0.9497222
7291,P=0.44,53,54,217,223,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7291,-1,0.064994544,0.9350054
7295,P=0.11,35,36,148,154,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7295,-1,0.033384744,0.96661526
7296,P=0.37,55,56,226,232,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7296,-1,0.04358543,0.9564146
7302,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,-1,-1,7302,-1,0.00011105188,0.9998889
7303,Hepatonecrosis,0,1,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7303,-1,0.00018671612,0.99981326
7304,cholangitis,2,3,19,30,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7304,-1,0.00011453951,0.99988544
7307,PB,2,3,15,17,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7307,-1,0.99981016,0.00018983449
7308,chronic liver disease,31,34,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7308,-1,9.910756e-05,0.99990094
7310,PB,15,16,82,84,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7310,-1,0.99920446,0.00079557113
7312,bronchopneumonia,31,32,161,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7312,-1,0.00016040917,0.99983954
7314,PB,4,5,29,31,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7314,-1,0.99972874,0.00027127643
7316,lead,15,16,87,91,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7316,-1,0.0025931564,0.9974068
7317,hepatic enzyme dysfunction,18,21,126,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,-1,7317,-1,0.0005304714,0.9994696
7320,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,-1,-1,7320,-1,0.000116295654,0.99988365
7323,amyloid beta peptide(1-42),10,16,67,93,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7323,-1,0.9974559,0.0025441102
7325,H2O2,19,20,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7325,-1,0.99986887,0.00013112341
7327,reactive oxygen species,12,15,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7327,-1,0.64397174,0.35602823
7328,c,17,18,128,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7328,-1,0.99933845,0.0006615086
7329,caspase 3,21,23,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7329,-1,0.9969633,0.0030366702
7330,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7330,-1,0.00026194597,0.99973804
7332,decline of cognitive function,35,39,230,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7332,-1,0.00018884194,0.99981123
7335,terminal damage,12,14,98,113,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,-1,7335,-1,0.008132097,0.99186796
7337,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,-1,7337,-1,0.01491252,0.98508745
7342,"3,4-dihydroxyphenylacetic acid",9,11,99,129,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,-1,7342,-1,0.9998932,0.00010683642
7346,"3,4-dihydroxyphenylacetic acid",30,32,190,220,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,-1,-1,-1,7346,-1,0.99987805,0.0001219053
7350,"3,4-dihydroxyphenylacetic acid",15,17,125,155,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,-1,7350,-1,0.99989426,0.0001057065
7354,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,-1,7354,-1,0.014493143,0.9855069
7368,psychosis,11,12,79,88,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7368,-1,0.00010816596,0.9998919
7371,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7371,-1,0.00012131482,0.99987864
7374,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7374,-1,0.9999341,6.5895496e-05
7377,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7377,-1,0.9999362,6.3826345e-05
7379,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7379,-1,0.00011966154,0.9998803
7380,human immunodeficiency virus,8,11,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7380,-1,0.7816984,0.21830162
7381,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7381,-1,0.00015339088,0.9998466
7382,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7382,-1,0.0002538423,0.99974614
7383,hyperlipidemia,20,21,132,146,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7383,-1,0.00013584798,0.9998641
7386,mg simvastatin,5,7,26,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7386,-1,0.9998166,0.00018340645
7388,mg,22,23,109,111,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7388,-1,0.9975793,0.0024207768
7389,mg,30,31,139,141,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7389,-1,0.99814665,0.0018533912
7390,mg atazanavir,41,43,185,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7390,-1,0.9998109,0.00018913168
7391,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,-1,-1,-1,7391,-1,0.9998927,0.000107234155
7398,human immunodeficiency virus,8,11,43,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,-1,7398,-1,0.49384454,0.50615543
7399,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,-1,7399,-1,0.99985695,0.00014303533
7405,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,-1,-1,-1,7405,-1,0.9999175,8.2468214e-05
7409,fluvastatin,14,15,88,99,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7409,-1,0.9999238,7.6153876e-05
7410,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7410,-1,0.99994457,5.5478722e-05
7411,atorvastatin,26,27,162,174,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7411,-1,0.99993765,6.22975e-05
7418,fluoroquinolone,3,4,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,-1,-1,-1,7418,-1,0.9999002,9.978768e-05
7430,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7430,-1,0.00012367374,0.99987626
7432,leukaemia,26,27,203,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7432,-1,0.000106009444,0.999894
7433,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,-1,-1,7433,-1,0.00015802763,0.9998419
7437,carmofur,24,25,160,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,-1,7437,-1,0.99993384,6.61701e-05
7439,lesions within the subcortical white matter of the cerebral hemispheres and the,13,25,87,166,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,-1,7439,-1,0.012161295,0.98783875
7440,white matter abnormalities,13,16,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,-1,-1,-1,7440,-1,0.00018704579,0.999813
7442,oedema,9,10,56,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,-1,7442,-1,0.0001223405,0.9998777
7446,serotonin reuptake inhibitor antidepressant,6,10,37,80,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,-1,-1,-1,7446,-1,0.99981636,0.00018368891
7455,P,32,33,194,195,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7455,-1,0.055001114,0.9449989
7456,P,46,47,263,264,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7456,-1,0.03541179,0.9645882
7458,P,26,27,161,162,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,-1,7458,-1,0.081756905,0.9182431
7460,P,18,19,101,102,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7460,-1,0.044058118,0.95594186
7461,P,30,31,167,168,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7461,-1,0.04986649,0.9501335
7463,P,29,30,179,180,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,-1,7463,-1,0.10607545,0.8939246
7464,contrast,3,4,16,24,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,-1,7464,-1,0.00667886,0.9933211
7470,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,-1,7470,-1,0.34687257,0.65312743
7471,loss of vision,8,11,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7471,-1,0.00031542697,0.9996846
7472,headaches,16,17,97,106,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7472,-1,0.00025727635,0.9997427
7473,paraesthesia,4,5,22,34,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7473,-1,0.00014032831,0.9998597
7474,numbness,6,7,40,48,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7474,-1,0.00015325462,0.9998467
7475,scotomata,6,7,56,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,-1,-1,-1,7475,-1,0.00034416743,0.99965584
7479,lead,2,3,27,31,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,-1,-1,-1,7479,-1,0.07010363,0.92989635
7481,hepatitis B virus (HBV) infected,8,15,66,98,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7481,-1,0.0036362784,0.9963637
7482,hepatitis B virus,8,11,66,83,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7482,-1,0.011594128,0.98840594
7483,human immunodeficiency virus,25,28,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7483,-1,0.9912539,0.00874612
7484,HBV infected,4,6,30,42,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,-1,7484,-1,0.010217755,0.9897822
7485,HBsAg,0,1,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,-1,7485,-1,0.9970573,0.0029426867
7486,C,32,33,209,210,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,-1,7486,-1,0.6689449,0.33105505
7487,chronic hepatitis B,10,13,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,-1,7487,-1,0.0010568586,0.99894315
7488,Rabbit syndrome,0,2,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,-1,-1,-1,7488,-1,0.00056411745,0.99943584
7490,rabbit syndrome,1,3,4,19,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7490,-1,0.00035901595,0.99964094
7491,neuroleptic,11,12,77,88,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7491,-1,0.99983084,0.00016908604
7492,imipramine,8,9,47,57,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,-1,7492,-1,0.9999356,6.440007e-05
7494,decreased basal ganglia,6,9,49,72,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7494,-1,0.00036407757,0.99963593
7495,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7495,-1,0.0001487928,0.9998512
7496,rabbit syndrome,25,27,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7496,-1,0.00036074407,0.9996393
7498,cholesteryl ester,2,4,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7498,-1,0.9999373,6.2745494e-05
7499,HIV protease inhibitor ritonavir,10,14,79,111,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7499,-1,0.99976283,0.00023712013
7500,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,-1,-1,-1,7500,-1,0.9998481,0.00015185628
7504,atherosclerotic lesion,8,10,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,-1,7504,-1,0.00015178954,0.99984825
7505,cholesteryl ester,11,13,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,-1,-1,-1,7505,-1,0.99993277,6.722289e-05
7507,HIV protease inhibitor ritonavir,24,28,160,192,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,-1,-1,-1,7507,-1,0.9998135,0.00018653108
7508,h,7,8,42,43,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7508,-1,0.058585886,0.9414141
7509,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7509,-1,0.9998672,0.00013273946
7513,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7513,-1,0.997029,0.0029710638
7514,cholesteryl esters,5,7,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7514,-1,0.99990857,9.141289e-05
7518,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,-1,-1,-1,7518,-1,0.9997688,0.00023120888
7519,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,-1,7519,-1,0.9995566,0.00044335664
7520,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7520,-1,0.9986192,0.0013807775
7521,cholesteryl ester,22,24,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7521,-1,0.99992776,7.224401e-05
7526,antimicrobial agents,4,6,23,43,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7526,-1,0.99980885,0.00019118104
7528,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7528,-1,0.00041738298,0.9995826
7529,cm,13,14,63,65,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7529,-1,0.03405403,0.96594596
7530,Emergency Department,24,26,127,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7530,-1,0.001179579,0.99882036
7532,malaise,39,40,201,208,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7532,-1,0.00019850685,0.99980146
7536,upper respiratory tract infection,11,15,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7536,-1,0.00019405806,0.999806
7539,alkaline phosphatase,34,36,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,-1,7539,-1,0.9998135,0.000186559
7542,toxin,1,2,3,8,"No toxin, alcohol, or other drugs were reported.",17919553_6,-1,-1,-1,7542,-1,0.9997638,0.0002362448
7544,acute hepatitis,9,11,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,-1,-1,7544,-1,0.0001221711,0.9998778
7547,hepatic dysfunction,10,12,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,-1,7547,-1,0.000112707596,0.9998872
7548,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7548,-1,0.00086693536,0.99913305
7550,acute hepatitis,21,23,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7550,-1,0.000106475156,0.99989355
7551,toxic hepatitis,32,34,200,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7551,-1,0.0001018024,0.9998982
7554,acute hepatitis,8,10,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,-1,7554,-1,0.00011654022,0.9998834
7556,uveitis,5,6,38,45,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7556,-1,0.000121355784,0.99987864
7557,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7557,-1,0.99993455,6.5494736e-05
7558,elevated intraocular pressure,9,12,53,82,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7558,-1,0.00033314378,0.9996668
7559,uveitis,18,19,106,113,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7559,-1,0.00011558335,0.99988437
7560,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7560,-1,0.99993455,6.543324e-05
7561,FA,25,26,155,157,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7561,-1,0.999742,0.0002580684
7562,FA,28,29,166,168,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,-1,7562,-1,0.9998124,0.00018759251
7563,mm Hg,18,20,88,93,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7563,-1,0.0037324596,0.9962676
7564,mm Hg,41,43,172,177,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7564,-1,0.0041582203,0.9958418
7565,mm Hg,47,49,190,195,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7565,-1,0.004705127,0.99529487
7566,mm Hg,54,56,212,217,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7566,-1,0.0040265094,0.9959735
7567,mm Hg,14,16,93,98,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,-1,7567,-1,0.011239843,0.98876023
7568,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7568,-1,0.00011326484,0.99988675
7569,mm Hg,9,11,32,37,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7569,-1,0.0063267336,0.9936733
7570,P,36,37,158,159,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7570,-1,0.14522953,0.8547705
7571,FA,10,11,64,66,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,-1,7571,-1,0.9995615,0.0004385083
7600,DCM,5,6,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7600,-1,0.00012418035,0.9998758
7602,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7602,-1,0.00011486304,0.9998851
7603,acquired immunodeficiency syndrome,14,17,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7603,-1,0.0002975704,0.9997024
7604,AIDS,18,19,134,138,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7604,-1,0.0006380098,0.99936205
7605,and skeletal myopathies,29,32,184,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7605,-1,0.0001727044,0.9998273
7607,"3'-azido-2',3'-deoxythymidine",14,15,85,114,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7607,-1,0.99985003,0.00014999852
7608,AZT,16,17,116,119,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7608,-1,0.99988663,0.0001134116
7609,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7609,-1,0.00011986699,0.9998801
7610,Tg,45,46,296,298,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7610,-1,0.028465873,0.9715341
7611,NTg,50,51,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7611,-1,0.1338905,0.8661095
7612,ad,55,56,345,347,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7612,-1,0.9573078,0.042692177
7613,AZT,61,62,395,398,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7613,-1,0.9999088,9.116157e-05
7614,NTg,0,1,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7614,-1,0.9971246,0.0028753828
7615,Tg,4,5,23,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7615,-1,0.16243298,0.83756703
7616,contrast,1,2,3,11,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7616,-1,0.033087667,0.96691227
7617,Tg,5,6,30,32,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7617,-1,0.029991083,0.9700089
7618,cardiac dilation,8,10,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7618,-1,0.000110266395,0.99988973
7619,depressed cardiac function,11,14,69,95,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7619,-1,0.00013688422,0.99986315
7620,caspase 3,20,22,123,132,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,-1,-1,-1,7620,-1,0.99491477,0.0050851973
7621,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,-1,7621,-1,0.9997867,0.00021337731
7623,cardiac dilation and dysfunction,33,37,221,253,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7623,-1,0.00011516332,0.99988484
7624,etoricoxib,3,4,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7624,-1,0.99993587,6.410999e-05
7626,etoricoxib,12,13,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7626,-1,0.9999294,7.055364e-05
7627,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7627,-1,0.99993455,6.544803e-05
7628,etoricoxib,41,42,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7628,-1,0.9999367,6.334822e-05
7631,RA,50,51,372,374,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7631,-1,0.00019796174,0.99980205
7632,RA,17,18,84,86,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7632,-1,0.00039637473,0.9996037
7633,etoricoxib,22,23,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7633,-1,0.99994016,5.9795762e-05
7634,mg,24,25,128,130,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7634,-1,0.9953181,0.0046818983
7635,n,27,28,138,139,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7635,-1,0.22920115,0.77079886
7637,mg,34,35,165,167,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7637,-1,0.996031,0.0039689485
7638,n,38,39,181,182,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7638,-1,0.22585791,0.7741421
7641,SD,4,5,15,17,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7641,-1,0.11786299,0.88213706
7642,etoricoxib,28,29,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7642,-1,0.99994123,5.876081e-05
7644,GI AEs,6,8,43,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7644,-1,0.00022950867,0.99977046
7645,etoricoxib,12,13,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7645,-1,0.999943,5.7006222e-05
7647,p,38,39,201,202,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7647,-1,0.05892668,0.9410733
7648,etoricoxib,13,14,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7648,-1,0.9999447,5.532946e-05
7651,oedema,39,40,247,253,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7651,-1,0.0001328039,0.9998672
7652,Etoricoxib,0,1,0,10,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,-1,-1,-1,7652,-1,0.9999422,5.7852456e-05
7654,Etoricoxib,2,3,13,23,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7654,-1,0.99993324,6.669673e-05
7655,mg,4,5,27,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7655,-1,0.9970401,0.002959906
7656,GI AEs,15,17,105,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7656,-1,0.00038248417,0.99961746
7658,mg,21,22,141,143,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7658,-1,0.9975866,0.002413384
7659,AEs,12,13,91,94,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7659,-1,0.00017113268,0.9998288
7660,etoricoxib,18,19,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7660,-1,0.9999391,6.0936927e-05
7662,norfloxacin,5,6,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,-1,7662,-1,0.9999341,6.593384e-05
7663,fluoroquinolones,7,8,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7663,-1,0.99993145,6.85531e-05
7665,norfloxacin,12,13,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7665,-1,0.99993443,6.557986e-05
7666,anxious behaviour,11,13,86,103,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,-1,7666,-1,0.0001568275,0.9998431
7668,norfloxacin,15,16,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,-1,7668,-1,0.99993384,6.62129e-05
7677,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,-1,7677,-1,0.000115151684,0.99988484
7683,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,-1,7683,-1,0.00013167044,0.9998683
7688,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,-1,-1,7688,-1,0.9999403,5.9774447e-05
7693,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,-1,7693,-1,0.9999391,6.0889874e-05
7695,Ce,17,18,124,126,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7695,-1,0.85543424,0.14456578
7696,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7696,-1,0.99994206,5.7984238e-05
7698,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7698,-1,0.99994457,5.5439104e-05
7699,Ce,25,26,147,149,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7699,-1,0.85737437,0.1426257
7700,ng,28,29,155,157,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7700,-1,0.97348166,0.026518386
7701,ng,36,37,173,175,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7701,-1,0.9684155,0.031584486
7702,ng,45,46,194,196,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7702,-1,0.9858952,0.014104704
7703,Ce,3,4,17,19,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,-1,-1,-1,7703,-1,0.012823965,0.987176
7705,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,-1,7705,-1,0.9999404,5.9651793e-05
7711,P<0.001,17,18,76,83,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,-1,7711,-1,0.083924994,0.91607505
7714,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7714,-1,0.99994326,5.678291e-05
7717,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7717,-1,0.99994516,5.479748e-05
7718,Ce,33,34,233,235,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7718,-1,0.84516907,0.15483092
7719,ng,36,37,241,243,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7719,-1,0.9721657,0.027834253
7722,SD,10,11,47,49,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,-1,7722,-1,0.105728224,0.89427173
7723,n,6,7,23,24,"Of these, nearly half (n = 78)",18020536_4,-1,-1,-1,7723,-1,0.13459459,0.8654054
7724,n,10,11,55,56,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,-1,7724,-1,0.11302581,0.88697416
7725,n,12,13,60,61,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,-1,7725,-1,0.09337327,0.9066267
7726,oxazepam,5,6,37,45,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7726,-1,0.99992514,7.480184e-05
7727,temazepam,7,8,47,56,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7727,-1,0.99992657,7.344909e-05
7728,zopiclone,9,10,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7728,-1,0.9999366,6.346946e-05
7729,SD,6,7,22,24,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,-1,7729,-1,0.11801364,0.8819864
7730,n,13,14,64,65,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,-1,7730,-1,0.1250302,0.8749698
7733,inability to sleep,10,13,56,74,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7733,-1,0.00074791245,0.999252
7734,tiredness,18,19,102,111,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7734,-1,0.00016538179,0.99983454
7735,depressive symptoms,31,33,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7735,-1,0.00013362423,0.99986637
7736,temazepam,6,7,41,50,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,-1,7736,-1,0.99993086,6.9098234e-05
7737,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,-1,-1,7737,-1,0.00024164276,0.9997583
7740,disulfiram overdose,6,8,40,59,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7740,-1,0.09424783,0.9057521
7741,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7741,-1,0.0002052326,0.9997948
7742,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7742,-1,0.00013882278,0.9998611
7744,sensory loss,15,17,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7744,-1,0.00013814365,0.99986184
7745,paresthesia,19,20,116,127,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7745,-1,0.00012420405,0.9998758
7749,giddiness,21,22,104,113,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,-1,-1,7749,-1,0.00016070849,0.9998393
7751,and sensory dysfunction,7,10,54,77,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,-1,-1,-1,7751,-1,0.00024284748,0.9997571
7754,palsy,6,7,25,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,-1,-1,7754,-1,0.00012304785,0.999877
7759,valproate,6,7,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,-1,-1,7759,-1,0.9999306,6.937362e-05
7763,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7763,-1,0.000117356416,0.9998826
7764,LEV,15,16,106,109,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7764,-1,0.99981266,0.00018737049
7765,mg,18,19,116,118,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7765,-1,0.9890855,0.0109145045
7766,valproate,22,23,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7766,-1,0.9999367,6.328837e-05
7767,VPA,24,25,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7767,-1,0.9998859,0.000114095834
7768,mg,28,29,151,153,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7768,-1,0.9843612,0.015638744
7770,"impaired word fluency, psychomotor speed and working memory",3,12,34,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,-1,-1,-1,7770,-1,0.0014147721,0.9985852
7771,LEV,5,6,38,41,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,-1,-1,7771,-1,0.9993279,0.0006721203
7774,anxiety,11,12,105,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,-1,-1,-1,7774,-1,0.00013278288,0.9998672
7778,anxiety,29,30,184,191,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,-1,7778,-1,0.00012249572,0.99987745
7781,NE,24,25,134,136,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7781,-1,0.99987245,0.00012755334
7782,anxiety,44,45,245,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7782,-1,0.00013183139,0.99986815
7785,anxiety,1,2,16,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,-1,7785,-1,0.00012623047,0.99987376
7788,adrenergic antagonists,4,6,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,-1,7788,-1,0.9998894,0.00011065486
7792,anxiety,15,16,127,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,-1,-1,-1,7792,-1,0.00014076143,0.9998592
7793,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,-1,7793,-1,0.9999317,6.828019e-05
7794,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,-1,7794,-1,0.9999356,6.437581e-05
7795,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,-1,7795,-1,0.99993217,6.777387e-05
7796,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7796,-1,0.9999329,6.7136156e-05
7797,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7797,-1,0.00011554568,0.9998845
7798,myocardial ischaemia,49,51,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7798,-1,0.00010805676,0.9998919
7802,p,10,11,64,65,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,-1,-1,7802,-1,0.19968632,0.8003137
7803,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,-1,7803,-1,0.99993634,6.369295e-05
7804,Myocardial infarction,0,2,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7804,-1,0.00014220116,0.9998578
7805,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7805,-1,0.9999285,7.14791e-05
7806,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7806,-1,0.99992526,7.473254e-05
7807,CC,5,6,32,34,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7807,-1,0.9959409,0.004059058
7808,Thromboembolism,0,1,0,15,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7808,-1,0.00015062312,0.9998493
7809,CC,15,16,114,116,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7809,-1,0.998752,0.0012480459
7811,thromboembolism,4,5,35,50,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7811,-1,0.00013465286,0.9998653
7812,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7812,-1,0.00012452957,0.9998754
7813,MI,23,24,156,158,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7813,-1,0.0001435514,0.9998565
7814,CC,12,13,72,74,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7814,-1,0.9981516,0.0018483344
7815,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7815,-1,0.0001550922,0.9998449
7816,myocardial infarction,8,10,56,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,-1,-1,7816,-1,0.00013072579,0.9998692
7817,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,-1,7817,-1,0.9996401,0.00035986098
7818,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,-1,7818,-1,0.0011592044,0.99884087
7819,CC,15,16,98,100,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7819,-1,0.0068295994,0.9931704
7820,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7820,-1,0.00011957178,0.99988043
7822,CC,9,10,57,59,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,-1,-1,7822,-1,0.021083599,0.9789164
7823,ribonucleic acid,4,6,42,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7823,-1,0.999775,0.00022497572
7824,hyperprolactinemic,12,13,92,110,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7824,-1,0.00023545192,0.9997645
7825,luteinizing hormone,16,18,135,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7825,-1,0.9997863,0.00021370531
7830,dopamine antagonist sulpiride,5,8,42,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,-1,-1,7830,-1,0.9999007,9.930565e-05
7842,ventricular apical ballooning syndrome,4,8,25,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7842,-1,0.00017882974,0.99982125
7843,Takotsubo cardiomyopathy,10,12,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7843,-1,0.0012888783,0.9987111
7845,apical ballooning syndrome,3,6,27,53,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7845,-1,0.00039215185,0.99960786
7846,Takotsubo cardiomyopathy,13,15,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7846,-1,0.0017998633,0.99820006
7847,akinesia,17,18,92,100,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7847,-1,0.00024394724,0.99975604
7848,apical ballooning,27,29,140,157,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7848,-1,0.00041080333,0.99958926
7849,apical ballooning syndrome,21,24,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,-1,-1,-1,7849,-1,0.0002554291,0.9997446
7854,ADHD,21,22,157,161,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,-1,-1,-1,7854,-1,0.00018829622,0.9998117
7855,ADHD,13,14,72,76,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7855,-1,0.00022043036,0.9997795
7857,n,20,21,114,115,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7857,-1,0.07234165,0.9276583
7859,n,27,28,140,141,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7859,-1,0.065137304,0.9348627
7862,n,36,37,180,181,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7862,-1,0.07677189,0.92322814
7863,n,44,45,201,202,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7863,-1,0.08088899,0.9191111
7869,p,27,28,152,153,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,-1,7869,-1,0.023378028,0.97662205
7873,p,19,20,97,98,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,-1,7873,-1,0.04501469,0.9549853
7874,Drowsiness,0,1,0,10,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,-1,-1,-1,7874,-1,0.00014605408,0.99985397
7878,ADHD,17,18,105,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,-1,7878,-1,0.00034811988,0.9996519
7881,drowsiness,16,17,121,131,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,-1,-1,7881,-1,0.00013864077,0.99986136
7882,Renal Fanconi syndrome,0,3,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,-1,7882,-1,0.00044288015,0.9995571
7884,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,-1,7884,-1,0.0004341522,0.9995658
7886,MMF,2,3,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,-1,-1,-1,7886,-1,0.9998542,0.00014571451
7889,hepatitis B infection,7,10,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,-1,-1,-1,7889,-1,0.0002288372,0.9997712
7890,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7890,-1,0.00029382994,0.9997061
7892,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7892,-1,0.00032838478,0.9996716
7894,aminoaciduria,19,20,134,147,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7894,-1,0.05109753,0.9489024
7899,muscle weakness,1,3,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,-1,-1,-1,7899,-1,0.00014193144,0.999858
7900,Fanconi syndrome,0,2,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7900,-1,0.00071272784,0.9992873
7902,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7902,-1,0.00043906688,0.9995609
7903,tubular dysfunction,6,8,30,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,-1,-1,7903,-1,0.00014796921,0.99985206
7908,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7908,-1,0.99993324,6.6749875e-05
7909,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7909,-1,0.9999411,5.888023e-05
7910,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7910,-1,0.9999368,6.321949e-05
7912,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7912,-1,0.99993753,6.245579e-05
7913,mg,25,26,135,137,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7913,-1,0.9942041,0.0057959342
7914,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7914,-1,0.9999443,5.5619035e-05
7915,mg,29,30,153,155,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7915,-1,0.9955811,0.004418884
7916,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7916,-1,0.99993825,6.174698e-05
7919,FDC,5,6,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,-1,7919,-1,0.9997756,0.00022444162
7920,in,6,7,43,45,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7920,-1,0.017342225,0.98265773
7921,ie,26,27,146,148,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7921,-1,0.0077241384,0.9922759
7922,mm Hg,36,38,197,202,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7922,-1,0.013118708,0.98688126
7923,P,50,51,198,199,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,-1,7923,-1,0.06934021,0.9306598
7924,P,23,24,87,88,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,-1,7924,-1,0.051224783,0.9487752
7926,cough,28,29,121,126,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7926,-1,0.00013543604,0.9998646
7934,HIT,15,16,112,115,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,-1,7934,-1,0.0010145907,0.99898535
7940,HIT,5,6,21,24,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,-1,7940,-1,0.0005033982,0.9994966
7945,HIT,10,11,63,66,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,-1,7945,-1,0.0010317763,0.99896824
7948,n,12,13,70,71,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7948,-1,0.03126512,0.9687349
7950,n,33,34,170,171,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7950,-1,0.018406596,0.98159343
7957,lymphomas,11,12,93,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7957,-1,0.00014027719,0.9998597
7958,Cancer and Leukemia,19,22,128,147,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7958,-1,0.0003602947,0.99963975
7959,B.Thalidomide,23,24,154,167,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7959,-1,0.9988135,0.0011864761
7960,multiple myeloma,32,34,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7960,-1,0.00013875357,0.99986124
7961,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7961,-1,0.00015110243,0.99984884
7962,lymphoplasmacytic lymphoma,39,41,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7962,-1,0.00015987885,0.99984014
7963,tumour,10,11,53,59,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,-1,7963,-1,0.0005726405,0.99942744
7964,lymphomas,12,13,80,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7964,-1,0.0001626328,0.9998374
7966,mg,16,17,115,117,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7966,-1,0.99819154,0.001808506
7967,mg,22,23,147,149,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7967,-1,0.9973356,0.0026643644
7968,mg,38,39,209,211,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7968,-1,0.996316,0.0036840672
7972,dyspnea,16,17,104,111,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,-1,-1,7972,-1,0.00012917108,0.9998708
7975,lymphomas,15,16,101,110,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7975,-1,0.00015840569,0.9998416
7976,contrast,17,18,115,123,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7976,-1,0.047362603,0.95263743
7977,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7977,-1,0.9999467,5.3290016e-05
7978,NMDA,3,4,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7978,-1,0.9998872,0.00011276543
7982,acute pain,22,24,146,156,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7982,-1,0.00013243339,0.99986756
7983,acute pain,1,3,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7983,-1,0.00015366405,0.99984634
7984,NMDA,7,8,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7984,-1,0.99987924,0.00012074816
7987,acute pain,20,22,124,134,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,-1,7987,-1,0.00016389188,0.9998361
7990,acute pain,8,10,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,-1,7990,-1,0.00016592801,0.99983406
7991,NMDA,5,6,30,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7991,-1,0.9998821,0.000117932024
7992,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7992,-1,0.99994695,5.3026106e-05
7995,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7995,-1,0.99994814,5.181264e-05
7996,acute pain,15,17,102,112,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7996,-1,0.00014001432,0.9998599
7997,NMDA antagonists,7,9,68,84,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7997,-1,0.99990034,9.968857e-05
8000,acute pain,24,26,174,184,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,8000,-1,0.0001794075,0.99982065
8001,mental slowing,1,3,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,-1,8001,-1,0.00012088307,0.9998791
8005,blind,6,7,30,35,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,-1,8005,-1,0.18763335,0.8123666
8006,mg,4,5,30,32,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,8006,-1,0.96832126,0.03167876
8007,mg trihexyphenidyl,7,9,40,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,8007,-1,0.999783,0.00021703725
8009,mental slowness,14,16,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,-1,-1,-1,8009,-1,0.00022687326,0.9997731
8010,mg trihexyphenidyl,9,11,60,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,8010,-1,0.9998109,0.0001891113
8011,mental slowness,16,18,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,8011,-1,0.00021475132,0.99978524
8012,mental slowing,13,15,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,-1,8012,-1,0.00014000777,0.9998599
8015,lead,3,4,34,38,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,-1,-1,8015,-1,0.0025308272,0.9974692
8017,sirolmus,7,8,38,46,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8017,-1,0.9999392,6.0803304e-05
8018,Srl,9,10,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8018,-1,0.99985933,0.00014061895
8021,Srl,20,21,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,8021,-1,0.99981076,0.00018925813
8023,Srl,10,11,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,-1,8023,-1,0.99920315,0.0007968906
8025,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,-1,-1,-1,8025,-1,0.99994063,5.9404854e-05
8028,p,29,30,136,137,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,-1,8028,-1,0.13167708,0.8683229
8030,p,24,25,114,115,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,-1,8030,-1,0.05141097,0.948589
8031,ACE inhibitor,0,2,0,13,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8031,-1,0.99990845,9.157387e-05
8032,ARB,6,7,49,52,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,8032,-1,0.99986315,0.00013681946
8035,increased renal function,4,7,33,57,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8035,-1,0.00016672445,0.9998332
8036,p,13,14,81,82,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8036,-1,0.075814955,0.9241851
8038,decreased renal function,25,28,153,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8038,-1,0.0001440865,0.9998559
8039,p,39,40,225,226,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,8039,-1,0.07891146,0.9210885
8041,Srl,12,13,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,-1,8041,-1,0.9998043,0.00019567097
8042,Srl,0,1,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,-1,-1,8042,-1,0.9990382,0.00096177077
8045,Ginsenoside Rg1,0,2,0,15,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8045,-1,0.9998271,0.00017296858
8046,of learning,5,7,40,51,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,8046,-1,0.0004555004,0.99954444
8048,Rg1,0,1,0,3,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8048,-1,0.99861336,0.0013866291
8049,ginsenoside,4,5,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8049,-1,0.9998167,0.00018336519
8050,spatial learning impairment,12,15,69,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,8050,-1,0.00025801896,0.999742
8051,Rg1,5,6,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,-1,-1,-1,8051,-1,0.9995203,0.00047975002
8053,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8053,-1,0.99738747,0.0026124946
8054,learning impairment,13,15,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,8054,-1,0.00014286276,0.99985707
8057,Rg1,23,24,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,-1,8057,-1,0.99980634,0.00019362057
8059,Rg1,14,15,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,-1,8059,-1,0.9982968,0.0017031722
8061,Rg1,7,8,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8061,-1,0.99988353,0.00011647036
8063,NMDA,42,43,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8063,-1,0.9998777,0.00012225592
8064,MK801,46,47,295,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,8064,-1,0.9998988,0.000101224105
8065,Rg1,3,4,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,-1,8065,-1,0.9404839,0.059516013
8067,NMDA,3,4,15,19,This effect is NMDA receptor dependent.,18308784_10,-1,-1,-1,8067,-1,0.9998141,0.00018588584
8069,antagonists,7,8,73,84,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,-1,-1,-1,8069,-1,0.97536325,0.024636744
8071,antagonists,7,8,61,72,A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described.,18329269_1,-1,-1,-1,8071,-1,0.991905,0.008095044
8073,Parkinson's disease,41,44,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,-1,8073,-1,0.00020853244,0.99979144
8078,dopamine receptor antagonists,24,27,161,190,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,-1,-1,-1,8078,-1,0.99985754,0.00014248688
8081,increase in locomotor activity,8,12,42,72,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,-1,8081,-1,0.00046932578,0.9995307
8083,mecamylamine,12,13,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,-1,-1,-1,8083,-1,0.9999449,5.5037817e-05
8086,SCH 23390,9,11,74,83,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8086,-1,0.99986696,0.00013297317
8087,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8087,-1,0.9999429,5.7112495e-05
8088,fluphenazine,21,22,149,161,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,8088,-1,0.9999404,5.9561633e-05
8089,PHNO,5,6,33,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8089,-1,0.9998473,0.00015271021
8091,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,8091,-1,0.9998771,0.00012293116
8096,vein occlusion,2,4,16,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,-1,8096,-1,0.00016372488,0.9998362
8097,vein occlusion,9,11,47,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8097,-1,0.00016394892,0.99983597
8098,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8098,-1,0.9999287,7.123944e-05
8099,CC,16,17,98,100,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,8099,-1,0.9951149,0.004885067
8100,infertility,8,9,50,61,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8100,-1,0.0008320985,0.9991679
8101,blurred vision,11,13,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,8101,-1,0.00017940596,0.99982065
8102,CC,5,6,46,48,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,-1,8102,-1,0.9992925,0.00070750614
8103,retinal vein occlusion,5,8,33,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8103,-1,0.00023374439,0.9997663
8104,CC,12,13,87,89,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,8104,-1,0.9975502,0.0024498226
8105,retinal vein occlusion,8,11,57,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8105,-1,0.00015760901,0.9998424
8106,CC,15,16,103,105,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,8106,-1,0.44708434,0.5529157
8108,CC,10,11,66,68,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8108,-1,0.032046236,0.9679538
8109,visual disturbance,21,23,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8109,-1,0.00013548214,0.99986446
8110,CC,24,25,162,164,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,8110,-1,0.9966893,0.0033106916
8111,retinal vein occlusion,10,13,58,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8111,-1,0.00017573118,0.99982435
8112,CC,16,17,102,104,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,8112,-1,0.9939839,0.006016089
8113,infertility,6,7,39,50,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8113,-1,0.00013872671,0.99986124
8114,CC,9,10,65,67,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,8114,-1,0.0010761105,0.99892384
8115,ipratropium bromide,4,6,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8115,-1,0.99994445,5.5527144e-05
8117,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,8117,-1,0.000118608456,0.9998814
8118,ipratropium bromide,8,10,47,66,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8118,-1,0.9999436,5.6407654e-05
8120,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,8120,-1,0.00012585729,0.9998741
8121,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,-1,8121,-1,0.9999435,5.652542e-05
8123,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,-1,8123,-1,0.9999453,5.472271e-05
8125,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,-1,-1,-1,8125,-1,0.99994445,5.556841e-05
8128,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8128,-1,0.99994445,5.5492896e-05
8130,airflow obstruction,17,19,116,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,8130,-1,0.00015703804,0.9998429
8131,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,-1,8131,-1,0.03646368,0.9635363
8134,febrile neutropenia,13,15,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,-1,-1,8134,-1,0.00010412531,0.9998958
8143,P,22,23,129,130,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,-1,8143,-1,0.083449215,0.91655076
8144,P,19,20,114,115,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,-1,8144,-1,0.06400741,0.9359926
8146,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8146,-1,0.9999305,6.949274e-05
8147,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8147,-1,0.99993217,6.785671e-05
8148,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,-1,8148,-1,0.9999379,6.2073814e-05
8149,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,-1,-1,-1,8149,-1,0.9999312,6.873468e-05
8150,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,-1,-1,-1,8150,-1,0.9999349,6.5117216e-05
8151,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,-1,-1,-1,8151,-1,0.99993265,6.736805e-05
8152,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,-1,-1,-1,8152,-1,0.9999355,6.452935e-05
8153,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8153,-1,0.999938,6.193775e-05
8154,P,30,31,177,178,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8154,-1,0.04554963,0.95445037
8156,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8156,-1,0.99993575,6.429398e-05
8157,P,60,61,349,350,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8157,-1,0.055354923,0.9446451
8158,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,-1,8158,-1,0.99992883,7.1113194e-05
8161,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,-1,8161,-1,0.99993086,6.9165755e-05
8162,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8162,-1,0.9999404,5.9657596e-05
8163,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,-1,-1,-1,8163,-1,0.9999305,6.944704e-05
8167,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8167,-1,0.0008212935,0.9991787
8168,ADRs,10,11,70,74,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8168,-1,0.0012567749,0.99874324
8169,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8169,-1,0.00039014075,0.9996099
8170,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8170,-1,0.0001040735,0.99989593
8171,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,-1,8171,-1,0.0056583043,0.99434173
8174,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,-1,8174,-1,0.00043966706,0.9995603
8177,hepatic failure,7,9,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,-1,-1,-1,8177,-1,0.0001302224,0.9998697
8178,skin rash,4,6,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,-1,-1,8178,-1,0.00012811003,0.99987185
8188,METH,2,3,17,21,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8188,-1,0.99979836,0.00020169551
8190,DA,7,8,41,43,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8190,-1,0.9998122,0.00018787765
8191,neurodegeneration,22,23,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8191,-1,0.0001126989,0.99988735
8192,DA,24,25,151,153,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8192,-1,0.89498925,0.10501079
8193,CNS damage,2,4,12,22,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8193,-1,0.000106477906,0.99989355
8194,METH,6,7,33,37,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8194,-1,0.9998142,0.0001857666
8195,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8195,-1,0.99985397,0.00014598307
8196,DA,14,15,75,77,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8196,-1,0.99920565,0.00079436356
8199,METH,25,26,141,145,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,-1,8199,-1,0.9997454,0.00025454027
8201,METH,0,1,0,4,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8201,-1,0.9997136,0.00028638516
8202,DA,2,3,14,16,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8202,-1,0.99974686,0.00025314503
8203,METH,3,4,15,19,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,-1,8203,-1,0.99973124,0.0002687925
8204,METH,9,10,83,87,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,-1,8204,-1,0.9994981,0.0005018883
8205,METH,22,23,152,156,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,-1,-1,-1,8205,-1,0.99975115,0.00024879994
8206,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,-1,8206,-1,0.015417449,0.98458254
8207,METH,9,10,68,72,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,-1,8207,-1,0.99962056,0.00037938816
8208,nystagmus,1,2,17,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,-1,8208,-1,0.00013349864,0.9998665
8209,nystagmus,4,5,39,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8209,-1,0.00019842887,0.9998016
8210,NIN,6,7,50,53,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8210,-1,0.0038083745,0.9961916
8211,NIN,14,15,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,-1,-1,-1,8211,-1,0.8427268,0.15727317
8213,NIN,0,1,0,3,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8213,-1,0.11065175,0.8893482
8215,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8215,-1,0.9998217,0.00017830564
8222,GABA,29,30,182,186,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8222,-1,0.9998858,0.00011414306
8223,N-(2-propylpentanoyl)urea,32,33,191,216,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8223,-1,0.9998186,0.00018146152
8224,VPU,34,35,218,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8224,-1,0.9997372,0.00026283605
8225,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8225,-1,0.9999291,7.086691e-05
8226,VPA,46,47,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8226,-1,0.9998385,0.00016147744
8227,VPU,0,1,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8227,-1,0.99982196,0.00017807729
8228,VPA,5,6,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8228,-1,0.9998764,0.00012360596
8230,VPA,30,31,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8230,-1,0.9998838,0.00011625653
8235,GABA,31,32,230,234,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,-1,8235,-1,0.9998895,0.00011055361
8236,VPU,3,4,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8236,-1,0.99990296,9.705653e-05
8237,VPA,11,12,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8237,-1,0.9999132,8.682219e-05
8240,GABA,14,15,85,89,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,-1,8240,-1,0.9998816,0.0001183143
8244,VPU,5,6,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8244,-1,0.99989617,0.00010382391
8245,VPA,7,8,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8245,-1,0.99990356,9.6431795e-05
8250,VPA,3,4,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8250,-1,0.9998184,0.0001816665
8251,VPU,8,9,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8251,-1,0.9997756,0.00022440887
8255,atrioventricular block,1,3,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,-1,8255,-1,0.00023950248,0.99976045
8257,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,-1,-1,8257,-1,0.000178879,0.9998211
8259,atrioventricular (AV) block,6,11,30,57,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8259,-1,0.0004757806,0.99952424
8260,syncopal attacks,12,14,63,79,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8260,-1,0.00013185112,0.99986815
8263,syncopal attacks,12,14,79,95,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,-1,8263,-1,0.0001440828,0.9998559
8266,gastric hemorrhagic ulcers,5,8,34,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,-1,-1,8266,-1,0.0001232128,0.99987674
8268,gastric hemorrhage,5,7,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,-1,-1,8268,-1,0.00011234053,0.9998877
8271,lipid peroxide,20,22,106,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8271,-1,0.99989665,0.00010337324
8272,LPO,23,24,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8272,-1,0.9997085,0.00029155903
8273,gastric hemorrhage,32,34,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8273,-1,0.00011382525,0.99988616
8276,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8276,-1,0.9998996,0.00010040696
8280,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8280,-1,0.999874,0.00012600787
8281,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8281,-1,0.9998939,0.00010608386
8284,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,-1,-1,-1,8284,-1,0.9998816,0.00011838292
8285,h,10,11,57,58,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,-1,8285,-1,0.046591673,0.9534083
8286,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,-1,8286,-1,0.98740953,0.0125904735
8293,gastric ulcers,1,3,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8293,-1,0.000110533896,0.9998895
8295,LPO,17,18,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8295,-1,0.9997713,0.0002286544
8297,gastric hemorrhage,8,10,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,-1,-1,8297,-1,0.000109920795,0.9998901
8300,hemorrhagic ulcer,1,3,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,-1,-1,8300,-1,0.00010328514,0.99989665
8303,gastric hemorrhagic ulcer,3,6,30,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8303,-1,0.00011654833,0.9998834
8304,LPO,13,14,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8304,-1,0.99916124,0.0008387083
8308,hepatitis B,5,7,33,44,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8308,-1,0.002669614,0.9973304
8309,HBSAG,14,15,96,101,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8309,-1,0.9988686,0.0011314297
8311,Hepatitis B virus (HBV),0,6,0,23,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8311,-1,0.60078305,0.39921695
8312,chronic liver disease,13,16,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8312,-1,0.00013212084,0.9998679
8314,hepatic complication,11,13,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,-1,8314,-1,0.00013609744,0.99986386
8316,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8316,-1,0.00016873285,0.9998312
8317,HBV infection,14,16,90,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8317,-1,0.0032031366,0.9967969
8318,antiviral agent lamivudine,18,21,117,143,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8318,-1,0.9998927,0.000107294916
8321,lamivudin,2,3,17,26,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,-1,-1,-1,8321,-1,0.9999385,6.151899e-05
8324,n=,5,6,22,24,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,-1,8324,-1,0.1108536,0.8891464
8329,p,21,22,109,110,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,-1,-1,8329,-1,0.05096501,0.94903505
8332,p,28,29,176,177,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,-1,8332,-1,0.23680836,0.76319164
8335,nucleoside,9,10,61,71,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8335,-1,0.9998764,0.0001236623
8336,nucleotide,11,12,75,85,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8336,-1,0.9998493,0.0001506323
8343,h,42,43,223,224,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,-1,8343,-1,0.03930386,0.9606961
8344,CYP,9,10,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8344,-1,0.9997603,0.00023968778
8345,h,13,14,71,72,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8345,-1,0.09082465,0.90917534
8346,CYP,20,21,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8346,-1,0.99973696,0.00026307476
8347,h,24,25,117,118,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8347,-1,0.07938579,0.9206142
8348,CYP,37,38,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8348,-1,0.9997652,0.00023482442
8349,h,41,42,187,188,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8349,-1,0.06123525,0.9387647
8350,CYP,47,48,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8350,-1,0.9997799,0.00022007377
8351,h,51,52,229,230,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8351,-1,0.05718929,0.94281065
8352,p,19,20,95,96,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,-1,-1,-1,8352,-1,0.117868334,0.88213164
8353,CYP,0,1,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8353,-1,0.99980754,0.00019246171
8354,p,4,5,29,30,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8354,-1,0.2995509,0.7004491
8355,CYP,34,35,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8355,-1,0.9998215,0.0001785692
8356,p,39,40,206,207,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8356,-1,0.25379166,0.74620837
8357,bladder inflammation,9,11,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8357,-1,0.00014849428,0.99985147
8358,CYP,22,23,134,137,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8358,-1,0.9989768,0.0010231589
8359,bladder dysfunction,8,10,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8359,-1,0.00011214862,0.9998878
8360,bladder inflammation,15,17,92,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8360,-1,0.00011884587,0.99988115
8361,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,-1,8361,-1,0.9999379,6.2109044e-05
8367,hypokalemia,11,12,80,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,-1,8367,-1,0.000112768554,0.9998872
8370,mg,4,5,21,23,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8370,-1,0.9848862,0.01511374
8372,mg,30,31,136,138,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8372,-1,0.9911782,0.008821743
8375,mg,18,19,97,99,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,-1,-1,-1,8375,-1,0.98411995,0.015880065
8384,P,31,32,142,143,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8384,-1,0.050676126,0.94932383
8385,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,-1,8385,-1,0.000115931274,0.999884
8387,TAC,0,1,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,-1,8387,-1,0.9998041,0.00019589292
8390,headaches,6,7,39,48,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8390,-1,0.00016877276,0.9998312
8392,neurological deficits,11,13,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8392,-1,0.00012895226,0.999871
8393,myelitis,17,18,113,121,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8393,-1,0.000118618416,0.9998814
8394,brachial plexitis,20,22,132,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8394,-1,0.00014421078,0.99985576
8395,TAC,6,7,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,-1,-1,-1,8395,-1,0.99970764,0.00029231413
8397,TAC,8,9,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,-1,-1,-1,8397,-1,0.99790937,0.0020905968
8406,blood loss,10,12,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,-1,8406,-1,0.0003836956,0.99961627
8409,in,10,11,67,69,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,-1,-1,8409,-1,0.0015182407,0.9984818
8412,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,-1,8412,-1,0.14293222,0.85706776
8413,coagulation factors,11,13,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8413,-1,0.5936485,0.40635148
8415,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8415,-1,9.753239e-05,0.9999025
8416,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,-1,8416,-1,0.99994445,5.5524444e-05
8417,hematological abnormalities,7,9,77,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,-1,8417,-1,9.900741e-05,0.99990094
8419,hyperlipidemia,5,6,56,70,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,-1,-1,8419,-1,0.00010167898,0.9998983
8421,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,-1,-1,8421,-1,9.994262e-05,0.9999001
8422,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,-1,-1,8422,-1,0.00010956415,0.99989045
8429,postoperative nausea and vomiting,15,19,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,-1,-1,-1,8429,-1,0.00016157629,0.99983835
8431,analgesia,17,18,97,106,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,-1,-1,-1,8431,-1,0.0003311905,0.99966884
8432,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8432,-1,0.00014305471,0.99985695
8434,h,21,22,131,132,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8434,-1,0.009315794,0.9906843
8440,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8440,-1,0.00013269733,0.9998673
8444,P,49,50,278,279,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8444,-1,0.061932713,0.9380673
8445,P,14,15,61,62,Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012).,18544179_6,-1,-1,-1,8445,-1,0.16604576,0.8339542
8447,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,-1,-1,8447,-1,0.0001424286,0.99985754
8449,postoperative nausea and vomiting,16,20,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8449,-1,0.00015225296,0.99984777
8451,P,38,39,209,210,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8451,-1,0.06493712,0.9350629
8453,P,65,66,311,312,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8453,-1,0.06254248,0.9374575
8461,postoperative nausea and vomiting,5,9,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8461,-1,0.00015324251,0.9998467
8462,postoperative pain,13,15,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,-1,8462,-1,0.00014431599,0.99985564
8465,Parkinson's disease,6,9,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,-1,8465,-1,0.00023435339,0.9997657
8467,Valvular heart abnormalities,0,3,0,28,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8467,-1,0.00013577496,0.9998642
8468,Parkinson's disease,9,12,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8468,-1,0.00024996957,0.9997501
8469,PD,13,14,86,88,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8469,-1,0.00013201075,0.9998679
8471,valvular heart abnormality,9,12,54,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,-1,8471,-1,0.00012555187,0.9998745
8472,PD,3,4,13,15,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,-1,8472,-1,0.00058070046,0.99941933
8474,PD,1,2,7,9,Thirty PD patients participated in the study.,18560792_6,-1,-1,-1,8474,-1,0.0016268706,0.99837315
8476,n=10,16,17,97,101,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,-1,8476,-1,0.04002903,0.95997095
8477,aortic regurgitation,6,8,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8477,-1,0.00015331368,0.9998467
8479,PD,41,42,153,155,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8479,-1,0.0020916967,0.99790835
8480,NS,46,47,177,179,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8480,-1,0.0029174497,0.99708253
8481,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8481,-1,0.015561198,0.98443884
8482,n=2.8+/-1.09,15,16,81,93,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8482,-1,0.01753025,0.9824698
8483,p=0.008,20,21,108,115,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8483,-1,0.048339944,0.95166004
8486,valvular regurgitation,4,6,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8486,-1,0.00011250583,0.99988747
8488,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8488,-1,0.00011292276,0.9998871
8491,p=0.01,18,19,113,119,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8491,-1,0.03050012,0.9694998
8492,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8492,-1,0.0001093455,0.9998907
8493,valve regurgitation,8,10,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8493,-1,0.0001746309,0.9998254
8494,PD,11,12,77,79,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8494,-1,0.00026471267,0.9997353
8496,dopamine agonists,31,33,209,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8496,-1,0.9999007,9.931096e-05
8498,Unfractionated heparin sodium,2,5,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8498,-1,0.9996803,0.00031970703
8499,UFH,6,7,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8499,-1,0.9997929,0.00020709669
8501,LMWH,13,14,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8501,-1,0.9998816,0.00011840314
8504,HIT,3,4,34,37,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,-1,8504,-1,0.00018258653,0.99981743
8506,HIT,3,4,19,22,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8506,-1,0.0008616524,0.99913836
8507,HIT,13,14,100,103,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8507,-1,0.8221449,0.17785509
8508,LMWH,2,3,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8508,-1,0.9999025,9.748849e-05
8509,UFH,17,18,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8509,-1,0.999884,0.000115961564
8510,UFH,3,4,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,-1,8510,-1,0.9998784,0.000121625024
8511,HIT,0,1,0,3,HIT antibody levels were measured the day before surgery and on POD 7 and 14.,18589141_7,-1,-1,-1,8511,-1,0.9096643,0.09033572
8512,hepatic artery thrombosis,3,6,23,48,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8512,-1,0.00012610668,0.9998739
8513,HIT,17,18,100,103,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8513,-1,0.9124603,0.087539665
8515,HIT,3,4,18,21,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,-1,8515,-1,0.98043895,0.019561088
8516,HIT,6,7,52,55,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,-1,8516,-1,0.0004937431,0.99950624
8517,HIT,9,10,46,49,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,-1,-1,-1,8517,-1,0.0006075893,0.9993924
8519,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,-1,8519,-1,0.00011261939,0.99988735
8520,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,-1,-1,8520,-1,0.00010906474,0.9998909
8522,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8522,-1,0.0001099298,0.9998901
8524,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8524,-1,0.00011354469,0.9998864
8526,3MA,4,5,26,29,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8526,-1,0.99977976,0.00022026921
8527,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8527,-1,0.00012418545,0.9998758
8529,3MA,20,21,140,143,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,-1,8529,-1,0.99916553,0.0008345287
8530,3MA,2,3,9,12,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8530,-1,0.9996512,0.00034884067
8531,mitochondrial injury,9,11,65,85,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8531,-1,0.00052243914,0.99947757
8533,3MA,11,12,74,77,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,-1,8533,-1,0.99856466,0.0014353647
8535,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,-1,-1,8535,-1,0.00010135469,0.9998987
8537,Mitochondrial injury,0,2,0,20,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8537,-1,0.00029580537,0.9997042
8538,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8538,-1,0.00010814667,0.9998919
8542,anthracycline doxorubicin,4,6,20,45,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8542,-1,0.9998926,0.00010735816
8543,DOX,7,8,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8543,-1,0.9998344,0.00016560366
8545,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8545,-1,0.009766088,0.9902339
8548,DOX,0,1,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,-1,8548,-1,0.9996024,0.0003976198
8550,cardiac apoptosis,23,25,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,-1,8550,-1,0.0001533242,0.9998467
8551,DOX,1,2,3,6,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8551,-1,0.9998355,0.00016443817
8553,DOX,12,13,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8553,-1,0.9998149,0.00018512581
8554,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,-1,8554,-1,0.002918643,0.99708134
8555,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,-1,8555,-1,0.010646843,0.9893532
8557,protein excretion,2,4,16,33,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8557,-1,0.0026649716,0.997335
8558,calcineurin inhibitors,10,12,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8558,-1,0.9999249,7.507439e-05
8561,chronic allograft nephropathy,30,33,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8561,-1,0.00012930183,0.99987066
8565,calcineurin inhibitors,11,13,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,-1,8565,-1,0.9999356,6.436569e-05
8569,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,-1,-1,8569,-1,0.00014167359,0.99985826
8571,epileptiform activity,6,8,57,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,-1,8571,-1,0.00012381274,0.99987614
8574,epileptiform activity,14,16,92,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,-1,8574,-1,0.00013236937,0.99986756
8575,urethane,8,9,45,53,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,-1,8575,-1,0.9999013,9.870445e-05
8578,epileptiform activity,8,10,57,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,-1,8578,-1,0.00023741742,0.9997626
8579,epileptiform activity,20,22,111,132,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8579,-1,0.00015301137,0.99984694
8580,epileptiform activity,43,45,269,290,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8580,-1,0.00015847397,0.99984145
8581,epilepsies,39,40,246,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,-1,8581,-1,0.00011054222,0.9998895
8585,psychoses,7,8,46,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8585,-1,0.00017067885,0.9998293
8586,anxiety neurosis,9,11,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8586,-1,0.00016682911,0.9998331
8588,neuropsychiatric,27,28,157,173,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,-1,8588,-1,0.00011438789,0.99988556
8590,malaria,5,6,35,42,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,-1,-1,-1,8590,-1,0.0004762584,0.99952376
8592,fat,1,2,5,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8592,-1,0.99940896,0.00059106015
8593,obese,3,4,18,23,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8593,-1,0.0023907276,0.99760926
8599,triglycerides,10,11,79,92,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8599,-1,0.99983346,0.00016646061
8600,ATP,17,18,137,140,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8600,-1,0.99981993,0.00018013155
8601,fat,16,17,95,98,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8601,-1,0.99930704,0.0006929219
8602,obesity,24,25,125,132,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8602,-1,0.000118201206,0.99988174
8604,mg,6,7,17,19,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8604,-1,0.98751926,0.012480687
8607,obese,37,38,186,191,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8607,-1,0.0008225137,0.9991775
8608,OB,39,40,193,195,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8608,-1,0.0177814,0.98221856
8609,hepatic toxicity,50,52,245,261,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8609,-1,0.0001289952,0.999871
8612,doxorubicinol,11,12,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8612,-1,0.9999021,9.782663e-05
8613,ND,21,22,146,148,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8613,-1,0.09496567,0.90503436
8614,OB,24,25,154,156,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8614,-1,0.12859361,0.87140644
8615,OB,4,5,34,36,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8615,-1,0.5957829,0.40421712
8616,peroxisome proliferators,33,35,180,204,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8616,-1,0.9991836,0.0008163346
8617,ND,58,59,349,351,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8617,-1,0.7601666,0.23983341
8618,OB,64,65,392,394,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8618,-1,0.6263476,0.37365246
8619,ATP,85,86,480,483,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8619,-1,0.99985266,0.0001472928
8621,obese,4,5,27,32,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8621,-1,0.00046783977,0.9995322
8623,ATP,17,18,152,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8623,-1,0.9997602,0.00023974078
8626,PD,7,8,44,46,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,-1,8626,-1,0.34932026,0.6506797
8630,PD,11,12,93,95,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,-1,8630,-1,0.00029265683,0.9997073
8631,PD,3,4,13,15,"In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex.",18703024_6,-1,-1,-1,8631,-1,0.035637442,0.96436256
8632,PD,0,1,0,2,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,-1,-1,-1,8632,-1,0.007896615,0.9921034
8634,PD,12,13,83,85,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,-1,-1,-1,8634,-1,0.006432572,0.9935674
8635,nutritional deficiency,13,15,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,-1,-1,8635,-1,0.6288195,0.37118044
8638,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,-1,-1,8638,-1,0.99994075,5.9234804e-05
8640,cranial nerve dysfunction,1,4,10,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,-1,-1,-1,8640,-1,0.0001224648,0.9998776
8642,adverse effect on the auditory nerve,11,17,84,120,This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve.,18726058_3,-1,-1,-1,8642,-1,0.0019671754,0.99803287
8654,adverse effect on the proximal eighth nerve,14,21,98,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,-1,-1,8654,-1,0.0043777227,0.99562234
8655,cranial nerve deficits,4,7,35,57,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,-1,-1,8655,-1,0.00013874895,0.99986124
8657,hepatic failure,1,3,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,-1,-1,-1,8657,-1,0.000102197286,0.99989784
8658,coenzyme A,12,14,109,119,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,-1,-1,-1,8658,-1,0.99988616,0.00011388193
8661,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,-1,-1,8661,-1,0.9999291,7.0982576e-05
8665,mg-ezetimibe,25,26,188,200,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,-1,-1,-1,8665,-1,0.9997558,0.00024415643
8668,Simvastatinezetimibe,0,1,0,20,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8668,-1,0.9999143,8.565747e-05
8669,escitalopram,2,3,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8669,-1,0.99993706,6.2973995e-05
8672,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,-1,-1,8672,-1,0.009510395,0.9904896
8673,Ezetimibe,0,1,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8673,-1,0.9999248,7.51767e-05
8674,uridine diphosphate,5,7,49,68,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8674,-1,0.99991155,8.8414046e-05
8675,simvastatin hydroxy acid,23,26,173,197,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8675,-1,0.9999254,7.4646225e-05
8678,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,-1,-1,8678,-1,0.00011346005,0.9998865
8681,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,-1,-1,8681,-1,0.99993396,6.60597e-05
8684,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8684,-1,0.00011624677,0.9998838
8685,bisphosphonate,8,9,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8685,-1,0.9999287,7.1308496e-05
8686,alendronate,10,11,71,82,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8686,-1,0.99993074,6.927203e-05
8687,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8687,-1,0.00012717964,0.9998728
8688,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8688,-1,0.00010812253,0.9998919
8689,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8689,-1,0.00013771189,0.9998623
8691,bisphosphonate,18,19,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8691,-1,0.99992764,7.235348e-05
8692,alendronate sodium,20,22,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8692,-1,0.9999238,7.6182274e-05
8693,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8693,-1,0.000111468406,0.99988854
8694,alendronate,4,5,29,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,-1,8694,-1,0.9999391,6.0967912e-05
8696,bisphosphonates,11,12,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8696,-1,0.9999112,8.883425e-05
8698,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8698,-1,0.000115889394,0.9998841
8699,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,-1,8699,-1,9.8999866e-05,0.99990094
8702,volume retention,8,10,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,-1,-1,8702,-1,0.0046688146,0.9953311
8706,volume retention,13,15,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8706,-1,0.0043785144,0.9956215
8708,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8708,-1,0.00011389701,0.99988604
8712,mg,9,10,58,60,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8712,-1,0.8658014,0.1341986
8713,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8713,-1,0.0001030626,0.9998969
8715,lipidemia,32,33,179,188,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8715,-1,0.00035171045,0.99964833
8716,hypoalbuminemia,35,36,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8716,-1,0.00010285996,0.9998971
8720,body weight gain,39,42,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,-1,8720,-1,0.0005735978,0.9994265
8721,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8721,-1,9.578439e-05,0.99990416
8723,uremia,24,25,150,156,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8723,-1,0.00011980129,0.9998802
8724,volume retention,9,11,62,78,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8724,-1,0.0043728473,0.99562716
8726,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8726,-1,0.00011192277,0.99988806
8728,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,-1,8728,-1,0.00010959278,0.99989045
8731,abdominal pain,7,9,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8731,-1,0.00012584277,0.9998741
8734,urinary tract infection,21,24,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8734,-1,0.00016757092,0.9998324
8736,haemolysis,10,11,83,93,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,-1,-1,8736,-1,0.000100176374,0.99989986
8737,petechiae,4,5,36,45,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8737,-1,0.00016784997,0.99983215
8738,purpura,6,7,50,57,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8738,-1,0.00032977242,0.99967027
8739,haemorrhages,9,10,64,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,-1,-1,-1,8739,-1,0.00022098888,0.99977905
8740,bone marrow depression,3,6,12,34,No signs of bone marrow depression were found.,18791946_7,-1,-1,-1,8740,-1,0.00022662187,0.99977344
8742,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,-1,-1,8742,-1,0.0001272301,0.9998728
8745,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,-1,8745,-1,0.00010063403,0.9998994
8751,myocardial hyperactivity,21,23,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8751,-1,0.00011515036,0.99988484
8756,ischaemic injury,5,7,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,-1,-1,-1,8756,-1,0.00013358702,0.99986637
8758,mitochondrial damage,3,5,27,47,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,-1,-1,8758,-1,0.00027878108,0.9997212
8762,mitochondrial damage,14,16,110,130,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8762,-1,0.00039898674,0.99960107
8763,neurodegenerative,22,23,162,179,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8763,-1,0.0001285622,0.9998714
8767,axonal damage,11,13,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8767,-1,0.00014444458,0.9998555
8770,mitochondrial impairment,10,12,71,95,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8770,-1,0.00031837207,0.9996816
8772,mitochondrial toxicity,16,18,127,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,-1,-1,8772,-1,0.00053664687,0.9994634
8777,peripheral nerve toxicity,12,15,82,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,-1,8777,-1,0.000110061024,0.99988997
8780,5-(l-hexyloxy)-6-methoxy-4-methylquinoline,10,11,110,152,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,-1,-1,8780,-1,0.9998165,0.00018357721
8783,8-aminoquinoline WR242511,5,7,26,51,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,-1,8783,-1,0.9997708,0.00022918309
8784,WR242511,6,7,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8784,-1,0.9998807,0.00011934181
8785,WR242511,34,35,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8785,-1,0.99988925,0.000110783876
8786,WR242511,6,7,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8786,-1,0.9997727,0.00022728031
8787,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8787,-1,0.06797703,0.9320229
8788,hemoglobinuria,3,4,23,37,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8788,-1,0.000115247465,0.9998847
8789,WR242511,11,12,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8789,-1,0.9997825,0.0002174818
8790,Myoglobinuria,0,1,0,13,Myoglobinuria was also observed following the 7.0 mg/kg dose.,18821488_7,-1,-1,-1,8790,-1,0.00020904467,0.99979097
8793,WR242511,4,5,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8793,-1,0.9997036,0.00029636823
8796,liver tumors,6,8,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,-1,8796,-1,0.00011916145,0.9998808
8798,liver tumors,8,10,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8798,-1,0.0001344263,0.99986553
8799,oral contraceptive steroids,17,20,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8799,-1,0.9999119,8.8103996e-05
8800,Liver Tumors,3,5,17,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,-1,8800,-1,0.00015846506,0.99984145
8802,focal nodular hyperplasia,11,14,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8802,-1,0.00015782511,0.99984217
8803,adenoma,15,16,92,99,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8803,-1,0.00019053064,0.99980944
8804,hamartoma,17,18,101,110,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8804,-1,0.00046055656,0.9995395
8805,hepatoma,20,21,116,124,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8805,-1,0.0001710286,0.99982893
8806,oral contraceptive steroids,9,12,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,-1,8806,-1,0.9998987,0.00010128783
8808,liver rupture,3,5,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,-1,-1,8808,-1,0.00014272415,0.9998573
8810,Parkinson's disease,8,11,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,-1,-1,8810,-1,0.00023690116,0.9997631
8812,Parkinson's disease,39,42,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8812,-1,0.00026740858,0.99973255
8813,PD,43,44,235,237,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8813,-1,0.00016060402,0.9998394
8814,PD,3,4,18,20,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,-1,8814,-1,0.00015861489,0.99984133
8820,PD,14,15,77,79,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,-1,8820,-1,0.00024731396,0.9997527
8822,PD,20,21,153,155,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,-1,8822,-1,0.00017011732,0.9998299
8841,priapism,8,9,63,71,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8841,-1,0.0002007745,0.9997992
8842,emergency department,11,13,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8842,-1,0.00035656334,0.99964345
8843,Priapism,0,1,0,8,Priapism is the prolonged erection of the penis in the absence of sexual arousal.,18996674_1,-1,-1,-1,8843,-1,0.00024533487,0.9997546
8845,Emergency Department,13,15,71,91,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8845,-1,0.0012025572,0.9987974
8846,priapism,26,27,141,149,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8846,-1,0.0001697717,0.99983025
8855,ventricular ectopy,26,28,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,-1,8855,-1,0.00012460227,0.9998754
8856,cardiac disease,9,11,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8856,-1,0.00013099107,0.999869
8858,bigeminy,16,17,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8858,-1,0.0010055662,0.9989944
8864,rheumatologic disorders,9,11,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,-1,8864,-1,0.0001340924,0.9998659
8866,hepatitis B virus surface antigen,20,25,138,171,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8866,-1,0.75166523,0.24833475
8867,HBs Ag,26,28,173,179,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8867,-1,0.9954438,0.0045561935
8868,rheumatologic disease,32,34,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8868,-1,0.000120422985,0.9998796
8869,HBs Ag,8,10,35,41,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8869,-1,0.9799778,0.020022191
8870,rheumatologic diseases,13,15,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8870,-1,0.00012812493,0.99987185
8872,hepatitis B virus,4,7,22,39,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,-1,8872,-1,0.86031145,0.13968854
8874,abnormal liver function,15,18,100,123,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,-1,-1,-1,8874,-1,0.00029133033,0.9997086
8878,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8878,-1,0.9999145,8.542271e-05
8880,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8880,-1,0.000109061,0.9998909
8882,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8882,-1,0.99990666,9.328317e-05
8883,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8883,-1,0.0014664751,0.9985335
8885,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8885,-1,0.00010668524,0.9998933
8886,ISO,7,8,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8886,-1,0.9998752,0.0001247473
8887,h,23,24,91,92,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8887,-1,0.18098144,0.8190186
8888,P<0.05,28,29,115,121,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8888,-1,0.05911061,0.94088936
8889,weight,33,34,142,148,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8889,-1,0.0004660442,0.999534
8890,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8890,-1,0.0007286223,0.99927133
8892,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8892,-1,0.99991894,8.10414e-05
8893,ISO,29,30,139,142,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8893,-1,0.9998461,0.00015382325
8894,P<0.05,41,42,191,197,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8894,-1,0.11390963,0.8860904
8895,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8895,-1,0.0007156989,0.9992843
8896,ISO,77,78,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8896,-1,0.9998423,0.00015764055
8898,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8898,-1,0.99991345,8.6507556e-05
8900,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8900,-1,0.9999068,9.3259165e-05
8901,ISO,14,15,92,95,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8901,-1,0.9998288,0.00017110967
8902,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8902,-1,0.000107992906,0.999892
8903,haemopericardium,1,2,6,22,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8903,-1,0.00035400965,0.99964595
8904,gastrointestinal haemorrhage,3,5,27,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8904,-1,0.00012519586,0.99987483
8906,haemorrhage,7,8,35,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,-1,-1,-1,8906,-1,0.00013455442,0.9998654
8908,flavonoids,8,9,54,64,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,-1,8908,-1,0.99987626,0.00012376152
8911,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,-1,-1,8911,-1,0.0003762623,0.99962366
8916,bupropion HCl,13,15,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,-1,8916,-1,0.9999348,6.524949e-05
8919,bupropion HCl,22,24,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,-1,8919,-1,0.99992836,7.163688e-05
8920,Bupropion HCl,0,2,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,-1,8920,-1,0.99992955,7.040429e-05
8923,bupropion HCl,9,11,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,-1,8923,-1,0.9999366,6.3394196e-05
8925,p,10,11,74,75,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8925,-1,0.2341242,0.7658758
8926,bupropion HCl,26,28,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8926,-1,0.99993575,6.41976e-05
8934,sinusoidal obstruction syndrome,14,17,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8934,-1,0.00012542946,0.9998746
8935,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8935,-1,0.000109162334,0.9998908
8936,calcineurin inhibitor,1,3,2,23,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8936,-1,0.99992,7.999962e-05
8938,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8938,-1,0.00015987459,0.99984014
8943,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8943,-1,0.000117569805,0.99988246
8944,MDS,24,25,132,135,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8944,-1,0.00012415726,0.9998758
8945,n,26,27,137,138,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8945,-1,0.0027709194,0.99722904
8946,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8946,-1,0.00013500925,0.99986494
8947,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8947,-1,0.00013026364,0.9998697
8948,n,37,38,177,178,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8948,-1,0.0029521284,0.99704784
8949,n,50,51,249,250,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8949,-1,0.018366022,0.98163396
8950,n,57,58,270,271,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8950,-1,0.020473221,0.9795268
8952,GVHD,10,11,48,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8952,-1,0.0001303915,0.9998696
8953,GVHD,25,26,120,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8953,-1,0.00012777868,0.9998722
8954,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8954,-1,0.00013876072,0.99986124
8955,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8955,-1,0.0007536979,0.99924636
8956,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8956,-1,0.00011533344,0.9998846
8957,sinusoidal obstruction syndrome,15,18,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8957,-1,0.00017808628,0.99982196
8958,SOS,19,20,119,122,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8958,-1,0.0005434334,0.9994566
8959,GVHD,14,15,90,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8959,-1,0.00011761689,0.99988234
8960,TMA,19,20,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8960,-1,0.0068954476,0.9931045
8961,SOS,21,22,121,124,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8961,-1,0.0027442689,0.99725574
8962,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8962,-1,0.99994373,5.6265555e-05
8964,colorectal adenomas,20,22,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8964,-1,0.00013837252,0.9998616
8965,adenomatous polyps,9,11,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8965,-1,0.00019078387,0.9998092
8966,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8966,-1,0.9999448,5.5216293e-05
8967,DFMO,19,20,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8967,-1,0.9998883,0.000111693975
8969,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8969,-1,0.00014448923,0.9998555
8971,DFMO,10,11,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8971,-1,0.99989045,0.00010955684
8972,DFMO,17,18,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8972,-1,0.9999032,9.674808e-05
8974,P,37,38,200,201,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8974,-1,0.11940391,0.8805961
8975,P,23,24,101,102,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,-1,8975,-1,0.21450588,0.7854941
8976,DFMO,11,12,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8976,-1,0.99989784,0.000102093734
8978,hearing reduction,33,35,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8978,-1,0.00054116733,0.99945885
8979,P,49,50,233,234,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8979,-1,0.046150494,0.95384955
8980,P,29,30,158,159,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,-1,8980,-1,0.19262272,0.8073773
8981,DFMO,12,13,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8981,-1,0.99990666,9.331734e-05
8983,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8983,-1,0.00013961186,0.9998604
8985,P,26,27,123,124,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,-1,8985,-1,0.15030512,0.8496949
8986,DFMO,14,15,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,-1,8986,-1,0.9999058,9.4205716e-05
8990,RPN,4,5,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,-1,-1,8990,-1,0.0005967035,0.99940336
8993,to,16,17,115,117,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8993,-1,0.0052146763,0.99478537
8994,RPN,27,28,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8994,-1,0.0022802588,0.9977197
8995,to the,15,17,108,114,The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla.,1919871_7,-1,-1,-1,8995,-1,0.09642878,0.90357125
8998,ulcerative colitis,4,6,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8998,-1,0.000115102266,0.99988484
8999,pleural effusion,10,12,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8999,-1,0.00013182813,0.99986815
9001,urinary abnormalities,15,17,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,9001,-1,0.00024127995,0.9997588
9003,segmental necrotizing glomerulonephritis,7,10,45,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,-1,-1,9003,-1,0.00017299861,0.9998271
9004,pleural effusions,8,10,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,-1,-1,-1,9004,-1,0.00024069012,0.99975926
9007,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9007,-1,0.00012758741,0.99987245
9008,pleural effusions,25,27,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9008,-1,0.00015699884,0.999843
9010,pleural effusion,50,52,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,9010,-1,0.00012606652,0.9998739
9012,pleural effusion,7,9,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,-1,-1,-1,9012,-1,0.00013188833,0.99986804
9017,contrast,1,2,3,11,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,-1,9017,-1,0.061036013,0.938964
9020,in,9,10,47,49,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,-1,-1,9020,-1,0.0006454167,0.99935454
9021,excretion,15,16,74,83,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,-1,-1,9021,-1,0.00022480701,0.99977523
9028,idiopathic Parkinson's disease,9,13,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,-1,-1,-1,9028,-1,0.00026252726,0.99973744
9029,idiopathic Parkinson's disease,20,24,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9029,-1,0.00032924218,0.99967074
9030,PD,25,26,177,179,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,9030,-1,0.00021919969,0.99978083
9033,Parkinson's Disease,8,11,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,9033,-1,0.001388347,0.9986117
9036,homonymous,11,12,60,70,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9036,-1,0.00088517,0.9991148
9037,hemianopsia,12,13,71,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9037,-1,0.0001314083,0.99986863
9038,Valproate,33,34,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,9038,-1,0.9999454,5.4651784e-05
9039,PD,22,23,137,139,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,-1,9039,-1,0.00027544584,0.99972457
9048,pains,4,5,29,34,Subjects also recalled their pains one week later.,19269743_5,-1,-1,-1,9048,-1,0.00042194818,0.99957806
9050,p<0.001,8,9,61,68,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,-1,9050,-1,0.06358878,0.93641126
9054,p<0.001,15,16,101,108,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,-1,9054,-1,0.09935246,0.9006476
9058,myeloma,21,22,166,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,-1,9058,-1,0.00013363901,0.99986637
9060,bortezomib,15,16,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9060,-1,0.999943,5.702515e-05
9062,multiple myeloma,31,33,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9062,-1,0.00017133026,0.9998287
9063,MM,34,35,249,251,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,9063,-1,0.0003194648,0.9996805
9064,bortezomib,9,10,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9064,-1,0.99994004,5.9940547e-05
9066,mg,26,27,126,128,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9066,-1,0.995918,0.004082023
9067,bortezomib,31,32,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,9067,-1,0.999926,7.4015516e-05
9070,CR,8,9,46,48,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9070,-1,0.0011592,0.99884087
9071,CR,29,30,121,123,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,9071,-1,0.0011307315,0.99886924
9074,bortezomib,4,5,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9074,-1,0.99994063,5.9332153e-05
9077,MM,25,26,176,178,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,9077,-1,0.0006714825,0.9993285
9080,captopril overdose,6,8,40,58,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,-1,-1,9080,-1,0.11323303,0.88676697
9082,inhibitors,9,10,77,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,-1,-1,-1,9082,-1,0.99979645,0.0002035696
9086,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,-1,9086,-1,0.11085266,0.88914734
9094,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,-1,9094,-1,0.9999008,9.9129575e-05
9097,critically ill,9,11,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,-1,-1,-1,9097,-1,0.0003435885,0.99965644
9099,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,-1,9099,-1,0.99992216,7.7825374e-05
9107,Pneumocystis pneumonia,10,12,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,-1,-1,9107,-1,0.00018101893,0.999819
9108,Pneumocystis pneumonia,0,2,0,22,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9108,-1,0.00029329816,0.9997067
9109,PCP,3,4,24,27,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9109,-1,0.00045346053,0.99954647
9110,opportunistic infection,8,10,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,9110,-1,0.00016732773,0.99983263
9111,intrahepatic cholestasis,14,16,99,123,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9111,-1,0.00012719516,0.9998728
9112,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9112,-1,0.00010980963,0.9998902
9113,PCP,34,35,243,246,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,9113,-1,0.053356443,0.94664353
9114,cm,9,10,44,46,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,-1,9114,-1,0.0012260642,0.9987739
9115,apical ballooning syndrome,2,5,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,-1,-1,-1,9115,-1,0.00018126697,0.99981874
9116,apical ballooning syndrome,1,4,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9116,-1,0.00084647856,0.9991535
9117,ABS,5,6,32,35,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9117,-1,0.0021576702,0.9978423
9118,acute cardiac syndrome,12,15,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9118,-1,0.00013715152,0.9998628
9119,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9119,-1,0.00013991636,0.99986005
9120,epicardial coronary disease,38,41,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,9120,-1,0.0001550168,0.9998449
9122,ABS,7,8,33,36,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,-1,9122,-1,0.0036778275,0.99632215
9124,ischemic chest pain,6,9,43,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,-1,-1,9124,-1,0.00013467211,0.9998653
9125,fluorouracil,5,6,39,51,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9125,-1,0.99991286,8.712649e-05
9126,colorectal cancer,8,10,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,9126,-1,0.00017542246,0.9998246
9128,akinesis,12,13,82,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,-1,-1,-1,9128,-1,0.00012431674,0.99987566
9129,cardiac complications,3,5,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9129,-1,0.00012220838,0.9998778
9131,coronary vasospasm,11,13,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9131,-1,0.00011971862,0.9998803
9132,thrombus,18,19,154,162,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,9132,-1,0.00016961085,0.99983037
9135,ABS,28,29,194,197,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,-1,9135,-1,0.0044123125,0.9955877
9137,antagonists,2,3,21,32,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9137,-1,0.99975926,0.0002406869
9138,nitric oxide synthase inhibitors,4,8,37,69,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9138,-1,0.99983907,0.00016093513
9142,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,9142,-1,0.000114543436,0.99988544
9144,HOE 140,68,70,385,392,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9144,-1,0.99954295,0.00045709236
9145,des Arg10 HOE 140,76,80,412,429,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,9145,-1,0.9998167,0.00018326133
9150,diabetic hyperalgesia,24,26,155,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,-1,-1,-1,9150,-1,0.00012867038,0.99987125
9151,HOE 140,14,16,105,112,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9151,-1,0.99950445,0.00049555604
9152,des Arg10 HOE 140,17,21,117,134,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,9152,-1,0.9997243,0.00027569226
9156,HOE 140,12,14,80,87,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9156,-1,0.99967945,0.00032061693
9157,toxic neuropathy,18,20,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,9157,-1,9.9543424e-05,0.99990046
9159,toxic neuropathy,23,25,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,-1,9159,-1,0.00011923271,0.9998808
9162,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,-1,9162,-1,0.6202688,0.37973118
9163,bradykinin receptor antagonists,8,11,56,87,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,-1,-1,9163,-1,0.9999083,9.163343e-05
9164,inhibitors,14,15,104,114,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,-1,-1,9164,-1,0.999826,0.00017397656
9167,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9167,-1,0.00040981235,0.9995902
9168,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9168,-1,0.9999386,6.136121e-05
9170,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9170,-1,0.00046922022,0.9995308
9171,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9171,-1,0.99993455,6.5428685e-05
9172,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,-1,-1,9172,-1,0.00043302466,0.999567
9174,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,-1,9174,-1,0.99993765,6.235397e-05
9176,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,-1,-1,9176,-1,0.9999368,6.3185435e-05
9178,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,-1,-1,9178,-1,0.99993336,6.668116e-05
9179,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,-1,9179,-1,0.0010666706,0.9989334
9181,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9181,-1,0.99993896,6.105477e-05
9182,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9182,-1,0.0005093545,0.9994906
9184,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,-1,-1,9184,-1,0.000108310436,0.99989164
9185,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,-1,9185,-1,0.00014108367,0.99985886
9187,prothrombin complex concentrate,15,18,89,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9187,-1,0.9998361,0.00016393
9188,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9188,-1,0.99969685,0.0003031589
9191,h,12,13,59,60,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,-1,9191,-1,0.15926456,0.8407355
9192,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,-1,9192,-1,0.99978524,0.00021481009
9194,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9194,-1,0.9997943,0.00020575282
9195,n=12,20,21,96,100,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9195,-1,0.1465997,0.85340035
9199,P=0.015,22,23,139,146,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,-1,9199,-1,0.08290739,0.9170927
9200,hematomas,12,13,53,62,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,-1,9200,-1,0.00018653854,0.9998135
9201,contrast,1,2,3,11,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9201,-1,0.022281319,0.97771865
9202,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,-1,9202,-1,0.9986506,0.0013494452
9204,inferior colliculus lesion,1,4,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,-1,9204,-1,0.00032577108,0.9996742
9206,inferior colliculus lesions,7,10,41,68,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,-1,9206,-1,0.00022082437,0.99977916
9211,map,26,27,146,149,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,-1,9211,-1,0.15824047,0.8417595
9213,map,13,14,80,83,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9213,-1,0.018973244,0.98102677
9214,map,39,40,200,203,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9214,-1,0.016120782,0.9838792
9215,callosal lesion,32,34,163,178,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,-1,9215,-1,0.0005511217,0.99944884
9216,inferior colliculus lesions,3,6,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,-1,9216,-1,0.000265416,0.9997346
9222,calcineurin inhibitor,19,21,125,146,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,-1,-1,9222,-1,0.99992406,7.588008e-05
9249,PA,16,17,111,113,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,-1,9249,-1,0.043886065,0.95611393
9250,memory impaired,9,11,60,75,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9250,-1,0.00021473758,0.99978524
9253,of,21,22,141,143,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9253,-1,0.0010680275,0.99893194
9254,PA,25,26,166,168,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9254,-1,0.97028595,0.029714117
9258,HT,5,6,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9258,-1,0.9997533,0.0002467153
9259,menopausal symptoms,12,14,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9259,-1,0.00029319501,0.9997068
9260,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9260,-1,0.00014337835,0.9998566
9263,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,-1,9263,-1,0.99954283,0.0004571891
9267,Menstrual Disorders,17,19,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9267,-1,0.0015140006,0.998486
9268,Subfertility,20,21,127,139,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9268,-1,0.0014082843,0.9985917
9269,HT,7,8,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,-1,9269,-1,0.99981266,0.0001873076
9270,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9270,-1,0.62906903,0.37093097
9271,oestrogens,2,3,12,22,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9271,-1,0.99991536,8.4622974e-05
9272,progestogens,7,8,40,52,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9272,-1,0.9998901,0.0001098774
9273,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,-1,9273,-1,0.99978155,0.00021845003
9277,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,-1,9277,-1,0.9998029,0.00019712129
9281,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9281,-1,0.99969065,0.00030942503
9283,HT,17,18,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9283,-1,0.9992435,0.00075649045
9284,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9284,-1,0.0001578397,0.99984217
9285,HT,22,23,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,-1,9285,-1,0.99931085,0.0006891312
9287,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9287,-1,0.0001328319,0.9998672
9288,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9288,-1,0.99981755,0.00018252824
9289,HT,17,18,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9289,-1,0.99984026,0.00015973196
9290,HT,22,23,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9290,-1,0.99982893,0.00017099599
9291,HT,15,16,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,-1,-1,-1,9291,-1,0.9997235,0.00027650592
9292,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9292,-1,0.99597484,0.0040251343
9293,disease,14,15,80,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9293,-1,0.00019260435,0.9998074
9294,HT,8,9,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,-1,9294,-1,0.99979645,0.00020351386
9302,painful,19,20,125,132,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,-1,9302,-1,0.00016314985,0.9998368
9307,salvianolic acid A,3,6,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9307,-1,0.9999268,7.314768e-05
9308,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9308,-1,0.0001111768,0.9998888
9309,salvianolic acid A,11,14,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9309,-1,0.99992204,7.796897e-05
9310,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9310,-1,0.000108380395,0.99989164
9311,lactate,9,10,73,80,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9311,-1,0.99986756,0.00013244324
9313,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9313,-1,0.99985015,0.00014977483
9315,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9315,-1,0.99982315,0.00017689032
9316,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9316,-1,0.99972695,0.00027306197
9317,respiratory dysfunction,4,6,27,50,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,-1,9317,-1,0.00059651356,0.9994035
9318,salvianolic acid A,2,5,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,-1,9318,-1,0.99991274,8.723939e-05
9321,salvianolic acid A,4,7,23,41,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,-1,-1,9321,-1,0.9999045,9.545231e-05
9323,salvianolic acid A,7,10,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9323,-1,0.99984956,0.0001504394
9324,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9324,-1,0.00010715412,0.99989283
9330,PAC,14,15,101,104,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9330,-1,0.99984217,0.00015779787
9332,amino acid glutamine,23,26,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9332,-1,0.9998635,0.00013647483
9333,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9333,-1,0.01718385,0.98281616
9338,mg,37,38,226,228,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9338,-1,0.99792093,0.002079088
9339,P,51,52,277,278,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9339,-1,0.97822875,0.02177124
9340,signs or symptoms,9,12,56,73,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9340,-1,0.00018508415,0.9998149
9343,P,44,45,291,292,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9343,-1,0.061971784,0.9380282
9344,P,21,22,118,119,Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%).,19473225_6,-1,-1,-1,9344,-1,0.0631588,0.9368412
9347,PAC,21,22,147,150,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9347,-1,0.998889,0.0011110087
9348,myasthenia,3,4,22,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9348,-1,0.0001306084,0.99986935
9349,pegylated interferon,5,7,40,60,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9349,-1,0.99993145,6.8560425e-05
9351,hepatitis C.A,12,14,97,110,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9351,-1,0.0028926465,0.9971073
9352,diplopia,18,19,147,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9352,-1,0.00010689776,0.99989307
9353,pegylated interferon (IFN) alpha-2b,25,31,191,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9353,-1,0.99988234,0.00011765032
9355,chronic hepatitis C,34,37,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9355,-1,0.00023960164,0.99976045
9356,CHC,38,39,266,269,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9356,-1,0.00020541174,0.99979466
9357,ptosis on the right upper lid,3,9,35,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9357,-1,0.0005768772,0.99942315
9358,restricted right eye movement,10,14,69,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9358,-1,0.00020694904,0.9997931
9360,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,-1,-1,-1,9360,-1,0.9998708,0.00012923182
9361,pegylated IFN alpha-2b,12,15,90,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,-1,-1,-1,9361,-1,0.99990916,9.078811e-05
9363,myasthenia,2,3,11,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9363,-1,0.00013331357,0.9998667
9364,pegylated IFN alpha-2b,8,11,61,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9364,-1,0.9999075,9.2527305e-05
9366,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9366,-1,0.00021758153,0.9997824
9367,IFN,35,36,213,216,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9367,-1,0.99985886,0.00014115742
9368,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,-1,9368,-1,0.00015477075,0.99984515
9377,hypoactivity,10,11,82,94,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,-1,9377,-1,0.00015887342,0.9998411
9382,hypoactivity,1,2,17,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,-1,9382,-1,0.00017473068,0.9998253
9388,Acute renal failure,0,3,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9388,-1,0.00012081069,0.9998791
9389,AIDS,6,7,37,41,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9389,-1,0.00021648234,0.9997836
9390,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9390,-1,0.999943,5.6980898e-05
9392,osteomyelitis,15,16,103,116,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9392,-1,0.00012186626,0.99987817
9393,Renal failure,0,2,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9393,-1,0.000119486525,0.99988055
9395,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9395,-1,0.9999361,6.387359e-05
9396,Tenofovir,0,1,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9396,-1,0.9999392,6.0769213e-05
9397,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9397,-1,0.0010878578,0.9989121
9398,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9398,-1,0.00012710241,0.9998729
9399,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,-1,9399,-1,0.0037296345,0.9962703
9401,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9401,-1,0.9999417,5.8339872e-05
9402,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9402,-1,0.00011916872,0.9998808
9404,hydrogen cyanamide,3,5,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,-1,9404,-1,0.9999118,8.815038e-05
9405,Hydrogen cyanamide,0,2,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,-1,9405,-1,0.99991834,8.1599115e-05
9406,aldehyde dehydrogenase,14,16,91,113,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9406,-1,0.9998356,0.0001644161
9407,acetaldehyde,19,20,129,141,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9407,-1,0.99991894,8.105176e-05
9409,hydrogen cyanamide,18,20,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,-1,9409,-1,0.9999198,8.019484e-05
9410,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9410,-1,0.9856493,0.01435073
9411,hydrogen cyanamide,13,15,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9411,-1,0.99990666,9.331137e-05
9414,malaise,13,14,65,72,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9414,-1,0.0001805523,0.99981946
9415,flushing of the face,15,19,78,98,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9415,-1,0.00045965586,0.9995403
9417,dyspnea,23,24,117,124,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9417,-1,0.0001427918,0.9998572
9418,Dormex,12,13,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,-1,9418,-1,0.9776249,0.022375138
9419,flushing,10,11,70,78,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9419,-1,0.00019051484,0.99980956
9423,Dormex,17,18,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,-1,-1,-1,9423,-1,0.9992786,0.0007213682
9424,dysosmia,1,2,10,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9424,-1,0.00010712316,0.99989283
9425,pyrazinamide,4,5,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9425,-1,0.99994063,5.9350998e-05
9426,Pyrazinamide,0,1,0,12,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9426,-1,0.99994373,5.6271565e-05
9427,hepatic toxicity,7,9,46,62,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9427,-1,0.00010878534,0.99989116
9428,hyperuricemia,10,11,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9428,-1,0.00010770659,0.99989223
9429,digestive disorders,12,14,81,100,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9429,-1,0.00011765301,0.99988234
9430,pyrazinamide,14,15,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,-1,-1,-1,9430,-1,0.9999449,5.5038498e-05
9431,olfactory disorder,6,8,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9431,-1,0.00018547705,0.99981457
9432,pyrazinamide,10,11,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9432,-1,0.9999409,5.9091726e-05
9433,Dysosmia,0,1,0,8,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9433,-1,0.00012124464,0.99987876
9434,pyrazinamide,4,5,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9434,-1,0.9999342,6.575776e-05
9435,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,-1,9435,-1,9.686412e-05,0.9999031
9438,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,-1,9438,-1,0.00010152648,0.99989843
9442,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,-1,9442,-1,9.8759716e-05,0.9999012
9445,prostaglandin,9,10,49,62,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9445,-1,0.99983776,0.00016222034
9446,PG,11,12,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9446,-1,0.9998035,0.00019650483
9448,prostaglandin E,14,16,100,115,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,-1,-1,9448,-1,0.9998318,0.00016818897
9449,LiCl,4,5,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,-1,9449,-1,0.9999105,8.949089e-05
9451,PGE(2),12,14,87,93,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9451,-1,0.99907863,0.0009213305
9452,contrast,1,2,3,11,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9452,-1,0.024334753,0.9756653
9454,PGE(2),26,28,169,175,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9454,-1,0.999546,0.00045402395
9455,cAMP,29,30,180,184,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9455,-1,0.999856,0.00014401262
9457,contrast,1,2,3,11,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,-1,9457,-1,0.038813524,0.96118647
9458,PGE(2),4,6,33,39,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,-1,-1,9458,-1,0.9995466,0.0004533309
9461,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,-1,-1,9461,-1,0.99994195,5.810934e-05
9463,Fenoldopam mesylate,0,2,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,-1,-1,-1,9463,-1,0.9999231,7.690401e-05
9464,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,-1,-1,9464,-1,0.9999453,5.4661992e-05
9466,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,-1,9466,-1,0.99994314,5.6839577e-05
9469,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9469,-1,0.99994576,5.4243206e-05
9471,NS,41,42,221,223,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9471,-1,0.06506333,0.93493664
9475,P,29,30,170,171,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,-1,9475,-1,0.026095193,0.9739048
9478,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,-1,-1,9478,-1,0.9999397,6.0286446e-05
9489,Etodolac,0,1,0,8,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9489,-1,0.9999162,8.38332e-05
9490,E,2,3,10,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9490,-1,0.99926573,0.000734316
9492,etodolac,8,9,56,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9492,-1,0.99992335,7.667482e-05
9493,EAI,10,11,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9493,-1,0.9964078,0.0035922132
9495,Etodolac,0,1,0,8,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,-1,9495,-1,0.9999267,7.3313335e-05
9496,etodolac,8,9,26,34,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,-1,9496,-1,0.99993086,6.909619e-05
9497,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9497,-1,0.99990094,9.8996185e-05
9498,writhing,11,12,91,99,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9498,-1,0.00022150044,0.99977857
9499,paw edema,19,21,141,150,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9499,-1,0.00012727523,0.9998727
9500,E,5,6,26,27,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9500,-1,0.99957174,0.0004282954
9501,p,16,17,109,110,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9501,-1,0.15499598,0.84500396
9502,etodolac,25,26,193,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,-1,-1,-1,9502,-1,0.99993646,6.357388e-05
9509,fibrillation,20,21,142,154,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9509,-1,0.00011712075,0.9998828
9511,arrhythmic,32,33,217,227,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9511,-1,0.00013401866,0.999866
9512,aconitine,5,6,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,-1,9512,-1,0.9999361,6.384606e-05
9516,4-DAMP,9,10,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,-1,9516,-1,0.99972993,0.00027003675
9519,arrhythmic,9,10,71,81,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9519,-1,0.00015482314,0.99984515
9520,aconitine,17,18,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9520,-1,0.9999256,7.4339194e-05
9525,blind,9,10,66,71,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,-1,9525,-1,0.4593479,0.5406521
9528,P,11,12,74,75,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9528,-1,0.04922952,0.9507705
9529,P,37,38,209,210,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9529,-1,0.04531429,0.95468575
9534,SSR103800,4,5,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,-1,9534,-1,0.99984014,0.00015982427
9538,NMDA,11,12,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9538,-1,0.99987304,0.00012697715
9539,NMDA,33,34,218,222,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9539,-1,0.99985003,0.00014999107
9540,NMDA,32,33,204,208,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9540,-1,0.9998386,0.00016136505
9542,SSR103800,11,12,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9542,-1,0.9997743,0.0002256832
9543,NMDA,16,17,100,104,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9543,-1,0.99978775,0.00021222827
9545,NMDA,28,29,171,175,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9545,-1,0.9998122,0.00018788142
9546,SSR103800,10,11,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9546,-1,0.9998615,0.00013851204
9548,ie,26,27,177,179,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9548,-1,0.014491863,0.98550814
9550,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9550,-1,0.9998343,0.00016562718
9551,ie,36,37,225,227,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9551,-1,0.0143333115,0.9856667
9552,NMDA,38,39,229,233,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9552,-1,0.9998011,0.00019890016
9553,SSR103800,3,4,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9553,-1,0.9998729,0.00012703164
9555,NMDA,18,19,102,106,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9555,-1,0.99985766,0.00014228618
9556,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9556,-1,0.99985754,0.00014245589
9558,NMDA,29,30,187,191,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9558,-1,0.9998342,0.00016584512
9559,contrast,1,2,3,11,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9559,-1,0.108961195,0.8910388
9560,SSR103800,3,4,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9560,-1,0.9998332,0.00016672366
9567,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9567,-1,0.9999286,7.138292e-05
9568,antipsychotics,16,17,96,110,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9568,-1,0.99982005,0.00018003247
9570,SSR103800,6,7,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,-1,9570,-1,0.9998311,0.00016885549
9572,SSR103800,9,10,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,-1,9572,-1,0.999828,0.00017202203
9573,Hibiscus rosa sinensis,2,5,10,32,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,-1,-1,-1,9573,-1,0.83542013,0.16457987
9574,Hibiscus rosa sinensis,5,8,32,54,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9574,-1,0.9828734,0.017126646
9575,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9575,-1,0.00014490921,0.99985504
9578,Hibiscus rosa sinensis,15,18,125,147,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,-1,-1,-1,9578,-1,0.9851077,0.014892226
9580,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9580,-1,0.99988115,0.00011880881
9581,glutathione reductase,28,30,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9581,-1,0.99986255,0.00013747206
9582,GSH,31,32,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9582,-1,0.99986124,0.00013876165
9583,GSH,18,19,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,-1,-1,-1,9583,-1,0.9998642,0.00013570233
9584,Hibiscus rosa sinensis,8,11,48,70,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9584,-1,0.8304698,0.16953021
9585,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9585,-1,0.00014698357,0.999853
9586,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9586,-1,0.9999356,6.432384e-05
9587,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9587,-1,0.059124753,0.9408752
9588,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9588,-1,0.9999212,7.879385e-05
9589,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9589,-1,0.9998116,0.00018849368
9590,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,-1,9590,-1,0.9432383,0.056761697
9592,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,-1,9592,-1,0.9997533,0.00024666567
9594,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9594,-1,0.99984133,0.0001586533
9595,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9595,-1,0.00020931075,0.9997907
9596,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9596,-1,0.999892,0.00010797189
9597,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9597,-1,0.00012360596,0.9998764
9598,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,-1,9598,-1,0.00017205303,0.99982786
9600,PDTC,1,2,9,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9600,-1,0.99988496,0.00011507572
9601,lesions in the piriform cortex,7,12,57,87,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9601,-1,0.0010243093,0.99897575
9602,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,-1,9602,-1,0.00016174957,0.99983823
9603,PDTC,8,9,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9603,-1,0.999894,0.00010601005
9604,neuronal loss,20,22,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9604,-1,0.00015694284,0.999843
9605,reactive oxygen species,8,11,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,-1,-1,9605,-1,0.8597165,0.14028352
9607,PDTC,14,15,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,-1,-1,-1,9607,-1,0.9998908,0.000109179724
9608,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9608,-1,0.0003611594,0.9996388
9609,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9609,-1,0.00039678754,0.9996032
9610,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9610,-1,0.00023624752,0.9997638
9611,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9611,-1,0.00016913007,0.99983084
9614,human immunodeficiency virus infection,17,21,92,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,-1,-1,9614,-1,0.25178885,0.74821115
9615,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,-1,-1,9615,-1,0.000115356976,0.9998846
9618,right heart failure,8,11,71,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,-1,9618,-1,0.00015170503,0.99984825
9634,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9634,-1,0.00020689302,0.9997931
9635,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9635,-1,0.00059773546,0.9994023
9636,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,-1,-1,9636,-1,0.00015171849,0.99984825
9637,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9637,-1,0.00028623175,0.9997137
9638,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9638,-1,0.00032918254,0.99967086
9639,n,39,40,235,236,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9639,-1,0.081515774,0.9184842
9640,n,55,56,319,320,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9640,-1,0.14950973,0.8504902
9641,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,-1,9641,-1,0.00017189233,0.9998281
9642,Sulfonamides,0,1,0,12,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9642,-1,0.99992275,7.722605e-05
9644,hypoplastic left heart syndrome,27,31,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9644,-1,0.00013619586,0.99986374
9645,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9645,-1,0.0006013663,0.9993986
9646,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9646,-1,0.00018784057,0.9998122
9647,transverse limb deficiency,79,82,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9647,-1,0.00030226944,0.9996978
9648,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9648,-1,0.00016077515,0.9998392
9649,Nitrofurantoins,0,1,0,15,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9649,-1,0.9998925,0.00010749583
9650,anophthalmia,4,5,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9650,-1,0.00012286482,0.9998771
9651,microphthalmos,6,7,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9651,-1,0.00018969245,0.9998103
9652,hypoplastic left heart syndrome,21,25,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9652,-1,0.00013108828,0.99986887
9653,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9653,-1,0.0002236862,0.9997763
9654,cleft lip,57,59,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9654,-1,0.00024494407,0.9997551
9655,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9655,-1,0.00025467962,0.9997453
9656,antibacterial agents,1,3,6,26,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9656,-1,0.9995479,0.00045203374
9657,erythromycins,7,8,61,74,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9657,-1,0.9999089,9.103162e-05
9658,penicillins,13,14,88,99,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9658,-1,0.9998332,0.00016670315
9660,quinolones,26,27,143,153,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9660,-1,0.9999089,9.102294e-05
9661,penicillins,4,5,27,38,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9661,-1,0.999835,0.00016500092
9662,erythromycins,6,7,40,53,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9662,-1,0.99989676,0.00010320993
9664,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9664,-1,0.00013906126,0.9998609
9665,Sulfonamides,0,1,0,12,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9665,-1,0.9999291,7.0883e-05
9666,nitrofurantoins,2,3,17,32,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9666,-1,0.9999207,7.931083e-05
9667,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9667,-1,0.00012249421,0.99987745
9668,hepatitis B virus e,15,19,106,125,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9668,-1,0.7949789,0.20502105
9669,hepatitis B virus,5,8,30,47,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,-1,9669,-1,0.9866614,0.013338577
9671,LAM,40,41,274,277,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9671,-1,0.9997985,0.00020156613
9672,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9672,-1,0.9998155,0.00018446328
9673,LAM,9,10,60,63,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9673,-1,0.9997024,0.00029752046
9674,HBsAg,5,6,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9674,-1,0.99957675,0.00042322982
9675,mutants,19,20,126,133,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9675,-1,0.9087537,0.09124627
9676,HBsAg,7,8,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,-1,9676,-1,0.9990637,0.00093633996
9677,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9677,-1,0.9997304,0.00026958605
9678,LAM,16,17,78,81,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9678,-1,0.99964464,0.0003553144
9679,LAM,8,9,46,49,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9679,-1,0.08150571,0.9184942
9680,nucleotide analogues adefovir,13,16,76,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9680,-1,0.99988806,0.000111933885
9681,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9681,-1,0.9999405,5.942898e-05
9682,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,-1,9682,-1,0.00011911112,0.9998809
9683,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,-1,9683,-1,0.00012019779,0.99987984
9685,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,-1,9685,-1,0.9999201,7.991453e-05
9689,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,-1,9689,-1,0.9999125,8.7459615e-05
9690,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,-1,9690,-1,0.9999144,8.559158e-05
9691,myocardial hypertrophy,1,3,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,-1,-1,9691,-1,0.00011175566,0.9998882
9695,myocardial hypertrophy,4,6,29,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,-1,-1,9695,-1,0.000112955495,0.999887
9699,myocardial hypertrophy,18,20,120,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,-1,-1,9699,-1,0.000118327625,0.9998816
9702,Myocardial hypertrophy,0,2,0,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,-1,-1,-1,9702,-1,0.00012681537,0.99987316
9705,myocardial hypertrophy,8,10,53,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,-1,-1,-1,9705,-1,0.00013399987,0.999866
9707,cardiac involvement,17,19,123,142,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,-1,-1,-1,9707,-1,0.00015388106,0.9998461
9712,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,-1,-1,9712,-1,9.82224e-05,0.9999018
9714,NIMO,7,8,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,-1,9714,-1,0.9997801,0.00021986489
9717,PA,6,7,32,34,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,-1,-1,-1,9717,-1,0.6708932,0.32910684
9718,PA,1,2,4,6,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,-1,9718,-1,0.99599695,0.0040030205
9720,h,4,5,27,28,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,-1,9720,-1,0.086823426,0.9131766
9721,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9721,-1,0.9997669,0.00023308583
9722,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9722,-1,0.99964464,0.00035534697
9723,h,38,39,144,145,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9723,-1,0.07440304,0.925597
9724,NTG,44,45,165,168,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9724,-1,0.99985456,0.00014537534
9725,NIMO,46,47,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9725,-1,0.99989736,0.00010261405
9726,NIMO,55,56,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9726,-1,0.999897,0.000102994614
9729,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9729,-1,0.99989116,0.000108789594
9730,NIMO,28,29,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9730,-1,0.9998596,0.00014038853
9731,NTG,32,33,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9731,-1,0.99988353,0.00011641893
9732,H,16,17,109,110,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9732,-1,0.3864862,0.6135138
9733,NTG,16,17,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9733,-1,0.9998964,0.0001036008
9734,n,18,19,87,88,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9734,-1,0.5709427,0.4290573
9735,NTG,23,24,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9735,-1,0.9998845,0.00011549819
9736,NIMO,25,26,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9736,-1,0.99986947,0.00013046601
9737,n,27,28,110,111,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9737,-1,0.5673931,0.4326069
9738,mm Hg,43,45,183,188,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9738,-1,0.0063738213,0.99362624
9739,mm Hg,51,53,209,214,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9739,-1,0.008631177,0.99136883
9740,mm Hg,60,62,241,246,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9740,-1,0.008686377,0.99131364
9741,mm Hg,68,70,267,272,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9741,-1,0.00941617,0.9905839
9742,NIMO,8,9,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9742,-1,0.9999145,8.543892e-05
9743,mm Hg,16,18,89,94,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9743,-1,0.0021357413,0.9978643
9744,mm Hg,23,25,111,116,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9744,-1,0.0020054688,0.99799454
9745,P,7,8,57,58,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,-1,9745,-1,0.1274689,0.87253106
9746,mm Hg,8,10,36,41,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9746,-1,0.04441527,0.9555847
9747,mm Hg,16,18,62,67,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9747,-1,0.028632471,0.9713676
9748,NTG,21,22,79,82,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9748,-1,0.999767,0.00023299431
9749,mm Hg,29,31,111,116,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9749,-1,0.03128708,0.96871287
9750,mm Hg,37,39,137,142,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9750,-1,0.042278364,0.9577216
9751,NTG,42,43,154,157,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9751,-1,0.9998242,0.00017581145
9752,NIMO,44,45,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9752,-1,0.9998869,0.00011308925
9753,PA,4,5,17,19,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9753,-1,0.9948515,0.0051484443
9754,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9754,-1,0.99987805,0.000121898796
9756,NIMO,0,1,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9756,-1,0.99989426,0.00010576125
9757,NTG,11,12,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9757,-1,0.99984,0.00015999062
9759,NIMO,4,5,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,-1,9759,-1,0.9999033,9.672872e-05
9765,peptic ulcer disease,12,15,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9765,-1,0.00013546355,0.99986446
9766,reflux esophagitis,16,18,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9766,-1,0.00013744688,0.99986255
9771,lethargy,5,6,32,40,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9771,-1,0.00015649515,0.9998435
9772,shortness of breath,8,11,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9772,-1,0.0002809651,0.99971896
9779,Parkinson's disease,12,15,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,-1,-1,-1,9779,-1,0.00022809222,0.9997719
9781,Parkinson's disease,23,26,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9781,-1,0.00031988783,0.99968016
9782,PD,27,28,195,197,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9782,-1,0.00016190804,0.9998381
9783,PD,28,29,163,165,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,-1,9783,-1,0.00014490425,0.99985504
9784,"N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride",3,7,15,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9784,-1,0.9998097,0.00019034272
9785,AMN082,8,9,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9785,-1,0.99873084,0.0012691196
9786,PD,28,29,185,187,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9786,-1,0.00023325859,0.99976677
9787,AMN082,20,21,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,-1,9787,-1,0.999871,0.00012891082
9789,AMN082,0,1,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,-1,9789,-1,0.9997161,0.00028388255
9792,PD,13,14,76,78,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9792,-1,0.00020881876,0.9997912
9793,AMN082,18,19,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9793,-1,0.99990594,9.4095194e-05
9794,AMN082,3,4,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,-1,9794,-1,0.9998399,0.00016003913
9796,AMN082,3,4,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9796,-1,0.9998833,0.00011674288
9797,PD,20,21,83,85,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9797,-1,0.0005683573,0.99943167
9798,motor dysfunction,10,12,74,91,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,-1,9798,-1,0.00011172093,0.9998883
9801,coronary artery spasm,6,9,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,-1,-1,9801,-1,0.0001295971,0.9998704
9802,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9802,-1,0.0009083141,0.99909174
9803,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9803,-1,0.00015481637,0.99984515
9805,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,-1,-1,9805,-1,0.0001227312,0.9998772
9807,Coronary artery spasm,0,3,0,21,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,-1,-1,9807,-1,0.00015221172,0.99984777
9809,nitrates,9,10,68,76,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,-1,-1,-1,9809,-1,0.99987555,0.00012443984
9811,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9811,-1,0.9999392,6.081131e-05
9812,angina,10,11,71,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9812,-1,0.00014391118,0.9998561
9813,coronary artery spasm,7,10,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,-1,-1,9813,-1,0.00012353268,0.9998765
9815,coronary artery spasm,16,19,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,-1,9815,-1,0.00014177334,0.99985826
9817,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9817,-1,0.9999361,6.391057e-05
9818,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9818,-1,0.99986625,0.0001336785
9820,hippocampal damage,13,15,99,117,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9820,-1,0.0001467129,0.99985325
9821,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,-1,9821,-1,0.9999286,7.137836e-05
9823,of neuronal cells,8,11,72,89,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9823,-1,0.000668629,0.99933136
9824,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9824,-1,0.9999298,7.0206115e-05
9834,mg,10,11,61,63,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9834,-1,0.97577816,0.024221813
9836,mg,18,19,90,92,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9836,-1,0.9789796,0.021020373
9838,mg,29,30,142,144,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9838,-1,0.9730971,0.026902843
9840,mg,39,40,188,190,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9840,-1,0.9795686,0.020431435
9841,MAP,48,49,230,233,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9841,-1,0.0060599516,0.9939401
9842,MAP,6,7,17,20,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9842,-1,0.0060323244,0.99396765
9844,CO,17,18,58,60,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9844,-1,0.2950155,0.7049845
9845,MAP,11,12,63,66,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9845,-1,0.009719816,0.9902802
9846,CO,18,19,80,82,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9846,-1,0.84134537,0.1586546
9848,MAP,5,6,39,42,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9848,-1,0.010263558,0.98973644
9849,P,19,20,83,84,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9849,-1,0.037406594,0.96259344
9850,SD,26,27,103,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9850,-1,0.0626532,0.9373468
9851,P,24,25,68,69,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9851,-1,0.08625379,0.91374624
9852,CO,33,34,105,107,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9852,-1,0.99842083,0.0015791166
9854,increase in MAP,8,11,49,64,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9854,-1,0.0038696888,0.99613035
9855,P,23,24,93,94,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9855,-1,0.03245699,0.96754307
9856,CO,29,30,114,116,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9856,-1,0.97579485,0.024205117
9860,CO,31,32,214,216,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,-1,9860,-1,0.84503037,0.15496968
9861,tranexamic Acid,1,3,10,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,-1,9861,-1,0.9999474,5.2625375e-05
9863,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,-1,-1,9863,-1,0.00011149425,0.99988854
9864,tranexamic acid,11,13,74,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9864,-1,0.9999467,5.3259224e-05
9865,TXA,14,15,91,94,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9865,-1,0.9998859,0.00011407331
9866,TXA,19,20,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,-1,-1,9866,-1,0.9998996,0.00010036445
9869,cerebral ischemic injury,13,16,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9869,-1,0.00010725635,0.9998927
9871,ischemic brain injury,23,26,126,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9871,-1,0.000114410694,0.99988556
9873,neurological abnormalities,8,10,50,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,-1,-1,9873,-1,0.00012455785,0.9998754
9875,TXA,9,10,53,56,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,-1,-1,9875,-1,0.9998975,0.000102475205
9876,ischemic,4,5,21,29,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,-1,-1,9876,-1,0.00016861978,0.9998313
9878,TXA,9,10,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,-1,9878,-1,0.999905,9.5002906e-05
9883,Direct thrombin inhibitors,2,5,12,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9883,-1,0.9998547,0.00014526781
9884,DTIs,6,7,40,44,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9884,-1,0.9971813,0.0028187477
9886,HIT,23,24,160,163,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9886,-1,0.00020756261,0.9997924
9887,HIT,26,27,168,171,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9887,-1,0.0001875335,0.99981254
9889,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9889,-1,0.00047134192,0.99952865
9890,critically ill,7,9,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9890,-1,0.00039244996,0.9996076
9891,HITT,15,16,90,94,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9891,-1,0.0050419085,0.9949581
9893,recombinant Factor VIIa,34,37,183,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9893,-1,0.999782,0.00021802826
9898,hepatic impairment,54,56,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,-1,9898,-1,0.00013639366,0.9998636
9905,psychotropic drugs,8,10,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,-1,-1,9905,-1,0.99989235,0.00010768894
9906,psychotropic drugs,12,14,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9906,-1,0.9998673,0.00013264331
9907,phenothiazines,16,17,117,131,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9907,-1,0.9999238,7.613521e-05
9909,Mellaril,8,9,53,61,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9909,-1,0.99987984,0.00012011723
9910,thioridazine,10,11,63,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9910,-1,0.9999268,7.3195566e-05
9912,Supraventricular tachycardia,0,2,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9912,-1,0.00012248114,0.99987745
9913,Thorazine,7,8,64,73,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9913,-1,0.999925,7.4993404e-05
9915,Aventyl,0,1,0,7,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9915,-1,0.99988866,0.000111355264
9916,nortriptyline,2,3,9,22,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9916,-1,0.99993694,6.301557e-05
9917,Elavil,5,6,28,34,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9917,-1,0.99993587,6.415934e-05
9919,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9919,-1,0.00034019575,0.9996598
9924,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,-1,-1,9924,-1,0.00011036917,0.9998896
9925,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,-1,-1,9925,-1,0.00019526003,0.9998048
9927,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9927,-1,0.0001359334,0.9998641
9928,psychotropic drugs,19,21,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9928,-1,0.9999049,9.51635e-05
9929,cardiac complications,11,13,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9929,-1,0.00011917576,0.9998808
9930,phenothiazines,16,17,110,124,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9930,-1,0.9999255,7.4441064e-05
9933,immunodeficient,10,11,89,104,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,-1,-1,-1,9933,-1,0.0015073372,0.9984926
9934,anaemia,1,2,4,11,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9934,-1,0.0001109818,0.999889
9935,3'-azido-3'dideoxythymidine,4,5,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9935,-1,0.9998599,0.00014001112
9936,AZT,6,7,52,55,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9936,-1,0.99979657,0.00020345453
9937,AIDS,7,8,31,35,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9937,-1,0.00019676788,0.99980325
9939,leukaemia,17,18,89,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9939,-1,0.00018004188,0.99981993
9940,anaemia,27,28,141,148,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9940,-1,0.000101725534,0.9998983
9941,AZT,11,12,58,61,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9941,-1,0.999874,0.00012597328
9942,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9942,-1,0.99817216,0.0018278526
9943,AZT,0,1,0,3,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9943,-1,0.99987805,0.00012191333
9944,anaemia,2,3,13,20,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9944,-1,0.00010959059,0.99989045
9945,anaemia,2,3,12,19,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9945,-1,0.00011536413,0.9998846
9946,AZT,13,14,68,71,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9946,-1,0.9998797,0.000120306606
9947,AZT,18,19,113,116,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,-1,9947,-1,0.99988854,0.00011139232
9948,AZT,8,9,42,45,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,-1,-1,-1,9948,-1,0.99985147,0.00014853098
9949,anaemia,6,7,35,42,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9949,-1,0.000105095314,0.99989486
9950,phenylhydrazine,11,12,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9950,-1,0.99992406,7.5878634e-05
9951,PHZ,13,14,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9951,-1,0.99982613,0.00017384555
9952,AZT,15,16,97,100,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9952,-1,0.9999008,9.9133074e-05
9953,PHZ,17,18,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9953,-1,0.99988115,0.00011884348
9954,anaemia,24,25,146,153,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9954,-1,0.000107455766,0.9998925
9955,reticulocytosis,2,3,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9955,-1,0.00018006885,0.99981993
9956,anaemia,9,10,61,68,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9956,-1,9.694378e-05,0.9999031
9957,AZT,12,13,81,84,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9957,-1,0.99987876,0.00012117054
9958,anaemia,2,3,23,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,-1,9958,-1,0.00010969347,0.9998903
9959,postoperative delirium,9,11,63,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9959,-1,0.00012475015,0.9998752
9960,hip fracture,15,17,117,129,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9960,-1,0.00042938444,0.99957067
9961,hip fracture,13,15,100,112,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9961,-1,0.00034532775,0.99965465
9962,postoperative delirium,24,26,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9962,-1,0.00012536669,0.9998746
9965,hip fracture,33,35,207,219,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,-1,9965,-1,0.00022975563,0.9997702
9968,Mental Disorders,12,14,87,103,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9968,-1,0.0035840215,0.996416
9970,postoperative delirium,3,5,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9970,-1,0.00012517162,0.99987483
9971,P=.02,31,32,149,154,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9971,-1,0.043381628,0.9566184
9973,SD,4,5,13,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9973,-1,0.080653474,0.9193466
9975,P=.01,32,33,171,176,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9975,-1,0.034214668,0.9657854
9977,postoperative delirium,12,14,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,-1,-1,9977,-1,0.00012957596,0.9998704
9978,postoperative delirium,18,20,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,-1,-1,9978,-1,0.00014355003,0.9998565
9981,serotonin reuptake inhibitor,14,17,90,118,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,-1,9981,-1,0.9998419,0.00015809096
9984,SD,20,21,123,125,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9984,-1,0.00020719961,0.9997929
9985,selective serotonin reuptake inhibitor,25,29,140,178,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9985,-1,0.99984694,0.00015302333
9986,SSRI,30,31,180,184,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9986,-1,0.99986494,0.00013504298
9987,SD,34,35,190,192,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9987,-1,0.00018838907,0.9998116
9988,SSRIs,40,41,220,225,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9988,-1,0.9982584,0.0017415389
9989,SSRI,18,19,106,110,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,-1,9989,-1,0.99987197,0.00012796241
9991,mg,10,11,52,54,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,-1,-1,-1,9991,-1,0.99513185,0.004868231
9992,Erectile Dysfunction,37,39,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,-1,9992,-1,0.00041231577,0.9995877
9993,sd,11,12,48,50,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9993,-1,0.095071405,0.90492857
9995,P=,47,48,193,195,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9995,-1,0.10108989,0.89891016
9997,P=,20,21,94,96,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,-1,9997,-1,0.05591193,0.9440881
9999,P=,29,30,133,135,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,-1,9999,-1,0.07387919,0.9261208
10001,P=,21,22,91,93,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,-1,10001,-1,0.087287106,0.9127129
10002,P=,9,10,49,51,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,-1,10002,-1,0.15844,0.84156
10003,SD,15,16,97,99,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,10003,-1,0.0005846198,0.9994154
10004,SSRI,19,20,109,113,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,10004,-1,0.99981636,0.00018368261
10006,SD,9,10,58,60,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,10006,-1,0.0011933993,0.9988066
10007,SSRIs,12,13,72,77,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,10007,-1,0.46087977,0.5391202
10013,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,10013,-1,0.0002085744,0.99979144
10014,SE,22,23,146,148,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,10014,-1,0.00039057352,0.9996094
10015,Spontaneous recurrent seizures,0,3,0,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,10015,-1,0.00018380911,0.99981624
10016,SRS,4,5,32,35,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,10016,-1,0.00028219115,0.9997178
10019,SRS,11,12,72,75,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,-1,10019,-1,0.00018317295,0.99981683
10028,neuronal loss,15,17,91,104,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,-1,-1,-1,10028,-1,0.00014647764,0.9998535
10032,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,-1,-1,10032,-1,0.0001276312,0.9998723
10035,mg,13,14,95,97,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10035,-1,0.99841654,0.0015834945
10036,N=10,15,16,99,103,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10036,-1,0.17512372,0.82487625
10037,N=10,21,22,118,122,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,10037,-1,0.19258992,0.80741006
10043,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,-1,10043,-1,0.00013485835,0.9998652
10045,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,-1,10045,-1,0.00014465435,0.9998553
10048,Midazolan,13,14,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10048,-1,0.99994636,5.3690183e-05
10049,MZ,15,16,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10049,-1,0.9998276,0.00017231028
10050,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10050,-1,0.9999387,6.126637e-05
10051,FL,20,21,100,102,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,10051,-1,0.9997694,0.00023063445
10052,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,-1,10052,-1,0.99934894,0.00065104914
10053,MZ,14,15,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,-1,-1,-1,10053,-1,0.99978167,0.00021838403
10055,myocardiopathy,21,22,108,122,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10055,-1,0.00013441565,0.99986553
10056,MP,23,24,124,126,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10056,-1,0.00042803047,0.999572
10058,MR,34,35,173,175,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10058,-1,0.00022452424,0.99977547
10059,MZ,38,39,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,10059,-1,0.9996735,0.00032654317
10060,MZ,4,5,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10060,-1,0.999778,0.00022198944
10061,FL,6,7,25,27,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10061,-1,0.9997619,0.00023813607
10062,mg,9,10,43,45,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10062,-1,0.96067154,0.03932841
10063,mg,12,13,61,63,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,10063,-1,0.9795125,0.02048744
10066,obstruction,29,30,128,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10066,-1,0.00013401713,0.999866
10068,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,10068,-1,0.9997435,0.0002564134
10070,MR,6,7,45,47,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10070,-1,0.0001664265,0.9998336
10071,MP,8,9,49,51,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10071,-1,0.0002635477,0.9997365
10072,MZ,17,18,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10072,-1,0.9998073,0.0001927039
10073,mg,21,22,85,87,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10073,-1,0.99399215,0.00600786
10074,p<0.001,28,29,118,125,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,10074,-1,0.047054626,0.9529453
10075,MP,10,11,34,36,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10075,-1,0.00083197077,0.99916804
10076,MR,19,20,70,72,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,10076,-1,0.0002660879,0.99973387
10077,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,-1,10077,-1,0.9999385,6.147601e-05
10079,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10079,-1,0.99994016,5.9838665e-05
10081,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10081,-1,0.00011545425,0.9998845
10082,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,10082,-1,0.00013255014,0.99986744
10083,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,-1,-1,-1,10083,-1,0.99993837,6.159383e-05
10086,SD,25,26,114,116,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,-1,-1,10086,-1,0.08460658,0.9153935
10087,ischemic,5,6,29,37,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,-1,10087,-1,0.0001624121,0.9998375
10090,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,-1,10090,-1,0.9999405,5.9538695e-05
10095,cardiac dysrhythmias,23,25,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10095,-1,0.00012735247,0.9998727
10098,violent behavior,31,33,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,10098,-1,0.00015458286,0.9998454
10100,xerostomia,11,12,76,86,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10100,-1,0.00017057992,0.9998294
10101,caries,14,15,96,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10101,-1,0.0001677335,0.9998323
10103,tooth wear,24,26,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,10103,-1,0.00019067877,0.9998093
10106,bad breath,12,14,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,-1,-1,10106,-1,0.0001902442,0.9998098
10107,carious lesions,16,18,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,-1,-1,-1,10107,-1,0.00025480107,0.9997452
10109,carious episodes,15,17,89,105,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,-1,-1,-1,10109,-1,0.000364835,0.9996351
10110,lead,15,16,98,102,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,-1,10110,-1,0.006910668,0.9930894
10112,oral manifestations,7,9,50,69,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10112,-1,0.00021075744,0.9997893
10114,methamphetamines,26,27,176,192,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,10114,-1,0.9998865,0.000113500755
10117,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10117,-1,0.000110477406,0.9998895
10118,reactive oxygen species,21,24,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,10118,-1,0.9747394,0.025260594
10125,DNA damage,16,18,100,110,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,-1,-1,10125,-1,0.00078317046,0.9992168
10131,Metformin,0,1,0,9,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,-1,10131,-1,0.9998778,0.00012222867
10133,metformin,3,4,22,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10133,-1,0.9998785,0.00012148152
10134,vascular dysfunction,16,18,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,10134,-1,0.00011890299,0.999881
10135,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,-1,10135,-1,0.01756685,0.9824332
10136,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10136,-1,0.965511,0.034488972
10137,c,17,18,122,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,10137,-1,0.99969816,0.00030191752
10139,Metformin,0,1,0,9,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10139,-1,0.9998715,0.00012844187
10140,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,10140,-1,0.00010890075,0.99989104
10141,Metformin,0,1,0,9,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,-1,-1,-1,10141,-1,0.99988437,0.00011562437
10143,kidney dysfunction,5,7,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10143,-1,0.00013607694,0.99986386
10144,metformin,11,12,68,77,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,10144,-1,0.99987197,0.00012797315
10146,c,10,11,79,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,10146,-1,0.99978834,0.0002116356
10147,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10147,-1,0.28359047,0.7164095
10148,metformin,22,23,135,144,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,10148,-1,0.99987876,0.000121213525
10149,metformin,9,10,53,62,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10149,-1,0.999894,0.00010599832
10150,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,10150,-1,0.003941818,0.9960582
10152,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,-1,10152,-1,0.9997458,0.00025424027
10153,contrast,5,6,39,47,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10153,-1,0.9996879,0.00031209947
10155,CIN,9,10,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,10155,-1,0.00039615447,0.9996038
10156,CIN,7,8,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10156,-1,0.0002283614,0.99977165
10157,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10157,-1,0.99953735,0.00046269954
10158,CM,14,15,88,90,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10158,-1,0.9983205,0.0016794236
10159,iopromide,17,18,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10159,-1,0.9999397,6.037148e-05
10160,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10160,-1,0.9999379,6.21398e-05
10161,CM,43,44,239,241,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,10161,-1,0.027610127,0.9723899
10162,iopromide,9,10,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10162,-1,0.9999466,5.3364158e-05
10163,n,14,15,79,80,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10163,-1,0.11490473,0.88509524
10164,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10164,-1,0.9999442,5.58043e-05
10165,n,24,25,108,109,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,10165,-1,0.12259444,0.8774056
10167,Na,3,4,14,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10167,-1,0.99983907,0.00016096214
10169,K,8,9,30,31,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10169,-1,0.99986076,0.00013924412
10171,Cr,14,15,50,52,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10171,-1,0.9997917,0.00020835815
10172,h,19,20,71,72,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10172,-1,0.065189555,0.9348104
10173,CM,38,39,170,172,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,10173,-1,0.9982601,0.0017399697
10174,Na,3,4,18,20,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10174,-1,0.99966884,0.00033120476
10175,Cr,5,6,25,27,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10175,-1,0.9996685,0.00033151303
10176,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10176,-1,0.00013329819,0.9998667
10177,Injury to the kidney,5,9,23,43,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10177,-1,0.0005525905,0.9994474
10178,Failure of kidney function,10,14,45,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10178,-1,0.0002541857,0.9997458
10179,Loss of kidney function,15,19,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10179,-1,0.00025405316,0.9997459
10181,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10181,-1,0.00084591215,0.9991541
10182,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,-1,10182,-1,0.00036026258,0.99963975
10185,CIN,7,8,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10185,-1,0.00015360692,0.99984634
10186,CM,17,18,90,92,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10186,-1,0.99968743,0.00031264714
10187,CIN,40,41,217,220,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10187,-1,0.00013774128,0.9998622
10188,CM,47,48,257,259,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10188,-1,0.99971694,0.00028304802
10189,p,49,50,261,262,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10189,-1,0.068625264,0.9313747
10190,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10190,-1,0.0009439537,0.99905604
10191,congenital heart diseases,10,13,47,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10191,-1,0.00013665012,0.9998634
10192,p,28,29,161,162,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10192,-1,0.12667324,0.87332684
10193,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,-1,10193,-1,0.000687647,0.9993124
10194,CM,13,14,73,75,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10194,-1,0.99911004,0.0008899468
10195,cyanosis,20,21,100,108,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10195,-1,0.00012458647,0.9998754
10196,CIN,24,25,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10196,-1,0.00031166984,0.9996884
10197,Antituberculosis,0,1,0,16,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,-1,-1,10197,-1,0.9997547,0.00024525067
10199,Antituberculosis,0,1,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10199,-1,0.99956757,0.00043245542
10201,ALF,13,14,102,105,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10201,-1,0.00022164767,0.99977833
10202,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,-1,10202,-1,0.0007059207,0.99929404
10203,hepatitis virus infection,10,13,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,-1,10203,-1,0.00041628114,0.9995838
10205,icterus encephalopathy,7,9,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,-1,-1,10205,-1,0.00025929394,0.99974066
10206,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,-1,10206,-1,0.0004070996,0.99959296
10208,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,-1,-1,10208,-1,0.000106756765,0.9998932
10209,Gastrointestinal bleed,0,2,0,22,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10209,-1,0.00016241876,0.9998375
10212,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10212,-1,0.00014446609,0.9998555
10213,hepatitis E virus (HEV,2,7,14,36,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10213,-1,0.9903098,0.0096901925
10214,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10214,-1,0.0001906824,0.9998093
10215,n,13,14,64,65,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,-1,10215,-1,0.042255033,0.957745
10218,ALF,7,8,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,-1,10218,-1,0.0004783235,0.99952173
10221,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,-1,10221,-1,0.99985194,0.0001480306
10223,nitrous oxide,6,8,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,-1,-1,-1,10223,-1,0.9999162,8.37413e-05
10233,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,-1,10233,-1,0.00011710357,0.99988294
10235,ACE) inhibitors,8,11,57,72,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10235,-1,0.9998368,0.00016322719
10236,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10236,-1,0.000110704976,0.99988925
10238,ACE inhibitor enalapril,6,9,28,51,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,-1,-1,10238,-1,0.9998981,0.000101944024
10240,mg enalapril,4,6,25,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,-1,10240,-1,0.99978,0.00021997496
10247,dysgenesis,1,2,10,20,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,-1,-1,-1,10247,-1,0.00011988505,0.9998801
10250,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,-1,-1,10250,-1,0.0001980248,0.99980205
10251,brainstem dysgenesis,11,13,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,-1,10251,-1,0.00013249122,0.99986744
10253,serotonin reuptake inhibitors,10,13,72,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,-1,-1,-1,10253,-1,0.9998342,0.00016581318
10257,n,12,13,59,60,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,-1,10257,-1,0.08769151,0.91230845
10261,P,29,30,181,182,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,-1,10261,-1,0.15976611,0.8402339
10262,serotonin reuptake inhibitors,11,14,76,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10262,-1,0.99984264,0.00015731921
10263,SSRIs,15,16,107,112,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10263,-1,0.99978,0.00022005533
10264,P,28,29,172,173,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10264,-1,0.07423898,0.92576104
10265,P,41,42,218,219,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10265,-1,0.055552755,0.9444473
10268,SSRIs,10,11,61,66,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,-1,-1,10268,-1,0.99900764,0.0009923336
10271,SSRI,12,13,88,92,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,-1,10271,-1,0.9999138,8.6182656e-05
10272,fracture,20,21,135,143,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,-1,10272,-1,0.00019951061,0.9998005
10273,startle,1,2,17,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10273,-1,0.0004043762,0.9995956
10274,startle,6,7,49,56,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10274,-1,0.00031806898,0.99968195
10275,startle,6,7,45,52,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10275,-1,0.088840276,0.9111597
10276,anxiety,15,16,90,97,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10276,-1,0.00015932701,0.9998406
10277,contrast,1,2,3,11,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10277,-1,0.057617884,0.94238216
10278,startle,5,6,34,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10278,-1,0.0031918047,0.9968081
10280,5-HT(2C,20,21,116,123,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10280,-1,0.99903095,0.0009691221
10281,m-chlorophenylpiperazine,24,25,142,166,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10281,-1,0.99991393,8.611341e-05
10282,mCPP,26,27,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10282,-1,0.9997757,0.00022428395
10283,pentylenetetrazole,39,40,228,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10283,-1,0.9999405,5.9473496e-05
10284,PTZ,41,42,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10284,-1,0.9997223,0.00027768765
10285,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,-1,10285,-1,0.9998548,0.00014521657
10288,startle,5,6,42,49,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10288,-1,0.0007398302,0.9992601
10289,mCPP,12,13,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10289,-1,0.99976355,0.00023649947
10290,startle,15,16,103,110,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10290,-1,0.00055954105,0.9994405
10291,PTZ,23,24,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10291,-1,0.99957997,0.00042003367
10292,startle,26,27,163,170,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10292,-1,0.0004780197,0.999522
10293,contrast,3,4,16,24,"CONCLUSIONS: In contrast to findings in the FPS paradigm, none of the drugs were able to exacerbate the LES response.",20394767_8,-1,-1,-1,10293,-1,0.009896951,0.990103
10296,dermatitis eruptions,8,10,57,77,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10296,-1,0.00012797401,0.99987197
10298,facial dermatitis,20,22,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10298,-1,0.00012364039,0.9998764
10299,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,-1,-1,10299,-1,0.0001593635,0.9998406
10301,pimecrolimus,9,10,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,-1,10301,-1,0.9999366,6.344198e-05
10303,Central nervous system complications,0,4,0,36,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,-1,-1,10303,-1,0.0001756325,0.99982435
10305,Central nervous system (CNS) complications,0,7,0,42,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10305,-1,0.00033274447,0.9996673
10307,neurological complications,6,8,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,-1,-1,-1,10307,-1,0.00012324947,0.99987674
10308,leukemic infiltration,4,6,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10308,-1,0.00012445895,0.99987555
10311,neurocognitive defects,18,20,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10311,-1,0.000107451066,0.9998926
10313,n,8,9,78,79,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10313,-1,0.0052825366,0.99471754
10315,n,15,16,95,96,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10315,-1,0.0036626158,0.9963374
10317,n,24,25,127,128,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10317,-1,0.002826384,0.99717355
10318,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10318,-1,0.0144511275,0.9855489
10319,n,33,34,168,169,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10319,-1,0.0031395047,0.9968605
10320,syndrome of inappropriate antidiuretic hormone secretion,38,44,176,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10320,-1,0.0012266827,0.9987733
10321,n,45,46,234,235,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10321,-1,0.0047846385,0.9952154
10322,n,55,56,273,274,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10322,-1,0.0052959435,0.99470407
10324,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,-1,-1,-1,10324,-1,0.9999466,5.3354543e-05
10325,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,-1,10325,-1,0.017881637,0.98211837
10326,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,-1,-1,10326,-1,0.010109858,0.9898901
10327,nitric oxide synthase,8,11,56,77,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10327,-1,0.9997198,0.0002801784
10328,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10328,-1,0.99994683,5.314573e-05
10329,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10329,-1,0.023508664,0.9764913
10332,GSH,16,17,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10332,-1,0.99987054,0.0001294837
10333,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10333,-1,0.99985564,0.00014439817
10335,contrast,1,2,3,11,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10335,-1,0.03134991,0.96865016
10336,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10336,-1,0.9996227,0.0003772252
10338,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,-1,-1,-1,10338,-1,0.9999447,5.533347e-05
10339,Coenzyme Q10,0,2,0,12,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10339,-1,0.99992764,7.238566e-05
10340,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10340,-1,0.003571332,0.99642867
10341,coenzyme Q10,4,6,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10341,-1,0.9999113,8.870236e-05
10342,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10342,-1,0.0001241736,0.9998758
10344,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,-1,-1,-1,10344,-1,0.9999182,8.172636e-05
10346,Coenzyme Q10,0,2,0,12,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,-1,-1,-1,10346,-1,0.99991274,8.728515e-05
10350,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10350,-1,0.99991524,8.476811e-05
10351,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10351,-1,0.99497694,0.005023095
10352,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10352,-1,0.9998808,0.00011913826
10353,tumor necrosis,28,30,208,222,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10353,-1,0.0010498166,0.9989502
10354,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10354,-1,0.99989617,0.000103842125
10355,platinum,35,36,254,262,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10355,-1,0.99987924,0.000120745164
10356,selenium,44,45,315,323,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10356,-1,0.99989486,0.00010512368
10357,zinc,46,47,328,332,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10357,-1,0.9998889,0.000111082176
10359,renal tissue damage,3,6,24,43,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10359,-1,0.00012251314,0.99987745
10361,coenzyme Q10,12,14,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10361,-1,0.9999316,6.841165e-05
10362,coenzyme Q10,4,6,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10362,-1,0.9999174,8.261549e-05
10363,nitric oxide synthase,13,16,130,151,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10363,-1,0.99966276,0.00033724878
10364,coenzyme Q10,4,6,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10364,-1,0.9998883,0.00011163254
10365,cisplatin nephrotoxicity,15,17,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10365,-1,0.003536352,0.9964637
10367,bile duct injury,3,6,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,-1,-1,10367,-1,0.00026282805,0.9997372
10369,polymyositis,6,7,36,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,-1,-1,10369,-1,0.00015309047,0.99984694
10376,bile duct injury,19,22,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,-1,10376,-1,0.00025170873,0.9997483
10382,bipolar I disorder,24,27,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10382,-1,0.00036638408,0.99963355
10383,psychotic,30,31,187,196,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10383,-1,0.00014644358,0.9998535
10386,mg,21,22,137,139,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10386,-1,0.9831297,0.016870338
10388,mg,31,32,175,177,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10388,-1,0.981471,0.018529058
10390,mg,40,41,212,214,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10390,-1,0.98963237,0.0103675835
10392,mg,29,30,185,187,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10392,-1,0.9973659,0.002634107
10395,mg,73,74,381,383,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10395,-1,0.9984446,0.0015554368
10398,mg,24,25,138,140,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10398,-1,0.9962011,0.0037989574
10400,mg,27,28,106,108,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,-1,-1,-1,10400,-1,0.9977562,0.0022438576
10404,mg,26,27,107,109,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,-1,-1,10404,-1,0.99807644,0.001923539
10412,leukaemia,14,15,120,129,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10412,-1,0.00013155799,0.9998684
10413,lymphoma,16,17,134,142,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10413,-1,0.00013427717,0.99986565
10415,AraG,8,9,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10415,-1,0.9996958,0.00030422586
10417,VP,16,17,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10417,-1,0.99978286,0.00021719169
10419,CPM,21,22,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10419,-1,0.9997811,0.00021888556
10420,leukaemia,40,41,219,228,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10420,-1,0.000116846124,0.9998832
10421,lymphoma,42,43,232,240,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10421,-1,0.0001306474,0.99986935
10422,AraG,8,9,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10422,-1,0.9990087,0.0009913434
10423,sensory and motor neuropathy,14,18,77,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10423,-1,0.00017562746,0.99982435
10424,musculoskeletal pain,19,21,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10424,-1,0.00011883896,0.99988115
10425,Haematological toxicity,0,2,0,23,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10425,-1,0.00011679098,0.9998832
10426,AraG,8,9,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10426,-1,0.9998927,0.00010725645
10427,AraG,7,8,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10427,-1,0.9998323,0.00016765481
10430,neurological toxicity,19,21,128,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10430,-1,0.00011661771,0.9998834
10434,DA,7,8,37,39,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10434,-1,0.9998541,0.00014588941
10437,DA,23,24,155,157,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10437,-1,0.9998324,0.0001676203
10439,DA,32,33,223,225,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10439,-1,0.9998394,0.00016051337
10441,DA,13,14,78,80,"However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.",20533999_2,-1,-1,-1,10441,-1,0.99969244,0.0003075451
10442,DA neurotoxicity,19,21,155,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,-1,10442,-1,0.012639735,0.9873603
10443,DA,13,14,75,77,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10443,-1,0.9992636,0.00073642825
10444,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10444,-1,0.011848939,0.9881511
10445,METH,25,26,140,144,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10445,-1,0.9997472,0.00025272273
10446,DA deficits,13,15,86,97,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10446,-1,0.0151451025,0.9848549
10447,dopaminergic deficits,17,19,119,140,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10447,-1,0.016084444,0.9839155
10448,DA,7,8,48,50,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10448,-1,0.999861,0.0001389213
10450,DA,24,25,174,176,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10450,-1,0.9998572,0.00014284629
10461,and kidney injury,20,23,123,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,-1,10461,-1,0.00026103572,0.999739
10463,C,9,10,49,50,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,-1,-1,10463,-1,0.31523427,0.68476576
10464,cardiac and renal lesions,25,29,147,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,-1,10464,-1,0.00018249899,0.99981755
10467,atrial tachyarrhythmia,1,3,19,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,-1,10467,-1,9.682128e-05,0.9999032
10469,atrial tachyarrhythmia,5,7,34,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,-1,-1,10469,-1,0.000114681796,0.9998853
10471,atenolol,6,7,43,51,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,-1,-1,10471,-1,0.99991727,8.272577e-05
10473,atenolol,11,12,59,67,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,-1,-1,10473,-1,0.9999162,8.383624e-05
10475,atrial tachyarrhythmia,3,5,31,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10475,-1,0.0001428358,0.9998572
10476,SIAT,6,7,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10476,-1,0.0042894403,0.9957106
10477,SIAT,5,6,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,-1,-1,-1,10477,-1,0.039261006,0.960739
10478,SIAT,19,20,122,126,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,-1,10478,-1,0.6977375,0.30226249
10480,SIAT,14,15,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,-1,10480,-1,0.013573859,0.9864261
10482,SIAT,11,12,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,-1,-1,-1,10482,-1,0.08964105,0.9103589
10485,atenolol,47,48,272,280,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,-1,-1,10485,-1,0.9999095,9.0504946e-05
10486,diabetes mellitus.1,18,20,128,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,-1,10486,-1,0.004809367,0.9951906
10488,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,-1,10488,-1,0.0013409882,0.998659
10490,ATP,22,23,139,142,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10490,-1,0.9998771,0.00012293257
10491,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10491,-1,0.9999316,6.8432266e-05
10493,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,-1,10493,-1,0.0014543731,0.99854565
10495,ATP,19,20,130,133,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10495,-1,0.9998784,0.000121622004
10496,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10496,-1,0.9999323,6.766499e-05
10498,NMDA,4,5,44,48,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,-1,10498,-1,0.9998671,0.00013285039
10505,glutamate NMDA,9,11,91,105,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10505,-1,0.9998336,0.00016644015
10506,antagonists,12,13,115,126,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10506,-1,0.99982625,0.00017382951
10507,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10507,-1,0.9998901,0.00010984115
10508,AP7,23,24,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10508,-1,0.99989104,0.00010893108
10509,NMDA,35,36,208,212,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10509,-1,0.99986374,0.00013625548
10510,NMDA,40,41,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10510,-1,0.99987423,0.0001257396
10511,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10511,-1,0.9998995,0.00010044018
10512,AP7,9,10,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10512,-1,0.99976474,0.00023523314
10515,NMDA,5,6,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,-1,10515,-1,0.9998863,0.00011375559
10517,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,-1,10517,-1,0.13328442,0.86671555
10519,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10519,-1,0.18526027,0.8147397
10520,PAN,5,6,43,46,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10520,-1,0.0018922007,0.9981078
10523,PAN,2,3,13,16,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,-1,-1,10523,-1,0.009847536,0.9901524
10525,PAN,13,14,78,81,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,-1,-1,-1,10525,-1,0.04633554,0.9536645
10526,OCD,9,10,68,71,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10526,-1,0.0002868259,0.9997131
10527,stereotypies,23,24,161,173,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10527,-1,0.00022386842,0.9997762
10528,anxiety,25,26,177,184,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10528,-1,0.00014690623,0.999853
10529,antidepressant clomipramine,9,11,55,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,-1,10529,-1,0.999902,9.7922384e-05
10531,anxiety,16,17,126,133,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10531,-1,0.00012690706,0.99987304
10532,behavioral inflexibility,26,28,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10532,-1,0.00015803668,0.9998419
10534,hoarding,51,52,338,346,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10534,-1,0.00035829007,0.99964166
10535,corticostriatal dysfunction,54,56,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10535,-1,0.0021401432,0.9978599
10539,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,-1,10539,-1,0.00043889994,0.99956113
10540,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10540,-1,0.00022267947,0.9997774
10541,psychiatric disorders,33,35,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10541,-1,0.00013998458,0.99986005
10542,aortic aneurysm,16,18,112,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,-1,10542,-1,0.00013311516,0.99986684
10543,thoracic aortic aneurysm,12,15,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10543,-1,0.00016891975,0.9998311
10544,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10544,-1,0.0003848818,0.9996151
10545,calcium chloride,19,21,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10545,-1,0.9998907,0.00010935457
10546,arterial injury,23,25,130,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10546,-1,0.00015390379,0.9998461
10547,matrix metalloproteinases,40,42,227,252,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10547,-1,0.99900633,0.0009936932
10548,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10548,-1,0.0006093807,0.9993906
10549,CaCl(2),13,15,72,79,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10549,-1,0.9995838,0.00041619816
10550,NaCl,19,20,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10550,-1,0.9998385,0.00016151776
10551,n=12,12,13,80,84,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10551,-1,0.020785352,0.97921467
10552,n=12,19,20,120,124,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10552,-1,0.023584157,0.9764158
10553,aneurymal alteration,14,16,114,134,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10553,-1,0.00013466839,0.9998653
10554,n=6,17,18,136,139,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10554,-1,0.011981594,0.9880184
10555,media degeneration,23,25,147,165,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10555,-1,0.00040563333,0.9995944
10556,n=12,39,40,259,263,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10556,-1,0.013397065,0.9866029
10557,p<0.01,16,17,94,100,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,-1,10557,-1,0.055212356,0.9447877
10558,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10558,-1,0.0022756725,0.99772435
10559,CaCl(2),10,12,63,70,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10559,-1,0.9990908,0.0009092015
10560,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10560,-1,0.00016960227,0.99983037
10565,organophosphorus (OP) poisons,13,18,105,134,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10565,-1,0.9994752,0.00052481436
10568,OP compound,13,15,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,-1,-1,10568,-1,0.9995814,0.00041856355
10569,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,-1,-1,10569,-1,0.00012734116,0.9998727
10574,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10574,-1,0.00011942535,0.99988055
10575,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10575,-1,0.00012436355,0.99987566
10580,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10580,-1,0.99964833,0.00035170725
10581,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10581,-1,0.99973756,0.00026245145
10582,CHF,2,3,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,-1,10582,-1,0.00012289647,0.9998771
10586,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,-1,10586,-1,0.00025660146,0.9997434
10588,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,-1,10588,-1,0.00031243436,0.99968755
10592,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,-1,-1,10592,-1,0.00010898709,0.99989104
10595,drugs,2,3,18,23,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10595,-1,0.9997687,0.00023128538
10598,cognitive impairment,12,14,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10598,-1,0.00011159508,0.9998884
10599,cognitive impairment,16,18,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,-1,10599,-1,0.00010764724,0.99989235
10602,cognitive impairment,20,22,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,-1,-1,-1,10602,-1,0.00010369232,0.9998963
10609,reduced glutathione,16,18,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,-1,-1,-1,10609,-1,0.99987364,0.00012631138
10612,impairment of learning and memory,11,16,87,120,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,-1,-1,-1,10612,-1,0.00024580644,0.99975425
10614,cognitive impairment,5,7,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,-1,-1,-1,10614,-1,0.000103821236,0.99989617
10619,deterioration of cognitive functions,11,15,73,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,-1,10619,-1,0.00017440776,0.99982566
10625,cognitive impairment,22,24,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,-1,10625,-1,9.898081e-05,0.99990106
10626,crocin,9,10,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10626,-1,0.9999031,9.688749e-05
10627,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10627,-1,0.00026277793,0.9997372
10628,carotenoids,6,7,45,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10628,-1,0.99990237,9.764452e-05
10629,crocins,8,9,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10629,-1,0.9998858,0.00011422691
10630,crocins,8,9,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10630,-1,0.99990773,9.224486e-05
10631,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10631,-1,0.00022985447,0.9997701
10632,streptozocin,20,21,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10632,-1,0.99992573,7.4258285e-05
10633,STZ,22,23,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10633,-1,0.99962175,0.00037822017
10634,n,7,8,33,34,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10634,-1,0.15183546,0.84816456
10635,crocins,27,28,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10635,-1,0.99991596,8.400581e-05
10636,STZ,37,38,124,127,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10636,-1,0.99875283,0.0012471731
10637,STZ,43,44,138,141,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10637,-1,0.99839145,0.0016085122
10638,crocins,45,46,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10638,-1,0.99992263,7.731601e-05
10639,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,-1,10639,-1,0.00045253,0.9995474
10640,STZ,1,2,3,6,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10640,-1,0.40505108,0.59494895
10641,crocin,3,4,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10641,-1,0.99989736,0.000102631086
10642,crocin,7,8,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10642,-1,0.99991846,8.1531914e-05
10643,crocin,2,3,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,-1,-1,-1,10643,-1,0.99990916,9.0830974e-05
10644,crocin,7,8,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,-1,10644,-1,0.9999273,7.2708724e-05
10645,crocin,3,4,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,-1,10645,-1,0.9999174,8.25772e-05
10647,crocin,10,11,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10647,-1,0.99992275,7.7227516e-05
10649,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10649,-1,0.00011653656,0.9998834
10650,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10650,-1,0.00022671219,0.9997733
10652,hemolytic anemia?BACKGROUND/AIMS,10,12,67,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10652,-1,0.0047194,0.99528056
10654,angiogenesis inhibitors,25,27,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10654,-1,0.7164384,0.28356165
10655,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10655,-1,0.99992573,7.430065e-05
10659,chronically infected with hepatitis C virus,4,10,27,70,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10659,-1,0.0021694202,0.99783057
10660,pegylated interferon alpha 2a,13,17,87,116,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10660,-1,0.9999081,9.194303e-05
10662,contrast,1,2,3,11,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10662,-1,0.033183508,0.9668164
10663,pegylated interferon,16,18,102,122,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10663,-1,0.9999318,6.8196576e-05
10667,hepatitis C,24,26,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,-1,-1,10667,-1,0.0004359656,0.999564
10681,P,28,29,140,141,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,-1,10681,-1,0.10144499,0.89855504
10685,psychosis,8,9,69,78,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,-1,10685,-1,0.00010871347,0.9998913
10686,psychotic disorders,14,16,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,-1,10686,-1,0.00015357966,0.99984634
10689,antipsychotics,14,15,90,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,-1,10689,-1,0.9998703,0.00012962341
10693,phencyclidine,11,12,75,88,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,-1,10693,-1,0.99993575,6.4213644e-05
10695,psychotic disorders,28,30,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,-1,-1,10695,-1,0.0001080716,0.9998919
10697,psychosis,5,6,47,56,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10697,-1,0.00010779013,0.99989223
10698,paranoid type schizophrenia,11,14,81,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10698,-1,0.0001786966,0.99982136
10699,psychosis,18,19,98,107,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10699,-1,0.00010672349,0.9998933
10700,psychosis,30,31,178,187,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,-1,10700,-1,0.0001330007,0.99986696
10702,psychosis,7,8,52,61,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,-1,10702,-1,0.00014071741,0.9998592
10703,psychosis,31,32,185,194,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,-1,10703,-1,0.00011861819,0.9998814
10704,psychosis,13,14,83,92,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,-1,10704,-1,0.000106680556,0.9998933
10710,h,12,13,31,32,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,-1,10710,-1,0.06708389,0.9329161
10711,impairment of attention and memory,13,18,72,106,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,-1,-1,-1,10711,-1,0.00033133329,0.9996687
10714,Fluoropyrimidines,5,6,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10714,-1,0.99988604,0.00011393199
10716,5-FU,11,12,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10716,-1,0.9998628,0.00013720672
10718,head and neck cancers,30,34,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10718,-1,0.0005731226,0.99942696
10721,renal and kidney disease,27,31,154,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10721,-1,0.0002371276,0.99976283
10724,5-FU,10,11,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,-1,10724,-1,0.99987495,0.00012502239
10725,head and neck cancers,25,29,157,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,-1,-1,10725,-1,0.0007361714,0.9992638
10728,"nausea, vomiting",11,14,71,87,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,-1,-1,10728,-1,0.00027697027,0.999723
10731,hepatic and renal dysfunctions,17,21,106,136,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,-1,-1,-1,10731,-1,0.00029573482,0.9997042
10732,psychosis,5,6,40,49,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10732,-1,0.000111745234,0.9998883
10733,NMDA,4,5,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,-1,-1,10733,-1,0.9998585,0.00014146003
10735,NMDA,11,12,80,84,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10735,-1,0.99987614,0.00012381298
10740,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,-1,10740,-1,0.056940377,0.9430596
10742,psychosis,2,3,18,27,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10742,-1,0.00012129805,0.99987864
10747,NMDA,10,11,61,65,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10747,-1,0.9998313,0.00016861384
10748,dysfunction,12,13,75,86,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10748,-1,0.00035304608,0.9996469
10753,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,-1,10753,-1,0.00011942364,0.99988055
10761,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,-1,10761,-1,0.010350918,0.98964906
10764,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10764,-1,0.00011649223,0.99988353
10765,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10765,-1,0.00011894824,0.999881
10767,Parkinson's disease,5,8,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,-1,10767,-1,0.00024705566,0.99975294
10769,Parkinson's disease,10,13,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,-1,-1,-1,10769,-1,0.00025093998,0.999749
10773,Parkinson's disease,9,12,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10773,-1,0.00022718802,0.99977285
10774,dyskinetic movements,31,33,218,238,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10774,-1,0.00011414654,0.9998858
10779,parkinsonian catalepsy,6,8,55,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,-1,10779,-1,0.00010571185,0.99989426
10782,parkinsonian symptoms,13,15,98,119,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,-1,10782,-1,0.00010955642,0.99989045
10784,parkinsonian catalepsy,12,14,98,120,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,-1,-1,-1,10784,-1,0.000108915396,0.99989104
10787,neurotensin type-1 receptor antagonist SR48692,1,6,4,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,-1,10787,-1,0.99986565,0.00013437016
10790,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,-1,10790,-1,0.0001276743,0.9998723
10791,Organic mental disorder,0,3,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,-1,10791,-1,0.00014263245,0.9998573
10793,organic personality syndrome,17,20,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10793,-1,0.00020108794,0.99979895
10794,frontal lobe syndrome,34,37,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10794,-1,0.00020023329,0.9997998
10795,the,9,10,56,59,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,-1,-1,10795,-1,0.28004435,0.7199557
10796,the,17,18,108,111,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,-1,-1,-1,10796,-1,0.19338675,0.80661327
10798,organic personality syndrome,8,11,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,-1,-1,10798,-1,0.00016153688,0.9998385
10799,structural damage to the frontal lobe,6,12,28,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,-1,-1,10799,-1,0.0017276345,0.9982723
10801,Parkinson's disease,14,17,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,-1,10801,-1,0.00024843984,0.9997515
10802,adenosine A(2A)/A(1,7,9,39,58,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10802,-1,0.9994856,0.00051435444
10803,Parkinson's disease,17,20,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10803,-1,0.00020773984,0.9997923
10804,Parkinson's disease,44,47,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10804,-1,0.00018157733,0.9998185
10806,akinesia,60,61,316,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10806,-1,0.00012715696,0.9998728
10808,6-OHDA,65,66,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10808,-1,0.99980265,0.0001973353
10809,rotation,71,72,386,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10809,-1,0.00016852093,0.99983144
10824,n=10,3,4,12,16,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10824,-1,0.06146804,0.93853194
10825,n=10,14,15,62,66,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10825,-1,0.060441,0.939559
10826,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10826,-1,0.9998807,0.00011933043
10828,lead,8,9,52,56,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,-1,10828,-1,0.026072366,0.9739276
10832,CCNU,0,1,0,4,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10832,-1,0.9998524,0.00014760352
10833,lomustine,2,3,6,15,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10833,-1,0.99992347,7.647809e-05
10835,gastrointestinal,26,27,142,158,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10835,-1,0.00016056832,0.9998394
10837,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,32,33,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10837,-1,0.9998147,0.00018529817
10838,CCNU,34,35,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10838,-1,0.9998796,0.00012040428
10839,CCNU,12,13,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,-1,10839,-1,0.9998317,0.0001683112
10840,CCNU,8,9,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,-1,10840,-1,0.9998896,0.0001103659
10842,CCNU,0,1,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10842,-1,0.99981946,0.00018057556
10843,lymphoma,9,10,48,56,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10843,-1,0.00015144343,0.9998485
10844,mast cell tumour,11,14,58,74,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10844,-1,0.00029691381,0.9997031
10845,brain tumour,15,17,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10845,-1,0.0001912846,0.9998087
10846,histiocytic tumours,18,20,90,109,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10846,-1,0.00032886225,0.9996711
10847,epitheliotropic lymphoma,21,23,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10847,-1,0.0005650053,0.999435
10849,anaemia,13,14,79,86,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,-1,-1,10849,-1,0.00011061276,0.9998894
10851,Gastrointestinal toxicosis,0,2,0,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,-1,-1,10851,-1,0.00011496352,0.9998851
10855,hepatic failure,3,5,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,-1,-1,-1,10855,-1,0.00012676363,0.99987316
10861,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,-1,10861,-1,0.000121868354,0.99987817
10862,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,-1,-1,10862,-1,0.00010510153,0.99989486
10864,vein thrombosis,1,3,8,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10864,-1,0.00014939644,0.99985063
10865,dipivalyl epinephrine,5,7,36,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10865,-1,0.99994564,5.4391196e-05
10866,vein thrombosis,11,13,64,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10866,-1,0.00017272186,0.9998273
10867,dipivalyl epinephrine,25,27,151,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10867,-1,0.9999496,5.0384922e-05
10871,Pirarubicin,12,13,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,-1,10871,-1,0.99994624,5.37269e-05
10873,renal and/or hepatic dysfunction,23,27,106,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10873,-1,0.00027764315,0.9997223
10874,granulocytopenia,7,8,59,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,-1,10874,-1,0.000107997635,0.999892
10878,alopecia,12,13,76,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10878,-1,0.00014691644,0.999853
10879,phlebitis,14,15,86,95,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10879,-1,0.00015887024,0.9998411
10882,hepatic dysfunction,6,8,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,-1,-1,10882,-1,0.00011485274,0.9998851
10883,Pirarubicin,6,7,49,60,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10883,-1,0.99994326,5.6735385e-05
10884,SE,14,15,85,87,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10884,-1,0.21239498,0.78760505
10885,Adriamycinol,0,1,0,12,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10885,-1,0.9999348,6.523537e-05
10887,adriamycinone,4,5,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10887,-1,0.99993443,6.5571105e-05
10888,tetrahydropyranyladriamycinol,7,8,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10888,-1,0.9999341,6.596371e-05
10890,Pirarubicin,3,4,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,-1,-1,-1,10890,-1,0.9999496,5.042934e-05
10891,mesothelioma,4,5,22,34,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10891,-1,0.00022057648,0.9997794
10892,leiomyosarcoma,6,7,36,50,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10892,-1,0.0002154022,0.99978465
10893,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10893,-1,0.0012734734,0.99872655
10897,audiovisual toxicity,29,31,169,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,-1,10897,-1,0.00013707504,0.9998629
10899,Visual toxicity,0,2,0,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10899,-1,0.00013518264,0.9998648
10900,dyschromatopsy,12,13,77,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10900,-1,0.00017889435,0.9998211
10901,loss of visual acuity,18,22,121,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10901,-1,0.00020713876,0.9997929
10902,retinal deposits,24,26,158,174,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10902,-1,0.00016269591,0.9998373
10903,Auditory toxicity,0,2,0,17,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10903,-1,0.00017599443,0.999824
10904,neurosensorial hearing loss,9,12,64,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10904,-1,0.00014254746,0.9998574
10906,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,-1,-1,10906,-1,0.00017032784,0.99982965
10909,aluminium,19,20,132,141,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,-1,10909,-1,0.999848,0.00015191635
10910,audiovisual toxicity,4,6,23,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,-1,-1,10910,-1,0.00017303637,0.99982697
10912,Benzylacyclouridine,0,1,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10912,-1,0.9999385,6.150321e-05
10913,marrow suppression,3,5,52,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10913,-1,0.00035823663,0.9996418
10914,immunodeficiency,9,10,104,120,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10914,-1,0.1604227,0.8395773
10915,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10915,-1,0.9999207,7.92121e-05
10916,Urd,6,7,51,54,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10916,-1,0.99975854,0.00024144056
10918,immunodeficiency virus,30,32,221,243,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10918,-1,0.8729593,0.12704065
10920,Urd,8,9,59,62,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10920,-1,0.9997305,0.0002694324
10921,benzylacyclouridine,14,15,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10921,-1,0.999943,5.6998506e-05
10922,BAU,16,17,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10922,-1,0.99982566,0.00017439478
10925,Urd,3,4,20,23,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10925,-1,0.99983513,0.00016483502
10926,Urd,15,16,87,90,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10926,-1,0.9998522,0.0001477725
10928,anemic,3,4,17,23,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10928,-1,0.00015569958,0.9998443
10929,leukopenic,5,6,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10929,-1,0.00013015041,0.9998698
10930,AZT,10,11,64,67,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10930,-1,0.99991477,8.5260355e-05
10931,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10931,-1,0.99941576,0.000584319
10932,AZT,26,27,143,146,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10932,-1,0.9999063,9.3639756e-05
10933,BAU,29,30,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10933,-1,0.999876,0.00012399543
10936,P,43,44,236,237,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10936,-1,0.016075758,0.9839242
10937,P,57,58,299,300,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10937,-1,0.01951694,0.98048306
10938,megaloblastosis,71,72,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10938,-1,0.00010980796,0.9998902
10939,AZT,3,4,25,28,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10939,-1,0.9998964,0.00010359112
10940,BAU,11,12,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10940,-1,0.9998252,0.0001748695
10941,marrow toxicity,14,16,92,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10941,-1,0.00015796196,0.99984205
10942,BAU,10,11,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10942,-1,0.99988806,0.00011187923
10943,AZT,23,24,121,124,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10943,-1,0.9998977,0.00010227176
10946,hallucinosis,43,44,259,271,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,-1,-1,10946,-1,0.00015825864,0.9998417
10948,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,-1,-1,10948,-1,0.9998983,0.00010168654
10950,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,-1,10950,-1,0.00036868293,0.9996313
10951,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10951,-1,0.99991953,8.050947e-05
10953,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10953,-1,0.00042611465,0.9995739
10955,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10955,-1,0.99977416,0.00022585457
10956,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10956,-1,0.00041180177,0.9995882
10957,contractures,3,4,17,29,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10957,-1,0.0001624011,0.9998375
10960,P,28,29,138,139,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,-1,-1,10960,-1,0.2987286,0.7012714
10963,decreased appetite,6,8,47,65,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10963,-1,0.000201999,0.999798
10965,gastrointestinal symptoms,28,30,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10965,-1,0.000119732525,0.9998802
10971,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,-1,10971,-1,0.00028850656,0.99971145
10989,nalozone,29,30,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,-1,10989,-1,0.9999449,5.5049783e-05
11001,halogenated hydroxyquinolines,2,4,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,-1,-1,11001,-1,0.9998276,0.0001723785
11003,halogenated hydroxyquinolines,12,14,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,-1,11003,-1,0.99982125,0.00017879409
11004,clioquinol,19,20,122,132,In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded.,230316_2,-1,-1,-1,11004,-1,0.9999404,5.9653386e-05
11005,clioquinol,7,8,36,46,"Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases.",230316_3,-1,-1,-1,11005,-1,0.99992335,7.6649085e-05
11006,neurological disturbance,7,9,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,11006,-1,0.00010942184,0.99989057
11008,clioquinol,25,26,157,167,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,11008,-1,0.9999403,5.9724647e-05
11009,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,-1,-1,11009,-1,0.00011594079,0.999884
11010,clioquinol,13,14,70,80,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,11010,-1,0.999944,5.6000372e-05
11011,acrodermatitis enteropathica,17,19,98,126,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,11011,-1,0.00016823658,0.9998317
11012,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,11012,-1,0.000108698965,0.9998913
11013,visual disturbance,10,12,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,11013,-1,0.00013508987,0.99986494
11015,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,-1,-1,11015,-1,0.0001087676,0.99989116
11029,Myocardial infarction,0,2,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11029,-1,0.0001252331,0.9998747
11030,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,11030,-1,0.99993646,6.358316e-05
11032,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11032,-1,0.00012201113,0.9998779
11033,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11033,-1,0.9999416,5.8387566e-05
11034,mg,22,23,161,163,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,11034,-1,0.9926912,0.007308792
11036,myocardial ischemia,17,19,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11036,-1,0.000107318665,0.9998927
11037,coronary arterial stenosis,23,26,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11037,-1,0.00019336837,0.9998067
11038,acute coronary insufficiency,30,33,222,250,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,11038,-1,0.00012928827,0.99987066
11042,impaired renal function,14,17,96,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,-1,-1,11042,-1,0.00019145085,0.9998086
11045,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,-1,-1,11045,-1,0.00011679064,0.9998832
11048,Postrenal failure,0,2,0,17,Postrenal failure was excluded by echography.,2320800_2,-1,-1,-1,11048,-1,0.00064066367,0.9993593
11049,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11049,-1,0.0001275592,0.99987245
11051,ascitis,19,20,118,125,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,11051,-1,0.00026232185,0.9997377
11055,tubulopathies,8,9,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,-1,11055,-1,0.00013716474,0.9998628
11062,prostaglandin D2,7,9,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11062,-1,0.9998827,0.00011723874
11063,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11063,-1,0.9998493,0.00015071493
11064,F2 alpha,13,15,86,94,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,11064,-1,0.9998908,0.00010919784
11067,acetic acid writhing,20,23,134,154,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,-1,11067,-1,0.14084393,0.85915613
11068,Prostaglandin D2,0,2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11068,-1,0.99989486,0.00010517854
11069,hyperalgesic,10,11,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,11069,-1,0.00016504813,0.9998349
11070,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11070,-1,0.99989295,0.00010709539
11071,hyperalgesic,4,5,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11071,-1,0.00014617656,0.99985385
11072,pg,10,11,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11072,-1,0.9992625,0.00073746336
11073,prostaglandin D2,29,31,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,11073,-1,0.999884,0.00011595449
11074,acetic acid writhing,5,8,33,53,Similar results were obtained by acetic acid writhing tests.,2322844_4,-1,-1,-1,11074,-1,0.54765415,0.45234585
11075,hyperalgesic,1,2,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11075,-1,0.00015123794,0.9998487
11076,prostaglandin D2,4,6,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11076,-1,0.9998969,0.00010315828
11077,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11077,-1,0.99989486,0.00010511456
11078,ng,23,24,140,142,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11078,-1,0.99128824,0.008711805
11079,AH6809,28,29,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,11079,-1,0.9998784,0.00012163778
11080,prostaglandin,2,3,12,25,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11080,-1,0.99988127,0.000118669304
11082,AH6809,8,9,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11082,-1,0.9999145,8.547307e-05
11083,ng,16,17,102,104,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11083,-1,0.9879274,0.012072595
11084,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,11084,-1,0.9998975,0.000102488695
11085,Prostaglandin F2 alpha,0,3,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,-1,-1,11085,-1,0.9998801,0.00011987842
11087,prostaglandin D2,5,7,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11087,-1,0.99985945,0.00014048454
11088,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,11088,-1,0.99985623,0.00014380335
11090,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,-1,-1,11090,-1,0.00011535489,0.9998846
11091,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11091,-1,0.00014200414,0.999858
11092,organ involvement,6,8,49,66,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11092,-1,0.00022150044,0.99977857
11093,lesions,17,18,123,130,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,11093,-1,0.00017957231,0.9998204
11094,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,-1,-1,11094,-1,0.00014674215,0.99985325
11095,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,-1,11095,-1,0.000108481516,0.9998915
11096,cutaneous lesions,13,15,76,93,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,-1,-1,-1,11096,-1,0.00014305198,0.99985695
11097,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11097,-1,0.00010374643,0.9998963
11099,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,11099,-1,0.000110490786,0.9998895
11100,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,-1,-1,11100,-1,0.00011260201,0.99988735
11102,analgesia,5,6,35,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,-1,-1,-1,11102,-1,0.0005832779,0.9994167
11105,mg,6,7,32,34,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11105,-1,0.9787685,0.021231435
11107,mg,23,24,128,130,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,11107,-1,0.9851327,0.014867238
11108,carbon dioxide,7,9,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,-1,11108,-1,0.9998282,0.00017177584
11109,P,3,4,18,19,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11109,-1,0.027211951,0.97278804
11111,P,12,13,56,57,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,11111,-1,0.026913777,0.9730862
11113,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11113,-1,0.00011059778,0.9998894
11114,P,9,10,55,56,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11114,-1,0.030056559,0.9699434
11115,ventricular ectopic beats,15,18,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11115,-1,0.00013635386,0.9998636
11116,P,19,20,104,105,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,11116,-1,0.0252642,0.97473574
11118,sinus thrombosis,1,3,9,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11118,-1,0.00013504027,0.99986494
11119,menorrhagia,11,12,81,92,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,11119,-1,0.0002702227,0.9997298
11121,menorrhagia,21,22,165,176,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,-1,11121,-1,0.00017626093,0.99982375
11122,menorrhagia,9,10,56,67,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,11122,-1,0.00020714785,0.9997929
11124,sinus thrombosis,16,18,126,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,11124,-1,0.00012267973,0.99987733
11126,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,-1,11126,-1,0.9999348,6.519003e-05
11127,cerebral vascular accident,8,11,46,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11127,-1,0.00012435253,0.99987566
11128,CVA,12,13,74,77,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11128,-1,0.00021659031,0.99978346
11129,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11129,-1,0.00014274579,0.9998572
11130,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,11130,-1,0.00016004813,0.9998399
11137,ventricular fibrillation,8,10,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11137,-1,0.00011760175,0.99988234
11138,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,11138,-1,0.00016229213,0.99983764
11140,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,-1,-1,11140,-1,0.00015015033,0.9998498
11141,cardiac disturbances,9,11,68,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11141,-1,0.000110823166,0.99988914
11142,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,11142,-1,0.00012910545,0.9998709
11144,ventricular fibrillation,6,8,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11144,-1,0.00012617341,0.99987376
11145,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,11145,-1,0.00015742694,0.9998425
11146,ventricular fibrillation,1,3,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,-1,-1,-1,11146,-1,0.00014651677,0.9998535
11148,ventricular fibrillation,7,9,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11148,-1,0.00013449669,0.99986553
11150,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11150,-1,0.9997272,0.00027281969
11151,carbon dioxide,31,33,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11151,-1,0.9998957,0.00010425228
11152,CO2,34,35,190,193,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,11152,-1,0.9997447,0.0002552947
11153,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11153,-1,0.00013784102,0.9998622
11154,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11154,-1,0.0001268156,0.99987316
11155,mm Hg,17,19,90,95,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11155,-1,0.9696269,0.03037304
11156,mm Hg,24,26,110,115,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11156,-1,0.9666696,0.033330433
11158,ventricular fibrillation,38,40,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,11158,-1,0.000115931056,0.999884
11160,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,-1,-1,11160,-1,0.00014282436,0.9998572
11163,Trental,2,3,16,23,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,-1,-1,11163,-1,0.9998173,0.0001827309
11165,peripheral vascular disease,12,15,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,-1,11165,-1,0.00011629888,0.99988365
11167,Trental,8,9,50,57,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11167,-1,0.999846,0.00015398556
11168,methylxanthine,12,13,62,76,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11168,-1,0.9999232,7.6750744e-05
11169,intermittent claudication,17,19,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,11169,-1,0.00012278037,0.9998772
11172,methylxanthines,8,9,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,11172,-1,0.99991596,8.4039224e-05
11174,hyperemic,5,6,26,35,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,-1,-1,-1,11174,-1,0.000113580645,0.9998864
11180,p,2,3,16,17,pentoxifylline (p less than 0.002).,2348231_7,-1,-1,-1,11180,-1,0.18850483,0.8114951
11184,p,21,22,166,167,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,-1,11184,-1,0.07209973,0.92790025
11185,pentoxyifylline,3,4,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,11185,-1,0.9999342,6.5822016e-05
11188,Parkinson's disease,6,9,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11188,-1,0.00041274182,0.99958724
11189,haemorrhage,16,17,89,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,11189,-1,0.00012863039,0.9998714
11191,haemorrhage,9,10,52,63,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11191,-1,0.00012246959,0.9998776
11192,Parkinson's disease,17,20,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,11192,-1,0.0003785473,0.9996214
11194,pneumonia,6,7,33,42,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11194,-1,0.00014313901,0.9998568
11195,bronchitis,8,9,47,57,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11195,-1,0.00018279905,0.9998172
11196,neoplasms,15,16,77,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11196,-1,0.00021049233,0.99978954
11197,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11197,-1,0.00019689457,0.9998031
11198,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11198,-1,0.0001420861,0.9998579
11199,septicaemia,35,36,150,161,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,11199,-1,0.000133925,0.999866
11206,Parkinson's disease,14,17,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,-1,11206,-1,0.00024572582,0.99975425
11212,cardiorespiratory arrest,3,5,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,-1,-1,11212,-1,0.00011551218,0.9998845
11214,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,-1,-1,-1,11214,-1,0.9999341,6.593308e-05
11216,cardiorespiratory arrest,8,10,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,-1,11216,-1,0.00012248989,0.99987745
11220,Myasthenia gravis,0,2,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,-1,-1,11220,-1,0.00027236177,0.99972767
11223,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11223,-1,0.00013855207,0.9998615
11224,quadriplegic,14,15,89,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11224,-1,0.0007449829,0.999255
11226,preeclampsia,20,21,148,160,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11226,-1,0.00015593761,0.9998441
11229,neuromuscular blockade,23,25,160,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,-1,11229,-1,0.001085361,0.9989146
11233,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,-1,11233,-1,0.00017902302,0.999821
11235,disorder of neuromuscular transmission,18,22,123,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,-1,-1,-1,11235,-1,0.000491203,0.99950874
11239,hepatocellular carcinomas,5,7,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,-1,-1,11239,-1,0.0001331182,0.99986684
11242,hepatocellular carcinomas,7,9,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,-1,-1,-1,11242,-1,0.00013049413,0.99986947
11255,mm Hg,32,34,192,197,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11255,-1,0.0024206906,0.9975794
11256,h,41,42,221,222,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11256,-1,0.026909543,0.97309047
11258,"5,7-dihydroxytryptamine",51,52,290,313,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11258,-1,0.99989736,0.00010265458
11259,"5,7-DHT",53,54,315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11259,-1,0.9998166,0.00018348587
11260,"5,7-DHT",5,6,34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,-1,11260,-1,0.99989164,0.000108339984
11263,"5,7-DHT",2,3,9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11263,-1,0.99984574,0.00015428981
11266,in,31,32,175,177,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11266,-1,0.001159839,0.99884015
11267,serotonin methyldopa,39,41,222,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11267,-1,0.99989533,0.000104660685
11273,Liver enlargement,0,2,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11273,-1,0.00012123249,0.99987876
11274,muscle wastage,3,5,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11274,-1,0.00020042372,0.99979955
11277,cibenzoline,4,5,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,-1,-1,11277,-1,0.9999403,5.971952e-05
11280,cibenzoline,16,17,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,-1,11280,-1,0.9999423,5.7734065e-05
11282,Cibenzoline,0,1,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11282,-1,0.99993074,6.9207046e-05
11285,digitalis,24,25,167,176,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11285,-1,0.018848758,0.9811513
11287,n,86,87,368,369,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11287,-1,0.18244751,0.8175525
11291,tocainide,10,11,67,76,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,-1,-1,11291,-1,0.9999443,5.56158e-05
11292,cibenzoline,1,2,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,-1,11292,-1,0.9999356,6.440744e-05
11300,pentylenetrazol,21,22,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11300,-1,0.99994254,5.747961e-05
11301,PTZ,23,24,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11301,-1,0.99940753,0.0005924733
11302,h,26,27,163,164,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11302,-1,0.018523151,0.98147684
11304,h,39,40,254,255,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11304,-1,0.03867348,0.9613265
11305,h,19,20,101,102,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,-1,11305,-1,0.03427023,0.9657298
11306,h,23,24,143,144,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,-1,11306,-1,0.051198106,0.9488019
11308,PTZ,4,5,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11308,-1,0.99970967,0.00029031915
11310,PTX,8,9,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11310,-1,0.9998317,0.00016835264
11312,3-mercaptopropionic acid,20,22,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11312,-1,0.9999151,8.48476e-05
11313,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11313,-1,0.99982977,0.00017023871
11315,BCC,28,29,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11315,-1,0.9994167,0.00058332377
11316,DMCM,34,35,218,222,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11316,-1,0.9994006,0.00059938297
11317,strychnine,38,39,228,238,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11317,-1,0.9999274,7.259303e-05
11318,STR,40,41,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11318,-1,0.99957794,0.00042202076
11319,pentylenetetrazol,5,6,21,38,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,-1,11319,-1,0.9999411,5.8887865e-05
11321,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11321,-1,0.996678,0.0033219822
11322,BCC,2,3,5,8,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11322,-1,0.9818848,0.018115241
11323,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11323,-1,0.992851,0.007148952
11324,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11324,-1,0.9916339,0.008366101
11326,PTZ,14,15,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11326,-1,0.9998666,0.00013341646
11327,PTX,16,17,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11327,-1,0.9998492,0.00015080247
11328,h,18,19,114,115,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11328,-1,0.10819544,0.8918046
11330,h,16,17,92,93,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11330,-1,0.032187592,0.9678124
11331,chloride,24,25,144,152,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11331,-1,0.99984396,0.00015601167
11333,Argentine hemorrhagic fever,9,12,61,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,-1,-1,11333,-1,0.022780389,0.97721964
11335,Argentine hemorrhagic fever,12,15,75,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11335,-1,0.012798838,0.9872012
11336,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11336,-1,0.0010964182,0.9989035
11338,viremia,8,9,60,67,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11338,-1,0.00013265279,0.9998673
11339,interferon,14,15,93,103,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11339,-1,0.9997992,0.00020088309
11343,AHF,16,17,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,-1,-1,11343,-1,0.0003611952,0.9996388
11346,AHF,11,12,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,-1,-1,-1,11346,-1,0.0037176355,0.9962824
11347,fluorouracil,5,6,44,56,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,-1,11347,-1,0.99991035,8.96018e-05
11349,fluorouracil,11,12,79,91,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11349,-1,0.99990976,9.028832e-05
11350,5-FU,13,14,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11350,-1,0.99988484,0.00011518968
11351,5-FU,11,12,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11351,-1,0.9998909,0.00010901588
11353,ischemic,25,26,170,178,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11353,-1,0.00012938828,0.99987054
11354,5-FU,10,11,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11354,-1,0.9998611,0.00013885893
11355,5-FU,20,21,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11355,-1,0.9998698,0.00013018033
11356,Anginal,0,1,0,7,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11356,-1,0.00025491626,0.9997451
11357,angina,9,10,49,55,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11357,-1,0.00011471604,0.9998853
11358,5-FU,12,13,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11358,-1,0.9998797,0.00012032313
11359,mm,12,13,61,63,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11359,-1,0.0024359247,0.9975641
11360,5-FU,31,32,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11360,-1,0.9998783,0.00012167756
11361,5-FU,40,41,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11361,-1,0.9998858,0.0001142036
11362,P,43,44,185,186,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11362,-1,0.02083493,0.9791651
11363,ischemic,3,4,17,25,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,-1,11363,-1,0.0001629311,0.99983704
11364,5-FU,3,4,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11364,-1,0.999876,0.0001239888
11365,5-FU,11,12,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11365,-1,0.99988866,0.000111387664
11366,P,14,15,66,67,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11366,-1,0.04336271,0.9566373
11367,5-FU,36,37,165,169,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11367,-1,0.99988484,0.00011509173
11368,5-FU,48,49,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11368,-1,0.99989545,0.00010452065
11369,P,50,51,226,227,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11369,-1,0.039921887,0.9600782
11370,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,-1,-1,11370,-1,0.00029786702,0.99970216
11372,5-FU,3,4,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11372,-1,0.99991727,8.269596e-05
11374,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11374,-1,0.00016821078,0.9998318
11375,scabies,4,5,20,27,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11375,-1,0.0002534534,0.9997465
11376,scabies,7,8,52,59,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11376,-1,0.00021650935,0.99978346
11378,gamma benzene,19,21,130,143,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11378,-1,0.999711,0.00028901122
11379,hexachloride,21,22,144,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11379,-1,0.9998988,0.00010121175
11382,toxic to the central nervous system,7,13,45,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11382,-1,0.0005128891,0.99948704
11383,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11383,-1,0.000101810256,0.9998982
11387,biogenic amines,9,11,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,-1,-1,-1,11387,-1,0.9998828,0.00011715404
11388,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11388,-1,0.99994266,5.7309284e-05
11389,biogenic amines,29,31,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11389,-1,0.9998424,0.00015759878
11391,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,-1,11391,-1,0.83184206,0.16815794
11395,suppression of motility,26,29,173,196,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,-1,11395,-1,0.0002799007,0.99972004
11398,"3,4-dihydroxyphenylacetic acid",15,17,97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,-1,11398,-1,0.9998909,0.0001090738
11399,normetanephrine,3,4,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,-1,11399,-1,0.99988985,0.000110159606
11403,biogenic amines,5,7,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11403,-1,0.99985707,0.00014286059
11405,monoamine oxidase,22,24,152,169,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11405,-1,0.9998312,0.00016881897
11407,behavioral depression,37,39,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11407,-1,0.000106298336,0.99989367
11409,Chloroacetaldehyde,0,1,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,-1,11409,-1,0.9999018,9.821247e-05
11412,chloroacetaldehyde,7,8,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11412,-1,0.99993694,6.301749e-05
11413,CAA,9,10,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11413,-1,0.99954396,0.00045601852
11414,CAA,32,33,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11414,-1,0.997686,0.0023139569
11415,hemorrhagic cystitis,37,39,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11415,-1,0.00010197542,0.99989796
11416,CAA,4,5,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11416,-1,0.9974368,0.0025631825
11417,bladder damage,13,15,79,93,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11417,-1,0.00017191922,0.9998281
11418,CAA,7,8,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,-1,11418,-1,0.99968994,0.00031008472
11424,blind,37,38,229,234,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,-1,11424,-1,0.04748828,0.9525117
11436,leukemoid reaction,6,8,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11436,-1,0.00024397447,0.99975604
11438,erythroderma,11,12,86,98,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11438,-1,0.0008206763,0.9991793
11439,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11439,-1,0.00015270179,0.9998473
11442,generalized erythroderma,11,13,77,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11442,-1,0.00031468476,0.9996853
11443,leukemoid reaction,16,18,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11443,-1,0.00022121085,0.9997788
11446,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11446,-1,0.00015259466,0.9998474
11449,HIV disease,30,32,161,172,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,-1,11449,-1,0.003267867,0.9967321
11454,megaloblastosis,8,9,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,-1,-1,11454,-1,0.00014682094,0.99985313
11456,hepatitis B virus,9,12,68,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11456,-1,0.993566,0.0064340294
11457,infection by hepatitis B virus (HBV),24,32,162,198,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11457,-1,0.33272353,0.66727644
11458,hepatitis B surface antigen,18,22,116,143,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11458,-1,0.99627626,0.0037237175
11459,HBsAg,23,24,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11459,-1,0.99964964,0.00035040287
11460,hepatitis B e antigen,26,30,156,177,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11460,-1,0.99825853,0.0017415226
11461,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11461,-1,0.99966276,0.00033719154
11462,hepatitis B,8,10,49,60,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11462,-1,0.9997054,0.00029464433
11463,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11463,-1,0.99973124,0.0002687351
11464,HBsAg,11,12,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,-1,11464,-1,0.99688077,0.0031192538
11465,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11465,-1,0.99964297,0.00035701692
11466,HBsAg,5,6,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11466,-1,0.9994758,0.0005242994
11467,HBsAg,1,2,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,-1,-1,-1,11467,-1,0.99951744,0.0004826036
11468,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,-1,-1,11468,-1,0.006244007,0.99375594
11470,obsessive compulsive disorder,8,11,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11470,-1,0.00014367234,0.99985635
11472,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11472,-1,0.00041581588,0.99958414
11473,restlessness,5,6,43,55,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11473,-1,0.00012455357,0.9998754
11474,anxiety,20,21,129,136,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11474,-1,0.0001216285,0.9998784
11475,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11475,-1,0.00018402532,0.999816
11476,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11476,-1,0.00043319026,0.99956685
11477,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11477,-1,0.0004150219,0.999585
11478,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,-1,-1,11478,-1,0.0062476033,0.9937524
11481,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11481,-1,0.002363694,0.9976363
11482,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11482,-1,0.008478209,0.9915217
11483,analgesia,7,8,52,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,-1,-1,-1,11483,-1,0.00018841782,0.9998116
11485,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11485,-1,0.99903655,0.00096344727
11486,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide",15,18,98,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11486,-1,0.99967766,0.00032230557
11487,prostaglandin,18,19,116,129,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,-1,11487,-1,0.99986017,0.00013980648
11491,pertussis toxin,17,19,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,-1,11491,-1,0.9999105,8.954962e-05
11494,8-bromo cyclic adenosine monophosphate,11,15,61,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,-1,-1,11494,-1,0.999908,9.202776e-05
11495,cyclic adenosine monophosphate,36,39,221,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,-1,11495,-1,0.9998852,0.00011474448
11498,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,-1,11498,-1,0.12178041,0.8782196
11503,mm Hg,20,22,104,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11503,-1,0.0014953883,0.99850464
11504,P,28,29,126,127,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11504,-1,0.034127496,0.96587247
11505,mm Hg,47,49,201,206,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11505,-1,0.0020546908,0.99794537
11506,P,50,51,208,209,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11506,-1,0.036013555,0.96398646
11510,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,-1,11510,-1,0.102416836,0.8975832
11514,P,33,34,150,151,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,-1,11514,-1,0.09082855,0.90917146
11516,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,-1,-1,11516,-1,0.00011113568,0.9998889
11517,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,-1,11517,-1,0.000119460216,0.99988055
11520,CO2,10,11,68,71,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,-1,-1,-1,11520,-1,0.9984932,0.0015067898
11522,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,-1,11522,-1,0.000104441846,0.9998956
11525,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,-1,11525,-1,0.00010717722,0.99989283
11527,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11527,-1,0.9999393,6.0703947e-05
11528,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11528,-1,0.00011232961,0.9998877
11529,alpha-2 adrenergic agonist dexmedetomidine,2,6,21,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11529,-1,0.9998816,0.000118327625
11530,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11530,-1,0.00013939184,0.99986064
11531,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,-1,-1,11531,-1,0.00011746346,0.9998826
11533,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,-1,-1,11533,-1,0.000110835754,0.99988914
11535,n,2,3,9,10,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11535,-1,0.0799545,0.92004555
11536,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11536,-1,0.999913,8.706902e-05
11537,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11537,-1,0.9999399,6.010058e-05
11538,DG-5128,76,77,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11538,-1,0.9998939,0.00010608225
11540,ALF,8,9,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,-1,-1,-1,11540,-1,0.99959165,0.00040838035
11541,ALF,0,1,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,-1,11541,-1,0.9995597,0.00044026494
11542,contrast,1,2,3,11,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11542,-1,0.07802525,0.9219748
11543,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11543,-1,0.00010831757,0.99989164
11545,startle,12,13,65,72,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,-1,-1,11545,-1,0.00048268525,0.9995173
11546,acute hepatitis,1,3,20,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,-1,-1,11546,-1,0.000105995285,0.999894
11547,acute hepatitis,9,11,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11547,-1,0.00011692905,0.99988306
11548,hepatocellular necrosis,13,15,77,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11548,-1,0.000110796755,0.99988914
11549,clotiazepam,24,25,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11549,-1,0.99994373,5.6319615e-05
11550,thienodiazepine,27,28,163,178,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11550,-1,0.99993515,6.480234e-05
11551,Clotiazepam,0,1,0,11,Clotiazepam withdrawal was followed by prompt recovery.,2572625_2,-1,-1,-1,11551,-1,0.9999354,6.4628184e-05
11553,clotiazepam,9,10,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,-1,11553,-1,0.99994254,5.7426132e-05
11555,clotiazepam,4,5,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11555,-1,0.99994755,5.2415762e-05
11556,acute hepatitis,7,9,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11556,-1,0.00011081947,0.99988914
11558,clotiazepam,18,19,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11558,-1,0.99994624,5.376027e-05
11560,fluvoxamine,7,8,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,-1,11560,-1,0.99993587,6.417299e-05
11561,fluvoxamine,8,9,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11561,-1,0.99994004,6.001794e-05
11563,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11563,-1,0.999941,5.8949663e-05
11564,fluvoxamine,4,5,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,-1,-1,11564,-1,0.9999399,6.005383e-05
11567,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11567,-1,0.9999471,5.2886022e-05
11568,fluvoxamine,10,11,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11568,-1,0.9999348,6.523431e-05
11569,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11569,-1,0.9999498,5.0143866e-05
11570,fluvoxamine,16,17,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11570,-1,0.9999429,5.7119243e-05
11571,fluvoxamine,3,4,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,-1,11571,-1,0.99994373,5.6294855e-05
11572,fluvoxamine,4,5,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11572,-1,0.99994445,5.5518725e-05
11577,carcinogens,5,6,48,59,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,-1,-1,-1,11577,-1,0.99942315,0.00057683245
11578,carcinogenic process,19,21,112,132,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11578,-1,0.00073547295,0.99926454
11580,5-AzC,24,25,149,154,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11580,-1,0.9998229,0.0001771271
11581,carcinogens,51,52,277,288,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11581,-1,0.9988085,0.0011914973
11582,benzo[a]-pyrene,53,54,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11582,-1,0.9999082,9.1836206e-05
11584,"1,2-DMH",67,68,380,387,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11584,-1,0.9995963,0.00040376495
11586,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11586,-1,0.9998864,0.000113549235
11587,carcinogens,8,9,50,61,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11587,-1,0.99949765,0.0005023135
11588,5-AzC,12,13,81,86,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11588,-1,0.9999275,7.2442475e-05
11589,5-AzC,30,31,191,196,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11589,-1,0.99991906,8.092511e-05
11590,"1,2-DMH",9,10,81,88,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11590,-1,0.9997856,0.00021442703
11591,cytosine,17,18,124,132,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11591,-1,0.9997844,0.00021559309
11592,5-AzC,31,32,216,221,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11592,-1,0.99987924,0.00012069808
11593,5-AzC,7,8,34,39,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,-1,11593,-1,0.9999136,8.6405664e-05
11594,se,8,9,52,54,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,-1,-1,-1,11594,-1,0.046381053,0.95361894
11595,BN 52021,9,11,71,79,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11595,-1,0.99965,0.0003499453
11596,cardiovascular impairments,14,16,104,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11596,-1,0.0001130266,0.999887
11598,decrease of mean arterial blood pressure,20,26,101,141,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,-1,-1,-1,11598,-1,0.0023901032,0.99760985
11600,BN 52021,11,13,82,90,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,-1,11600,-1,0.9997807,0.00021928748
11602,contrast,1,2,3,11,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11602,-1,0.28645048,0.7135495
11603,BN 52021,7,9,30,38,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11603,-1,0.9998542,0.00014581655
11605,BN 52021,1,3,5,13,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,-1,11605,-1,0.99949896,0.0005009691
11607,BN 52021,15,17,107,115,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,-1,11607,-1,0.99982905,0.00017091677
11608,BN 52021,4,6,28,36,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11608,-1,0.9998653,0.00013465414
11609,BN 52021,34,36,173,181,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11609,-1,0.99985445,0.00014553261
11610,cardiovascular toxicity,45,47,241,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11610,-1,0.00010947935,0.99989057
11611,cardiovascular alterations,17,19,102,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,-1,11611,-1,0.00012249444,0.99987745
11612,flank pain,5,7,30,40,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11612,-1,0.00014388056,0.9998561
11613,suprofen,9,10,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11613,-1,0.99980384,0.00019619557
11614,Suprofen,0,1,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,-1,11614,-1,0.99978286,0.00021710347
11615,flank pain,7,9,50,60,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,-1,11615,-1,0.00013737113,0.99986255
11616,hay fever,26,28,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11616,-1,0.00015592406,0.9998441
11617,asthma,29,30,121,127,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11617,-1,0.00014792194,0.99985206
11618,p,75,76,316,317,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11618,-1,0.1520186,0.84798145
11620,agents,12,13,76,82,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11620,-1,0.9997919,0.0002080667
11622,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11622,-1,0.00013420242,0.9998658
11623,kidney stones,25,27,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11623,-1,0.00014617055,0.99985385
11624,gout,31,32,175,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11624,-1,0.00016625377,0.9998337
11625,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,-1,11625,-1,0.9998603,0.00013971947
11626,Antihypertensive drugs,0,2,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,-1,-1,11626,-1,0.9998369,0.0001630357
11634,depressions,9,10,50,61,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11634,-1,0.00015909596,0.99984086
11635,methyl,12,13,75,81,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11635,-1,0.9998665,0.00013346224
11636,dopa,13,14,82,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11636,-1,0.9998704,0.00012951283
11639,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11639,-1,0.99993825,6.173055e-05
11640,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11640,-1,0.9999356,6.440842e-05
11641,Voltarol,3,4,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11641,-1,0.99981636,0.0001836616
11643,abnormalities of liver function,5,9,48,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,-1,-1,11643,-1,0.00015696813,0.999843
11647,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11647,-1,0.99994457,5.5382825e-05
11650,Cushing's syndrome,5,8,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,-1,-1,11650,-1,0.00021962372,0.99978036
11656,deoxycorticosterone,7,8,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,-1,11656,-1,0.99992085,7.913736e-05
11658,deoxycorticosterone,11,12,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,-1,11658,-1,0.999923,7.7010794e-05
11665,and renal insufficiency,13,16,82,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11665,-1,0.00023035074,0.9997696
11666,intravascular coagulation,18,20,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11666,-1,0.00011668957,0.9998833
11667,intravascular coagulation,2,4,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11667,-1,0.00010684772,0.9998932
11668,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11668,-1,0.9999435,5.6551195e-05
11669,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11669,-1,0.9998609,0.00013909374
11670,pulmonary and renal insufficiency,24,28,147,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11670,-1,0.00013274985,0.9998672
11671,trauma,32,33,213,219,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11671,-1,0.00015098578,0.99984896
11675,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,-1,-1,11675,-1,0.00012979015,0.9998702
11680,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,-1,-1,-1,11680,-1,0.99990165,9.834818e-05
11682,Angiotension II,27,29,151,166,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11682,-1,0.9995728,0.0004272014
11683,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11683,-1,0.99991393,8.611358e-05
11686,kidney damage,48,50,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,-1,11686,-1,0.00013237188,0.99986756
11691,SD,9,10,38,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,-1,11691,-1,0.15500139,0.8449986
11695,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11695,-1,0.00017592314,0.9998241
11696,cerebral vasculitis,18,20,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11696,-1,0.00010586518,0.99989414
11697,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11697,-1,0.000113521965,0.9998865
11698,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11698,-1,0.00012935042,0.99987066
11699,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11699,-1,0.00015127861,0.9998487
11707,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11707,-1,0.0001132738,0.99988675
11708,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11708,-1,0.0001811032,0.999819
11710,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11710,-1,0.00010775909,0.99989223
11711,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11711,-1,0.00010921701,0.9998908
11717,reductions in mean arterial blood pressure,12,18,88,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11717,-1,0.0030140022,0.996986
11719,p,8,9,58,59,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11719,-1,0.05278731,0.94721264
11720,increase in heart rate and cardiac output,13,20,76,117,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11720,-1,0.0004047733,0.9995952
11724,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,-1,11724,-1,0.9867697,0.013230366
11728,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,-1,11728,-1,0.0034866983,0.9965133
11729,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11729,-1,0.00012159498,0.9998784
11730,DM,7,8,60,62,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11730,-1,0.00024155616,0.9997584
11732,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11732,-1,0.00011357556,0.9998864
11733,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11733,-1,0.0001297957,0.9998702
11734,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11734,-1,0.0037564896,0.9962435
11736,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11736,-1,0.999944,5.6009554e-05
11737,P,24,25,176,177,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11737,-1,0.99983966,0.00016028716
11738,DM,0,1,0,2,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11738,-1,0.0038412665,0.9961588
11740,P,13,14,63,64,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11740,-1,0.99970454,0.00029549137
11741,P,3,4,9,10,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11741,-1,0.9984195,0.0015804734
11742,P,7,8,27,28,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11742,-1,0.9997845,0.00021549752
11743,P,19,20,65,66,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11743,-1,0.99885726,0.0011426888
11746,DM,35,36,130,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11746,-1,0.8891501,0.110849984
11750,P,4,5,12,13,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11750,-1,0.999699,0.00030104053
11752,SE,18,19,75,77,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11752,-1,0.34683192,0.6531681
11755,P,4,5,13,14,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11755,-1,0.99912995,0.0008700805
11756,P,19,20,85,86,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11756,-1,0.21694225,0.78305775
11758,P,18,19,86,87,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,-1,11758,-1,0.049549486,0.95045054
11765,analgesia,9,10,70,79,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,-1,-1,11765,-1,0.00013899697,0.999861
11771,cataleptic,22,23,169,179,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,-1,-1,-1,11771,-1,0.00020510191,0.9997949
11783,cataleptic,4,5,31,41,Naloxone inhibited the induced cataleptic effects.,2716967_6,-1,-1,-1,11783,-1,0.00039617557,0.9996038
11795,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11795,-1,0.008129117,0.9918709
11796,p,23,24,124,125,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11796,-1,0.0935039,0.9064961
11797,increased cardiac output,32,35,162,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11797,-1,0.00054430874,0.99945575
11798,p,46,47,219,220,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11798,-1,0.103219345,0.8967806
11799,mm,9,10,60,62,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11799,-1,0.25944623,0.7405538
11800,p,17,18,87,88,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11800,-1,0.090235464,0.9097646
11801,mm,26,27,166,168,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11801,-1,0.50433767,0.4956623
11802,p,47,48,259,260,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11802,-1,0.09287937,0.90712065
11806,p,53,54,288,289,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,-1,11806,-1,0.07293937,0.9270606
11810,rise in resting blood pressure,1,6,4,34,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11810,-1,0.0013571706,0.99864286
11812,increased cardiac output,12,15,77,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11812,-1,0.0009470635,0.99905294
11813,blood,20,21,131,136,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11813,-1,0.15612948,0.8438705
11814,Neuromuscular blockade,0,2,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11814,-1,0.00017185332,0.9998281
11815,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11815,-1,0.9998987,0.000101344835
11818,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11818,-1,0.00012114293,0.9998789
11819,mg,12,13,92,94,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11819,-1,0.9971397,0.0028603806
11820,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11820,-1,0.99991083,8.9178844e-05
11829,CBZ,5,6,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11829,-1,0.9998673,0.00013260903
11831,CBZ,28,29,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11831,-1,0.99988294,0.00011699116
11832,CBZ,2,3,13,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,-1,11832,-1,0.9998735,0.00012642959
11835,CBZ,1,2,8,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,-1,11835,-1,0.9997925,0.00020754879
11836,CBZ,1,2,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,-1,11836,-1,0.99424064,0.005759383
11838,CBZ,2,3,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,-1,-1,11838,-1,0.9998915,0.00010847531
11840,CBZ,4,5,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,-1,11840,-1,0.9998965,0.00010349949
11843,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,-1,11843,-1,0.9998965,0.00010351924
11844,CBZ,5,6,32,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,-1,11844,-1,0.9998167,0.00018326798
11847,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,-1,11847,-1,0.048949935,0.9510501
11849,amphotericin B,4,6,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,-1,11849,-1,0.9999424,5.7526715e-05
11850,amphotericin B,4,6,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,-1,11850,-1,0.9999416,5.839943e-05
11852,contrast,1,2,3,11,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,-1,-1,-1,11852,-1,0.03443901,0.96556103
11855,amphotericin B,2,4,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,-1,-1,-1,11855,-1,0.999926,7.402751e-05
11856,amphotericin B,9,11,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,-1,11856,-1,0.9999443,5.5611454e-05
11858,amphotericin B,9,11,60,74,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11858,-1,0.9999312,6.874674e-05
11859,amphotericin B,14,16,102,116,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11859,-1,0.99993515,6.481303e-05
11862,venous thrombosis,5,7,39,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,-1,11862,-1,0.00014236858,0.99985766
11863,venous thrombosis,8,10,56,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,-1,11863,-1,0.00014905803,0.99985087
11865,hypokalemia,1,2,29,40,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11865,-1,0.00010726545,0.9998927
11866,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11866,-1,0.99992967,7.03792e-05
11867,hypokalemia,8,9,77,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,-1,11867,-1,9.801105e-05,0.999902
11868,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11868,-1,0.9999281,7.184059e-05
11869,hypokalemia,10,11,77,88,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11869,-1,0.00010508348,0.99989486
11870,mg,7,8,38,40,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11870,-1,0.9749278,0.025072204
11872,mg oxprenolol,29,31,158,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11872,-1,0.99976975,0.00023024094
11877,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,-1,-1,-1,11877,-1,0.99992716,7.284551e-05
11880,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11880,-1,0.9999306,6.9377325e-05
11881,hypokalemia,11,12,81,92,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11881,-1,0.00010792209,0.9998921
11882,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11882,-1,0.00011987442,0.9998801
11884,ACTH,20,21,90,94,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11884,-1,0.99987364,0.00012632307
11885,NE,36,37,170,172,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11885,-1,0.99977666,0.00022330305
11887,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11887,-1,0.00012193425,0.99987805
11888,c,79,80,430,431,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11888,-1,0.09525324,0.9047467
11891,ACC-9089,2,3,11,19,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,-1,11891,-1,0.9990088,0.0009911979
11899,contrast,1,2,3,11,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,-1,11899,-1,0.06705445,0.93294555
11901,supraventricular tachyarrhythmia,8,10,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,-1,-1,11901,-1,0.00011335343,0.99988663
11902,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11902,-1,0.000112084264,0.99988794
11904,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11904,-1,0.00011230037,0.9998877
11909,h,14,15,92,93,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,-1,11909,-1,0.91571504,0.08428494
11922,Phentolamine,0,1,0,12,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,-1,11922,-1,0.9999453,5.4718217e-05
11924,phentolamine,5,6,32,44,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,-1,-1,-1,11924,-1,0.99994564,5.4315515e-05
11926,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,-1,11926,-1,0.00014088806,0.9998591
11931,h,26,27,194,195,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11931,-1,0.040519666,0.95948035
11932,h,29,30,202,203,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11932,-1,0.020725168,0.9792748
11934,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11934,-1,0.09988669,0.90011334
11935,h,1,2,4,5,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,-1,11935,-1,0.060255624,0.9397444
11938,h,2,3,5,6,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,-1,11938,-1,0.045236826,0.9547631
11941,h,13,14,87,88,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11941,-1,0.093041025,0.906959
11943,adenoma,19,20,126,133,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11943,-1,0.0005270773,0.9994729
11945,GABA,0,1,0,4,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11945,-1,0.9997079,0.000292045
11947,respiratory paralysis,7,9,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11947,-1,0.00014188112,0.99985814
11948,thiopental,11,12,83,93,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11948,-1,0.99993503,6.496222e-05
11949,respiratory paralysis,7,9,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11949,-1,0.00014718343,0.9998528
11950,CNS depressants,11,13,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11950,-1,0.9139389,0.08606118
11952,respiratory paralysis,5,7,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11952,-1,0.00014502615,0.9998549
11953,thiopental,9,10,65,75,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11953,-1,0.999933,6.693459e-05
11954,thiopental,5,6,15,25,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11954,-1,0.9999367,6.325368e-05
11955,GABA,14,15,91,95,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11955,-1,0.999895,0.000105067265
11959,thiosemicarbazide,4,5,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11959,-1,0.99993265,6.736201e-05
11960,thiopental,20,21,139,149,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11960,-1,0.999938,6.194614e-05
11961,thiopental,5,6,15,25,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11961,-1,0.99993587,6.413201e-05
11962,respiratory arrest,7,9,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11962,-1,0.00023113901,0.9997689
11963,GABA,13,14,79,83,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11963,-1,0.99989104,0.00010889524
11965,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11965,-1,0.9998135,0.00018655437
11967,respiratory paralysis,9,11,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11967,-1,0.00019364512,0.99980634
11969,GABA,14,15,73,77,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11969,-1,0.9998869,0.000113111135
11971,respiratory paralysis,5,7,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11971,-1,0.00014345985,0.9998565
11972,thiopental,9,10,71,81,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11972,-1,0.99993896,6.1090075e-05
11973,GABA,12,13,95,99,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11973,-1,0.9999026,9.740477e-05
11978,mg,8,9,45,47,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,-1,11978,-1,0.97536236,0.024637615
11986,chloride channels,25,27,171,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,-1,11986,-1,0.848919,0.15108104
11989,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,-1,11989,-1,0.0001224133,0.9998776
11990,Pneumonitis,0,1,0,11,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11990,-1,0.00011458014,0.99988544
11991,pleural effusions,3,5,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11991,-1,0.00015369675,0.99984634
11992,cardiac tamponade,9,11,72,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11992,-1,0.00015189842,0.9998481
11994,ulcerative colitis,29,31,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11994,-1,0.00010898979,0.99989104
11997,lupus,8,9,59,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11997,-1,0.00011520362,0.9998847
11998,serositis,13,14,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11998,-1,0.00012598865,0.999874
11999,pulmonary parenchymal involvement,15,18,102,135,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11999,-1,0.000120074175,0.99987996
12000,joint symptoms,22,24,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,12000,-1,0.00013104967,0.999869
12002,inflammatory bowel disease,8,11,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,12002,-1,0.00012206839,0.9998779
12003,lupus syndrome,19,21,137,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,12003,-1,0.00010234327,0.9998976
12005,hypokalaemia,4,5,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12005,-1,0.00011719069,0.9998828
12006,chlorthalidone,6,7,47,61,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12006,-1,0.9999368,6.3130086e-05
12007,essential hypertension,11,13,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,12007,-1,0.00012926705,0.99987066
12010,hypokalaemia,9,10,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12010,-1,0.000129326,0.99987066
12011,diuretic,16,17,111,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12011,-1,0.99992204,7.791501e-05
12012,essential hypertension,27,29,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12012,-1,0.00011466059,0.9998853
12013,hypokalaemia,32,33,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12013,-1,0.00012731699,0.9998727
12014,diuretic,36,37,250,258,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,12014,-1,0.99991727,8.274707e-05
12015,Chlorthalidone,0,1,0,14,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,12015,-1,0.9999422,5.786459e-05
12016,mg,3,4,19,21,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,12016,-1,0.9873268,0.012673168
12018,K,11,12,58,59,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,-1,12018,-1,0.9987538,0.00124616
12019,bromide,6,7,34,41,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,-1,12019,-1,0.99708396,0.0029160662
12031,buspirone,5,6,27,36,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,-1,12031,-1,0.99993944,6.050484e-05
12034,buspirone,6,7,41,50,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12034,-1,0.99993837,6.166213e-05
12035,5-hydroxytryptaminergic agonists,9,11,61,93,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,12035,-1,0.9999063,9.3658244e-05
12039,5-HT,5,6,30,34,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,-1,-1,-1,12039,-1,0.9998301,0.000169846
12040,5-HT,5,6,36,40,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,-1,-1,12040,-1,0.9998915,0.00010847613
12042,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12042,-1,0.9998919,0.000108158216
12043,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,12043,-1,0.9999318,6.818649e-05
12044,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12044,-1,0.99992967,7.0348266e-05
12045,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12045,-1,0.999926,7.398305e-05
12046,mg,30,31,184,186,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,12046,-1,0.9916794,0.008320565
12047,P,9,10,63,64,Significant differences between the four groups were detected (P less than 0.001).,2917114_2,-1,-1,-1,12047,-1,0.06513268,0.93486726
12048,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12048,-1,0.9999211,7.894005e-05
12049,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12049,-1,0.99992967,7.031506e-05
12050,bradycardias,26,27,177,189,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,12050,-1,0.000122036385,0.9998779
12051,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,-1,-1,-1,12051,-1,0.9999324,6.754913e-05
12054,folate,17,18,96,102,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,-1,-1,12054,-1,0.9998617,0.00013830698
12055,Folate,0,1,0,6,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,-1,-1,-1,12055,-1,0.9998621,0.00013795712
12057,CBZ,2,3,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,-1,12057,-1,0.999741,0.00025901204
12058,CBZ,11,12,60,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12058,-1,0.99989974,0.000100256184
12059,folate,14,15,77,83,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,12059,-1,0.99986005,0.00013996002
12060,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12060,-1,0.99994195,5.8044647e-05
12062,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,12062,-1,0.00057167164,0.99942833
12064,hexafluorodiethyl ether,3,5,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12064,-1,0.9999224,7.765755e-05
12065,HFDE,6,7,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12065,-1,0.9997718,0.00022818531
12066,CBZ,20,21,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,12066,-1,0.99987376,0.00012628405
12068,CBZ,3,4,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12068,-1,0.9998914,0.00010857247
12069,h,10,11,60,61,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12069,-1,0.30988947,0.6901105
12071,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,12071,-1,0.00046860942,0.9995314
12072,CBZ,1,2,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,-1,-1,-1,12072,-1,0.9998623,0.00013772068
12073,CBZ,3,4,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12073,-1,0.9998987,0.000101347934
12074,folate,10,11,58,64,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12074,-1,0.99986756,0.00013236495
12075,folate,21,22,109,115,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,12075,-1,0.99987197,0.00012806544
12076,myocardial ischemia,1,3,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,-1,-1,-1,12076,-1,0.00010410606,0.99989593
12077,Angina,0,1,0,6,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12077,-1,0.00011769711,0.99988234
12078,ischemic,2,3,11,19,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,12078,-1,0.00012958993,0.9998704
12081,myocardial ischemia,21,23,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12081,-1,0.00010060612,0.9998994
12082,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,12082,-1,0.000118517346,0.9998815
12084,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,-1,12084,-1,0.9999149,8.514848e-05
12088,p,37,38,155,156,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12088,-1,0.03259965,0.9674004
12089,p,48,49,184,185,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12089,-1,0.04195693,0.9580431
12090,p,61,62,217,218,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12090,-1,0.02469072,0.9753093
12093,contrast,92,93,381,389,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12093,-1,0.0018192371,0.99818075
12095,hydralazine,98,99,427,438,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,12095,-1,0.99994516,5.4777942e-05
12098,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12098,-1,0.9999051,9.483555e-05
12099,p,34,35,170,171,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12099,-1,0.035327826,0.9646722
12100,p,53,54,252,253,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,12100,-1,0.33986366,0.6601363
12101,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12101,-1,0.9998957,0.00010434917
12102,n,16,17,95,96,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12102,-1,0.06607868,0.9339213
12103,n,31,32,151,152,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12103,-1,0.053703167,0.9462968
12104,n,42,43,182,183,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,12104,-1,0.04405175,0.95594823
12105,iopentol,3,4,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12105,-1,0.9999417,5.830928e-05
12106,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12106,-1,0.9999454,5.4541193e-05
12107,metrizoate,7,8,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,12107,-1,0.9999404,5.9660553e-05
12108,ventricular fibrillation,2,4,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,-1,-1,-1,12108,-1,0.00010755757,0.9998925
12109,iopentol,14,15,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12109,-1,0.99994314,5.6869612e-05
12110,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12110,-1,0.9999472,5.2854364e-05
12111,metrizoate,18,19,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,12111,-1,0.99993944,6.0528968e-05
12112,iopentol,1,2,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12112,-1,0.9999399,6.007285e-05
12113,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12113,-1,0.999943,5.693815e-05
12114,metrizoate,9,10,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,12114,-1,0.9999387,6.124364e-05
12115,ventricular fibrillation,2,4,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12115,-1,0.00011636011,0.99988365
12116,p,8,9,66,67,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12116,-1,0.077026136,0.92297393
12117,iopentol,14,15,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12117,-1,0.9999471,5.2938904e-05
12118,iohexol,20,21,108,115,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12118,-1,0.9999465,5.3506228e-05
12119,metrizoate,27,28,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,12119,-1,0.9999422,5.7824156e-05
12120,Iopentol,0,1,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12120,-1,0.9999429,5.708924e-05
12121,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12121,-1,0.99994755,5.2397372e-05
12122,decrease in,7,9,54,65,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12122,-1,0.0007671499,0.9992329
12123,blood,10,11,73,78,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12123,-1,0.00058595923,0.9994141
12124,metrizoate,13,14,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,12124,-1,0.99993837,6.1606814e-05
12126,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,-1,-1,12126,-1,0.00018260237,0.99981743
12133,euthyroid,6,7,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,-1,-1,12133,-1,0.00044824104,0.9995517
12137,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,-1,12137,-1,0.2064979,0.7935021
12141,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,-1,-1,-1,12141,-1,0.9999167,8.333497e-05
12144,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,-1,12144,-1,0.9999143,8.571811e-05
12152,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,-1,-1,12152,-1,0.9999175,8.250346e-05
12153,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12153,-1,0.9999201,7.988313e-05
12154,THC,18,19,125,128,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12154,-1,0.99989605,0.00010397213
12156,6-OHDA,28,29,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12156,-1,0.9998041,0.0001959172
12158,6-OHDA,34,35,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,12158,-1,0.999892,0.000108015774
12159,THC,4,5,29,32,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12159,-1,0.9998927,0.00010723805
12160,6-OHDA,12,13,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12160,-1,0.9998965,0.00010344995
12161,of the locus,18,21,112,124,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12161,-1,0.0036677592,0.9963322
12163,6-OHDA,30,31,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,12163,-1,0.9999027,9.724403e-05
12166,6-OHDA,18,19,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12166,-1,0.99990535,9.46193e-05
12167,6-OHDA,25,26,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,12167,-1,0.99989915,0.00010084297
12169,THC,17,18,118,121,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,-1,-1,12169,-1,0.9998752,0.00012481751
12172,azelastine,12,13,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12172,-1,0.99994254,5.745583e-05
12173,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12173,-1,0.99994624,5.3764725e-05
12174,spring allergic rhinitis,22,25,149,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,12174,-1,0.00014619314,0.99985373
12175,Azelastine,0,1,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12175,-1,0.99991345,8.6532316e-05
12176,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12176,-1,0.99993265,6.731501e-05
12177,spring allergic rhinitis,22,25,144,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,12177,-1,0.0001511948,0.9998487
12178,spring allergic rhinitis,19,22,87,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,-1,12178,-1,0.00019034144,0.9998097
12179,azelastine,8,9,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12179,-1,0.9999391,6.0882794e-05
12180,mg,17,18,89,91,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12180,-1,0.99489117,0.005108812
12181,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12181,-1,0.9999435,5.6470948e-05
12182,mg,37,38,205,207,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,12182,-1,0.9965708,0.0034291507
12183,body weights,3,5,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,-1,12183,-1,0.004583409,0.99541664
12184,azelastine,10,11,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12184,-1,0.99994385,5.6144097e-05
12185,mg,13,14,84,86,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,12185,-1,0.9838621,0.016137883
12186,azelastine,3,4,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,-1,-1,-1,12186,-1,0.99994385,5.6182398e-05
12187,contrast,1,2,3,11,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12187,-1,0.0349613,0.9650388
12188,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,12188,-1,0.99994063,5.9389164e-05
12189,Drowsiness,0,1,0,10,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12189,-1,0.00013631629,0.9998636
12190,altered taste perception,2,5,15,39,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12190,-1,0.0002577411,0.9997422
12191,azelastine,14,15,104,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,12191,-1,0.99994314,5.6902165e-05
12192,Azelastine,0,1,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12192,-1,0.9999393,6.072751e-05
12193,seasonal allergic rhinitis,10,13,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,12193,-1,0.00016879351,0.9998312
12194,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12194,-1,0.0001048017,0.9998952
12195,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,12195,-1,0.00011133297,0.99988866
12197,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12197,-1,0.00017300517,0.99982697
12198,deterioration of renal function,20,24,113,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,12198,-1,0.00018214625,0.9998179
12201,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,-1,12201,-1,0.00010514063,0.99989486
12202,HMG CoA,0,2,0,7,HMG CoA reductase inhibitors.,3076126_0,-1,-1,-1,12202,-1,0.9998481,0.00015182585
12205,HMG CoA,16,18,103,110,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,-1,12205,-1,0.99982184,0.00017822371
12210,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,-1,-1,-1,12210,-1,0.9998919,0.000108069646
12212,myoglobinuria,7,8,40,53,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12212,-1,0.0001600068,0.99984
12213,renal failure,15,17,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12213,-1,0.000120966884,0.999879
12215,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12215,-1,0.99991834,8.165143e-05
12216,gemfibrozil,33,34,205,216,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12216,-1,0.9999366,6.338912e-05
12217,niacin,35,36,220,226,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,12217,-1,0.99992776,7.219483e-05
12221,hypercholesterolaemia,18,19,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,-1,12221,-1,0.0001835268,0.9998165
12225,RA,6,7,48,50,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12225,-1,0.00017725179,0.9998228
12228,HLA antigens,30,32,196,208,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,12228,-1,0.65141773,0.34858224
12229,nephritis,7,8,44,53,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12229,-1,0.00010252906,0.9998975
12231,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12231,-1,0.99993205,6.7894514e-05
12233,gold thiosulphate,30,32,180,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12233,-1,0.99989104,0.00010888683
12234,B35,33,34,202,205,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12234,-1,0.99971765,0.00028236394
12235,RA,13,14,81,83,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12235,-1,0.0002964406,0.9997036
12236,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12236,-1,0.9999149,8.5106425e-05
12237,nephritis,19,20,117,126,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12237,-1,0.00010209141,0.99989796
12238,contralateral rotation,1,3,10,32,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12238,-1,0.00027238356,0.99972755
12239,substantia nigra lesion,5,8,54,77,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12239,-1,0.0008366856,0.99916327
12241,6-OHDA,2,3,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12241,-1,0.9998809,0.00011906127
12242,SN lesion,4,6,36,45,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12242,-1,0.00048410398,0.9995159
12243,contralateral rotation,11,13,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12243,-1,0.0003177477,0.9996823
12244,ipsilateral circling,20,22,137,157,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12244,-1,0.00030238705,0.9996977
12245,contralateral rotation,9,11,47,69,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12245,-1,0.00038875634,0.9996113
12246,rotational behavior,27,29,169,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12246,-1,0.00018061792,0.99981946
12247,contralateral rotation,1,3,5,27,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12247,-1,0.0033339362,0.996666
12248,DA,11,12,89,91,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12248,-1,0.9997665,0.0002335185
12249,DA,18,19,128,130,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12249,-1,0.9997534,0.00024661465
12251,contralateral rotation,29,31,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,-1,12251,-1,0.0006459468,0.99935406
12253,rotation,26,27,161,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,-1,12253,-1,0.00023166343,0.9997683
12256,DA,12,13,86,88,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12256,-1,0.9997924,0.00020761903
12257,contralateral rotation,16,18,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12257,-1,0.0011883882,0.9988116
12265,hepatocellular injury,8,10,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,-1,-1,-1,12265,-1,0.00013337116,0.9998666
12266,contrast,1,2,3,11,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,-1,-1,12266,-1,0.027977137,0.9720229
12268,Allergic,0,1,0,8,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,-1,-1,12268,-1,0.00016638794,0.9998336
12281,sulfonylureas,12,13,87,100,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,-1,12281,-1,0.99991775,8.2304425e-05
12282,glyburide,1,2,4,13,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12282,-1,0.99993527,6.472206e-05
12283,sulfonylurea,5,6,35,47,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12283,-1,0.99992335,7.668374e-05
12285,type II diabetes mellitus,3,7,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12285,-1,0.00017942702,0.99982065
12286,glyburide,16,17,112,121,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12286,-1,0.9999267,7.329132e-05
12287,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,-1,12287,-1,0.00072537095,0.9992747
12289,glyburide,6,7,47,56,Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow-up period of 1 year.,3107448_5,-1,-1,-1,12289,-1,0.9999263,7.364771e-05
12290,Glyburide,0,1,0,9,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,-1,-1,-1,12290,-1,0.99993515,6.4877044e-05
12291,Mitomycin C,0,2,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,-1,-1,12291,-1,0.9999323,6.769022e-05
12293,Mitomycin C,0,2,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12293,-1,0.9999354,6.464268e-05
12295,HUS,7,8,50,53,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12295,-1,0.00014134085,0.9998586
12296,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12296,-1,0.0001063111,0.99989367
12298,progressive renal failure,9,12,71,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12298,-1,0.00011433654,0.9998857
12299,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12299,-1,0.9999386,6.1399136e-05
12300,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12300,-1,0.000110203415,0.99988973
12301,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12301,-1,0.99992573,7.4284995e-05
12302,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12302,-1,0.00011182453,0.9998882
12303,pulmonary edema,27,29,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12303,-1,0.00010667455,0.9998933
12304,Renal lesions,0,2,0,13,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12304,-1,0.00016221292,0.99983776
12305,idiopathic HUS,8,10,43,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12305,-1,0.00016584212,0.9998342
12307,ischemic,24,25,158,166,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12307,-1,0.00017462806,0.9998254
12308,gastric adenocarcinoma,14,16,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12308,-1,0.00014406658,0.9998559
12309,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12309,-1,0.00012818079,0.99987185
12311,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12311,-1,0.99993896,6.10131e-05
12312,pulmonary edema,31,33,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12312,-1,0.0001029952,0.999897
12313,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12313,-1,0.9999522,4.776283e-05
12314,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12314,-1,0.000109955174,0.9998901
12315,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12315,-1,0.9999541,4.5938545e-05
12317,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12317,-1,0.00011590962,0.9998841
12320,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,-1,12320,-1,0.9999554,4.4559165e-05
12321,Chlordiazepoxide,0,1,0,16,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,-1,-1,12321,-1,0.999943,5.6966936e-05
12325,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,-1,-1,12325,-1,0.99995434,4.568895e-05
12328,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12328,-1,0.99995315,4.6824058e-05
12330,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12330,-1,0.99995124,4.881066e-05
12331,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,-1,12331,-1,0.00013159112,0.9998684
12332,serotonin antagonists,3,5,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12332,-1,0.9998791,0.00012091824
12334,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12334,-1,0.00014599854,0.99985397
12335,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,-1,12335,-1,0.9998752,0.00012474849
12336,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12336,-1,0.9999095,9.0475594e-05
12337,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12337,-1,0.9999169,8.3067585e-05
12339,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,-1,12339,-1,0.999869,0.0001309751
12342,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,-1,12342,-1,0.99988246,0.0001175642
12343,Chorea,0,1,0,6,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12343,-1,0.00017788791,0.9998222
12344,oral contraception,3,5,23,41,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12344,-1,0.9998369,0.00016308855
12345,chorea,3,4,25,31,Three patients developed chorea while receiving oral contraceptives.,3123611_1,-1,-1,-1,12345,-1,0.00014692303,0.999853
12347,chorea,5,6,30,36,Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued.,3123611_2,-1,-1,-1,12347,-1,0.00014437175,0.99985564
12348,chorea,6,7,48,54,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12348,-1,0.00021819877,0.9997818
12349,oral contraception,9,11,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12349,-1,0.9997489,0.00025112837
12350,chorea,11,12,71,77,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12350,-1,0.00014913341,0.99985087
12351,chorea,19,20,115,121,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12351,-1,0.00016955375,0.99983037
12352,rheumatic fever,21,23,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12352,-1,0.00011533036,0.9998846
12356,normocarbia,7,8,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12356,-1,0.026541425,0.9734586
12357,SE,20,21,96,98,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12357,-1,0.06252813,0.93747187
12363,metocurine,10,11,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,-1,-1,12363,-1,0.9999428,5.720254e-05
12367,retinyl acetate,3,5,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12367,-1,0.99994373,5.629658e-05
12369,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12369,-1,0.99994266,5.7352914e-05
12370,retinyl acetate,5,7,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12370,-1,0.999938,6.2039726e-05
12371,RA,8,9,51,53,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12371,-1,0.9998746,0.00012535974
12372,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12372,-1,0.9999409,5.909331e-05
12373,tumorigenesis,16,17,113,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12373,-1,0.00012629728,0.99987364
12374,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12374,-1,0.9999058,9.412417e-05
12375,drinking water,25,27,112,126,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12375,-1,0.9994081,0.0005919391
12376,RA,29,30,145,147,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12376,-1,0.9998926,0.000107340136
12377,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12377,-1,0.99985814,0.0001418696
12378,RA,25,26,148,150,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12378,-1,0.9998964,0.00010357353
12379,P,28,29,166,167,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12379,-1,0.1503261,0.8496739
12381,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12381,-1,0.00028102673,0.99971896
12385,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12385,-1,0.999828,0.00017203893
12386,RA,7,8,22,24,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12386,-1,0.9998932,0.00010682124
12387,epithelial hyperplasia,32,34,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12387,-1,0.00012179132,0.99987817
12389,papillomas,3,4,12,22,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12389,-1,0.0001609764,0.99983895
12390,RA,17,18,64,66,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12390,-1,0.99988973,0.0001102153
12391,RA,29,30,99,101,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12391,-1,0.999889,0.00011100975
12392,RA,0,1,0,2,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,-1,-1,-1,12392,-1,0.9998319,0.00016803731
12393,RA,4,5,29,31,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12393,-1,0.9998704,0.0001296175
12394,BHA,11,12,64,67,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12394,-1,0.97859573,0.021404287
12397,mitomycin C.Since,11,13,72,89,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12397,-1,0.9717197,0.028280353
12398,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12398,-1,0.99993944,6.0515693e-05
12399,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12399,-1,0.9987796,0.0012204477
12402,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12402,-1,0.00011586298,0.9998841
12403,mg,9,10,55,57,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12403,-1,0.98954725,0.010452693
12404,MMC,11,12,62,65,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12404,-1,0.9995123,0.00048767953
12405,mg,15,16,79,81,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12405,-1,0.9899344,0.010065583
12407,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,-1,12407,-1,0.000115244606,0.9998847
12410,mg,29,30,174,176,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,-1,12410,-1,0.9866224,0.013377649
12413,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,-1,-1,12413,-1,0.00010303087,0.999897
12417,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,-1,12417,-1,0.00011630886,0.99988365
12426,cerebral lesions,1,3,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12426,-1,0.00011670114,0.9998833
12427,tiazofurin,5,6,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12427,-1,0.99993813,6.1833474e-05
12428,MR,8,9,62,64,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12428,-1,0.0037830055,0.99621695
12429,Tiazofurin,0,1,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,-1,12429,-1,0.99993587,6.408798e-05
12430,MR,8,9,47,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12430,-1,0.044339508,0.95566046
12431,cerebral abnormalities,13,15,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12431,-1,0.00010918816,0.9998908
12432,MR,3,4,21,23,The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.,3183120_3,-1,-1,-1,12432,-1,0.032227084,0.9677729
12433,MR,3,4,15,17,The utility of MR in the evaluation of patients receiving this new agent is illustrated.,3183120_4,-1,-1,-1,12433,-1,0.010324673,0.98967534
12435,head and neck carcinoma,5,9,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12435,-1,0.0006899573,0.99931
12436,esophageal carcinoma,10,12,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12436,-1,0.0003394178,0.9996606
12437,5-FU,13,14,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,-1,-1,-1,12437,-1,0.99989927,0.00010074983
12438,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,-1,12438,-1,0.00014366096,0.99985635
12440,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,-1,12440,-1,0.00011521901,0.9998847
12442,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12442,-1,0.00012179655,0.99987817
12443,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12443,-1,0.00012416851,0.9998758
12444,ventricular fibrillation,4,6,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12444,-1,0.00011903085,0.9998809
12445,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12445,-1,0.00016563902,0.9998343
12446,5-FU,6,7,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12446,-1,0.9998952,0.00010483348
12447,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12447,-1,0.00012033482,0.9998796
12448,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12448,-1,0.00010785582,0.9998921
12450,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,-1,-1,12450,-1,0.00019414355,0.99980587
12451,choriocarcinoma,16,17,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,-1,12451,-1,0.00042667496,0.9995733
12455,Actomycin-D,14,15,89,100,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,-1,-1,-1,12455,-1,0.9999219,7.812899e-05
12460,pulmonary obstruction,16,18,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,-1,-1,-1,12460,-1,0.00011538657,0.9998846
12461,tumor necrosis,9,11,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,-1,12461,-1,0.0001279712,0.99987197
12465,embolism,18,19,103,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,-1,-1,12465,-1,0.00012195833,0.99987805
12475,DA,41,42,255,257,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,-1,12475,-1,0.99983895,0.00016104996
12477,DA,27,28,180,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,-1,12477,-1,0.999841,0.00015903833
12480,DA,26,27,187,189,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12480,-1,0.99987006,0.00012990939
12481,DA,32,33,226,228,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12481,-1,0.9998678,0.0001321958
12485,cm H2O,5,7,33,39,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12485,-1,0.9954705,0.004529511
12486,P,10,11,60,61,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12486,-1,0.28756574,0.71243423
12487,decreased arterial blood pressure,15,19,77,110,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12487,-1,0.00073494465,0.999265
12488,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12488,-1,0.95719194,0.042808045
12490,decrease in arterial blood pressure,10,15,65,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12490,-1,0.00087885687,0.9991211
12491,increased heart rate,17,20,119,139,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12491,-1,0.0003779653,0.999622
12492,decreased cardiac output,21,24,144,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12492,-1,0.00045479473,0.99954516
12494,decreases in arterial blood pressure and systemic vascular resistance,3,12,33,102,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12494,-1,0.0003658651,0.99963415
12495,increases in,13,15,107,119,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12495,-1,0.0015565442,0.9984434
12496,rate,16,17,126,130,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12496,-1,0.00056787505,0.99943215
12497,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,-1,12497,-1,0.8036348,0.19636516
12499,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,-1,12499,-1,0.998744,0.0012559671
12502,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12502,-1,0.9981402,0.0018598064
12503,decreases in arterial blood pressure and cardiac output,31,39,172,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12503,-1,0.00042795666,0.9995721
12504,hypokalemia,3,4,39,50,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,-1,-1,-1,12504,-1,0.000105850144,0.99989414
12507,hypokalemia,12,13,66,77,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12507,-1,0.000100587116,0.9998994
12508,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12508,-1,0.99994695,5.3054537e-05
12512,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,-1,12512,-1,0.99993944,6.0569735e-05
12515,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,-1,-1,12515,-1,0.99992836,7.16448e-05
12516,ergot,6,7,31,36,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12516,-1,0.99989986,0.00010014592
12517,gangrene,15,16,87,95,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12517,-1,0.00013354653,0.9998665
12518,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12518,-1,0.00011845293,0.9998815
12519,calcium channel blockers,4,7,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12519,-1,0.999887,0.00011302198
12520,ergot,11,12,80,85,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12520,-1,0.99991965,8.033492e-05
12536,mm Hg,7,9,43,48,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12536,-1,0.009282452,0.9907176
12538,HEM,16,17,86,89,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12538,-1,0.0005441964,0.99945575
12539,n,18,19,91,92,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12539,-1,0.017301345,0.9826987
12541,SNP,30,31,149,152,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12541,-1,0.99987555,0.00012438881
12542,n,32,33,154,155,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12542,-1,0.048292287,0.9517077
12544,SNP,19,20,140,143,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,-1,-1,12544,-1,0.99984,0.00015994486
12546,mm Hg,9,11,44,49,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12546,-1,0.004917025,0.995083
12547,HEM,13,14,57,60,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12547,-1,0.99220896,0.007790987
12548,mm Hg,22,24,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12548,-1,0.0038855723,0.9961144
12549,SNP,26,27,107,110,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12549,-1,0.9996433,0.00035664253
12550,P,29,30,118,119,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12550,-1,0.036662966,0.96333706
12551,mm Hg,27,29,117,122,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12551,-1,0.0031932492,0.99680674
12552,HEM,31,32,130,133,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12552,-1,0.9990939,0.0009061106
12553,SNP,33,34,138,141,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12553,-1,0.99973005,0.00026998552
12555,P,41,42,184,185,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12555,-1,0.04838368,0.9516163
12557,hypovolemia,7,8,45,56,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,-1,-1,12557,-1,0.00011233614,0.9998877
12559,Ventricular tachyarrhythmias,0,2,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12559,-1,0.00012677595,0.99987316
12560,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12560,-1,0.99994195,5.8034464e-05
12561,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12561,-1,0.999943,5.7008183e-05
12562,preterm labor,8,10,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12562,-1,0.000146287,0.99985373
12563,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12563,-1,0.9999441,5.5869627e-05
12564,cardiovascular complications,6,8,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12564,-1,0.00012155081,0.9998784
12565,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12565,-1,0.9999423,5.765176e-05
12571,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,-1,12571,-1,0.22722672,0.7727733
12572,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,-1,12572,-1,0.22043908,0.7795609
12579,Ethopropazine,0,1,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12579,-1,0.99994695,5.305944e-05
12580,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12580,-1,0.999936,6.401078e-05
12582,ethopropazine,5,6,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12582,-1,0.999949,5.1075414e-05
12583,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12583,-1,0.9999399,6.005108e-05
12587,Ethopropazine,0,1,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12587,-1,0.99995315,4.6808877e-05
12588,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12588,-1,0.99994004,5.9948554e-05
12590,procyclidine,18,19,129,141,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12590,-1,0.99995077,4.9194776e-05
12591,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12591,-1,0.99994075,5.923605e-05
12592,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12592,-1,0.00010426362,0.9998957
12593,procyclindine,17,18,122,135,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12593,-1,0.999948,5.20249e-05
12594,anxiety,23,24,170,177,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12594,-1,0.00012615023,0.9998739
12596,ethopropazine,27,28,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12596,-1,0.999949,5.1007846e-05
12597,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12597,-1,0.9999386,6.133394e-05
12598,parkinsonian symptoms,16,18,113,134,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12598,-1,9.807088e-05,0.9999019
12601,renal and hepatic failure,6,10,49,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12601,-1,0.000158906,0.9998411
12603,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12603,-1,0.00012034182,0.9998796
12604,hepatic failure,10,12,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12604,-1,0.000115394825,0.9998846
12611,osteoarthritis,16,17,116,130,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12611,-1,0.00014302605,0.99985695
12612,spondyloarthropathy,18,19,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12612,-1,0.0002451048,0.99975485
12614,Sexual dysfunctions,0,2,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12614,-1,0.00022593727,0.99977404
12615,Impotence,0,1,0,9,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,-1,12615,-1,0.00088869105,0.99911124
12617,Depressed mood,0,2,0,14,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12617,-1,0.00017983824,0.9998202
12618,sexual difficulties,12,14,78,97,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12618,-1,0.00022786051,0.99977213
12619,impotence,18,19,112,121,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12619,-1,0.0013435762,0.9986564
12622,Quinidine,0,1,0,9,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12622,-1,0.99991834,8.1618884e-05
12623,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12623,-1,0.00025794518,0.9997421
12624,Laotian,7,8,36,43,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12624,-1,0.8446895,0.1553105
12625,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12625,-1,0.00021049635,0.99978954
12626,quinidine phenylethylbarbiturate,25,27,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12626,-1,0.9999304,6.957496e-05
12627,Quinidine,0,1,0,9,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12627,-1,0.99993086,6.912038e-05
12628,phenylethylbarbiturate,3,4,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12628,-1,0.99993205,6.7922294e-05
12629,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12629,-1,0.00015910187,0.99984086
12631,urothelial cancer,3,5,23,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12631,-1,0.00015850618,0.99984145
12632,renal papillary necrosis?The,6,9,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12632,-1,0.0054751085,0.99452496
12640,ureteric cancer,31,33,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,-1,-1,12640,-1,0.00015957317,0.9998404
12641,contrast,1,2,3,11,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12641,-1,0.04933349,0.9506665
12645,cancer of the ureter,32,36,199,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12645,-1,0.00048683467,0.99951315
12646,myocardial ischemia,2,4,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,-1,-1,12646,-1,0.000109741275,0.9998902
12650,myocardial ischemia,6,8,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12650,-1,0.00010673622,0.9998933
12651,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12651,-1,0.00015792913,0.99984205
12656,myocardial ischemia,5,7,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12656,-1,0.00010945514,0.99989057
12658,angina,14,15,101,107,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12658,-1,0.000115553274,0.9998845
12659,myocardial ischemia,5,7,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,-1,-1,-1,12659,-1,0.00010996995,0.99988997
12661,myocardial ischemia,1,3,17,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,-1,12661,-1,0.000114673494,0.9998853
12666,hemoglobin E,10,12,73,85,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,-1,12666,-1,0.99453235,0.005467579
12667,hemoglobin E,4,6,23,35,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12667,-1,0.23208998,0.76791006
12668,leprosy,11,12,51,58,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12668,-1,0.0004055249,0.9995945
12672,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12672,-1,0.9997181,0.00028188166
12673,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12673,-1,0.9998455,0.00015453024
12674,GSH,23,24,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12674,-1,0.99983644,0.00016352987
12675,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,-1,-1,-1,12675,-1,0.99986994,0.00013001844
12677,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12677,-1,0.9998429,0.00015710006
12678,GSH,21,22,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12678,-1,0.9998386,0.00016142109
12679,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,-1,-1,-1,12679,-1,0.999869,0.00013095285
12683,thymidylate synthase,7,9,49,69,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12683,-1,0.9998417,0.00015824144
12684,"N10-propargyl-5,8-dideazafolic acid",10,12,80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12684,-1,0.99983656,0.00016342591
12685,"N10-propargyl-5,8-dideazafolic acid",17,19,135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12685,-1,0.99978226,0.00021780324
12686,thymidylate synthase,25,27,204,224,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12686,-1,0.9996202,0.00037975635
12687,TS,28,29,226,228,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12687,-1,0.97689635,0.023103671
12688,cytotoxicity,31,32,236,248,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12688,-1,0.00021093833,0.99978906
12689,CB 3717,10,12,74,81,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,-1,12689,-1,0.999762,0.00023798514
12690,CB 3717,24,26,133,140,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,-1,12690,-1,0.9998129,0.0001871223
12691,TS,5,6,32,34,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12691,-1,0.09455469,0.90544534
12692,CB 3717,7,9,36,43,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12692,-1,0.9997688,0.00023121946
12693,CB 3717,27,29,130,137,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12693,-1,0.99980515,0.00019488485
12694,CB 3717 cytotoxicity,44,47,220,240,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12694,-1,0.16806306,0.8319369
12695,CB 3717,5,7,31,38,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12695,-1,0.9997255,0.0002744565
12698,hepatoma,19,20,97,105,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12698,-1,0.0001993986,0.9998006
12699,mesothelioma,22,23,111,123,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12699,-1,0.0001776882,0.9998223
12702,malaise,4,5,36,43,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,-1,-1,12702,-1,0.00040529997,0.99959475
12704,CB 3717,23,25,124,131,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,-1,12704,-1,0.99964833,0.0003517101
12705,CB 3717,12,14,60,67,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,-1,12705,-1,0.9998053,0.00019476691
12709,malaise,2,3,19,26,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,-1,-1,12709,-1,0.0009144629,0.99908555
12710,CB 3717,10,12,80,87,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,-1,12710,-1,0.999645,0.00035502156
12711,Type B hepatitis,0,3,0,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12711,-1,0.00042007296,0.99957997
12712,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12712,-1,0.9439451,0.05605483
12713,Hepatitis B,0,2,0,11,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12713,-1,0.1615068,0.8384932
12714,type B hepatitis,29,32,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12714,-1,0.00024179142,0.9997582
12715,hepatitis B surface antigen,36,40,215,242,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12715,-1,0.9309425,0.06905755
12717,P,16,17,76,77,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12717,-1,0.0614512,0.93854874
12718,P,37,38,167,168,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12718,-1,0.035038475,0.96496147
12719,e,12,13,65,66,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12719,-1,0.99898535,0.001014647
12720,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12720,-1,0.9997178,0.0002821575
12721,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,-1,12721,-1,0.9998795,0.00012054983
12722,Hepatitis B,0,2,0,11,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12722,-1,0.0046399473,0.9953601
12723,type B hepatitis,11,14,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12723,-1,0.00024570213,0.99975425
12724,type B hepatitis,6,9,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,-1,-1,12724,-1,0.00022310558,0.9997769
12726,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,-1,12726,-1,0.9999503,4.9710223e-05
12729,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12729,-1,0.0002594564,0.99974054
12731,AV block,0,2,0,8,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12731,-1,0.00018577723,0.9998142
12733,impairment of ventricular function,7,11,34,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12733,-1,0.00025260088,0.99974734
12735,mg,14,15,77,79,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12735,-1,0.9864531,0.01354688
12736,mg,20,21,100,102,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12736,-1,0.98571694,0.014283089
12738,mg,7,8,40,42,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,-1,-1,-1,12738,-1,0.97300255,0.026997507
12743,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,-1,12743,-1,0.9999502,4.9846647e-05
12745,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,-1,12745,-1,0.00038653644,0.99961346
12748,prostate adenocarcinomas,15,17,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12748,-1,0.00021352606,0.99978644
12749,PAs,18,19,101,104,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12749,-1,0.0008665052,0.9991335
12750,testosterone propionate,34,36,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12750,-1,0.9998938,0.00010619479
12751,TP,38,39,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12751,-1,0.9996995,0.00030054356
12752,PA,12,13,67,69,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12752,-1,0.00074344996,0.99925655
12753,TP,17,18,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12753,-1,0.99983203,0.00016787939
12754,TP,4,5,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,-1,12754,-1,0.9997768,0.00022319065
12757,bromperidol,8,9,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12757,-1,0.99993825,6.175263e-05
12758,blind,22,23,112,117,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12758,-1,0.033760663,0.96623933
12760,mg,17,18,82,84,The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets.,347884_2,-1,-1,-1,12760,-1,0.9009932,0.0990068
12761,mg,8,9,32,34,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12761,-1,0.9578665,0.042133525
12762,mg,20,21,76,78,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12762,-1,0.9623571,0.037642892
12763,extrapyramidal concomitant symptoms,6,9,41,76,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,-1,-1,12763,-1,0.00017057358,0.9998294
12764,blind,3,4,14,19,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12764,-1,0.045400385,0.9545996
12766,psychotic syndromes,20,22,114,133,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12766,-1,0.000109054134,0.9998909
12768,bromperidol,17,18,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,-1,12768,-1,0.9999354,6.456289e-05
12770,acute hepatitis,4,6,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,-1,12770,-1,0.00010589528,0.99989414
12774,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12774,-1,0.9999157,8.429036e-05
12775,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12775,-1,0.00031718868,0.9996828
12779,alkaline phosphatase,19,21,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,-1,-1,12779,-1,0.9998685,0.00013141907
12783,acute hepatitis,9,11,91,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,-1,12783,-1,0.0001052299,0.99989474
12784,auditory neurotoxicity,3,5,18,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,-1,-1,12784,-1,0.00012132604,0.99987864
12786,auditory neurotoxicity,2,4,11,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,-1,-1,12786,-1,0.0001493188,0.99985063
12790,abnormal audiograms,7,9,46,65,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12790,-1,0.00036379724,0.9996362
12791,"deficits mostly in the high frequency range of 4,000 to 8,000 Hz",10,22,71,135,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12791,-1,0.019650962,0.9803491
12794,auditory abnormality,41,43,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,-1,-1,12794,-1,0.00015410999,0.99984586
12802,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,-1,-1,12802,-1,0.00015572853,0.9998442
12803,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,-1,12803,-1,0.00016134736,0.9998386
12805,netilmicin,5,6,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,-1,12805,-1,0.9999298,7.023679e-05
12807,netilmicin sulfate,8,10,53,71,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12807,-1,0.99993277,6.722725e-05
12808,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12808,-1,0.999918,8.205693e-05
12809,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12809,-1,0.99994147,5.8537033e-05
12812,netilmicin,10,11,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,-1,12812,-1,0.9999238,7.617864e-05
12815,netilmicin,10,11,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12815,-1,0.999933,6.6962486e-05
12816,piperacillin,12,13,57,69,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12816,-1,0.9999424,5.7559857e-05
12818,netilmicin,10,11,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,-1,12818,-1,0.9999168,8.318903e-05
12820,netilmicin,34,35,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,-1,12820,-1,0.999913,8.695964e-05
12823,netilmicin,13,14,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,-1,-1,12823,-1,0.9999323,6.772348e-05
12828,bradyarrhythmias,16,17,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,-1,-1,-1,12828,-1,0.00010316478,0.9998969
12830,Flurbiprofen,0,1,0,12,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12830,-1,0.9999175,8.2513056e-05
12831,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12831,-1,0.00013543268,0.9998646
12832,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12832,-1,0.000112027104,0.99988794
12833,flurbiprofen,11,12,79,91,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12833,-1,0.999938,6.194903e-05
12835,tender joints,7,9,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12835,-1,0.0001385213,0.9998615
12836,swelling,13,14,71,79,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12836,-1,0.000130121,0.9998698
12837,tenderness,15,16,84,94,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12837,-1,0.00012639705,0.99987364
12838,stiffness,28,29,146,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12838,-1,0.00012042804,0.9998796
12839,fecal occult blood,7,10,45,63,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12839,-1,0.0005085687,0.99949145
12840,gastrointestinal (GI) bleeding,25,30,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12840,-1,0.00024681434,0.9997532
12842,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,-1,-1,12842,-1,0.00011654156,0.9998834
12846,antiinflammatory agents,10,12,76,99,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12846,-1,0.9998148,0.00018520243
12847,NSAID,13,14,101,106,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12847,-1,0.99990606,9.397235e-05
12850,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,-1,12850,-1,0.999858,0.00014198195
12859,NSAID,19,20,123,128,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,-1,12859,-1,0.9999174,8.2581064e-05
12862,sodium pentothal,9,11,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12862,-1,0.99991405,8.595991e-05
12863,ischaemia,17,18,123,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12863,-1,0.00011363525,0.9998864
12865,gangrene,4,5,34,42,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,-1,-1,12865,-1,0.00013301669,0.99986696
12878,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,-1,12878,-1,0.08612896,0.91387105
12879,Cephalosporin,0,1,0,13,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12879,-1,0.99992466,7.534637e-05
12880,hematologic disturbances,6,8,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12880,-1,0.00011181344,0.9998882
12881,blood dyscrasias,12,14,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,-1,12881,-1,0.000492973,0.99950707
12889,cytopenias,9,10,58,68,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,-1,-1,12889,-1,0.00010616704,0.9998938
12892,cytopenias,2,3,10,20,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,-1,-1,-1,12892,-1,0.00012887987,0.99987113
12893,cephalosporin,4,5,29,42,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12893,-1,0.99994564,5.431826e-05
12894,hematologic syndrome,7,9,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12894,-1,0.00010536896,0.9998946
12896,hemolytic,22,23,117,126,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12896,-1,0.00013484817,0.9998652
12897,cytopenia,38,39,241,250,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12897,-1,0.00013525225,0.9998647
12900,hematotoxicity,16,17,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12900,-1,9.9808036e-05,0.9999002
12901,blood dyscrasias,21,23,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12901,-1,0.0001559202,0.9998441
12902,injury to,8,10,54,63,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12902,-1,0.0013271365,0.99867284
12903,regions of the kidney,11,15,74,95,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12903,-1,0.0035787753,0.9964212
12905,hexachloro-1:3-butadiene,24,25,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12905,-1,0.9998925,0.00010757398
12906,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12906,-1,0.9994942,0.0005057671
12907,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12907,-1,0.99992895,7.100613e-05
12908,PAN,32,33,207,210,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12908,-1,0.99972624,0.0002737932
12909,2-bromoethylamine,36,37,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12909,-1,0.99991465,8.53938e-05
12910,BEA,38,39,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12910,-1,0.9997727,0.00022723567
12912,phosphatase,9,10,67,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12912,-1,0.99961394,0.00038609377
12913,protein excretion,18,20,142,159,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12913,-1,0.0070307376,0.9929692
12914,Tubular damage,0,2,0,14,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12914,-1,0.00013774839,0.9998622
12915,HCBD,4,5,27,31,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12915,-1,0.9998247,0.00017534754
12916,BEA,6,7,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12916,-1,0.9997806,0.0002193684
12917,glomerular damage,14,16,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12917,-1,0.00013320264,0.9998667
12918,PAN,18,19,130,133,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12918,-1,0.9993988,0.0006011967
12919,protein excretion,9,11,57,74,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12919,-1,0.018789344,0.9812106
12920,Da,20,21,138,140,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12920,-1,0.96322876,0.036771223
12921,contrast,1,2,3,11,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12921,-1,0.024914222,0.97508574
12922,protein excretion,3,5,13,30,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12922,-1,0.026618412,0.9733815
12923,tubular damage,6,8,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12923,-1,0.00015875697,0.9998412
12924,excretion,15,16,95,104,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12924,-1,0.00058537984,0.9994147
12925,proteins,17,18,108,116,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12925,-1,0.9985875,0.0014125198
12926,Proximal tubular damage,0,3,0,23,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12926,-1,0.00018251169,0.99981755
12927,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12927,-1,0.021309577,0.9786904
12928,papillary damage,7,9,43,59,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12928,-1,0.00016312371,0.9998368
12929,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12929,-1,0.30625084,0.6937491
12930,Alkaline phosphatase,0,2,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12930,-1,0.99989736,0.0001025804
12932,proximal tubular damage,10,13,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12932,-1,0.00020716699,0.9997929
12933,papillary damage,20,22,165,181,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12933,-1,0.00015906742,0.99984086
12935,Reye,4,5,15,19,A catch in the Reye.,3670965_0,-1,-1,-1,12935,-1,0.1318468,0.86815315
12936,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,-1,12936,-1,0.00040243805,0.9995976
12937,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,-1,12937,-1,0.0011204196,0.9988796
12939,salicylate,2,3,11,21,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,-1,-1,-1,12939,-1,0.9999262,7.373245e-05
12943,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,-1,-1,12943,-1,0.00035876327,0.9996412
12944,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,-1,12944,-1,0.00044310227,0.99955684
12945,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,-1,12945,-1,0.0006949172,0.9993051
12949,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12949,-1,0.00038212846,0.9996178
12950,salicylates,14,15,90,101,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12950,-1,0.99991834,8.163617e-05
12953,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,-1,-1,12953,-1,0.00012039899,0.9998796
12956,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,-1,12956,-1,0.00015729477,0.99984264
12957,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,-1,12957,-1,0.00017588118,0.9998241
12959,nitrous oxide,15,17,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,-1,12959,-1,0.9998958,0.00010415888
12962,MAP,5,6,37,40,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12962,-1,0.0014650724,0.9985349
12963,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12963,-1,0.0051157144,0.9948843
12968,psychosis,1,2,11,20,Postpartum psychosis induced by bromocriptine.,3686155_0,-1,-1,-1,12968,-1,0.000109208464,0.9998908
12971,psychosis,12,13,86,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12971,-1,0.0001033014,0.99989665
12973,inhibition of lactation,18,21,131,154,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12973,-1,0.006287864,0.9937122
12975,psychosis,9,10,59,68,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12975,-1,0.00011423824,0.9998858
12976,Parkinson's disease,16,19,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12976,-1,0.00023419946,0.9997658
12978,psychosis,7,8,53,62,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,-1,-1,-1,12978,-1,0.00010881491,0.99989116
12979,mania,5,6,46,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,-1,12979,-1,0.00015237191,0.99984765
12981,triazolam,3,4,15,24,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12981,-1,0.99993896,6.100001e-05
12982,mania,9,10,62,67,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12982,-1,0.00016026286,0.99983966
12984,organic mental disorder,2,5,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,-1,-1,12984,-1,0.00020776657,0.9997923
12987,triazolam,10,11,63,72,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,-1,-1,12987,-1,0.9999286,7.142378e-05
12988,triazolo,5,6,33,41,The possible contribution of the triazolo group to changes in affective status is discussed.,3693336_4,-1,-1,-1,12988,-1,0.9998603,0.0001396968
12989,Hyperglycemic,0,1,0,13,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,-1,-1,12989,-1,0.0005672874,0.99943274
12993,lethargy,10,11,65,73,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12993,-1,0.00013387177,0.9998661
12996,polyphagia,17,18,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12996,-1,0.00023225417,0.9997677
13000,hyperglycemia,13,14,77,90,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,-1,-1,13000,-1,0.000119578624,0.99988043
13002,lactic acidosis,1,3,11,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13002,-1,0.00064266735,0.9993573
13003,ketosis,8,9,50,57,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13003,-1,0.00037069246,0.99962926
13004,lactate,13,14,80,87,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,13004,-1,0.99983776,0.0001622069
13005,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,-1,-1,13005,-1,0.00015302391,0.99984694
13006,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,-1,13006,-1,0.012663739,0.9873362
13008,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,-1,13008,-1,0.9998604,0.00013955194
13010,CSA,4,5,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,-1,-1,-1,13010,-1,0.99988985,0.00011009869
13011,CSA,4,5,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13011,-1,0.9998795,0.00012053431
13014,amphothericin B,23,25,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13014,-1,0.9999194,8.0592414e-05
13016,CSA,40,41,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,13016,-1,0.9998492,0.00015073777
13019,CSA nephrotoxicity,8,10,46,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,-1,13019,-1,0.0035867216,0.9964133
13021,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,-1,13021,-1,0.9998486,0.00015136244
13023,neuropathic damage,8,10,75,93,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,-1,13023,-1,0.00010091839,0.999899
13024,neuropathic damage,3,5,24,42,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13024,-1,0.00010302518,0.999897
13027,Mipafox,24,25,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13027,-1,0.9998754,0.00012452672
13028,"N, N'-diisopropylphosphorodiamidofluoridate",26,29,164,207,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13028,-1,0.99982786,0.00017211669
13029,neurotoxic organophosphate,32,34,212,238,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,13029,-1,0.830362,0.16963795
13030,Mipafox,19,20,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,-1,13030,-1,0.9999273,7.2743824e-05
13031,cord damage,8,10,63,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,-1,13031,-1,0.00014554997,0.99985445
13032,cord,50,51,242,246,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,-1,-1,13032,-1,0.00019097098,0.9998091
13033,contrast,1,2,3,11,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13033,-1,0.06769122,0.9323088
13034,Mipafox,5,6,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13034,-1,0.9999263,7.362243e-05
13035,cord damage,43,45,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,13035,-1,0.00014577317,0.9998542
13036,Mipafox,18,19,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13036,-1,0.99992824,7.179651e-05
13037,neuropathic damage,22,24,141,159,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,13037,-1,0.00010745066,0.9998926
13041,angioneurotic edema,5,7,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13041,-1,0.00011043537,0.9998895
13043,carcinoma of the oral cavity,18,23,140,168,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13043,-1,0.00034913357,0.99965084
13045,impaired renal function,28,31,203,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,13045,-1,0.00016055409,0.9998394
13046,diphenhydramine,1,2,5,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,-1,-1,13046,-1,0.9999373,6.2647436e-05
13049,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,-1,-1,13049,-1,0.00014068281,0.99985933
13050,Diuretics,0,1,0,9,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13050,-1,0.9999105,8.954971e-05
13053,hypertensive coronary disease,6,9,40,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,13053,-1,0.00013798606,0.99986196
13056,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,-1,-1,13056,-1,0.00022234023,0.9997776
13057,essential hypertension,11,13,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13057,-1,0.00013511485,0.9998648
13058,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13058,-1,0.00014834582,0.9998516
13059,diuretic,26,27,188,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13059,-1,0.999915,8.4993204e-05
13061,diuretic,37,38,252,260,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13061,-1,0.9999131,8.695202e-05
13062,chlorthalidone,39,40,262,276,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,13062,-1,0.9999435,5.6501813e-05
13064,chlorthalidone,11,12,74,88,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,-1,-1,-1,13064,-1,0.9999336,6.644827e-05
13069,chlorthalidone,6,7,37,51,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13069,-1,0.9999391,6.086166e-05
13070,ventricular ectopic beats,15,18,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,13070,-1,0.00014553429,0.99985445
13071,diuretic,7,8,57,65,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13071,-1,0.99993,6.996004e-05
13072,ischaemic heart disease,17,20,139,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,13072,-1,0.00013437067,0.99986565
13074,Myasthenia gravis,0,2,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,-1,-1,13074,-1,0.00016967246,0.99983025
13078,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,-1,-1,13078,-1,0.00013071169,0.9998692
13083,Wernicke's encephalopathy,4,7,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,-1,13083,-1,0.0007204414,0.99927956
13085,Wernicke's encephalopathy,16,19,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13085,-1,0.00046871236,0.99953127
13086,tolazamide,22,23,152,162,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13086,-1,0.99994564,5.4380824e-05
13087,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13087,-1,0.99992764,7.2393246e-05
13088,TPP,42,43,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,13088,-1,0.99980134,0.00019872199
13090,Wernicke's encephalopathy,19,22,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,-1,13090,-1,0.0027824647,0.99721754
13092,Wernicke's encephalopathy,16,19,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13092,-1,0.01495765,0.9850424
13093,TPP,28,29,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,13093,-1,0.99975663,0.00024334628
13094,Wernicke's encephalopathy,14,17,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,-1,13094,-1,0.0006089714,0.99939096
13096,trihexyphenidyl hydrochloride,3,5,19,48,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,-1,-1,13096,-1,0.9999219,7.810948e-05
13098,trihexyphenidyl hydrochloride,11,13,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,-1,13098,-1,0.9999311,6.8913985e-05
13105,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,-1,13105,-1,0.0001436707,0.99985635
13109,diethylnitrosamine,7,8,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,-1,-1,-1,13109,-1,0.99991715,8.2865045e-05
13111,PB,15,16,85,87,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13111,-1,0.999584,0.00041601554
13112,mg,18,19,92,94,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13112,-1,0.92492396,0.075076014
13114,diethylnitrosamine,33,34,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13114,-1,0.9999143,8.568689e-05
13115,DEN,35,36,203,206,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,13115,-1,0.99934894,0.000650997
13116,DEN,9,10,36,39,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13116,-1,0.99981886,0.00018113031
13117,DEN,13,14,52,55,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13117,-1,0.99981457,0.00018551367
13118,PB,15,16,58,60,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13118,-1,0.9997911,0.0002089307
13119,hepatocarcinogenesis,28,29,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,13119,-1,0.00013070757,0.9998692
13120,PAS,14,15,67,70,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13120,-1,0.9757923,0.024207775
13121,preneoplastic foci,16,18,80,98,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13121,-1,0.00046961624,0.99953043
13122,PB,22,23,130,132,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13122,-1,0.99950135,0.00049864926
13123,DEN,27,28,163,166,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,13123,-1,0.9995895,0.00041046645
13124,micronuclei,7,8,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13124,-1,0.00034252557,0.9996575
13125,DEN,14,15,104,107,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13125,-1,0.9997998,0.00020017447
13126,DEN,22,23,158,161,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13126,-1,0.99981517,0.00018485592
13127,PB,24,25,164,166,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,13127,-1,0.9998216,0.0001784708
13128,PB,11,12,54,56,"When the treatment last only 2 weeks, the presence of PB did not change significantly the last parameters.",3780814_5,-1,-1,-1,13128,-1,0.01840638,0.98159367
13129,DEN,1,2,3,6,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13129,-1,0.9997707,0.0002293033
13130,PB,3,4,9,11,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13130,-1,0.99972695,0.00027305077
13132,DEN,23,24,128,131,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,13132,-1,0.9997646,0.00023541467
13133,PB,4,5,21,23,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13133,-1,0.9997943,0.0002057426
13135,DEN,13,14,83,86,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13135,-1,0.99978787,0.00021215988
13136,DEN,24,25,159,162,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,13136,-1,0.9998093,0.00019074569
13137,precancerous lesions,17,19,88,108,This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.,3780814_8,-1,-1,-1,13137,-1,0.00023354008,0.9997664
13138,PB,14,15,95,97,Biochemical investigations are in progress to obtain more information about this 'paradoxical' PB effect.,3780814_9,-1,-1,-1,13138,-1,0.99970144,0.00029849412
13139,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,-1,-1,13139,-1,0.00012391373,0.999876
13141,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,-1,-1,13141,-1,0.00011056245,0.9998894
13146,h,13,14,63,64,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,-1,-1,13146,-1,0.21029134,0.7897087
13152,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13152,-1,0.00018788787,0.9998122
13153,K,28,29,158,159,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,13153,-1,0.013670897,0.98632914
13163,molindone,6,7,43,52,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,-1,-1,13163,-1,0.99993324,6.675834e-05
13166,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,-1,-1,13166,-1,0.00022912584,0.99977094
13170,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13170,-1,0.00012148361,0.9998785
13171,molindone,18,19,130,139,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,13171,-1,0.9999248,7.52579e-05
13172,molindone,3,4,25,34,Physicians who prescribe molindone should be aware of this reaction.,3782049_4,-1,-1,-1,13172,-1,0.9999294,7.055525e-05
13173,Compression neuropathy,0,2,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13173,-1,0.00012485785,0.99987507
13174,fibrous myopathy,9,11,70,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,13174,-1,0.000116755116,0.9998832
13175,Fibrous myopathy,0,2,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,-1,-1,13175,-1,0.0001317404,0.9998683
13177,compression neuropathy,2,4,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,-1,-1,13177,-1,0.00011998157,0.99987996
13179,fibrous myopathy,7,9,59,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13179,-1,0.00012452065,0.9998754
13180,fibrous myopathy,49,51,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,13180,-1,0.0001168733,0.99988306
13181,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13181,-1,0.00012625492,0.99987376
13182,amphotericin,6,7,46,58,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,13182,-1,0.99993634,6.364558e-05
13184,sporotrichosis,7,8,54,68,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13184,-1,0.00030516734,0.9996948
13185,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13185,-1,0.00012185429,0.99987817
13186,amphotericin B,17,19,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,13186,-1,0.99993086,6.909e-05
13187,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,-1,-1,13187,-1,0.00012300537,0.999877
13189,amphotericin,3,4,16,28,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13189,-1,0.9999473,5.2646796e-05
13190,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,13190,-1,0.00012383873,0.99987614
13191,Cerebral infarction,0,2,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13191,-1,0.000119898774,0.9998801
13192,phenylpropanolamine,8,9,47,66,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,13192,-1,0.9999398,6.0169736e-05
13193,Phenylpropanolamine,0,1,0,19,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13193,-1,0.9999429,5.7128455e-05
13194,PPA,2,3,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,13194,-1,0.9996629,0.00033717294
13197,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13197,-1,0.000120158475,0.99987984
13198,neuropsychiatric symptoms,14,16,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13198,-1,0.0001195035,0.99988043
13199,cerebral infarction,19,21,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,13199,-1,0.000111346664,0.99988866
13200,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13200,-1,0.00010898927,0.99989104
13201,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,13201,-1,0.9998286,0.00017135752
13202,optic neuropathy,1,3,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13202,-1,0.00011223356,0.9998877
13203,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,13203,-1,0.9999417,5.8311507e-05
13205,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,-1,-1,-1,13205,-1,0.9999453,5.4742228e-05
13207,retrobulbar neuropathy,2,4,12,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13207,-1,0.00021484654,0.9997851
13208,scotoma,10,11,81,88,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,13208,-1,0.00014450355,0.9998555
13209,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,-1,-1,-1,13209,-1,0.99993575,6.423569e-05
13211,optic nerve toxicity,3,6,15,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13211,-1,0.00013925009,0.99986076
13212,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,13212,-1,0.9999423,5.7642854e-05
13213,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,-1,-1,-1,13213,-1,0.99994516,5.4856566e-05
13215,meningeal leukemia,3,5,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,-1,-1,-1,13215,-1,0.00014721318,0.9998528
13218,meningeal disease,8,10,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,13218,-1,0.00015617778,0.99984384
13222,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,-1,13222,-1,0.9999316,6.842639e-05
13230,hemiparesis,7,8,45,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,-1,-1,13230,-1,0.0001370472,0.9998629
13233,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13233,-1,0.99991846,8.154638e-05
13234,antineoplastic agents,5,7,34,55,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,13234,-1,0.99689084,0.0031092288
13236,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13236,-1,0.99992216,7.785596e-05
13237,leukemia,16,17,103,111,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,13237,-1,0.00011716342,0.9998828
13239,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13239,-1,0.9999255,7.449845e-05
13240,leukemic infiltration of bone marrow,14,19,109,145,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,13240,-1,0.0002477359,0.9997522
13242,hyperbilirubinemia,10,11,65,83,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13242,-1,0.0001422546,0.9998578
13243,antineoplastic,21,22,130,144,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,13243,-1,0.0010278973,0.99897206
13245,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,-1,-1,-1,13245,-1,0.99992573,7.421114e-05
13251,thrombophlebitis,2,3,19,35,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,-1,13251,-1,0.00012402049,0.999876
13256,Thrombophlebitis,0,1,0,16,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,-1,-1,13256,-1,0.000121732235,0.9998783
13269,P,16,17,108,109,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,-1,-1,13269,-1,0.123265445,0.8767346
13271,contrast,1,2,3,11,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13271,-1,0.072271034,0.92772895
13272,P,14,15,92,93,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,13272,-1,0.1108547,0.88914526
13274,P,25,26,120,121,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,-1,13274,-1,0.11475077,0.8852492
13275,contrast,1,2,3,11,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,-1,13275,-1,0.07196486,0.92803514
13278,angina,6,7,32,38,Report of a case of spontaneous angina.,3952818_1,-1,-1,-1,13278,-1,0.00012675818,0.9998733
13279,colon carcinoma,8,10,35,50,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13279,-1,0.00015010955,0.9998499
13280,liver metastasis,11,13,55,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13280,-1,0.00014635382,0.9998536
13281,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13281,-1,0.00012298625,0.999877
13283,5-FU,20,21,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13283,-1,0.9998672,0.00013273781
13284,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13284,-1,0.003863433,0.9961365
13285,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13285,-1,0.00012475111,0.9998752
13289,5-FU,14,15,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13289,-1,0.9998914,0.00010862914
13290,calcium antagonists,18,20,96,115,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13290,-1,0.9998994,0.00010060957
13291,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13291,-1,0.022073472,0.97792655
13295,TOTP,3,4,27,31,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13295,-1,0.99971706,0.00028293577
13296,"0,0'-diisopropyl phosphorofluoridate",12,14,53,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13296,-1,0.99968493,0.00031506902
13297,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13297,-1,0.999859,0.0001409551
13299,signs and lesions,6,9,49,66,Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared.,3961813_2,-1,-1,-1,13299,-1,0.00019868788,0.99980134
13303,TOTP,35,36,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13303,-1,0.99978155,0.00021841233
13304,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13304,-1,0.99984,0.00015994822
13306,TOTP,6,7,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13306,-1,0.99965835,0.00034165478
13307,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13307,-1,0.99981517,0.00018484377
13309,TOTP,6,7,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13309,-1,0.99973947,0.00026051953
13310,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13310,-1,0.9998381,0.0001618733
13311,Degenerating myelinated fibers,0,3,0,30,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13311,-1,0.00026999274,0.99973005
13312,TOTP,16,17,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13312,-1,0.9997731,0.00022695161
13313,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13313,-1,0.9998642,0.00013570336
13317,tachyarrhythmias,12,13,85,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,-1,-1,13317,-1,0.000105723644,0.99989426
13319,cholestatic hepatitis,3,5,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,-1,-1,13319,-1,0.00014614129,0.99985385
13325,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13325,-1,0.00012594913,0.999874
13326,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13326,-1,0.00013706066,0.9998629
13327,cholestatic hepatitis,23,25,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13327,-1,0.00019458572,0.9998054
13328,cirrhosis of the liver,27,31,194,216,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13328,-1,0.00036932353,0.9996307
13330,cholestatic injury,8,10,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,-1,-1,13330,-1,0.00024093052,0.999759
13333,fat,6,7,48,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13333,-1,0.9998901,0.00010984094
13335,adenocarcinomas,20,21,96,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,-1,13335,-1,0.00020492286,0.99979514
13340,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13340,-1,0.99987674,0.00012322831
13341,fat,24,25,139,142,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13341,-1,0.9992488,0.00075114134
13343,SD,4,5,24,26,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,-1,-1,13343,-1,0.7803912,0.21960872
13345,SD,1,2,13,15,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13345,-1,0.00847768,0.9915223
13347,prostatitis,12,13,81,92,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13347,-1,0.00013351649,0.9998665
13349,neoplasms,2,3,13,22,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,-1,13349,-1,0.00013778463,0.9998622
13351,Immunosuppressive drugs,0,2,0,23,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,-1,-1,13351,-1,0.9988292,0.0011707831
13354,chlorambucil,7,8,49,61,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13354,-1,0.99993527,6.466881e-05
13355,alkylating agents,9,11,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13355,-1,0.9996568,0.0003431557
13357,purine,15,16,97,103,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13357,-1,0.9999149,8.515189e-05
13359,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13359,-1,0.9999225,7.752206e-05
13360,synovitis,10,11,67,76,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,-1,13360,-1,0.00014009688,0.9998599
13361,alkylating agents,3,5,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13361,-1,0.9999212,7.8770776e-05
13362,nonlymphocytic leukemia,13,15,87,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13362,-1,0.00012946395,0.99987054
13363,alkylating agents,18,20,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13363,-1,0.99992406,7.591497e-05
13365,lymphoma,30,31,209,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13365,-1,0.00010702739,0.99989295
13374,immunosuppressive drugs,26,28,156,179,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13374,-1,0.99978906,0.00021096691
13375,alkylating agents,30,32,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13375,-1,0.9998965,0.00010345588
13377,hypaque 76.Sequential,8,10,47,68,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13377,-1,0.84478843,0.15521154
13378,hypaque 76,34,36,208,218,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13378,-1,0.9997174,0.00028253763
13379,QTC prolongation,1,3,12,28,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13379,-1,0.0002587351,0.99974126
13381,elevation of cardiac output,16,20,109,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13381,-1,0.0005269357,0.99947304
13383,femoral nerve palsy,5,8,54,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,-1,-1,13383,-1,0.0002650137,0.99973494
13385,muscle tear,16,18,91,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13385,-1,0.00017878113,0.99982125
13387,contracture,25,26,147,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13387,-1,0.00013505739,0.99986494
13389,femoral nerve entrapment,7,10,56,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13389,-1,0.0005921828,0.99940777
13390,femoral nerve palsy,14,17,97,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13390,-1,0.00035337306,0.99964666
13391,loss of quadriceps functions,19,23,129,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13391,-1,0.00042674068,0.9995733
13392,femoral nerve palsy,1,4,22,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13392,-1,0.00020265841,0.9997974
13395,motor and sensory impairment,28,32,195,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13395,-1,0.00016766951,0.9998323
13396,contracture,35,36,237,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13396,-1,0.00012978532,0.9998702
13397,Pneumonitis,0,1,0,11,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13397,-1,0.00011288163,0.9998871
13398,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13398,-1,0.00013974796,0.9998603
13401,sinuatrial disease,3,5,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13401,-1,0.00096641027,0.9990336
13403,mg,16,17,105,107,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13403,-1,0.9977761,0.0022239583
13404,mg,21,22,130,132,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13404,-1,0.9977221,0.0022779221
13405,supraventricular tachyarrhythmias,31,33,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13405,-1,0.00010821722,0.99989176
13406,pneumonitis,2,3,13,24,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13406,-1,0.00012847825,0.9998715
13407,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13407,-1,0.0001991894,0.99980086
13408,proximal motor neuropathy,12,15,81,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13408,-1,0.00016069638,0.9998393
13411,amiodarone pneumonitis,14,16,87,109,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,-1,-1,-1,13411,-1,0.06054461,0.93945545
13414,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,-1,13414,-1,0.18895093,0.8110491
13415,sinoatrial block,2,4,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13415,-1,0.0008579174,0.99914205
13417,primary cardiomyopathy,14,16,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13417,-1,0.00012927804,0.99987066
13418,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13418,-1,0.00011674622,0.9998833
13420,sinoatrial block,12,14,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,-1,-1,13420,-1,0.00131487,0.9986852
13427,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13427,-1,0.99992704,7.298284e-05
13428,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13428,-1,0.9999311,6.889822e-05
13429,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13429,-1,0.9998517,0.00014822352
13431,degeneration of the extraocular muscles,5,10,39,78,All three anesthetics produced massive degeneration of the extraocular muscles.,4038130_4,-1,-1,-1,13431,-1,0.0004093994,0.9995906
13432,Muscle degeneration,0,2,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,-1,13432,-1,0.00018773136,0.9998123
13433,muscle damage,3,5,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13433,-1,0.00013185074,0.99986815
13434,mepivacaine,19,20,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13434,-1,0.99994445,5.5537737e-05
13437,diplopia,12,13,67,75,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13437,-1,0.00010519989,0.99989474
13438,damage to the extraocular,25,29,163,188,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13438,-1,0.0011373416,0.9988626
13439,muscles,29,30,189,196,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13439,-1,0.00040864517,0.9995914
13440,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,-1,13440,-1,0.014161491,0.9858385
13441,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,-1,-1,13441,-1,0.00012631885,0.99987364
13446,PAS,5,6,31,34,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13446,-1,0.999734,0.000265954
13448,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,-1,13448,-1,0.00012230071,0.9998777
13449,renal failure,8,10,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13449,-1,0.00012422407,0.9998758
13453,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13453,-1,0.00046317835,0.9995369
13456,oliguria,22,23,152,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,-1,13456,-1,0.00010254989,0.9998975
13458,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,-1,13458,-1,0.00012370618,0.99987626
13460,tumours,7,8,46,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,-1,-1,-1,13460,-1,0.00013493614,0.99986506
13462,Papillomas,0,1,0,10,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13462,-1,0.00016416825,0.99983585
13463,bladder carcinomas,18,20,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13463,-1,0.00013273048,0.9998672
13464,bladder tumours,5,7,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,-1,-1,-1,13464,-1,0.00013869641,0.99986124
13465,hyperplasia,10,11,62,73,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13465,-1,0.00012177634,0.99987817
13466,bladder calculi,24,26,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13466,-1,0.00014927654,0.99985075
13467,tumours,4,5,15,22,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,-1,-1,-1,13467,-1,0.00016432987,0.9998356
13469,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,-1,13469,-1,0.7362114,0.26378858
13475,tender hepatomegaly,2,4,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13475,-1,0.00013827492,0.9998617
13476,malaise,10,11,67,74,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13476,-1,0.00021597886,0.99978405
13477,anorexia,12,13,76,84,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13477,-1,0.00014438992,0.99985564
13478,nausea and vomiting,14,17,86,105,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13478,-1,0.00018127786,0.99981874
13479,upper abdominal pain,21,24,127,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13479,-1,0.00012898794,0.999871
13480,hepatocellular necrosis,5,7,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13480,-1,0.00011869739,0.99988127
13482,fatty change,22,24,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13482,-1,0.0002133765,0.9997867
13483,hepatocellular necrosis,26,28,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13483,-1,0.000120530975,0.9998795
13484,hepatic necrosis,30,32,225,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13484,-1,0.00011182868,0.9998882
13485,acute hepatitis,6,8,40,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13485,-1,0.00013507633,0.99986494
13488,hepatic failure,7,9,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,-1,-1,-1,13488,-1,0.000109738765,0.9998902
13490,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,-1,13490,-1,0.000143469,0.9998565
13493,hepatic dysfunction,16,18,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,-1,13493,-1,0.000114583316,0.99988544
13495,hemiparesis,1,2,10,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13495,-1,0.00012754094,0.99987245
13496,diphenylhydantoin toxicity,7,9,47,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13496,-1,0.37060136,0.62939864
13497,diphenylhydantoin,6,7,33,50,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13497,-1,0.99993014,6.986144e-05
13498,DPH,8,9,52,55,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13498,-1,0.9996551,0.00034486997
13500,cerebellar dysfunction,21,23,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13500,-1,0.00011144662,0.99988854
13501,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13501,-1,0.00013034751,0.9998696
13502,DPH overdose,10,12,71,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13502,-1,0.0017316912,0.99826825
13503,DPH,5,6,30,33,Both had brain surgery before DPH treatment.,430165_5,-1,-1,-1,13503,-1,0.99983394,0.00016607426
13504,cerebral damage,7,9,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13504,-1,0.000115929724,0.999884
13505,DPH toxicity,13,15,77,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13505,-1,0.0070151323,0.99298483
13507,fasciculations,5,6,41,55,Suxamethonium infusion rate and observed fasciculations.,435349_0,-1,-1,-1,13507,-1,0.0001904985,0.99980956
13508,Suxamethonium chloride,0,2,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13508,-1,0.99992335,7.669712e-05
13509,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13509,-1,0.99917656,0.0008234572
13510,mg,18,19,88,90,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13510,-1,0.9777338,0.02226614
13511,mg,22,23,101,103,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13511,-1,0.9819886,0.01801145
13512,tetanic,12,13,76,83,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13512,-1,0.00062012055,0.9993799
13513,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13513,-1,0.9912417,0.008758304
13514,mg,22,23,131,133,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13514,-1,0.9938261,0.006173826
13515,Fasciculations,0,1,0,14,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,-1,-1,13515,-1,0.00026693786,0.99973303
13518,twitch,6,7,34,40,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13518,-1,0.00022233344,0.99977773
13519,tetanus,9,10,57,64,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13519,-1,0.00031274435,0.9996873
13520,Fasciculations,0,1,0,14,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,-1,-1,13520,-1,0.00020731759,0.99979275
13523,Tiapride,0,1,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13523,-1,0.9999211,7.8909936e-05
13524,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13524,-1,0.00014195309,0.999858
13525,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13525,-1,0.9999337,6.630149e-05
13526,benzamide,4,5,24,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13526,-1,0.9999206,7.939884e-05
13528,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13528,-1,0.00015199344,0.999848
13529,idiopathic Parkinson's disease,21,25,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13529,-1,0.0001984974,0.9998016
13531,akinesia,13,14,98,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13531,-1,0.001361339,0.9986387
13532,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,-1,13532,-1,0.99993706,6.2941224e-05
13544,Quinidine hepatitis,0,2,0,19,Quinidine hepatitis.,48362_0,-1,-1,-1,13544,-1,0.22705981,0.7729402
13545,quinidine,3,4,28,37,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13545,-1,0.9999354,6.4551685e-05
13546,lactic acid,15,17,112,123,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13546,-1,0.99984133,0.00015862667
13547,alkaline phosphatase,20,22,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13547,-1,0.99981695,0.00018311446
13549,quinidine,2,3,18,27,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,-1,-1,-1,13549,-1,0.9999248,7.518875e-05
13550,quinidine,4,5,20,29,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13550,-1,0.99993587,6.416914e-05
13551,phosphatase,15,16,94,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13551,-1,0.99928313,0.0007168729
13552,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13552,-1,0.99986994,0.00013008168
13553,quinidine hepatotoxicity,6,8,35,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,-1,-1,13553,-1,0.025318213,0.97468185
13554,hepatic toxicity,12,14,73,89,"This report also suggests that, even after long-term administration, the hepatic toxicity is reversible.",48362_6,-1,-1,-1,13554,-1,0.00013350694,0.9998665
13555,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,-1,13555,-1,0.00014604196,0.99985397
13557,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13557,-1,0.00013935103,0.99986064
13558,adenocarcinoma,16,17,103,117,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13558,-1,0.00014389511,0.9998561
13560,Angiosarcoma,0,1,0,12,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,-1,-1,-1,13560,-1,0.00016101863,0.99983895
13561,intraarterial,4,5,25,38,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,-1,-1,13561,-1,0.0020225702,0.99797744
13563,thromboembolism,1,2,9,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,-1,13563,-1,0.000119819575,0.9998802
13566,thromboembolism,1,2,9,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,-1,-1,-1,13566,-1,0.00013473108,0.9998653
13568,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13568,-1,0.00015971184,0.99984026
13573,and,9,10,70,73,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13573,-1,0.0007661322,0.99923384
13574,ischemic,16,17,117,125,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13574,-1,0.00013770124,0.9998623
13576,thromboembolism,4,5,27,42,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,-1,-1,13576,-1,0.00011096191,0.999889
13580,sodium warfarin,11,13,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,-1,-1,-1,13580,-1,0.99990356,9.644237e-05
13581,Galanthamine,0,1,0,12,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13581,-1,0.99994504,5.4941167e-05
13583,(Hyoscine).Galanthamine,18,19,123,146,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13583,-1,0.99962056,0.00037936645
13585,hyoscine,42,43,304,312,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13585,-1,0.99990845,9.152043e-05
13586,overdosage,44,45,314,324,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13586,-1,0.0004952302,0.9995048
13587,physostigmine,5,6,25,38,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13587,-1,0.99993455,6.5439795e-05
13589,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,-1,-1,-1,13589,-1,0.99992836,7.1598486e-05
13590,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13590,-1,0.99992526,7.479415e-05
13591,mg,6,7,30,32,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13591,-1,0.98968375,0.010316278
13592,mg,13,14,71,73,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,-1,-1,-1,13592,-1,0.99880946,0.001190587
13595,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,-1,-1,-1,13595,-1,0.9999393,6.070655e-05
13596,h,10,11,61,62,The drug was still present in measurable quantities after 24 h even with the smallest dose.,6103707_11,-1,-1,-1,13596,-1,0.044186965,0.95581305
13597,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13597,-1,0.9991499,0.0008500666
13598,chlorpropanol,5,6,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13598,-1,0.99993765,6.235034e-05
13599,Tobanum,7,8,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13599,-1,0.99983585,0.00016412551
13600,GYKI-41 099,2,4,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,-1,13600,-1,0.999156,0.00084395806
13603,pindolol,8,9,67,75,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13603,-1,0.9999362,6.371396e-05
13604,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13604,-1,0.2389525,0.7610475
13605,GYKI-41 900,0,2,0,11,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,-1,13605,-1,0.9993812,0.00061876624
13606,14C-41 099,12,14,78,88,There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs.,6111982_5,-1,-1,-1,13606,-1,0.9996928,0.00030723124
13607,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,-1,-1,13607,-1,0.99993134,6.865568e-05
13612,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,-1,13612,-1,0.9999392,6.082766e-05
13614,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13614,-1,0.9999416,5.838818e-05
13615,impotence,9,10,69,78,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13615,-1,0.00077604596,0.99922395
13616,impotence,12,13,84,93,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13616,-1,0.0006370416,0.999363
13618,impaired glucose tolerance,9,12,71,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13618,-1,0.00044169332,0.99955827
13619,gout,17,18,119,123,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13619,-1,0.00016392392,0.9998361
13620,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13620,-1,0.99993515,6.484945e-05
13621,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13621,-1,0.0017916358,0.9982084
13622,dyspnoea,31,32,203,211,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13622,-1,0.000117520925,0.99988246
13624,corneal disease,1,3,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,-1,-1,-1,13624,-1,0.00012863235,0.9998714
13628,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13628,-1,0.9999044,9.561849e-05
13629,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13629,-1,0.9999355,6.443176e-05
13632,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,-1,13632,-1,0.99990547,9.4525334e-05
13635,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,-1,13635,-1,0.999928,7.201084e-05
13637,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,-1,-1,13637,-1,0.99993277,6.725688e-05
13641,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,-1,-1,-1,13641,-1,0.9999337,6.62549e-05
13643,MK-212,12,13,55,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13643,-1,0.9998902,0.00010981791
13644,muscimol,21,22,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13644,-1,0.99993885,6.113733e-05
13646,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,-1,-1,13646,-1,0.9999348,6.517741e-05
13649,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,-1,-1,-1,13649,-1,0.99994373,5.6259225e-05
13650,5-HTP,4,5,26,31,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,-1,13650,-1,0.999913,8.7018874e-05
13654,MK-212,8,9,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,-1,-1,13654,-1,0.9999,9.996367e-05
13656,ischaemic heart disease,3,6,20,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13656,-1,0.00011980621,0.9998802
13657,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13657,-1,0.000108812936,0.99989116
13663,inflammatory bowel disease,8,11,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13663,-1,0.0001345058,0.99986553
13665,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13665,-1,0.0001454645,0.99985456
13666,ulcerative colitis,8,10,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13666,-1,0.00013737453,0.99986255
13667,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13667,-1,0.00085105706,0.99914896
13668,ventricular septal defect,25,28,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13668,-1,0.00030521213,0.9996948
13669,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,-1,13669,-1,0.0005901684,0.9994098
13670,uterine cornu,18,20,94,107,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,-1,-1,13670,-1,0.016359193,0.98364085
13671,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13671,-1,0.002663722,0.9973362
13672,hypoplastic lungs,15,17,63,80,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13672,-1,0.00019934005,0.9998006
13673,absent kidneys and ureters,18,22,82,108,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13673,-1,0.0006344038,0.9993656
13674,talipes equinovarus,24,26,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13674,-1,0.081635006,0.91836494
13676,teratogenic,13,14,76,87,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,-1,-1,-1,13676,-1,0.0008219195,0.9991781
13681,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,-1,13681,-1,0.00012344516,0.9998765
13688,impotence,9,10,55,64,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,-1,-1,-1,13688,-1,0.0005034157,0.9994966
13694,hematologic toxicity,36,38,165,185,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13694,-1,0.000111743735,0.9998883
13695,gastrin,42,43,210,217,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,-1,13695,-1,0.9997925,0.00020755631
13706,generalized seizures,9,11,54,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,-1,-1,-1,13706,-1,0.00013047236,0.99986947
13711,epileptic foci,16,18,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,-1,-1,13711,-1,0.0001445435,0.9998554
13713,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13713,-1,0.00012253207,0.99987745
13714,antineoplastic,7,8,61,75,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13714,-1,0.9982741,0.001725864
13717,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13717,-1,0.00012015389,0.99987984
13718,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13718,-1,0.00011221902,0.9998878
13721,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13721,-1,0.99993014,6.982821e-05
13722,vinca alkaloid,30,32,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13722,-1,0.9999212,7.880347e-05
13723,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,-1,13723,-1,0.0001822166,0.9998178
13724,intravascular coagulation,9,11,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,-1,-1,-1,13724,-1,0.00012728943,0.9998727
13727,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13727,-1,0.00011442641,0.99988556
13728,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13728,-1,0.0028673606,0.99713266
13735,ISO,19,20,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13735,-1,0.99985397,0.00014596316
13736,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13736,-1,0.18322505,0.81677496
13737,hydroxyproline,20,21,93,107,"A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.",6203632_2,-1,-1,-1,13737,-1,0.9999038,9.614348e-05
13738,h,9,10,50,51,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,-1,13738,-1,0.13567065,0.8643293
13739,hydroxyproline,4,5,21,35,The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.,6203632_6,-1,-1,-1,13739,-1,0.99990475,9.528045e-05
13740,hypertrophic,16,17,75,87,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,-1,13740,-1,0.00021522831,0.99978477
13742,P,12,13,73,74,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,-1,13742,-1,0.14954145,0.8504585
13743,ISO,8,9,50,53,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13743,-1,0.9997454,0.00025451186
13744,hypertrophic,12,13,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13744,-1,0.00021046543,0.99978954
13746,hyperplasia,21,22,119,130,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,-1,-1,13746,-1,0.00013814945,0.99986184
13750,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,-1,13750,-1,0.00010280132,0.99989724
13756,gastrointestinal problems,8,10,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,-1,-1,13756,-1,0.00011608051,0.9998839
13760,Skin rashes,0,2,0,11,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13760,-1,0.00014821759,0.9998517
13762,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13762,-1,0.00011885731,0.99988115
13763,polymyositis,9,10,56,68,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13763,-1,0.00014855718,0.99985147
13764,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13764,-1,0.0001686489,0.9998313
13767,skin lesion,1,3,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13767,-1,0.00014668786,0.99985325
13768,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13768,-1,0.00047373376,0.99952626
13769,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13769,-1,0.00024188112,0.99975806
13773,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,-1,-1,13773,-1,0.00011473999,0.9998852
13775,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,-1,13775,-1,0.000119043674,0.9998809
13777,contrast,15,16,100,108,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,-1,13777,-1,0.0053432663,0.9946568
13779,cardiomegaly,3,4,17,29,"In patients with cardiomegaly, the increase in heart size was similar in both groups.",6229975_6,-1,-1,-1,13779,-1,0.00012430926,0.99987566
13781,hypercalcaemia,4,5,18,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13781,-1,0.00011387182,0.99988616
13784,bicarbonate,23,24,165,176,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13784,-1,0.9998493,0.00015065818
13785,Vitamin D3 toxicity,0,3,0,19,Vitamin D3 toxicity in dairy cows.,6286738_0,-1,-1,-1,13785,-1,0.16114797,0.838852
13786,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13786,-1,0.99988604,0.00011398437
13787,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13787,-1,0.9998838,0.00011617518
13789,hyperphosphatemia,23,24,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13789,-1,0.0002206291,0.9997794
13790,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13790,-1,0.9998895,0.00011044486
13792,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,-1,13792,-1,0.9999043,9.570241e-05
13793,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,-1,13793,-1,0.9999087,9.131401e-05
13796,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13796,-1,0.12423612,0.8757639
13797,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13797,-1,0.12340342,0.8765965
13800,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13800,-1,0.9999068,9.324227e-05
13801,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13801,-1,0.9999137,8.6335e-05
13804,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13804,-1,0.9999093,9.072295e-05
13806,Diseases of peripheral nerves,0,4,0,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,-1,-1,-1,13806,-1,0.00046148224,0.99953854
13807,peripheral nerve disease,6,9,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,-1,-1,-1,13807,-1,0.0001766353,0.9998234
13809,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,-1,13809,-1,0.0001110986,0.9998889
13811,nutritional deficiency,4,6,29,51,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13811,-1,0.0164325,0.9835675
13812,thiamine,7,8,55,63,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13812,-1,0.9999287,7.132087e-05
13813,riboflavin,9,10,68,78,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13813,-1,0.9999367,6.323818e-05
13815,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,-1,-1,13815,-1,0.00016088986,0.99983907
13820,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,-1,-1,13820,-1,0.00011935944,0.9998807
13823,connective tissue disorders,2,5,19,46,Heredofamilial and connective tissue disorders were rare.,6287825_10,-1,-1,-1,13823,-1,0.0004113078,0.99958867
13824,neuropathies,13,14,81,93,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,-1,-1,-1,13824,-1,0.00012211566,0.9998778
13825,Doxorubicin cardiomyopathy,0,2,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13825,-1,0.01339375,0.9866063
13826,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13826,-1,0.00019643085,0.9998036
13827,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13827,-1,0.00014271164,0.9998573
13828,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13828,-1,0.060697198,0.9393028
13832,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,-1,13832,-1,0.0001534216,0.9998466
13835,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,-1,13835,-1,0.00016382859,0.9998361
13842,DA,15,16,100,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13842,-1,0.9998708,0.00012919708
13843,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13843,-1,0.99991596,8.398674e-05
13845,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,-1,13845,-1,0.01959627,0.9804037
13847,sodium acetylsalicylate,12,14,89,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,-1,-1,-1,13847,-1,0.99991167,8.83736e-05
13851,salicylates,1,2,8,19,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,-1,-1,13851,-1,0.9999149,8.5104635e-05
13868,pentylenetetrezol,30,31,161,178,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,-1,13868,-1,0.99994504,5.496937e-05
13871,ATP,16,17,103,106,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,-1,-1,-1,13871,-1,0.99982965,0.00017032165
13874,Naloxazone,0,1,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,-1,13874,-1,0.9999442,5.5750144e-05
13877,naloxazone,18,19,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,-1,13877,-1,0.99993634,6.369872e-05
13878,naloxazone,2,3,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13878,-1,0.99994624,5.3767955e-05
13879,morphine analgesia,5,7,51,69,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13879,-1,0.025675865,0.9743241
13882,naloxazone,2,3,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13882,-1,0.99994195,5.806978e-05
13884,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13884,-1,0.00012463304,0.9998753
13889,NH4Ac,5,6,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13889,-1,0.99990845,9.156295e-05
13890,incoordination,28,29,172,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13890,-1,0.00014098038,0.999859
13892,NH4Ac,33,34,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13892,-1,0.99991965,8.030266e-05
13897,mM NH4Ac,21,23,140,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13897,-1,0.9996051,0.00039485106
13898,mM NH4Ac,35,37,222,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13898,-1,0.99964774,0.000352207
13902,acetaldehyde,16,17,117,129,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13902,-1,0.99994004,5.9914142e-05
13903,NH4Ac,21,22,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13903,-1,0.999894,0.000106006104
13904,ammonia,4,5,29,36,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13904,-1,0.99986637,0.00013366807
13905,calcium channels,6,8,44,60,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13905,-1,0.9581286,0.04187147
13906,NH4Ac,5,6,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,-1,-1,-1,13906,-1,0.99983585,0.00016412849
13910,NH4Ac,9,10,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13910,-1,0.9998976,0.000102379585
13912,muscular incoordination,16,18,104,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13912,-1,0.0001171029,0.99988294
13914,NH4Ac,28,29,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13914,-1,0.99990964,9.0307854e-05
13915,metrazol,34,35,246,254,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13915,-1,0.9999449,5.507252e-05
13918,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,-1,13918,-1,0.96594495,0.034055002
13922,choreic,13,14,86,93,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13922,-1,0.00047853737,0.9995215
13923,dystonic,17,18,108,116,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,-1,13923,-1,0.00015236987,0.99984765
13925,thalamic lesions,5,7,43,59,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,-1,-1,13925,-1,0.00018868427,0.99981135
13927,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13927,-1,0.9999368,6.313586e-05
13928,major depressive disorder,15,18,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13928,-1,0.00014406301,0.9998559
13929,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,-1,13929,-1,0.99994326,5.6762176e-05
13932,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13932,-1,0.99993765,6.238513e-05
13934,depressive illness,11,13,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13934,-1,0.00011098646,0.999889
13935,blurred vision,12,14,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13935,-1,0.00013933842,0.99986064
13937,drowsiness,19,20,103,113,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13937,-1,0.00014124358,0.99985874
13938,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13938,-1,0.9999292,7.077007e-05
13940,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,-1,13940,-1,0.9999366,6.338598e-05
13941,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,-1,13941,-1,0.9999418,5.820162e-05
13947,panic disorder,9,11,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,-1,-1,13947,-1,0.00011738967,0.9998826
13950,mg,12,13,57,59,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13950,-1,0.99676585,0.0032340996
13952,mg,31,32,139,141,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13952,-1,0.994823,0.0051769707
13953,panic disorders,49,51,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13953,-1,0.00012531219,0.9998747
13955,impaired immediate free recall,2,6,11,41,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,-1,-1,-1,13955,-1,0.000975811,0.99902415
13958,Delayed free recall was also impaired,0,6,0,37,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13958,-1,0.0006315016,0.9993685
13963,h,11,12,48,49,"After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance.",6387529_5,-1,-1,-1,13963,-1,0.13762552,0.8623745
13964,behavioral impairment,8,10,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,-1,-1,-1,13964,-1,0.000114062874,0.9998859
13965,urothelial toxicity,3,5,32,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13965,-1,0.0001471398,0.9998529
13966,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13966,-1,0.9999093,9.069016e-05
13968,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13968,-1,0.00012349722,0.9998765
13969,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13969,-1,0.99971396,0.0002860239
13970,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13970,-1,0.99990046,9.954949e-05
13972,urothelial toxicity,17,19,118,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13972,-1,0.00015741015,0.9998425
13974,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13974,-1,0.00011898817,0.999881
13976,haematuria,17,18,99,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13976,-1,0.00010763791,0.99989235
13977,haematuria,23,24,135,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13977,-1,0.0001101093,0.99988985
13979,haematuria,24,25,121,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13979,-1,0.00010871441,0.9998913
13980,bladder irritation,28,30,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13980,-1,0.00012763802,0.9998723
13982,pollakisuria,33,34,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13982,-1,0.00031605133,0.999684
13987,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,-1,-1,13987,-1,0.00013335541,0.9998666
13996,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,-1,13996,-1,0.00082806806,0.999172
13997,prostaglandin,2,3,10,23,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,-1,-1,13997,-1,0.9998579,0.00014210682
14000,PGs,7,8,51,54,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14000,-1,0.99979407,0.00020590606
14002,PG,17,18,97,99,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14002,-1,0.99984217,0.00015777921
14004,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14004,-1,0.99994254,5.7442678e-05
14006,pentetrazol,28,29,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14006,-1,0.9999393,6.0674774e-05
14007,PTZ,30,31,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,14007,-1,0.99977034,0.0002296928
14011,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14011,-1,0.9999422,5.7806563e-05
14012,meclofenamic acid,10,12,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14012,-1,0.99995136,4.8677895e-05
14013,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14013,-1,0.99993706,6.296295e-05
14014,PTZ,19,20,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,14014,-1,0.40998587,0.5900141
14017,PGs,4,5,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,-1,14017,-1,0.9988631,0.001136917
14020,ammonia,4,5,23,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,14020,-1,0.9980221,0.0019779352
14021,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,14021,-1,0.9999337,6.6234556e-05
14022,Valproic acid,0,2,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,14022,-1,0.9999428,5.7276557e-05
14023,VPA,3,4,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,14023,-1,0.99987316,0.00012681731
14025,VPA,5,6,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,-1,14025,-1,0.99989533,0.00010461358
14026,Ammonia,0,1,0,7,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14026,-1,0.9998745,0.00012548042
14027,NH3,2,3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14027,-1,0.9998375,0.00016245223
14028,drowsiness,16,17,83,93,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14028,-1,0.00015786798,0.99984205
14029,VPA,33,34,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,14029,-1,0.99986994,0.00013008193
14030,NH3,6,7,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,14030,-1,0.9998529,0.00014702394
14031,VPA,22,23,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,14031,-1,0.9999106,8.935053e-05
14038,renal abnormality,6,8,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,-1,14038,-1,0.00014021235,0.9998598
14044,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,-1,14044,-1,0.9999418,5.8199843e-05
14049,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,-1,-1,14049,-1,0.0024048255,0.99759513
14050,ketone,2,3,9,15,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,-1,14050,-1,0.99986887,0.00013115656
14069,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14069,-1,0.00014140151,0.9998586
14070,trazodone,8,9,48,57,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,14070,-1,0.99993324,6.6747896e-05
14071,trazodone,9,10,56,65,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14071,-1,0.99993014,6.982135e-05
14072,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,14072,-1,0.00012703359,0.9998729
14073,trazodone,12,13,67,76,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,14073,-1,0.9999292,7.07532e-05
14075,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14075,-1,0.99994063,5.94074e-05
14076,DTIC,7,8,56,60,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14076,-1,0.99394256,0.0060573984
14077,melanoma,10,11,66,74,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,14077,-1,0.00020652445,0.99979347
14078,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14078,-1,0.99994683,5.3133313e-05
14079,DTIC,14,15,84,88,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14079,-1,0.99977523,0.00022475598
14080,melanoma,18,19,102,110,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,14080,-1,0.00016257742,0.9998374
14082,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,-1,-1,14082,-1,0.00017955572,0.99982053
14084,Eosinophilic,0,1,0,12,Eosinophilic infiltrations were found around the vessels.,6503301_5,-1,-1,-1,14084,-1,0.00042985292,0.9995702
14086,neurologic impairment,5,7,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,-1,-1,14086,-1,0.0001173769,0.9998826
14090,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,-1,-1,14090,-1,0.00013401393,0.999866
14094,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,-1,-1,14094,-1,0.00012161923,0.9998784
14096,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,-1,-1,14096,-1,0.0020540094,0.99794596
14098,Ebstein's anomaly,4,7,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,-1,-1,14098,-1,0.004392956,0.9956071
14099,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,-1,-1,14099,-1,0.0032921142,0.9967079
14101,cardiac malformations,24,26,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,-1,14101,-1,0.0001116103,0.9998884
14102,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,-1,14102,-1,0.00010769734,0.99989223
14103,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,-1,14103,-1,0.000106635285,0.9998933
14104,infarcts,3,4,18,26,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,-1,14104,-1,0.00019422204,0.99980575
14105,sedentary-isoproterenols,11,12,56,80,Elevations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls.,6534871_4,-1,-1,-1,14105,-1,0.99981874,0.00018127388
14106,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,-1,-1,14106,-1,0.00011401828,0.9998859
14108,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,-1,14108,-1,0.22210869,0.77789134
14110,PEG 400,13,15,70,77,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14110,-1,0.9997377,0.00026235738
14112,ADR,30,31,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,14112,-1,0.9996037,0.0003963815
14113,PEG 400,0,2,0,7,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,-1,14113,-1,0.9998528,0.000147167
14114,cardiac morphological alterations,9,12,79,112,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,-1,14114,-1,0.00012583917,0.9998741
14115,ADR,6,7,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14115,-1,0.99981624,0.0001838021
14116,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14116,-1,0.001235462,0.9987645
14117,Ehrlich ascites tumor,14,17,84,105,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,14117,-1,0.0002462507,0.9997538
14118,amine,2,3,11,16,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14118,-1,0.9998559,0.00014406246
14119,ketamine catatonia,5,7,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,14119,-1,0.0079811355,0.9920189
14121,catatonia,16,17,114,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,-1,14121,-1,0.00019310451,0.99980694
14123,catatonia,12,13,83,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,14123,-1,0.0010234294,0.9989766
14129,melatonin,22,23,121,130,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,-1,14129,-1,0.9998983,0.00010163594
14132,melatonin,22,23,132,141,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,-1,-1,14132,-1,0.99989855,0.00010144191
14135,amines,13,14,78,84,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,-1,14135,-1,0.99981326,0.00018677293
14137,melatonin,20,21,111,120,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,-1,-1,-1,14137,-1,0.99988544,0.00011452006
14139,ketamine catatonia,15,17,93,111,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,-1,-1,-1,14139,-1,0.02341303,0.976587
14147,falling platelet count,5,8,34,56,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,-1,-1,-1,14147,-1,0.00026276565,0.9997372
14157,Ventricular fibrillation,0,2,0,24,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14157,-1,0.00012225185,0.9998777
14158,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14158,-1,0.9999379,6.212457e-05
14159,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,14159,-1,0.9998747,0.00012523573
14161,Renografin 76%,3,6,16,30,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14161,-1,0.7487147,0.2512853
14162,Hypaque 76%,11,14,57,68,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,14162,-1,0.66348124,0.33651873
14163,Renografin,0,1,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14163,-1,0.99942833,0.0005716191
14164,chelating agents sodium citrate,3,7,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14164,-1,0.99976546,0.00023459594
14165,disodium edetate,8,10,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14165,-1,0.99990904,9.093427e-05
14166,Hypaque,12,13,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14166,-1,0.9974613,0.0025386226
14167,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,14167,-1,0.99989843,0.00010161463
14169,Ventricular fibrillation,0,2,0,24,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14169,-1,0.000112532456,0.99988747
14170,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14170,-1,0.99986696,0.00013303928
14171,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,14171,-1,0.9998623,0.00013766487
14173,quaternary ammonium,4,6,29,48,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14173,-1,0.9998398,0.00016021947
14174,N,11,12,86,87,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14174,-1,0.9990089,0.0009910988
14175,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,14175,-1,0.0001295888,0.9998704
14176,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14176,-1,0.99978346,0.00021657604
14177,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,14177,-1,0.99978346,0.00021657604
14182,ventricular fibrillation,12,14,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,-1,-1,14182,-1,0.000102312355,0.9998977
14185,VT,14,15,100,102,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14185,-1,0.000159696,0.99984026
14186,n,17,18,105,106,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14186,-1,0.0109775495,0.9890225
14188,n,26,27,135,136,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,14188,-1,0.0050845705,0.9949155
14190,VT,14,15,104,106,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14190,-1,0.00014443122,0.9998555
14191,ventricular fibrillation,16,18,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14191,-1,0.00013343032,0.9998666
14192,VF,19,20,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,14192,-1,0.00014162417,0.9998584
14193,VT,10,11,57,59,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,-1,14193,-1,0.00015326281,0.9998467
14195,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,-1,-1,14195,-1,0.00045548542,0.99954444
14201,anorexia,17,18,86,94,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14201,-1,0.00015630486,0.9998437
14202,visual halos or blurring,23,27,101,125,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14202,-1,0.00022396322,0.99977607
14203,thyroid function abnormalities,32,35,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14203,-1,0.0006387612,0.9993612
14204,pulmonary interstitial infiltrates,40,43,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,14204,-1,0.00017380413,0.99982625
14206,VT,11,12,81,83,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14206,-1,0.00015375903,0.9998462
14207,VF,13,14,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,14207,-1,0.00015938324,0.9998406
14209,VT,23,24,122,124,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14209,-1,0.00014756524,0.9998524
14210,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,14210,-1,0.00013050657,0.99986947
14213,bladder carcinoma,5,7,41,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,-1,-1,-1,14213,-1,0.0001625658,0.9998374
14214,transitional cell carcinoma,10,13,67,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,-1,-1,-1,14214,-1,0.0005637449,0.9994362
14216,h,11,12,67,68,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14216,-1,0.029033614,0.9709664
14217,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,14217,-1,0.00025954747,0.9997404
14221,angiopathy,1,2,24,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,-1,14221,-1,0.00010130174,0.9998987
14222,D-pen,8,9,60,65,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,-1,-1,-1,14222,-1,0.99979573,0.00020424285
14223,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,-1,14223,-1,0.99991286,8.7172695e-05
14224,EACA,5,6,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,-1,-1,14224,-1,0.9986228,0.0013772821
14227,EACA,12,13,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14227,-1,0.99910104,0.00089902367
14228,subarachnoid haemorrhage,21,23,119,143,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14228,-1,0.00015868191,0.99984133
14229,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,14229,-1,0.0001330413,0.99986696
14231,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14231,-1,0.4667624,0.5332376
14232,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14232,-1,0.4667624,0.5332376
14233,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,-1,14233,-1,0.4667624,0.5332376
14235,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14235,-1,0.9998154,0.00018462693
14236,FANFT,7,8,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14236,-1,0.9997173,0.00028265212
14237,bladder carcinomas,18,20,149,167,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,14237,-1,0.00012743907,0.99987257
14239,FANFT,12,13,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14239,-1,0.999166,0.0008340231
14242,FANFT,40,41,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,14242,-1,0.9990928,0.000907187
14245,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14245,-1,0.010510498,0.9894895
14247,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,14247,-1,0.16632992,0.83367
14249,Cerebral hemorrhage,0,2,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14249,-1,0.00011461903,0.9998853
14250,phenylpropanolamine,4,5,36,55,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,14250,-1,0.99993885,6.1138904e-05
14252,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14252,-1,0.9999405,5.952121e-05
14253,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,14253,-1,0.9996012,0.00039881314
14256,lead,7,8,42,46,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,-1,-1,14256,-1,0.0018215002,0.9981785
14259,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,-1,14259,-1,0.00012017498,0.99987984
14261,lead,8,9,49,53,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,-1,14261,-1,0.016418332,0.98358166
14264,lead,6,7,44,48,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14264,-1,0.0020495758,0.9979505
14265,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,14265,-1,0.000100977115,0.999899
14267,papillary necrosis,1,3,6,24,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14267,-1,0.00014205954,0.9998579
14268,naproxen,5,6,32,40,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,14268,-1,0.9999337,6.630091e-05
14271,fenoprofen calcium,15,17,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14271,-1,0.99994004,5.9903177e-05
14272,salicylates,20,21,122,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14272,-1,0.9999292,7.0842325e-05
14273,gold salts,22,24,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14273,-1,0.9998753,0.00012471685
14275,RPN,30,31,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14275,-1,0.00056706404,0.99943286
14276,naproxen,37,38,221,229,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,14276,-1,0.99993956,6.039025e-05
14277,RPN,5,6,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,-1,14277,-1,0.0028872257,0.99711275
14279,naproxen,4,5,29,37,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,-1,-1,-1,14279,-1,0.99993706,6.2903295e-05
14280,RPN,5,6,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,-1,-1,14280,-1,0.5346495,0.46535045
14283,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,-1,14283,-1,0.000108496926,0.9998915
14285,Abnormal involuntary movements,0,3,0,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14285,-1,0.00016310552,0.9998369
14287,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14287,-1,0.00011477479,0.9998852
14288,mg,30,31,187,189,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,14288,-1,0.9954444,0.004555547
14290,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,-1,14290,-1,0.00010478551,0.9998952
14295,netilmicin,9,10,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,14295,-1,0.9999354,6.462283e-05
14300,netilmicin,2,3,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,-1,-1,-1,14300,-1,0.9999366,6.338815e-05
14306,netilmicin,4,5,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,-1,14306,-1,0.99993527,6.473848e-05
14310,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14310,-1,0.06893773,0.93106234
14311,of,14,15,104,106,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14311,-1,0.004101187,0.9958988
14312,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14312,-1,0.00012405383,0.9998759
14313,androgen,12,13,74,82,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14313,-1,0.99987674,0.00012326392
14314,syndrome of obstructive sleep apnea,25,30,167,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14314,-1,0.00012719905,0.9998728
14315,androgens,34,35,238,247,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14315,-1,0.9999052,9.4795774e-05
14316,androgens,2,3,9,18,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,-1,-1,-1,14316,-1,0.9998041,0.00019593982
14317,androgen,3,4,19,27,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14317,-1,0.99987817,0.00012182002
14318,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14318,-1,0.00012670382,0.9998733
14319,androgens,7,8,40,49,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14319,-1,0.9998927,0.0001073074
14320,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14320,-1,0.00012736143,0.99987257
14321,androgens,6,7,53,62,Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.,6732043_6,-1,-1,-1,14321,-1,0.99989283,0.00010712091
14322,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14322,-1,0.000118795666,0.99988115
14323,androgen,15,16,97,105,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14323,-1,0.9998647,0.00013528657
14324,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14324,-1,0.99987495,0.00012508225
14325,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14325,-1,0.00015655231,0.9998435
14326,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14326,-1,0.9999063,9.3724724e-05
14328,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14328,-1,0.00015100666,0.99984896
14329,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,-1,14329,-1,0.9998946,0.000105394596
14330,astrocytomas,7,8,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,-1,14330,-1,0.0005511333,0.99944884
14334,astrocytomas,8,9,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14334,-1,0.000373151,0.9996269
14335,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14335,-1,0.9998932,0.0001067866
14336,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,-1,-1,-1,14336,-1,0.9999012,9.875669e-05
14337,loss of vision,9,12,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14337,-1,0.00021427905,0.9997857
14338,retinal vasculitis,15,17,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14338,-1,0.00011878094,0.99988115
14344,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,-1,-1,14344,-1,0.00010847448,0.9998915
14346,myocardial lesions,3,5,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,-1,-1,14346,-1,0.000119746575,0.9998802
14348,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,-1,-1,14348,-1,0.000111473724,0.99988854
14351,leukemia,18,19,98,106,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,-1,-1,-1,14351,-1,0.00011188179,0.99988806
14354,diabetic autonomic neuropathy?The,7,10,56,89,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14354,-1,0.0052390527,0.99476093
14365,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,-1,-1,14365,-1,0.9998667,0.0001333081
14368,Tricuspid valve regurgitation,0,3,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14368,-1,0.00019387827,0.9998061
14369,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14369,-1,0.06324482,0.9367552
14370,tricuspid regurgitation,4,6,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14370,-1,0.00015042277,0.99984956
14371,atrial flutter,7,9,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14371,-1,0.00020300692,0.99979705
14372,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14372,-1,0.00012310535,0.99987686
14374,tricuspid regurgitation,8,10,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14374,-1,0.00014670297,0.99985325
14375,atrial flutter,11,13,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14375,-1,0.00019946649,0.9998005
14376,cardiac disease,20,22,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14376,-1,0.00012590844,0.9998741
14377,lithium compounds,26,28,169,186,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14377,-1,0.9998827,0.00011727766
14378,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14378,-1,0.9999008,9.922027e-05
14379,congenital heart disease,11,14,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14379,-1,0.00012551152,0.9998745
14381,cyanosis,6,7,38,46,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14381,-1,0.00012264721,0.99987733
14382,cardiac arrhythmia,9,11,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14382,-1,0.00012513284,0.99987483
14383,aniracetam,5,6,30,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14383,-1,0.9999263,7.3662464e-05
14384,Ro 13-5057,7,11,42,52,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14384,-1,0.9994344,0.0005655891
14385,learning and memory,14,17,68,87,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14385,-1,0.0002726031,0.9997274
14386,aniracetam,3,4,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14386,-1,0.99991596,8.406047e-05
14387,Ro 13-5057,5,9,26,36,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14387,-1,0.99957746,0.0004225683
14388,1-anisoyl-2-pyrrolidinone,10,11,38,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14388,-1,0.9998797,0.00012023514
14389,impaired cognitive functions,19,22,112,140,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14389,-1,0.00014495096,0.99985504
14390,hypercapnia,55,56,324,335,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14390,-1,0.0001611103,0.9998388
14394,chloramphenicol,130,131,781,796,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14394,-1,0.99994814,5.1879346e-05
14396,h,149,150,903,904,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14396,-1,0.04456197,0.955438
14398,hypercapnia,197,198,1178,1189,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14398,-1,0.00032298785,0.99967706
14399,h,205,206,1239,1240,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14399,-1,0.051347356,0.9486526
14400,impaired cognitive functions,5,8,40,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14400,-1,0.00015410573,0.99984586
14401,aniracetam,12,13,87,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14401,-1,0.9999074,9.263422e-05
14402,aniracetam,6,7,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,-1,14402,-1,0.99992895,7.105991e-05
14403,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14403,-1,0.99994683,5.3191015e-05
14404,pyrrolidinone,3,4,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14404,-1,0.99993324,6.6738736e-05
14405,aniracetam,16,17,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,-1,-1,-1,14405,-1,0.99991477,8.522938e-05
14406,aniracetam,4,5,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,-1,-1,-1,14406,-1,0.9999175,8.253903e-05
14408,Sodium chloride,0,2,0,15,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,-1,14408,-1,0.9999051,9.4843694e-05
14419,adenohypophyseal tumors,3,5,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,-1,-1,14419,-1,0.0007608632,0.9992392
14420,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14420,-1,0.00015681869,0.9998431
14422,DES,14,15,96,99,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14422,-1,0.99979967,0.00020030222
14423,mg,19,20,106,108,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14423,-1,0.9392117,0.060788292
14424,DES,9,10,30,33,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,-1,14424,-1,0.9998266,0.0001734697
14425,PRL,17,18,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14425,-1,0.99984515,0.00015485284
14426,PRL,28,29,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14426,-1,0.99982697,0.00017310849
14427,acriflavine,51,52,340,351,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14427,-1,0.9999298,7.017332e-05
14428,PRL,1,2,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14428,-1,0.9998374,0.00016261729
14429,PRL,13,14,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14429,-1,0.99983776,0.00016223303
14430,DES,31,32,178,181,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14430,-1,0.9997708,0.00022918418
14431,DES,4,5,17,20,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,-1,14431,-1,0.9997179,0.0002821312
14432,PRL,5,6,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14432,-1,0.9997787,0.0002213199
14433,PRL,14,15,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14433,-1,0.9974262,0.0025737665
14434,DES,4,5,21,24,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,-1,14434,-1,0.99983835,0.00016166198
14436,PRL,20,21,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,-1,14436,-1,0.9993907,0.0006093021
14437,calcium chloride,2,4,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14437,-1,0.9999138,8.6171975e-05
14439,eserine,12,13,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14439,-1,0.9999349,6.5082386e-05
14440,calcium chloride,3,5,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14440,-1,0.9999275,7.253359e-05
14441,mydriasis,41,42,233,242,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14441,-1,0.00012992475,0.99987006
14445,eserine,51,52,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14445,-1,0.9999441,5.5939523e-05
14446,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14446,-1,0.63254404,0.367456
14448,eserine,15,16,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14448,-1,0.99993837,6.159284e-05
14449,mydriasis,5,6,19,28,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14449,-1,0.00010313437,0.9998969
14453,eserine,15,16,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14453,-1,0.9999362,6.3822634e-05
14454,calcium chloride,21,23,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14454,-1,0.9999193,8.075128e-05
14455,calcium chloride,4,6,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14455,-1,0.99991524,8.4804975e-05
14456,mydriasis,20,21,123,132,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14456,-1,0.00011906127,0.9998809
14460,eserine,30,31,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14460,-1,0.99992895,7.107367e-05
14461,Calcium chloride,0,2,0,16,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14461,-1,0.9999113,8.867631e-05
14463,eserine,11,12,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14463,-1,0.99993956,6.0379654e-05
14465,Thiazide,0,1,0,8,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14465,-1,0.99991846,8.157812e-05
14466,hypokalemia,3,4,20,31,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14466,-1,0.00011504676,0.99988496
14468,Thiazide,0,1,0,8,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,-1,14468,-1,0.99992406,7.589817e-05
14469,Hypokalemia,0,1,0,11,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14469,-1,0.00012252355,0.99987745
14470,thiazide,9,10,71,79,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14470,-1,0.9999291,7.0883405e-05
14472,hydrochlorothiazide,18,19,97,116,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14472,-1,0.99994457,5.5432654e-05
14473,HCTC,20,21,118,122,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14473,-1,0.99947363,0.0005263609
14474,mg,4,5,20,22,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14474,-1,0.98744607,0.012553914
14475,mg,15,16,78,80,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14475,-1,0.98830044,0.011699602
14476,mg,18,19,86,88,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14476,-1,0.9930749,0.006925128
14477,mg,21,22,97,99,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14477,-1,0.9954673,0.0045327046
14478,K,2,3,10,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14478,-1,0.99542445,0.004575571
14479,mg HCTZ,22,24,87,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14479,-1,0.9995882,0.00041186577
14480,K,5,6,37,38,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,-1,14480,-1,0.99841523,0.0015848106
14481,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14481,-1,0.9999138,8.616499e-05
14482,mg,12,13,60,62,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14482,-1,0.9918972,0.008102793
14483,PVC,19,20,91,94,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14483,-1,0.0006628054,0.99933714
14484,PVC,8,9,37,40,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,-1,14484,-1,0.002842392,0.9971576
14485,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14485,-1,0.9998523,0.00014771531
14486,mg,6,7,46,48,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14486,-1,0.9858322,0.01416775
14487,PVC,3,4,18,21,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14487,-1,0.00072363793,0.99927634
14488,p,18,19,94,95,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14488,-1,0.070390865,0.9296092
14489,thiazide,5,6,28,36,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14489,-1,0.99992955,7.041457e-05
14490,hypokalemia,8,9,53,64,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14490,-1,0.0001394724,0.9998605
14492,hypokalemia,3,4,18,29,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14492,-1,0.000113103255,0.9998869
14493,PVC,13,14,80,83,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14493,-1,0.00059596635,0.9994041
14494,acute hepatic necrosis,4,7,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,-1,-1,14494,-1,0.00013924172,0.99986076
14495,phosphatase,15,16,101,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,-1,14495,-1,0.9996917,0.00030825372
14497,cathepsin D,3,5,15,26,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14497,-1,0.99937457,0.00062544714
14499,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14499,-1,0.1757662,0.8242338
14501,viral hepatitis,42,44,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14501,-1,0.00020738064,0.99979264
14502,cathepsin D,17,19,103,114,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,-1,14502,-1,0.99981683,0.00018321977
14518,or kidney disease,33,36,161,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,-1,-1,14518,-1,0.00024509497,0.99975485
14522,6-thioguanine,5,6,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,-1,-1,-1,14522,-1,0.9999193,8.07475e-05
14523,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14523,-1,0.00012284958,0.9998771
14524,6-thioguanine,23,24,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14524,-1,0.9999155,8.4569416e-05
14526,6-thioguanine,31,32,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,-1,-1,-1,14526,-1,0.9999075,9.250913e-05
14527,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,-1,-1,14527,-1,0.00010459652,0.99989533
14529,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14529,-1,0.99994504,5.4931792e-05
14530,Diabenese,10,11,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14530,-1,0.9998431,0.00015682794
14531,optic neuropathy,15,17,98,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14531,-1,0.000113476286,0.9998865
14532,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14532,-1,0.9999391,6.0874434e-05
14534,diabetics,4,5,22,31,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,-1,-1,14534,-1,0.0005906912,0.9994093
14535,optic neuropathy,5,7,34,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14535,-1,0.000110426336,0.9998896
14537,diabetics,18,19,120,129,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14537,-1,0.00042141456,0.99957854
14538,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14538,-1,9.980252e-05,0.9999002
14539,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14539,-1,0.99993646,6.354042e-05
14540,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14540,-1,9.471671e-05,0.9999052
14541,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14541,-1,0.9999392,6.0791706e-05
14542,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14542,-1,9.422421e-05,0.9999058
14543,se,26,27,186,188,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14543,-1,0.0049312306,0.9950688
14544,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14544,-1,0.9999242,7.586952e-05
14545,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14545,-1,0.99994016,5.9865833e-05
14546,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14546,-1,9.2726565e-05,0.99990726
14549,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14549,-1,0.9999,9.997473e-05
14550,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14550,-1,0.9999207,7.921717e-05
14551,cholesteryl esters,19,21,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14551,-1,0.99992156,7.841426e-05
14553,lipoproteinuria,4,5,27,42,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,-1,-1,14553,-1,0.0045825653,0.9954175
14555,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,-1,14555,-1,0.9999324,6.758387e-05
14558,chloramphenicol,8,9,69,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,-1,-1,14558,-1,0.9999372,6.276985e-05
14561,chloramphenicol,20,21,137,152,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,-1,-1,14561,-1,0.99994147,5.858786e-05
14562,pancytopenia,4,5,19,31,The first signs of pancytopenia began within one month of the surgery.,7072798_2,-1,-1,-1,14562,-1,0.00011976188,0.9998802
14564,chloramphenicol,13,14,84,99,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,-1,14564,-1,0.9999361,6.3864325e-05
14566,chloramphenicol,13,14,81,96,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14566,-1,0.9999442,5.58356e-05
14567,bone marrow hypoplasia,23,26,153,175,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14567,-1,0.00014165712,0.9998584
14569,chloramphenicol,11,12,79,94,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14569,-1,0.9999411,5.8863832e-05
14572,atrial tachycardia,14,16,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14572,-1,0.000125515,0.9998745
14573,intraventricular conduction abnormalities,21,24,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14573,-1,0.00015675723,0.99984324
14574,atrial tachycardia,5,7,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,-1,14574,-1,0.00015333094,0.9998467
14576,atrial flutter,10,12,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,-1,-1,-1,14576,-1,0.00030329823,0.99969673
14578,clear cell adenocarcinoma,2,5,15,40,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,-1,14578,-1,0.00018811104,0.99981195
14579,clear cell adenocarcinoma,3,6,13,38,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,-1,14579,-1,0.00022836271,0.99977165
14587,mg nitrazepam,10,12,57,70,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,-1,14587,-1,0.9997243,0.0002756313
14597,EPS,7,8,46,49,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,-1,-1,-1,14597,-1,0.00047283713,0.9995272
14602,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14602,-1,0.0033952922,0.9966047
14603,benzodiazepine lorazepam,5,7,32,56,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14603,-1,0.9999095,9.0461275e-05
14604,EPS,16,17,102,105,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,-1,-1,-1,14604,-1,0.00023024928,0.99976975
14611,chloroprocaine,28,29,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,-1,14611,-1,0.9999424,5.754169e-05
14614,chloroprocaine,20,21,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,-1,-1,-1,14614,-1,0.99994254,5.740281e-05
14617,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,-1,-1,14617,-1,0.000115811505,0.9998841
14620,chloroprocaine,29,30,133,147,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,-1,-1,14620,-1,0.9999374,6.259537e-05
14623,REM sleep deprivation,0,3,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,-1,14623,-1,0.049401745,0.9505983
14624,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14624,-1,0.010831382,0.98916864
14625,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14625,-1,0.015429289,0.9845707
14627,head twitches,14,16,104,117,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14627,-1,0.00020779412,0.9997923
14628,REMD,3,4,18,22,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14628,-1,0.0054106577,0.9945893
14630,REMD,15,16,114,118,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14630,-1,0.0011539008,0.99884605
14631,REMD,25,26,160,164,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14631,-1,0.0014139654,0.99858606
14632,twitches,29,30,189,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14632,-1,0.00015008292,0.9998499
14636,N,22,23,109,110,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14636,-1,0.176058,0.823942
14637,N,29,30,139,140,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14637,-1,0.11406827,0.8859318
14638,N,43,44,179,180,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14638,-1,0.11119912,0.8888009
14639,N,52,53,206,207,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14639,-1,0.14682171,0.8531783
14648,mg,15,16,111,113,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,-1,-1,14648,-1,0.99910176,0.0008982315
14652,premature ventricular contractions,14,17,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14652,-1,0.00013086972,0.9998691
14653,atrial flutter,18,20,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14653,-1,0.0006376022,0.9993624
14659,ventricular fibrillation,9,11,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,-1,-1,14659,-1,0.000105842875,0.99989414
14664,enlargement of the liver,1,5,23,47,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14664,-1,0.00033916772,0.99966085
14665,carbon,12,13,80,86,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14665,-1,0.99987805,0.000121883444
14667,cirrhosis of the liver,4,8,20,42,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14667,-1,0.00034818245,0.9996518
14669,splenomegaly,33,34,179,191,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14669,-1,0.000107556334,0.9998925
14670,testicular atrophy,41,43,214,232,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14670,-1,0.00014133626,0.9998586
14671,carbon tetrachloride,52,54,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14671,-1,0.9999263,7.364658e-05
14672,carbon tetrachloride,77,79,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14672,-1,0.9999236,7.641299e-05
14673,enlargement of the liver,85,89,499,523,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14673,-1,0.00031612904,0.99968386
14675,body weight,36,38,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,-1,-1,-1,14675,-1,0.0038900306,0.99611
14676,carbon tetrachloride,8,10,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,-1,-1,-1,14676,-1,0.9999156,8.437447e-05
14682,allopurinol,14,15,74,85,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,-1,-1,14682,-1,0.9999379,6.208032e-05
14687,Triamterene nephrolithiasis,0,2,0,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14687,-1,0.050470505,0.9495295
14688,dyazide,3,4,41,48,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14688,-1,0.99992967,7.036262e-05
14689,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,-1,14689,-1,0.061849475,0.9381505
14691,triamterene,10,11,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14691,-1,0.9999329,6.712027e-05
14692,uric acid salts,14,17,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14692,-1,0.9998766,0.0001233534
14693,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,-1,14693,-1,0.06490917,0.9350908
14694,hemorrhagic cystitis,1,3,17,37,Busulfan-induced hemorrhagic cystitis.,7269015_0,-1,-1,-1,14694,-1,0.00010330337,0.99989665
14695,hemorrhage cystitis,5,7,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,-1,-1,-1,14695,-1,0.00012224042,0.9998777
14696,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,-1,14696,-1,0.078989565,0.92101043
14700,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,-1,14700,-1,0.012308048,0.98769194
14702,CM,3,4,20,22,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14702,-1,0.0002693687,0.99973065
14704,DXR,12,13,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14704,-1,0.9998431,0.0001568652
14706,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14706,-1,0.00010995676,0.9998901
14707,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,-1,14707,-1,0.9998387,0.00016130738
14708,DXR,11,12,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,-1,-1,-1,14708,-1,0.9998741,0.00012591624
14710,DXR,13,14,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,-1,14710,-1,0.99982893,0.00017105127
14712,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,-1,14712,-1,0.19319959,0.8068004
14714,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,-1,14714,-1,0.20254958,0.7974505
14718,cerebral edema,1,3,8,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14718,-1,0.00010569068,0.99989426
14720,acetaminophen overdose,9,11,68,90,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14720,-1,0.10332836,0.89667165
14721,Cerebral edema,0,2,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,-1,-1,14721,-1,0.00011887058,0.99988115
14724,signs and symptoms,12,15,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14724,-1,0.000229517,0.99977046
14725,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14725,-1,9.566363e-05,0.9999043
14733,SNP,15,16,77,80,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,-1,14733,-1,0.9998591,0.00014091683
14735,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,-1,-1,-1,14735,-1,0.9998586,0.00014141122
14736,SNP,4,5,15,18,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14736,-1,0.9998585,0.00014143657
14737,SNP,2,3,11,14,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14737,-1,0.99984014,0.00015979227
14738,increase in blood pressure,10,14,71,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14738,-1,0.00059257157,0.9994074
14739,SNP,3,4,29,32,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,-1,14739,-1,0.99985325,0.00014673038
14741,SNP,16,17,106,109,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,-1,14741,-1,0.9998047,0.00019532107
14745,SNP,19,20,135,138,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,-1,14745,-1,0.9998733,0.00012670382
14747,digoxin,11,12,87,94,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,-1,-1,14747,-1,0.9999232,7.676875e-05
14748,digoxin,9,10,58,65,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14748,-1,0.9999281,7.1918745e-05
14751,luteinizing hormone,27,29,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14751,-1,0.9999217,7.825873e-05
14752,digoxin,13,14,91,98,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14752,-1,0.9999366,6.3457104e-05
14753,digoxin,23,24,146,153,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14753,-1,0.9999268,7.322488e-05
14756,digoxin,10,11,53,60,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14756,-1,0.9999194,8.052282e-05
14757,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14757,-1,0.00018296803,0.9998171
14758,digoxin,6,7,44,51,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,-1,-1,-1,14758,-1,0.99992335,7.6607874e-05
14765,Gentamicin sulfate,0,2,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14765,-1,0.9998499,0.0001500875
14766,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14766,-1,0.99991333,8.67104e-05
14769,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14769,-1,0.9998838,0.0001162287
14770,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14770,-1,0.99991727,8.2670325e-05
14771,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14771,-1,0.00010763123,0.99989235
14772,reduction in renal function,49,53,302,329,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14772,-1,0.00018795273,0.99981207
14773,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,-1,-1,14773,-1,0.00012773152,0.9998722
14774,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,-1,14774,-1,0.00011608648,0.9998839
14776,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,-1,14776,-1,0.00010776001,0.99989223
14778,Endometrial carcinoma,0,2,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14778,-1,0.0003178377,0.9996822
14779,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14779,-1,0.0007793735,0.9992206
14780,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14780,-1,0.00020248574,0.9997975
14781,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14781,-1,0.00037162268,0.9996283
14782,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14782,-1,0.00014146246,0.9998585
14783,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14783,-1,0.00032470754,0.9996753
14784,estrogens,16,17,113,122,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14784,-1,0.99988484,0.00011511655
14786,estrogens,4,5,27,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14786,-1,0.999856,0.00014403557
14787,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14787,-1,0.00013677956,0.99986315
14789,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14789,-1,0.00014358577,0.99985635
14790,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,-1,14790,-1,0.06743565,0.9325643
14794,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,-1,14794,-1,0.99991727,8.2765546e-05
14795,phophorylcreatine,13,14,79,96,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,-1,14795,-1,0.9998691,0.00013093188
14797,mM adenosine,4,6,18,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14797,-1,0.9996244,0.0003756194
14798,ATP,14,15,86,89,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14798,-1,0.99983656,0.00016346503
14799,ATP,24,25,164,167,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14799,-1,0.99982184,0.00017813212
14810,Streptomycin sulfate,0,2,0,20,Streptomycin sulfate (300 mg/kg s.c.) was injected for various periods into preweanling rats and for 3 weeks into weanling rats.,7444978_1,-1,-1,-1,14810,-1,0.99987054,0.00012940938
14811,Abnormal movements,0,2,0,18,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14811,-1,0.00011925636,0.9998807
14812,deafness,3,4,23,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14812,-1,0.0001176032,0.99988234
14815,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,-1,14815,-1,0.0030504093,0.9969496
14826,LiCl,35,36,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,-1,14826,-1,0.9999033,9.66107e-05
14828,h,16,17,77,78,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,-1,14828,-1,0.16628492,0.8337151
14829,h,1,2,2,3,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,-1,-1,-1,14829,-1,0.044903893,0.95509607
14832,h,2,3,6,7,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,-1,14832,-1,0.050110128,0.9498899
14843,Cardiovascular complications,0,2,0,28,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14843,-1,0.00013089043,0.9998691
14845,preterm labor,7,9,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14845,-1,0.00013213797,0.9998678
14846,cardiovascular complications,1,3,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14846,-1,0.000116904856,0.99988306
14848,preterm labor,13,15,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14848,-1,0.0001269125,0.99987304
14849,corticosteroid,1,2,11,25,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,-1,14849,-1,0.9997875,0.00021253811
14851,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14851,-1,0.9997696,0.00023032348
14853,benzylthiouracil,16,17,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14853,-1,0.99993336,6.664245e-05
14854,hepatic adverse effects,11,14,64,87,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14854,-1,0.00013205974,0.9998679
14855,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14855,-1,0.9998621,0.00013785888
14857,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14857,-1,0.00011136696,0.99988866
14858,cholestatic hepatitis,4,6,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14858,-1,0.00018440878,0.99981564
14860,N,10,11,65,66,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14860,-1,0.99856,0.0014400335
14861,cholestatic,6,7,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,-1,-1,14861,-1,0.0002958234,0.9997042
14865,Benzylthiouracil,14,15,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14865,-1,0.9999335,6.651318e-05
14866,ne,18,19,118,120,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14866,-1,0.998928,0.0010719778
14871,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14871,-1,0.99983,0.00016993735
14872,haematological disturbances,17,19,102,129,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14872,-1,0.00010323493,0.99989676
14874,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,-1,-1,14874,-1,0.9993154,0.00068458903
14875,Na,8,9,59,61,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14875,-1,0.9998827,0.00011728247
14876,Ca,10,11,66,68,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14876,-1,0.9998791,0.00012087304
14878,mM Na,5,7,39,44,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14878,-1,0.99902153,0.000978504
14879,mM Ca,9,11,54,59,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14879,-1,0.9986816,0.0013183301
14880,N,12,13,61,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14880,-1,0.9991518,0.0008481369
14881,mM,13,14,50,52,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14881,-1,0.9203755,0.07962452
14882,mM,29,30,109,111,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14882,-1,0.76233524,0.23766479
14883,mM,34,35,131,133,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14883,-1,0.9138581,0.086141884
14884,mM,49,50,182,184,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14884,-1,0.80083776,0.19916226
14885,mM,55,56,214,216,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14885,-1,0.9129009,0.08709912
14886,mM,7,8,33,35,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14886,-1,0.9524739,0.0475261
14887,mM,13,14,54,56,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14887,-1,0.9525191,0.047480874
14888,mM,29,30,118,120,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14888,-1,0.9364726,0.06352737
14891,Na,6,7,40,42,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14891,-1,0.99986506,0.00013494902
14892,Ca,8,9,47,49,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14892,-1,0.99986446,0.00013557832
14893,N,42,43,203,204,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14893,-1,0.99349904,0.0065010074
14896,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14896,-1,0.9999291,7.0963826e-05
14897,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14897,-1,0.9999138,8.621061e-05
14898,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14898,-1,0.999928,7.202753e-05
14899,CsA,3,4,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14899,-1,0.99987245,0.0001274935
14900,Fujimycine,9,10,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14900,-1,0.99993074,6.929462e-05
14901,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14901,-1,0.9999168,8.32314e-05
14902,macrolide,21,22,83,92,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14902,-1,0.99965084,0.00034918386
14905,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14905,-1,0.9998715,0.00012843845
14906,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14906,-1,0.10402353,0.8959764
14907,Cyclophilin A,0,2,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14907,-1,0.999803,0.00019699633
14908,CsA,11,12,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14908,-1,0.999876,0.00012395887
14909,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14909,-1,0.99991333,8.664957e-05
14910,immunosuppressants CsA,19,21,121,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14910,-1,0.9998455,0.0001544772
14911,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14911,-1,0.99991393,8.610709e-05
14913,CsA,11,12,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14913,-1,0.9998903,0.000109636676
14914,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14914,-1,0.99991834,8.1598184e-05
14917,CsA,8,9,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14917,-1,0.99988794,0.000111992806
14918,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14918,-1,0.99991596,8.4084044e-05
14919,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,-1,-1,14919,-1,0.00012281282,0.9998772
14922,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,-1,-1,14922,-1,0.0001168186,0.9998832
14924,rhabdomyosarcoma,16,17,114,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,-1,-1,-1,14924,-1,0.0001744302,0.99982566
14925,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,-1,-1,14925,-1,0.00013477307,0.9998652
14928,Triniol,7,8,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,-1,14928,-1,0.9997745,0.00022550857
14931,conjunctivitis,19,20,97,111,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,-1,-1,14931,-1,0.00013128806,0.99986875
14934,Triniol,5,6,41,48,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,-1,14934,-1,0.9999244,7.556583e-05
14941,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14941,-1,0.999936,6.399577e-05
14942,beraprost,9,10,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14942,-1,0.99994326,5.6683573e-05
14943,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14943,-1,0.99994564,5.4403023e-05
14944,prostacyclin,10,11,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14944,-1,0.9999243,7.569608e-05
14945,beraprost,12,13,81,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14945,-1,0.9999417,5.8233647e-05
14946,BPT,14,15,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14946,-1,0.9995598,0.00044020198
14947,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14947,-1,0.99994457,5.5413788e-05
14948,CLZ,23,24,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14948,-1,0.9996513,0.00034869666
14949,cAMP,38,39,250,254,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14949,-1,0.9998679,0.00013202989
14950,"cyclic adenosine 3',5'-monophosphate",40,43,256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14950,-1,0.99977523,0.00022481687
14951,BPT,13,14,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14951,-1,0.9998242,0.0001758589
14952,CLZ,31,32,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14952,-1,0.99984145,0.00015855367
14953,mg,34,35,164,166,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14953,-1,0.9942362,0.0057638986
14955,cAMP,19,20,137,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,-1,14955,-1,0.9997564,0.00024357282
14957,facial flush,12,14,79,91,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14957,-1,0.00017534352,0.9998247
14959,CLZ,25,26,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14959,-1,0.9996176,0.00038233964
14960,cAMP,1,2,14,18,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,-1,14960,-1,0.999864,0.00013601714
14964,coenzyme A,18,20,123,133,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14964,-1,0.99988437,0.00011564245
14965,diabetes mellitus,10,12,69,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,-1,-1,14965,-1,0.0001635759,0.99983644
14972,thyroiditis,10,11,72,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,-1,-1,14972,-1,0.00018231757,0.99981767
14977,ammonia coma,2,4,12,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,-1,14977,-1,0.013044484,0.9869556
14978,Ammonia coma,0,2,0,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14978,-1,0.011328731,0.9886713
14979,NH4CL,17,18,101,106,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14979,-1,0.99990237,9.763838e-05
14981,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,-1,14981,-1,0.99990416,9.588914e-05
14982,ammonia,13,14,71,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14982,-1,0.99985623,0.00014375112
14984,ammonia,28,29,149,156,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14984,-1,0.99985754,0.00014242601
14988,ammonia coma,18,20,116,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14988,-1,0.01900863,0.98099136
14989,ammonia,26,27,160,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14989,-1,0.99983907,0.00016088388
14990,ammonia,12,13,84,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14990,-1,0.999624,0.00037599306
14991,ammonia coma,15,17,100,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14991,-1,0.017122954,0.9828771
14992,ammonia,8,9,39,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14992,-1,0.9995758,0.00042417314
14993,ammonia coma,13,15,69,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14993,-1,0.014347601,0.98565245
14995,encephalopathic,13,14,91,106,These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.,761833_7,-1,-1,-1,14995,-1,0.0001098666,0.9998901
14996,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,-1,-1,14996,-1,0.00011070635,0.99988925
14997,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14997,-1,0.00010854939,0.9998914
14999,coronary heart disease,21,24,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14999,-1,0.00013106078,0.99986887
15000,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,15000,-1,0.9999007,9.92886e-05
15002,hematologic toxicity,13,15,80,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,15002,-1,0.00010828319,0.99989176
15004,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,-1,15004,-1,0.9999013,9.872601e-05
15008,human immunodeficiency virus,1,4,13,41,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15008,-1,0.9918493,0.008150735
15009,ZDV,18,19,132,135,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15009,-1,0.99989307,0.00010692641
15010,mg,21,22,141,143,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15010,-1,0.9956808,0.0043191314
15011,n,29,30,167,168,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15011,-1,0.042086728,0.9579132
15013,mg,41,42,215,217,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15013,-1,0.99644417,0.0035558208
15014,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15014,-1,0.99990785,9.2174174e-05
15015,n,57,58,292,293,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,15015,-1,0.051543616,0.94845635
15017,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,15017,-1,0.99990606,9.395989e-05
15018,folate,7,8,34,40,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,15018,-1,0.9998934,0.00010652654
15019,hematologic toxicity,1,3,7,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,-1,15019,-1,0.0001085701,0.9998914
15020,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,15020,-1,0.99990225,9.7699e-05
15021,folate,8,9,48,54,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,15021,-1,0.99988353,0.000116420706
15023,Vitamin B12,0,2,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15023,-1,0.999907,9.302361e-05
15025,ZDV,7,8,48,51,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15025,-1,0.99987984,0.00012012364
15026,myelotoxicity,18,19,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,15026,-1,0.00010784255,0.9998921
15031,Halothane hepatitis,0,2,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,-1,-1,-1,15031,-1,0.20192672,0.7980733
15032,trifluoroacetyl,9,10,67,82,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,15032,-1,0.9999201,7.9850375e-05
15033,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,15033,-1,0.24002153,0.7599785
15044,halothane hepatitis,23,25,159,178,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,-1,-1,-1,15044,-1,0.8063283,0.19367176
15047,echothiophate iodide,7,9,59,79,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,15047,-1,0.9998795,0.00012055201
15048,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15048,-1,0.99981123,0.0001887602
15049,muscle weakness,19,21,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15049,-1,0.00012447305,0.99987555
15050,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,15050,-1,0.00018926807,0.99981076
15053,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,-1,-1,15053,-1,0.9999342,6.5849636e-05
15054,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15054,-1,0.99993837,6.1575745e-05
15056,antagonist,5,6,40,50,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15056,-1,0.9995977,0.00040225434
15057,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,15057,-1,0.00015215004,0.99984777
15063,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,-1,-1,-1,15063,-1,0.99993944,6.0568695e-05
15065,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,-1,-1,15065,-1,0.99994004,6.0002258e-05
15066,neuroblastoma,9,10,55,68,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,-1,15066,-1,0.00017436918,0.99982566
15067,neuroblastoma,4,5,22,35,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,-1,15067,-1,0.0006375412,0.9993625
15068,neuroblastoma,7,8,52,65,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,-1,15068,-1,0.00026223608,0.9997378
15070,neuroblastoma,29,30,182,195,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,-1,15070,-1,0.00020273028,0.9997973
15072,DLT,13,14,77,80,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,-1,-1,15072,-1,0.00060366397,0.9993963
15075,n,13,14,88,89,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15075,-1,0.0017878821,0.9982121
15077,n,20,21,102,103,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15077,-1,0.0020481437,0.9979519
15078,n,28,29,151,152,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,15078,-1,0.003171754,0.99682826
15080,metastases,7,8,49,59,Three complete responses were observed in marrow metastases.,7707116_10,-1,-1,-1,15080,-1,0.00018124156,0.99981874
15081,neuroblastoma,7,8,43,56,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,-1,15081,-1,0.0005726257,0.99942744
15085,oxypurines,6,7,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15085,-1,0.9999057,9.434433e-05
15086,nucleosides,9,10,59,70,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15086,-1,0.99989724,0.000102791906
15087,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,15087,-1,0.00010775611,0.99989223
15088,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,-1,-1,15088,-1,0.00011888974,0.99988115
15092,oxypurines,19,20,148,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15092,-1,0.99989223,0.00010778386
15093,nucleosides,22,23,164,175,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,15093,-1,0.99988544,0.000114561684
15095,oxypurines,8,9,53,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15095,-1,0.9998908,0.00010916098
15096,nucleosides,10,11,68,79,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,15096,-1,0.9998857,0.00011436576
15098,SD,17,18,100,102,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15098,-1,0.09930964,0.9006903
15100,SD,44,45,240,242,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,15100,-1,0.08789919,0.91210073
15102,acetylsalicylate,29,30,184,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,-1,15102,-1,0.9999225,7.74789e-05
15109,oxypurines,10,11,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15109,-1,0.9998963,0.000103701415
15110,nucleosides,13,14,85,96,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15110,-1,0.9998933,0.000106713516
15111,ischemic,30,31,195,203,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,15111,-1,0.00013709189,0.9998629
15114,cyanoacrylate,6,7,56,69,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,15114,-1,0.99987185,0.00012807704
15118,DX,10,11,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,-1,15118,-1,0.9998585,0.00014146583
15120,DX,16,17,94,96,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,-1,-1,15120,-1,0.9998559,0.00014411936
15122,DX,14,15,81,83,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15122,-1,0.99984276,0.00015716779
15123,p,16,17,85,86,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,15123,-1,0.2459116,0.7540884
15125,DX,10,11,68,70,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15125,-1,0.99983263,0.00016732837
15126,contrast,17,18,94,102,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,15126,-1,0.0074796393,0.99252033
15128,p,15,16,68,69,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,15128,-1,0.036398016,0.96360195
15130,DX,16,17,101,103,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,-1,15130,-1,0.99985695,0.00014298009
15133,Prostaglandin,0,1,0,13,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15133,-1,0.9998561,0.00014383078
15134,bladder hyperactivity,2,4,25,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15134,-1,0.0001241298,0.9998759
15135,tachykinins?In,12,13,89,103,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15135,-1,0.30560488,0.69439507
15136,prostaglandin (PG) E2,23,28,190,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,15136,-1,0.9998368,0.00016322266
15137,"RP 67,580",11,13,72,81,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15137,-1,0.9996526,0.00034733553
15138,"SR 48,968",19,21,124,133,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,15138,-1,0.9997434,0.00025657477
15139,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15139,-1,0.99990547,9.452038e-05
15140,PG,19,20,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,15140,-1,0.9998423,0.00015770491
15141,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15141,-1,0.99990857,9.140635e-05
15142,"RP 67,580",11,13,73,82,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15142,-1,0.999741,0.00025895078
15143,"SR 48,968",14,16,86,95,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15143,-1,0.9997615,0.00023848827
15144,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15144,-1,0.9999106,8.945275e-05
15145,PG,40,41,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,15145,-1,0.9998684,0.00013163919
15146,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,-1,-1,15146,-1,0.9998919,0.000108140164
15147,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15147,-1,0.99990165,9.839434e-05
15148,tachykinins,12,13,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,15148,-1,0.9997439,0.00025612608
15149,tachykinins,1,2,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,-1,-1,-1,15149,-1,0.9997991,0.00020088842
15150,Prostanoids,0,1,0,11,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15150,-1,0.9999268,7.317267e-05
15151,tachykinins,6,7,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15151,-1,0.99956805,0.00043190067
15152,bladder hyperactivity,13,15,73,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,15152,-1,0.00016840882,0.99983156
15153,cardiogenic shock,1,3,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15153,-1,9.8370685e-05,0.99990165
15154,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,15154,-1,0.00012263305,0.99987733
15157,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,-1,15157,-1,0.00012601534,0.999874
15162,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,-1,-1,15162,-1,0.00013018565,0.9998698
15166,calcium chloride,8,10,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15166,-1,0.99990845,9.155998e-05
15168,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,15168,-1,0.00012161226,0.9998784
15169,misoprostol,3,4,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,-1,-1,15169,-1,0.9999436,5.6393077e-05
15172,misoprostol,9,10,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,-1,15172,-1,0.9999472,5.2835712e-05
15174,NSAID,20,21,130,135,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15174,-1,0.99991953,8.0418846e-05
15177,misoprostol,42,43,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,15177,-1,0.9999461,5.3881085e-05
15180,BUN,13,14,79,82,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,-1,15180,-1,0.9998392,0.00016076119
15182,BUN,17,18,82,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15182,-1,0.99984634,0.00015360911
15184,p,52,53,237,238,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,15184,-1,0.059722703,0.94027734
15186,K,2,3,11,12,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15186,-1,0.99982053,0.00017944958
15187,p,29,30,114,115,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,15187,-1,0.061991535,0.9380085
15188,BUN,4,5,23,26,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15188,-1,0.9998318,0.00016823549
15190,K,9,10,44,45,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,15190,-1,0.9998356,0.00016437625
15193,misoprostol,2,3,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15193,-1,0.99993825,6.170094e-05
15194,renal impairment,6,8,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,15194,-1,0.00013570997,0.9998642
15198,panic disorder,5,7,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,-1,15198,-1,0.00019669041,0.99980336
15201,panic disorder,7,9,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,-1,15201,-1,0.00011911396,0.9998809
15203,panic disorder,13,15,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,-1,15203,-1,0.00015338972,0.9998466
15207,mg,7,8,36,38,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,-1,-1,-1,15207,-1,0.98380923,0.016190693
15210,enuresis,21,22,112,120,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15210,-1,0.0001638578,0.9998361
15213,impaired memory,36,38,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15213,-1,0.00013741804,0.99986255
15214,weight loss,39,41,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,15214,-1,0.00021928057,0.9997807
15217,Cognitive deterioration,0,2,0,23,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15217,-1,0.0001374883,0.99986255
15218,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,15218,-1,0.9999374,6.2625935e-05
15219,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15219,-1,0.9999354,6.462578e-05
15220,DM,2,3,18,20,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,15220,-1,0.99961483,0.00038511798
15222,restlessness,17,18,82,94,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15222,-1,0.00013474021,0.9998653
15223,insomnia,19,20,96,104,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15223,-1,0.00011286419,0.9998871
15225,nystagmus,26,27,133,142,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15225,-1,0.00014264483,0.9998573
15226,inattention,34,35,184,195,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15226,-1,0.00023077149,0.9997693
15227,disorientation,36,37,197,211,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15227,-1,0.00011582002,0.9998841
15229,al,43,44,247,249,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15229,-1,0.5782324,0.42176756
15230,al,58,59,314,316,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15230,-1,0.5961611,0.40383893
15231,al,74,75,389,391,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,15231,-1,0.5580801,0.4419199
15232,DM,8,9,50,52,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,-1,15232,-1,0.9967694,0.0032306355
15233,cognitive deterioration,6,8,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15233,-1,0.00010868715,0.9998913
15234,DM,13,14,88,90,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,15234,-1,0.999622,0.0003780255
15237,coronary artery disease,13,16,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,-1,15237,-1,0.0001981965,0.9998018
15238,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,-1,-1,15238,-1,0.00015418905,0.99984574
15239,digitalis glycosides,3,5,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15239,-1,0.99978274,0.0002172683
15241,coronary artery disease,20,23,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,15241,-1,0.00013913368,0.9998609
15243,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15243,-1,0.48186216,0.5181378
15244,coronary artery disease,26,29,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15244,-1,0.00015761607,0.9998424
15245,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,15245,-1,0.000113615315,0.9998864
15248,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15248,-1,0.09043091,0.9095691
15249,mm Hg,12,14,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15249,-1,0.017391335,0.9826087
15250,P,15,16,93,94,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15250,-1,0.04280498,0.957195
15251,P,32,33,191,192,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15251,-1,0.043494903,0.9565051
15252,h,38,39,211,212,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,15252,-1,0.05448157,0.9455184
15254,P,15,16,120,121,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,-1,15254,-1,0.06857011,0.9314299
15258,coronary artery disease,7,10,42,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15258,-1,0.00016206664,0.9998379
15259,congestive heart failure,15,18,90,114,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,15259,-1,0.00013782262,0.9998622
15265,pulmonary tuberculosis,9,11,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,-1,15265,-1,0.00016189832,0.9998381
15270,pulmonary tuberculosis,11,13,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15270,-1,0.00014531797,0.9998547
15271,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,15271,-1,0.00012060742,0.99987936
15277,ocular hypertension,1,3,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,-1,-1,-1,15277,-1,0.00010138851,0.99989855
15278,lead,5,6,43,47,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15278,-1,0.009577384,0.9904226
15279,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15279,-1,0.000108344735,0.99989164
15280,corticosteroid glaucoma,13,15,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,15280,-1,0.015281415,0.9847186
15283,mm Hg,30,32,170,175,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,-1,15283,-1,0.0041472386,0.9958528
15286,contrast,1,2,3,11,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15286,-1,0.018105077,0.9818949
15287,hypertensive eyes,5,7,39,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,15287,-1,0.0002860468,0.99971396
15289,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,-1,15289,-1,0.00011021751,0.99988973
15291,corticosteroid glaucoma,15,17,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15291,-1,0.021327425,0.9786726
15292,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,15292,-1,0.00028227913,0.99971765
15293,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15293,-1,0.020685883,0.97931415
15294,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,15294,-1,0.00026244216,0.99973756
15298,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15298,-1,0.9998536,0.00014638326
15302,gastric adenocarcinoma,26,28,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,15302,-1,0.00012718096,0.9998728
15304,disorientation,9,10,60,74,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,-1,-1,15304,-1,0.000120030105,0.99987996
15314,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15314,-1,0.17678517,0.8232149
15315,fluoroacetate,14,15,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15315,-1,0.9999428,5.7273333e-05
15316,fluorocitrate,16,17,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15316,-1,0.99993396,6.60194e-05
15317,thiamine,18,19,122,130,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15317,-1,0.9999273,7.2677394e-05
15318,dihydrouracil,22,23,146,159,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,15318,-1,0.9999244,7.552901e-05
15321,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15321,-1,0.99992955,7.0417256e-05
15322,neuroleptics,11,12,75,87,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,15322,-1,0.9998491,0.0001509203
15324,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15324,-1,0.9999311,6.894199e-05
15326,organic psychotic,13,15,111,128,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,15326,-1,0.00037125856,0.9996288
15330,neuroleptics,21,22,92,104,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,-1,-1,15330,-1,0.9998797,0.00012031624
15332,contrast,11,12,57,65,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15332,-1,0.45219663,0.54780334
15333,carbamazepine oxcarbazepine,13,15,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15333,-1,0.9999368,6.315634e-05
15334,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,15334,-1,0.99986243,0.00013760266
15338,h,23,24,104,105,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,-1,-1,-1,15338,-1,0.043085247,0.9569148
15339,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,-1,-1,15339,-1,0.0001789812,0.999821
15341,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,-1,-1,15341,-1,0.00014359714,0.99985635
15343,Reactive oxygen species,0,3,0,23,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15343,-1,0.7068418,0.2931581
15344,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15344,-1,0.9999175,8.2454535e-05
15348,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15348,-1,0.999938,6.1975865e-05
15349,PAN,13,14,76,79,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15349,-1,0.99960774,0.0003922777
15350,N,32,33,178,179,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15350,-1,0.07584002,0.92416
15351,thiobarbituric acid reactive substances,17,21,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,-1,15351,-1,0.9989023,0.0010977089
15353,proteinuric injury,11,13,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15353,-1,0.0006470402,0.999353
15354,PAN nephropathy,14,16,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15354,-1,0.00046372565,0.9995363
15355,gall bladder stones,2,5,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15355,-1,0.00023328885,0.99976677
15357,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15357,-1,0.999943,5.6959492e-05
15359,acromegaly,6,7,39,49,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15359,-1,0.00013654212,0.9998634
15360,gall bladder stones,9,12,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15360,-1,0.00016260719,0.9998374
15362,acromegalic,30,31,192,203,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15362,-1,0.0006388802,0.9993611
15363,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15363,-1,0.0004180237,0.999582
15364,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,-1,-1,15364,-1,0.0015436375,0.99845636
15370,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15370,-1,0.99994123,5.880223e-05
15371,UDCA,10,11,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15371,-1,0.99991083,8.9171524e-05
15372,UDCA,25,26,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15372,-1,0.9999063,9.37164e-05
15373,n,16,17,88,89,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15373,-1,0.018097224,0.9819027
15374,n,23,24,108,109,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15374,-1,0.016242895,0.9837571
15375,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15375,-1,0.006115337,0.9938846
15377,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,-1,-1,15377,-1,0.37655646,0.6234436
15379,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15379,-1,0.00020102794,0.99979895
15381,gall stone disease,22,25,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15381,-1,0.00015980826,0.99984014
15382,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15382,-1,0.0002112179,0.9997888
15384,SC-48334,8,9,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15384,-1,0.99947876,0.00052124984
15386,HIV-1 infection,15,17,107,122,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15386,-1,0.0026045376,0.9973955
15387,SC-48334,43,44,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15387,-1,0.99946374,0.00053623266
15391,SC-48334,19,20,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15391,-1,0.99976486,0.0002350941
15392,mg,22,23,121,123,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15392,-1,0.98967767,0.010322266
15393,h,25,26,132,133,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15393,-1,0.37235865,0.6276413
15395,mg,31,32,155,157,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15395,-1,0.98766065,0.012339285
15396,h,34,35,166,167,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15396,-1,0.3791317,0.62086827
15400,p,25,26,120,121,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,-1,-1,-1,15400,-1,0.06428201,0.935718
15401,SC-48334,2,3,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15401,-1,0.9996724,0.00032763273
15402,human immunodeficiency virus,21,24,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15402,-1,0.99613696,0.0038630592
15404,p,24,25,136,137,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,-1,15404,-1,0.11964033,0.8803597
15408,p,32,33,143,144,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15408,-1,0.07689163,0.9231084
15409,p,52,53,194,195,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15409,-1,0.074199066,0.9258009
15411,flatulence,2,3,10,20,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15411,-1,0.00013894713,0.999861
15412,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15412,-1,0.00012983831,0.9998702
15413,weight loss,8,10,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15413,-1,0.00027993915,0.99972004
15415,nondepolarizing neuromuscular blocking agents,4,8,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,-1,15415,-1,0.9982205,0.0017794245
15417,nondepolarizing neuromuscular blocking agents,4,8,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15417,-1,0.999225,0.00077498844
15418,muscle weakness,20,22,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15418,-1,0.00011060864,0.9998894
15419,respiratory insufficiency,13,15,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,-1,-1,15419,-1,0.00013287089,0.9998671
15423,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,-1,-1,-1,15423,-1,0.99993336,6.666647e-05
15425,pathology at both the neuromuscular junction,8,14,41,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15425,-1,0.001678343,0.9983216
15426,and muscle,21,23,115,125,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15426,-1,0.0054084077,0.99459153
15428,Hepatic dysfunction,0,2,0,19,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,-1,-1,15428,-1,0.00013543927,0.9998646
15430,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15430,-1,0.0004416805,0.99955827
15431,hypersensitivity myocarditis,3,5,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15431,-1,0.00012012181,0.99987984
15433,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15433,-1,0.000413989,0.99958605
15434,hypersensitivity myocarditis,10,12,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15434,-1,0.00011935046,0.9998807
15438,septicemia,15,16,96,106,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,-1,-1,-1,15438,-1,0.00010710242,0.99989283
15439,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15439,-1,0.00045627114,0.9995437
15440,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15440,-1,0.000121827215,0.99987817
15445,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,-1,15445,-1,0.00032356664,0.99967647
15450,Hypersensitivity myocarditis,2,4,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15450,-1,0.00012891353,0.999871
15451,allergy,11,12,83,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15451,-1,0.00015787462,0.99984205
15452,penicillins,13,14,94,105,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15452,-1,0.9998319,0.00016807002
15453,sleep disturbance,1,3,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,-1,-1,-1,15453,-1,0.00011090025,0.99988914
15454,sleep disturbance,10,12,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15454,-1,0.00014694937,0.999853
15456,PRL,25,26,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15456,-1,0.99954057,0.00045941691
15457,n,19,20,117,118,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15457,-1,0.06048608,0.9395139
15458,n,32,33,162,163,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15458,-1,0.04920661,0.95079345
15459,mg,6,7,34,36,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,-1,15459,-1,0.9896862,0.010313803
15461,PRL,1,2,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,-1,15461,-1,0.9998524,0.00014753739
15462,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,-1,15462,-1,0.999556,0.00044392858
15464,PRL,5,6,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15464,-1,0.9996648,0.00033516984
15465,sleep disturbance,46,48,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15465,-1,0.00013665974,0.99986327
15466,se,56,57,275,277,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15466,-1,0.07371235,0.92628765
15468,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,-1,-1,-1,15468,-1,0.99991775,8.229139e-05
15469,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,-1,-1,-1,15469,-1,0.99993086,6.911194e-05
15470,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15470,-1,0.99993205,6.7963956e-05
15471,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15471,-1,0.9999211,7.8956386e-05
15472,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,-1,-1,-1,15472,-1,0.9999062,9.382952e-05
15473,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,-1,-1,-1,15473,-1,0.99992716,7.286156e-05
15474,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15474,-1,0.9999323,6.764756e-05
15475,mg,13,14,74,76,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15475,-1,0.9513152,0.04868481
15477,exanthema,22,23,99,108,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15477,-1,0.00013758981,0.99986243
15478,urtication,24,25,110,120,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15478,-1,0.00014727439,0.99985266
15479,itchiness,26,27,122,131,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15479,-1,0.000217352,0.9997826
15484,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15484,-1,0.9999417,5.834911e-05
15485,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15485,-1,0.9998965,0.00010346446
15486,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15486,-1,0.99994075,5.9257745e-05
15490,pulmonary edema,12,14,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15490,-1,0.00011169739,0.9998883
15491,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15491,-1,0.000118632546,0.9998814
15492,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15492,-1,0.00021438327,0.9997856
15493,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15493,-1,0.0002832307,0.9997167
15495,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15495,-1,0.00024391957,0.99975604
15497,lisinopril,6,7,37,47,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,-1,-1,15497,-1,0.9999428,5.7223053e-05
15498,enzyme inhibitors,6,8,59,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,-1,-1,-1,15498,-1,0.9998099,0.00019009641
15503,diphenhydramine hydrochloride,9,11,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,-1,-1,15503,-1,0.99992216,7.786064e-05
15512,Water intoxication,0,2,0,18,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15512,-1,0.0043707904,0.9956292
15514,abortion,8,9,81,89,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,-1,15514,-1,0.00012506628,0.99987495
15515,water intoxication,3,5,14,32,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15515,-1,0.0057547763,0.99424523
15517,abortions,12,13,98,107,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15517,-1,0.00017218923,0.99982774
15518,water intoxication,3,5,17,35,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,-1,-1,-1,15518,-1,0.006117291,0.9938828
15520,abortions,4,5,52,61,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15520,-1,0.00019687224,0.9998031
15521,water intoxication,28,30,184,202,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15521,-1,0.004969599,0.9950304
15522,asthenia,45,46,287,295,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15522,-1,0.00014630679,0.99985373
15524,headaches,51,52,323,332,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15524,-1,0.00016800751,0.9998319
15526,lactate,8,9,45,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15526,-1,0.99982905,0.00017090389
15527,lactate,15,16,81,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15527,-1,0.99984133,0.00015869764
15528,dextrose,21,22,106,114,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15528,-1,0.99989974,0.00010023008
15539,tuberculous,8,9,35,46,as well as of those of seven other tuberculous patients.,804391_4,-1,-1,-1,15539,-1,0.0005979326,0.99940205
15541,KF17837,0,1,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,-1,-1,-1,15541,-1,0.9971199,0.0028800892
15543,KF17837,0,1,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,-1,-1,-1,15543,-1,0.9984119,0.0015880459
15545,KF17837,3,4,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15545,-1,0.9998004,0.0001996722
15546,cataleptic,15,16,88,98,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15546,-1,0.00021049596,0.99978954
15548,CGS 21680,28,30,197,206,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15548,-1,0.99983835,0.00016167185
15549,KF17837,0,1,0,7,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,-1,-1,15549,-1,0.99938583,0.00061408785
15553,KF17837,2,3,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15553,-1,0.9989557,0.0010443084
15554,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15554,-1,0.9998534,0.00014661503
15555,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15555,-1,0.9999411,5.8942984e-05
15556,KF17837,4,5,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15556,-1,0.9994642,0.00053577597
15558,antagonist,12,13,82,92,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15558,-1,0.99927694,0.00072303065
15560,antagonists,28,29,198,209,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15560,-1,0.99974626,0.0002537242
15561,KF17837,2,3,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,-1,-1,15561,-1,0.9997056,0.000294361
15565,teratogenic,17,18,82,93,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,-1,15565,-1,0.00041723106,0.9995828
15566,teratogenic,2,3,10,21,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15566,-1,0.00017871619,0.99982136
15567,arthrogryposis,5,6,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15567,-1,0.00015355098,0.99984646
15569,arthrogryposis,7,8,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15569,-1,0.00015990093,0.99984
15570,teratogenic,16,17,89,100,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15570,-1,0.0003200263,0.99968004
15575,deformations,3,4,22,34,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,-1,15575,-1,0.0001499542,0.99985003
15576,nicotine sulfate,3,5,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,-1,15576,-1,0.9998869,0.00011307662
15578,deformations,1,2,4,16,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15578,-1,0.00014099854,0.999859
15581,excessive flexion or extension of one or more toes,10,19,66,116,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15581,-1,0.0007639298,0.9992361
15582,cranial hemorrhage,25,27,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,-1,15582,-1,0.00011467502,0.9998853
15584,P,6,7,39,40,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,-1,15584,-1,0.14118767,0.8588124
15588,arthrogryposis,16,17,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,-1,15588,-1,0.00017549927,0.9998246
15592,allergic,27,28,159,167,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15592,-1,0.0002522346,0.9997478
15593,allergic,34,35,219,227,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15593,-1,0.0001457462,0.9998542
15595,AX,39,40,254,256,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15595,-1,0.99894303,0.0010569859
15597,benzylpenicilloate,10,11,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15597,-1,0.99991095,8.898549e-05
15598,benzylpenicillin,12,13,94,110,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15598,-1,0.9999114,8.856155e-05
15599,PG,14,15,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15599,-1,0.9998343,0.00016570711
15601,AMP,19,20,129,132,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15601,-1,0.99986744,0.0001325462
15602,AX,23,24,139,141,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15602,-1,0.9993782,0.00062171713
15603,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15603,-1,0.9997067,0.00029324475
15604,PG,22,23,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15604,-1,0.9996711,0.0003289463
15605,AX,26,27,155,157,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15605,-1,0.9994211,0.0005789183
15606,allergic,8,9,42,50,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,-1,-1,-1,15606,-1,0.0002874487,0.9997125
15607,AX allergy,11,13,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15607,-1,0.003183499,0.9968166
15608,PG,17,18,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15608,-1,0.99883765,0.001162343
15612,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15612,-1,0.9746163,0.025383707
15613,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15613,-1,0.9136107,0.086389355
15614,PG,32,33,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15614,-1,0.9896846,0.010315419
15615,AX,3,4,16,18,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,-1,15615,-1,0.99752444,0.0024755548
15616,AX,4,5,22,24,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15616,-1,0.34324375,0.6567562
15617,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15617,-1,0.6745708,0.32542923
15618,AX,8,9,40,42,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15618,-1,0.9536124,0.04638759
15619,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15619,-1,0.95684516,0.043154847
15620,AX,3,4,21,23,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15620,-1,0.9991032,0.00089681154
15622,AX,22,23,121,123,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15622,-1,0.99924505,0.00075492956
15623,AX,38,39,175,177,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15623,-1,0.9987073,0.0012926549
15624,PG,0,1,0,2,PG was well tolerated by all 54 patients.,8092427_14,-1,-1,-1,15624,-1,0.9994252,0.0005748396
15625,PG,11,12,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,-1,15625,-1,0.99977356,0.00022641559
15634,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15634,-1,0.00017567773,0.99982435
15636,mm Hg,27,29,165,170,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15636,-1,0.03322024,0.96677977
15637,P,30,31,172,173,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15637,-1,0.10654301,0.893457
15638,mm Hg,15,17,70,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15638,-1,0.030789968,0.96921
15639,P,18,19,77,78,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15639,-1,0.08240198,0.91759807
15640,P,14,15,77,78,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,-1,-1,-1,15640,-1,0.15325242,0.8467476
15643,mm Hg,17,19,108,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15643,-1,0.016989244,0.98301077
15644,P,20,21,115,116,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15644,-1,0.061077483,0.9389225
15645,mm Hg,39,41,206,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15645,-1,0.008635327,0.9913647
15646,P,42,43,213,214,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15646,-1,0.049763232,0.95023674
15647,P,53,54,273,274,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15647,-1,0.097058795,0.90294117
15653,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,-1,-1,15653,-1,0.99984884,0.00015117985
15656,dyskinetic movements,22,24,135,155,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,-1,-1,15656,-1,0.00011743446,0.9998826
15658,physostigmine,6,7,36,49,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15658,-1,0.9999342,6.581034e-05
15659,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15659,-1,0.9999294,7.061664e-05
15660,5-MDOT,10,11,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15660,-1,0.9993291,0.0006709526
15662,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15662,-1,0.9998691,0.00013089669
15663,dyskinetic movements,20,22,119,139,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15663,-1,0.00010965341,0.9998903
15666,meperidine,4,5,23,33,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15666,-1,0.9999429,5.7102745e-05
15667,dyskinetic movements,8,10,60,80,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15667,-1,0.000115882875,0.9998841
15668,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15668,-1,0.9999343,6.562684e-05
15669,dystonic,10,11,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15669,-1,0.00014202484,0.9998579
15672,dystonic,3,4,23,31,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15672,-1,0.00013079164,0.9998692
15673,chorea,6,7,47,53,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15673,-1,0.00012750372,0.99987245
15688,hallucinatory,22,23,148,161,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,-1,-1,15688,-1,0.00014951614,0.9998505
15690,neuroleptics,6,7,42,54,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,-1,-1,15690,-1,0.9998939,0.00010614286
15693,neuromuscular disorders,7,9,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,-1,-1,15693,-1,0.00012585452,0.9998741
15696,myotonia,14,15,109,117,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15696,-1,0.00011211771,0.9998878
15697,acetazolamide,3,4,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15697,-1,0.9999356,6.4327025e-05
15698,renal calculi,9,11,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15698,-1,0.00016969463,0.99983025
15699,calculus,6,7,56,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15699,-1,0.00030584165,0.9996942
15700,calculus,15,16,111,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15700,-1,0.00037865774,0.9996213
15702,acetazolamide,5,6,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,-1,-1,15702,-1,0.99993443,6.554953e-05
15703,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,-1,15703,-1,0.9998871,0.00011290208
15705,calcium channel blockers,11,14,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,-1,15705,-1,0.99989176,0.0001082742
15707,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15707,-1,0.9998851,0.00011494018
15711,n,45,46,222,223,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15711,-1,0.07466258,0.9253375
15713,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,-1,15713,-1,0.99988806,0.00011196804
15715,calcium channel blockers,10,13,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,-1,-1,15715,-1,0.9998946,0.0001053747
15718,telangiectasia,3,4,43,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,-1,-1,15718,-1,0.00011722825,0.9998828
15720,Adalat,6,7,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15720,-1,0.9988985,0.0011015036
15721,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15721,-1,0.0001250937,0.99987495
15722,flushing,6,7,50,58,Neither patient complained of photosensitivity or flushing.,8251368_2,-1,-1,-1,15722,-1,0.0006037698,0.9993962
15723,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15723,-1,0.9999459,5.4152395e-05
15724,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15724,-1,0.0001447921,0.99985516
15725,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,-1,15725,-1,0.00014033473,0.9998597
15730,RPGN,11,12,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,-1,-1,15730,-1,0.0004439995,0.999556
15734,antiplatelet agents,12,14,81,100,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,-1,15734,-1,0.9998839,0.000116120136
15735,RPGN,4,5,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,-1,-1,15735,-1,0.00029515094,0.9997048
15737,polymyositis,3,4,10,22,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15737,-1,0.00016979255,0.9998301
15738,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15738,-1,0.00014575664,0.9998542
15739,rheumatologic diseases,7,9,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,-1,-1,15739,-1,0.00013335768,0.9998666
15741,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15741,-1,0.00012837343,0.9998716
15742,polymyositis,11,12,66,78,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15742,-1,0.0001286526,0.9998714
15751,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,-1,-1,15751,-1,0.00011062362,0.9998894
15753,neuralgia,5,6,29,38,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,-1,-1,-1,15753,-1,0.00011844276,0.9998815
15757,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15757,-1,0.999894,0.000106003776
15758,trimethaphan,7,8,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15758,-1,0.999946,5.3963977e-05
15760,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15760,-1,0.99988556,0.0001144502
15761,PGE1,8,9,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15761,-1,0.9998739,0.0001261536
15762,trimethaphan,11,12,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15762,-1,0.99994195,5.8079637e-05
15763,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15763,-1,0.9998567,0.00014330755
15766,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15766,-1,0.9999051,9.482669e-05
15767,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15767,-1,0.9998746,0.00012544489
15768,MAP,42,43,243,246,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15768,-1,0.003978701,0.99602133
15770,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15770,-1,0.9999064,9.352142e-05
15771,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15771,-1,0.9995665,0.0004334885
15772,MAP,6,7,28,31,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15772,-1,0.00543518,0.9945648
15773,P,21,22,122,123,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15773,-1,0.064385146,0.9356149
15775,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15775,-1,0.99989855,0.00010138291
15776,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15776,-1,0.9998753,0.0001246674
15777,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15777,-1,0.99982965,0.00017028188
15778,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15778,-1,0.99984753,0.0001525033
15779,P,10,11,35,36,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,-1,15779,-1,0.09354509,0.90645486
15780,P,10,11,33,34,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,-1,15780,-1,0.097591326,0.9024087
15781,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15781,-1,0.9998902,0.000109782515
15782,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15782,-1,0.99984694,0.00015304667
15784,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15784,-1,0.99983656,0.00016344724
15786,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,-1,15786,-1,0.00047550947,0.9995245
15788,AIDS,24,25,143,147,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15788,-1,0.000603412,0.99939656
15789,Kaposi's sarcoma,26,29,156,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15789,-1,0.00038317195,0.99961674
15790,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,-1,15790,-1,0.00096432253,0.9990357
15791,oedema,7,8,39,45,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,-1,15791,-1,0.0001463224,0.9998536
15793,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,-1,15793,-1,0.0008779341,0.9991221
15795,haematological toxicity,5,7,33,56,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,-1,-1,15795,-1,0.00011467174,0.9998853
15799,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,-1,15799,-1,0.00042150254,0.99957854
15800,Dup 753,0,2,0,7,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,-1,-1,15800,-1,0.99894184,0.0010581576
15802,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15802,-1,0.00010061073,0.9998994
15804,hypoalbuminemia,9,10,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15804,-1,0.00011029573,0.99988973
15806,in blood nitrogen urea,14,18,110,132,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15806,-1,0.9723808,0.027619174
15807,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15807,-1,0.99994266,5.7392306e-05
15808,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15808,-1,0.9998116,0.00018847318
15810,angiotensin II,42,44,269,283,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15810,-1,0.9998128,0.00018730137
15812,hearing loss,9,11,72,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,-1,-1,15812,-1,0.0004784582,0.9995215
15813,hearing loss,17,19,110,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,-1,-1,15813,-1,0.0006392371,0.99936074
15816,hearing loss,16,18,100,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,-1,-1,15816,-1,0.0002525392,0.99974746
15818,Lymphoma,5,6,34,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15818,-1,0.0001221231,0.9998778
15820,mg,17,18,110,112,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15820,-1,0.9873674,0.012632583
15822,neuropathic symptoms,7,9,47,67,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,-1,-1,-1,15822,-1,0.00013369636,0.99986625
15824,neuropathic symptoms,3,5,31,51,Twenty-seven patients reported neuropathic symptoms.,8384253_4,-1,-1,-1,15824,-1,0.00012651668,0.9998735
15825,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,-1,-1,15825,-1,0.00020128916,0.9997987
15826,Neuropathic,0,1,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,-1,15826,-1,0.00015297737,0.99984705
15828,signs and symptoms,11,14,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15828,-1,0.00021670765,0.99978334
15829,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15829,-1,0.20722428,0.7927757
15830,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15830,-1,0.99991524,8.4737956e-05
15832,erectile dysfunction,10,12,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15832,-1,0.00017392018,0.99982613
15835,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,-1,15835,-1,0.99991095,8.900654e-05
15836,impotence,12,13,68,77,A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml.,8386779_2,-1,-1,-1,15836,-1,0.005971674,0.99402833
15837,mg,8,9,31,33,of a combination of 3 drugs: 6 mg.,8386779_3,-1,-1,-1,15837,-1,0.97864646,0.021353567
15839,phentolamine,0,1,0,12,phentolamine and 10 micrograms.,8386779_5,-1,-1,-1,15839,-1,0.9999434,5.6662448e-05
15840,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15840,-1,0.99980277,0.00019723843
15841,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15841,-1,0.99989355,0.00010640086
15842,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15842,-1,0.99992406,7.5884345e-05
15844,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15844,-1,0.99992263,7.732088e-05
15849,ddI,7,8,36,39,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15849,-1,0.9997336,0.0002663887
15851,(AZT)One,16,17,103,111,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15851,-1,0.7251874,0.27481258
15853,AZT,25,26,169,172,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15853,-1,0.9998235,0.00017656693
15855,ddI,30,31,195,198,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15855,-1,0.99969375,0.0003062241
15856,opportunistic infections,4,6,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15856,-1,0.00015369893,0.9998462
15857,AIDS,14,15,96,100,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15857,-1,0.0003413074,0.9996587
15858,AIDS,12,13,68,72,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,-1,15858,-1,0.0006039344,0.9993961
15860,diarrhoea,5,6,32,41,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,-1,-1,15860,-1,0.00011407875,0.9998859
15862,pancreatitis,7,8,50,62,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,-1,-1,15862,-1,0.00012357284,0.9998764
15863,abdominal pain,8,10,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,-1,-1,-1,15863,-1,0.00012329532,0.99987674
15864,glucose tolerance curves,3,6,25,49,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,-1,-1,-1,15864,-1,0.010936285,0.9890637
15867,adenomas,1,2,8,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15867,-1,0.00014574788,0.9998542
15868,focal nodular hyperplasia,3,6,21,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15868,-1,0.00016113043,0.9998388
15870,adenoma,4,5,21,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15870,-1,0.00014013241,0.9998598
15871,focal nodular hyperplasia,8,11,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15871,-1,0.000138659,0.99986136
15873,adenoma,7,8,65,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15873,-1,0.00017341314,0.9998266
15874,focal nodular hyperplasia,9,12,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15874,-1,0.00019397371,0.9998061
15875,neurofilament proteins,5,7,47,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15875,-1,0.99847263,0.0015273795
15876,axonal damage,8,10,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15876,-1,0.00015082232,0.9998492
15877,neurofilament,5,6,56,69,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15877,-1,0.9960968,0.0039031932
15878,axonal injury,26,28,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15878,-1,0.00014951758,0.9998505
15879,injury in the cortex,1,5,6,26,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15879,-1,0.0007131104,0.99928695
15880,lactate,10,11,55,62,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15880,-1,0.9998833,0.00011666398
15881,Infarcts,0,1,0,8,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15881,-1,0.00019641098,0.9998036
15882,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15882,-1,0.00014365096,0.99985635
15883,axonal damage,11,13,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15883,-1,0.00016468327,0.99983525
15884,traumatic,16,17,105,114,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15884,-1,0.0001800917,0.99981993
15885,ischemic lesions,18,20,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15885,-1,0.00013644191,0.9998635
15888,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,-1,15888,-1,0.9999075,9.250543e-05
15893,neuronal degeneration,9,11,71,92,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15893,-1,0.00013755623,0.99986243
15894,glial fibrillary acidic protein,17,21,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15894,-1,0.99713933,0.0028607426
15895,neuronal loss,36,38,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15895,-1,0.00012890004,0.99987113
15896,GABA,12,13,89,93,Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.,8410199_9,-1,-1,-1,15896,-1,0.999318,0.000681958
15897,confusion.15,9,10,83,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,-1,15897,-1,0.0017403564,0.9982596
15900,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15900,-1,0.000115981704,0.999884
15901,P,10,11,55,56,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15901,-1,0.016629413,0.98337054
15903,P,27,28,150,151,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15903,-1,0.03003804,0.96996194
15908,hepatic dysfunction,17,19,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,-1,-1,15908,-1,0.00013998992,0.99986005
15911,gallstone,16,17,107,116,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15911,-1,0.00045288773,0.99954706
15912,acromegalic,20,21,138,149,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15912,-1,0.00026382675,0.99973613
15913,acromegaly,17,18,120,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,-1,15913,-1,0.00014477731,0.99985516
15916,gallstones,12,13,71,81,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15916,-1,0.00022381163,0.9997762
15917,cholecystitis,18,19,105,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15917,-1,0.00012949013,0.99987054
15920,gallstones,8,9,54,64,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,-1,-1,-1,15920,-1,0.00051466806,0.99948525
15921,gallstones,9,10,48,58,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,-1,-1,15921,-1,0.00032358392,0.99967647
15923,gallstones,20,21,127,137,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15923,-1,0.00046905607,0.9995309
15924,cholecystitis,23,24,143,156,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15924,-1,0.00012286974,0.9998771
15926,acromegalic,29,30,194,205,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15926,-1,0.0011402968,0.99885976
15928,acromegalic,17,18,116,127,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,-1,-1,-1,15928,-1,0.00035107127,0.9996489
15929,Parkinson,2,3,12,21,Increase of Parkinson disability after fluoxetine medication.,8423889_0,-1,-1,-1,15929,-1,0.00017830395,0.9998217
15932,Parkinson's disease,7,10,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,-1,-1,15932,-1,0.00043947538,0.99956053
15934,idiopathic Parkinson's disease,12,16,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15934,-1,0.00019226344,0.9998078
15935,antidepressant fluoxetine,20,22,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15935,-1,0.9998913,0.00010875029
15937,Parkinson's disease,11,14,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,-1,-1,-1,15937,-1,0.0002980386,0.9997019
15950,anxiety,37,38,214,221,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,-1,15950,-1,0.00036254482,0.9996375
15955,Sinus arrest,0,2,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,-1,15955,-1,0.00012261867,0.99987733
15958,bradyarrhythmias,15,16,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,-1,15958,-1,0.000102058606,0.99989796
15959,leukemia,4,5,23,31,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15959,-1,0.00011233486,0.9998877
15960,cardiac disease,9,11,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15960,-1,0.00014280828,0.9998572
15961,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15961,-1,0.00012990393,0.99987006
15966,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,-1,15966,-1,0.0001278022,0.9998722
15969,erosive rheumatoid arthritis,12,15,78,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15969,-1,0.0001470168,0.999853
15970,RA,16,17,108,110,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15970,-1,0.00031772893,0.9996823
15972,gold,12,13,65,69,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,-1,-1,15972,-1,0.99983954,0.00016045492
15973,RA,26,27,140,142,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,-1,15973,-1,0.021547973,0.978452
15974,RA,6,7,40,42,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,-1,15974,-1,0.000574526,0.99942553
15975,synovitis,20,21,129,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,-1,-1,-1,15975,-1,0.00013131309,0.99986863
15978,fluvoxamine,6,7,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15978,-1,0.9999393,6.06959e-05
15979,phenothiazines,8,9,53,67,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15979,-1,0.9999269,7.304195e-05
15980,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,-1,-1,15980,-1,0.9999367,6.330189e-05
15982,Pentamidine isethionate,0,2,0,23,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15982,-1,0.99992573,7.427727e-05
15983,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15983,-1,0.000112055735,0.99988794
15984,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15984,-1,0.00065719034,0.99934274
15985,torsade de pointes,1,4,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15985,-1,0.00046504478,0.99953496
15987,hypomagnesemia,12,13,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15987,-1,0.00025220428,0.9997478
15988,Torsade de pointes,0,3,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15988,-1,0.00087259494,0.99912745
15989,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15989,-1,0.9999373,6.266596e-05
15990,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,-1,-1,15990,-1,0.99993277,6.72656e-05
15991,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15991,-1,0.0009018849,0.9990982
15992,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15992,-1,0.9999299,7.0111186e-05
15993,QTc interval prolongation,1,4,5,30,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,-1,-1,-1,15993,-1,0.00035623278,0.9996438
16001,mg,40,41,234,236,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,16001,-1,0.9971819,0.0028181633
16002,mg,48,49,261,263,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,16002,-1,0.99875915,0.001240906
16003,n,4,5,17,18,PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers.,8480959_4,-1,-1,-1,16003,-1,0.1430729,0.85692704
16005,triglycerides,20,21,111,124,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,-1,16005,-1,0.9998584,0.00014164495
16007,P,23,24,108,109,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,16007,-1,0.035902604,0.96409744
16009,triglycerides,39,40,166,179,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,16009,-1,0.9997918,0.0002082084
16014,symptoms,5,6,28,36,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16014,-1,0.0001382019,0.99986184
16015,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16015,-1,0.9998535,0.00014642878
16017,mg,34,35,200,202,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,16017,-1,0.99571437,0.0042856312
16025,hypokalemia,3,4,21,32,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,16025,-1,0.00011740152,0.9998826
16027,hypomagnesemia,7,8,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,16027,-1,0.00015031436,0.9998497
16028,hypokalemia,2,3,13,24,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16028,-1,0.00011551383,0.9998845
16029,muscle weakness,5,7,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16029,-1,0.0001157764,0.99988425
16030,hypomagnesemia,9,10,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16030,-1,0.00012559236,0.99987435
16031,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,16031,-1,0.00013015141,0.9998698
16035,diuretic,1,2,14,22,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16035,-1,0.99992347,7.649005e-05
16036,obese,16,17,101,106,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16036,-1,0.00093055103,0.9990695
16037,edematous,18,19,110,119,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,16037,-1,0.0004722619,0.9995278
16038,hypokalemia,1,2,12,23,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,-1,16038,-1,0.00010964494,0.9998903
16046,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,-1,-1,16046,-1,0.000122052086,0.9998779
16049,Allergic interstitial nephritis,0,3,0,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,-1,16049,-1,0.00012503457,0.99987495
16050,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,-1,16050,-1,0.00011096233,0.999889
16059,p,25,26,123,124,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,16059,-1,0.02682054,0.9731794
16062,p,36,37,148,149,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,-1,-1,-1,16062,-1,0.032891136,0.9671088
16066,p,35,36,148,149,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,-1,-1,16066,-1,0.0225014,0.97749865
16067,Swelling,0,1,0,8,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,-1,16067,-1,0.00018272777,0.9998173
16075,uremia,14,15,83,89,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16075,-1,0.00026149655,0.9997385
16076,se,16,17,94,96,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,16076,-1,0.014554061,0.985446
16078,macrolide,13,14,92,101,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16078,-1,0.9998653,0.00013467648
16079,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,16079,-1,0.9999429,5.7086952e-05
16080,renal disease,10,12,52,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16080,-1,0.00018176335,0.99981827
16081,ESRD,13,14,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,16081,-1,0.00022688539,0.9997731
16082,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16082,-1,0.9999461,5.3931002e-05
16084,aluminum,23,24,145,153,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,16084,-1,0.99174505,0.008254931
16087,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,-1,16087,-1,0.00019529148,0.9998047
16088,preneoplastic,4,5,26,39,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16088,-1,0.0004986309,0.99950135
16089,hepatoma,7,8,50,58,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,16089,-1,0.0001705557,0.9998294
16090,hepatomas,2,3,15,24,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16090,-1,0.00013329019,0.9998667
16091,liver lesions,6,8,56,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,16091,-1,0.00012275204,0.9998772
16092,hepatomas,4,5,21,30,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,-1,16092,-1,0.00020931712,0.9997907
16095,hepatomas,17,18,96,105,"These cells proliferated further, replacing the most part of the nodules, and with this process hepatomas appeared to have been formed.",85485_6,-1,-1,-1,16095,-1,0.00025530884,0.9997447
16097,squamous cell esophageal carcinoma,7,11,44,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,-1,16097,-1,0.00025982974,0.9997402
16101,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16101,-1,0.9991689,0.00083112175
16102,squamous cell esophageal carcinoma,36,40,230,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,16102,-1,0.00020737926,0.99979264
16104,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,-1,16104,-1,0.9997346,0.00026545397
16105,CR,16,17,73,75,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,-1,16105,-1,0.00053051027,0.99946946
16106,DI,4,5,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,-1,-1,-1,16106,-1,0.9686817,0.031318292
16107,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,-1,16107,-1,0.99941444,0.00058554945
16109,granulocytopenia,9,10,37,53,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,-1,-1,16109,-1,0.00011383372,0.99988616
16112,peripheral neurotoxicity,7,9,34,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,-1,-1,16112,-1,0.0001230116,0.999877
16113,VNB,6,7,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16113,-1,0.999788,0.00021208344
16114,esophageal squamous cell carcinoma,13,17,74,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,16114,-1,0.00025647206,0.9997435
16116,VNB,12,13,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,-1,-1,16116,-1,0.99979573,0.00020423175
16120,sodium chloride,30,32,202,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,-1,16120,-1,0.9999032,9.680363e-05
16122,sodium chloride,25,27,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16122,-1,0.9998857,0.00011430361
16123,sodium chloride,33,35,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,16123,-1,0.9998791,0.000120914076
16127,in MAP,12,14,89,95,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16127,-1,0.003546579,0.9964534
16129,increase in MAP,20,23,148,163,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,16129,-1,0.0017087392,0.9982913
16130,central nervous system alpha2-adrenergic receptor agonist clonidine,3,10,16,83,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16130,-1,0.99557686,0.004423165
16131,reduction in MAP,15,18,111,127,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16131,-1,0.0032401616,0.99675983
16132,sodium chloride,34,36,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,16132,-1,0.9998983,0.00010172563
16133,sodium chloride,22,24,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,-1,16133,-1,0.9998957,0.00010433504
16134,aponidine hydrochloride,5,7,35,58,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,-1,-1,16134,-1,0.9999343,6.573043e-05
16135,apraclonidine,7,8,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16135,-1,0.9999428,5.7207282e-05
16136,apraclonidine,20,21,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,16136,-1,0.99994195,5.8034682e-05
16137,ocular hypotensive,1,3,4,22,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16137,-1,0.00010483767,0.9998951
16138,apraclonidine,29,30,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,16138,-1,0.9999479,5.2146042e-05
16139,Decreases in systolic blood pressure,0,5,0,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,-1,-1,-1,16139,-1,0.00052957056,0.9994704
16140,Conjunctival blanching,0,2,0,22,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16140,-1,0.00022650498,0.99977356
16141,mydriasis,3,4,27,36,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,16141,-1,0.00014415673,0.9998559
16142,lid,1,2,6,9,Upper lid retraction was frequently noted.,8590259_7,-1,-1,-1,16142,-1,0.00095492095,0.9990451
16143,lid,6,7,34,37,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16143,-1,0.0010859587,0.998914
16144,mm,16,17,83,85,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16144,-1,0.010666964,0.98933303
16145,entropion,31,32,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16145,-1,0.00016854166,0.99983144
16146,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,16146,-1,0.00013033571,0.9998697
16153,C,3,4,18,19,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16153,-1,0.3537251,0.64627486
16155,mg,21,22,81,83,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16155,-1,0.98819387,0.01180612
16157,mg,34,35,124,126,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,16157,-1,0.98241216,0.017587844
16159,Loss of consciousness,0,3,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16159,-1,0.00025893745,0.999741
16160,SD,16,17,78,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16160,-1,0.087044485,0.9129555
16161,C,42,43,170,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16161,-1,0.8220424,0.1779576
16162,P,50,51,187,188,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,16162,-1,0.12370175,0.87629825
16163,P,14,15,64,65,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16163,-1,0.09934142,0.9006586
16164,C,21,22,88,89,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,16164,-1,0.87669367,0.12330633
16166,P,24,25,121,122,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,-1,16166,-1,0.11831867,0.8816813
16167,C,7,8,44,45,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,-1,16167,-1,0.33365875,0.6663412
16174,droperidol,3,4,27,37,Angioedema associated with droperidol administration.,8599504_0,-1,-1,-1,16174,-1,0.99991286,8.712101e-05
16176,angioneurotic edema,5,7,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16176,-1,0.00012325229,0.99987674
16177,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,16177,-1,0.0062467987,0.99375325
16179,drug allergies,13,15,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16179,-1,0.006071019,0.993929
16181,swelling,21,22,131,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16181,-1,0.00012689678,0.99987304
16182,droperidol,37,38,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,16182,-1,0.99990916,9.082907e-05
16184,bone tumor,7,9,52,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,-1,-1,16184,-1,0.00022309345,0.9997769
16185,bone tumors,9,11,66,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16185,-1,0.00025862877,0.9997414
16186,Rosen's T5,16,19,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16186,-1,0.9357722,0.06422779
16187,T10,20,21,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,16187,-1,0.96007323,0.039926805
16192,ventricular dilation,31,33,172,192,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,-1,-1,16192,-1,0.00012120948,0.99987876
16193,cardiac abnormalities,3,5,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16193,-1,0.000117433105,0.9998826
16194,P,11,12,75,76,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,16194,-1,0.13042408,0.869576
16204,n,4,5,29,30,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16204,-1,0.15202531,0.84797466
16205,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16205,-1,0.010793233,0.9892068
16206,mm Hg,30,32,144,149,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,16206,-1,0.009816192,0.9901838
16207,n,3,4,19,20,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16207,-1,0.33049467,0.6695053
16209,mm Hg,19,21,102,107,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,16209,-1,0.01666726,0.98333275
16211,mm Hg,23,25,120,125,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16211,-1,0.002943224,0.99705684
16212,p,26,27,127,128,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,16212,-1,0.0442192,0.9557808
16217,hypertensives,34,35,219,232,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,-1,16217,-1,0.00027909438,0.9997209
16219,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,-1,-1,16219,-1,0.00014235624,0.99985766
16221,cognitive impairment,9,11,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,-1,16221,-1,0.00010574855,0.99989426
16227,mg,12,13,65,67,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,-1,16227,-1,0.99830127,0.0016987596
16230,Impairment of cognitive function,2,6,9,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,-1,16230,-1,0.00018160518,0.9998184
16238,cognitive impairment,8,10,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,-1,-1,-1,16238,-1,0.000103787184,0.99989617
16241,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,-1,-1,16241,-1,0.9999373,6.271535e-05
16243,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16243,-1,0.99905664,0.00094340893
16244,NMBAs,4,5,31,36,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,16244,-1,0.99985874,0.00014122984
16246,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,-1,-1,16246,-1,0.99993765,6.239804e-05
16248,Atracurium besylate,0,2,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16248,-1,0.99991596,8.4034014e-05
16249,benzylisoquinolinium NMBA,5,7,36,61,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,16249,-1,0.9998765,0.00012352243
16254,carotid artery thrombosis,7,10,50,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,-1,16254,-1,0.00018712337,0.9998129
16258,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,16258,-1,0.00014179225,0.99985814
16262,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16262,-1,0.00033060127,0.99966943
16263,DM,3,4,19,21,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,16263,-1,0.0006579693,0.999342
16264,hemorrhagic infarct,4,6,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,-1,-1,16264,-1,0.00015455573,0.9998454
16265,occlusion of the,4,7,31,47,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,-1,-1,16265,-1,0.0057657934,0.99423426
16266,carotid artery,9,11,62,76,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,-1,-1,16266,-1,0.004394226,0.99560577
16267,venous sinus thrombosis,15,18,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,-1,-1,16267,-1,0.00020816254,0.9997918
16270,DM,17,18,98,100,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,-1,-1,16270,-1,0.027533349,0.97246665
16272,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,-1,-1,16272,-1,0.00017786957,0.9998222
16275,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16275,-1,0.9998975,0.00010250101
16276,antineoplastic,15,16,93,107,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,16276,-1,0.0028996638,0.9971003
16280,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16280,-1,0.00026191323,0.99973804
16281,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,16281,-1,0.00021038238,0.99978966
16286,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,-1,16286,-1,0.00017250115,0.9998275
16287,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,-1,16287,-1,0.00036035033,0.99963963
16289,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,-1,-1,16289,-1,0.00023665917,0.9997633
16290,Hematologic toxicities,0,2,0,22,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,-1,-1,16290,-1,0.00013534553,0.9998646
16299,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,-1,16299,-1,0.00022201783,0.999778
16303,head and neck cancers,12,16,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,-1,16303,-1,0.00048981747,0.99951017
16304,head and neck carcinomas,5,9,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,-1,16304,-1,0.0004574243,0.9995426
16306,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16306,-1,0.9999287,7.124229e-05
16307,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,16307,-1,0.00025503244,0.99974495
16312,head and neck carcinoma,32,36,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,-1,16312,-1,0.00033766284,0.9996624
16320,factor,11,12,78,84,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,-1,-1,-1,16320,-1,0.9993231,0.00067690125
16321,Alopecia,0,1,0,8,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16321,-1,0.00013675583,0.99986327
16322,paresthesias,2,3,10,22,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,16322,-1,0.00017669528,0.9998234
16324,hematologic toxicity,2,4,17,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,-1,-1,16324,-1,0.00012420818,0.9998758
16325,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,-1,16325,-1,0.00039090918,0.9996092
16331,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,-1,16331,-1,0.9999263,7.36834e-05
16341,granulocytopenia,11,12,80,96,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,-1,-1,16341,-1,0.00011594012,0.999884
16344,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,-1,-1,16344,-1,0.00021476955,0.99978524
16351,Parkinson's disease,7,10,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,-1,-1,16351,-1,0.0001801652,0.9998198
16352,Parkinson's disease,4,7,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16352,-1,0.00024900926,0.99975103
16353,PD,8,9,51,53,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,16353,-1,0.00014431379,0.99985564
16361,PD,18,19,135,137,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,-1,16361,-1,0.00014425107,0.99985576
16366,C,15,16,85,86,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16366,-1,0.9990847,0.0009152344
16368,triamcinolone,24,25,116,129,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16368,-1,0.9999404,5.960857e-05
16369,reduction of food,45,48,225,242,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16369,-1,0.020416487,0.97958356
16370,loss in body weight,6,10,35,54,This was associated with a similar loss in body weight.,8665051_4,-1,-1,-1,16370,-1,0.00086630665,0.99913377
16372,C,9,10,52,53,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16372,-1,0.97560024,0.024399767
16373,NS,48,49,172,174,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16373,-1,0.037518717,0.9624813
16375,tetanic,20,21,111,118,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,-1,16375,-1,0.0027139166,0.9972861
16377,p,22,23,130,131,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,-1,16377,-1,0.05703499,0.942965
16382,C,14,15,54,55,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16382,-1,0.9743944,0.02560567
16383,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16383,-1,0.000117779855,0.9998822
16388,muscle necrosis,50,52,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,-1,-1,16388,-1,0.0001112066,0.9998888
16395,renal disease,26,28,173,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16395,-1,0.00013105168,0.999869
16396,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16396,-1,0.00013751976,0.99986243
16400,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,-1,16400,-1,0.000113365866,0.99988663
16403,ESRD,14,15,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,-1,-1,-1,16403,-1,0.00017510328,0.99982494
16409,ESRD,12,13,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,-1,-1,-1,16409,-1,0.00014315828,0.9998568
16411,hemorrhagic cystitis,8,10,78,98,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,-1,16411,-1,0.000106161475,0.9998938
16412,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,-1,-1,16412,-1,0.00011353667,0.9998864
16420,emesis,34,35,223,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,-1,16420,-1,0.0001038452,0.99989617
16426,cardiovascular toxicities,6,8,43,68,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,-1,-1,-1,16426,-1,0.00014504415,0.9998549
16430,critically ill,4,6,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,-1,-1,16430,-1,0.00019365712,0.99980634
16437,Leg and back pain,0,4,0,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,-1,-1,16437,-1,0.00025691136,0.99974304
16442,p,6,7,36,37,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16442,-1,0.10819896,0.89180106
16443,p,20,21,93,94,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16443,-1,0.11669904,0.8833009
16448,Leg and/or back pain,0,4,0,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,-1,16448,-1,0.0003003064,0.9996997
16453,cuprolinic blue,33,35,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,-1,16453,-1,0.9999442,5.5832083e-05
16454,heparan sulphate,1,3,4,20,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16454,-1,0.9999094,9.057452e-05
16455,cuprolinic blue,6,8,40,55,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16455,-1,0.99994576,5.420954e-05
16457,p<0.001,33,34,202,209,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,-1,16457,-1,0.08442175,0.9155783
16461,h,13,14,82,83,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16461,-1,0.78101057,0.21898939
16462,contrast,18,19,102,110,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16462,-1,0.003362206,0.9966378
16463,h,31,32,155,156,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16463,-1,0.7053469,0.2946531
16464,p<0.002,33,34,158,165,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16464,-1,0.04366467,0.9563353
16465,heparan sulphate,8,10,32,48,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16465,-1,0.99990916,9.08509e-05
16466,heparan sulphate,15,17,104,120,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,-1,16466,-1,0.9999155,8.445271e-05
16469,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,-1,16469,-1,0.9998869,0.00011315149
16473,FLA-63,0,1,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,-1,-1,16473,-1,0.99956816,0.00043179712
16476,Pimozide,0,1,0,8,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,-1,-1,-1,16476,-1,0.99994636,5.3652562e-05
16480,5-HTP,0,1,0,5,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,-1,-1,16480,-1,0.99988854,0.00011141208
16486,Microangiopathic hemolytic anemia,0,3,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16486,-1,0.00011441255,0.99988556
16487,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16487,-1,0.9999119,8.806016e-05
16489,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16489,-1,0.000114985334,0.99988496
16490,MAHA,9,10,61,65,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16490,-1,0.00052154507,0.9994785
16491,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16491,-1,0.99991953,8.045589e-05
16493,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16493,-1,0.99992836,7.169688e-05
16497,MAHA,28,29,173,177,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16497,-1,0.0052629164,0.9947371
16498,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16498,-1,0.99992,8.0025864e-05
16499,MAHA,12,13,67,71,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16499,-1,0.03157819,0.96842176
16500,MAHA,1,2,17,21,FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.,8701950_4,-1,-1,-1,16500,-1,0.0023541173,0.9976459
16501,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16501,-1,0.9999298,7.0222995e-05
16502,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16502,-1,0.99992406,7.593915e-05
16503,CyA,19,20,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16503,-1,0.999605,0.00039502425
16504,MAHA,29,30,163,167,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16504,-1,0.022675756,0.9773243
16505,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,-1,16505,-1,0.9996896,0.0003103953
16509,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,-1,16509,-1,0.99974376,0.0002562357
16510,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,-1,16510,-1,0.9999224,7.761038e-05
16512,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,-1,16512,-1,0.9999198,8.022674e-05
16513,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16513,-1,0.9999291,7.093399e-05
16514,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16514,-1,0.999936,6.406581e-05
16515,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16515,-1,0.99995255,4.740852e-05
16516,deoxycholate,4,5,22,34,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16516,-1,0.99991775,8.222009e-05
16517,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16517,-1,0.9998512,0.0001487125
16518,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16518,-1,0.9999219,7.8020064e-05
16519,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16519,-1,0.9999168,8.320054e-05
16520,Ethinyl estradiol,0,2,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16520,-1,0.999951,4.9046008e-05
16521,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16521,-1,0.9999193,8.064216e-05
16522,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16522,-1,0.99993,6.9946436e-05
16523,P,32,33,182,183,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16523,-1,0.043207575,0.9567925
16524,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,-1,16524,-1,0.99992514,7.487164e-05
16525,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16525,-1,0.99990904,9.09518e-05
16526,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16526,-1,0.9999298,7.026828e-05
16527,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16527,-1,0.9999473,5.2742587e-05
16528,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16528,-1,0.9998392,0.0001607566
16529,anticancer drugs,3,5,15,31,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,-1,-1,-1,16529,-1,0.9996666,0.0003333795
16532,anticancer drugs,4,6,26,42,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16532,-1,0.9996841,0.00031593922
16533,nitrogranulogen,8,9,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16533,-1,0.9998925,0.00010757357
16534,NG,10,11,68,70,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16534,-1,0.9997656,0.00023437524
16536,MTX,15,16,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16536,-1,0.99987376,0.00012624601
16538,5-FU,20,21,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16538,-1,0.9998814,0.00011860925
16540,CY,25,26,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16540,-1,0.99986005,0.00013998484
16541,MTX,33,34,179,182,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16541,-1,0.99986684,0.00013312696
16542,5-FU,35,36,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16542,-1,0.9999037,9.627339e-05
16543,CY,37,38,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16543,-1,0.9998679,0.00013207221
16546,MTX,1,2,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16546,-1,0.99983835,0.00016158092
16547,p,7,8,49,50,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16547,-1,0.106582776,0.89341724
16549,p,20,21,119,120,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16549,-1,0.08743624,0.91256374
16551,NG,4,5,28,30,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16551,-1,0.9998247,0.00017533048
16552,5-FU,6,7,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16552,-1,0.9999168,8.3217274e-05
16553,CY,8,9,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16553,-1,0.9998772,0.00012281143
16556,CMF,5,6,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16556,-1,0.996765,0.003235001
16557,p,13,14,90,91,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16557,-1,0.14457567,0.8554243
16560,CY,0,1,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16560,-1,0.98521197,0.014788076
16561,hemorrhagic cystitis,2,4,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16561,-1,0.00011278459,0.9998872
16562,5-FU,20,21,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16562,-1,0.9999093,9.068453e-05
16563,MTX,22,23,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16563,-1,0.9998803,0.000119698074
16564,MTX,10,11,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16564,-1,0.99989307,0.00010697006
16565,CY,12,13,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16565,-1,0.9998658,0.00013415789
16566,NG,14,15,81,83,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16566,-1,0.99981624,0.00018381928
16567,5-FU,23,24,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16567,-1,0.9999131,8.684032e-05
16568,MTX,28,29,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16568,-1,0.9998895,0.00011046824
16569,5-FU,30,31,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16569,-1,0.99991536,8.4618936e-05
16570,CY,32,33,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16570,-1,0.99986553,0.00013444066
16572,MTX,6,7,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16572,-1,0.99988055,0.000119398246
16573,5-FU,8,9,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16573,-1,0.9999206,7.93631e-05
16574,CY,10,11,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16574,-1,0.99986863,0.00013135506
16576,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,-1,16576,-1,0.9999442,5.5817072e-05
16577,p,8,9,61,62,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16577,-1,0.47078162,0.5292183
16578,locomotor hypoactivity,21,23,110,132,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16578,-1,0.00015642757,0.9998436
16580,mg,28,29,157,159,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16580,-1,0.967845,0.032154936
16583,p,15,16,120,121,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,-1,16583,-1,0.29700577,0.7029942
16586,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,-1,16586,-1,0.06439527,0.93560475
16587,nicotinic acid amide,8,11,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,-1,-1,16587,-1,0.99993217,6.786235e-05
16590,NAD,13,14,75,78,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16590,-1,0.9998561,0.00014390376
16591,AAP,27,28,139,142,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16591,-1,0.9994516,0.0005483796
16594,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,-1,16594,-1,0.00014054417,0.99985945
16595,AAP,1,2,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16595,-1,0.99984324,0.00015678012
16597,nicotinic acid amide,28,31,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16597,-1,0.9999336,6.639316e-05
16598,NAA,32,33,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16598,-1,0.99985886,0.00014117303
16599,NAD,48,49,278,281,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16599,-1,0.9998901,0.00010994679
16600,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,-1,16600,-1,0.9996922,0.00030778887
16605,NAA,11,12,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,-1,-1,16605,-1,0.9998845,0.00011547319
16608,NAA,23,24,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16608,-1,0.99987423,0.00012573588
16609,NAD,33,34,205,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16609,-1,0.9998568,0.00014311267
16610,NAA,6,7,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,-1,16610,-1,0.6734337,0.32656628
16613,cognitive and functional deficits,1,5,19,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16613,-1,0.00014265612,0.9998573
16614,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16614,-1,0.99992883,7.118146e-05
16616,bipolar disorder,14,16,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,-1,16616,-1,0.00036664057,0.9996333
16622,loss of creativity,33,36,189,207,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16622,-1,0.0002447496,0.9997552
16623,functional impairments,38,40,213,235,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16623,-1,0.00014746819,0.99985254
16626,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16626,-1,0.99993575,6.419993e-05
16627,cognitive and functional impairments,17,21,120,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16627,-1,0.00016197165,0.999838
16629,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16629,-1,0.9999298,7.019514e-05
16630,"cognitive, motivational, or creative deficits",25,32,150,195,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16630,-1,0.00031435103,0.99968565
16633,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16633,-1,0.99993324,6.6723966e-05
16637,loss of creativity,22,25,149,167,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16637,-1,0.0002738723,0.9997261
16638,functional impairments,27,29,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16638,-1,0.00016225454,0.99983776
16640,tramadol,7,8,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,-1,-1,16640,-1,0.9999405,5.9509122e-05
16642,Tramadol,0,1,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16642,-1,0.99994516,5.481379e-05
16643,cancer pain,17,19,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16643,-1,0.00014814272,0.9998518
16644,malignant pain,22,24,138,152,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16644,-1,0.00018892586,0.9998111
16646,dosulepine hydrochloride,9,11,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16646,-1,0.99993455,6.54928e-05
16647,tetraparetic,13,14,89,101,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16647,-1,0.00035535783,0.99964464
16648,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16648,-1,0.000119693046,0.9998803
16650,tramadol,21,22,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,-1,-1,16650,-1,0.99993944,6.0558414e-05
16654,calcium chloride,2,4,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16654,-1,0.9999075,9.2531714e-05
16655,4-aminopyridine,5,6,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16655,-1,0.9999167,8.332225e-05
16656,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16656,-1,0.18578653,0.8142135
16658,antidepressant overdose,11,13,73,96,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,-1,-1,16658,-1,0.009249266,0.99075073
16665,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16665,-1,0.9998313,0.00016864728
16666,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16666,-1,0.9999052,9.4709925e-05
16667,antidepressant desipramine,5,7,41,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,-1,16667,-1,0.99989486,0.000105173924
16670,CaCl2,6,7,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16670,-1,0.99987507,0.00012497079
16671,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16671,-1,0.9998634,0.00013657806
16672,antidepressant desipramine,8,10,48,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16672,-1,0.9998958,0.00010420896
16673,4-aminopyridine,16,17,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16673,-1,0.99992716,7.285962e-05
16674,NaHCO3,2,3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,-1,16674,-1,0.99988794,0.000112032445
16676,CaCl2,0,1,0,5,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16676,-1,0.9998677,0.00013233694
16677,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16677,-1,0.99991417,8.581142e-05
16679,p,6,7,42,43,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16679,-1,0.0326037,0.9673963
16681,p,13,14,67,68,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16681,-1,0.042447638,0.9575524
16682,CaCl2,19,20,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16682,-1,0.9998871,0.00011288228
16683,CaCl2,5,6,34,39,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16683,-1,0.9998977,0.00010227118
16684,4-aminopyridine,7,8,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16684,-1,0.9999231,7.688187e-05
16686,CaCl2,0,1,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16686,-1,0.999889,0.000110951114
16687,central nervous system toxicity,8,12,58,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16687,-1,0.000146221,0.99985373
16706,comatose,5,6,32,40,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16706,-1,0.0005006171,0.9994993
16707,stuporous,7,8,44,53,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16707,-1,0.0005747834,0.9994253
16708,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16708,-1,0.00022396941,0.99977607
16709,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16709,-1,0.99993753,6.244566e-05
16710,alcohol withdrawal symptoms,8,11,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16710,-1,0.007012426,0.9929876
16712,nitrazepam,19,20,123,133,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16712,-1,0.99993813,6.1896724e-05
16713,nitrazepam overdose,3,5,17,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16713,-1,0.045092296,0.95490766
16714,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16714,-1,0.99993193,6.804274e-05
16716,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,-1,16716,-1,0.999926,7.3969364e-05
16717,neurological sequelae,5,7,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,-1,-1,-1,16717,-1,0.00013117731,0.99986875
16720,hypoxaemia,21,22,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,-1,16720,-1,0.00010835177,0.99989164
16721,Valsartan,0,1,0,9,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16721,-1,0.9999449,5.5123277e-05
16722,angiotensin II antagonist,4,7,17,42,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16722,-1,0.99968505,0.00031500057
16723,essential hypertension,11,13,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16723,-1,0.00012373792,0.99987626
16724,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16724,-1,0.99994373,5.628037e-05
16725,angiotensin II antagonist,10,13,61,86,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16725,-1,0.99969137,0.00030864778
16726,valsartan,14,15,88,97,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16726,-1,0.9999467,5.3330994e-05
16727,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16727,-1,0.9999459,5.4148986e-05
16729,mg valsartan,24,26,165,177,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16729,-1,0.9997209,0.00027909916
16730,mg amlodipine,28,30,183,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16730,-1,0.9997731,0.0002269384
16731,mg amlodipine,15,17,84,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,-1,-1,-1,16731,-1,0.99972993,0.0002700898
16732,valsartan,3,4,14,23,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16732,-1,0.99994445,5.5517663e-05
16733,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16733,-1,0.99994564,5.429988e-05
16734,mm Hg,8,10,48,53,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16734,-1,0.03574977,0.96425027
16735,valsartan,13,14,66,75,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16735,-1,0.9999324,6.757716e-05
16736,p,15,16,77,78,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16736,-1,0.28006184,0.71993816
16737,valsartan,9,10,42,51,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16737,-1,0.9999447,5.532207e-05
16738,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16738,-1,0.9999497,5.0269115e-05
16739,p,16,17,78,79,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16739,-1,0.12987857,0.8701214
16741,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16741,-1,0.9999465,5.357015e-05
16742,mg,20,21,120,122,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16742,-1,0.9938121,0.006187921
16743,mg valsartan,28,30,144,156,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16743,-1,0.999681,0.00031905636
16744,mg amlodipine,35,37,169,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16744,-1,0.99965835,0.0003416605
16745,valsartan,41,42,191,200,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16745,-1,0.99994755,5.2415864e-05
16746,mg amlodipine,44,46,208,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16746,-1,0.9996691,0.00033089257
16747,mg amlodipine,51,53,236,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16747,-1,0.99971503,0.00028491046
16748,valsartan,6,7,32,41,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16748,-1,0.99994767,5.2339044e-05
16749,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16749,-1,0.9999459,5.4082517e-05
16751,valsartan,4,5,22,31,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16751,-1,0.9999466,5.337342e-05
16752,dihydropyridine calcium antagonists,25,28,150,185,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16752,-1,0.999899,0.00010098251
16753,pupillary oscillation,3,5,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16753,-1,0.00029273218,0.9997073
16754,paranoia,10,11,66,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16754,-1,0.0007142451,0.99928576
16755,paranoia,1,2,16,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16755,-1,0.00049342314,0.9995066
16756,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16756,-1,0.0049253637,0.9950747
16757,paranoia,12,13,85,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16757,-1,0.00043065805,0.99956936
16758,pupillary oscillation,2,4,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16758,-1,0.0006601527,0.9993399
16759,crack cocaine,13,15,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16759,-1,0.99984217,0.00015779275
16760,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16760,-1,0.0015515302,0.9984485
16761,n,20,21,136,137,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16761,-1,0.055988237,0.9440117
16762,crack,28,29,166,171,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16762,-1,0.99978024,0.00021979657
16763,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16763,-1,0.001287793,0.9987122
16764,n,35,36,201,202,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16764,-1,0.04512773,0.95487225
16766,phenytoin overdosages,10,12,75,96,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,-1,16766,-1,0.20287259,0.79712737
16768,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,-1,-1,16768,-1,0.00011775806,0.9998822
16772,phenytoin overdosage,3,5,17,37,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16772,-1,0.089155614,0.9108444
16773,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16773,-1,0.000114929004,0.9998851
16775,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16775,-1,0.00011507277,0.99988496
16776,cerebellar disorders,13,15,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,-1,16776,-1,0.00015359504,0.99984634
16777,Serotonin syndrome,0,2,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,-1,16777,-1,0.0015654335,0.9984346
16780,shivering,15,16,106,115,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16780,-1,0.0001527749,0.9998472
16781,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16781,-1,0.0001346155,0.9998654
16782,salivation,20,21,134,144,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16782,-1,0.0001782543,0.9998217
16786,monoamine oxidase,12,14,67,84,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,-1,-1,-1,16786,-1,0.9999012,9.8847246e-05
16792,serotonin syndrome,9,11,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16792,-1,0.020575838,0.9794241
16793,tranylcypromine,18,19,115,130,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16793,-1,0.99994564,5.4307282e-05
16798,shivering,17,18,90,99,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16798,-1,0.00018960657,0.9998104
16801,salivation,24,25,128,138,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16801,-1,0.000173637,0.9998264
16802,diaphoresis,26,27,143,154,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16802,-1,0.00026478435,0.9997352
16803,mm,4,5,18,20,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,-1,-1,-1,16803,-1,0.022450052,0.9775499
16804,mm Hg,7,9,40,45,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16804,-1,0.014192753,0.9858072
16805,mg,24,25,124,126,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16805,-1,0.9864884,0.013511631
16807,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16807,-1,0.00014822099,0.9998517
16808,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16808,-1,0.00012090612,0.9998791
16809,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16809,-1,0.00028573166,0.9997142
16812,neuromuscular paralysis,11,13,74,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,-1,-1,-1,16812,-1,0.00011069083,0.99988925
16815,HUS,10,11,53,56,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,-1,16815,-1,0.00013890714,0.9998611
16820,HUS,6,7,42,45,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16820,-1,0.00013429958,0.99986565
16821,oliguria,18,19,115,123,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16821,-1,0.00011198118,0.99988806
16822,HUS,7,8,41,44,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16822,-1,0.00012214453,0.9998778
16824,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16824,-1,0.00011410563,0.9998859
16828,urothelial cancer,15,17,102,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,-1,-1,16828,-1,0.00023991414,0.9997601
16832,transitional cell carcinoma,9,12,38,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,-1,-1,16832,-1,0.0011748481,0.99882513
16835,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,-1,-1,16835,-1,0.00015627297,0.9998437
16836,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,-1,-1,16836,-1,0.00035506382,0.9996449
16838,valproate,11,12,96,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,-1,16838,-1,0.99994004,5.9953465e-05
16839,sodium valproate,7,9,61,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16839,-1,0.9999181,8.1926904e-05
16840,neurological disorders,40,42,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16840,-1,0.00010057906,0.9998994
16841,cerebellum damage,43,45,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16841,-1,0.00013788781,0.9998621
16842,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16842,-1,0.22176531,0.77823466
16847,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,-1,16847,-1,0.19121814,0.80878186
16848,intracranial bleeding,1,3,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,-1,-1,16848,-1,0.00012246726,0.9998776
16851,pulmonary edema,23,25,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16851,-1,0.000105021085,0.999895
16852,wheezing,26,27,147,155,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16852,-1,0.00013491401,0.99986506
16853,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,-1,-1,16853,-1,0.00013839589,0.9998616
16857,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,-1,-1,16857,-1,0.00016585807,0.99983406
16869,Hoe-140,24,25,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,-1,16869,-1,0.99987555,0.00012440507
16874,antipurine,7,8,32,42,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16874,-1,0.9998499,0.0001500792
16875,lometrexol,9,10,54,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16875,-1,0.99994123,5.8770223e-05
16876,DDATHF,11,12,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16876,-1,0.9998779,0.00012207957
16877,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16877,-1,0.99993753,6.24306e-05
16878,Lometrexol,0,1,0,10,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16878,-1,0.9999317,6.834214e-05
16880,purine,19,20,129,135,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16880,-1,0.99987376,0.00012622843
16881,lometrexol,9,10,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16881,-1,0.99994886,5.113428e-05
16882,tumours,13,14,97,104,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16882,-1,0.0001822583,0.9998178
16884,lometrexol,7,8,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,-1,-1,16884,-1,0.99994326,5.6708283e-05
16887,lometrexol,8,9,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16887,-1,0.99994993,5.0119634e-05
16888,folic acid,15,17,101,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16888,-1,0.9999454,5.4622134e-05
16889,lometrexol,9,10,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16889,-1,0.9999418,5.8206006e-05
16890,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16890,-1,0.9999318,6.820984e-05
16892,lometrexol,22,23,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16892,-1,0.9999455,5.44569e-05
16893,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16893,-1,0.9999317,6.832116e-05
16898,folate,13,14,83,89,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,-1,-1,16898,-1,0.9998385,0.00016154534
16899,lometrexol,4,5,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16899,-1,0.9999422,5.7858466e-05
16900,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16900,-1,0.99993706,6.290006e-05
16902,lometrexol,24,25,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16902,-1,0.9999404,5.9578222e-05
16906,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,-1,16906,-1,0.017206019,0.98279405
16909,EDDs,11,12,73,77,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,-1,-1,16909,-1,0.00037565074,0.9996244
16911,EDDs,19,20,90,94,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16911,-1,0.0010032868,0.9989967
16912,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16912,-1,0.0061226217,0.99387735
16914,EDDs,4,5,24,28,"Compared with controls, EDDs were more frequently black, male, and younger.",8988571_3,-1,-1,-1,16914,-1,0.001143547,0.9988564
16917,EDDs,0,1,0,4,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,-1,-1,-1,16917,-1,0.057802934,0.94219714
16925,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,-1,16925,-1,0.00013148088,0.9998685
16927,preterm,7,8,46,53,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,-1,16927,-1,0.0011366311,0.99886334
16928,preterm infants,2,4,10,25,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16928,-1,0.0013141674,0.9986858
16929,sensorineural,28,29,145,158,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,-1,-1,16929,-1,0.0003134969,0.9996865
16931,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16931,-1,0.00020101911,0.99979895
16932,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,-1,-1,16932,-1,0.00015676278,0.99984324
16934,ototoxic,13,14,92,100,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,-1,16934,-1,0.0006190962,0.9993808
16937,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,-1,-1,16937,-1,0.00021179466,0.9997882
16938,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16938,-1,0.9999262,7.375187e-05
16939,choreoathetosis,3,4,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16939,-1,0.00040837316,0.99959165
16940,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16940,-1,0.9999323,6.7701396e-05
16941,oxazolidine,5,6,27,38,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16941,-1,0.9999188,8.11708e-05
16942,amphetamines,12,13,86,98,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16942,-1,0.99990153,9.84805e-05
16943,attention deficit disorder,19,22,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16943,-1,0.0002599075,0.99974006
16944,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16944,-1,0.99992645,7.3493225e-05
16945,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16945,-1,0.000112869144,0.9998871
16946,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16946,-1,0.9999348,6.5172004e-05
16947,choreoathetosis,13,14,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16947,-1,0.0003525873,0.9996474
16948,emergency department,14,16,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16948,-1,0.00072897825,0.999271
16949,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16949,-1,0.99992573,7.4299096e-05
16950,attention deficit disorder,8,11,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,-1,16950,-1,0.00026452699,0.9997354
16952,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,-1,-1,-1,16952,-1,0.9999242,7.58134e-05
16953,choreoathetoid movements,1,3,4,28,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16953,-1,0.008067621,0.99193233
16954,h,8,9,47,48,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16954,-1,0.04946151,0.9505385
16955,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16955,-1,0.00015325098,0.9998467
16956,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16956,-1,0.00016011119,0.9998399
16958,choreoathetoid movements,17,19,130,154,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,-1,-1,-1,16958,-1,0.013139907,0.9868601
16959,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,-1,16959,-1,0.0005291064,0.9994709
16960,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16960,-1,0.9999291,7.096024e-05
16961,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16961,-1,0.00011801369,0.999882
16962,choreoathetoid movements,3,5,19,43,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16962,-1,0.0013290591,0.99867094
16963,pemoline overdose,12,14,94,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16963,-1,0.055009604,0.9449904
16965,venlafaxine overdose,4,6,25,45,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,-1,-1,16965,-1,0.33696574,0.6630342
16966,venlafaxine overdose,7,9,31,51,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,-1,-1,-1,16966,-1,0.31882545,0.6811745
16973,venlafaxine overdose,13,15,65,85,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,-1,-1,16973,-1,0.3168559,0.6831441
16976,venlafaxine overdose,3,5,17,37,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16976,-1,0.300365,0.69963497
16977,generalized seizure,14,16,85,104,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16977,-1,0.00011542344,0.9998846
16978,elevated intraocular pressure,12,15,65,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16978,-1,0.00046933923,0.9995307
16979,corticosteroid,21,22,121,135,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16979,-1,0.99983156,0.00016841525
16980,IOP rise,3,5,30,38,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16980,-1,0.017111193,0.9828888
16982,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,-1,-1,16982,-1,0.9998957,0.000104320316
16985,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16985,-1,0.9998996,0.00010039969
16988,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16988,-1,0.00016941609,0.9998306
16990,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16990,-1,0.0012159223,0.9987841
16991,paracetamol overdose,14,16,76,96,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16991,-1,0.15460551,0.8453945
16992,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16992,-1,0.0078651635,0.9921348
16993,ALF,15,16,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16993,-1,0.9994572,0.00054277264
16995,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16995,-1,0.9998932,0.000106787615
16996,ALF,6,7,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16996,-1,0.56367266,0.43632734
16997,ALF,13,14,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16997,-1,0.99905187,0.00094817637
16998,P,24,25,174,175,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16998,-1,0.08825609,0.9117439
16999,P,12,13,72,73,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,-1,-1,-1,16999,-1,0.13576682,0.8642332
17001,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17001,-1,0.99988854,0.000111438334
17002,fMLP,11,12,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17002,-1,0.9998704,0.00012958696
17003,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,17003,-1,0.0030653104,0.99693465
17004,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,17004,-1,0.0006469717,0.999353
17005,P,15,16,102,103,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,17005,-1,0.17651461,0.82348543
17006,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,17006,-1,0.0004356933,0.99956435
17007,paracetamol overdose,10,12,60,80,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,17007,-1,0.14119259,0.8588074
17008,Cholesteryl hemisuccinate,0,2,0,25,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17008,-1,0.99992764,7.2310446e-05
17011,carbon tetrachloride,14,16,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17011,-1,0.9999014,9.851731e-05
17012,chloroform,17,18,128,138,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17012,-1,0.9998771,0.00012291146
17013,galactosamine,19,20,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,17013,-1,0.9999281,7.1885835e-05
17014,cholesteryl hemisuccinate,11,13,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17014,-1,0.99991953,8.0418155e-05
17015,tris salt,14,16,91,100,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17015,-1,0.9998572,0.00014284725
17016,CS,17,18,102,104,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17016,-1,0.9997986,0.00020138784
17018,carbon tetrachloride,32,34,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17018,-1,0.9998952,0.000104819694
17019,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,17019,-1,0.999782,0.00021800207
17020,CS,8,9,49,51,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17020,-1,0.99966955,0.00033042193
17021,CS,21,22,125,127,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17021,-1,0.99970347,0.0002965333
17022,ether,25,26,153,158,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17022,-1,0.99812573,0.0018742695
17023,CS,28,29,167,169,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17023,-1,0.9997477,0.0002522502
17024,tris salt,33,35,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17024,-1,0.9997942,0.000205867
17025,CSE,36,37,216,219,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17025,-1,0.9981365,0.0018634391
17026,carbon,43,44,258,264,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,17026,-1,0.999879,0.00012096574
17028,CS,13,14,64,66,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17028,-1,0.99974614,0.0002538849
17030,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17030,-1,0.99983096,0.00016900628
17031,CHCl3,32,33,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17031,-1,0.99985826,0.00014168817
17033,galactosamine,36,37,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,17033,-1,0.99992645,7.3574774e-05
17036,h,10,11,82,83,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,-1,17036,-1,0.18969052,0.81030947
17037,CS,4,5,24,26,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,-1,17037,-1,0.99231344,0.007686542
17039,CS,3,4,17,19,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,17039,-1,0.99102587,0.008974133
17040,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,17040,-1,0.0361402,0.96385986
17041,CS,15,16,78,80,"However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.",9067481_8,-1,-1,-1,17041,-1,0.9998167,0.00018332497
17042,CS,16,17,101,103,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17042,-1,0.99979144,0.00020860623
17043,CSE,20,21,131,134,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17043,-1,0.99973935,0.0002605978
17044,CS,25,26,156,158,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,17044,-1,0.9997707,0.00022928645
17045,prostaglandin,4,5,30,43,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,-1,-1,17045,-1,0.9998666,0.00013339125
17048,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,-1,-1,17048,-1,0.99987876,0.00012125701
17051,n,16,17,79,80,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17051,-1,0.14325134,0.8567487
17053,n,32,33,153,154,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17053,-1,0.07832652,0.9216734
17055,C,43,44,203,204,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17055,-1,0.48323977,0.51676023
17056,n,45,46,206,207,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,17056,-1,0.10835204,0.89164793
17060,C,5,6,30,31,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,-1,17060,-1,0.53581667,0.46418333
17063,C,6,7,39,40,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17063,-1,0.5085525,0.4914475
17064,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,17064,-1,0.9999033,9.6617434e-05
17065,ketone,3,4,31,37,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,-1,17065,-1,0.99986625,0.00013377747
17066,C,20,21,115,116,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,-1,17066,-1,0.2856493,0.7143507
17071,impairment of hepatic function,20,24,137,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,-1,17071,-1,0.00020892153,0.9997911
17072,adenomyosis,4,5,18,29,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17072,-1,0.00012582034,0.9998741
17074,fluoxetine hydrochloride,12,14,76,100,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17074,-1,0.99992657,7.341758e-05
17075,serotonin reuptake inhibitor,17,20,114,142,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17075,-1,0.99973804,0.0002619867
17076,adenomyosis,22,23,147,158,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,17076,-1,0.00011778659,0.9998822
17079,adenomyosis,26,27,170,181,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,-1,17079,-1,0.00012571385,0.99987423
17081,serotonin reuptake inhibitor,5,8,22,50,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,-1,-1,17081,-1,0.99974734,0.00025265384
17084,adenomyosis,6,7,42,53,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,-1,17084,-1,0.00012448161,0.99987555
17087,adenomyosis,5,6,39,50,This invasion eventually progresses to adenomyosis.,9098464_10,-1,-1,-1,17087,-1,0.00015454777,0.9998454
17088,Cardiovascular alterations,0,2,0,26,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17088,-1,0.000148356,0.9998516
17089,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,17089,-1,0.999897,0.00010294925
17091,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17091,-1,0.9997731,0.0002269001
17092,cardiovascular alterations,17,19,104,130,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,17092,-1,0.00013717847,0.9998628
17093,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17093,-1,0.99987006,0.00012993938
17094,cardiovascular malformations,16,18,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,17094,-1,0.00011670871,0.9998833
17095,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,-1,-1,-1,17095,-1,0.99980646,0.00019359896
17099,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17099,-1,0.9998895,0.000110512294
17100,cardiovascular malformations,26,28,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,17100,-1,0.00012520564,0.99987483
17101,cardiovascular malformations,4,6,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17101,-1,0.00012410022,0.9998759
17102,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,17102,-1,0.9998982,0.00010175832
17105,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,-1,17105,-1,0.99986506,0.00013489484
17107,ventricular septal defect,1,4,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,-1,17107,-1,0.00021455852,0.9997855
17109,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,-1,17109,-1,0.00016391344,0.9998361
17112,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,-1,-1,17112,-1,0.00022065369,0.9997794
17115,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,-1,-1,17115,-1,0.00014482524,0.99985516
17117,deoxycorticosterone,12,13,96,115,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,-1,-1,17117,-1,0.9999256,7.443696e-05
17122,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,17122,-1,0.00012844923,0.9998715
17124,benzodiazepine clonazepam,10,12,73,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17124,-1,0.99990904,9.089821e-05
17125,pilocarpine seizures,15,17,121,141,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17125,-1,0.23304428,0.76695573
17128,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,17128,-1,0.9999224,7.764562e-05
17133,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,-1,17133,-1,0.99994266,5.7379337e-05
17137,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,-1,-1,17137,-1,0.00012548915,0.9998745
17139,NMDA,8,9,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17139,-1,0.9998259,0.0001740763
17140,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,17140,-1,0.017655881,0.98234415
17143,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17143,-1,0.00012248068,0.99987745
17144,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,17144,-1,0.000115915034,0.9998841
17145,nephrotic syndrome,10,12,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,-1,17145,-1,0.000110165805,0.99988985
17146,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17146,-1,0.00013059856,0.99986935
17147,NS,18,19,127,129,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,17147,-1,0.0019270143,0.998073
17148,ribonucleic acid,5,7,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,-1,17148,-1,0.99829155,0.0017083951
17150,NS,0,1,0,2,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17150,-1,0.0046273256,0.9953727
17151,PAN,11,12,68,71,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,17151,-1,0.9998258,0.00017428359
17152,PAN,17,18,100,103,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17152,-1,0.9996706,0.0003294133
17153,NS,21,22,120,122,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,17153,-1,0.04836392,0.9516361
17154,PAN,36,37,155,158,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,-1,17154,-1,0.999595,0.0004050524
17155,NS,19,20,118,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17155,-1,0.004196053,0.995804
17156,PAN,22,23,132,135,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,17156,-1,0.9996692,0.00033083235
17157,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,-1,-1,-1,17157,-1,0.0004471283,0.9995529
17159,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,-1,-1,17159,-1,0.005578418,0.99442154
17162,benzisoxazole,3,4,15,28,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17162,-1,0.99991345,8.654123e-05
17163,serotonin 5-HT2,9,11,64,79,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,17163,-1,0.99967515,0.00032483914
17167,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,-1,-1,17167,-1,0.029832367,0.97016764
17168,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,-1,17168,-1,0.0006302954,0.9993697
17171,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,-1,-1,-1,17171,-1,0.99990857,9.137986e-05
17174,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,-1,-1,17174,-1,0.0040894425,0.9959105
17176,Atypical sensations,0,2,0,19,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,-1,-1,-1,17176,-1,0.00021397426,0.9997861
17178,tingling,5,6,32,40,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17178,-1,0.0001987957,0.9998012
17179,burning sensations,7,9,44,62,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17179,-1,0.0002895396,0.9997104
17180,sunburn,16,17,100,107,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,17180,-1,0.0012542086,0.9987458
17184,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,-1,-1,17184,-1,0.00027911193,0.9997209
17186,amikacin retinal toxicity,8,11,39,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17186,-1,0.08787842,0.9121216
17189,streptococcal endophthalmitis,19,21,135,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,17189,-1,0.0002445264,0.99975544
17190,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,-1,-1,17190,-1,0.00024199371,0.99975806
17192,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,-1,-1,17192,-1,0.00015915514,0.99984086
17193,retinal toxicity,9,11,75,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17193,-1,0.00012270303,0.99987733
17194,ischaemia,13,14,104,113,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,17194,-1,0.000114069066,0.9998859
17195,retinal toxicity,5,7,39,55,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,-1,17195,-1,0.00015528029,0.9998447
17196,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,-1,-1,17196,-1,0.9999299,7.003607e-05
17198,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17198,-1,0.42634603,0.57365394
17199,neuroleptic,23,24,149,160,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,17199,-1,0.99982435,0.00017566315
17201,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17201,-1,0.00044473386,0.9995553
17203,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,17203,-1,0.00082513725,0.9991749
17204,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17204,-1,0.9999417,5.828949e-05
17207,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,17207,-1,0.9996525,0.00034744214
17208,Carteolol,0,1,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17208,-1,0.99992883,7.111739e-05
17210,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,17210,-1,0.9998005,0.00019948874
17212,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17212,-1,0.9999397,6.0303697e-05
17214,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,17214,-1,0.99979335,0.00020663161
17215,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17215,-1,0.9999274,7.2636656e-05
17217,hyperlocomotion,13,14,107,122,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,17217,-1,0.00014194104,0.999858
17218,Carteolol,0,1,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,-1,-1,-1,17218,-1,0.99992955,7.039738e-05
17220,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17220,-1,0.99992406,7.590903e-05
17221,twitch,25,26,182,188,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,17221,-1,0.00012733437,0.9998727
17222,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,-1,17222,-1,0.9999273,7.266021e-05
17223,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17223,-1,0.99994147,5.8554455e-05
17225,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17225,-1,0.35329774,0.6467023
17226,antipsychotic effects,28,30,235,256,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,17226,-1,0.04389976,0.9561002
17228,Granulosa cell tumor of the ovary,0,6,0,33,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,-1,17228,-1,0.0005407912,0.9994592
17239,granulosa cell tumor of the ovary,19,25,104,137,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,-1,-1,17239,-1,0.0010242424,0.99897575
17240,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17240,-1,0.000102735656,0.99989724
17241,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,17241,-1,0.0003324572,0.9996675
17244,AZT,7,8,48,51,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17244,-1,0.9998431,0.0001568459
17245,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,17245,-1,0.00011158753,0.9998884
17246,AZT,0,1,0,3,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17246,-1,0.99990225,9.77953e-05
17247,macrocytic anemia,4,6,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17247,-1,0.00010906308,0.9998909
17248,AIDS,7,8,39,43,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17248,-1,0.0002103515,0.99978966
17249,AZT,12,13,66,69,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,17249,-1,0.99990714,9.29004e-05
17250,AZT,13,14,75,78,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17250,-1,0.99981993,0.00018010252
17251,thymidine,20,21,106,115,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17251,-1,0.9999075,9.243919e-05
17252,phosphate hydroxyl,24,26,136,154,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,17252,-1,0.99977237,0.00022760646
17253,AZT,5,6,28,31,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17253,-1,0.999871,0.00012891438
17254,H2O,8,9,43,46,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17254,-1,0.99976176,0.00023820784
17255,H2O,27,28,126,129,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17255,-1,0.9997869,0.00021304267
17256,AZT,36,37,170,173,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17256,-1,0.99983203,0.00016792648
17257,mg,47,48,224,226,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,17257,-1,0.9988135,0.0011864988
17258,mg,9,10,39,41,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,-1,-1,-1,17258,-1,0.9972264,0.0027735534
17260,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17260,-1,0.00013124112,0.99986875
17261,MDS,17,18,125,128,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,17261,-1,0.00012825853,0.99987173
17262,myelodysplasia,6,7,37,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17262,-1,0.00012763194,0.9998723
17263,myelodysplastic granulocytosis,12,14,81,111,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17263,-1,0.00013291488,0.9998671
17264,myelosis,31,32,224,232,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17264,-1,0.00013020553,0.9998698
17265,hyperplastic marrow,35,37,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17265,-1,0.00019188286,0.99980813
17266,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17266,-1,0.00022834289,0.99977165
17267,hypocellular,41,42,294,306,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17267,-1,0.00020791462,0.99979216
17268,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17268,-1,0.00012825547,0.99987173
17269,dyserythropoiesis,49,50,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17269,-1,0.00013120283,0.99986875
17270,hemosiderosis,51,52,370,383,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,17270,-1,0.00019724765,0.99980277
17271,AZT,2,3,16,19,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17271,-1,0.99989116,0.000108874905
17272,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,17272,-1,0.000116650066,0.9998833
17276,mg,10,11,56,58,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,-1,17276,-1,0.9972555,0.0027444619
17281,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,-1,17281,-1,0.00026412302,0.9997359
17283,Estrogens,0,1,0,9,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,-1,17283,-1,0.9998578,0.00014214775
17287,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,-1,17287,-1,0.020694137,0.9793059
17290,factor VIII,27,29,155,166,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,-1,17290,-1,0.9996613,0.00033865447
17291,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,-1,-1,-1,17291,-1,0.9998048,0.0001952766
17293,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,-1,17293,-1,0.9993948,0.0006052073
17294,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,-1,17294,-1,0.9997454,0.00025452717
17295,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,-1,17295,-1,0.99973875,0.00026118485
17298,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,-1,17298,-1,0.00020067517,0.9997993
17301,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,-1,-1,17301,-1,0.0001852918,0.9998147
17302,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,-1,17302,-1,0.00018010217,0.99981993
17304,polyuric,4,5,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17304,-1,0.0006800645,0.9993199
17307,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,17307,-1,0.00023487637,0.9997651
17309,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,-1,-1,17309,-1,0.00015703327,0.999843
17312,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,-1,-1,17312,-1,0.00025096917,0.999749
17313,NIK-247,2,3,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,-1,17313,-1,0.99941254,0.00058750383
17315,NIK-247,3,4,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17315,-1,0.99895155,0.0010484233
17317,cholinesterase inhibitors tacrine,21,24,151,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17317,-1,0.999899,0.00010100379
17318,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,17318,-1,0.99982953,0.00017043554
17319,NIK-247,0,1,0,7,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17319,-1,0.99939,0.0006100104
17320,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17320,-1,0.9999113,8.870592e-05
17321,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,17321,-1,0.99981254,0.00018746196
17322,NIK-247,3,4,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17322,-1,0.99959105,0.00040891167
17323,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17323,-1,0.99992275,7.7203214e-05
17324,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,17324,-1,0.999785,0.0002149949
17325,NIK-247,6,7,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,-1,-1,-1,17325,-1,0.9997986,0.0002013936
17328,NIK-247,4,5,28,35,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,-1,-1,17328,-1,0.9994436,0.0005564168
17330,NIK-247,4,5,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17330,-1,0.9997305,0.00026951206
17331,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,17331,-1,0.00034988945,0.9996501
17333,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,-1,-1,17333,-1,0.00013575915,0.9998642
17335,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,-1,-1,17335,-1,0.00015124775,0.9998487
17341,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,-1,17341,-1,0.9999087,9.129468e-05
17346,cardiovascular,25,26,159,173,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,-1,-1,-1,17346,-1,0.00015575734,0.9998442
17349,atrioventricular reentrant tachycardia,3,6,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17349,-1,0.00019677839,0.99980325
17351,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,17351,-1,0.00012294653,0.9998771
17352,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17352,-1,0.00030994316,0.99969006
17353,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17353,-1,0.00013091715,0.9998691
17354,atrioventricular reentrant tachycardia,12,15,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17354,-1,0.00029179733,0.99970824
17355,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,17355,-1,0.00070127466,0.9992987
17357,AVRT,24,25,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,-1,17357,-1,0.002181755,0.99781823
17359,A-86929,11,12,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,-1,17359,-1,0.99932945,0.0006705217
17362,DA,6,7,34,36,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17362,-1,0.99985254,0.00014747887
17363,agonists,10,11,50,58,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17363,-1,0.99977237,0.00022766335
17364,Parkinson's disease,15,18,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17364,-1,0.0002894524,0.9997105
17365,PD,19,20,100,102,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,17365,-1,0.00014199453,0.999858
17366,DA,5,6,33,35,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17366,-1,0.9998275,0.00017246859
17367,receptor agonists,7,9,39,56,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17367,-1,0.9993742,0.0006257894
17368,SKF-82958,11,12,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17368,-1,0.9996977,0.00030234724
17369,"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide",13,16,76,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17369,-1,0.99960846,0.00039151293
17370,A-77636,18,19,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17370,-1,0.9995813,0.00041876957
17371,"[1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride",20,28,180,275,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17371,-1,0.9995623,0.00043767222
17372,SKF-82958,43,44,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17372,-1,0.9997533,0.00024670048
17373,A-77636,53,54,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,17373,-1,0.99971896,0.00028103718
17374,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10,11,69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17374,-1,0.9998574,0.00014254285
17376,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17376,-1,0.00012117874,0.99987876
17377,A-86929,39,40,301,308,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17377,-1,0.99956423,0.0004357001
17378,DA,54,55,439,441,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,17378,-1,0.9996618,0.00033816844
17380,DA,3,4,17,19,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17380,-1,0.99983907,0.00016089907
17381,LY-171555,8,9,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17381,-1,0.99954224,0.0004578221
17382,hydrochloride,14,15,134,147,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17382,-1,0.9996482,0.00035173222
17383,A-86929,3,4,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17383,-1,0.99981135,0.0001886695
17386,LY-171555,14,15,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17386,-1,0.9998803,0.00011965277
17388,LY-171555,31,32,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17388,-1,0.9998635,0.00013645232
17390,DA,4,5,29,31,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17390,-1,0.999877,0.00012306323
17392,DA,37,38,230,232,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17392,-1,0.99987733,0.00012267074
17393,DA,1,2,7,9,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17393,-1,0.99982077,0.00017926283
17394,agents,4,5,22,28,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17394,-1,0.9992505,0.0007495601
17395,A-86929,13,14,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17395,-1,0.9995401,0.00045988642
17396,PD,28,29,166,168,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17396,-1,0.00091191614,0.99908805
17398,hydrochlorofluorocarbons,6,7,36,60,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17398,-1,0.9999405,5.9437938e-05
17399,chlorofluorocarbons,12,13,98,117,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17399,-1,0.99989223,0.00010771707
17400,Hydrochlorofluorocarbons,2,3,12,36,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17400,-1,0.99993193,6.8013556e-05
17401,HCFCs,4,5,38,43,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17401,-1,0.9998357,0.00016423603
17402,chlorofluorocarbons,15,16,114,133,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17402,-1,0.99990284,9.710142e-05
17403,CFCs,17,18,135,139,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17403,-1,0.9998449,0.00015512003
17407,HCFC 123,23,25,165,173,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17407,-1,0.99913365,0.00086635817
17409,HCFC,29,30,215,219,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17409,-1,0.99972874,0.0002712477
17412,trifluoroacetyl,16,17,118,133,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17412,-1,0.9998621,0.00013785533
17415,HCFCs,5,6,25,30,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,-1,-1,17415,-1,0.9994524,0.00054759125
17417,trifluoroacetyl,16,17,109,124,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,-1,17417,-1,0.9999287,7.133815e-05
17418,hepatocellular necrosis,7,9,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,-1,17418,-1,0.0001321977,0.9998678
17420,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,-1,17420,-1,0.15529701,0.844703
17421,HCFCs,8,9,53,58,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,-1,17421,-1,0.9997944,0.0002056471
17424,duct hamartoma,1,3,5,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,-1,-1,17424,-1,0.0004240743,0.9995759
17426,hamartoma,7,8,30,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,-1,-1,17426,-1,0.0002721476,0.9997278
17428,liver mass,5,7,26,36,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,-1,-1,-1,17428,-1,0.00020346598,0.99979657
17432,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,-1,17432,-1,0.00043658508,0.9995634
17435,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17435,-1,0.00017851232,0.9998215
17438,TLE,33,34,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17438,-1,0.0011864998,0.9988135
17439,Parkinson's disease,5,8,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,-1,17439,-1,0.00033768214,0.9996623
17440,Parkinson's disease,13,16,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,-1,-1,-1,17440,-1,0.00025509618,0.99974495
17441,Parkinson's disease,5,8,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,-1,17441,-1,0.00021857483,0.9997814
17446,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,-1,17446,-1,0.00010917327,0.9998908
17449,Parkinson's disease,4,7,27,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17449,-1,0.00022069977,0.9997793
17452,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17452,-1,0.9999387,6.1268125e-05
17453,macrolide,5,6,35,44,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17453,-1,0.99978894,0.00021112831
17454,erythromycin,3,4,16,28,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17454,-1,0.99989414,0.00010583208
17455,hydroxyl,10,11,60,68,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17455,-1,0.99852127,0.0014787891
17456,erythromycin,5,6,36,48,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17456,-1,0.99992466,7.5330914e-05
17457,gastroenteritis,10,11,75,90,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17457,-1,0.00010927502,0.9998907
17458,macrolides,27,28,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17458,-1,0.9999021,9.790447e-05
17460,erythromycin,11,12,87,99,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17460,-1,0.99993145,6.851141e-05
17461,macrolides,20,21,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17461,-1,0.99989164,0.00010835063
17462,ventricular dysrhythmias,5,7,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17462,-1,0.00019677784,0.99980325
17463,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17463,-1,0.9999453,5.46998e-05
17464,dysrhythmias,1,2,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,-1,-1,-1,17464,-1,0.00012615841,0.9998739
17465,erectile dysfunction,6,8,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,-1,17465,-1,0.0001929867,0.99980706
17467,erectile dysfunction,18,20,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,-1,17467,-1,0.00014356781,0.99985635
17471,gynecomastia,20,21,115,127,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,-1,-1,17471,-1,0.00013815485,0.99986184
17473,erectile dysfunction,15,17,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,-1,17473,-1,0.00019280663,0.9998072
17475,gynecomastia,17,18,117,129,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17475,-1,0.00015675888,0.99984324
17476,testosterone heptylate,4,6,31,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17476,-1,0.999897,0.00010304472
17477,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17477,-1,0.99982977,0.00017019454
17478,hypogonadism,11,12,90,102,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17478,-1,0.00015926293,0.99984074
17483,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,-1,-1,17483,-1,0.00014293825,0.99985707
17486,hypothalamic dysfunction,12,14,75,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17486,-1,0.00012747372,0.99987257
17487,luteinizing hormone,18,20,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17487,-1,0.99991274,8.720644e-05
17488,erectile dysfunction,30,32,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17488,-1,0.00013531858,0.9998647
17489,androgen,45,46,263,271,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17489,-1,0.9998727,0.00012732658
17493,androgen,33,34,199,207,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,-1,-1,17493,-1,0.9998826,0.00011735138
17495,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,-1,-1,17495,-1,0.00024930478,0.9997507
17499,erectile dysfunction,13,15,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,-1,17499,-1,0.00014222856,0.9998578
17500,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,-1,-1,17500,-1,0.0001632376,0.9998367
17504,gynecomastia,12,13,67,79,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,-1,-1,17504,-1,0.00013020354,0.9998698
17509,antipsychotic drug,3,5,18,36,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17509,-1,0.99981385,0.00018616789
17511,serotonin 5-HT2,12,14,75,90,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17511,-1,0.9992029,0.0007971587
17514,neuroleptics,33,34,241,253,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,-1,17514,-1,0.99981946,0.00018060743
17517,n,40,41,254,255,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17517,-1,0.0832225,0.91677755
17519,n,47,48,278,279,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17519,-1,0.12913041,0.87086964
17530,5-FU,15,16,118,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17530,-1,0.9999205,7.9484504e-05
17531,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17531,-1,0.9999372,6.277146e-05
17532,MFL,19,20,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17532,-1,0.9997874,0.0002126798
17537,5-FU,8,9,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17537,-1,0.99987173,0.00012827027
17538,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17538,-1,0.999933,6.697475e-05
17539,MFL,13,14,92,95,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17539,-1,0.9989134,0.0010865876
17542,5-FU,30,31,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17542,-1,0.9999263,7.365972e-05
17543,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17543,-1,0.9999316,6.836579e-05
17544,h,44,45,246,247,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17544,-1,0.063777655,0.9362223
17545,metastasis,13,14,69,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,-1,-1,-1,17545,-1,0.00017822065,0.99982184
17547,MFL,5,6,28,31,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,-1,17547,-1,0.98762405,0.0123760095
17553,MFL,1,2,4,7,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,-1,17553,-1,0.9995146,0.00048540888
17556,impaired heart function,17,20,110,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,-1,-1,17556,-1,0.00024071652,0.99975926
17559,Agranulocytosis,0,1,0,15,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,-1,17559,-1,0.00021034908,0.99978966
17563,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,-1,-1,-1,17563,-1,0.9998883,0.000111637324
17565,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,-1,17565,-1,0.0007606182,0.99923944
17566,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17566,-1,0.99991345,8.65272e-05
17567,AVP,6,7,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17567,-1,0.99979585,0.0002041642
17570,LiCl,9,10,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,-1,17570,-1,0.99989176,0.00010824365
17573,AVP,3,4,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17573,-1,0.99985397,0.00014595898
17574,AVP,7,8,47,50,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17574,-1,0.99968314,0.00031682718
17576,AVP,19,20,131,134,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17576,-1,0.9998659,0.00013408154
17577,AVP,24,25,159,162,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17577,-1,0.99984956,0.00015041688
17578,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17578,-1,0.00040823396,0.99959177
17579,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,-1,-1,17579,-1,0.9999392,6.0772112e-05
17581,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17581,-1,0.9999318,6.81701e-05
17583,sphincter of Oddi dyskinesia,24,28,162,190,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17583,-1,0.00022880797,0.9997712
17585,mg prostigmine,13,15,88,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17585,-1,0.9997842,0.00021590022
17586,mg morphine,18,20,126,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17586,-1,0.9997292,0.00027072607
17587,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17587,-1,0.99993277,6.7252266e-05
17588,Nitrolingual,10,11,71,83,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17588,-1,0.99984705,0.00015298059
17590,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17590,-1,0.99994123,5.871174e-05
17591,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17591,-1,0.999941,5.9003603e-05
17592,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,-1,17592,-1,0.9999294,7.058628e-05
17594,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17594,-1,0.99993324,6.679196e-05
17596,sphincter of Oddi dyskinesia,23,27,128,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17596,-1,0.00033735426,0.99966264
17597,mg,23,24,182,184,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17597,-1,0.9563414,0.043658577
17598,mg,31,32,202,204,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17598,-1,0.9717476,0.02825247
17599,mg,39,40,222,224,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,-1,17599,-1,0.9792085,0.020791516
17601,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17601,-1,0.9999465,5.35771e-05
17602,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17602,-1,0.99994445,5.5531644e-05
17604,hemicholinium-3,24,25,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17604,-1,0.9998635,0.00013648486
17606,quinpirole,49,50,403,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17606,-1,0.99993896,6.102235e-05
17608,2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride,54,59,451,531,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17608,-1,0.99978966,0.00021040185
17610,hydrobromide,64,65,626,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17610,-1,0.9998419,0.00015800142
17611,polyamines,67,68,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17611,-1,0.9999038,9.613495e-05
17613,mg,5,6,18,20,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17613,-1,0.9717288,0.028271247
17616,mg,20,21,86,88,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17616,-1,0.96312577,0.036874183
17617,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17617,-1,0.9999511,4.8861653e-05
17618,mg,29,30,119,121,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17618,-1,0.97147346,0.028526532
17620,glomerular disease,3,5,41,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,-1,17620,-1,9.89472e-05,0.99990106
17623,mesangial,20,21,136,145,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,-1,-1,17623,-1,0.0033682273,0.9966318
17625,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,-1,17625,-1,0.00014864533,0.99985135
17636,burning painful,15,17,93,108,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,-1,-1,17636,-1,0.00014515704,0.9998548
17638,acute pain,21,23,124,134,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,-1,-1,17638,-1,0.00017972701,0.9998203
17642,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,-1,-1,17642,-1,0.00012644238,0.9998735
17643,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,-1,-1,17643,-1,0.00015846358,0.9998416
17644,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,-1,-1,17644,-1,0.00016551271,0.9998344
17646,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17646,-1,0.00017343745,0.9998266
17647,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17647,-1,0.00018404901,0.999816
17651,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17651,-1,0.00016669171,0.9998332
17653,P,27,28,126,127,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17653,-1,0.04257919,0.9574208
17654,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,-1,-1,17654,-1,0.00023343858,0.9997665
17657,hearing loss,7,9,46,58,None of the patients complained of subjective hearing loss.,9522143_7,-1,-1,-1,17657,-1,0.00015810513,0.9998419
17658,neurological deficit,2,4,12,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,-1,17658,-1,0.000118904805,0.999881
17660,neurological deficit,6,8,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17660,-1,0.00011704886,0.99988294
17661,mg,16,17,110,112,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17661,-1,0.98292196,0.017078057
17663,hypoaesthesia,19,20,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17663,-1,0.000147544,0.9998524
17664,loss of pinprick,32,35,178,194,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17664,-1,0.0011128649,0.9988871
17665,lead,49,50,304,308,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17665,-1,0.0006265192,0.9993735
17666,neurological deficit,53,55,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17666,-1,0.00010951411,0.99989045
17667,Transient neurologic symptoms,0,3,0,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,-1,-1,-1,17667,-1,0.00013147284,0.9998685
17671,transient neurologic symptoms,6,9,42,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17671,-1,0.00013694896,0.999863
17672,TNSs,10,11,73,77,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17672,-1,0.00025847077,0.9997415
17681,TNSs,24,25,164,168,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,-1,17681,-1,0.00058090006,0.9994191
17688,TNSs,12,13,67,71,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,-1,17688,-1,0.00093231886,0.9990677
17690,TNSs,9,10,61,65,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17690,-1,0.0005398791,0.99946016
17692,P,18,19,106,107,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17692,-1,0.5431459,0.45685413
17694,TNSs,33,34,176,180,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17694,-1,0.00050533755,0.9994947
17698,P,37,38,190,191,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,-1,-1,-1,17698,-1,0.060211215,0.93978876
17701,TNSs,25,26,154,158,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,-1,17701,-1,0.00043884284,0.99956113
17703,iron dextran,16,18,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17703,-1,0.9999174,8.262234e-05
17704,blind,21,22,143,148,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17704,-1,0.063191034,0.93680894
17705,iron dextran,12,14,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,-1,-1,-1,17705,-1,0.99991536,8.4687636e-05
17707,MP,23,24,148,150,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,-1,17707,-1,0.99978155,0.00021850775
17708,mg,29,30,129,131,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,-1,-1,-1,17708,-1,0.9948999,0.005100148
17709,MP,0,1,0,2,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17709,-1,0.97002083,0.02997922
17710,mg,13,14,49,51,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17710,-1,0.9967385,0.0032615613
17711,MP,0,1,0,2,MP before and after TDI (group 3).,9523850_6,-1,-1,-1,17711,-1,0.16031581,0.8396842
17712,MP,6,7,46,48,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,-1,-1,-1,17712,-1,0.99974364,0.0002563914
17713,mg,4,5,21,23,We conclude that 125 mg i.v.,9523850_12,-1,-1,-1,17713,-1,0.9871041,0.012895947
17714,MP,0,1,0,2,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17714,-1,0.3499289,0.65007114
17715,iron dextran,10,12,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17715,-1,0.9999069,9.307188e-05
17716,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,-1,17716,-1,0.00071190234,0.99928814
17718,gastrointestinal motility disorders,18,21,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,-1,-1,17718,-1,0.00013156515,0.9998684
17719,Prolongation of QT interval,0,4,0,27,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17719,-1,0.00026762538,0.9997323
17720,torsades de pointes,5,8,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17720,-1,0.0004357381,0.99956423
17721,sudden cardiac death,10,13,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17721,-1,0.00012484692,0.9998752
17722,erythromycin,20,21,132,144,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17722,-1,0.999926,7.3981355e-05
17723,azole antifungal agents,22,25,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17723,-1,0.99992394,7.602849e-05
17725,gastroesophageal reflux disorder,14,17,89,121,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,-1,-1,17725,-1,0.00013537418,0.9998646
17736,n,47,48,288,289,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17736,-1,0.008044447,0.9919556
17738,n,59,60,346,347,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17738,-1,0.0077884253,0.9922116
17739,dyskinetic parkinsonian,1,3,4,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,-1,17739,-1,0.0002217889,0.9997782
17741,hyperkinetic abnormal involuntary movement,9,13,57,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,-1,17741,-1,0.00013288294,0.9998671
17744,sinusitis,10,11,75,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,-1,17744,-1,0.00012352808,0.9998765
17746,mg,12,13,66,68,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17746,-1,0.991384,0.008616
17747,sinusitis,29,30,157,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17747,-1,0.00012193541,0.99987805
17748,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,-1,-1,17748,-1,0.00023796766,0.999762
17751,flatulence,9,10,59,69,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,-1,-1,17751,-1,0.00014188341,0.99985814
17754,mg,11,12,69,71,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17754,-1,0.9953635,0.0046364604
17755,sinusitis,23,24,138,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17755,-1,0.00012049512,0.9998795
17756,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,-1,17756,-1,0.00015658663,0.99984336
17767,n,9,10,59,60,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,-1,17767,-1,0.05848314,0.9415168
17771,p,26,27,152,153,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,-1,17771,-1,0.08151575,0.9184842
17772,p,15,16,94,95,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17772,-1,0.091823824,0.9081762
17774,p,27,28,152,153,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17774,-1,0.08643008,0.91356987
17775,p,18,19,95,96,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,-1,17775,-1,0.11213128,0.88786864
17777,p,14,15,82,83,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17777,-1,0.14010791,0.85989213
17778,p,27,28,132,133,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17778,-1,0.08850789,0.91149217
17779,p,35,36,167,168,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17779,-1,0.06398731,0.93601274
17782,disease,12,13,78,85,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,-1,-1,17782,-1,0.00016010401,0.9998399
17788,Endometrial cancers,0,2,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,-1,-1,17788,-1,0.00016579151,0.9998342
17798,hyperkalaemia,16,17,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,-1,-1,17798,-1,0.00010897814,0.99989104
17805,hyperkalaemia,30,31,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,-1,-1,-1,17805,-1,0.00010362462,0.9998964
17810,Acute hepatitis,0,2,0,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17810,-1,0.000110475194,0.9998895
17812,erythroblastocytopenia,8,9,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17812,-1,0.00013136382,0.99986863
17814,acute hepatitis,4,6,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,-1,-1,17814,-1,0.00012352761,0.9998765
17816,beta lactam,10,12,80,91,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17816,-1,0.9998834,0.000116628275
17819,erythroblastocytopenia,35,36,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17819,-1,0.000121425925,0.9998785
17821,beta lactam,20,22,122,133,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,-1,-1,17821,-1,0.9998288,0.00017118017
17823,NMDA,6,7,36,40,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,-1,17823,-1,0.99985313,0.00014680903
17825,NMDA,16,17,83,87,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,-1,-1,17825,-1,0.99985874,0.00014124978
17826,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,-1,-1,17826,-1,0.00012283413,0.9998771
17829,"5,7-DCKA",3,4,28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17829,-1,0.99971634,0.00028358388
17831,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17831,-1,0.00012907984,0.9998709
17832,"5,7-DCKA",0,1,0,8,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,-1,17832,-1,0.999731,0.00026895042
17835,NMDA,11,12,65,69,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,-1,17835,-1,0.9998524,0.00014750502
17837,on the peripheral nervous system,3,8,26,58,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,-1,-1,-1,17837,-1,0.0006621993,0.99933773
17839,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17839,-1,0.99768996,0.002310008
17841,CDDP,15,16,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17841,-1,0.99988115,0.0001187823
17843,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17843,-1,0.9998913,0.000108728826
17845,peripheral nervous system damage,27,31,177,209,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17845,-1,0.00011741855,0.9998826
17846,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,-1,17846,-1,0.99993384,6.617193e-05
17848,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17848,-1,0.9999217,7.825888e-05
17849,peripheral neurotoxicity,6,8,53,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17849,-1,0.00010165435,0.9998983
17851,CDDP,23,24,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,-1,17851,-1,0.9998628,0.00013721838
17852,platinum,5,6,33,41,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17852,-1,0.9997981,0.00020194221
17853,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17853,-1,0.9998704,0.00012960353
17854,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17854,-1,0.99985623,0.00014371451
17856,CDDP,25,26,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17856,-1,0.9998702,0.00012981119
17858,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,-1,-1,-1,17858,-1,0.99990845,9.159439e-05
17860,thyrotoxicosis,7,8,36,50,Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.,9653867_0,-1,-1,-1,17860,-1,0.000315461,0.9996846
17861,Eating disorders,0,2,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,-1,-1,17861,-1,0.00021833468,0.99978167
17863,eating disorders,14,16,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17863,-1,0.0006714237,0.9993286
17864,metabolic disturbances,23,25,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17864,-1,0.00014733213,0.99985266
17865,diuretic,26,27,173,181,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17865,-1,0.99988043,0.00011951216
17866,eating disorders,14,16,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17866,-1,0.0004492536,0.99955076
17867,thyrotoxicosis,24,25,148,162,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17867,-1,0.00018731116,0.99981266
17869,trimipramine,1,2,9,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,-1,17869,-1,0.99994016,5.9832382e-05
17871,Trimipramine,0,1,0,12,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17871,-1,0.99994576,5.4225056e-05
17872,TRI,2,3,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17872,-1,0.99971014,0.00028977657
17874,imipramine,16,17,93,103,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17874,-1,0.9999379,6.2099396e-05
17878,TRI,11,12,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,-1,17878,-1,0.99944085,0.0005591095
17880,TRI,0,1,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,-1,17880,-1,0.9994561,0.00054387044
17881,TRI,4,5,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17881,-1,0.99957746,0.0004225957
17882,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17882,-1,0.24342045,0.7565795
17884,twitches,25,26,148,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17884,-1,0.00017645233,0.99982363
17885,TRI,0,1,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17885,-1,0.99661714,0.0033828667
17887,quinpirole,13,14,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17887,-1,0.9999337,6.6260836e-05
17889,stereotypies,1,2,4,16,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17889,-1,0.00031804442,0.99968195
17891,TRI,11,12,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17891,-1,0.99982065,0.00017935858
17896,TRI,13,14,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,-1,-1,-1,17896,-1,0.99897265,0.0010273668
17901,irritable bowel syndrome,13,16,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,-1,17901,-1,0.00011823874,0.99988174
17902,Irritable bowel syndrome,2,5,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17902,-1,0.00012416246,0.9998758
17903,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17903,-1,0.00012258047,0.99987745
17904,disordered gastrointestinal motility,19,22,110,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17904,-1,0.00011181035,0.9998882
17906,motility and symptoms,20,23,117,138,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17906,-1,0.00015537729,0.99984455
17907,irritable bowel syndrome,25,28,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17907,-1,0.00012248056,0.99987745
17908,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17908,-1,0.00012971752,0.9998703
17909,IBS,5,6,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17909,-1,0.00016058562,0.9998394
17910,n,9,10,67,68,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17910,-1,0.013687612,0.98631245
17911,n,15,16,98,99,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17911,-1,0.012506809,0.9874933
17913,mg,35,36,201,203,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17913,-1,0.9910802,0.008919726
17914,n,40,41,223,224,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17914,-1,0.06109054,0.9389095
17915,n,47,48,243,244,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17915,-1,0.099432155,0.90056777
17917,mm Hg,20,22,128,133,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17917,-1,0.0031083033,0.9968917
17919,mm Hg,38,40,200,205,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17919,-1,0.0044537126,0.9955462
17922,IBS,11,12,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,-1,17922,-1,0.00019949045,0.9998005
17924,IBS,13,14,113,116,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17924,-1,0.0001514661,0.9998485
17925,mm,27,28,160,162,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17925,-1,0.0023231646,0.9976769
17927,P,33,34,190,191,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17927,-1,0.027661875,0.97233814
17928,mm,44,45,225,227,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17928,-1,0.0043549384,0.99564505
17929,IBS,1,2,22,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17929,-1,0.00015521974,0.9998448
17932,mm,23,24,118,120,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17932,-1,0.0014486478,0.9985513
17934,P,29,30,148,149,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17934,-1,0.028699314,0.97130066
17935,mm,40,41,183,185,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17935,-1,0.0018605288,0.9981395
17937,IBS,11,12,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,-1,-1,17937,-1,0.0001329837,0.99986696
17948,mg,7,8,46,48,"Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years.",9672273_5,-1,-1,-1,17948,-1,0.99820185,0.0017981646
17959,vascular events,13,15,77,92,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17959,-1,0.0001416039,0.9998584
17960,hypertriglyceridaemia,16,17,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17960,-1,0.00020062909,0.99979943
17970,postoperative pain,9,11,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,-1,-1,17970,-1,0.00023293278,0.9997671
17972,analgesia,13,14,102,111,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17972,-1,0.1618287,0.8381713
17973,postoperative pain,21,23,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17973,-1,0.00020991192,0.99979013
17974,h,1,2,13,14,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,-1,-1,17974,-1,0.06400353,0.9359965
17977,norpethidine,4,5,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,-1,17977,-1,0.9999144,8.5587904e-05
17981,norpethidine,17,18,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,-1,17981,-1,0.9999056,9.4417956e-05
17983,analgesia,12,13,68,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,-1,-1,17983,-1,0.00021588498,0.9997842
17984,mepivacaine,8,9,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,-1,-1,-1,17984,-1,0.9999429,5.7129164e-05
17986,increase in blood pressure,1,5,3,29,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17986,-1,0.00037907023,0.9996209
17987,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17987,-1,0.00010982566,0.9998902
17989,loss of consciousness,16,19,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17989,-1,0.00029745296,0.9997025
17990,mepivacaine,43,44,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17990,-1,0.99994516,5.481552e-05
17991,mg,45,46,283,285,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17991,-1,0.9973713,0.0026286144
17993,mg,49,50,314,316,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17993,-1,0.99814785,0.0018521883
17994,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17994,-1,0.025466215,0.97453386
17998,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,-1,-1,17998,-1,0.00012612075,0.9998739
17999,mepivacaine,18,19,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,-1,17999,-1,0.9999455,5.448152e-05
18001,vanishing bile duct,2,5,28,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,-1,18001,-1,0.00030636194,0.99969363
18002,vanishing bile duct syndrome,1,5,6,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,-1,-1,18002,-1,0.00022137079,0.9997787
18005,drug or infection,16,19,128,145,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,-1,18005,-1,0.013186599,0.9868134
18006,vanishing bile duct syndrome,12,16,76,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,-1,18006,-1,0.0001538438,0.9998461
18008,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,18008,-1,0.99994516,5.4816508e-05
18011,cholestatic disease,13,15,80,99,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,18011,-1,0.00048015578,0.9995198
18013,vanishing bile duct syndrome,5,9,39,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,18013,-1,0.00018345857,0.9998166
18014,vanishing bile duct syndrome,27,31,190,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,18014,-1,0.00019321998,0.9998068
18018,appetite suppressant drugs,20,23,122,148,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,-1,18018,-1,0.99986935,0.00013060891
18022,fenfluramines,11,12,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,18022,-1,0.99992704,7.299955e-05
18023,p<0.0001,27,28,150,158,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,18023,-1,0.08217318,0.91782683
18029,lead,9,10,67,71,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,-1,-1,18029,-1,0.0061790394,0.99382097
18034,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,-1,18034,-1,0.000120857476,0.9998791
18037,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,-1,-1,18037,-1,0.00012437032,0.99987566
18044,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18044,-1,0.9999136,8.639026e-05
18045,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18045,-1,0.99994516,5.4862478e-05
18046,ethosuximide,14,15,84,96,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,18046,-1,0.99994457,5.540269e-05
18047,Choreoathetoid movements,0,2,0,24,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,-1,18047,-1,0.0037085547,0.9962915
18049,hyperkinesias,1,2,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18049,-1,0.00012332588,0.9998766
18050,movement abnormalities,7,9,54,76,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,18050,-1,0.00014643533,0.9998535
18052,choreoathetoid movements,8,10,38,62,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18052,-1,0.0058109886,0.994189
18054,heroine,28,29,197,204,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,18054,-1,0.9999162,8.3841274e-05
18056,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18056,-1,0.99994123,5.8745733e-05
18057,SLE,8,9,56,59,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18057,-1,0.0005721358,0.99942786
18058,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18058,-1,0.9999361,6.388126e-05
18059,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18059,-1,0.0023654904,0.99763453
18061,birth defects,39,41,262,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,18061,-1,0.0001290391,0.9998709
18063,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,-1,-1,18063,-1,0.99994016,5.9849448e-05
18065,cleft,7,8,45,50,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,-1,-1,18065,-1,0.00030685743,0.99969316
18069,folic acid,11,13,81,91,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,-1,-1,18069,-1,0.9999336,6.6398476e-05
18070,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18070,-1,0.00019421354,0.99980587
18071,systemic lupus erythematodes,8,11,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,18071,-1,0.00028259528,0.9997174
18072,stillbirth,4,5,25,35,Her pregnancy ended with stillbirth.,9758264_7,-1,-1,-1,18072,-1,0.0002794482,0.9997205
18074,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18074,-1,0.00011132479,0.99988866
18075,lupus,12,13,88,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18075,-1,0.00011211953,0.9998878
18076,mg,29,30,173,175,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18076,-1,0.9947996,0.0052003483
18077,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,18077,-1,0.9999385,6.1559615e-05
18079,mg,5,6,23,25,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18079,-1,0.98724675,0.012753243
18080,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18080,-1,0.99993706,6.2962834e-05
18082,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18082,-1,0.00012570413,0.99987423
18083,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,18083,-1,0.00010632348,0.99989367
18084,antipsychotics,5,6,32,46,Adverse effects of the atypical antipsychotics.,9766615_0,-1,-1,-1,18084,-1,0.9998254,0.0001746299
18085,antipsychotics,3,4,19,33,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18085,-1,0.9998529,0.00014702843
18086,lead,5,6,40,44,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,18086,-1,0.0020598902,0.9979401
18087,antipsychotics,7,8,41,55,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18087,-1,0.9998419,0.00015800865
18088,neuroleptics,16,17,109,121,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,18088,-1,0.99987984,0.000120122044
18090,EPS,15,16,116,119,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18090,-1,0.00018700655,0.999813
18091,tardive dyskinesia,18,20,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18091,-1,0.00011079233,0.99988925
18094,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,18094,-1,0.00096801884,0.999032
18095,EPS,9,10,47,50,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18095,-1,0.00020646559,0.9997936
18096,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18096,-1,0.0005367338,0.99946326
18100,agranulocytosis,44,45,257,272,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,18100,-1,0.00019887171,0.9998011
18102,lead,27,28,175,179,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18102,-1,0.001235202,0.9987649
18103,antipsychotic,38,39,253,266,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,18103,-1,0.9997241,0.00027595102
18115,emergency department,25,27,143,163,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,-1,18115,-1,0.0035372556,0.99646276
18126,psychosis,9,10,74,83,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18126,-1,0.00011302553,0.999887
18127,disruptive behaviors,11,13,88,108,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18127,-1,0.00015071363,0.9998493
18128,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,18128,-1,0.00034189524,0.9996581
18130,psychosis,26,27,139,148,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18130,-1,0.00010378946,0.99989617
18131,disruptive behaviors,28,30,153,173,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18131,-1,0.00012594768,0.999874
18132,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,18132,-1,0.00025248263,0.99974746
18135,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,-1,18135,-1,0.00036411936,0.9996358
18141,psychosis,31,32,197,206,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18141,-1,0.00012206723,0.9998779
18142,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,18142,-1,9.962698e-05,0.99990034
18143,extrapyramidal signs,17,19,84,104,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,-1,18143,-1,0.0005825784,0.9994174
18146,extrapyramidal signs,26,28,156,176,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,-1,18146,-1,0.00014349911,0.9998565
18148,neuroleptics,12,13,80,92,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18148,-1,0.99985373,0.00014623691
18149,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18149,-1,0.00075502356,0.99924505
18150,psychosis,20,21,135,144,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18150,-1,0.00010830352,0.99989164
18151,disruptive behaviors,22,24,149,169,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,18151,-1,0.00015020563,0.9998498
18152,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18152,-1,0.00012932552,0.99987066
18153,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,18153,-1,0.99993193,6.8031324e-05
18154,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,-1,-1,18154,-1,0.00012633945,0.99987364
18155,renal failure,5,7,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18155,-1,0.00011395644,0.99988604
18156,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,18156,-1,0.9999325,6.742718e-05
18157,renal lesions,6,8,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,-1,-1,-1,18157,-1,0.00015764145,0.9998423
18166,radiocalcium,15,16,79,91,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,-1,18166,-1,0.9998667,0.00013322233
18168,Gm,13,14,91,93,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,-1,18168,-1,0.59842926,0.40157074
18169,calcium chloride,2,4,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,-1,18169,-1,0.9998716,0.00012840611
18172,radiocalcium,1,2,14,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,-1,18172,-1,0.9997104,0.00028954513
18178,mg,13,14,74,76,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18178,-1,0.9537179,0.04628207
18179,Gm,17,18,86,88,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,18179,-1,0.49265262,0.5073474
18184,SM-5887,9,10,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,-1,18184,-1,0.99975675,0.00024321498
18187,SM-5887,11,12,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18187,-1,0.9998599,0.00014002701
18188,SM-5887,18,19,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,18188,-1,0.9998604,0.00013961745
18192,SM-5887,29,30,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,-1,-1,-1,18192,-1,0.9998342,0.00016583214
18194,of blood pressure,17,20,114,131,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18194,-1,0.00039145924,0.9996086
18196,SM-5887,33,34,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,18196,-1,0.9998554,0.00014453456
18198,SM-5887,8,9,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,-1,-1,18198,-1,0.9998603,0.00013972905
18202,SM-5887,18,19,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,-1,18202,-1,0.9998572,0.00014277396
18205,SM-5887,5,6,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,-1,-1,18205,-1,0.9998683,0.00013166617
18207,SM-5887,3,4,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,-1,-1,18207,-1,0.999819,0.00018099824
18211,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,-1,-1,-1,18211,-1,0.9999025,9.7524484e-05
18213,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,-1,-1,-1,18213,-1,0.9999119,8.8096356e-05
18214,n,16,17,80,81,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18214,-1,0.011772356,0.98822767
18215,n=5,26,27,111,114,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18215,-1,0.008183984,0.991816
18216,n,31,32,124,125,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18216,-1,0.008094278,0.9919057
18217,IgA nephropathy,37,39,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18217,-1,0.0005166905,0.9994832
18218,n,40,41,158,159,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18218,-1,0.0059964973,0.9940035
18219,n,48,49,182,183,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18219,-1,0.0064983102,0.9935017
18220,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18220,-1,0.073764555,0.92623544
18221,n,58,59,229,230,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18221,-1,0.006558325,0.9934417
18222,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18222,-1,0.07340682,0.9265931
18223,n,68,69,270,271,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,18223,-1,0.0058733346,0.9941267
18224,FK506 nephropathy,14,16,87,104,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,-1,18224,-1,0.0722603,0.92773974
18225,FK506 nephropathy,1,3,8,25,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18225,-1,0.0835228,0.91647726
18226,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18226,-1,0.00014102193,0.999859
18227,interstitial fibrosis,39,41,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,18227,-1,0.000121714926,0.9998783
18229,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18229,-1,0.08559096,0.914409
18230,P,32,33,215,216,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,18230,-1,0.06799399,0.93200606
18231,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18231,-1,0.08082716,0.9191729
18232,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18232,-1,0.07904608,0.92095387
18233,lead,34,35,245,249,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,18233,-1,0.0011300929,0.99886984
18237,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18237,-1,0.9999478,5.2223273e-05
18238,EE,11,12,69,71,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,18238,-1,0.99985194,0.00014806278
18240,contrast,1,2,3,11,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,-1,18240,-1,0.048728835,0.9512712
18241,EE,1,2,6,8,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,-1,18241,-1,0.9990113,0.0009886939
18242,EE,25,26,151,153,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,-1,-1,-1,18242,-1,0.9997645,0.00023550694
18244,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18244,-1,0.9999291,7.088476e-05
18245,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,18245,-1,0.9999212,7.8745536e-05
18246,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18246,-1,0.9999311,6.893712e-05
18247,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18247,-1,0.9999229,7.714273e-05
18248,valvular disease,22,24,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,18248,-1,0.00015068805,0.9998493
18249,valvular abnormalities,10,12,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18249,-1,0.00012599381,0.999874
18250,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18250,-1,0.9999324,6.763868e-05
18251,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,18251,-1,0.99992394,7.605075e-05
18252,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18252,-1,0.99992704,7.2937066e-05
18253,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,18253,-1,0.9999198,8.019148e-05
18254,valvulopathy,7,8,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18254,-1,0.00018847802,0.9998116
18256,aortic regurgitation,39,41,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,18256,-1,0.00013011543,0.9998698
18259,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18259,-1,0.00025201775,0.99974793
18260,aortic regurgitation,8,10,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,18260,-1,0.00016689816,0.9998331
18261,aortic insufficiency,6,8,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,-1,-1,-1,18261,-1,0.00013526386,0.9998647
18263,nerve growth factor,6,9,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18263,-1,0.99954385,0.00045609937
18265,PG-9,17,18,130,134,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18265,-1,0.9998623,0.00013761263
18267,nerve growth factor,31,34,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18267,-1,0.9997043,0.00029570356
18268,NGF,35,36,253,256,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,18268,-1,0.9998305,0.00016946487
18269,PG-9,6,7,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18269,-1,0.99988675,0.000113276394
18272,S-(-)-ET-126,40,41,228,240,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,18272,-1,0.99977976,0.00022022429
18273,PG-9,6,7,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,18273,-1,0.999887,0.00011299212
18275,PG-9,6,7,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,-1,18275,-1,0.9998839,0.0001160618
18276,PG-9,0,1,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18276,-1,0.9998355,0.00016447848
18277,NGF,9,10,45,48,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,18277,-1,0.99980074,0.00019926956
18278,NGF,2,3,12,15,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18278,-1,0.99964035,0.00035968042
18279,PG-9,6,7,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,18279,-1,0.9997396,0.00026040955
18280,PG-9,12,13,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,-1,-1,-1,18280,-1,0.999892,0.00010800671
18281,PG-9,7,8,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18281,-1,0.9998871,0.00011291996
18282,NGF,19,20,125,128,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,18282,-1,0.99985075,0.00014928538
18283,PG-9,2,3,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,18283,-1,0.99983335,0.0001666825
18285,tobramicyn,15,16,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,-1,18285,-1,0.9998934,0.00010650917
18288,n,3,4,10,11,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18288,-1,0.13005291,0.8699471
18290,TD,15,16,69,71,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18290,-1,0.8608389,0.13916115
18291,n,17,18,73,74,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,18291,-1,0.11419994,0.88580006
18293,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,18293,-1,0.006614772,0.99338526
18294,TD,19,20,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18294,-1,0.9994085,0.00059151097
18295,P,22,23,91,92,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,18295,-1,0.06615955,0.9338404
18296,TD,15,16,108,110,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18296,-1,0.9995764,0.00042358885
18297,P,17,18,112,113,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,18297,-1,0.04878195,0.951218
18298,TD,14,15,84,86,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18298,-1,0.9055927,0.094407335
18299,h,26,27,132,133,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18299,-1,0.037473183,0.9625268
18300,TD,28,29,137,139,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18300,-1,0.89349735,0.10650264
18301,Vd,31,32,142,144,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18301,-1,0.83629864,0.16370133
18302,TD,41,42,193,195,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18302,-1,0.9896399,0.010360186
18303,Cl,44,45,198,200,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18303,-1,0.61264986,0.38735017
18304,TD,54,55,259,261,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,18304,-1,0.9927047,0.0072952528
18306,TD,18,19,91,93,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,-1,-1,18306,-1,0.2651572,0.7348428
18308,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18308,-1,0.006210029,0.99379
18309,decreased auditory function,7,10,38,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18309,-1,0.0001759159,0.9998241
18310,auditory loss,17,19,98,111,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18310,-1,0.00022330477,0.99977666
18311,decreased auditory function,32,35,174,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,18311,-1,0.00017458579,0.9998254
18317,vasodilators,8,9,56,68,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18317,-1,0.8938649,0.10613506
18320,GABA,29,30,215,219,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,18320,-1,0.99988115,0.00011882876
18326,pindolol,7,8,65,73,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18326,-1,0.9999335,6.651051e-05
18328,atenolol,11,12,89,97,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,18328,-1,0.9999237,7.633543e-05
18332,methylatropine,8,9,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,-1,-1,-1,18332,-1,0.9999361,6.387931e-05
18335,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,18335,-1,0.999818,0.0001820315
18336,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,-1,-1,18336,-1,0.9998647,0.00013528529
18340,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18340,-1,0.99988973,0.00011025293
18341,nitric oxide synthase,41,44,231,252,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,18341,-1,0.9993388,0.0006611332
18342,FR 139317,13,15,78,87,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,-1,-1,18342,-1,0.9997086,0.0002913795
18344,FK,0,1,0,2,"FK 506, 5 mg.",9931093_4,-1,-1,-1,18344,-1,0.9997497,0.00025030796
18345,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,-1,18345,-1,0.006348678,0.99365133
18346,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,-1,-1,-1,18346,-1,0.9998673,0.00013265165
18347,FR 139317,3,5,22,31,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,18347,-1,0.9997428,0.00025716747
18349,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,-1,-1,-1,18349,-1,0.99986434,0.00013561295
18350,Structural and functional impairment of mitochondria,0,6,0,52,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18350,-1,0.0013021952,0.99869776
18352,c,15,16,125,126,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,18352,-1,0.99966466,0.00033532424
18354,ADR,5,6,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18354,-1,0.9989944,0.0010055796
18356,cardiovascular toxicity,17,19,90,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,18356,-1,0.00019736127,0.99980265
18357,ADR,3,4,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18357,-1,0.9998709,0.00012910743
18358,c,8,9,70,71,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18358,-1,0.9997595,0.00024046305
18359,ADR,22,23,143,146,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18359,-1,0.99988854,0.00011143227
18360,ADR,40,41,256,259,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,18360,-1,0.9998977,0.00010225128
18361,ADR,10,11,53,56,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18361,-1,0.99957806,0.00042197696
18362,cardiovascular arrhythmias,12,14,64,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18362,-1,0.00010574512,0.99989426
18364,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18364,-1,0.85786664,0.14213336
18365,swelling,51,52,295,303,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,18365,-1,0.00015184135,0.9998481
18366,ADR,31,32,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,-1,18366,-1,0.9998982,0.000101775404
18367,ADR,21,22,126,129,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18367,-1,0.99984956,0.00015047441
18368,structural and functional impairment,27,31,179,215,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,18368,-1,0.00047763708,0.9995223
1434,losartan,9,10,59,67,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0,-1,0,1434,-1,0.999926,7.397924e-05
10811,succinylcholine,9,10,76,91,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,0,-1,0,10811,-1,0.9999261,7.385793e-05
7451,fluoxetine,5,6,28,38,OBJECTIVES: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate.,17702969_4,0,-1,0,7451,-1,0.9999211,7.887916e-05
10610,phenobarbitone,3,4,22,36,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0,-1,0,10610,-1,0.99994814,5.1905867e-05
7221,apomorphine,3,4,21,32,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0,7221,-1,0.99994755,5.24937e-05
14998,etoposide,11,12,84,93,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0,-1,0,14998,-1,0.99994695,5.3072756e-05
17926,cisapride,29,30,164,173,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,-1,0,17926,-1,0.9999311,6.892806e-05
13571,heparin,22,23,153,160,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,0,-1,0,13571,-1,0.99984276,0.00015725863
16699,creatinine,13,14,98,108,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0,-1,0,16699,-1,0.99984634,0.00015360866
11770,ketamine,17,18,135,143,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0,11770,-1,0.9998846,0.00011533926
8500,heparin,11,12,72,79,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0,-1,0,8500,-1,0.99989474,0.00010526282
10653,ribavirin,14,15,110,119,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0,10653,-1,0.9999391,6.0962913e-05
909,tacrolimus,8,9,42,52,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0,909,-1,0.999936,6.399198e-05
1890,fentanyl,12,13,77,85,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,0,-1,0,1890,-1,0.99993694,6.308122e-05
2111,cisplatin,9,10,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0,2111,-1,0.9997949,0.00020513321
12869,calcitonin,10,11,94,104,Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.,3615541_0,0,-1,0,12869,-1,0.99993336,6.663e-05
7349,dopamine,13,14,112,120,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,7349,-1,0.9998839,0.00011609379
1421,losartan,9,10,41,49,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0,1421,-1,0.99993134,6.8705194e-05
11134,phenytoin,8,9,55,64,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,0,-1,0,11134,-1,0.99994123,5.8727474e-05
2391,Spironolactone,0,1,0,14,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,0,-1,0,2391,-1,0.9999149,8.514295e-05
7835,estradiol,18,19,120,129,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0,-1,0,7835,-1,0.9998964,0.00010359982
12096,nitroglycerin,100,101,442,455,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0,-1,0,12096,-1,0.99993956,6.0488346e-05
1657,corticosteroids,20,21,133,148,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,0,-1,0,1657,-1,0.99988055,0.00011940941
10994,clonidine,7,8,56,65,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0,-1,0,10994,-1,0.99993896,6.1032653e-05
15899,cimetidine,36,37,205,215,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,0,-1,0,15899,-1,0.99993944,6.0596078e-05
13329,amiodarone,2,3,19,29,Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.,3962737_5,0,-1,0,13329,-1,0.9999372,6.2799125e-05
1321,cyclophosphamide,44,45,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1321,-1,0.9999373,6.268563e-05
13316,Amiodarone,0,1,0,10,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,0,-1,0,13316,-1,0.9999466,5.3456606e-05
15058,benzodiazepines,15,16,114,129,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0,-1,0,15058,-1,0.9999175,8.2447055e-05
12203,Lovastatin,0,1,0,10,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,0,-1,0,12203,-1,0.9999366,6.346177e-05
4373,diazepam,16,17,97,105,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0,4373,-1,0.9999291,7.098095e-05
12797,deferoxamine,26,27,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,12797,-1,0.99994385,5.6153738e-05
11892,Flestolol,0,1,0,9,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0,-1,0,11892,-1,0.99991846,8.154319e-05
13250,vancomycin,15,16,82,92,Drugs were ceased in six patients because of adverse reactions; in three of these vancomycin was considered the likely cause.,3934126_3,0,-1,0,13250,-1,0.9998572,0.00014273394
7285,creatinine,1,2,6,16,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0,-1,0,7285,-1,0.9998585,0.0001414665
17680,bupivacaine,13,14,96,107,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,17680,-1,0.9999385,6.1535364e-05
7438,capecitabine,27,28,174,186,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,7438,-1,0.99993014,6.990597e-05
2876,Capsaicin,0,1,0,9,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,0,-1,0,2876,-1,0.99993646,6.3551575e-05
670,lidocaine,11,12,71,80,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0,670,-1,0.999905,9.500527e-05
10039,modafinil,4,5,23,32,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0,-1,0,10039,-1,0.99993575,6.423557e-05
15544,adenosine,5,6,29,38,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,0,-1,0,15544,-1,0.99987125,0.00012868509
16253,corticosteroids,20,21,125,140,We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.,8638206_4,0,-1,0,16253,-1,0.9998809,0.000119055934
15579,coniine,5,6,32,39,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0,-1,0,15579,-1,0.9998481,0.00015186887
18129,haloperidol,19,20,95,106,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,0,-1,0,18129,-1,0.9999418,5.8116646e-05
11210,noradrenaline,31,32,189,202,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,0,-1,0,11210,-1,0.99993145,6.8576905e-05
18289,tobramycin,12,13,48,58,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,0,-1,0,18289,-1,0.999931,6.903804e-05
8129,theophylline,12,13,78,90,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,0,-1,0,8129,-1,0.99994445,5.5586963e-05
2577,tyrosine,13,14,81,89,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0,-1,0,2577,-1,0.99971694,0.00028298888
1218,cocaine,17,18,99,106,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,0,-1,0,1218,-1,0.9998474,0.00015252148
3730,diazepam,12,13,99,107,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0,-1,0,3730,-1,0.9999341,6.595559e-05
8769,paclitaxel,7,8,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,8769,-1,0.9998932,0.000106818385
9837,phenylephrine,26,27,123,136,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0,9837,-1,0.99993336,6.668682e-05
10736,ketamine,14,15,105,113,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,0,-1,0,10736,-1,0.99989736,0.00010265292
178,magnesium,8,9,50,59,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0,178,-1,0.99989295,0.00010705904
13645,benzodiazepines,2,3,7,22,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0,13645,-1,0.9999062,9.381091e-05
12574,calcium,19,20,149,156,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,0,-1,0,12574,-1,0.99989605,0.00010391582
3355,thalidomide,11,12,84,95,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0,3355,-1,0.9999403,5.9672835e-05
11792,hydrocortisone,1,2,5,19,Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects.,2722224_1,0,-1,0,11792,-1,0.9999329,6.7108114e-05
17433,pilocarpine,1,2,4,15,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,0,-1,0,17433,-1,0.99993145,6.857396e-05
6597,lithium,36,37,168,175,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0,6597,-1,0.999899,0.000100951496
17213,propranolol,11,12,68,79,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0,17213,-1,0.99994445,5.5604247e-05
922,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,922,-1,0.9999254,7.4672564e-05
12479,nicotine,13,14,104,112,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,0,-1,0,12479,-1,0.99988425,0.00011579263
808,Cyclophosphamide,0,1,0,16,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0,-1,0,808,-1,0.9999379,6.214945e-05
13277,5-fluorouracil,3,4,20,34,Cardiac toxicity of 5-fluorouracil.,3952818_0,0,-1,0,13277,-1,0.9999008,9.919946e-05
18191,doxorubicin,23,24,122,133,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,0,-1,0,18191,-1,0.9998839,0.000116143514
17702,methylprednisolone,2,3,9,27,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0,-1,0,17702,-1,0.99994147,5.8484027e-05
2527,levodopa,26,27,143,151,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,0,-1,0,2527,-1,0.99991834,8.16371e-05
15443,ampicillin,7,8,48,58,Macrophage-migration inhibition (MIF) test with ampicillin was positive.,7919560_5,0,-1,0,15443,-1,0.9998883,0.00011167811
8992,paracetamol,20,21,142,153,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0,-1,0,8992,-1,0.9999243,7.571168e-05
14127,serotonin,3,4,23,32,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0,14127,-1,0.99989045,0.00010955819
3424,dopamine,14,15,107,115,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0,-1,0,3424,-1,0.99987936,0.00012059983
7352,methamphetamine,40,41,319,334,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,7352,-1,0.999926,7.4073985e-05
8729,ciprofloxacin,7,8,63,76,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,0,-1,0,8729,-1,0.9998685,0.00013141608
7780,norepinephrine,22,23,118,132,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0,-1,0,7780,-1,0.99989116,0.00010882363
9563,dopamine,15,16,102,110,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0,-1,0,9563,-1,0.9998741,0.00012584588
6826,testosterone,18,19,99,111,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,0,-1,0,6826,-1,0.99990463,9.539208e-05
9687,creatinine,21,22,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0,9687,-1,0.9998833,0.000116651405
18147,haloperidol,6,7,44,55,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,0,-1,0,18147,-1,0.9999343,6.5670596e-05
7081,Methadone,2,3,9,18,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,0,-1,0,7081,-1,0.9999442,5.5743763e-05
14464,calcium,7,8,44,51,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,0,-1,0,14464,-1,0.9998795,0.000120541554
17875,noradrenaline,24,25,141,154,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0,-1,0,17875,-1,0.99993634,6.365784e-05
8532,adriamycin,2,3,13,23,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0,-1,0,8532,-1,0.999943,5.7006444e-05
3926,morphine,24,25,146,154,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,0,-1,0,3926,-1,0.9998877,0.00011228784
3793,methylphenidate,14,15,100,115,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,0,-1,0,3793,-1,0.99993324,6.680266e-05
13747,mexiletine,1,2,14,24,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,0,-1,0,13747,-1,0.99993515,6.488187e-05
17635,capsaicin,4,5,18,27,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,0,-1,0,17635,-1,0.9999443,5.5647793e-05
4305,quinine,23,24,132,139,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,0,-1,0,4305,-1,0.9999254,7.464166e-05
16688,calcium,8,9,41,48,These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.,8800187_14,0,-1,0,16688,-1,0.99987507,0.0001248906
15155,verapamil,8,9,60,69,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,0,-1,0,15155,-1,0.9999442,5.5812707e-05
16479,norepinephrine,8,9,51,65,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,0,-1,0,16479,-1,0.99988306,0.0001169818
2514,levodopa,18,19,113,121,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,0,-1,0,2514,-1,0.99992156,7.845091e-05
14730,sodium nitroprusside,18,20,111,131,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0,-1,0,14730,-1,0.99991786,8.218097e-05
9827,ephedrine,3,4,22,31,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,0,-1,0,9827,-1,0.9999422,5.7868343e-05
18042,carbamazepine,23,24,152,165,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0,18042,-1,0.9999378,6.217642e-05
16634,lithium,14,15,88,95,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,0,-1,0,16634,-1,0.9998956,0.00010437753
11576,5-azacytidine,0,1,0,13,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,0,-1,0,11576,-1,0.999926,7.400592e-05
14973,lovastatin,1,2,6,16,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,0,-1,0,14973,-1,0.9999393,6.0732953e-05
9488,levofloxacin,11,12,76,88,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0,-1,0,9488,-1,0.9999311,6.885854e-05
190,calcium,4,5,25,32,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0,190,-1,0.9998747,0.00012526773
16579,nicotine,25,26,143,151,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,0,-1,0,16579,-1,0.9998864,0.00011364133
8002,trihexyphenidyl,10,11,72,87,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0,-1,0,8002,-1,0.9999168,8.320728e-05
14830,amiloride,6,7,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,14830,-1,0.99994206,5.790814e-05
17389,levodopa,36,37,256,264,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0,-1,0,17389,-1,0.9999279,7.210786e-05
916,cyclosporine,16,17,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,916,-1,0.9999232,7.678941e-05
15648,phenylephrine,6,7,37,50,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,0,-1,0,15648,-1,0.9999367,6.327896e-05
7223,Amphetamine,0,1,0,11,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,0,-1,0,7223,-1,0.9999398,6.0229217e-05
12033,haloperidol,11,12,68,79,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,0,-1,0,12033,-1,0.99993646,6.353031e-05
10343,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0,10343,-1,0.9998677,0.000132356
17836,Carboplatin,0,1,0,11,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,0,-1,0,17836,-1,0.9999435,5.649761e-05
13765,penicillamine,20,21,134,147,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,0,-1,0,13765,-1,0.9999422,5.7758516e-05
9494,dextran,19,20,118,125,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0,-1,0,9494,-1,0.99896216,0.0010377988
928,Apomorphine,0,1,0,11,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,0,-1,0,928,-1,0.9999386,6.135149e-05
3962,aspirin,10,11,59,66,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0,3962,-1,0.99989164,0.00010835539
14095,lithium,1,2,9,16,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,0,-1,0,14095,-1,0.99984264,0.00015731921
1762,cocaine,38,39,279,286,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0,-1,0,1762,-1,0.99987876,0.000121180245
3058,Zonisamide,0,1,0,10,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0,-1,0,3058,-1,0.99994504,5.497089e-05
13702,enflurane,10,11,57,66,Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported.,6153967_1,0,-1,0,13702,-1,0.99992347,7.657778e-05
878,Ketamine,2,3,13,21,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,0,-1,0,878,-1,0.9998716,0.00012834859
17548,mitoxantrone,16,17,88,100,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0,-1,0,17548,-1,0.99994147,5.8521964e-05
7392,blood urea nitrogen,10,13,68,87,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,7392,-1,0.9995937,0.0004063557
10407,haloperidol,11,12,73,84,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0,-1,0,10407,-1,0.99993443,6.552823e-05
10958,mazindol,23,24,139,147,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,0,-1,0,10958,-1,0.99994576,5.428544e-05
12471,nicotine,22,23,123,131,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,0,-1,0,12471,-1,0.9999012,9.885451e-05
1901,Sirolimus,0,1,0,9,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0,-1,0,1901,-1,0.9999418,5.821994e-05
15798,daunorubicin,7,8,40,52,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0,-1,0,15798,-1,0.9999279,7.21263e-05
3920,scopolamine,6,7,54,65,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,0,-1,0,3920,-1,0.9999492,5.0777122e-05
14742,saralasin,30,31,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0,14742,-1,0.9999465,5.356392e-05
1817,risperidone,7,8,61,72,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,0,-1,0,1817,-1,0.99993837,6.162927e-05
3846,creatinine,23,24,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0,3846,-1,0.9998481,0.0001518722
529,Warfarin,32,33,191,199,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0,529,-1,0.9998926,0.000107407315
7336,lipopolysaccharide,9,10,40,58,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0,-1,0,7336,-1,0.9999057,9.426447e-05
18125,haloperidol,7,8,58,69,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,0,-1,0,18125,-1,0.9999355,6.4484746e-05
598,sodium,9,10,62,68,"In several models of hypertension, elevation of intracellular sodium level was documented in cardiac tissue.",10706004_3,0,-1,0,598,-1,0.9998325,0.00016749983
3960,quinine,17,18,105,112,The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine.,1415380_3,0,-1,0,3960,-1,0.9999033,9.6654214e-05
12616,methotrexate,21,22,127,139,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,0,-1,0,12616,-1,0.9998697,0.00013032179
8932,everolimus,4,5,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,8932,-1,0.9999391,6.0905903e-05
2430,spironolactone,6,7,35,49,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,0,-1,0,2430,-1,0.9999368,6.317875e-05
11864,oral contraceptive,9,11,42,60,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0,-1,0,11864,-1,0.9998729,0.00012709368
6385,haloperidol,17,18,65,76,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,0,-1,0,6385,-1,0.99993396,6.6031236e-05
11805,hydrocortisone,46,47,259,273,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0,11805,-1,0.999938,6.195967e-05
9593,pilocarpine,21,22,139,150,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,0,-1,0,9593,-1,0.99993503,6.502055e-05
2970,rizatriptan,7,8,52,63,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0,-1,0,2970,-1,0.99994385,5.617195e-05
18182,hydrocortisone,6,7,40,54,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,18182,-1,0.99992764,7.234232e-05
10358,cisplatin,53,54,368,377,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,10358,-1,0.99987376,0.00012621953
10985,Naloxone,0,1,0,8,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0,10985,-1,0.9999443,5.5610977e-05
18105,cocaine,2,3,11,18,Stroke and cocaine or amphetamine use.,9799166_0,0,-1,0,18105,-1,0.9998696,0.00013042572
1933,citalopram,8,9,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0,-1,0,1933,-1,0.9999398,6.015643e-05
10770,dopamine,7,8,35,43,"However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.",20880751_2,0,-1,0,10770,-1,0.9998884,0.000111529436
15003,zidovudine,16,17,104,114,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0,15003,-1,0.99993455,6.548893e-05
15827,vincristine,8,9,46,57,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,0,-1,0,15827,-1,0.9999403,5.9667884e-05
17227,dopamine,34,35,281,289,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0,-1,0,17227,-1,0.9998559,0.00014410699
3961,prednisone,8,9,47,57,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0,3961,-1,0.99992824,7.1717666e-05
3522,azathioprine,23,24,138,150,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0,-1,0,3522,-1,0.99987984,0.000120098106
16550,creatinine,26,27,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,16550,-1,0.9998313,0.00016869298
11905,flestolol,4,5,21,30,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0,-1,0,11905,-1,0.9999298,7.016034e-05
7407,statins,7,8,44,51,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0,7407,-1,0.9998919,0.000108085005
13946,propranolol,5,6,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0,13946,-1,0.9999442,5.581473e-05
10405,haloperidol,29,30,115,126,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0,-1,0,10405,-1,0.9999349,6.506309e-05
6505,mannitol,2,3,11,19,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,0,-1,0,6505,-1,0.99992394,7.608267e-05
18323,Isoniazid,0,1,0,9,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,18323,-1,0.99994457,5.5448625e-05
1844,cisapride,17,18,103,112,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0,1844,-1,0.9999397,6.035427e-05
7524,telithromycin,6,7,41,54,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0,-1,0,7524,-1,0.9999316,6.839899e-05
21,calcium,5,6,36,43,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,0,-1,0,21,-1,0.999853,0.0001469889
7546,Telithromycin,2,3,12,25,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0,-1,0,7546,-1,0.9999286,7.1399125e-05
16124,clonidine,19,20,95,104,"After 2 weeks, the rats were subjected to ganglionic blockade and 2 days later, an infusion of clonidine.",8586822_3,0,-1,0,16124,-1,0.99993646,6.351135e-05
14685,indomethacin,6,7,47,59,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,0,-1,0,14685,-1,0.99993396,6.600316e-05
12938,Aspirin,0,1,0,7,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0,12938,-1,0.9998833,0.00011666542
15681,ifosfamide,5,6,38,48,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,0,-1,0,15681,-1,0.9999447,5.536926e-05
151,rapamycin,5,6,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,151,-1,0.9998877,0.000112252186
16326,paclitaxel,8,9,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0,-1,0,16326,-1,0.9998528,0.000147183
17129,steroids,50,51,357,365,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0,17129,-1,0.9998752,0.00012478919
7435,methotrexate,13,14,88,100,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,7435,-1,0.9999008,9.923106e-05
5731,gabapentin,3,4,12,22,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,0,-1,0,5731,-1,0.9999429,5.7119352e-05
8466,pergolide,11,12,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0,-1,0,8466,-1,0.9999454,5.4542234e-05
6210,desipramine,4,5,36,47,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0,6210,-1,0.99993575,6.419025e-05
15308,folinic acid,37,39,214,226,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0,15308,-1,0.9999356,6.432224e-05
12876,cefonicid,4,5,27,36,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0,12876,-1,0.9999393,6.068039e-05
6544,warfarin,19,20,131,139,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0,-1,0,6544,-1,0.9998976,0.00010234806
7646,diclofenac,14,15,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0,-1,0,7646,-1,0.99994993,5.0110837e-05
6365,warfarin,17,18,89,97,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,0,-1,0,6365,-1,0.9998356,0.00016439428
15817,vincristine,3,4,21,32,Long-term effects of vincristine on the peripheral nervous system.,8384253_0,0,-1,0,15817,-1,0.9999424,5.7575064e-05
11977,diazepam,3,4,30,38,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,0,-1,0,11977,-1,0.99993885,6.115966e-05
15557,adenosine,9,10,59,68,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0,15557,-1,0.9998839,0.00011610475
7553,telithromycin,21,22,143,156,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,0,-1,0,7553,-1,0.9999399,6.0036822e-05
13734,isoproterenol,17,18,122,135,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,0,-1,0,13734,-1,0.99994075,5.9285776e-05
10433,dopamine,5,6,27,35,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,0,-1,0,10433,-1,0.9998801,0.00011986116
1425,losartan,7,8,28,36,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0,-1,0,1425,-1,0.99992514,7.481111e-05
507,phosphate,16,17,130,139,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,0,-1,0,507,-1,0.99987745,0.00012254025
8261,lithium,17,18,103,110,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,0,-1,0,8261,-1,0.9998754,0.00012452387
14397,cycloheximide,169,170,1012,1025,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,14397,-1,0.9999441,5.5925284e-05
17334,Nicotine,0,1,0,8,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,0,-1,0,17334,-1,0.99986756,0.00013243641
2910,Cocaine,0,1,0,7,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,0,-1,0,2910,-1,0.999793,0.00020700686
3844,furosemide,9,10,71,81,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0,3844,-1,0.9999453,5.4658136e-05
16401,phenacetin,5,6,32,42,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,0,-1,0,16401,-1,0.9999398,6.0166753e-05
2721,ribavirin,5,6,40,49,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,0,-1,0,2721,-1,0.99993575,6.426069e-05
11057,ifosfamide,11,12,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,11057,-1,0.9999397,6.027903e-05
2119,amifostine,16,17,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2119,-1,0.9999411,5.8925616e-05
16981,superoxide,1,2,11,21,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,0,-1,0,16981,-1,0.99985063,0.00014929817
2731,ribavirin,7,8,46,55,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,0,-1,0,2731,-1,0.99993145,6.851931e-05
5629,methamphetamine,18,19,114,129,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,0,-1,0,5629,-1,0.999881,0.000119002485
10337,cocaine,21,22,142,149,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,0,-1,0,10337,-1,0.99986804,0.00013198736
13679,ranitidine,4,5,38,48,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,0,-1,0,13679,-1,0.9999398,6.021027e-05
9383,ecstasy,2,3,8,15,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,0,-1,0,9383,-1,0.9999423,5.7651818e-05
7293,iopamidol,22,23,92,101,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0,7293,-1,0.9999486,5.1334893e-05
10379,Asenapine,0,1,0,9,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,0,-1,0,10379,-1,0.99992716,7.288283e-05
10986,clonidine,6,7,49,58,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0,10986,-1,0.9999379,6.205925e-05
18133,haloperidol,16,17,89,100,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0,-1,0,18133,-1,0.9999398,6.017083e-05
14986,dopamine,3,4,29,37,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,0,-1,0,14986,-1,0.9998872,0.00011274866
16617,lithium,15,16,90,97,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,0,-1,0,16617,-1,0.9998871,0.00011290306
7826,estradiol,22,23,182,191,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,0,-1,0,7826,-1,0.9998872,0.000112745445
2840,theophylline,2,3,16,28,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,0,-1,0,2840,-1,0.9999343,6.566277e-05
9069,cyclophosphamide,5,6,30,46,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,0,-1,0,9069,-1,0.99993753,6.247801e-05
3035,carboplatin,2,3,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,3035,-1,0.99994564,5.435013e-05
6132,cinacalcet,15,16,119,129,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0,6132,-1,0.99991894,8.10748e-05
11723,Labetalol,0,1,0,9,Labetalol administration was not associated with any of these findings.,2696505_4,0,-1,0,11723,-1,0.9999398,6.015511e-05
7254,ribavirin,18,19,123,132,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,0,-1,0,7254,-1,0.9999348,6.518612e-05
12524,azathioprine,19,20,105,117,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0,12524,-1,0.99994254,5.7462785e-05
15323,Carbamazepine,0,1,0,13,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0,15323,-1,0.99994576,5.4200493e-05
4509,estrogen,3,4,27,35,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,0,-1,0,4509,-1,0.9998895,0.00011048257
18010,tacrolimus,10,11,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0,18010,-1,0.9999372,6.278835e-05
11964,glutamate,17,18,100,109,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,0,-1,0,11964,-1,0.9998841,0.00011587283
13369,azathioprine,13,14,93,105,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0,-1,0,13369,-1,0.9999368,6.314815e-05
2754,ribavirin,2,3,21,30,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,0,-1,0,2754,-1,0.99993813,6.1814484e-05
4641,acetylcholine,5,6,33,46,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,0,-1,0,4641,-1,0.9998274,0.00017259592
5098,amiodarone,8,9,57,67,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,0,-1,0,5098,-1,0.9999471,5.2869178e-05
9231,sirolimus,26,27,166,175,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0,-1,0,9231,-1,0.9999423,5.7671336e-05
3959,quinine,3,4,36,43,"Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.",1415380_1,0,-1,0,3959,-1,0.9999006,9.9375735e-05
7301,iodixanol,25,26,173,182,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,7301,-1,0.9999465,5.3542517e-05
12670,dapsone,23,24,122,129,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,0,-1,0,12670,-1,0.9999404,5.963461e-05
12578,carbamazepine,26,27,175,188,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,12578,-1,0.99992585,7.416756e-05
5359,aspirin,13,14,74,81,"When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion.",15899738_9,0,-1,0,5359,-1,0.9998939,0.00010609034
10911,desferrioxamine,15,16,113,128,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0,-1,0,10911,-1,0.9999329,6.708802e-05
14575,amiodarone,3,4,18,28,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,0,-1,0,14575,-1,0.99993813,6.185347e-05
11828,carbamazepine,3,4,15,28,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0,-1,0,11828,-1,0.9999374,6.263692e-05
1519,diltiazem,3,4,22,31,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,0,-1,0,1519,-1,0.9999378,6.2214676e-05
14932,corticosteroids,11,12,78,93,"Clinical examinations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed.",7582165_4,0,-1,0,14932,-1,0.99987566,0.00012437566
7664,ciprofloxacin,10,11,74,87,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,0,-1,0,7664,-1,0.9998852,0.00011479625
1457,tacrolimus,5,6,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1457,-1,0.9999232,7.679878e-05
12727,diltiazem,19,20,123,132,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,12727,-1,0.9999418,5.8144306e-05
7420,levofloxacin,14,15,109,121,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0,7420,-1,0.99993825,6.173331e-05
8264,Lithium,0,1,0,7,"Lithium should be used with extreme caution, especially in patients with mild disturbance of AV conduction.",18441470_4,0,-1,0,8264,-1,0.9998945,0.00010552876
13370,cyclophosphamide,15,16,110,126,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0,-1,0,13370,-1,0.9999316,6.846281e-05
8133,aminoglycoside,3,4,15,29,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0,8133,-1,0.9998944,0.00010559921
8137,aminoglycoside,15,16,113,127,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,8137,-1,0.99993205,6.792605e-05
741,corticosteroids,27,28,149,164,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,0,-1,0,741,-1,0.99986935,0.00013064928
7427,warfarin,17,18,122,130,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0,7427,-1,0.9998728,0.00012719844
12476,nicotine,4,5,27,35,"In animals pretreated with nicotine for 14 days, the nicotine-induced locomotor response remained to be potentiated.",3220106_6,0,-1,0,12476,-1,0.9998882,0.00011186004
7063,methadone,8,9,56,65,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,0,-1,0,7063,-1,0.9999436,5.640631e-05
7888,Lamivudine,0,1,0,10,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,0,-1,0,7888,-1,0.9999429,5.708151e-05
7425,levofloxacin,20,21,121,133,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0,-1,0,7425,-1,0.99993515,6.487023e-05
287,ephedrine,12,13,54,63,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0,287,-1,0.9999404,5.9546866e-05
3454,tacrolimus,27,28,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0,-1,0,3454,-1,0.9999094,9.062144e-05
14307,kanamycin,15,16,98,107,"Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin.",6728084_9,0,-1,0,14307,-1,0.99992216,7.7816985e-05
2507,morphine,22,23,164,172,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0,2507,-1,0.99989164,0.000108406544
11027,prazosin,8,9,59,67,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,0,-1,0,11027,-1,0.9999348,6.5219814e-05
3732,Diazepam,7,8,54,62,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0,-1,0,3732,-1,0.9999274,7.258154e-05
14418,noradrenaline,18,19,143,156,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,0,-1,0,14418,-1,0.99992895,7.1037684e-05
1024,methylprednisolone,3,4,14,32,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0,-1,0,1024,-1,0.99993277,6.728844e-05
2813,metoclopramide,8,9,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0,-1,0,2813,-1,0.9999479,5.2038045e-05
8861,caffeine,2,3,21,29,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,0,-1,0,8861,-1,0.999879,0.000120996665
8475,pergolide,13,14,75,84,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0,-1,0,8475,-1,0.99994266,5.735001e-05
9778,glutamate,1,2,13,22,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,0,-1,0,9778,-1,0.9998702,0.0001298024
2107,amifostine,2,3,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0,-1,0,2107,-1,0.9999435,5.6506015e-05
14438,carbachol,10,11,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0,-1,0,14438,-1,0.99994445,5.557583e-05
9562,amphetamine,10,11,65,76,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0,-1,0,9562,-1,0.99993336,6.6617096e-05
7135,terbutaline,4,5,24,35,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0,-1,0,7135,-1,0.99994624,5.375335e-05
16224,haloperidol,14,15,103,114,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,0,-1,0,16224,-1,0.9999379,6.21123e-05
14153,heparin,13,14,82,89,"Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored.",6615052_6,0,-1,0,14153,-1,0.9998437,0.00015622035
14577,Amiodarone,0,1,0,10,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,0,-1,0,14577,-1,0.99994874,5.130103e-05
13282,5-fluorouracil,18,19,103,117,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0,-1,0,13282,-1,0.99989784,0.00010209655
8663,simvastatin,19,20,148,159,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,0,-1,0,8663,-1,0.9999316,6.847888e-05
7783,cocaine,5,6,23,30,"RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.",18083142_4,0,-1,0,7783,-1,0.99987864,0.000121352656
11497,enalapril,10,11,52,61,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0,-1,0,11497,-1,0.9999429,5.710416e-05
4729,Salbutamol,2,3,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0,-1,0,4729,-1,0.99994195,5.799783e-05
3152,iodixanol,3,4,21,30,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0,-1,0,3152,-1,0.99994934,5.0672348e-05
4101,amphetamine,44,45,271,282,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0,4101,-1,0.999926,7.400606e-05
16692,nifedipine,3,4,14,24,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0,-1,0,16692,-1,0.99994814,5.180711e-05
6776,Sirolimus,0,1,0,9,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0,-1,0,6776,-1,0.99993753,6.249815e-05
3383,ticlopidine,11,12,87,98,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0,-1,0,3383,-1,0.9999447,5.5279354e-05
14920,carboplatin,6,7,33,44,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,0,-1,0,14920,-1,0.99993134,6.860817e-05
2715,ribavirin,1,2,12,21,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,0,-1,0,2715,-1,0.9999399,6.0065973e-05
8173,sulfasalazine,7,8,37,50,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0,-1,0,8173,-1,0.99993837,6.1652725e-05
14286,metoclopramide,21,22,123,137,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0,-1,0,14286,-1,0.999943,5.6998724e-05
12940,paracetamol,19,20,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0,12940,-1,0.99992144,7.856343e-05
16048,creatinine,5,6,30,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0,-1,0,16048,-1,0.9998616,0.00013838321
5085,glutamate,10,11,49,58,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0,-1,0,5085,-1,0.9998648,0.0001352038
17472,testosterone,22,23,131,143,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,0,-1,0,17472,-1,0.99988425,0.00011574615
16447,alcohol,27,28,107,114,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,0,-1,0,16447,-1,0.99982685,0.00017315736
10978,naloxone,33,34,211,219,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0,10978,-1,0.9999484,5.1648763e-05
4186,nitroglycerin,1,2,11,24,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,0,-1,0,4186,-1,0.9999329,6.71012e-05
16787,serotonin,21,22,117,126,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0,-1,0,16787,-1,0.99987423,0.00012570569
14740,halothane,6,7,38,47,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0,14740,-1,0.9999279,7.216497e-05
8652,papaverine,3,4,21,31,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,0,-1,0,8652,-1,0.9999443,5.56505e-05
15129,doxorubicin,22,23,99,110,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,0,-1,0,15129,-1,0.9998523,0.0001476739
18167,calcium,3,4,29,36,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,0,-1,0,18167,-1,0.9998857,0.00011429488
10719,capecitabine,14,15,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0,-1,0,10719,-1,0.99991584,8.420641e-05
6480,lamivudine,5,6,31,41,"However, the administration of lamivudine, a reverse transcriptase inhibitor, for 23 months dramatically improved her liver severity.",16960342_6,0,-1,0,6480,-1,0.99994445,5.551555e-05
17485,testosterone,5,6,22,34,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,0,-1,0,17485,-1,0.99988806,0.00011194637
3476,cortisol,75,76,434,442,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0,3476,-1,0.9998783,0.0001217104
6889,statin,8,9,65,71,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,0,-1,0,6889,-1,0.99985623,0.00014376003
1265,picrotoxin,21,22,124,134,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0,-1,0,1265,-1,0.9999443,5.567407e-05
12725,metoprolol,15,16,98,108,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,12725,-1,0.999946,5.402891e-05
2941,succinylcholine,11,12,56,71,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0,-1,0,2941,-1,0.9999399,6.0069644e-05
12418,captopril,13,14,83,92,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,0,-1,0,12418,-1,0.9999455,5.447082e-05
16989,oxygen,5,6,22,28,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0,-1,0,16989,-1,0.99971086,0.00028913195
11803,norepinephrine,8,9,68,82,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0,11803,-1,0.99989104,0.00010892786
159,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0,159,-1,0.9999418,5.81792e-05
5709,nicotine,11,12,60,68,Patients were randomized in a 1:1 ratio to receive the 4-mg nicotine lozenge or 4-mg nicotine gum.,16330293_5,0,-1,0,5709,-1,0.999887,0.000112958296
17668,prilocaine,11,12,78,88,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0,17668,-1,0.99993706,6.296631e-05
10854,alanine,5,6,38,45,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,0,-1,0,10854,-1,0.9998623,0.0001376889
964,pilocarpine,2,3,6,17,"Thus, pilocarpine may be useful to assess variations in central cholinergic function in elderly patients.",11022397_17,0,-1,0,964,-1,0.9999429,5.708347e-05
8765,paclitaxel,32,33,191,201,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,8765,-1,0.999879,0.0001209534
18068,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0,18068,-1,0.99994075,5.9248927e-05
12008,sodium,18,19,143,149,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,0,-1,0,12008,-1,0.9998611,0.0001388903
6347,serotonin,8,9,37,46,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,0,-1,0,6347,-1,0.99989474,0.00010519618
15160,metoprolol,24,25,183,193,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0,-1,0,15160,-1,0.9999479,5.2070707e-05
4515,estrogen,8,9,54,62,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0,-1,0,4515,-1,0.99986756,0.00013236646
17068,bilirubin,68,69,307,316,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0,-1,0,17068,-1,0.9998123,0.00018768445
16317,paclitaxel,5,6,39,49,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0,-1,0,16317,-1,0.9998006,0.00019943264
6586,lithium,28,29,146,153,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,0,-1,0,6586,-1,0.99990046,9.9576275e-05
6634,Dex,4,5,13,16,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0,6634,-1,0.999864,0.00013594789
12483,sodium nitroprusside,27,29,160,180,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0,-1,0,12483,-1,0.9999149,8.5119245e-05
5860,acetylcholine,20,21,139,152,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0,-1,0,5860,-1,0.99985504,0.00014489291
15236,oxygen,5,6,33,39,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0,-1,0,15236,-1,0.99980944,0.00019060752
8070,adenosine,4,5,45,54,A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described.,18329269_1,0,-1,0,8070,-1,0.99980634,0.00019365952
15915,octreotide,3,4,22,32,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0,-1,0,15915,-1,0.9999471,5.2867967e-05
3339,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0,3339,-1,0.99988294,0.00011706013
9133,catecholamines,9,10,55,69,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,0,-1,0,9133,-1,0.99990356,9.6479715e-05
4368,acetylcholine,25,26,133,146,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,0,-1,0,4368,-1,0.9998375,0.00016250738
2601,Reserpine,0,1,0,9,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,0,-1,0,2601,-1,0.99992085,7.910974e-05
5533,Cocaine,0,1,0,7,"Cocaine generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects.",1610717_4,0,-1,0,5533,-1,0.99984074,0.0001592529
7445,Fluoxetine,2,3,11,21,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,0,-1,0,7445,-1,0.9999161,8.387246e-05
7367,clozapine,2,3,17,26,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,0,-1,0,7367,-1,0.9999269,7.30862e-05
2365,steroids,15,16,111,119,These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.,11860495_11,0,-1,0,2365,-1,0.9998611,0.00013884304
13848,caffeine,15,16,114,122,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0,13848,-1,0.9998976,0.000102433885
12472,nicotine,19,20,144,152,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,0,-1,0,12472,-1,0.99989223,0.000107779335
14513,cimetidine,22,23,122,132,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0,14513,-1,0.9999399,6.00449e-05
8214,oxygen,4,5,26,32,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,0,-1,0,8214,-1,0.99970263,0.00029734804
2442,5-azacytidine,6,7,39,52,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0,-1,0,2442,-1,0.99991906,8.090635e-05
9233,sirolimus,10,11,69,78,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0,-1,0,9233,-1,0.99993694,6.300938e-05
18033,vigabatrin,5,6,39,49,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,18033,-1,0.99993885,6.11809e-05
9049,Capsaicin,0,1,0,9,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,0,-1,0,9049,-1,0.9999434,5.658204e-05
5735,gabapentin,43,44,248,258,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,0,-1,0,5735,-1,0.9999387,6.124166e-05
609,dopamine,20,21,122,130,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0,-1,0,609,-1,0.99988747,0.00011252547
9518,pilocarpine,4,5,24,35,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0,-1,0,9518,-1,0.99995065,4.9368286e-05
13971,MESNA,14,15,103,108,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,13971,-1,0.99990237,9.764918e-05
14610,lidocaine,20,21,101,110,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0,14610,-1,0.99988043,0.00011957942
15629,Nitroglycerin,0,1,0,13,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,0,-1,0,15629,-1,0.99994004,5.9949463e-05
14732,halothane,3,4,22,31,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,0,-1,0,14732,-1,0.9999368,6.322733e-05
13410,prednisolone,11,12,87,99,Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone.,3997294_3,0,-1,0,13410,-1,0.9999374,6.2526036e-05
14836,lithium,24,25,165,172,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0,14836,-1,0.99988365,0.00011639175
12948,acetaminophen,32,33,151,164,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0,12948,-1,0.9999336,6.63424e-05
9105,heparin,9,10,45,52,This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.,19289093_6,0,-1,0,9105,-1,0.9998405,0.00015951766
5845,methylphenidate,20,21,133,148,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,0,-1,0,5845,-1,0.99993706,6.297532e-05
5221,cyclosporine,5,6,28,40,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,5221,-1,0.9999198,8.021962e-05
4512,estrogen,5,6,28,36,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,0,-1,0,4512,-1,0.99989533,0.000104648505
2465,dopamine,2,3,17,25,Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats.,11890511_5,0,-1,0,2465,-1,0.9998841,0.00011586641
8436,fentanyl,12,13,70,78,"Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.",18544179_4,0,-1,0,8436,-1,0.99993694,6.304731e-05
17340,smoking,34,35,235,242,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0,-1,0,17340,-1,0.9998739,0.00012607552
5855,methylphenidate,20,21,110,125,"This potential side-effect, though very rare, represents one more reason to be very restrictive in the use of methylphenidate.",16428221_6,0,-1,0,5855,-1,0.9999317,6.834996e-05
18271,scopolamine,35,36,184,195,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,0,-1,0,18271,-1,0.9999442,5.5837518e-05
9212,metronidazole,15,16,93,106,Follow-up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration.,19346865_5,0,-1,0,9212,-1,0.99990165,9.836618e-05
9481,levofloxacin,3,4,25,37,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0,-1,0,9481,-1,0.9999392,6.0738683e-05
8656,papaverine,8,9,63,73,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,0,-1,0,8656,-1,0.9999379,6.209619e-05
17170,risperidone,5,6,42,53,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0,17170,-1,0.9999378,6.225213e-05
1010,ketamine,19,20,125,133,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,0,-1,0,1010,-1,0.99988353,0.00011641038
10513,haloperidol,15,16,108,119,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,0,-1,0,10513,-1,0.99993885,6.114474e-05
11518,fentanyl,13,14,88,96,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,0,-1,0,11518,-1,0.9999306,6.935319e-05
1743,dopamine,15,16,104,112,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0,-1,0,1743,-1,0.9998808,0.00011919395
7838,Sulpiride,0,1,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0,7838,-1,0.99992645,7.357906e-05
14590,midazolam,10,11,67,76,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,0,-1,0,14590,-1,0.99993587,6.407527e-05
838,pyridoxine,1,2,9,19,Neonatal pyridoxine responsive convulsions due to isoniazid therapy.,1085609_0,0,-1,0,838,-1,0.99994326,5.6705958e-05
5003,potassium,17,18,107,116,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,0,-1,0,5003,-1,0.99988425,0.00011579075
17216,dopamine,5,6,37,45,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,0,-1,0,17216,-1,0.9998559,0.0001440589
9990,bupropion,6,7,34,43,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0,-1,0,9990,-1,0.99994564,5.4322405e-05
15714,bupivacaine,4,5,27,38,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,15714,-1,0.99994755,5.2491698e-05
686,Lidocaine,0,1,0,9,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,0,-1,0,686,-1,0.99985504,0.00014492552
18026,appetite suppressants,17,19,97,118,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,0,-1,0,18026,-1,0.9998834,0.000116620045
8487,pergolide,12,13,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0,-1,0,8487,-1,0.9999441,5.5932906e-05
14588,midazolam,22,23,129,138,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0,14588,-1,0.99994993,5.00072e-05
10999,clonidine,27,28,164,173,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0,10999,-1,0.9999325,6.7457404e-05
17697,bupivacaine,28,29,146,157,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,17697,-1,0.99994147,5.852107e-05
16818,dipyridamole,6,7,30,42,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0,16818,-1,0.99994123,5.8735204e-05
17627,capsaicin,5,6,38,47,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,0,-1,0,17627,-1,0.9999399,6.0074453e-05
15297,folinic acid,10,12,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0,15297,-1,0.9999372,6.280655e-05
11492,Morphine,0,1,0,8,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,0,-1,0,11492,-1,0.99987924,0.000120783174
10241,prazosin,8,9,45,53,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,0,-1,0,10241,-1,0.9999337,6.625729e-05
192,calcium,9,10,60,67,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,0,-1,0,192,-1,0.9998673,0.00013264976
4838,cyclophosphamide,6,7,34,50,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0,4838,-1,0.9999368,6.316567e-05
12577,carbamazepine,19,20,130,143,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,12577,-1,0.9999294,7.0557006e-05
14987,dopamine,9,10,68,76,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,0,-1,0,14987,-1,0.9998776,0.00012240805
13588,scopolamine,9,10,54,65,"However, studies into the dose necessary to combating scopolamine intoxication are indicated.",603022_2,0,-1,0,13588,-1,0.99993515,6.488001e-05
13461,paracetamol,19,20,97,108,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0,-1,0,13461,-1,0.9999156,8.444063e-05
15390,zidovudine,16,17,78,88,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0,-1,0,15390,-1,0.99993646,6.348531e-05
12128,lithium,22,23,157,164,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,0,-1,0,12128,-1,0.99987197,0.00012798756
17686,bupivacaine,51,52,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,17686,-1,0.99994314,5.6891422e-05
8396,methylprednisolone,17,18,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0,8396,-1,0.999936,6.400236e-05
90,amphetamine,18,19,128,139,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0,-1,0,90,-1,0.9999379,6.21539e-05
14154,heparin,15,16,85,92,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,0,-1,0,14154,-1,0.9998665,0.00013350222
5429,steroid,4,5,30,37,Dose reduction or concomitant steroid therapy may have a role in selected patients.,1595783_6,0,-1,0,5429,-1,0.9998388,0.00016111908
17828,"5,7-dichlorokynurenic acid",0,2,0,26,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0,-1,0,17828,-1,0.9998777,0.00012224031
16449,lignocaine,14,15,77,87,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0,-1,0,16449,-1,0.9999273,7.267795e-05
9700,tacrolimus,2,3,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,9700,-1,0.9999273,7.2684394e-05
6298,superoxide,21,22,92,102,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0,6298,-1,0.99989295,0.00010699923
942,apomorphine,8,9,52,63,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,0,-1,0,942,-1,0.99993753,6.2489926e-05
12146,corticosterone,40,41,272,286,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0,12146,-1,0.9998635,0.00013647223
13214,isoniazid,11,12,63,72,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,0,-1,0,13214,-1,0.99994075,5.9213904e-05
6011,Pilocarpine,0,1,0,11,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,0,-1,0,6011,-1,0.99994135,5.8627087e-05
12796,deferoxamine,14,15,113,125,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,12796,-1,0.9999448,5.5173026e-05
16419,mesna,29,30,175,180,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0,16419,-1,0.99989414,0.000105897394
12872,calcitonin,16,17,103,113,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,0,-1,0,12872,-1,0.9999423,5.7726746e-05
994,ketamine,7,8,37,45,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,0,-1,0,994,-1,0.9999043,9.5691e-05
1904,cyclosporine,5,6,32,44,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,1904,-1,0.9999293,7.067653e-05
864,ketamine,9,10,61,69,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,0,-1,0,864,-1,0.99989533,0.000104637926
12676,dapsone,9,10,51,58,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0,-1,0,12676,-1,0.9999305,6.946995e-05
6483,lamivudine,3,4,22,32,"The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.",16960342_10,0,-1,0,6483,-1,0.9999447,5.5256114e-05
7184,methylprednisolone,19,20,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0,7184,-1,0.99993455,6.539432e-05
11441,carbamazepine,8,9,48,61,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,0,-1,0,11441,-1,0.999936,6.400938e-05
5441,azithromycin,11,12,64,76,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,0,-1,0,5441,-1,0.9999261,7.393186e-05
17425,danazol,10,11,75,82,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,0,-1,0,17425,-1,0.9999316,6.8369576e-05
16371,steroid,10,11,77,84,Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment.,8665051_6,0,-1,0,16371,-1,0.9998677,0.00013230514
14053,atropine,2,3,19,27,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0,14053,-1,0.9999429,5.7089732e-05
5321,doxorubicin,15,16,78,89,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,5321,-1,0.99988985,0.00011017978
11654,ketoconazole,14,15,89,101,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0,-1,0,11654,-1,0.9999435,5.6531622e-05
1851,terfenadine,10,11,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,1851,-1,0.99993956,6.0420894e-05
1520,verapamil,4,5,34,43,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,0,-1,0,1520,-1,0.9999418,5.8133886e-05
8435,sevoflurane,23,24,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0,-1,0,8435,-1,0.99994147,5.857814e-05
12209,cholesterol,11,12,73,84,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,0,-1,0,12209,-1,0.9998455,0.00015442607
9413,alcohol,9,10,43,50,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,0,-1,0,9413,-1,0.9998591,0.00014089936
4311,Doxorubicin,0,1,0,11,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,0,-1,0,4311,-1,0.99986935,0.00013066623
5124,Methamphetamine,0,1,0,15,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,0,-1,0,5124,-1,0.9999262,7.378001e-05
15309,5-fluorouracil,11,12,65,79,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,15309,-1,0.9999229,7.7165685e-05
13661,verapamil,7,8,68,77,Simultaneously administration of beta-adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution.,6127992_4,0,-1,0,13661,-1,0.99994004,5.9911807e-05
5370,cocaine,9,10,48,55,This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae.,1592014_2,0,-1,0,5370,-1,0.99986386,0.00013611082
8242,glutamate,24,25,139,148,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0,8242,-1,0.9998834,0.00011653177
14504,cimetidine,5,6,27,37,Age and renal clearance of cimetidine.,7053303_0,0,-1,0,14504,-1,0.9999361,6.3927764e-05
10812,succinylcholine,11,12,78,93,BACKGROUND: patients undergoing electroconvulsive therapy (ECT) often receive succinylcholine as part of the anesthetic procedure.,21029050_1,0,-1,0,10812,-1,0.9999294,7.059416e-05
11228,magnesium,1,2,4,13,The magnesium was stopped and she recovered over a few days.,2385256_3,0,-1,0,11228,-1,0.99983406,0.00016593623
5698,nicotine,4,5,20,28,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,0,-1,0,5698,-1,0.9998765,0.00012346142
5714,smoking,11,12,61,68,"Stratification of patients by sex, age, extent of concurrent smoking, extent of product use, and severity of adverse events revealed no clinically significant differences between the lozenge and gum.",16330293_13,0,-1,0,5714,-1,0.9998165,0.00018349406
6128,desipramine,10,11,45,56,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0,6128,-1,0.9999428,5.7208268e-05
14289,metoclopramide,2,3,9,23,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0,-1,0,14289,-1,0.99994147,5.855675e-05
13416,amiodarone,7,8,44,54,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,0,-1,0,13416,-1,0.9999424,5.7557278e-05
4042,cephalosporins,18,19,143,157,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,0,-1,0,4042,-1,0.999925,7.5021446e-05
10142,gentamicin,11,12,74,84,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,0,-1,0,10142,-1,0.9998503,0.00014972815
14679,indomethacin,1,2,9,21,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,0,-1,0,14679,-1,0.9999367,6.332333e-05
5613,cocaine,6,7,41,48,RESULTS: Thirteen patients with positive cocaine toxicology were compared to 26 controls.,16174948_7,0,-1,0,5613,-1,0.99979407,0.00020597127
10372,azathioprine,28,29,192,204,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,0,-1,0,10372,-1,0.9998821,0.000117896496
6853,ifosfamide,16,17,77,87,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,6853,-1,0.9999466,5.3366803e-05
8003,trihexyphenidyl,19,20,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0,8003,-1,0.999941,5.9061644e-05
2669,morphine,3,4,26,34,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,0,-1,0,2669,-1,0.999866,0.00013400281
5551,paclitaxel,20,21,138,148,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0,5551,-1,0.9998926,0.000107376385
18032,carbamazepine,3,4,21,34,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,18032,-1,0.99993837,6.1654486e-05
8909,warfarin,22,23,129,137,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,0,-1,0,8909,-1,0.99987805,0.00012187717
3817,cocaine,39,40,264,271,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,3817,-1,0.9998636,0.00013634346
13939,amitriptyline,27,28,163,176,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,0,-1,0,13939,-1,0.99994147,5.8531117e-05
9437,antidepressant,9,10,71,85,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0,-1,0,9437,-1,0.99986696,0.00013296405
804,nimodipine,11,12,70,80,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0,-1,0,804,-1,0.99994266,5.7318466e-05
18000,adrenaline,20,21,132,142,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,0,-1,0,18000,-1,0.9999124,8.763862e-05
2129,oral contraceptives,28,30,178,197,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2129,-1,0.9998568,0.00014315419
12200,captopril,13,14,79,88,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,0,-1,0,12200,-1,0.99994457,5.542182e-05
17822,glycine,3,4,20,27,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,0,-1,0,17822,-1,0.9998461,0.00015381737
8456,Fentanyl,0,1,0,8,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,0,-1,0,8456,-1,0.9999399,6.0088205e-05
5326,daunorubicin,12,13,85,97,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,5326,-1,0.9999311,6.889874e-05
2768,paracetamol,17,18,74,85,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0,2768,-1,0.9999255,7.4523035e-05
17410,"1-bromo-1-chloro-2,2,2-trifluoroethane",9,10,50,88,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0,17410,-1,0.999788,0.00021204118
16348,carboplatin,12,13,71,82,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0,16348,-1,0.9999362,6.380869e-05
3588,succinylcholine,6,7,53,68,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,0,-1,0,3588,-1,0.99993396,6.607369e-05
6779,sirolimus,11,12,65,74,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0,-1,0,6779,-1,0.99993765,6.234469e-05
17296,estrogen,27,28,147,155,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,0,-1,0,17296,-1,0.9998362,0.00016379922
9403,vancomycin,17,18,113,123,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,0,-1,0,9403,-1,0.9998832,0.00011681704
3738,fentanyl,39,40,191,199,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0,3738,-1,0.9999373,6.274705e-05
1372,carboplatin,1,2,8,19,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0,-1,0,1372,-1,0.999943,5.6941244e-05
6656,phenytoin,1,2,10,19,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,0,-1,0,6656,-1,0.9999391,6.0892315e-05
10972,morphine,6,7,45,53,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,0,-1,0,10972,-1,0.9998524,0.00014751205
12204,simvastatin,2,3,15,26,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,0,-1,0,12204,-1,0.9999275,7.246521e-05
11170,pentoxifylline,1,2,8,22,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,0,-1,0,11170,-1,0.9999263,7.3662464e-05
13639,serotonin,3,4,21,30,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0,-1,0,13639,-1,0.99988437,0.00011559923
13913,verapamil,26,27,192,201,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0,13913,-1,0.9999417,5.830689e-05
5874,acetylcholine,10,11,58,71,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,0,-1,0,5874,-1,0.9998435,0.00015649454
11677,Renal damage,0,2,0,12,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,1,1,11677,-1,0.00014746735,0.99985254
6282,encephalopathy,21,22,160,174,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1,6282,-1,0.000104488165,0.99989545
73,orthostatic hypotension,15,17,98,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,1,1,73,-1,9.193066e-05,0.9999081
8534,death,4,5,37,42,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,1,1,8534,-1,0.00012992177,0.99987006
7800,bradycardia,21,22,76,87,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1,7800,-1,9.513591e-05,0.9999049
7370,rhabdomyolysis,1,2,7,21,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,1,1,7370,-1,0.00011361813,0.9998864
1190,incontinence,24,25,131,143,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,1,1,1190,-1,0.00013648564,0.9998635
3494,hematoma,10,11,68,76,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,1,1,3494,-1,0.00014151105,0.9998585
1477,cardiotoxicity,25,26,159,173,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,1,1,1477,-1,9.903811e-05,0.99990094
10578,coma,1,2,9,13,Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment.,20635749_3,-1,1,1,10578,-1,0.00014048064,0.99985945
1914,nephrotoxicity,16,17,106,120,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,1,1,1914,-1,0.00010796716,0.999892
4737,tremor,10,11,67,73,"Support of the arm decreased tremor severity, exhaustion increased tremor severity significantly.",15338796_16,-1,1,1,4737,-1,0.00016035473,0.99983966
11164,hyperemia,9,10,72,81,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,1,1,11164,-1,9.87599e-05,0.9999012
8004,confusion,25,26,174,183,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,-1,1,1,8004,-1,0.00011622848,0.9998838
16904,delirium,2,3,14,22,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,1,1,16904,-1,0.00010868953,0.9998913
7423,bleeding,6,7,29,37,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,-1,1,1,7423,-1,0.00012042655,0.9998796
14856,hyperthyroidism,11,12,70,85,METHODS: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department (in- or out-patients) from 1986 to 1992.,7504976_2,-1,1,1,14856,-1,0.00014417763,0.99985576
11202,deaths,17,18,92,98,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1,11202,-1,0.00021400911,0.99978596
12306,thrombi,14,15,88,95,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,1,1,12306,-1,0.00024690965,0.99975306
13388,hematoma,5,6,43,51,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,1,1,13388,-1,0.00015510982,0.9998449
10306,acute lymphoblastic leukemia,11,14,73,101,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,1,1,10306,-1,0.00025974007,0.9997403
11059,hypotension,30,31,193,204,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,-1,1,1,11059,-1,9.7443895e-05,0.9999026
4788,gallbladder disease,7,9,53,72,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1,4788,-1,0.00018058246,0.99981946
14607,convulsions,4,5,37,48,Deaths from local anesthetic-induced convulsions in mice.,7189975_0,-1,1,1,14607,-1,0.0001365937,0.9998634
15266,glomerulonephritis,11,12,79,97,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,-1,1,1,15266,-1,0.00016662959,0.99983335
10729,stomatitis,15,16,89,99,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1,10729,-1,0.0001297242,0.9998703
17513,psychotic symptoms,16,18,124,142,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,1,1,17513,-1,0.00011388844,0.99988616
17968,seizure,1,2,21,28,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,1,1,17968,-1,0.00011791313,0.9998821
12310,thrombocytopenia,21,22,137,153,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,1,1,12310,-1,0.00010003901,0.9999
17070,haemodilution,17,18,111,124,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,1,1,17070,-1,9.989916e-05,0.9999001
14870,hepatitis,3,4,18,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,1,1,14870,-1,0.00010829133,0.99989164
16178,edema,17,18,100,105,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,1,1,16178,-1,0.00012397792,0.999876
11325,seizure,10,11,71,78,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,1,1,11325,-1,0.00011768803,0.99988234
6394,hyperactivity,2,3,23,36,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,1,1,6394,-1,0.00011194028,0.99988806
15694,nephrolithiasis,5,6,40,55,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,-1,1,1,15694,-1,0.00011873293,0.99988127
3276,pulmonary hypertension,3,5,33,55,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,1,1,3276,-1,0.00010279848,0.99989724
2776,bradycardia,6,7,50,61,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,1,1,2776,-1,0.00010451407,0.99989545
15106,ischemia,56,57,384,392,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1,15106,-1,0.00011771305,0.9998822
16868,hypertension,17,18,146,158,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,1,1,16868,-1,0.00010697475,0.99989307
725,aggressive behavior,15,17,111,130,"In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.",10791295_4,-1,1,1,725,-1,0.0001627029,0.9998373
4802,gallbladder disease,22,24,136,155,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,4802,-1,0.00014417982,0.99985576
17622,proteinuria,7,8,56,67,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1,17622,-1,0.00011219044,0.9998878
1977,headache,21,22,120,128,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,1,1,1977,-1,0.00016880898,0.9998312
17732,parkinsonian,4,5,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1,17732,-1,0.00012970837,0.9998703
6657,bradycardia,9,10,71,82,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,-1,1,1,6657,-1,9.6532254e-05,0.99990344
10877,nausea,9,10,63,69,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1,10877,-1,0.00012502252,0.99987495
14629,aggressiveness,6,7,53,67,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,1,1,14629,-1,0.00012260769,0.99987733
5905,apnea,7,8,43,48,"None of the patients experienced sedation, apnea, nausea, or pruritus after injection of both drugs.",16563323_9,-1,1,1,5905,-1,0.00012878038,0.99987125
9843,stroke,8,9,22,28,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,1,1,9843,-1,0.0008251175,0.9991749
1692,manic,4,5,23,28,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,1,1,1692,-1,0.004655605,0.99534434
14219,tumors,7,8,33,39,"Of these recurrences, 27 were T1 tumors while five progressed to more highly invasive lesions.",6640832_10,-1,1,1,14219,-1,0.00019509961,0.9998049
493,artery calcification,4,6,16,36,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,1,1,493,-1,0.00013679157,0.99986315
3092,acute liver failure,2,5,13,32,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,1,1,3092,-1,0.00012824741,0.99987173
10119,diabetic nephropathy,13,15,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,-1,1,1,10119,-1,0.00011297671,0.999887
12261,deaths,23,24,146,152,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,1,1,12261,-1,0.0001535668,0.99984646
3635,anemia,9,10,70,76,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1,3635,-1,0.00010354124,0.9998964
9554,hyperactivity,13,14,57,70,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,1,1,9554,-1,0.000117686905,0.99988234
17584,spasm,5,6,26,31,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,1,1,17584,-1,0.00011211226,0.9998878
6150,visual loss,8,10,59,70,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,1,1,6150,-1,0.0001577404,0.9998423
7326,death,9,10,74,79,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,1,1,7326,-1,0.0001301102,0.9998698
114,thrombosis,25,26,106,116,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,1,1,114,-1,0.00011858776,0.9998814
1260,seizures,9,10,82,90,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,-1,1,1,1260,-1,0.00010586609,0.99989414
8741,thrombi,1,2,3,10,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,1,1,8741,-1,0.00019235347,0.99980766
11493,hyperalgesia,8,9,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,1,1,11493,-1,0.00011130208,0.99988866
10088,spasm,10,11,62,67,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,1,1,10088,-1,0.00012002232,0.99987996
15074,hypercalcemia,11,12,73,86,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,1,1,15074,-1,0.00011822296,0.99988174
11554,hepatitis,23,24,148,157,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,1,1,11554,-1,0.0001105924,0.9998894
16459,Diabetic,0,1,0,8,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,1,1,16459,-1,0.00015457135,0.9998454
5035,hyperemia,2,3,28,37,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,1,1,5035,-1,0.00010141298,0.99989855
6904,Seizure,0,1,0,7,Seizure susceptibility varies among inbred mouse strains.,17242861_1,-1,1,1,6904,-1,0.00014954395,0.9998504
17780,endometrial cancer,3,5,14,32,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1,17780,-1,0.00016292691,0.99983704
6261,amnesia,5,6,43,50,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,-1,1,1,6261,-1,0.000119443124,0.99988055
10516,catalepsy,16,17,127,136,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,-1,1,1,10516,-1,0.000114506736,0.99988544
342,Headache,0,1,0,8,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,1,1,342,-1,0.0001350283,0.99986494
14081,death,11,12,67,72,There was a fulminant clinical course from start of symptoms until death.,6503301_2,-1,1,1,14081,-1,0.00016122479,0.9998387
13371,cancers,24,25,167,174,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1,13371,-1,0.00013833042,0.9998616
15447,allergic reaction,16,18,109,126,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,1,1,15447,-1,0.00013193942,0.99986804
5251,toxicity,3,4,18,26,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,1,1,5251,-1,0.000118430115,0.9998815
12466,necrosis,25,26,152,160,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,1,1,12466,-1,0.00011770127,0.99988234
3095,sepsis,6,7,41,47,His condition was further complicated by sepsis and coagulopathy.,12549952_6,-1,1,1,3095,-1,0.000118579504,0.9998814
15677,neurotoxicity,8,9,51,64,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1,15677,-1,0.000104656196,0.99989533
15103,ischemia,33,34,234,242,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1,15103,-1,0.00012621266,0.99987376
16074,chronic renal failure,7,10,42,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1,16074,-1,0.00012763911,0.9998723
5487,hypercalcemia,16,17,92,105,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,-1,1,1,5487,-1,0.00013218849,0.9998678
18092,orthostatic hypotension,37,39,232,255,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,18092,-1,0.00010244932,0.9998976
7937,thrombocytopenia,15,16,80,96,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,1,1,7937,-1,9.21965e-05,0.99990785
11988,bradycardia,20,21,164,175,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,-1,1,1,11988,-1,9.1687194e-05,0.9999083
12094,hypotension,95,96,404,415,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,1,1,12094,-1,0.00010208771,0.99989796
587,hemolysis,3,4,23,32,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,-1,1,1,587,-1,9.8603225e-05,0.9999014
706,cardiomyopathy,37,38,168,182,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,706,-1,0.00012797999,0.99987197
15052,Seizure,0,1,0,7,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,1,1,15052,-1,0.00013512206,0.9998648
12067,seizures,22,23,124,132,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,1,1,12067,-1,0.00013079088,0.9998692
10751,acute liver failure,9,12,79,98,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,-1,1,1,10751,-1,0.00011560408,0.99988437
639,hypotension,7,8,50,61,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,1,1,639,-1,0.00010639933,0.99989355
4215,headache,17,18,100,108,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,1,1,4215,-1,0.000110119174,0.99988985
3857,blood coagulation,7,9,48,65,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,-1,1,1,3857,-1,0.00029759732,0.9997024
12382,carcinoma,44,45,259,268,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1,12382,-1,0.00014396716,0.999856
13896,depressed,13,14,108,117,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,1,1,13896,-1,0.0011488097,0.9988512
14187,cardiac arrest,23,25,119,133,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,14187,-1,0.00010841574,0.9998915
16831,tumors,3,4,13,19,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,1,1,16831,-1,0.0003290981,0.99967086
6829,aggression,4,5,24,34,"Animals were tested for aggression in their home cage, both with and without physical provocation (mild tail pinch).",17194457_5,-1,1,1,6829,-1,0.00035444362,0.9996456
10705,amnesia,4,5,48,55,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,-1,1,1,10705,-1,0.0001235733,0.9998764
17957,breast cancer,38,40,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,17957,-1,0.00011746905,0.99988246
17430,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1,17430,-1,0.00014084198,0.9998591
12384,carcinoma,66,67,336,345,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1,12384,-1,0.0001442292,0.99985576
13548,hepatitis,4,5,27,36,Liver biopsy showed active hepatitis.,48362_2,-1,1,1,13548,-1,0.00012465849,0.9998753
1906,nephrotoxicity,21,22,145,159,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,-1,1,1,1906,-1,9.998007e-05,0.9999
17785,endometrial cancer,9,11,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,17785,-1,0.00015239834,0.99984753
12041,catalepsy,13,14,97,106,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,1,1,12041,-1,0.00012193262,0.99987805
15119,proteinuria,4,5,17,28,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,1,1,15119,-1,0.00011059599,0.9998894
1061,deaths,3,4,14,20,There were no deaths.,11063349_10,-1,1,1,1061,-1,0.00030548932,0.9996946
16423,hypotension,1,2,22,33,Acetaminophen-induced hypotension.,8682684_0,-1,1,1,16423,-1,9.864573e-05,0.9999013
1368,anemia,8,9,38,44,"In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c.",11245434_3,-1,1,1,1368,-1,9.2411174e-05,0.9999076
1380,anemia,5,6,48,54,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,1,1,1380,-1,0.000105335304,0.9998946
2651,aplastic anemia,8,10,58,73,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,1,1,2651,-1,0.000101851336,0.9998982
4202,migraine,19,20,125,133,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,1,1,4202,-1,0.00017106727,0.99982893
17624,hyperactivity,22,23,151,164,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,1,1,17624,-1,0.00012032611,0.9998797
2006,urticaria,19,20,114,123,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,-1,1,1,2006,-1,0.00013101568,0.999869
10872,tumors,25,26,156,162,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,1,1,10872,-1,0.00013338223,0.9998666
8781,toxicity,27,28,257,265,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,1,1,8781,-1,0.00019402344,0.999806
8217,seizure,11,12,110,117,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,1,1,8217,-1,0.00011057816,0.9998894
16021,Tetany,0,1,0,6,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1,16021,-1,0.0011906844,0.99880934
64,dyskinesia,15,16,78,88,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,1,1,64,-1,0.000117234165,0.9998827
13009,renal toxicity,18,20,108,122,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,1,1,13009,-1,0.000119471835,0.99988055
10657,hemolysis,38,39,262,271,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,1,1,10657,-1,9.566281e-05,0.9999043
8660,hepatotoxic,2,3,9,20,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,1,1,8660,-1,0.00011289831,0.9998871
18195,cardiomyopathy,23,24,165,179,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,1,1,18195,-1,0.000104172985,0.9998958
1962,vomiting,15,16,87,95,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1,1962,-1,0.00013403222,0.999866
2010,glaucoma,14,15,94,102,PURPOSE: Topical beta-blocker treatment is routine therapy in the management of patients with glaucoma.,11704023_1,-1,1,1,2010,-1,0.00014763702,0.9998523
18203,cardiotoxic,2,3,14,25,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,-1,1,1,18203,-1,0.00013171918,0.9998683
5825,vasculitis,1,2,15,25,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,1,1,5825,-1,0.000117614196,0.99988234
9043,pain,14,15,89,93,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1,9043,-1,0.00015308493,0.99984694
10375,cholestasis,13,14,87,98,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,1,1,10375,-1,0.00023949884,0.99976045
2101,nephrotoxicity,15,16,109,123,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2101,-1,0.00010643202,0.99989355
15865,diabetes,8,9,68,76,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,-1,1,1,15865,-1,0.00011307425,0.9998869
4469,temporal lobe epilepsy,11,14,63,85,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,-1,1,1,4469,-1,0.00019193284,0.99980813
12063,Seizures,0,1,0,8,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,1,1,12063,-1,0.00011918179,0.9998808
10021,seizures,21,22,131,139,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1,10021,-1,0.00013609653,0.99986386
9376,hyperactivity,7,8,49,62,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,1,1,9376,-1,0.00013241544,0.99986756
3512,myocardial injury,9,11,56,73,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,1,1,3512,-1,0.00011877676,0.99988127
10207,encephalopathy,4,5,26,40,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,1,1,10207,-1,0.00010985937,0.9998901
10868,glaucoma,29,30,186,194,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,1,1,10868,-1,0.00014093227,0.9998591
884,atrophy,7,8,58,65,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,1,1,884,-1,0.00011051851,0.9998895
17757,breast cancer,8,10,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1,17757,-1,0.00015385171,0.9998461
13241,confusion,7,8,39,48,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,1,1,13241,-1,0.000110037094,0.99988997
616,hypotension,12,13,79,90,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,-1,1,1,616,-1,0.00010178171,0.9998982
14160,toxicity,1,2,4,12,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,1,1,14160,-1,0.00018664832,0.9998134
1593,necrotic,9,10,58,66,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1,1593,-1,0.00017089608,0.99982905
16664,overdose,19,20,127,135,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,-1,1,1,16664,-1,0.00058056077,0.99941945
5431,pain,16,17,106,110,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,1,1,5431,-1,0.00012439427,0.99987555
14814,dyskinesias,60,61,346,357,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,1,1,14814,-1,0.00010558994,0.9998944
17360,parkinsonian,17,18,100,112,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,1,1,17360,-1,0.00032296445,0.99967706
388,sepsis,11,12,52,58,Three patients with severe neutropenia (6%) died of sepsis.,10526274_16,-1,1,1,388,-1,0.000116247546,0.9998838
13741,hypertrophy,18,19,134,145,Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy.,6203632_8,-1,1,1,13741,-1,0.00012529868,0.9998747
8597,cardiotoxicity,14,15,83,97,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,-1,1,1,8597,-1,0.00011156209,0.9998884
194,hypothyroidism,10,11,59,73,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,1,1,194,-1,0.00011848795,0.9998815
9922,shock,14,15,112,117,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,1,1,9922,-1,0.00013016531,0.9998698
7080,syncope,14,15,80,87,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,1,1,7080,-1,0.00011854399,0.9998814
11791,hypertension,1,2,23,35,Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.,2722224_0,-1,1,1,11791,-1,0.00010397867,0.99989605
7361,myocarditis,12,13,75,86,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,-1,1,1,7361,-1,0.00011633981,0.99988365
682,hyperalgesia,25,26,142,154,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1,682,-1,0.00010501257,0.999895
2955,fasciculation,12,13,70,83,"Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.",12452237_5,-1,1,1,2955,-1,0.00017924473,0.99982077
17185,infarction,14,15,123,133,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,1,1,17185,-1,0.000111017274,0.999889
16811,rhabdomyolysis,20,21,107,121,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,-1,1,1,16811,-1,0.00014482567,0.99985516
1197,Seizure,0,1,0,7,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,1,1,1197,-1,0.00017343597,0.9998266
11201,death,9,10,57,62,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1,11201,-1,0.00016763677,0.9998324
6189,depressive,10,11,56,66,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,1,1,6189,-1,0.00038615486,0.9996138
3565,seizure,9,10,56,63,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,-1,1,1,3565,-1,0.00016896774,0.99983096
1252,hypertension,19,20,130,142,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,1,1,1252,-1,0.00011118316,0.9998888
8405,hypotension,1,2,17,28,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,1,1,8405,-1,0.00010778447,0.99989223
12756,prostate cancer,19,21,96,111,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,1,1,12756,-1,0.00013217803,0.9998678
14033,proteinuria,7,8,64,75,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,-1,1,1,14033,-1,0.00010499124,0.999895
11089,hyperalgesia,11,12,80,92,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,1,1,11089,-1,0.0001236174,0.9998764
11125,Seizure,0,1,0,7,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,1,1,11125,-1,0.00014568426,0.9998543
17850,Pain,0,1,0,4,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,-1,1,1,17850,-1,0.00015113673,0.99984884
3076,seizure,13,14,100,107,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,1,1,3076,-1,0.00013518044,0.9998648
16983,acute liver failure,9,12,72,91,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,1,1,16983,-1,0.00012640489,0.99987364
6703,hypocalcemia,18,19,115,127,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,1,1,6703,-1,0.000109746405,0.9998902
11421,migraine,7,8,44,52,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,1,1,11421,-1,0.00012215583,0.9998778
4462,dyskinesias,16,17,82,93,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,1,1,4462,-1,0.00010725542,0.9998927
9169,Confusion,2,3,14,23,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,1,1,9169,-1,0.00015717333,0.99984276
1136,parkinsonian,50,51,260,272,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,1,1,1136,-1,0.00015777485,0.99984217
17950,breast cancer,10,12,60,73,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,1,1,17950,-1,0.00017454602,0.99982554
14723,fulminant hepatic failure,7,10,54,79,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1,14723,-1,0.00014845804,0.99985147
10129,diabetic nephropathy,12,14,70,90,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,10129,-1,0.000113113514,0.9998869
13337,prostate cancer,17,19,99,114,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1,13337,-1,0.00012752402,0.99987245
3110,inflammation,13,14,90,102,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,1,1,3110,-1,0.00012742254,0.99987257
12260,hepatotoxicity,15,16,90,104,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,1,1,12260,-1,0.000104828585,0.9998952
4199,migraine,17,18,107,115,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,1,1,4199,-1,0.00016298224,0.99983704
12070,seizures,22,23,134,142,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,1,1,12070,-1,0.00010710845,0.99989283
6334,neurotoxicity,7,8,71,84,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,-1,1,1,6334,-1,0.000108276996,0.99989176
10064,hypoxia,1,2,5,12,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1,10064,-1,0.00011440698,0.99988556
11041,breast cancer,9,11,66,79,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,1,1,11041,-1,0.00015903849,0.999841
2972,migraine,13,14,100,108,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,1,1,2972,-1,0.00016598766,0.99983394
17640,pain,26,27,158,162,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1,17640,-1,0.00013249755,0.99986744
581,hemolysis,24,25,131,140,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,1,1,581,-1,0.00010473206,0.9998952
7969,myelosuppression,7,8,35,51,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1,7969,-1,0.00021027768,0.9997898
12414,hypertensive,11,12,71,83,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,1,1,12414,-1,0.0001447043,0.9998553
16098,Cancer,7,8,52,58,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1,16098,-1,0.0003811781,0.99961877
14525,fibrosis,9,10,65,73,"Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted.",7053705_3,-1,1,1,14525,-1,0.00014596873,0.99985397
17405,liver disease,5,7,31,44,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,1,1,17405,-1,0.00011240621,0.9998876
11715,hypotension,6,7,41,52,"In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.",2696505_1,-1,1,1,11715,-1,9.340155e-05,0.99990654
4721,tremor,5,6,37,43,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,1,1,4721,-1,0.0001224976,0.99987745
5632,aggressiveness,16,17,92,106,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,1,1,5632,-1,0.00018631101,0.99981374
4237,seizures,26,27,168,176,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1,4237,-1,0.000113859765,0.99988616
7586,bruising,3,4,18,26,Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.,17931375_7,-1,1,1,7586,-1,0.00028173873,0.99971825
17422,liver injury,16,18,93,105,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,1,1,17422,-1,0.00010768894,0.99989235
17528,breast cancer,5,7,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,17528,-1,0.00012856258,0.9998714
11515,glomerular sclerosis,9,11,56,76,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,-1,1,1,11515,-1,0.00011053262,0.9998895
761,aneurysms,15,16,97,106,METHODS: A review of admissions during a 6-year period revealed 14 patients with cocaine-related aneurysms.,10807237_3,-1,1,1,761,-1,0.00013068554,0.99986935
4060,parkinsonian,5,6,47,59,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1,4060,-1,0.00016209448,0.9998379
3170,renal injury,5,7,49,61,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1,3170,-1,0.00011891728,0.999881
4337,pruritus,16,17,83,91,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,1,1,4337,-1,0.00023114649,0.9997689
12804,toxicity,3,4,22,30,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,1,1,12804,-1,0.00022275654,0.99977726
13225,toxicities,3,4,16,26,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1,13225,-1,0.00012496435,0.99987507
868,pain,30,31,150,154,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1,868,-1,0.00016469363,0.99983525
5530,seizures,2,3,26,34,Cocaine-induced brainstem seizures and behavior.,1610717_0,-1,1,1,5530,-1,0.00010753152,0.9998925
6066,hemolysis,9,10,75,84,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,1,1,6066,-1,9.150735e-05,0.99990845
15116,glomerulonephritis,18,19,120,138,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,-1,1,1,15116,-1,0.00015508881,0.9998449
17752,nausea,12,13,75,81,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,1,1,17752,-1,0.0001238274,0.99987614
5190,hepatotoxicity,13,14,99,113,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,1,1,5190,-1,0.00010594031,0.999894
11632,psychiatric,3,4,27,38,Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients.,26094_3,-1,1,1,11632,-1,0.0023378148,0.9976622
13089,diabetic,13,14,68,76,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,1,1,13089,-1,0.00021553967,0.9997845
11431,pain,17,18,113,117,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,1,1,11431,-1,0.00012100866,0.999879
13533,dystonia,13,14,83,91,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,1,1,13533,-1,0.00010245009,0.9998975
16338,toxicity,2,3,18,26,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1,16338,-1,0.00013491286,0.99986506
8458,hypotension,16,17,126,137,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1,8458,-1,0.00011074764,0.99988925
1778,jaundice,5,6,23,31,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,1,1,1778,-1,0.00012743444,0.99987257
10366,cholestasis,1,2,11,22,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,1,1,10366,-1,0.00014432508,0.99985564
13578,platelet aggregation,9,11,83,103,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,1,1,13578,-1,0.0001110397,0.9998889
12595,depression,25,26,182,192,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,1,1,12595,-1,0.0001155774,0.99988437
6865,toxicity,27,28,146,154,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,1,1,6865,-1,9.951125e-05,0.99990046
9728,hypotensive,3,4,18,29,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,1,1,9728,-1,0.00012025464,0.9998797
9147,neuropathy,99,100,538,548,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,1,1,9147,-1,0.00010264792,0.99989736
5544,dyskinesias,10,11,58,69,"rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.",16116131_3,-1,1,1,5544,-1,0.00010018087,0.99989986
3835,nephropathy,7,8,60,71,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,-1,1,1,3835,-1,0.00011285752,0.9998871
9400,nephrotoxic,11,12,84,95,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,1,1,9400,-1,0.00025411643,0.9997459
10566,depressed,10,11,50,59,"Here, we present a similar incident in a severely depressed patient who received electroconvulsive therapy (ECT).",20633755_2,-1,1,1,10566,-1,0.00018977243,0.9998103
5583,amnesia,12,13,66,73,"Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.",1616457_1,-1,1,1,5583,-1,0.00013344672,0.9998665
2827,tumor,20,21,110,115,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,1,1,2827,-1,0.00066782156,0.99933213
314,hypertension,4,5,38,50,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,1,1,314,-1,0.0001118273,0.9998882
4493,bladder cancer,7,9,37,51,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,4493,-1,0.00015182109,0.9998481
11452,fatigue,19,20,89,96,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11452,-1,0.00012346319,0.9998765
176,psychiatric,9,10,51,62,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,-1,1,1,176,-1,0.0005784679,0.9994216
8450,nausea,21,22,150,156,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,1,1,8450,-1,0.00013443385,0.99986553
15759,hypotension,9,10,68,79,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,1,1,15759,-1,0.000101035854,0.9998989
2515,dyskinesias,24,25,164,175,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,1,1,2515,-1,0.00010836179,0.99989164
2394,cancer,15,16,95,101,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,1,1,2394,-1,0.00013207145,0.9998679
5565,myoclonic jerks,22,24,140,155,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,1,1,5565,-1,0.00013499302,0.99986494
3216,fibrosis,16,17,118,126,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,-1,1,1,3216,-1,0.00013073614,0.9998692
8679,hepatotoxicity,8,9,68,82,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,1,1,8679,-1,0.000105205305,0.99989474
8996,glomerulonephritis,7,8,81,99,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,-1,1,1,8996,-1,0.00018595518,0.9998141
7866,bradycardia,7,8,38,49,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,1,1,7866,-1,0.000105564985,0.9998944
15501,angioedema,1,2,4,14,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,1,1,15501,-1,0.00011027796,0.99988973
4718,tremor,4,5,20,26,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,-1,1,1,4718,-1,0.00016669426,0.9998332
5852,vasculitis,5,6,42,52,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,1,1,5852,-1,0.00011750972,0.99988246
9261,osteoporosis,28,29,168,180,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,1,1,9261,-1,0.00012434684,0.99987566
9264,cancer,15,16,88,94,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1,9264,-1,0.0001564635,0.9998435
7743,pain,13,14,92,96,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,1,1,7743,-1,0.00012098823,0.999879
10952,weakness,13,14,75,83,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,1,1,10952,-1,0.00011109701,0.9998889
10827,epileptic,11,12,89,98,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,-1,1,1,10827,-1,0.00011377609,0.99988616
9879,seizures,26,27,180,188,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,1,1,9879,-1,0.000112384885,0.9998876
1643,Necrotic,0,1,0,8,Necrotic blisters were noted on his fingers.,11337188_2,-1,1,1,1643,-1,0.00025986345,0.9997402
8425,vomiting,5,6,37,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,1,1,8425,-1,0.00012197485,0.99987805
13799,toxicity,4,5,23,31,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13799,-1,0.00015979685,0.99984014
13648,myoclonic jerks,30,32,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,1,1,13648,-1,0.00016882348,0.9998312
16022,rhabdomyolysis,2,3,11,25,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1,16022,-1,0.00015366009,0.99984634
9225,proteinuria,8,9,63,74,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,-1,1,1,9225,-1,0.00010281396,0.9998971
16208,hypertension,12,13,59,71,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,1,1,16208,-1,0.00016627707,0.9998337
9788,catalepsy,23,24,124,133,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,1,1,9788,-1,0.00011240482,0.9998876
10474,arrhythmia,14,15,73,83,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,1,1,10474,-1,0.00012379469,0.99987614
6594,tremor,14,15,75,81,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,1,1,6594,-1,0.00010655468,0.9998934
2812,cardiac arrest,18,20,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,2812,-1,0.0001079618,0.999892
8037,proteinuria,23,24,134,145,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,1,1,8037,-1,0.0001094232,0.99989057
17787,breast cancer,11,13,74,87,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,1,1,17787,-1,0.00018412345,0.9998159
14184,ventricular tachycardia,11,13,75,98,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,14184,-1,0.00011619668,0.9998838
13802,milk fever,25,27,140,150,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,13802,-1,0.00016117316,0.9998388
9026,hypertension,6,7,47,59,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1,9026,-1,0.000105917075,0.999894
867,Pain,12,13,74,78,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1,867,-1,0.0002824571,0.99971753
12657,depression,12,13,86,96,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,1,1,12657,-1,0.00011863912,0.9998814
9561,hyperactivity,7,8,40,53,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,1,1,9561,-1,0.00011292577,0.9998871
16043,Nephrotoxicity,0,1,0,14,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,-1,1,1,16043,-1,0.00011773741,0.9998822
12131,Hypothyroidism,0,1,0,14,Hypothyroidism developed in eight patients while they were taking lithium.,3001299_3,-1,1,1,12131,-1,0.00013666574,0.99986327
14557,aplastic anemia,1,3,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,1,1,14557,-1,0.00010756578,0.9998925
3079,epilepsy,20,21,134,142,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,1,1,3079,-1,0.00010895539,0.99989104
10494,diabetic,13,14,94,102,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,1,1,10494,-1,0.00021742623,0.9997826
17842,neurotoxic,23,24,120,130,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,1,1,17842,-1,0.00012919042,0.9998708
12462,tumor,30,31,162,167,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1,12462,-1,0.00031702968,0.999683
966,pain,1,2,10,14,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1,966,-1,0.0002616921,0.9997383
16511,cholestasis,11,12,104,115,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,1,1,16511,-1,0.0002796556,0.9997203
3634,anemia,4,5,30,36,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,-1,1,1,3634,-1,0.00010645638,0.99989355
7799,hypotension,1,2,15,26,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1,7799,-1,0.00010660074,0.9998934
9507,arrhythmias,10,11,72,83,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,1,1,9507,-1,0.00010873473,0.9998913
967,pain,21,22,127,131,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1,967,-1,0.00017308224,0.99982697
13305,Neurotoxic,0,1,0,10,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,1,1,13305,-1,0.0001852245,0.9998148
3026,seizures,7,8,54,62,"beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.",12481039_7,-1,1,1,3026,-1,0.000105659245,0.9998944
16196,cardiotoxicity,4,5,37,51,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,-1,1,1,16196,-1,0.000109759174,0.9998902
15505,thrombosis,7,8,60,70,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,-1,1,1,15505,-1,0.00011813326,0.99988186
2544,dyskinesias,3,4,22,33,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,1,1,2544,-1,0.00011571117,0.99988425
500,artery calcification,24,26,160,180,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,1,1,500,-1,0.00013599664,0.999864
12531,nephrotoxicity,12,13,73,87,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,-1,1,1,12531,-1,0.00010569129,0.99989426
295,tachycardia,3,4,16,27,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,-1,1,1,295,-1,0.00010332139,0.99989665
3541,seizure,6,7,41,48,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,1,1,3541,-1,0.000119434,0.99988055
2675,constipation,25,26,181,193,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,1,1,2675,-1,0.00010316073,0.9998969
7428,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1,7428,-1,0.00011974635,0.9998802
16636,cognitive deficits,19,21,129,147,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,1,1,16636,-1,0.000118965145,0.999881
9207,encephalopathy,12,13,94,108,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,1,1,9207,-1,0.00010399722,0.99989605
11120,thrombosis,13,14,90,100,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,1,1,11120,-1,0.00011452214,0.99988544
11929,prolactinoma,7,8,43,55,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,11929,-1,0.00021547389,0.9997845
14618,convulsions,8,9,41,52,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,1,1,14618,-1,0.00013429536,0.99986565
7454,pulmonary hypertension,10,12,65,87,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,1,1,7454,-1,0.000116055926,0.9998839
2259,thrombocytopenia,9,10,71,87,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,1,1,2259,-1,0.00010057638,0.9998994
1937,lymphadenopathy,11,12,67,82,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,1937,-1,0.00012236871,0.9998776
4705,hypertension,52,53,373,385,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,4705,-1,0.00012692486,0.99987304
13339,tumors,41,42,224,230,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1,13339,-1,0.00012741925,0.99987257
6207,convulsions,11,12,95,106,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,-1,1,1,6207,-1,0.0001283733,0.9998716
6700,hypocalcemia,19,20,136,148,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,-1,1,1,6700,-1,0.00013594063,0.999864
13352,rheumatoid arthritis,16,18,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,1,1,13352,-1,0.0001266852,0.9998733
10499,catalepsy,13,14,119,128,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,1,1,10499,-1,0.00011984289,0.9998802
15121,proteinuria,6,7,28,39,Free NP did not provoke any proteinuria.,7724492_4,-1,1,1,15121,-1,0.00010794905,0.999892
5724,Secondary hyperalgesia,0,2,0,22,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,5724,-1,0.00015215004,0.99984777
1781,Liver disease,0,2,0,13,Liver disease caused by propylthiouracil.,1147734_0,-1,1,1,1781,-1,0.0001138816,0.99988616
5911,myoclonus,8,9,63,72,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1,5911,-1,0.00016253139,0.9998374
4500,bladder cancer,3,5,12,26,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,1,1,4500,-1,0.00013339825,0.9998666
6663,hypothermia,7,8,47,58,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,1,1,6663,-1,0.00011754245,0.99988246
13920,dyskinesia,1,2,17,27,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,1,1,13920,-1,0.00011050723,0.9998895
6894,myopathy,13,14,69,77,"What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.",17241784_2,-1,1,1,6894,-1,0.0001066774,0.9998933
4919,proteinuria,6,7,26,37,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,1,1,4919,-1,0.000103848666,0.99989617
8735,thrombocytopenia,8,9,62,78,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,1,1,8735,-1,9.381852e-05,0.9999062
5750,nephrotoxic,2,3,11,22,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,1,1,5750,-1,0.00011071131,0.99988925
272,hemorrhage,19,20,109,119,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,1,1,272,-1,0.0001215987,0.9998784
16277,tumor,19,20,135,140,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1,16277,-1,0.00018079106,0.9998192
13725,tumor,10,11,56,61,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1,13725,-1,0.0001613686,0.9998386
11133,seizures,1,2,4,12,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,-1,1,1,11133,-1,0.00011361509,0.9998864
650,bradycardia,18,19,154,165,"Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.",10737864_5,-1,1,1,650,-1,9.583465e-05,0.99990416
4612,mitral regurgitation,15,17,118,138,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,1,1,4612,-1,0.00014506129,0.9998549
1563,cardiomyopathy,38,39,237,251,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,1,1,1563,-1,0.00011260941,0.99988735
7533,nausea,41,42,210,216,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,1,1,7533,-1,0.00013700382,0.999863
16861,hypertension,25,26,152,164,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,16861,-1,0.00010993515,0.9998901
10226,Hypotension,0,1,0,11,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,-1,1,1,10226,-1,0.00011454038,0.99988544
3804,autoimmune hemolytic anemia,13,16,87,114,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1,3804,-1,0.00010822031,0.99989176
9477,hypotension,22,23,156,167,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,-1,1,1,9477,-1,9.572797e-05,0.9999043
152,psoriasis,4,5,25,34,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,1,1,152,-1,0.00013394967,0.999866
13569,thrombi,9,10,70,77,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,1,1,13569,-1,0.0002065928,0.99979347
6424,catalepsy,9,10,55,64,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,1,1,6424,-1,0.00013841172,0.9998616
18185,cardiomyopathy,16,17,112,126,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,1,1,18185,-1,0.00010140718,0.99989855
2609,tremor,9,10,61,67,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,1,1,2609,-1,0.00011047814,0.9998895
1093,variant angina,14,16,85,99,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,1,1,1093,-1,0.00013331676,0.9998667
1366,Anemia,0,1,0,6,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,-1,1,1,1366,-1,0.000100933015,0.999899
12682,infection,22,23,127,136,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,1,1,12682,-1,0.00024547597,0.9997545
2161,pain,7,8,41,45,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2161,-1,0.00013090717,0.9998691
16173,Angioedema,0,1,0,10,Angioedema associated with droperidol administration.,8599504_0,-1,1,1,16173,-1,0.00010613,0.9998939
4059,dyskinesias,3,4,32,43,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1,4059,-1,0.000103618586,0.9998964
17557,aplastic anemia,1,3,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,-1,1,1,17557,-1,9.579024e-05,0.99990416
13719,thrombocytopenia,19,20,152,168,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,13719,-1,0.00010198476,0.99989796
14528,diabetes,5,6,37,45,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,1,1,14528,-1,0.00012299036,0.999877
15898,confusion,14,15,134,143,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,1,1,15898,-1,0.00011067784,0.99988925
4689,depression,19,20,126,136,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,1,1,4689,-1,0.000104080944,0.99989593
5214,Thrombotic microangiopathy,2,4,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,-1,1,1,5214,-1,0.000127477,0.99987257
7901,myopathy,6,7,29,37,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,1,1,7901,-1,0.000103528604,0.9998964
12294,Hemolytic Uremic Syndrome,3,6,23,48,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,1,1,12294,-1,0.00011930015,0.9998807
12227,toxicity,19,20,128,136,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1,12227,-1,0.00012575448,0.99987423
14582,carcinoma,9,10,48,57,"In both instances, suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix.",7088431_3,-1,1,1,14582,-1,0.00018652075,0.9998135
8924,convulsions,17,18,105,116,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,1,1,8924,-1,0.00014822492,0.9998517
6085,drug abuse,21,23,148,158,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,-1,1,1,6085,-1,0.017687395,0.9823126
12827,depression,16,17,106,116,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,-1,1,1,12827,-1,0.00016080812,0.9998392
13829,tumor,17,18,122,127,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,1,1,13829,-1,0.00019614505,0.99980384
12608,arthritis,3,4,20,29,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1,12608,-1,0.000120578785,0.99987936
7523,hepatitis,1,2,6,15,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,1,1,7523,-1,0.00012421898,0.9998758
6461,atherosclerosis,1,2,7,22,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,1,1,6461,-1,0.00014572826,0.9998542
7893,glycosuria,16,17,118,128,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,7893,-1,0.001891096,0.99810886
13705,seizures,5,6,23,31,"Until the cause of the seizures was correctly identified, the patient was inappropriately treated with anticonvulsants.",6153967_3,-1,1,1,13705,-1,0.00011693741,0.99988306
8794,poisoning,14,15,77,86,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,1,1,8794,-1,0.000146475,0.9998535
9386,neurotoxic,16,17,114,124,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,-1,1,1,9386,-1,0.00015026936,0.9998497
8732,jaundice,10,11,61,69,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,1,1,8732,-1,0.00014082414,0.9998592
16441,pain,5,6,39,43,Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.,8686832_2,-1,1,1,16441,-1,0.00017712897,0.9998229
367,toxicity,27,28,158,166,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,1,1,367,-1,0.00017595214,0.9998241
14560,cataract,13,14,82,90,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,1,1,14560,-1,0.000387139,0.99961287
18338,nephrotoxicity,12,13,78,92,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,1,1,18338,-1,0.00010988546,0.9998901
2735,nephrotoxicity,21,22,122,136,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,1,1,2735,-1,9.9557765e-05,0.99990046
14743,hypotensive,14,15,98,109,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,1,1,14743,-1,0.00019522854,0.9998048
13196,seizures,9,10,54,62,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,1,1,13196,-1,0.000114563976,0.99988544
17431,temporal lobe epilepsy,19,22,121,143,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,1,1,17431,-1,0.00019940393,0.9998006
14179,toxicity,3,4,23,31,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,1,1,14179,-1,0.00018769,0.9998123
6778,proteinuria,3,4,15,26,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,-1,1,1,6778,-1,0.000109983484,0.99988997
4310,coma,23,24,166,170,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,1,1,4310,-1,0.00011480019,0.9998852
8817,dyskinesia,12,13,80,90,"However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo.",18951540_4,-1,1,1,8817,-1,0.00012249152,0.99987745
2772,hypotension,10,11,61,72,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,1,1,2772,-1,0.00010851825,0.9998915
604,hypertension,6,7,47,59,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,1,1,604,-1,0.00010519366,0.99989474
15550,catalepsy,4,5,25,34,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,1,1,15550,-1,0.000106916414,0.99989307
5012,hyperprolactinemia,13,14,83,101,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,-1,1,1,5012,-1,0.00010440968,0.9998956
12609,sexual dysfunction,5,7,34,52,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1,12609,-1,0.0001957167,0.9998043
984,cancer,6,7,44,50,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,-1,1,1,984,-1,0.00017916202,0.9998209
7096,hypothyroidism,9,10,87,101,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,1,1,7096,-1,0.00011060611,0.9998894
8186,neurotoxicity,1,2,24,37,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,1,1,8186,-1,0.000108390115,0.99989164
10243,hypotension,11,12,104,115,Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).,2024540_5,-1,1,1,10243,-1,0.000105108345,0.99989486
12584,parkinsonism,14,15,92,104,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,1,1,12584,-1,0.000103754144,0.9998963
16394,chronic renal failure,21,24,137,158,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,1,1,16394,-1,0.00010153626,0.99989843
11444,eosinophilia,19,20,132,144,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1,11444,-1,0.00011814475,0.99988186
17443,dyskinesias,90,91,488,499,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,1,1,17443,-1,0.000102181206,0.99989784
11841,seizure,9,10,56,63,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,1,1,11841,-1,0.00014124911,0.99985874
15331,extrapyramidal symptoms,26,28,127,150,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,1,1,15331,-1,0.00012730145,0.9998727
